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The development of nuclear medicine as a medical specialty has resulted in the 
large-scale application of its effective imaging methods in everyday practice as a 
primary method of diagnosis. The introduction  of positron-emitting tracers (PET) 
has represented another fundamental leap forward in the ability of nuclear medicine 
to exert a profound impact on patient management, while the ability to produce 
radioisotopes of different elements initiated a variety of tracer studies in biology 
and medicine, facilitating enhanced interactions of nuclear medicine specialists and 
specialists in other disciplines. At present, nuclear medicine is an essential part of 
diagnosis of many diseases, particularly in cardiologic, nephrologic and oncologic 
applications and it is well-established in its therapeutic approaches, notably in the 
treatment of thyroid cancers. Data from official sources of different countries confirm 
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Nuclear Medicine is a collection of 12 chapters providing a comprehesnive overview 
of the nuclear medicine, with insights into both its historical and contemporary 
practices. I hope that readers enjoy the chapters greatly and find it informative, 
practical and educational in the presented discussions.  
I would like to convey my respects and thanks to the authors for their efforts and 
contribution. Collaboration has always been important in academic environment. I am 
very happy to see that the publication and chapters are the result of fruitful 
international collaboration involving more than 20 leading scientists and investigators 
from all over the world. I hope the "12 Chapters on Nuclear Medicine" encourage 
continued close cooperation and collaboration among its authors. 
Best regards, 
Ali Gholamrezanezhad, MD, FEBNM 
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Physiologic and False Positive Pathologic 
Uptakes on Radioiodine Whole Body Scan 
Byeong-Cheol Ahn 
Kyungpook National University School of Medicine and Hospital, 
South Korea 
1. Introduction  
A radioiodine whole body scan relies on the fact that differentiated thyroid cancer is more 
efficient at trapping circulating radioiodine than any other tissues.(Hyer, Newbold et al. 
2010) Therefore, when I-131 is administered it accumulates in the thyroid cancer tissues and 
a radioiodine whole body scan plays an important role in the management of patients with 
differentiated thyroid cancer. Uptake of iodine by the cancer is related to the expression of 
sodium iodide symporter (NIS), which actively transports iodide into the cancer cells. 
Extrathyroidal tissues, such as stomach, salivary glands and breast, are known to have the 
NIS expression and the organs can physiologically take up iodine.(Riesco-Eizaguirre and 
Santisteban 2006) 
On a whole body scan with diagnostic or therapeutic doses of I-131, except for the 
physiological radioiodine uptake in the salivary glands, stomach, gastrointestinal and 
urinary tracts, the lesions with radioiodine uptake can be considered as metastatic lesions in 
thyroid cancer patients who previously underwent total thyroidectomy. 
However, a variety of unusual lesions may cause a false positive result on the radioiodine 
whole body scan and so careful evaluation of an abnormal scan is imperative to 
appropriately manage patients with differentiated thyroid cancer.(Mitchell, Pratt et al. 2000; 
Shapiro, Rufini et al. 2000; Carlisle, Lu et al. 2003; Ahn, Lee et al. 2011) The decision to 
administer radioiodine treatment is mainly based on the diagnostic scan, and 
misinterpretation of physiological or other causes of radioiodine uptake as metastatic 
thyroid cancer could lead to the decision to perform unnecessary surgical removal or to 
administer a high dose of I-131, which results in fruitless radiation exposure. Therefore, 
correct interpretation of the diagnostic scan is critical for the proper management.  
Physiologic iodine uptake, pathologic iodine uptakes that are not related to thyroid cancer 
and contamination by physiologic excretion of tracer on the whole body scan are presented 
and discussed in this chapter. The purpose of this chapter is to make readers consider the 
possibility of physiologic or pathologic false positive uptake as a reason for the tracer 
uptake seen on the radioiodine whole body scan. 
2. Iodine and the thyroid gland  
Iodine is an element with a high atomic number 53, it is purple in colour and it is 
represented by the symbol I, and the iodine is an essential component of the hormones  
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Fig. 1. Simplified diagram of the metabolic circuit of iodine. Iodine (I) ingested orally is 
absorbed from the small bowel into the circulating iodine pool. About one fifth of the iodine 
in the pool is removed by the thyroid gland and surplus iodine is rapidly excreted by the 
kidney and bowel. In the thyroid gland, iodine is used to produce thyroid hormones (Hr), 
which act in peripheral tissues. Iodine released from thyroid hormones re-enter into the 
circulating iodine pool.  
produced by the thyroid gland. The thyroid hormones are essential for the health and well-
being for mammals. Iodine comprises about 60% of the weights of thyroid hormones. The 
body of an adult contains 15~20mg of iodine, of which 70~80% is in the thyroid gland.(Ahad 
and Ganie 2010) To produce a normal quantity of thyroid hormone, about 50 mg of ingested 
iodine in the form of iodides are required each year. Oceans are the world’s main 
repositories of iodine and very little iodine is found in the soil.(Ahad and Ganie 2010) The 
major dietary sources of iodine are bread and milk in the US and Europe, but the main 
source is seaweed in some Asian countries.(Zimmermann and Crill; Ahad and Ganie 2010; 
Hall 2011) Iodine is found in various forms in nature such as inorganic sodium or potassium 
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salts (sodium iodide or potassium iodide), inorganic diatomic iodine or organic monoatomic 
iodine. (Ahad and Ganie 2010) Iodide, represented by I − , is the ion of iodine and it 
combines with another element or elements to form a compound. Although the iodine 
content of iodised salt may vary from country to country, common table salt has a small 
portion of sodium iodide to prevent iodine deficiency.(Hall 2011)  
 
Fig. 2. Cellular mechanism for iodine uptake in thyroid follicular cells. This commences with 
the uptake of iodide from the capillary into the follicular cell of the thyroid gland. This 
process occurs against chemical and electrical gradients via the sodium iodide symporter 
(NIS) located in the basal membrane of the follicular cell. Increased intracellular sodium is 
pumped out by the action of Na+/K+ ATPase. The iodide within the follicular cell moves 
towards the apical membrane to enter into the follicular lumen and then it is oxidized to 
iodine by peroxidase. Organification of the iodine follows the oxidation by iodination of the 
tyrosine residues present within the thyroglobulin (TG) molecule, and the iodine stays in the 
follicle before it is released into the circulation as thyroid hormones. Thyroid stimulating 
hormone (TSH) activates the follicular cell via TSH receptor (TSH-R) and increases the 
expression of the NIS and the TG. 
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2.1 Iodine absorption and metabolism 
Ingested iodides are rapidly and nearly completely absorbed (>90%) from the duodenum 
into the blood and most of the iodides are excreted by kidneys. Sodium iodide symporter 
(NIS) on the apical membrane of enterocytes mediates active iodide uptake. Normally about 
one fifth of absorbed iodides are taken up by thyroid follicular cells and this is used for 
thyroid hormone synthesis, yet the clearance of circulating iodide varies with iodine intake. 
In the condition of an adequate iodine supply, ≤10% of absorbed iodides are taken up by the 
thyroid and in chronic iodine deficiency, this fraction can exceed 80%.(Zimmermann and Crill) 
The basal membrane of the thyroid follicular cell is able to actively transport iodide to the 
interior of the cell against a concentration gradient by the action of the NIS, which co-transports 
one iodide ion along with two sodium ions. The process of concentrating iodide in the thyroid 
follicular cells is called iodide trapping and presence of the NIS is essential for the process.(Hall 
2011) Thyroid hormones are produced by oxidation, organification and coupling processes in 
the thyroid gland and they are finally released into the blood stream for their action.   
2.2 Sodium iodide symporter 
The rat NIS gene and the human NIS gene were cloned in 1996.(Dai, Levy et al. 1996; 
Smanik, Liu et al. 1996) NIS is a 13 transmembrane domain protein with an extracellular 
amino- and intracellular carboxyl-terminus and the expression of the NIS gene is mainly 
regulated by thyroid stimulating hormone (TSH). Binding of TSH to its receptor activates 
the NIS gene transcription and controls translocation and retention of NIS at the plasma 
membrane, and so this increases iodide uptake. 
In addition to its expression in the thyroid follicular cells, NIS is detectable and active in 
some extrathyroidal tissues such as the salivary glands, gastric mucosa, lactating mammary 
glands, etc. Therefore, these tissues are able to take up iodide by the action of the NIS. 
However, contrary to thyroid follicular cells, there are no long-term retention of iodide and 
TSH dependency. (Baril, Martin-Duque et al. 2010) The physiologic function of the NIS in 
the extrathyroidal tissues is not yet clear. 
3. Procedures for radioiodine whole body imaging 
3.1 Patients preparation 
Thyroid hormone replacement must be withheld for a sufficient time to permit an adequate 
rise of TSH (>30 uIU/mL). This is at least 2 weeks for triiodothyronine (T3) and 3–4 weeks 
for thyroxine (T4). This is also achieved by the administration of recombinant human TSH 
(rhTSH, Thyrogen®, given as two injections of 0.9 mg intramuscularly on each of two 
consecutive days) without stopping thyroid hormone replacement. rhTSH must be used in 
patients who may not have an elevation of TSH to the adequate level due to a large residual 
volume of functioning thyroid tissue or pituitary abnormalities, which precludes elevation 
of TSH. rhTSH might be used to prevent severe hypothyroidism related to the stopping of 
thyroid hormone replacement.(Silberstein, Alavi et al. 2005; Silberstein, Alavi et al. 2006)  
All patients must discontinue eating/using iodide-containing foods or preparations, and other 
medications that could potentially affect the ability of thyroid cancer tissue to accumulate 
iodide for a sufficient time before radioiodine administration. A low-iodine diet is followed for 
7–14 days before the radioiodine is given, as it significantly increases the uptake of radioiodine 
by the well differentiated thyroid cancer tissue. The avoided or permitted food items are 
summarized in table 1. The recommended time interval of drug withdrawal is summarized in 
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table 2. Imaging should be delayed for a long enough period to eliminate the effects of these 
interfering factors. The goal of a low iodine diet and the drug withdrawal is to make a 24-hour 
urine iodine output of about 50 ug.(Silberstein, Alavi et al. 2006). 
 
 Allowed Not-allowed 
Salts Non -iodized salt  Iodized salt Sea salt 
Fruits and 
vegetables Fresh fruits and juices 
Rhubarb 
Fruit or juice with red dye # 3 
Canned or preserved 
Seafood and 













Chocholate (has milk content) 
Paultries and 
Meats Fresh unsalted  Canned and processed 





breads, cereal and crackers without salt 
unsalted pasta, rice, rice cakes, and 
popcorn 
Breads, cereals or crackers made 
with salt 
Salted pasta, rice or popcorn 
drinks 
Cola, diet cola, lemonade  
Coffee or tea without milk or cream 
Fruit juice without red dye#3 
Fruit smoothies made without dairy or 
soy products 
Beer, wine and spirits 
Milk, cream or drinks made with 
dairy 
Fruit juice and soft drinks with 
red dye#3 
Table 1. Food guide for a low iodine diet. Some items on the allowed list may not be low in 
iodine in some forms or merchandise brands. The labels must be checked to be sure that the 
items meet the requirements of the low-iodine diet. (Amin, Junco et al.; Nostrand, Bloom et 
al. 2004) 
3.2 Types of radioiodine 
3.2.1 I-131  
I-131 is produced in a nuclear reactor by neutron bombardment of natural tellurium (Te-127) 
and decays by beta emission with a half-life of 8.02 days to xenon-133 (Xe-133) and it emits 
gamma emission as well. It most often (89% of the time) expends its 971 keV of decay energy 
 
12 Chapters on Nuclear Medicine 
 
4 
2.1 Iodine absorption and metabolism 
Ingested iodides are rapidly and nearly completely absorbed (>90%) from the duodenum 
into the blood and most of the iodides are excreted by kidneys. Sodium iodide symporter 
(NIS) on the apical membrane of enterocytes mediates active iodide uptake. Normally about 
one fifth of absorbed iodides are taken up by thyroid follicular cells and this is used for 
thyroid hormone synthesis, yet the clearance of circulating iodide varies with iodine intake. 
In the condition of an adequate iodine supply, ≤10% of absorbed iodides are taken up by the 
thyroid and in chronic iodine deficiency, this fraction can exceed 80%.(Zimmermann and Crill) 
The basal membrane of the thyroid follicular cell is able to actively transport iodide to the 
interior of the cell against a concentration gradient by the action of the NIS, which co-transports 
one iodide ion along with two sodium ions. The process of concentrating iodide in the thyroid 
follicular cells is called iodide trapping and presence of the NIS is essential for the process.(Hall 
2011) Thyroid hormones are produced by oxidation, organification and coupling processes in 
the thyroid gland and they are finally released into the blood stream for their action.   
2.2 Sodium iodide symporter 
The rat NIS gene and the human NIS gene were cloned in 1996.(Dai, Levy et al. 1996; 
Smanik, Liu et al. 1996) NIS is a 13 transmembrane domain protein with an extracellular 
amino- and intracellular carboxyl-terminus and the expression of the NIS gene is mainly 
regulated by thyroid stimulating hormone (TSH). Binding of TSH to its receptor activates 
the NIS gene transcription and controls translocation and retention of NIS at the plasma 
membrane, and so this increases iodide uptake. 
In addition to its expression in the thyroid follicular cells, NIS is detectable and active in 
some extrathyroidal tissues such as the salivary glands, gastric mucosa, lactating mammary 
glands, etc. Therefore, these tissues are able to take up iodide by the action of the NIS. 
However, contrary to thyroid follicular cells, there are no long-term retention of iodide and 
TSH dependency. (Baril, Martin-Duque et al. 2010) The physiologic function of the NIS in 
the extrathyroidal tissues is not yet clear. 
3. Procedures for radioiodine whole body imaging 
3.1 Patients preparation 
Thyroid hormone replacement must be withheld for a sufficient time to permit an adequate 
rise of TSH (>30 uIU/mL). This is at least 2 weeks for triiodothyronine (T3) and 3–4 weeks 
for thyroxine (T4). This is also achieved by the administration of recombinant human TSH 
(rhTSH, Thyrogen®, given as two injections of 0.9 mg intramuscularly on each of two 
consecutive days) without stopping thyroid hormone replacement. rhTSH must be used in 
patients who may not have an elevation of TSH to the adequate level due to a large residual 
volume of functioning thyroid tissue or pituitary abnormalities, which precludes elevation 
of TSH. rhTSH might be used to prevent severe hypothyroidism related to the stopping of 
thyroid hormone replacement.(Silberstein, Alavi et al. 2005; Silberstein, Alavi et al. 2006)  
All patients must discontinue eating/using iodide-containing foods or preparations, and other 
medications that could potentially affect the ability of thyroid cancer tissue to accumulate 
iodide for a sufficient time before radioiodine administration. A low-iodine diet is followed for 
7–14 days before the radioiodine is given, as it significantly increases the uptake of radioiodine 
by the well differentiated thyroid cancer tissue. The avoided or permitted food items are 
summarized in table 1. The recommended time interval of drug withdrawal is summarized in 
 
Physiologic and False Positive Pathologic Uptakes on Radioiodine Whole Body Scan 
 
5 
table 2. Imaging should be delayed for a long enough period to eliminate the effects of these 
interfering factors. The goal of a low iodine diet and the drug withdrawal is to make a 24-hour 
urine iodine output of about 50 ug.(Silberstein, Alavi et al. 2006). 
 
 Allowed Not-allowed 
Salts Non -iodized salt  Iodized salt Sea salt 
Fruits and 
vegetables Fresh fruits and juices 
Rhubarb 
Fruit or juice with red dye # 3 
Canned or preserved 
Seafood and 













Chocholate (has milk content) 
Paultries and 
Meats Fresh unsalted  Canned and processed 





breads, cereal and crackers without salt 
unsalted pasta, rice, rice cakes, and 
popcorn 
Breads, cereals or crackers made 
with salt 
Salted pasta, rice or popcorn 
drinks 
Cola, diet cola, lemonade  
Coffee or tea without milk or cream 
Fruit juice without red dye#3 
Fruit smoothies made without dairy or 
soy products 
Beer, wine and spirits 
Milk, cream or drinks made with 
dairy 
Fruit juice and soft drinks with 
red dye#3 
Table 1. Food guide for a low iodine diet. Some items on the allowed list may not be low in 
iodine in some forms or merchandise brands. The labels must be checked to be sure that the 
items meet the requirements of the low-iodine diet. (Amin, Junco et al.; Nostrand, Bloom et 
al. 2004) 
3.2 Types of radioiodine 
3.2.1 I-131  
I-131 is produced in a nuclear reactor by neutron bombardment of natural tellurium (Te-127) 
and decays by beta emission with a half-life of 8.02 days to xenon-133 (Xe-133) and it emits 
gamma emission as well. It most often (89% of the time) expends its 971 keV of decay energy 
 
12 Chapters on Nuclear Medicine 
 
6 
by transforming into the stable Xe-131 in two steps, with gamma decay following rapidly 
after beta decay. The primary emissions of I-131 decay are beta particles with a maximal 
energy of 606 keV (89% abundance, others 248–807 keV) and 364 keV gamma rays (81% 
abundance, others 723 keV). 
I-131 is administered orally with activities of 1–5 mCi or less, with many preferring a range 
of 1–2 mCi because of the data suggesting that stunning (decreased uptake of the therapy 
dose of I-131 by the residual functioning thyroid tissue or tumour due to cell death or 
dysfunction caused by the activity administered for diagnostic imaging) is less likely at the 
lower activity range. However, detection of more iodine concentrating tissue has been 
reported with higher dosages.(Silberstein, Alavi et al. 2006) 
 
Type of medication Recommended time interval of withdrawal 
Natural synthetic thyroid hormone 
    Thyroxine (T4) 
    Triiodothyroinine (T3) 
 
3 to 4 weeks 
10 to 14 days 
Amiodarone 3 to 6 months 
Multivitamine 6 weeks 
Lugol’s solution, potassium iodide solution 
(SSKI) 
6 weeks  
Topical iodine  6 weeks 
Radiographic contrast agents 3 to 6 months, depending on iodide content  
Iodinated eyedrops and antiseptics 6 weeks 
Iodine containing expectorants and anti-
tussives 
2 to 4 weeks 
Table 2. Recommended time intervals of withdrawal for drugs affecting radioiodine uptake. 
The time interval can be changed by the administered doses of the medications. The amount 
of iodine for the drug must also be considered.(Nostrand, Bloom et al. 2004; Silberstein, 
Alavi et al. 2005; Luster, Clarke et al. 2008)  
3.2.2 I-123 
I-123 is produced in a cyclotron by proton irradiation of enriched Xe-124 in a capsule and  
I-123 decays by electron capture with a half-life of 13.22 hours to Te-123 and it emits gamma 
radiation with predominant energies of 159 keV (the gamma ray primarily used for 
imaging) and 127 keV.  
I-123 is mainly a gamma emitter with a high counting rate compared with I-131, and I-123 
provides a higher lesion-to-background signal, thereby improving the sensitivity and imaging 
quality. Moreover, with the same administered activity, I-123 delivers an absorbed radiation 
dose that is approximately one-fifth that of I-131 to the thyroid tissue, thereby lessening the 
likelihood of stunning from imaging. I-123 is administered orally with activities of 0.4–5.0 mCi, 
which may avoid stunning.(Ma, Kuang et al. 2005; Silberstein, Alavi et al. 2006) 
3.2.3 I-124 
I-124 is a proton-rich isotope of iodine produced in a cyclotron by numerous nuclear 
reactions and it decays to Te-124 with a half-life of 4.18 days. Its modes of decay are: 74.4% 
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electron capture and 25.6% positron emission. It emits gamma radiation with energies of 511 
and 602 keV.(Rault, Vandenberghe et al. 2007)  
I-124 is administered intravenously with activities of 0.5–2.0 mCi for detection of metastatic 
lesions or assessment of the radiation dose related to I-131 therapy. 
 
Types Advantages Disadvantages 
I-131 
• Cheap 
• Readily available 
• Allows longer delayed image 
• Potential stunning 
• Requirement of possible radiation 
safety precautions for family and 
caregivers 
I-123 • No stunning 
• Good image quality 
• Limited availablity 
• Expensive 
I-124 
• Superior image quality 
• Tomographic image 
• Allows intermediate delayed 
image 
• Fusion image with CT or MR 
• Very limited availability 
• Very expensive 
Table 3. Advantages and disadvantages according to the types of radioiodine.(Nostrand, 
Bloom et al. 2004) 
3.3 Planar, SPECT and PET imaging 
3.3.1 Planar imaging 
Planar gamma camera imaging can be obtained with gamma emitting I-123 or I-131 for the 
detection of thyroid cancer tissue expressing the NIS gene which takes up iodine. The main 
emission energy peak of I-131 is approximately 364 keV, so it requires the use of a high-energy 
all-purpose collimator for imaging acquisition. The peak of the I-123 is 159 keV, which is close 
to the 140 keV from Tc-99m for which the gamma camera’s design has traditionally been 
optimized. I-123 can be imaged with a low-energy high-resolution collimator, which is 
optimized for image acquisition with Tc-99m. (Rault, Vandenberghe et al. 2007) 
With radioiodine’s avidity for differentiated thyroid cancer tissues, planar radioiodine 
whole body image has been mainly used for the detection of metastatic thyroid cancer 
lesions. However, the limited resolution of planar imaging together with the background 
activity in the radioiodine images can give false-negative results for small lesions. 
Physiologic uptake of radioiodine is not always easily differentiable from pathologic uptake 
and it can give false-positive results. (Spanu, Solinas et al. 2009) Therefore, the sensitivity 
and specificity of planar images for the diagnosis of metastatic thyroid cancer may be 
limited. (Oh, Byun et al. 2011) 
3.3.2 SPECT (Single Photon Emission Computed Tomography) or SPECT/CT imaging 
Although a radioiodine whole body scan is one of the excellent imaging tools for the 
detection of thyroid cancer, false negative results may be observed in cases with small 
recurrent lesions in an area of rather high background activity or in cases with poorly 
differentiated cancer tissues, which have low uptake ability for radioiodine (due to 
dedifferentiation).(Geerlings, van Zuijlen et al.) SPECT, which can provide cross-sectional 
scintigraphic images, has been proposed as a way to overcome the limitations of planar 
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scintigraphic images, has been proposed as a way to overcome the limitations of planar 
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imaging and it is known to have higher sensitivity and better contrast resolution than planar 
imaging. Radioiodine SPECT has higher performance for detecting recurrent lesion 
compared to planar imaging in thyroidectomized thyroid cancer patients and it also changes 
the patients’ management. 
Radioiodine SPECT has excellent capability to detect thyroid cancer tissues, yet the anatomic 
evaluation of lesion sites with radioiodine uptake remains difficult due to the minimal 
background uptake of the radioiodine. The performance of SPECT with radioiodine may be 
further improved by fusing the SPECT and CT images or by using an integrated SPECT/CT 
system that permits simultaneous anatomic mapping and functional imaging.(Geerlings, van 
Zuijlen et al.; Spanu, Solinas et al. 2009) The fusion imaging modality can synergistically and 
significantly improve the diagnostic process and its outcome when compared to a single 
diagnostic technique. (Von Schulthess and Hany 2008) Therefore, SPECT/CT with radioiodine 
can demonstrate a higher number of radioiodine uptake lesions, and it can more correctly 
differentiate between physiologic and pathologic uptakes, and so it permits a more 
appropriate therapeutic approach to be chosen.(Spanu, Solinas et al. 2009) Despite its many 
advantages, SPECT/CT cannot be applied for routine use or whole body imaging due to the 
long scanning time and the additional radiation burden, and so the fusion image should be 
selected on a personalized basis for those who clinically need the imaging. (Oh, Byun et al. 2011) 
3.3.3 PET (Positron Emission Tomography) or PET/CT imaging 
PET detects a pair of gamma rays produced by annihilation of a positron which is 
introduced by a positron emitting radionuclide and this produces three-dimensional image. 
Owing to its electronic collimation, I-124 PET gives better efficiency and resolution than in I-
123 or I-131 SPECT, and so it offers the best image quality. (Rault, Vandenberghe et al. 2007)  
A fusion imaging modality with I-124 PET and CT can improve the diagnostic efficacy when 
compared to I-124 PET imaging by the same reasons of SPECT/CT over SEPCT only. I-124 
PET/CT has superiority due to the better spatial resolution and faster imaging speed 
compared to I-123 or I-131 SPECT/CT.(Van Nostrand, Moreau et al. 2010) PET fused with 
MR is recently being used for research and in clinic fields and it will allow state of art 
imaging in the near future. 
4. Physiologic radioiodine uptake 
Following thyroid ablation, physiologic activity is expected in the salivary glands, stomach, 
breast, oropharynx, nasopharynx, oesophagus, gastrointestinal tract and genitourinary 
tract.(Ozguven, Ilgan et al. 2004) Physiologic radioiodine accumulation is related to the 
expression of the NIS and metabolism related to or the retention of excreted iodine. (Bakheet, 
Hammami et al. 2000; Ahn, Lee et al. 2011) Uptake of radioiodine in the thyroid tissue, salivary 
gland, stomach, lacrimal sac, nasolacrimal duct and choroid plexus is related to the NIS 
expression of the cells of the organs.(Morgenstern, Vadysirisack et al. 2005) Ectopic thyroid 
tissues are found by a variety of embryological maldevelopments of the thyroid gland such as 
lingual or sublingual thyroid (by failure of migration), a thyroglossal duct (by functioning 
thyroid tissue in the migration route) and a mediastinal thyroid gland (by excessive 
migration). Other abnormal migration may produce widely divergent ectopic thyroid tissue in 
many organs such as liver, oesophagus, trachea, etc. In addition, normal thyroid tissue can be 
in the ovary (Struma ovarii. It can be classified as uptake in a pathologic lesion.). (Shapiro, 
Rufini et al. 2000) Ectopic gastric mucosa can be located in the small bowel (Meckel's 
 
Physiologic and False Positive Pathologic Uptakes on Radioiodine Whole Body Scan 
 
9 
diverticulum) or terminal oesophagus (Barrett's oesophagus). (Ma, Kuang et al. 2005) The 
ectopic thyroid and gastric mucosal tissues are able to take up radioiodine.  
Uptake of iodine in the liver after radioiodine administration is related to the metabolism of 
radioiodinated thyroglobulin and thyroid hormones in the organ. The gall bladder also may 
occasionally be depicted with the biliary excretion of the radioiodine. (Shapiro, Rufini et al. 
2000; Carlisle, Lu et al. 2003) A simultaneous hepatobiliary scan with Tc-99m DISIDA 
(Diisopropyl Iminodiacetic Acid) or mebrofenin is useful for characterizing the gall bladder 
uptake. Tracer accumulation in the oropharynx, nasopharynx and oesophagus is related to 
retention of salivary excretion of administered radioiodine.  
Visualization of the oesophagus is extremely common and vertical linear uptake in the 
thorax that is removed by drinking water is characteristic of oesophageal uptake by 
swallowing of radioactive saliva. The oesophageal activity may also arise from gastric 
reflux. (Carlisle, Lu et al. 2003) Image acquisition after a drink of water is able to distinguish 
the activity from mediastinal node metastasis. (Shapiro, Rufini et al. 2000)  
Urinary or gastrointestinal anomalies can be responsible for false positive radioiodine uptake. 
(Ma, Kuang et al. 2005) Visualization of kidney and bladder after radioiodine administration is 
possible and this is known to be related to the urinary excretion of radioiodine into the urinary 
collecting system. Administered radioiodine is excreted mainly by the urinary system, and so 
all dilations, diverticuli and fistulae of the kidney, ureter and bladder may produce 
radioiodine retention.(Shapiro, Rufini et al. 2000) Visualizing the location of the renal pelvis of 
ectopic, horseshoe and transplanted kidneys is not usual and radioiodine at the pelvis may 
lead to misinterpretation. In fact, the renal pelvis and ureter are usually not visualized due to 
the rapid transit time of the radioiodine. (Bakheet, Hammami et al. 1996) A simultaneous renal 
scan with Tc-99m DTPA (Diethylene Triamine Pentaacetic Acid) or MAG3 (Mercapto Acetyl 
Triglycine) is useful for characterizing the urinary tract uptakes. (Shapiro, Rufini et al. 2000) 
Although the incidence is very uncommon, renal cysts are known to produce radioiodine 
uptake. The proposed mechanisms for the renal cyst uptake are a communication between the 
cyst and the urinary tract and radioiodine secretion by the lining epithelium of the cyst. 
(Shapiro, Rufini et al. 2000) 
Tracer accumulation in the colon is very common. Incomplete absorption of the oral 
radioiodine administration is not considered as the reason of colonic activity due to the lack 
of colonic activity seen on the early images. Tracer accumulation is probably due to 
transport of radioiodine into the intestine from the mesenteric circulation and biliary 
excretion of the metabolites of radioiodinated thyroglobulin. (Hays 1993) Appropriate use of 
laxatives can be a simple remedy for the activity. (Shapiro, Rufini et al. 2000) 
 
Fig. 3. Physiologic uptake of radioiodine in the nasal cavity, the so called "hot nose". Intense 
tracer uptake was noted at the thyroid bed area (due to residual thyroid tissue), breast and 
salivary gland (by the NIS expression of the glands).  
right lateral left lateralanterior
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imaging and it is known to have higher sensitivity and better contrast resolution than planar 
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Zuijlen et al.; Spanu, Solinas et al. 2009) The fusion imaging modality can synergistically and 
significantly improve the diagnostic process and its outcome when compared to a single 
diagnostic technique. (Von Schulthess and Hany 2008) Therefore, SPECT/CT with radioiodine 
can demonstrate a higher number of radioiodine uptake lesions, and it can more correctly 
differentiate between physiologic and pathologic uptakes, and so it permits a more 
appropriate therapeutic approach to be chosen.(Spanu, Solinas et al. 2009) Despite its many 
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diverticulum) or terminal oesophagus (Barrett's oesophagus). (Ma, Kuang et al. 2005) The 
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Uptake of iodine in the liver after radioiodine administration is related to the metabolism of 
radioiodinated thyroglobulin and thyroid hormones in the organ. The gall bladder also may 
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ectopic, horseshoe and transplanted kidneys is not usual and radioiodine at the pelvis may 
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Tracer accumulation in the colon is very common. Incomplete absorption of the oral 
radioiodine administration is not considered as the reason of colonic activity due to the lack 
of colonic activity seen on the early images. Tracer accumulation is probably due to 
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Fig. 3. Physiologic uptake of radioiodine in the nasal cavity, the so called "hot nose". Intense 
tracer uptake was noted at the thyroid bed area (due to residual thyroid tissue), breast and 
salivary gland (by the NIS expression of the glands).  
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Fig. 4. Physiologic uptake of radioiodine in residual thyroid tissue. Intense tracer uptake 
was noted at the thyroid bed area due to residual thyroid tissue.  
Lactating mammary glands express the NIS, and so the lactating breast shows intense 
radioiodine uptake that might persist for months after cessation of lactation. Mild to 
moderate uptake is also seen in non-lactating breast tissue, which can be asymmetrical, 
presumably owing to the same mechanism that operates in lactation.(Shapiro, Rufini et al. 
2000; Tazebay, Wapnir et al. 2000)  
Uptake of radioiodine can occur in a residual normal thymus or in thymic hyperplasia and 
the suggested mechanisms for the uptake are the expression of the NIS in thymic tissues and 
the iodine concentration by the Hassal’s bodies that are present in the thymic tissue, which 
resemble the follicular cells of the thyroid. Thymic radioiodine uptake is more common in 
young patients compared to older patients. Even though the incidence is very rare, an 
intrathymic ectopic thyroid tissue or thyroid cancer metastases to the thymus can be a 
possible cause of uptake. (Mello, Flamini et al. 2009) 
 
 
Fig. 5. Physiologic uptake of radioiodine in residual thyroid tissue. Intense tracer uptake was 
noted at the midline of the upper neck due to residual thyroid tissue in the thyroglossal duct. 
Mild tracer uptake of the salivary gland (by the NIS expression of the glands) was also noted. 
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Fig. 6. Physiologic uptake of radioiodine in both the parotid and submandibular salivary 




Fig. 7. Physiologic uptake of radioiodine in the breast. Diffuse, moderate radioactivity in the 
breast was noted. There was also noted physiologic tracer uptake in the thyroid bed 
(suggesting remnant thyroid tissue, which has the NIS expression), salivary glands (by the 
NIS expression of the glands), stomach (by the NIS expression of the glands), bowel (by 
secretion of radioiodine into the intestine or biliary excretion of the metabolites of 
radioiodinated proteins) and urinary bladder (by urine activity). 
 
 
Fig. 8. Physiologic uptake of radioiodine in the breast. Intense tracer accumulation was 
noted in both breasts. Physiologic tracer uptake was also noted in the thyroid bed 
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was noted at the thyroid bed area due to residual thyroid tissue.  
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Fig. 6. Physiologic uptake of radioiodine in both the parotid and submandibular salivary 




Fig. 7. Physiologic uptake of radioiodine in the breast. Diffuse, moderate radioactivity in the 
breast was noted. There was also noted physiologic tracer uptake in the thyroid bed 
(suggesting remnant thyroid tissue, which has the NIS expression), salivary glands (by the 
NIS expression of the glands), stomach (by the NIS expression of the glands), bowel (by 
secretion of radioiodine into the intestine or biliary excretion of the metabolites of 
radioiodinated proteins) and urinary bladder (by urine activity). 
 
 
Fig. 8. Physiologic uptake of radioiodine in the breast. Intense tracer accumulation was 
noted in both breasts. Physiologic tracer uptake was also noted in the thyroid bed 









Fig. 9. Physiologic uptake of radioiodine in the breast. Focal tracer uptake in the breast was 
noted. SPECT/CT revealed the accurate location of the breast uptake. Physiologic intense 
tracer uptake was noted in the thyroid bed (suggesting remnant thyroid tissue, which has 
the NIS expression) and mild tracer uptake in the liver (by metabolism of radioiodinated 
thyroglobulin and thyroid hormones). 
 
 
Fig. 10. Physiologic uptake of radioiodine in the oesophagus. Vertical linear radioactivity in 
the chest was noted by stagnation of swallowed saliva containing radioiodine. There was 
also noted physiologic tracer uptake in the thyroid bed area (by residual thyroid tissue) and 
salivary glands (by the NIS expression of the glands).  
 
 
Fig. 11. Physiologic uptake of radioiodine in the gall bladder. Intense tracer accumulation 
was noted at the GB fossa area on the whole body scan and SPECT/CT revealed accurate 
localization of the uptake. There was also noted physiologic tracer uptake in the thyroid bed 










Fig. 12. Physiologic uptake of radioiodine in the thymus. Diffuse, mild radioactivity in the 
mid-thorax was noted. There was also noted physiologic tracer uptake in the salivary glands 
(by the NIS expression of the glands) and oral cavity (by saliva containing radioiodine). 
 
 
Fig. 13. Physiologic uptake of radioiodine in the stomach. Intense tracer uptake was noted at 
the left upper quadrant of abdomen due to stomach uptake of the tracer. There was also 
noted tracer uptake in the oral cavity (radioactivity of secreted saliva), salivary gland (by the 
NIS expression of the glands), thyroid bed (suggesting remnant thyroid tissue, which has 
the NIS expression) and urinary bladder (by urine activity). 
 
 
Fig. 14. Focal radioiodine uptake was noted at the center of the abdomen. The uptake might 
be related to ectopic gastric mucosa in the Meckel’s diverticulum. There was also noted 
tracer uptake in the stomach (by the NIS expression of the gastric mucosa), oral cavity 
(radioactivity of the secreted saliva) and salivary gland (by the NIS expression of the glands).   
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was noted at the GB fossa area on the whole body scan and SPECT/CT revealed accurate 
localization of the uptake. There was also noted physiologic tracer uptake in the thyroid bed 










Fig. 12. Physiologic uptake of radioiodine in the thymus. Diffuse, mild radioactivity in the 
mid-thorax was noted. There was also noted physiologic tracer uptake in the salivary glands 
(by the NIS expression of the glands) and oral cavity (by saliva containing radioiodine). 
 
 
Fig. 13. Physiologic uptake of radioiodine in the stomach. Intense tracer uptake was noted at 
the left upper quadrant of abdomen due to stomach uptake of the tracer. There was also 
noted tracer uptake in the oral cavity (radioactivity of secreted saliva), salivary gland (by the 
NIS expression of the glands), thyroid bed (suggesting remnant thyroid tissue, which has 
the NIS expression) and urinary bladder (by urine activity). 
 
 
Fig. 14. Focal radioiodine uptake was noted at the center of the abdomen. The uptake might 
be related to ectopic gastric mucosa in the Meckel’s diverticulum. There was also noted 
tracer uptake in the stomach (by the NIS expression of the gastric mucosa), oral cavity 
(radioactivity of the secreted saliva) and salivary gland (by the NIS expression of the glands).   








Fig. 15. Physiologic uptake of radioiodine in the lacrimal sac. The uptake is known to be 
related to active iodine transport by the NIS at the lining epithelium of the sac. There was 
also noted intense tracer accumulation in the thyroid bed (by remnant tissue of the thyroid, 
which has the NIS expression) and oral cavity (by the radioactivity of secreted saliva) and 
minimal tracer uptake in the salivary glands (by the NIS expression of the glands). 
 
 
Fig. 16. Physiologic uptake of radioiodine in the liver. The uptake is known to be related to 
metabolism of radioiodinated thyroglobulin and thyroid hormones in the liver. There was 




Fig. 17. Physiologic uptake of radioiodine in the urinary bladder. Intense tracer uptake was 
noted at the suprapubic area by radioactive urine in the bladder. Tracer uptake was noted in 












Fig. 18. Physiologic uptake of radioiodine in a simple cyst of the right kidney. Focal tracer 
uptake was noted at the right side abdomen. The proposed mechanisms are communication 
between the cyst and the urinary tract and radioiodine secretion by the lining epithelium of 
the cyst. There was intense tracer uptake noted in the thyroid bed area (by the remnant 
tissue of the gland) and mild tracer uptake in the salivary gland (by the NIS expression of 
the glands). 
 
             
          (A)                                (B) 
Fig. 19. Physiologic uptake of radioiodine in the colon. Intense tracer uptake was noted at 
the colon. The suggested mechanisms for the uptake are transportation of radioiodine into 
the intestine from the mesenteric circulation and biliary excretion of the metabolites of 
radioiodinated thyroglobulin or thyroid hormones. There was also noted tracer uptake in 
(A) the oral cavity (by the radioactivity of secreted saliva), (B) the salivary glands (by the 
NIS expression of the glands) and stomach (by the NIS expression of the gastric mucosa).   
5. Pathologic lesions might show false positive radioiodine uptake 
A variety of pathologic lesions producing a false positive radioiodine whole body scan have 
been reported and contrary to the physiologic uptakes that usually do not create diagnostic 
confusion, they might be tricky enough to cause some patients to undergo unnecessary 
fruitless invasive surgical or high dose radioiodine treatment.(Mitchell, Pratt et al. 2000)  
The not uncommon pathologic lesions showing radioiodine uptake are cystic, inflammatory, 
non-thyroidal neoplastic diseases. Cystic lesions in various organs can accumulate 
radioiodine and the mechanism of the uptake is passive diffusion of the tracer into the cysts. 
Radioiodine accumulation in ovarian, breast and pleuropericardial cysts has been reported. 
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(Shapiro, Rufini et al. 2000) Effusion of the pleural, pericardial and peritoneal cavities can 
also have radioiodine uptake by the same mechanism.(Shapiro, Rufini et al. 2000)  
A variety of inflammatory and infectious disease can have radioiodine accumulation by 
increased blood flow that delivers increased levels of radioiodine to the site, and enhanced 
permeability of the capillary that increases diffusion of the tracer to the extracellular water 
space.(Shapiro, Rufini et al. 2000) Radioiodine accumulation in bronchiectasis, pulmonary 
aspergilloma, skin wound, arthritis, paranasal sinusitis, skin infection, myocardial infarction 
and dacryocystitis has been reported.(Shapiro, Rufini et al. 2000; Ahn, Lee et al. 2011)  
Even though only a minority of such lesions accumulate the tracer, a variety of non-
thyroidal neoplasms are also known to take up radioiodine. The suggested mechanisms are 
i) a tumour expression of the NIS, which actively accumulates the tracer and ii) increased 
vascularity and enhanced capillary permeability that might be secondary to the 
inflammatory response associated with the neoplasm.(Mitchell, Pratt et al. 2000; Shapiro, 
Rufini et al. 2000) Radioiodine accumulation in breast cancer, gastric adenocarcinoma, 
bronchial adenocarcinoma, bronchial squamous carcinoma, salivary adenocarcinoma, 
teratoma, ovarian adenocarcinoma and meningioma has been reported.(Shapiro, Rufini et 
al. 2000)  
Fortunately, false positive uptake on a radioiodine whole body scan can be interpreted with 
using the serum thyroglobulin value, which is very sensitive marker for residual or 
recurrent thyroid cancer. Therefore, the false positive uptake usually does not cause a 
diagnostic dilemma for experienced practitioners. The clinical features and other imaging 
studies can also help to distinguish the false positive pathologic lesions from true positive 





Fig. 20. Pathologic uptake of radioiodine in the bronchectatic lesions of both lungs. There 
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Fig. 21. Pathologic uptake of radioiodine in a pulmonary fungus ball. There was also noted 
tracer uptake in the thyroid bed area (by the remnant tissue of the gland) and the liver (by 
metabolism of the radioiodinated thyroglobulin and thyroid hormones). 
 
 
Fig. 22. Pathologic uptake of radioiodine in a skin wound. There was tracer uptake in the left 
lower leg where the skin wound was located. There was tracer uptake in the salivary gland 
(by the NIS expression of the glands), thyroid bed (by the remnant tissue of the gland) and 
the liver (by metabolism of the radioiodinated thyroglobulin and thyroid hormones). 
6. Contaminations by physiological secretions 
External contamination by physiological or pathological body secretions or excretions can 
cause positive radioiodine uptake and this mimics metastatic involvement of differentiated 
thyroid cancer.(Bakheet, Hammami et al. 2000) Sweat, breast milk, urine, vomitus and nasal, 
tracheobronchial, lacrimal, salivary secretions and faeces contain radioiodine and their 
contamination on the hair, skin or clothes can be misinterpreted as metastasis of thyroid 
cancer.(Shapiro, Rufini et al. 2000) Any focus of radioiodine uptake that cannot be explained 
by physiological or pathological causation must also be suspected as arising from 
contamination by secretions. Fortunately, the contaminations are usually easily recognized by 
their pattern and acquiring images after removing the contamination with decontaminating 
procedures and with taking the stained clothes off. However, unusual patterns of 
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Patients' peculiar physical characteristics or odd habits produce extraordinary 
contamination patterns. Uptake in the scalp or a wig has been reported in patient with 
excessive sweating, and contamination of a wig was reported in patient with a bizarre habit 
of styling hair with sputum.(Bakheet, Hammami et al. 2000) False positive scans due to 
contamination can be kept to a minimum by careful preparation of patients, such as image 
acquisition in a clean gown after taking a shower. 
Contaminations are almost always superficial, (Carlisle, Lu et al. 2003), therefore, the use of 
lateral and/or oblique views to give a third dimension to the scan may help to identify the 
contamination. Furthermore, the SPECT image alone or the SPECT image fused with the 
anatomical image, which provides detailed information about the anatomic location of the 
radiotracer uptake sites, can be the best way to correctly determine that contamination is the 
reason for the uptakes.  
 
 
Fig. 23. Cases with contaminations at the hair and scalp. A case with unilateral hair 
contamination by saliva and cases with uni- or bilateral scalp contamination by excessive 




Fig. 24. Contamination at the right posterior chest wall by excessive perspiration. There was 
also noted intense tracer accumulation in the thyroid bed (by remnant tissue of the thyroid 
and edema of the cervical soft tissue). 
anterior 
right lateral left lateral
posterior 
 





Fig. 25. Contamination at the skin of the right upper arm. There was also noted intense 
tracer accumulation in the rectum and moderate tracer accumulation in the descending 
colon and the liver. 
 
 
Fig. 26. Vanishing contaminations after cleansing the right forearm, both thighs and right 
foot. There was also noted intense tracer accumulation in the thyroid bed area and colon 
and moderate tracer accumulation in the liver. 
 
 Sites of uptake Mechamism of radioiodine uptake 
Physiologic 
Residual thyroid tissue thyroid bed Active radioiodine uptake by expression of the NIS 
Ectopic normal thyroid 
tissues 
Lingual thyroid  
mediatinal thyroid 
Intratracheal thyroid 
Paracardiac thyroid  
Intraheaptic thyroid
Active radioiodine uptake by the 
expression of the NIS 
Salivary gland Parotid and submandibular salivary glands 
Active radioiodine uptake by the 




Ocular and periocular area 
Active radioiodine uptake by the 
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 Sites of uptake Mechamism of radioiodine uptake 





Oesophageal stricture or scarring 
Achalasia 
Focal accumulated saliva with 
radioiodine activity from the salivary 
glands  
By nasal secretion Nose "hot nose" Focal accumulated nasal secretion with radioiodine 




Urinary tract diverticulum 
Urinary tract fistula 
Renal cyst* 
Accumulated urine radioiodine 
activity excreted by the kidneys 
* Active radioiodine uptake by the 
expression of the NIS can be another 
mechanism 
Choroid plexus Brain Active radioiodine uptake by the expression of the NIS 
Thymic uptake Thymus 
Expression of the NIS in thymic 




Gastric duplication cyst 
Meckel‘s diverticulum 
Barrett esophagus 
Active radioiodine uptake by the 
expression of the NIS 





Translocation of excreted gastric 







Metabolism of radioiodinated thyroid 
hormones or thyroglobulin and their 
excretion into the gall bladder and 
bowels via the biliary tract 
Breast Breast, especially lactating Active radioiodine uptake by the expression of the NIS 
Colon Diffuse and/or focal (any part of colon) 
Transport of radioiodine into the 
intestine from the mesenteric 
circulation and biliary excretion of the 




tissue Struma ovarii 
Active radioiodine uptake by the 













Fungal infection (eg, aspergilloma) 
Increased perfusion and vasodilation, 
and enhanced capillary permeability 
by the inflammation 
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 Sites of uptake Mechamism of radioiodine uptake 









Active radioiodine uptake by the NIS 
of the tumor and/or incresed blood 
flow and enhanced capillary 
permeability in the tumor 
Trauma Biopsy site Tracheostomy site 
Increased perfusion and vasodilation, 
and enhanced capillary permeability 
by the tissue trauma 
Contaminations 
Tear 
Skin of any part of the body, hair, 
wig, cloth, etc 
Contamination by physiological or 








Table 4. Causes of radioiodine uptake not related to thyroid cancer on the radioiodine whole 
body scan.   
 
 
Fig. 27. Schematic presentation for the locations of physiologic uptake and possible 
contamination sources the radioiodine whole body scans. 
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A whole body scan obtained with the administration of a diagnostic or therapeutic dose of 
radioiodine has a definite role in the management of patients with well differentiated 
thyroid cancer after total thyroidectomy. Accurate interpretation of the scan requires a 
thorough knowledge and understanding of potential confounding factors for uptakes on the 
scan, and recognition of the variable causes of false positive uptake will provide correct 
prognostic inferences and prevent inappropriate therapeutic interventions. In addition, the 
cause of radioiodine uptake on the scan is always evaluated in conjunction with the serum 
thyroglobulin level and the clinico-radiological results in order to lessen the chance of an 
incorrect conclusion about the uptakes. 
This chapter was written to make readers consider a broad variety of diseases as the causes 
of the uptake on the radioiodine whole body scan and I have demonstrated a wide variety 
of causes of false positive uptakes on these scans.  
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1. Introduction 
Internal radiation dosimetry has a fundamental and growing role in planning nuclear 
medicine therapies with radionuclides. 
The principle of nuclear medicine therapy is to destroy pathologic tissues through the 
irradiation with the ionizing radiation emitted by properly chosen radionuclides, while 
preserving other organs and tissues from unnecessary exposure to the same radiation. 
In order to realize this result, proper pharmaceuticals are chosen with a biodistribution 
targeted on target tissues, and labelled with a suitably chosen radionuclide. The choice of the 
best radionuclide is carried on with the aim of maximizing radiation energy deposition in the 
target tissue during the desired treatment time. Beta-emitters are the best choice in most cases, 
because beta radiation has a mean range in tissue from few millimetres to few centimetres. 
Also used are alpha- and Auger-emitters, for millimetre and sub-millimetre ranges. 
The absorbed dose to the target tissues as well as to other organs and tissues depends from 
the biokinetics of the radiopharmaceutical and from the physical decay scheme of the 
radionuclide employed. While the physical properties of each nuclide are well known from 
experimental data, the biodistribution of the radiopharmaceutical within the patient's body 
depends on the dynamic biologic pathway that in turns is governed by the role of the 
molecule, by the characteristics of the patient, by the type and stage of the disease, and by 
the route of administration.  
The distribution of radioactivity within the human body must be sampled several times 
post-administration, by means of planar or tomographic (SPECT or PET) imaging 
techniques. Tomographic techniques are rapidly substituting planar whole body imaging, 
since, thanks also to the accurate attenuation correction and image co-registration brought 
by a simultaneous CT scan, they reach a spatial resolution and an accuracy in activity 
quantification unprecedented. 
After a general introduction on dosimetric quantities and their relationships, we focus on 
the dosimetric anthropomorphic models. We introduce also 3D techniques based on voxel 
dose factors, convolution of dose point-kernels and direct Monte Carlo computation, 
focusing on the contribution of Monte Carlo simulation to the development of new and 
more accurate dosimetric and microdosimetric models for internal dosimetry. 
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We describe the application of such dosimetric approaches in the main nuclear medicine 
therapies such as the 131I therapy of thyroid diseases, the therapy of neuroendocrine 
tumours (NET) with somatostatin analogues labelled with beta- or Auger-emitters, and the 
palliation of painful bone metastases, focusing on dose-efficacy relationships and on the 
limiting of side effects to other potentially critical organs. 
2. Definitions 
If we consider a radioactive volume containing, at the time t, N radioactive nuclei, we know 
that the activity A(t), representing the number of decays per second, is proportional to N 
through the decay constant λ: 
 ( ) dNA t = = λN
dt
−                     (1) 
Equation 1 can be integrated, leading to the exponential decay law for the number of radio-
atoms present at the time t in a radioactive sample: 
 λt0N = N e
−                                    (2) 
The decay constant λ is related to the decay time τ and to the half-life T1/2 by the 
relationships: 
 1/2
ln2 ln2T = = τ
λ
                                (3) 
The SI unit of activity is the Becquerel (Bq), defined as one disintegration per second: 
 11 1Bq = dis s−⋅ , (4) 
while the old unit of activity was the Curie (Ci): 
 101 3.7 10Ci = Bq×  (5) 
The radiation absorbed dose, commonly intended as dose, is defined as the average energy 
imparted by the radiation per unit mass of the irradiated volume: 
 dED =
dm
                                (6) 
In the SI system, the dose is expressed in joules per kilogram or Gray (Gy); the older unit, no 
longer employed but often encountered in aged texts, was the Rad (1 erg/g). The conversion 
is such that 1 Gy = 100 Rad. 
In internal dosimetry, the dose to an organ or tissue accumulating a radiopharmaceutical 
can be evaluated following the MIRD approach (Snyder et al., 1975).  
The dose imparted to a target volume k from a single source volume h, can be calculated as: 
 ( ) ( )k h h k hD r r = A S r r← ←                    (7) 
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where hA  is the cumulated activity in the source organ and S is the average dose absorbed 
by the target per unit cumulated activity in the source. The cumulated activity in h is 
defined as the total number of disintegrations in that organ, i.e. the integral of the activity A 
over the time: 
 ( )
0
h hA = A t dt
∞
∫  ,                       (8) 
The definition of the S factor appearing in Equation 7 is: 
 ( )










      (9) 
where Δi is the average energy emitted per transition as i-th radiation, φi is the “absorbed 
fraction”, i.e. the fraction of the energy emitted in the source volume rh which was absorbed 
in the target volume rk, and mk is the mass of the target. 
In general, if several organs accumulate the radiopharmaceutical, the overall dose to the 
target volume (organ or tissue) k is obtained by summing up all the contributions coming 
from the various regions h: 
 ( ) ( )/k h i i k h h
h i
D r = A ΔΦ r r m←∑ ∑                  (10) 
Another usually employed quantity is the residence time, defined as the ratio between the 








Even if the residence time has the physical dimensions of a time and it is often indicated 
with the same Greek letter, it must not be confused with the decay time of a radionuclide. In 
fact, while the decay time is the time necessary to reduce by 1/e = 0.37 the activity of an 
isolated sample, the residence time is the length of time an activity A0 would have to reside 
in the volume to give that cumulated activity.  
3. Radiobiological models of the radiation effects 
The estimation of the effect of the radiation absorbed dose in biological tissues can not 
neglect biological models accounting for the ability of tissues and cells to repair in some 
degree the radiation-induced injury. (Cremonesi, 2011; Strigari, 2011) 
The radiation damage can vary due to the different tissue properties (the “five Rs” of 
radiobiology: repair, repopulation, reoxigenation, redistribution and intrinsic radiosensitivity) in 
tumours and in healthy tissues, and due to the difference in possible irradiation regimes 
(type and energy of the radiation, dose rate, repetition or fractionation of treatments). 
In nuclear medicine therapies with radiopharmaceuticals, the radiation dose is often 
imparted by beta or Auger electrons, even if the role of alpha emitters as therapeutic agents 
is increasing again. 
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Thus, the dose and the dose rate in the single treatment are governed by the biokinetics of 
the radiopharmaceutical and by the administered activity and route of administration.  
The biological effect of such irradiation in tumours and in healthy tissues will depend firstly 
on the repair ability of the sub-lethal damage with related repair time Trep, which is due to 
the mechanisms that counteract all the natural damages to the DNA. This is the fastest 
mechanism influencing the response to irradiation, since its effects are detectable in external 
irradiations already after 30 minutes. 
The cell life cycle is divided in four consecutive steps: G1, S, G2 and M. The two gaps of 
apparent inactivity, G1 and G2, divide the two active phases, the DNA synthesis S and the 
mitosis M. Radiobiology studies demonstrated that the highest cell radiosensitivity belongs 
to G2 and M phases. After an irradiation,  the survival fraction will be higher for cells in the 
G1 or S phases; thus a redistribution of population is initiated, with a synchronization of cell 
life cycles. 
This effect could, in principle, play a certain role in external irradiations repeated at the 
times of higher sensitivity, but no clear evidence of efficacy has been demonstrated yet. 
Cells surviving to an exposure to radiations will continue to proliferate; such a repopulation 
has a detrimental effect on therapeutic results. On the other hand, tumour cell death leads to 
tumour tissue shrinkage and, consequently, can improve the reoxigenation of the residual 
hypoxic cells. Since hypoxic cells are more radio-resistant than the oxygenated ones, 
repeated cycles of irradiation are useful to improve therapeutic outcomes. 
As a consequence of these mechanisms, the effect of a radiation therapy depends not only 
on the radiation absorbed dose, but also on the dose rate and on the fractionation regime. 
The most widely applied radiobiological model describing cell survival after irradiations is 
the linear-quadratic model, in which the effect E, in logarithmic relation with the surviving 
fraction SF, is a function of the dose D and the dose squared: 
 ( )log 2E = SF = D + βDα−  (12) 
The linear component accounts for the lethal cell damage given by a single radiation 
producing, for example, double-strand breaks of the DNA helix, while the quadratic 
component accounts for the lethal damage obtained by summing up the effects of two 
consecutive ionizing radiations. It should be noticed that the parameter α has dimensions of 
Gy-1, while β of Gy-2. The dose in correspondence of which the linear contribution L equals 
the quadratic one Q (see Fig. 1), is given by D= α/β (Gy). This value expresses the intrinsic 
radiosensitivity of the tissue, and external as well as internal radiation therapies exploit the 
higher radiosensitivity of cancer cells with respect to normal tissue cells. 
When the radiation dose is imparted in a time T comparable or even longer than the repair 
time of the sub-lethal damage, Trep, Eq. 12 must be corrected in order to account for the 
competition between radiation-induced damage and cell repair rate: 
 ( ) ( )log 2E = SF = D + g T βDα−  (13) 
where g(T) is a properly chosen function of the irradiation time. When T>>Trep, as in the case 
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where Teff is the effective half-life of the radionuclide in the target tissue. 
 
 
Fig. 1. Cell surviving fraction as a function of the radiation dose, following the linear-
quadratic (LQ) model. Linear (L) and quadratic (Q) part of the equation are represented, too. 
In the proposed example, α/β = 25 Gy. 
The Biologically Effective Dose (BED) is defined in a way such that the effect E is linearly 
related to BED through the parameter α: 
 E = BEDα  (15) 
From Eq. 13, BED is related to the cell surviving fraction and to the dose with the 
relationships: 
 ( ) ( ) 21 log βBED = SF = D + g T D
α α
−    (16) 
For radionuclide therapies, Eq. 14 holds for the correction factor g, resulting, for a single 
irradiation imparting a radiation dose D: 
 2rep
rep eff
TβBED = D + D
T + Tα
 (17) 




TβBED = D + D
T + Tα∑ ∑  (18) 
In the next Sections, we will see how BED is related to the impairment of kidneys after 
repeated cycles of peptide radio-receptor therapies (PRRT) with somatostatin analogues 
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labelled with beta-emitting radioisotopes. In such evaluations, it is usually assumed α/β = 
2.4 Gy and for Trep a value of 2.8 hours. 
4. Time sampling and determination of the cumulated activity 
In Section 2, the main equations of internal dosimetry were introduced, and the role played 
by the cumulated activity, i.e. the total number of disintegrations in the considered target, 
was taken in evidence. 
In general, the biokinetics of a radiopharmaceutical within the human body will be 
influenced by the type of the carrier molecule and its physiologic and pathologic pathway, 
by the route of administration and by the preparation and clinical state of the patient. 
Clinical studies and trials give information about the average residence times of groups of 
patients, but, in order to plan the single treatment, only an accurate individualized 
dosimetry can be usefully employed. 
In order to calculate the cumulated activity, the activity up-taken in each organ or region of 
interest must be properly sampled after administration. In principle, more measurements 
allow a more accurate fit of the A=A(t) curve, and, consequently, a better estimation of the 
total number of disintegrations. 
However, we must remember that each measurement is carried out through planar 
scintigraphic or emission computed tomography (ECT) techniques, which are time 
consuming for both patient and hospital personnel. 
Even in the case of non-imaging techniques, such as thyroid uptake measurements with a 
scintillation probe, the patient must come back to the nuclear medicine department for each 
measurement. 
Hence the need to optimize dosimetric protocols in order to the number and timing of the 
acquisitions. The optimal choice will depend on the expected biokinetics of the 
radiopharmaceutical in the organs of interest, which can be assumed from previous clinical 
studies. 
The simplest model applies when the uptake phase, i.e. the phase in which the 
radiopharmaceutical is accumulating in the organ and its radioactivity rises with time, is 
short enough to be considered instantaneous. Consequently, immediately after 
administration, the washout phase begins.  
If, in the simplest assumption, the radiopharmaceutical is washed out with a mono-
exponential rate, the variation of N with time follows a law analogous to Eq. 1: 
 eff
dN = λ N
dt
 (19) 
where the effective decay constant eff bioλ = λ + λ  is given by the sum of the physical decay 
constant introduced in Eq. 1 and the biological decay constant, characteristic of the 
biological wash-out of the radiopharmaceutical from the organ. In analogy with Eq. 3, the 
effective decay time τeff and the effective half-life Teff can be defined as: 
 ln2 ln2eff eff
eff
T = = τ
λ
 (20) 
and the cumulated activity will be: 
 







t AA = A e dt =
λ
∞ −
∫  (21) 
In more complex cases, the uptake phase can require a certain amount of time and, 
consequently, the assumption of instantaneous uptake must be released and the uptake 
phase can be usually described by an exponential growth. Furthermore, the washout phase 
can be not accurately described by a simple mono-exponential decay. For example, a bi-
exponential curve can fit better to a biokinetical behaviour composed by a first phase of 
rapid clearance in which the biologic half-life is much smaller than the physical half-life, 
followed by a slower retention phase in which, on the contrary, it is the physical half-life 
that governs the overall effective half-life. 
In Figure 2, an example of near-instantaneous uptake, followed by a washout phase 
described by a bi-exponential decay, is shown. The renal uptake of a diagnostic dose of 111In-
DTPA-Octreotide, a somatostatin analogue used for the diagnosis of neuroendocrine 
tumours, was imaged at 1, 6, 24 and 48 hours post-injection. 
 
 
Fig. 2. Uptake curves for kidneys in four patients after 111In-DTPA-Octreotide intravenous 
administration. 
In Figure 3 we present three examples of 131I uptake curves for hyperthyroid patients (pt. 1 
and 2 affected by toxic nodular goitre, TNG, and the third by Basedow disease), acquired by 
means of a scintillation probe at six times after oral administration of a diagnostic activity of 
1.8 MBq.  
In these cases, the uptake phase is expected to last up to one day, followed by a decay phase 
with a characteristic half-life of 100-200 hours, deriving from both physical (eight days) and 
biological decay. 
Thanks to the simplicity and rapidity of thyroid uptake measurements with a gamma probe, 
it is possible to sample properly in time these patients. Usually, two measurements during 
the first day, 3 and 6 hours after oral administration, properly characterize the uptake phase. 
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labelled with beta-emitting radioisotopes. In such evaluations, it is usually assumed α/β = 
2.4 Gy and for Trep a value of 2.8 hours. 
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Measurements can proceed at 24, 48, 72 (or 96, or 120) and 168 hours, in order to detect the 
maximum uptake and the decay phase. 
Points can be then fitted with the function: 
 ( ) ( )in outin
out in





where the uptake and washout constants λin and λout depend upon the rapidity of the 
increase and decrease in uptake, respectively. 
Even if the maximum uptake is expected, on average, around 24 hours, this is not a rigid 
rule, of course. Patient 3, for example, reached the maximum uptake already at the sixth 
hour, and the fit of patient 1 data show its maximum earlier than 24 hours; cases of late 
maxima are observed, too. 
In order to evaluate properly the effective half-time of the washout phase, measurements 
should extend at least up to 120 hours, better up to 168 hours. In fact, since each point is 
affected by statistical fluctuations and by minor biases due to the practical procedure, 
repeated measurements help in reducing errors in fit.  
As an example, in Figure 3 we represent, together with the fits of the whole data series (solid 
lines), the fits obtained by considering only the first four points, i.e. 3, 6, 24 and 48 hours 
(dashed lines). 
It is apparent from figure the underestimation of the decay time for the first patient, and, on 
the contrary, the overestimation for the second one. 
Such outcome is confirmed numerically by the results reported in Table 1, where the 
effective half-time of the washout, Teff, is calculated from the decay constants obtained from 
the complete fit and from the 3-48 hours data. Results from incomplete data give a 24% 
shorter half-time for the first patient, while for the second one an overestimation as high as 
91% comes from a dosimetric protocol limited to 48 hours. 
 
 
Fig. 3. 131I uptake curves for the three patients. Solid curves represent the analytical fits of 
complete data series with Eq. 22, dashed lines represent fits of 3-48 hours data. 
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Pt. no. Umax λin λout λout(48h) Teff Teff(48h) error 
1 (TNG) 23184 0.184 7.41E-3 9.72E-3 93 71 -24% 
2 (TNG) 16755 0.142 5.62E-3 2.95E-3 123 235 +91% 
3 (Bas.) 35920 0.740 4.42E-3 4.66E-3 157 148 -6% 
Table 1. Fit parameters for the complete data series, and for the first four points. Relative 
error in Teff determination are reported. 
5. Anthropomorphic models for internal dosimetry 
In the past decades, several schematic anthropomorphic models were proposed in order to 
standardize and simplify dose calculation both in medical applications of radionuclides and 
in internal contamination evaluations for radiological protection purposes. 
Among these, a common approach to internal dosimetry is based on standardized phantoms 
and S factors pre-calculated for couples of Source-Target organs and for various 
radionuclides (Snyder et al., 1975). 
Organ S factors were calculated through Monte Carlo simulations and are currently 
available in a tabular form. As a consequence, once calculated the cumulated activity in the 
source organ with the methods described in the previous Section, the dose to the target 
organ is calculated with Equation 7, using the proper S factor accounting for the 
radionuclide emission and for the geometry of the source-target couple. 
An advantage of this method is the simplicity of measurements and the standardization of 
the dosimetric procedure, allowing easier comparisons between results. However, the 
simplified organ models, described by fixed geometrical shapes and volumes, do not 
account properly for the anatomy of the single patient. Furthermore, each organ is treated as 
a whole, neglecting inhomogeneity in the uptake within each organ or tissue. 
In real cases, the shape and size of an organ can be varied by a disease, and pathologic 
tissues, which are the target of the treatment, are not present in standard models of healthy 
humans.  
A sphere model is often employed in order to represent small target tissues such as tumours 
or pathologic lymph-nodes. Recently, we developed a model to calculate the absorbed 
fractions in ellipsoidal shapes uptaking beta-gamma emitting radionuclides (Amato et al. 
2009, 2011). 
Considering a radionuclide which emits mono-energetic and beta electrons, and gamma 
photons, the average dose to the target volume is given by: 
 ( ) ( ) ( )β e γ e,i e,i e,i γ,i γ,i γ,i
i
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where ne and nγ are the mono-energetic electron and gamma photon emission probabilities, 
respectively, of energies Ee and Eγ , φe and φγ are the electron and photon absorbed fractions. 











where ρ is the “generalized radius”, defined as: 
 
12 Chapters on Nuclear Medicine 
 
32
Measurements can proceed at 24, 48, 72 (or 96, or 120) and 168 hours, in order to detect the 
maximum uptake and the decay phase. 
Points can be then fitted with the function: 
 ( ) ( )in outin
out in





where the uptake and washout constants λin and λout depend upon the rapidity of the 
increase and decrease in uptake, respectively. 
Even if the maximum uptake is expected, on average, around 24 hours, this is not a rigid 
rule, of course. Patient 3, for example, reached the maximum uptake already at the sixth 
hour, and the fit of patient 1 data show its maximum earlier than 24 hours; cases of late 
maxima are observed, too. 
In order to evaluate properly the effective half-time of the washout phase, measurements 
should extend at least up to 120 hours, better up to 168 hours. In fact, since each point is 
affected by statistical fluctuations and by minor biases due to the practical procedure, 
repeated measurements help in reducing errors in fit.  
As an example, in Figure 3 we represent, together with the fits of the whole data series (solid 
lines), the fits obtained by considering only the first four points, i.e. 3, 6, 24 and 48 hours 
(dashed lines). 
It is apparent from figure the underestimation of the decay time for the first patient, and, on 
the contrary, the overestimation for the second one. 
Such outcome is confirmed numerically by the results reported in Table 1, where the 
effective half-time of the washout, Teff, is calculated from the decay constants obtained from 
the complete fit and from the 3-48 hours data. Results from incomplete data give a 24% 
shorter half-time for the first patient, while for the second one an overestimation as high as 
91% comes from a dosimetric protocol limited to 48 hours. 
 
 
Fig. 3. 131I uptake curves for the three patients. Solid curves represent the analytical fits of 
complete data series with Eq. 22, dashed lines represent fits of 3-48 hours data. 
 
Internal Radiation Dosimetry: Models and Applications 
 
33 
Pt. no. Umax λin λout λout(48h) Teff Teff(48h) error 
1 (TNG) 23184 0.184 7.41E-3 9.72E-3 93 71 -24% 
2 (TNG) 16755 0.142 5.62E-3 2.95E-3 123 235 +91% 
3 (Bas.) 35920 0.740 4.42E-3 4.66E-3 157 148 -6% 
Table 1. Fit parameters for the complete data series, and for the first four points. Relative 
error in Teff determination are reported. 
5. Anthropomorphic models for internal dosimetry 
In the past decades, several schematic anthropomorphic models were proposed in order to 
standardize and simplify dose calculation both in medical applications of radionuclides and 
in internal contamination evaluations for radiological protection purposes. 
Among these, a common approach to internal dosimetry is based on standardized phantoms 
and S factors pre-calculated for couples of Source-Target organs and for various 
radionuclides (Snyder et al., 1975). 
Organ S factors were calculated through Monte Carlo simulations and are currently 
available in a tabular form. As a consequence, once calculated the cumulated activity in the 
source organ with the methods described in the previous Section, the dose to the target 
organ is calculated with Equation 7, using the proper S factor accounting for the 
radionuclide emission and for the geometry of the source-target couple. 
An advantage of this method is the simplicity of measurements and the standardization of 
the dosimetric procedure, allowing easier comparisons between results. However, the 
simplified organ models, described by fixed geometrical shapes and volumes, do not 
account properly for the anatomy of the single patient. Furthermore, each organ is treated as 
a whole, neglecting inhomogeneity in the uptake within each organ or tissue. 
In real cases, the shape and size of an organ can be varied by a disease, and pathologic 
tissues, which are the target of the treatment, are not present in standard models of healthy 
humans.  
A sphere model is often employed in order to represent small target tissues such as tumours 
or pathologic lymph-nodes. Recently, we developed a model to calculate the absorbed 
fractions in ellipsoidal shapes uptaking beta-gamma emitting radionuclides (Amato et al. 
2009, 2011). 
Considering a radionuclide which emits mono-energetic and beta electrons, and gamma 
photons, the average dose to the target volume is given by: 
 ( ) ( ) ( )β e γ e,i e,i e,i γ,i γ,i γ,i
i





∑∫ , (23) 
where ne and nγ are the mono-energetic electron and gamma photon emission probabilities, 
respectively, of energies Ee and Eγ , φe and φγ are the electron and photon absorbed fractions. 











where ρ is the “generalized radius”, defined as: 
 






where V and S are the volume and surface of the ellipsoid. The parameters ρ0 and s in 
Equation 24 depend on the nature (electron or photon) and energy of the radiation, and can 
be derived from proper parametric functions described in (Amato et al. 2009, 2011). 
In Figure 4, the absorbed fraction as a function of the generalized radius is reported for 
photons and electrons uniformly emitted in ellipsoids of various shapes. These data are 
calculated by means of a Monte Carlo simulation in Geant4. 
 
 
Fig. 4. Electron and photon absorbed fraction in ellipsoidal volumes, as a function of the 
generalized radius (Amato et al. 2009, 2011). 
6. Three-dimensional dosimetry 
Traditional approaches to internal dosimetry employ anatomic models to obtain mean 
organ doses. With the diffusion of SPECT-CT and PET-CT tomographs,  dosimetric methods 
which can utilize non-uniform activity distributions to derive dose distributions within 
organs become increasingly important.  
This result can be obtained either with dose point-kernel convolution methods, or by means 
of a direct Monte Carlo simulation, or exploiting the voxel S factor approach. 
The voxel S factor approach, introduced in (Bolch et al., 1999), has been used more widely 
than dose point-kernel and direct Monte Carlo computation approaches, due to its 
recognized simplicity. 
Following this approach, the average dose to the k-th voxel can be calculated as: 
 k h k hD = A S ←⋅∑  (26) 
where hA  is the cumulated activity in the generic h-th voxel and k hS ←  is the voxel S factor, 
defined as: 
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where iΔ  is the mean energy emitted as radiation i per decay, iφ  is the absorbed fraction in 
k of the radiation i emitted in h, and mk is the mass of the k-th voxel. 
In (Bolch et al., 1999), voxel S factors were tabulated for five radionuclides and two cubic 
voxel sizes. Recently, Dieudonnè et al. (2010) presented a generalization of this approach to 
variable voxel sizes, which allows to obtain S factors for a generic voxel size for nine 
radionuclides by means of a resampling method. 
The dose point-kernel gives the dose per decay event at a given distance from a point source 
located inside an infinite and homogeneous absorbing medium. Dose point-kernels for 
electrons and photons were calculated by means of Monte Carlo simulations, and are 
available either in tabular form or as analytical functions obtained fitting the simulative data 
(Mainegra-Hing et al., 2005) (Maigne et al., 2011).  
By convolving the dose point-kernels evaluated for the actual radionuclide spectrum in the 
three-dimensional distribution obtained from the volume distribution of cumulated activity, 
obtained from SPECT-CT or PET-CT images, one can retrieve the volume distribution of the 
absorbed dose. In order to speed up calculations, fast Fourier or fast Hartley transformations 
can be employed. 
Finally, the Monte Carlo approach is the most demanding in terms of computational power, 
but it is the only one which can account accurately for tissue inhomogeneity. Known the 
three-dimensional map of tissue density and composition from CT scan and the volume 
distribution of the cumulated activity through SPECT or PET emission tomography, it is 
possible to generate a fixed number of decay events statistically distributed in space 
according to emission tomography data within the patient’s body reconstructed from CT 
and track all the emitted secondaries in order to calculate the geometrical distribution of 
energy deposition, i.e. the three-dimensional map of absorbed dose, and finally to rescale 
the results to the actual values of cumulated activity (Furhang et al., 1997). 
7. 131I therapy of hyperthyroidism 
Hyperthyroidism is a consequence of an excess in free-thyroid hormone action on the 
tissues. The most frequent causes of hyperthyroidism are: Graves' Disease (GD), Toxic 
Adenoma (TA) or Toxic Multinodular Goiter (TMG). In any cases, hyperthyroidism can be 
caused by sub-acute thyroiditis or silent thyroiditis. 
The treatment of GD, TA and TMG can be symptomatic with anti-thyroid drugs (often used 
as first line therapy) or definitive: radioiodine therapy (RaIT) or surgery (total or near-total 
thyroidectomy). 
RaIT is a well established method for the treatment of hyperthyroidism; aim of the RaIT is to 
achieve an euthyroid or hypothyroid (such as in the Graves patients) status. 
Presently, the optimal 131I activity to be administered is still matter of debate.  
Many authors evaluated the effectiveness of different dosimetric methodologies. The results 
were variable and often controversial, in order to the frequency of recurrence and 
hypothyroidism (Regalbuto et al., 2009) (Giovannella, 2000). 
In order to determine the 131I activity to be administered for the treatment of 
hyperthyroidism, fixed activity and adjusted activity approaches are currently employed. In 
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both cases it is necessary, if possible, to suspend anti-thyroid drugs treatment 4-6 days 
before RaIT or thyroid scintigraphy. 
The 131I “fixed”activity for RaIT is usually about 555 MBq. In such case, the thyroid 
scintigraphy with or without radioiodine thyroid uptake (RTU) curve can be not necessary. 
In the adjusted activity approach, a dosimetric procedure is employed which requires two 
diagnostic steps: a) thyroid ultrasonography to calculate the volume of the gland, or the hot 
thyroid nodule(s), assuming for them an ellipsoidal shape; b) thyroid scintigraphy and RTU 
measurements after 131I tracer activity administration (1.8 MBq).  
The dosimetric method most frequently employed was proposed by the MIRD commission 
(Snyder et al., 1975). In this approach, RTU measurements are usually conducted between 3 
and 120 hours after administration. Multiple RTU measurements allow to calculate the 
effective half-life of the radioiodine into the hot nodules or in the whole gland (Figure 3).  
In TMG and TA patients, the effective volume of the hot nodule(s) was calculated taking 
into account the presence of involving area(s) (whole nodule volume - involving area 
volume). 
The radiation doses to be imparted to the gland (GD) or to the nodule(s) (TA and TMG) are 
up to 200 and 300 Gy, respectively. 
In GD with ophtalmopathy, the radiation dose to be imparted must be adjusted, up to a 
maximum value of 250 Gy. In these patients, it is useful to administer anti-inflammatory 
drugs for a time duration ranging from 4 to 12 weeks after RaIT. 
In all patients, the choice of the therapeutic dose will be determined also in function of: sex 
and age, type of hyperthyroidism (overt or sub-clinical) and its temporal duration, 
concomitant Hashimoto thyroiditis, anti-thyroid drugs therapy and its temporal duration. 








where A is the activity to be administered in MBq in order to impart a dose D in cGy to the 
target (nodule or gland) of mass m in g, Umax is the maximum per cent radioiodine uptake 
(usually measured at 24 hours) and T1/2eff is the effective half-time in hours. 
Recently, Amato et al. (2011) proposed an improved calculation method for the activity to be 
administered during the radioiodine treatment of hyperthyroidism. In this approach, a 
Monte Carlo simulation had been employed to derive the radiation dose in nodules or in the 
whole gland within an anthropomorphic phantom, taking into account the ellipsoidal shape 
of the target volumes. 
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where we recall the definition of generalized radius, ρ=3V/S, stated in Equation 12, and 
here expressed in cm. The volume and the surface of the ellipsoidal target (nodule or 
thyroid lobe) can be calculated from the semiaxes measured through ultrasonography as: 
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8. 131I therapy of differentiated thyroid carcinoma 
Differentiated thyroid cancer (DTC) is the most common cancer of the endocrine system. 
The first line therapy is represented by total or near-total thyroidectomy (with dissect of the 
sixth lymph nodes level and, if necessary, of the lateral-cervical lymph nodes of the same 
side respect to primary lesion). 
After Total or near-Total Thyroidectomy (nTT) it is useful to ablate the thyroid remnant 
with 131-radioiodine therapy (RaIT). In fact, several Authors, such as Mazzaferri et al. (1997) 
demonstrated that the prognosis quod vitam and the survival curve of the DTC-patients 
significantly improve if RaIT follows TT or NTT. 
In addition, the ablation of thyroid remnant (TRA) allows a better management of the 
follow-up of these patients. 
In fact, in the patients treated with TT or NTT and TRA, the Thyroglobulin (hTg) serum 
levels should be undetectable. Thus, any enhancement of hTg serum (both under L-T4 
suppressive therapy or after exogenous TSH stimulation -rhTSH-) can be considered as a 
relapse of disease. 
RaIT can be carried out in hypothyroidism state (TSH>=30) or after rhTSH stimulation. 
Post dose whole body scan and static images of the head, neck and thorax acquired 4-8 days 
after RIT allow to identify the thyroid remnant and metastases (loco-regional and/or distant). 
For the RaIT of TRA, fixed activities are employed more frequently: 1110, 2220 or 3700 MBq. 
In the patients treated after rhTSH stimulation it is necessary to employ a medium-to-high 
activity of radioiodine (2220 and 3700 MBq, respectively), because in this condition the 
effective half-life of radioiodine in the thyroid remnant is shorter than in the state of 
hypothyroidism. 
However, the TRA activity can be adjusted through a dosimetric approach (Lassmann, 
2010), which requires a pre-therapeutic scintigraphy with 131I or 124I PET. The dose to the 
thyroid remnant can be calculated using 131I post-therapy whole body scan, too. 
Both methods show advantages and disadvantages. The main disadvantage of the pre-
therapeutic scintigraphic method is correlated to the stunning or mass change effects that 
could be determined by a diagnostic activity of 131I. 
On the other hand, the main disadvantage of the post-therapeutic scintigraphic method is 
correlated to technical difficulties such as the limitations deriving from the gamma-camera 
dead time. 
The clinical evidence demonstrated that the dosimetry adjusted activities do not differ 
significantly from the fixed values. Thus, in the clinical practice, the dosimetric approach is 
not employed frequently. However, the dosimetric approach is useful for the treatment of 
loco-regional and/or distant metastases. 
Dosimetry is particularly useful in patients with lung and/or bone metastases, where 
standard activities can lead to a radiation dose imparted to the lesions lower than the 
necessary. In such cases, it is necessary to acquire some whole scans starting from 6-7 hours 
after radio-iodine therapy. (Eschmann et al., 2002) (Sgouros et al., 2004). 
9. Usefulness of radiopharmaceuticals for the palliation of painful bone 
metastases 
The development of bone metastases is commonly related to a serious reduction in quality 
of patient life because of pain occurrence and side effects of analgesics intake, especially 
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where A is the activity to be administered in MBq in order to impart a dose D in cGy to the 
target (nodule or gland) of mass m in g, Umax is the maximum per cent radioiodine uptake 
(usually measured at 24 hours) and T1/2eff is the effective half-time in hours. 
Recently, Amato et al. (2011) proposed an improved calculation method for the activity to be 
administered during the radioiodine treatment of hyperthyroidism. In this approach, a 
Monte Carlo simulation had been employed to derive the radiation dose in nodules or in the 
whole gland within an anthropomorphic phantom, taking into account the ellipsoidal shape 
of the target volumes. 






U T ρ ρ+
⋅  (29) 
where we recall the definition of generalized radius, ρ=3V/S, stated in Equation 12, and 
here expressed in cm. The volume and the surface of the ellipsoidal target (nodule or 
thyroid lobe) can be calculated from the semiaxes measured through ultrasonography as: 
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8. 131I therapy of differentiated thyroid carcinoma 
Differentiated thyroid cancer (DTC) is the most common cancer of the endocrine system. 
The first line therapy is represented by total or near-total thyroidectomy (with dissect of the 
sixth lymph nodes level and, if necessary, of the lateral-cervical lymph nodes of the same 
side respect to primary lesion). 
After Total or near-Total Thyroidectomy (nTT) it is useful to ablate the thyroid remnant 
with 131-radioiodine therapy (RaIT). In fact, several Authors, such as Mazzaferri et al. (1997) 
demonstrated that the prognosis quod vitam and the survival curve of the DTC-patients 
significantly improve if RaIT follows TT or NTT. 
In addition, the ablation of thyroid remnant (TRA) allows a better management of the 
follow-up of these patients. 
In fact, in the patients treated with TT or NTT and TRA, the Thyroglobulin (hTg) serum 
levels should be undetectable. Thus, any enhancement of hTg serum (both under L-T4 
suppressive therapy or after exogenous TSH stimulation -rhTSH-) can be considered as a 
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Both methods show advantages and disadvantages. The main disadvantage of the pre-
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could be determined by a diagnostic activity of 131I. 
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correlated to technical difficulties such as the limitations deriving from the gamma-camera 
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9. Usefulness of radiopharmaceuticals for the palliation of painful bone 
metastases 
The development of bone metastases is commonly related to a serious reduction in quality 
of patient life because of pain occurrence and side effects of analgesics intake, especially 
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opiates (Silberstein, 2001). Therapeutic options for pain palliation include systemic therapy 
with cytotoxic agents, diphosphonate therapy, external beam radiotherapy and radionuclide 
therapy. Diphosphonate therapy has become a possible option for the treatment of patients 
affected by bone metastases since a new generation of diphosphonate has been developed; 
using zoledronic acid, indeed, the clinical benefits of diphosphonate (skeletal complications 
reduction and analgesic effects on bone pain), previously limited to patients with bone 
metastases from breast cancer or lesions due to multiple myeloma, have been extended to 
patients with bone metastases secondary to a broad range of solid tumors (Berenson, 2005). 
However, diphosphonates achieve only a modest analgesic effect and are associated with 
some non-renal adverse effects (Hillner, 2003; Lewington, 1996). External beam radiotherapy 
is the therapy of choice in cases of a single site of pain. However, when multiple painful 
metastases have been developed, local field radiotherapy is less effective and hemibody 
radiotherapy is associated with a significant morbidity (Lewington, 1996). Furthermore, 
external beam radiotherapy is often not suitable for repeated treatments. On the other hand, 
bone-seeking beta-emitting radiopharmaceuticals represent an effective tool for pain 
palliation in patients with multifocal bone disease, and make it possible to perform multiple 
administrations (Lam, 2004; Daformou, 2001; Englaro, 1992; Maini, 2003). Pain arises from 
both umoral and mechanical effects, including bone invasion, micro-fractures, increased 
intramedullary pressure and periosteal stretching (Lewington, 2005). Unlike opiates, which 
affect the entire nervous system, radionuclides exert their action mainly on cells at the 
peripheral nerve endings, where inflammatory, immune and malignant cells accumulate 
and release chemicals that modulate pain at the site of malignant invasion (Krishnamurthy, 
2000). Furthermore, early response gene induction and a psychological-placebo component 
could account for the pain alleviation effect (Lewington, 1996; Leondi, 2004; Roche, 1994; 
Hellmann, 1994).  
The goals of therapy are to alleviate pain, improve quality of life and mobility, reduce 
dependence on narcotic and non-narcotic analgesics, and improve performance status and 
possibly survival (Minutoli, 2006; Hindorf, 2011). 
Bone tumours can be divided into osteolytic and sclerotic tumours. Sclerotic tumours are 
more suitable for targeted radionuclide therapy because of higher uptake of the 
radiopharmaceutical within the lesions. The majority of bone metastases from prostate 
cancer are sclerotic whilst metastases of breast cancer generally are mixed 
osteolytic/sclerotic. Also patients with bone metastases from tumours other than prostate 
and breast cancer and increased 99mTc-MDP uptake on bone scan can benefit from targeted 
radionuclide therapy (Leondi, 2004; Minutoli, 2006).  
Two radiopharmaceuticals for the treatment of bone tumours are currently approved by the 
European Medicines Agency (EMEA): 153Sm-EDTMP (Quadramet®) and 89Sr-Cl2 (Metastron®). 
Other radiopharmaceuticals are at different stages of research, or are approved in some 
European Countries. These include 186Re-HEDP, 117mSn-DTPA and 223Ra-Cl2 (Alpharadin®). 
The use of 32P is now considered to be obsolete. 
Strontium-89 was suggested for the treatment of bone tumours during the 1940s. It is 
naturally taken up in bone and is a pure β- emitter with a long half-life (50.53 days). 
Pharmacokinetic and dosimetry studies have been based on imaging of 85Sr-Cl (Blake, 1986, 
1987, 1998; Breen, 1992), although imaging based on bremsstrahlung photons from 89Sr has 
also been performed (ICRP, 1997). Tumour dosimetry is generally performed under the 
assumption that the activity uptake is five times higher than for normal bone. Strontium 
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leaves the blood quickly after an intravenous injection. The kidneys are the main route of 
excretion, but the gut has been seen in scintillation camera images and IRCP report assumes 
4:1 ratio for urinary to faecal excretion. 
Tin-117m labelled DTPA is investigated for the treatment of bone pain from metastases. Tin-
117m can be imaged via the 156 keV gamma photons and the main energy deposition is 
performed by the corresponding conversion electrons. The conclusion from a phase I/II 
clinical study was that 117mSn-DTPA is an effective and safe radiopharmaceutical for the 
treatment of bone metastases (Krishnamurthy, 1997; Srivastava, 1998). 
153Sm-EDTMP is a therapeutic agent consisting of radioactive samarium and a 
tetraphosphonate chelator, ethylenediaminetetramethylenephosphonic acid (EDTMP). It is 
formulated as a sterile, non-pyrogenic, clear, colorless to light amber isotonic solution of 
samarium-153 lexidronam for intravenous administration (37 MBq/kg body weight) (Bodei, 
2008). Onset of pain relief comes within one week, lasting from four weeks up to four 
months. The highest absorbed dose is received by bone marrow and bone surfaces. Imaging 
is commonly performed three hours after injection to verify the activity uptake. All activity 
not taken up in bone is excreted via urine and no further activity is excreted 24 hours after 
the injection. Dosimetry can therefore be performed from one scintillation camera imaging 
acquired 24h after injection or from one single probe measurement. The activity uptake in 
bone has been reported  to increase with an increase in number of bone tumors (Farhangi, 
1992; Brenner, 2001). 
Renium-186 is a beta minus emitter with a maximum beta energy of 1.07 MeV. The physical 
half-life is 89 hours. The radiopharmaceutical is taken up in bone via the phosphor complex 
HEDP (hydroxyethylidene diphosphonate). Quantitative imaging for pharmacokinetics and 
dosimetry is possible via the emission of 137 keV photons with a 9.47% probability. 
Excretion is predominantly through the kidneys.  
Radium-223-chloride is taken up in bone by natural affinity. It decays in six steps into stable 
207Pb. The injected activity has been reported as 46-250 kBq per kg of whole body weight 
(Nilsson, 2005, 2007). A clinical phase II study showed an improved survival without severe 
toxicity after four weekly injections of 50 kBq per kg of whole body weight compared to 
placebo injections (Nilsson, 2007). The photon emissions at 81.1 keV and 83.8 keV show the 
highest emission probabilities and offer the best opportunity to perform quantitative 
imaging during the treatment, which enables pharmacokinetic and dosimetric studies to be 
performed. The main route of excretion is via faeces (Hindorf, 2008). 
Contraindications for radionuclide therapy are a life expectancy shorter than four weeks, 
severe renal insufficiency, and low blood counts due to a compromised bone marrow 
function. The absorbed dose to the tumour is the factor that determines the effectiveness of 
the therapy while the absorbed dose to the bone marrow correlates to the toxic effects 
received. The bone marrow is the dose limiting organ when bone-seeking 
radiopharmaceuticals are used (Lewington, 1993). Radionuclide therapy for pain palliation 
from bone metastases is currently performed based on a pre-set injected activity. The 
patients will, therefore, receive a range of absorbed doses due to individual differences in 
the pharmacokinetics. Voxel based, patient specific dosimetry automatically takes into 
account individual differences in pharmacokinetics and macroscopic anatomy. Furthermore, 
Monte Carlo simulations also take into account different cross sectional interaction data for 
all materials present in the body, which is, therefore, more accurate than convolution with a 
dose point kernel as this is based on an assumption of infinite, uniform medium. 
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Radionuclide therapy as a palliative treatment of bone pain is efficient, although improved 
dosimetry methods could help to improve the treatment further.  
10. Peptide radio-receptor therapy of neuroendocrine tumours 
Neuroendocrine tumours (NETs) derive from the neuroendocrine cell system, which is 
widely distributed in the body, and are a heterogeneous group of neoplasms characterized 
by embryological, biological and histo-pathological differences. The most frequent sites of 
NETs are the gastrointestinal tract (70%) and the bronco-pulmonary system (25%), followed 
by the skin, the adrenal glands, the thyroid and the genital tract.  
Present classification is based on tumour biology and patho-histological features (cellular 
grading, primary tumour size and site, cell proliferation markers, local or vascular 
invasivity and the production of biologically active substances), which are crucial to guide 
the diagnostic work-up and therapeutic planning.  
The great majority are benign (well-differentiated neuroendocrine tumours) or slow-
growing  neoplasms with a low grade of malignancy. Poorly differentiated endocrine 
carcinomas have a high grade of malignancy and a poor prognosis. Furthermore, a few 
moderately differentiated tumours with cellular and structural types intermediate between 
well and poorly differentiated NETs have also been found. 
A typical feature of differentiated NETs is the expression of several specific receptors on the 
cell membrane and in particular of somatostatin receptors (SSTR) which can be visualized 
by somatostatin receptor imaging with radiolabelled somatostatin analogues (111In-
OCTREOSCAN, 68Ga-DOTANOC). These radiopharmaceuticals bind with high affinity to 
subtypes 2, 5 and 3 of SSTR and provide an approximation of somatostatin receptor density, 
having a positive predictive value of the therapeutic efficacy of the somatostatin analogues.  
Peptide receptor radionuclide therapy (PRRT) is an effective tool for the treatment of 
tumours with a high somatostatin receptor density. 
This approach is based on the administration of a therapeutic activity of radiolabelled 
somatostatin analogues. Radiopharmaceutical with various radionuclides and peptides are 
currently available.  
High activities of 111In-DTPA-octreotide (OCTREOSCAN®), the same radiopharmaceutical 
used for imaging, have been used in pilot trials and in some experiences (Herberg, 2009, 
2011). Besides the gamma radiation of 111In used for scintigraphic scans (γ photons of 172 
and 245 keV),  its therapeutic effect is due to the emission of Auger and conversion electrons 
with a medium-to-short tissue penetration range (0.02-10 and 200-500 μm, respectively). Its 
potential effect depends on the preservation of mechanism of octreotide-receptor complex 
internalization (through endocytosis) and its translocation to the nuclear compartment, 
where short path-length Auger or conversion electrons are able to reach the target (DNA). In 
clinical trials, 111In-DTPA-octreotide showed a low rate of tumour regression: the most 
accredited explanation is that 111In electrons fail to reach the DNA helix, possibly due to the 
lack of nuclear receptors that were never definitely demonstrated (Kwekkeboom, 2005). 
The radiopeptides for PRRT that have been studied most extensively are 90Y-DOTATOC and 
177Lu-DOTATATE. These beta-emitting radiolabelled peptides are preferred for their 
advantageous physical properties. 
90Y (Emax = 2.28 MeV, Rmax = 11 mm, <E> = 0.935 MeV; half-life 2.67 days) has a pure beta 
emission with long range particles that, besides the direct action, lead to irradiation also of 
no-receptor expressing tumour-cell (cross-fire effect). For these reasons 90Y-peptides are 
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preferred especially for the treatment of larger and inhomogeneous  lesions. In figure 5, the 
comparison between electron paths within small and large inhomogeneous lesions is 
represented through a Monte Carlo simulation in Geant4, in which radiations emitted from 
177Lu and 90Y are compared. 
177Lu has a longer half-life (6.7 days) and lower energy beta-emission (Emax = 0.497 MeV; 
Rmax = 2 mm) that allows to concentrate all the energy inside smaller tumours; moreover the 
gamma-emission of 177Lu (113 keV and 208 keV) is suitable for scintigraphy and dosimetry 
during PRRT.  
 
 
Fig. 5. Comparison between the high-energy electron tracks (red) of 90Y and the ones of the 
lower-energy electrons from 177Lu. Photons originating from gamma ray emission or 
bremsstrahlung are represented in green. 
Concerning peptides, several new somatostatin analogues have been introduced for 
therapeutic and diagnostic purposes, including the agonists DOTA-(1-NaI3)octreotide 
(DOTANOC) and DOTA-(BzThi3)octreotide (DOTABOC).  
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These compounds have a broader somatostatin receptor affinity profile than DOTATATE 
and DOTATOC because of a higher affinity for sst3 and sst5 in addition to their high affinity 
for sst2. This could increase the number of tumours that could benefit from PRRT in the 
future.  
Recently, peptides targeting all the sst receptors (pansomatostatins) have shown high 
affinity of 90Y-DOTA-cyclo(D-diaminobutyric acid-Arg–Phe–Phe-D-Trp–Lys–Thr–Phe) (90Y-
KE88) for all 5 sst receptors and, in future, they could improve the therapeutic potential of 
sst-targeted PRRT. 
To date, the therapy administration protocols rely essentially on empirical criteria with 
injection of standard activities, as derived from escalation studies or clinical experience, at 
variable time intervals (6-12 weeks).  
For therapy optimization and prevention of toxicity, dosimetry represent a precious guide, 
providing evaluation of biodistribution, pharmacokinetics, radiation doses  and biological 
effective doses to healthy organs and tumours.  
The gamma-emission of 111In and 177Lu-peptide enable imaging, dosimetry and therapy with 
the same compound.  In the case of 90Y-peptide, for the lack of gamma emission, the same 
analogue radiolabeled with 111In or positron emitters as 86Y or 68Ga can be used as surrogates 
for dosimetric imaging. Some recent studies have been published for 90Y-peptide dosimetry 
with bremsstrahlung images through SPECT-TC systems, or exploiting the rare positron 
decay of 90Y imaged by new generation PET-CT scanners.  
A dosimetric protocol consists in the acquisition of multiple planar whole-body (WB) scan to 
obtain biokinetics data over the time (at least 4-5 acquisitions at different times), 
complementary SPECT imaging to evaluate intra-organ activity distribution (especially at 
the level of the kidneys and in tumour lesion), WB transmission imaging for attenuation 
correction, blood and urine samples. Anatomical imaging (CT or ultrasonographic) provide 
important parameters for organ mass evaluation (Cremonesi, 2011).   
Dose calculation can be performed in the framework of the MIRD formalism, in order to 
obtain average dose estimates at the organ level assuming standard phantom models, with 
possible organ mass adjustments according to patient data. Voxel dosimetry method or 
direct Monte Carlo simulation can provide more reliable dose estimates.   
Pharmacokinetic studies have shown fast blood clearance and urinary elimination. The 
higher uptake has been noticed in the spleen, kidneys and liver and no uptake is visible in 
the bone marrow in normal conditions. Pharmacokinetic data of different radiopeptides are 
similar but not identical: as the peptide influences biokinetics, for the single patient the data 
need to be assessed specifically with regard to the radiopharmaceutical.  
Furthermore, dosimetric data should be collected during therapeutic cycles because many 
factors can influence the results. 
The adsorbed doses, especially with regards to the tumour, are affected by wide intra-
patient variation between treatment cycles.  The adsorbed dose to the tumour is higher 
during the first two cycles with a gradually reduced uptake in the following treatments, 
probably due to saturation or down-regulation of peptide receptors. Tumour adsorbed dose 
should exceed 100 Gy to obtain a therapeutic  effect, with better results for higher doses 
(about 230 Gy).  
Nephrotoxicity is the dose-limiting factor, due to renal reabsorption and retention of 
radiolabeled peptides that results in high kidney radiation doses.   
The renal adsorbed dose is influenced by the radionuclide emission: using a microdosimetry 
model, Konijnenberg et al. (2004) found that 111In- and 177Lu-labelled somatostatin analogues 
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are likely to have higher renal toxicity thresholds than 90Y, whose emitted electrons have a 
path length of 12 mm.  
Renal doses can be reduced by co-administration of basic amino acids, bovine gelatine-
containing solution Gelofusine or albumin fragments, which interfere with the radiopeptide 
reabsorption pathway to achieve kidney protection. Amino acids, in particular, are already 
commonly used in the clinical setting during PRRT, being able to reduce the kidney 
adsorbed dose consistently (25-65% with respect to baseline data). The dose fraction 
markedly influences the total tolerated dose. 
The dose to kidneys should not exceed a limit value of 28 Gy, established for external beam 
radiotherapy, which results in a 50% probability of developing severe late renal failure. 
Nevertheless, for the difference between the two radiation therapy modalities, this 
recommendation has been questioned and the biological effective dose (BED) is considered 
a more accurate quantity, with a good correlation with the loss of kidney function.  
BED for a given organ or tissue was defined in Equation 18. We recall that BED is a function 
of the doses imparted in each PRRT cycle, and depends upon the effective half-time of the 
radiopeptide in the organ and upon its intrinsic radiosensitivity. 
Data in literature show that patients with risk factors, such as hypertension and diabetes, 
should not receive a BED higher than 28 Gy, while patients with no risk factors might have a 
renal BED threshold of 40 Gy (Bodei, 2008).  
The risk of bone marrow toxicity increases with increasing therapeutic dose. Studies aimed 
to increase the therapeutic dose (more cycles, higher dose per cycle, improvement in specific 
activity of the compound) to the tumour in a renoprotective (and bone marrow-protective) 
regimen are needed to further improve PRRT with somatostatin analogues in the future. 
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Medical Cyclotron 
Reina A. Jimenez V 
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Venezuela  
1. Introduction  
In this chapter we intend to illustrate the reader about the use of Cyclotrons to produce easy 
handle radioisotopes, to be used for medical diagnostics or therapies in Nuclear Medicine. 
Firstofall, we will describe different activation processes to generate artificial radioisotopes, 
characteristics needed to be safely used in medicine, such as the relationship between 
fathers and daughters that can compromise patient or environment health. It also will be 
describe radioisotopes desire behavior inside human body in order to clarify which isotopes 
can be activated or not in a cyclotron facility to be used in human medical applications.  
Nuclear Medicine radioisotopes must fulfill four main characteristics in order to be easy 
handle by operators and be easily and quickly disposed by patients and not to represent 
environmental radioactive contamination harm, so they have to have:   
1. Low activity 
2. Low energy 
3. Short half life 
4. Decay to a stable daughter 
In Nuclear Medicine, equipment also has to have a high sensitivity to small amounts of 
radiation and to different types of radioisotopes. The ideal radioisotopes must be easily 
eliminated by the patient just after the study has been done in a short period of time which 
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divided into two big groups: Linear accelerators and spiral path accelerators or Cyclotrons.  
The radioisotopes used in Medicine can be from natural ocurrences like 137Cs (used in the 
last century in Teletherapy machines and in low dose rate brachytherapy) or 192Ir (used 
nowadays in high dose rate brachytherapy), or can be produced in Reactors or Cyclotrons. 
Most common reactor products used in Medicine are: 
For diagnostic purposes: 51Cr, 125I, 131I, 59Fe, 42K, 177Lu, 99Mo (fission product), 75Se, 24Na, 
99mTc, 133Xe (fission product), 159Yt. 
For therapeutic purposes: 213Bi, 60Co, 165Dy, 169Er, 125I, 131I, 192Ir, 212Pb, 177Lu, 103Pd, 32P, 188Re, 
186Re, 153Sm, 89Sr (fission product), 90Y (fission product). 
For diagnostic and therapeutic or other purposes: 60Co, 166Ho, 125I, 99Mo (fission product), 177Yt. 
Most common radioisotopes produced in Cyclotrons used in Medicine are: 
For diagnostic purposes: 11C, 13N, 15O, 18F, (PET studies), 64Cu, 67Ga, 68Ga, 111In, 123I, 124I, 
81mKr, 99Mo (activation product), 82Rb, 201Th. 
For therapeutic purposes: 67Cu. 
For diagnostic, therapeutic or other purposes: 57Co, 82Sr, 68Ge. All of them have to fulfill the 
four conditions mentioned above. 
Knowing all this restrictions radioisotope has to accomplish, to be safely used in human, 
now we can talk about the characteristics of a cyclotron to produce such an isotope. Later in 
this chapter we will describe such an installation regarding shielding, environmental safety, 
radiopharmacy lab, etc. 
In Venezuela, we start to install the first baby cyclotron for medical purposes on 2001, so our 
last section of this chapter is to illustrate how  this installation works and how its programs 
has been accomplish to the present date. 
2. Basic physics of particle activation   
“Particle activation” means “artificial radioactivity” or “man made radioisotopes”, far away 
from “natural radioactivity” which is a basic characteristic of our Universe, that has been 
present all over the universe history, and it contains only four natural decay series 
characterized by their numbers of nucleons  as is shown in Table 1., artificial radioactivity is 
a very young phenomena born in 20th century.  
 
Series Parent Nucleons Stable end 
THORIUM 232Th90 4n 208Pb82
NEPTUNIUM 237Np93 4n+1 209Bi83
URANIUM 238U92 4n+2 206Pb82
ACTINIUM 235U92 4n+3 207Pb82
Table 1. Natural decay series. 
Firstofalll we have to define radioactivity: It is a property of nature in which atoms have 
such a big amount of energy so they need to discharge it to the surrounding media. The aim 
of it is to become stable, i.e. have the less amount of energy need to exist, because atom 
stability is the more cost/efficiency retail in matter. Atom then has design some method to 
discharge energy and diminish it energy level to become stable. Radioactive atoms can emit 
some energy packs splitting them in pieces of several dimensions and energy content to 
reach its stability: 
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Fig. 1. Decay mode of radioactive atoms to reach stability.The action of atoms to split means 
mass and energy transfer to media. For example, in a 226Ra atom energy excess push it to 
split out a 42 He  nucleus (an alpha particle) and 1.4 MeV package of pure energy and another 
atom of 222Rn, so where there was one atom now there are three different species born out it 
mass and energy 
There are several methods for atoms to transfer energy to the media. Remember Einstein´s 
principle of , which means energy is matter and matter is energy. So in their 
attempt to become stable emits energy/matter to discharge it excess in several ways as in 
figure 1. 
And scientist began to use this atom fraction to hit different nucleus of known atoms and to 
observe which was the results of the reverse experiment.  
Back in 1929, Ernest Lawrence device a Cyclotron to fulfill his own need to generate high 
speed ions without needing high voltages he has not access to in Berkeley University. This 
history began 10 years before when Lord Rutherford used alpha particles coming from 
Madame Curie´s 226Ra as projectiles to impact a Nitrogen nucleus to transform it into Oxygen. 
 
 
Fig. 2. Lawrence´s illustration about Rutherford Experiment. 
Radiactive Atoms
Discharge
Heavy ions βα γ
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In the same line of thoughts, Lawrence needs more projectiles to study this new phenomena. 
That 15th century dream of turning Lead into Gold was now though to be possible. 
Radioisotopes not always decay to a stable daughter but they continue trying, emitting 
different kinds of particles until they reach stability. In the sake for such stability they 
transform themselves into a partner they “believe” is more stable: The fifteen Century 
“Transmutation of Matter” occurs not for lead to become gold but something alike. Men 
made transmutation, which arise to be only the modification of the “positive electricity in 
the atomic nucleus”, as Lawrence said.1 He described his method of accelerating particles in 
Cyclotron as “resonance method” or “method of multiple acceleration:  
 
 
Fig. 3. Lawrence description of Cyclotron accelerating method. 
Few time pass, until man used that newly produce radioactive material to treat and 
diagnoses different affections. John Lawrence, Ernest brother was the first to use his brother 
product 32P  to treat leukemia starting the medical applications of cyclotron products. 
Method of particle activation then, need  a Nuclear Reactor or an accelerator (Cyclotron, 
Syncrothron or Linac) to be produced: Nuclear Reactor is an installation in which big rod of 
natural occurring radioisotopes are set inside a pile with some stable, neutron absorbent, 
material. The radioisotopes (Th, U)  initiates a chain reaction, the stable rod (such as carbon 
(graphite)) are used to absorb chain reaction debris, in order to moderate the amount of 
energy (heat) that is produce by nuclear reactions.  
They are considered of two kinds: Power Nuclear Reactors which are dedicated to use the 
energy to produce electricity, for example, boiling water to move turbines with the steam 
and in this way produce electric power. Nuclear Research Reactors are used as a source of 
neutron of different energies to impact different atoms nuclei to become radioactive. In both 
cases they need the fission product from the original radioactive atom to undergo the chain 
reaction. For example, 235U absorb a neutron, it become 236U and this split into 92Kr and 141Ba 
with several neutron that can impact other 235U and become 236U to repeat the reactions. 
                                                                 
1 E.O.Lawrence:(1939) University of California: ”Artificial Radiactivity” speech. 
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Fig. 4. Materials for particle absorption in a Reactor. 
 
Fig. 5. Percentage of activation products worldwide coming from Reactors or Cyclotrons 
including medical, industry and research production. 
In the other hand, cyclotron are electrical machines that generates particle acceleration thru 
helping them  to undergo a circular or elliptical path in which particles gain energy by 
external manipulation of electric an magnetic fields.   
Cyclotrons comes from a bigger family of electrical machines called Accelerators, because 
the make particles to gain energy letting them gain kinetic energy by applying electrical and 
magnetic fields to the particle trajectory so it can absorb energy from the media where it is 
travelling. Back to high school physics we can understand easily how cyclotrons accelerate 
particles: you must remember that force in an electrical field is:  
 � � �� (1)  
And also you remember that when you have and electrical and magnetic fields you can 
write  
 �� � ���� � ���)    (2) 
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Fig. 6. Cyclotron schematics: a) ion input location, b) , c) Ion path. 
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Where q is the charge, v is the velocity and B is the magnetic field 
Or in its escalar form 
 � = ���    (3) 





Where m is the mass of the particle to be accelerated and r is the radius of the circular path. 
If you equal 3 with 4 you can obtain the radius you need for a particular energy you  
want 
� = ����  (5)
Velocity has two components, linear that is tangential to the spiral trajectory and angular 
that is about circular path cover by the particle, so  
 � = ��    (6) 
Where ω is the angular velocity and  
 � = 2��     (7) 
Where f is the angular frequency of the movement, so using 3 and 4 we can know about 
cyclotron frequency 
���
� = ��� (8)




Where V is the potential between the d´s where the particle gain energy 
�� = 2���  (10)
 ������� = �� = ��    (11) 
So  � = ���� = �� = 2��� and finally 
� = ��2�� (12)
And remembering Einstein, particles with this energies travels near speed of light 
� = ��2���� (13)
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With  
� � 1
�1 � �� ��⁄ �
 (14)
3. Methods of particle activation   
Alpha particle Bombardment: Using natural produced alpha particles light elements can be 
activated, and as far as Pottasium. Such projectile induce the emission of a proton, the 
liberation of energy and a transmutation, not all the transmutation products are radioactive 
Neutron Capture: Firstly observed when matter is bombarded with deuteron, which also 
involve the emission of a proton, as we will illustrate forward. 
4. Reaction of particle activation   
1. Nuclear Activation in Reactors:  
( ),n γ  Reaction: Radioactive capture: Undergo mostly by thermal neutron 
59 1 60
29 0 29Co n Co γ+ ⎯⎯→ +           (s=36 b) 
98 1 99
42 0 42Mo n Mo γ+ ⎯⎯→ +           (s=0.12 b) 
In such a reaction father and daughter are of the same chemical species so they cannot be 
separated, reason why the target must have a very high enrichment rate. 
( ),n α  Reaction followed by β- decay 
130 1 131 131
52 0 52 53Te n Te I
β γ
−
+ ⎯⎯→ ⎯⎯⎯→ +  
Tellurium and iodine are easily chemical separated  
( ),n p  Reaction: Neutron Capture 
32 1 32 1
16 0 15 1S n P H+ ⎯⎯→ +  
58 1 59 1
28 0 28 1Ni n Co H+ ⎯⎯→ +  
This is similar to the first reaction produced in his cyclotron that be named “neutron 
capture” despite he was using deuterium as projectile, he observed that neutron stayed 
inside target nuclear and the remaining mass was expel as a proton. 
( ),n α  Reaction: Light fission 
6 1 3 4
3 0 1 2Li n H He+ ⎯⎯→ +  




σ= Φ  
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Where: 
N1      = Atoms of the target 
Φ     = Neutron flux 
actσ = Activation cross section 
( )N t = Number of atoms activated in a time period elapsed t 







= Φ  
And the activity of the sample is: 
1A Nλ= = ( )(1 )act
tN t e λσ −Φ −  
t is the time of irradiation  in seconds 
A is the activity at the saturation value that is a function of reactor neutron flue at which 
target has been exposed. 
3. Nuclear reaction in cyclotron production 
( ),p n  Reaction 
18 1 18 1
8 1 9 0O H F n+ ⎯⎯→ +  
( ),d α  Reaction: 
20 18 4
10 9 2Ne F He+ ⎯⎯→ +  
( ),p α  Reaction 
14 1 11 4
17 1 6 2N H C He+ ⎯⎯→ +  
16 1 13 4
8 1 7 2O H N He+ ⎯⎯→ +  
( ),d n  Reaction 
14 2 15 1
7 1 8 0N H O n+ ⎯⎯→ +  
( ),2d n  Reaction 
68 2 65 0
30 1 31 12Zn H Ga n+ ⎯⎯→ +  
124 1 123 1
52 1 53 02Te H I n+ ⎯⎯→ +  
( ),2nα  Reaction 
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65 4 67 1
29 2 31 02Cu He Ga n+ ⎯⎯→ +  
5. Differences and similarities between reactors and cyclotrons 
Cyclotron is not the only way of activating matter. Going through history, side by side  
cyclotron development in America, Europe was devoted to the natural radioactive material 
discovered by many scientists, from Madame  Curie (1898), Pierre, Irene and also Joliot  till 
Enrico Fermi, Otto Hahn, Lise Meitner and Fritz Strassman (1939). Neils Bohr and Jhon A.  
Wheeler published their explanation of the method for moderating, “modulating”, chain 
reactions in a paper published only 2 days after WWII starts in 1939. The first reactor was 
then brought into criticality in Fermi´s Lab on December 2nd, 1942 in very controlled 
experiment including radiation safety and protection considerations. Proving that chain 
reaction can be controlled, it was matter of time to find uses for the products obtain from a 
nuclear reactor. The neutron from reactors are projectiles for many (n,p), (n,β), reactions to 
produce many radioisotopes. So time has come to begin talking about which of all this 
radioactive products can be used in medicine. The first radioactive material used in humans 
with medical purposes was 226Ra, (1898) used by Madame and Mousier Curie to treat skin 
lesion they called “benign”. Their daughter Irene used 214Bi to measure blood flow, this two 
products come directly from the 238U natural decay series. By the artificial radioisotopes 
side, the first one was that 32P John Lawrence (1929) used to treat leukemia.  After of it, a lot 
of radioisotopes and a lot of uses have been developed for diagnostic and therapy uses,  so 
for this time,  we can say that the radioisotopes used in Medicine distributions is as it is 
shown in Table 2: 
 






133Xe, 99Mo 51Cr, 125I, 131I, 89Sr, 153Sm, 
59Fe, 177Lu, 42K, 75Se, 24Na,  
99mTc, 159Yt 
11C, 13N, 15O, 18F, 57Co, 
82Sr, 68Ge 64Cu,67Ga, 
68Ga, 111In, 123I, 124I, 
81mKr, 82Rb, 201Tl 
Therapeutic 
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89Sr, 90Y 213Bi, 60Co, 165Dy, 169Er, 125I, 
131I, 192Ir, 212Pb, 177Lu, 103Pd, 
32P, 186Re, 188Re, 153Sm 
67Cu, 57Co, 82Sr, 68Ge 
Table 2. Distribution of the radioisotope production for medical applications. 
Like the Curie’s began using their newly discovered natural radioisotopes to treat cancer 
lesion in the skin, very short time after the construction of the cyclotron and the production 
of its radioisotopes,  makes  the medical applications  to be easily spread. 
But there is another mechanism for particle activation and it comes from the nuclear reactor 
where a bunch of natural radioisotopes “bars” are used to produced spontaneous fission 
products to aim the nucleus of stable atom or its electronic crown. 
Nowadays reactors are the core of the nuclear power plants, but in their beginnings they 
were developed for research proposes to military applications only. Due to the natural 
“nuclear fuel” reactors were better in cost/efficiency fashion and in the late 30’s and early 
40’s many budgets and efforts were driven to their construction to regulated nuclear chain 
reaction and its control, until the atomic bomb development to win WWII. 
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But passing thru that dark hour, all the money spend in its development seems to be not 
that important. 
And cyclotron has to compete (and win) against reactors that were redeeming themselves 
by producing “atoms for the peace” trying to justify the large budget assign to them during 
WWII. 
And for a long period of time the guilt drop the balance to reactors side until middle 70’s 
when positron emission tomography arised based in a component containing 18F: 18FDG 
(Fluorodexoxy glucose). 
This isotope was only produced in cyclotron and the compound could be synthetized in a 
straight forward relative easy way. 
This made cyclotrons an Hospital equipment because, due to the short half-life of 18F, it was 
necessary to stablish the supplier so near to the costumer as it can be, and being a hospital a 
places were pureness and asepsie is well know, and treat with reverential respect, which 
other place would be better to activated pure 18F and synthetize the 18FDG in a sterile form 
to be safe to apply in human. 
And between 1929 and 1974 lot of things happened to cyclotron to develop its actual 
characteristic. From Lawrence Cyclotron to Hospital one, until CERN´s a lot of energy has 
pass through. 
 
   
                    a)                                                    b)                                                        c) 
Fig. 7. Different cyclotron size: a) Lawrence´s first one,  b) Venezuela First one (courtesy of 
Dorly Coehlo), c) Fermi National Laboratory at CERN. 
And size matters, and Cyclotrons win as best hospital candidates due to Reactors are bigger, 
harder and difficult to be set in a hospital installation. Can you imagine a nuclear reactor 
inside a health installation? Radiation Protection Program will consume all the budget 
available. Size, controlled reactions, electrical control, made cyclotrons easy to install, and 
baby cyclotrons come selfshielded so hospital don´t need to spend money in a extremely 
large bunker. Now on, we are going to talk about our first experience with the set up  of a 
baby cyclotron for medical uses inside the first PET installation in Latin America. “Baby” 
means its acceleration “D” diameters are  suitable to be set inside a standard hospital room 
dimensions, with all its needs to be safetly shielded for production transmision and 
synthetized for human uses for imaging in Nuclear Medicine PET routine. When we ask 
why Cyclotrons are better than reactors for radioisotopes production to be used in Medicine, 
we also have to have in mind that they has: 
1. Less radioactive waste 
2. Less harmful debris 
 
12 Chapters on Nuclear Medicine 56
65 4 67 1
29 2 31 02Cu He Ga n+ ⎯⎯→ +  
5. Differences and similarities between reactors and cyclotrons 
Cyclotron is not the only way of activating matter. Going through history, side by side  
cyclotron development in America, Europe was devoted to the natural radioactive material 
discovered by many scientists, from Madame  Curie (1898), Pierre, Irene and also Joliot  till 
Enrico Fermi, Otto Hahn, Lise Meitner and Fritz Strassman (1939). Neils Bohr and Jhon A.  
Wheeler published their explanation of the method for moderating, “modulating”, chain 
reactions in a paper published only 2 days after WWII starts in 1939. The first reactor was 
then brought into criticality in Fermi´s Lab on December 2nd, 1942 in very controlled 
experiment including radiation safety and protection considerations. Proving that chain 
reaction can be controlled, it was matter of time to find uses for the products obtain from a 
nuclear reactor. The neutron from reactors are projectiles for many (n,p), (n,β), reactions to 
produce many radioisotopes. So time has come to begin talking about which of all this 
radioactive products can be used in medicine. The first radioactive material used in humans 
with medical purposes was 226Ra, (1898) used by Madame and Mousier Curie to treat skin 
lesion they called “benign”. Their daughter Irene used 214Bi to measure blood flow, this two 
products come directly from the 238U natural decay series. By the artificial radioisotopes 
side, the first one was that 32P John Lawrence (1929) used to treat leukemia.  After of it, a lot 
of radioisotopes and a lot of uses have been developed for diagnostic and therapy uses,  so 
for this time,  we can say that the radioisotopes used in Medicine distributions is as it is 
shown in Table 2: 
 






133Xe, 99Mo 51Cr, 125I, 131I, 89Sr, 153Sm, 
59Fe, 177Lu, 42K, 75Se, 24Na,  
99mTc, 159Yt 
11C, 13N, 15O, 18F, 57Co, 
82Sr, 68Ge 64Cu,67Ga, 
68Ga, 111In, 123I, 124I, 
81mKr, 82Rb, 201Tl 
Therapeutic 
Application 
89Sr, 90Y 213Bi, 60Co, 165Dy, 169Er, 125I, 
131I, 192Ir, 212Pb, 177Lu, 103Pd, 
32P, 186Re, 188Re, 153Sm 
67Cu, 57Co, 82Sr, 68Ge 
Table 2. Distribution of the radioisotope production for medical applications. 
Like the Curie’s began using their newly discovered natural radioisotopes to treat cancer 
lesion in the skin, very short time after the construction of the cyclotron and the production 
of its radioisotopes,  makes  the medical applications  to be easily spread. 
But there is another mechanism for particle activation and it comes from the nuclear reactor 
where a bunch of natural radioisotopes “bars” are used to produced spontaneous fission 
products to aim the nucleus of stable atom or its electronic crown. 
Nowadays reactors are the core of the nuclear power plants, but in their beginnings they 
were developed for research proposes to military applications only. Due to the natural 
“nuclear fuel” reactors were better in cost/efficiency fashion and in the late 30’s and early 
40’s many budgets and efforts were driven to their construction to regulated nuclear chain 
reaction and its control, until the atomic bomb development to win WWII. 
 
Medical Cyclotron 57 
But passing thru that dark hour, all the money spend in its development seems to be not 
that important. 
And cyclotron has to compete (and win) against reactors that were redeeming themselves 
by producing “atoms for the peace” trying to justify the large budget assign to them during 
WWII. 
And for a long period of time the guilt drop the balance to reactors side until middle 70’s 
when positron emission tomography arised based in a component containing 18F: 18FDG 
(Fluorodexoxy glucose). 
This isotope was only produced in cyclotron and the compound could be synthetized in a 
straight forward relative easy way. 
This made cyclotrons an Hospital equipment because, due to the short half-life of 18F, it was 
necessary to stablish the supplier so near to the costumer as it can be, and being a hospital a 
places were pureness and asepsie is well know, and treat with reverential respect, which 
other place would be better to activated pure 18F and synthetize the 18FDG in a sterile form 
to be safe to apply in human. 
And between 1929 and 1974 lot of things happened to cyclotron to develop its actual 
characteristic. From Lawrence Cyclotron to Hospital one, until CERN´s a lot of energy has 
pass through. 
 
   
                    a)                                                    b)                                                        c) 
Fig. 7. Different cyclotron size: a) Lawrence´s first one,  b) Venezuela First one (courtesy of 
Dorly Coehlo), c) Fermi National Laboratory at CERN. 
And size matters, and Cyclotrons win as best hospital candidates due to Reactors are bigger, 
harder and difficult to be set in a hospital installation. Can you imagine a nuclear reactor 
inside a health installation? Radiation Protection Program will consume all the budget 
available. Size, controlled reactions, electrical control, made cyclotrons easy to install, and 
baby cyclotrons come selfshielded so hospital don´t need to spend money in a extremely 
large bunker. Now on, we are going to talk about our first experience with the set up  of a 
baby cyclotron for medical uses inside the first PET installation in Latin America. “Baby” 
means its acceleration “D” diameters are  suitable to be set inside a standard hospital room 
dimensions, with all its needs to be safetly shielded for production transmision and 
synthetized for human uses for imaging in Nuclear Medicine PET routine. When we ask 
why Cyclotrons are better than reactors for radioisotopes production to be used in Medicine, 
we also have to have in mind that they has: 
1. Less radioactive waste 
2. Less harmful debris 
 
12 Chapters on Nuclear Medicine 58
3. They can be installed inside hospital decentralizing radioisotope production.  
4. Almost zero risk of nuclear accidents (Because there is no chain reaction to control) 
5. There is no risk of nuclear proliferation 









                                      a)                                                                                b) 
 
Fig. 9. Difference in size between a) Venezuelan medical cyclotron (courtesy of Indira Lugo) 
and b)Venezuelan research reactor (in desuse). 
 
Medical Cyclotron 59 
Medical Cyclotrons generally often comes with 4 targets to activated: Fluor 18, Oxigen 15,  
Nitrogen 13 and Carbon 11. In Venezuela we have one with only one target to activated 
fluor 18  to sintethized 18FDG, for PET studies.  
6. Activation products medical uses 
Remembering what we want for a radioisotopes to be safely used in medicine, Natural 
decay series has had a very bad performance. For example, 226Ra was used in Medicine until 
users realized that its daughter was 222Rn, a gas. Since 226Ra was encapsulated in stainless 
steel tubes the accumulation of Radon from Radium decay inside the tube, cause the 
gaseous pressure to increase in a non controlled way, so more than 10 years after its 
encapsulation, the gas pressure was so high as to break the capsule and escape. So as 222Rn is 
a radioactive gas and it half life is not short (almost 4 days), contamination was hard to 
contain, so Radium use was declined.  
 
 
Fig. 10. Radium Tubes. 
Activation products from Cyclotrons are in general of short half life, so the control can be focus 
in the energy users can handle. In such a way, we can say activation products can be tailored 
to our needs. But medical uses are little complicated. Nuclear Medicine consist in mix the 
radioisotope with a pharmaceutical product which is characterized by the organ they are 
going to address the isotope. What Nuclear Medicine really needs is to send the radioisotope 
to get inside the organ we want to study, and as the radioisotope is inside a molecule that can 
be metabolized by this organ, this metabolization function can be easily watch and measure 
with the appropriate radiation detectors. The name “radiopharmaceuticals” refers to the 
metabolically stable combination of a biochemical molecule to which radioisotope in bind that 
act as the vehicle through which, organ of interest can be reach. There are several mechanism 
for the radioisotope to join the address molecule such as: 
1. Ionic compound: In which the radioisotopes determine the metabolic route to be follow 
as in 131I to thyroid uses, because thyroid likes iodine and do not distinguish between 
different isotopes of the same element iodine. 
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2. Isotopic Exchange: In which the radioactive isotope goes to replace the stable isotope of 
it own species  
3. Incorporation: In which radioisotope  get inside the molecule but not interacting with 
the chemical compound, so it did not change its structure neither biochemical nor 
physical  properties 
4. Coprecipitation: In which radionuclide is precipitated in the same reaction with the 
chemical compound. Many are the radioisotopes that can be combined with different 
molecules to be address to different parts of human body with diagnostic or therapeutic 









β energy Uses 
Fluorine-18  18F 9 109.77m β+ 511 
(193%) 
0.664 (97%) PET: Cancer detection and 
monitoring of treatment 
progress, in flurodexoxiglucose. 
(FDG)  Tracer  in flurothymidine 
(FLT) and fluromisonidazole (F-
MISO), and  18F-choline 
Gallium-67 67Ga 31 3.26d EC  93 (39%) 185 (21%), 
300 (17%) 
SPECT: Tumor imaging, 
infections localization 
Krypton-81m 81mKr 36 13.1s IT 190 (68%) - Refrigerant  
Rubidium-82 82Rb 37 1.27m β+ 511 
(191%) 
3.379 (95%) Tracer in positron emission 
tomography 
Technetium-99m 99mTc 43 6.01h IT 140 (89%) - Pulmonary ventilation studies. 
Indium-111 111In 49 2.80d EC 171 (90%) 245 (94%) Brain studies, infection and colon 
transit studies. 
Iodine-123 123I 53 13.3 h EC 159 (83%) - Gamma emitter: diagnosis of 
thyroid function, without the 
beta radiation of I-131. 
Xenon-133 133Xe 54 5.24d β- 81 (31%) 0.364 (99%) Studies of pulmonary function 
and organic blood flow. 
Thallium-201 201Tl 81 3.04d EC 69-83* 
(94%) 
167 (10%) Diagnostic aid in the form of 
thallous chloride TI 201 
Carbon-11 11C 6 20.39m β+ -- 0.96 (100%) PET: Studies of brain physiology: 
epileptic focus, dementia, etc 
Nitrogen-13 13N 9 9.965m β+ -- 1.2 (100%) PET: Cardiology 
Oxygen-15 15O 8 122.24s β+ -- 1.8 (100%) PET: Cardiology and cancer 
detection 
Cooper-64 64Cu 29 13 h β+ -- 0.65 (61%)
0.58(39%) 
genetic studies: copper 
metabolism: Wilson's and 
Menke's diseases.  PET: tumours, 
and therapy. 
Cooper-67 67Cu 29 2.6 d β− -- 0.56 (100%) Beta emitter therapy  
Gallium-68 68Ga 31 68 min β+ -- 1.90 (100%) PET: tumor detection, daughter 
in 68Ge generator 
Germanium-68 68Ge 32 271 d EC -- 0.1 (100%) 68Ga generator parent 
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Therapy: 
 





Yttrium-90 90Y 39 2.67d β- - 2.280 (100%) 
Iodine-131 131I 53 8.02 d γ, β- 364 (81%) 0.807 (100%) 
Table 3. Common Isotopes Used in Nuclear Medicine for diagnostic studies or therapy 
procedure. 
In the table above we can see some radioisotopes that say they are parent or daughter in a 
generator, but what is a generator? 
7. Generators 
In Nuclear Medicine environment, sometimes is useful to have a regular provision of 
radioisotopes for studies to be performed without the restrictions of providers time 
dependences, for example when studies has to be done anytime of the day in emergency 
conditions. If physician suspects an infection in a patient admitted in Emergency Room, it 
will be of utmost usefulness to have Nuclear Medicine images done with appropriate 
radiopharmaceuticals to solve the question about the most effective treatment to be offer to 
the patient. Either way, sometimes in Cardiology it is of high importance to know about 
percentage of isquemic muscle, but patient has not the luxury of time to undergo a 
catheterism, so it is more effective and quick to have Nuclear Medicine  images and cine of  
the heart. In many cases like this, have a good availability of radiotracers make the 
differences between a correct and opportune answer or a misdiagnosis. 
This is the reason why radioisotopes generators have become so popular beside the fact that 
in countries like Venezuela where there is no nuclear production, sometime become very 
hard to warranty a regular supply. A radioisotopes generator is a device in which you can 
contain a pair father/daughter in which the daughter is the product of interest for studies 
purposes and father only come to generate the full amount of daughter needed. Due to the 
short half life we need for the radioisotope to be safe handle in hospital conditions, it would 
be useful to find a pair father and daughter that warranty  the in time provision of 
radioisotope needed. During the generator useful life father has to decay completely to the 
useful daughter so it can be easily recharged, disposed or returned to provider. Such pair 
must that accomplish some conditions like: 
1. Father has to have long enough half life (physical) such as to overcome travel time from 
provider to user. In this way father will be generating enough amount of daughter that 
can be extract in site for studies and will continue generating daughter to fulfill the 
needs for its entire useful time. 
2. Father must be shipped in pyrogen free condition 
3. Daughter has to decay in a sufficient short life be secure for image acquisition and 
radiation protection of patient 
4. Father and daughter have to have different chemical characteristics so the can be easily 
separate to be sure the daughter is so pure to be safe for human applications and there 
are no traces of the father in the injection solution.  
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are no traces of the father in the injection solution.  
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5. This separation must be passive in terms of no violent chemical reaction must be 
involved in the process, to warranty the chemical safeness  
6. The daughter must be eluted with a human compatible solution to warranty biological 
safeness 
7. The human intervention would be minimum to warranty the minimum exposure to 
radiation 
8. Radiation protection now is not the unique concern but chemical and biological 
protection is also very critical 
9. The granddaughter must be of very long time as to be consider stable  
After radiochemist discover some pairs of father/daughter that accomplish this 
characteristics, some were built in a shielded container to be send to hospital to extract the 
daughter. It makes radiosotopes clinically useful and commercially available.  
Medicine is not the only client for radioisotopes generator, also we will talk about some 
other uses of them that are increasing its popularity thru years. So let´s have a few words 
about their relationship. As in any father/daughter relationship there are different kinds, in 
radioactive “family” we can talk about two kind of equilibrium that this families reach, they 
are called transient and secular equilibrium. Equilibrium meaning when father and 
daughter exist in significant proportion to one another.  Secular equilibrium is a condition 
that they can reach when father physical half life is 2 or 3 magnitude orders greater that 
daughter´s (100 to 1000 times greater). It means when daughter decay many times father 
seems no to be affected. While transient equilibrium is a condition that is reach when father 
physical half life is about 10 times daughter´s. It is, when daughter decay few times father 
can decay to its 50%, i.e a full half life.  Note that if physical half life of the daughter is larger 
that the father equilibrium can never be reach because father will be ever alone. 





Transient Equilibrium Generators 
 
 
Although this last one has a promising future in metastatic disease pain reliever and as a 
monoclonal antibody marker, the most popular generator in Nuclear Medicine is the Mo/Tc 
one. It is Techenetium is highly biocompatible in the Nuclear Medicine fashion so it can be 
used in a large number of studies.  
This Mo/Tc generators can be produced in cyclotrons or reactors and as in many 
radioisotope produced, the advantages of using that from cyclotron in front of that of 
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reactors is that in cyclotron you can use 98Mo enriched target to be activated by neutron 
irradiation in a (n,γ) reaction, while 99Mo coming from fission include very expensive 
production beside the complex regulations due to the highly enriched Uranium targets. 
 
TARGET ORGAN  99mTc RADIOPHARMACEUTICALS 
Brain  DTPA (DiethylTriaminoPentacetic Acid) 
(CaNa399mTc) 
Brain Perfusion ECD (EthylCysteinate Dimer) 







2,4 dimercaptosuccinic acid 
Liver 99mTc Sulphur 
Sn Hidroxide 
Sodium Phytate 
Sodium Calcium Phytate 







(MDP) Metilendiphosphonate  
Dynamic Studies Albumina 




Spleen  Red Blood Cell Markers 
Spleen and Bile Vitamine B6 glutamic 
HIDA (Hepatobiliary IminoDiacetic Acid) 
Blood Pool 99mTc  Albumina 
White Blood Cell  or platelets 
(infection or inflammation)  
99mTc HMPAO (HexaMethylPropileneAmineOxime) 
Table 4. Radiuopharmaceuticals used with 99mTc for diagnostic studies. 
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one. It is Techenetium is highly biocompatible in the Nuclear Medicine fashion so it can be 
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reactors is that in cyclotron you can use 98Mo enriched target to be activated by neutron 
irradiation in a (n,γ) reaction, while 99Mo coming from fission include very expensive 
production beside the complex regulations due to the highly enriched Uranium targets. 
 
TARGET ORGAN  99mTc RADIOPHARMACEUTICALS 
Brain  DTPA (DiethylTriaminoPentacetic Acid) 
(CaNa399mTc) 
Brain Perfusion ECD (EthylCysteinate Dimer) 







2,4 dimercaptosuccinic acid 
Liver 99mTc Sulphur 
Sn Hidroxide 
Sodium Phytate 
Sodium Calcium Phytate 







(MDP) Metilendiphosphonate  
Dynamic Studies Albumina 




Spleen  Red Blood Cell Markers 
Spleen and Bile Vitamine B6 glutamic 
HIDA (Hepatobiliary IminoDiacetic Acid) 
Blood Pool 99mTc  Albumina 
White Blood Cell  or platelets 
(infection or inflammation)  
99mTc HMPAO (HexaMethylPropileneAmineOxime) 
Table 4. Radiuopharmaceuticals used with 99mTc for diagnostic studies. 
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8. Baby cyclotron characteristics  
Baby cyclotrons are known as a hospital equipment be cause they are build to fulfill the 
medical proposes, in general, they can afford until 4 targets to activated most of 
radioisotopes needs to do PET studies  
In Venezuelan experience the first installed cyclotron has the following characteristics:  
• Generated beam for activation: H +  
• Energy required for the activation: 9.6 MeV  
• Output  Beam minimal current: 50 μ A  
• Material to Activate: H218O  
• Activation Product: 18F-  (fluorine ion).  
• Running average activity: 800 mCi  
• Activation efficiency: Greater than 60% 
Also the device dimensions where 3.6 x 2 x 2 m3 for the acceleration d´s and inner shielding. 
And the room has to have at least 7 x 5 m2 only for the cyclotron and another 6 x 5 m2 for the 
synthesis lab.  But the very concerning issue is the weight of the entire system, only in inner 
shielding it has 37 tons and the magnet alone has a weight of 11 tons the full system is over 
50 tons 
This cyclotron produce protons of 9.6 millions of electron volts (MeV) of energy with a 
maximum current of 50 μΑ, the target is made of oxigen to transmute to fluor. In this 
activation process there are some particles going out the path of the main beam so they have 
to be stopped by the inner shielding as to warranty 10 μSv/h at 1 m from shleding and 1 m 
from floor. Also the magnetic regulation permit 1 G at 6 m from the center of the D´s 
8.1 Venezuelan medical cyclotron 
In our experiences, the utmost importance matter in a Cyclotron is the Quality Assurance 
Program in which must be include:  
1. Electrical Aspects  
2. Mechanical and performance aspects and 
3. Radiation Safety Aspects 
In a broad approximation, we can say that: 
8.1.1 Electrical aspects that have to be under control are: 
• On/off switches 
• For operation  
• For Emergency 
• Failure Interlocks 
• Safety Interlocks 
• Audible alarm  
• Luminous alarm 
• Processing unit connection 
• Selfdiagnostic 
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• Stability  
• Mechanical movements of inner and outer doors 
• Beam Energy 
• Output flux 
• Output dose and exposition  
• Target effectiveness 
• Activation effectiveness 
8.1.3 Radiation Safety aspects to be under control are:  
• Area classification and signs 
• Area monitorization 
• Personal dosimetry 
• Activation control 
• Airborne debris 
• Chimney 
• Personnel Medical Check up: 
• Previous to begin working in the facility 
• Annual (prevocational) check up 
• Posterior to end laboral relationship with the facility 
• Shielding 
• Radiation Safety Committee 
8.1.4  Daily journey: Also three aspects need to  be controlled step by step, 
accounting to:  
• Radioisotope Production 
• Handling radioactive material for studies  
• Possible emergency 
8.1.4.1 In radioisotope production  it must be carefully checked: 
• Pre-start conditions  
• Area and ventilation ducts monitoring during cyclotron is on 
• Activation and contamination control after cyclotron is turn off 
• Pre and post Hot Cell monitoring 
• Radioactive waste disposal entry and release record 
• Fractionation residues and contamination  
• Radioactive waste disposal 
• Place design  
• Waste classification 
• Decay rate  
• Free release dates  
8.1.4.2 Radioactive material handling for diagnostic studies 
• Total activity produced in a cyclotron run  
• Fractionation doses 
• Patient injection site and procedure 
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• Patient waiting room= Controlled area  
• Adverse reaction, contraindication, diabetic patients 
8.1.4.3 Possible emergencies 
• Coolling system failure 
• Door interlocks during cyclotron is on 
• In use production line rupture 
• Vial rupture 
• Inside hot cell 
• Inside fractionation hood 
• Outside 
8.1.4.4 Radioactive material spills 
• Inside hot cell 
• Inside fractionation hood 
• During transportation  
This a  resume of our general procedure manual, reproduced for physicians to know about 
all procedures that will be under their responsibility because they are legally, the 
responsible for the facility and its practices, as is establish in BSS and many other documents 
regarding medical practice. Here we only intent to introduce a general framework about 
medical cyclotrons so we will only mention some useful concepts and its application in a 
new facility. 
8.1.5  
Regarding to electrical aspects we must emphasize that failure interlock never must be 
deactivated, before the in charge expert check it out and solve the situation, only after 
he/she sign the log describing the solution, operation can continue. It is important to 
remember that ignoring this interlocks and alarms has conducted, many times, to major 
accidents injuring personnel and patients.  
Before turning on cyclotron for a production run, the following operation parameters must 
be checked:  
STEP ONE: MORNING CHECK OUT BEFORE TURNING CYCLOTRON ON: (EXAMPLE) 
 
Water leakage NO
Normal operative ventilation  OK
Electrical power on, stable and normal Control cabinet OK 
Rf cabinet OK 
Vacumm 7x10-7 mbar (7 x 10 -5 Pa) 
Water conductivity 5 μSiemens 
Water cooling temperature  20+2 ºC
Gas valves Production  Máx 0.5 MPa  (73 psi) 
Operation 3 +0.1 MPa (435 + 14 psi) 
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Cyclotron door closed OK
Room door closed OK
Safety system on (green)  OK
8.1.6 
On mechanical and performance settings it is important to become religious with the daily 
log for parameters to be safely establish before start working, to be sure of, what we want to 
obtain is what we really will obtain after cyclotron runs in the desire conditions 
STEP TWO: TUNNING ON CYCLOTRON   (EXAMPLE) 
 
Turn on all the computers  
Run autocheck  
Define in the console Current  
Irradiation time  
Charge  
Activity  
Target water level   
8.1.7 
For personnel safety there exist three types of emergency interlocks: 
• Radiological emergency:  as described  
• Ergonomical emergency:  as feet trapped under the cyclotron doors 
• Nature emergency: earthquake, flood, etc  
8.1.8 
In radiation safety aspects it is important to notice that radiation protection is not a solely 
part body but a team work . Everybody in the facility must be involved in Radiation 
Protection (RP) tasks and in the Radiation Safety (RS) Program and must be accomplish this 
minimal recommendations:  
RADIATION PROTECTION BASIC RECOMMENDATIONS: (EXAMPLE) 
 
1. Use your badge all the time you are in the facility (body, ring, alarm dosimeters)  
2. Use also the handy personal monitor that has been assign to you anytime you access 
the supervised and controlled areas 
3. Inside cyclotron room, hot lab and  fractionation lab, use cloak, glove and glasses   
4. Do not use decorative rings (jewelry), scarf, bracelet or any other accessory that could 
transport contamination outward  
5. Never get in cyclotron room during production  
6. Never use mouth pipettes 
7. Never handle radioactive material outside cells or hoods 
8. Use long forceps or tweezers 
9. Never use controlled fridge for food or beverage 
10. Radioactive waste must be dispose by its nature and classification in the selected area 
for them  
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11. Monitor your working area before and after each assignation and whenever a 
contamination is suspected  
12. Wash your hands before living controlled area 
13. Monitor your hands before living controlled area and return to 12 until background 
is reached. In any case contact RSO  
14. Record every activity (cyclotron, Hot Lab, Synthsys lab, Fractionation Lab) in 
corresponding log 
15. Any unusual event must be report in corresponding log  
16. In any radiological event communication chain must be follow 
17. In case of inhalation or ingestion follew corresponding emergency procedure as it is 
written  
8.1.8.1 
In such a large facility it is mandatory to exist an ad hoc committee known s “Radiation 
Safety Committee” (RSC) as it is establish in Venezuelan safety standard NVC3299. In our 
case, this comitte must ever be conformed by: 
1. Radiation Safety Officer 
2. One delegate from maintenance and engineering department 
3. One delegate from directive or administrative board 
4. One delegated of security department  
5. One delegate from technician staff 
6. One delegate from nursing staff 
7. One delegated from physician (at least) 
Many other specialist, physician, physicist, chemist can be include 
8.1.8.2 
For radiation area classification, national standard recommendation will be follow as in 
NVC 2257: Any area must be classified as “Controlled” if in any moment of daily operation 
the exposition rate is above 0.5 mR/h. In this sense , cyclotron room, synthesis lab, hot lab, 
injection room pet/ct room are controlled areas by default. Classification of different areas 
will be consult to RSC and RSO and will be solve only after 24 h continuous measurements, 
and any other consideration in standard classification may be voted and solved by more that 
75% of delegates   
This is the figure that will take all the decisions regarding al RS concerns and its decisions 
must be voted to win with more of the 75% of the committee delegates.  
In radioisotope uses (for diagnostic or therapies) any patient application  can be supervised 
by committee  and logs must be all time up to date. All the details for all the task mentioned 
above must be clearly describe in each procedure manual and clearly understand by any of 
the participant of each task  
Notification chain must also be clearly establish and accomplish from personnel who needs 
to report,  thru RSO,  until the National Regulatory Authority 
8.1.8.3 Cyclotron Cycle 
• In cyclotron room protons hits water target transmuting  16O into 18F. 
•  In Hot Lab  18F ions are measured in activity, pureness, pyrogenicity, volume, etc  
• Synthesis Lab FDG is produced by substitution of oxygen  ion by the activated fluorine 
ion inside  the molecular chain yielding to labeled 18FDG  
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8.1.8.4 Parasite Activation  
One of the most relevant issues in Cyclotron facility is the activation of the materials inside 
the cyclotron room during daily operation. As cyclotron room is a close and hardly shielded 
facility all activation products will ever be contained inside its room and the activation 
levels will only be monitored and measured during providers maintenances, in this 
opportunity, frotis are taken of the most suitable materials to be activated and they are 
measure in spectrometer. On the other hand, gaseous activation is continuously monitored 
with proper devices set inside the chimney. As first defense line, the facility has a 200 m 
circuit through which gaseous particles travel  during 24 hours before getting into the 
chimney to be release to the atmosphere. As our cyclotron do not have gaseous target all the 
airborne particles come from the air inside the room, so they are characterized by their 
extremely short half lives, around nano or micro seconds. Periodcally, frotis are taken from 
the chimney to be measure in spectrometer.  
For any maintenance that need the “backdoor” of the cyclotron to be removed, exposition 
rate must be below 0.5 mR/h as it is establish in NVC2259. If it is not, maintenance 
personnel must wait until this level is reached. 
Finally, it must be said that in operation conditions Cyclotron is fully shielded allowing a 
maximum of 10 mSv at 1 m in the axial direction of the magnet, and  such a value is only 
reached one or twice a day in the production time that is less than 2 hours accounting  all 
the running.  
8.2 Synthesis laboratory  
In Pet studies a cyclotron is nothing without radiochemical laboratory , because cyclotron only 
produce the ion, in our case, 18F and it has to be joined to the glucose analogue  molecule 
(fluordexoxiglucose) to be driven to the body. In it  fluor is send into molecule via 
electrophilic fluorination or nucleophilic fluorination reaction in which stable fluor is 
substitute by the activated 18F.  
 
 
Fig. 11. Synthesis Lab in Venezuelan Cyclotron  facility (courtesy Dorly Coehlo) 
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8.3 Patient radiation protection  
Before finishing let´s have few words about the protection of patients. In patient protection 
we have to had in mind not only the physical half life because sometimes biological half life 
is longer and radiation protection must to be concern to the excretion system of patient so 
Nuclear Medicine define an effective half life to take into account the two contributions to 
patient doses coming from physical and biological behavior of radioisotope. Biological half 
live is the time living organism needs to excrete any radioisotope trace of radioactive 
material. It depends no only of physical time but on effectiveness of excretion system of the 







ISOTOPES HALF LIVES (days) 
TPhysical TBiological TEffective
3H 4.5 x 103 12 12 
14C 2.1 x 106 40 40 
22Na 850 11 11 
32P 14.3 1155 14.1 
35S 87.4 90 44.3 
36Cl 1.1 x 108 29 29 
45Ca 165 1.8 x 104 164 
59Fe 45 600 42 
60Co 1.93 x 103 10 10 
65Zn 244 933 193 
86Rb 18.8 45 13 
90Sr 1.1 x 104 1.8 x 104 6.8 x 104 
99mTc 0.25 1 0.20 
123I 0.54 138 0.54 
131I 8 138 7.6 
137Cs 1.1 x 104 70 70 
140Ba 12.8 65 10.7 
198Au 2.7 280 2.7 
210Po 138 60 42 
226Ra 5.8 x 105 1.6 x 104 1.5 x 104 
235U 2.6 x 1011 15 15 
239Pu 8.8 x 10 7.3 x 104 7.2 x 104 
Table 4. Physical and Biological half lives 
Radioisotopes like P and Sr like to stay in bone, so as far as they can be used to treat bone 
lesions the maximize its doses due to the combination of physical and biological exposure. 
Phosphorous decay faster so Sr is better to treat bone metastasis due to it relatively long 
physical and biological half life. For diagnostic studies Tc has proven to be the best due to its 
short physical and  biological lives, so it is excrete from the body just after images has be taken. 
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ISOTOPES HALF LIVES (days) 
TPhysical TBiological TEffective
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45Ca 165 1.8 x 104 164 
59Fe 45 600 42 
60Co 1.93 x 103 10 10 
65Zn 244 933 193 
86Rb 18.8 45 13 
90Sr 1.1 x 104 1.8 x 104 6.8 x 104 
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Table 4. Physical and Biological half lives 
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Radionuclide Infection Imaging:  
Conventional to Hybrid 
Muhammad Umar Khan and Muhammad Sharjeel Usmani 
Departments of Nuclear Medicine/PET Al-Jahra Hospital & Kuwait Cancer Control Centre, 
Kuwait 
1. Introduction  
Radionuclide imaging has been frequently used for detection and localization of infectious 
and inflammatory diseases for over five decades. Although there are many infection seeking 
agents available and currently being used but there is a general consensus that none of them 
is ideal. No clear cut guidelines exist to recommend a particular radionuclide imaging 
procedure for a particular clinical indication, however, in some instances the literature does 
provide us with ample evidence for the choice of the infection specific agent whereas one 
may have to depend upon the routine management protocols to decide which radionuclide 
imaging procedure to perform in a particular situation. In fact, presently, the clinical utility 
of radionuclide infection imaging varies under different circumstances and clinical 
scenarios; but with the incorporation of hybrid imaging systems, the fusion of functional 
and anatomical data in form of SPECT-CT and PET-CT has certainly improved the 
sensitivity and specificity of detecting and localizing an infectious process. Ga-67 citrate, 
bone seeking radiotracers, radiolabelled leukocytes, antibody and antibody fragments 
labelled white cells are used in different clinical situations such as osteomyelitis, diabetic 
foot, infected vascular grafts, infected hip or knee prostheses, intra-abdominal infections 
including acute appendicitis, cardiovascular, pulmonary infections, malignant otitis externa 
with variable sensitivity and specificity. Similarly, the ability of F-18 FDG PET to detect 
infection, inflammation and granulomatous diseases due to their increased glycolytic 
activity has provided us with another effective agent especially in cases of fever of unknown 
origin, vasculitis, chronic osteomyelitis, sarcoidosis, inflammatory bowel disease and 
assessing response to therapy. New advances in the form of SPECT-CT have now also 
incremented the diagnostic capability of conventional scintigraphic procedures to localize 
infection. Finally, many investigational new infection seeking agents are in the process of 
being developed in search of an ideal. These include Tc-99m ubiquicidin, Tc-99m labelled 
Interleukin-8, N-formyl products, chemotactic cytokines etc. Therefore, with on going 
research in development of infection specific agents and the advent of hybrid imaging the 
future offers definite hope for better infection detection and localization in our patients.  
2. Gallium scintigraphy 
2.1 Gallium-67 citrate: Pharmacological and physiochemical characteristics 
Ga-67 citrate has been used since 1971 to detect and localize infectious and inflammatory 
process. The exact mechanism of uptake has been studied extensively and various factors  
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are thought to govern the tracer accumulation at the infection site. Most of the circulating 
Ga-67 is in the plasma and nearly all of it complexes with transferrin. Due to the increased 
blood flow and vascular membrane permeability the Ga-67/transferrin complex is delivered 
to the inflammatory sites or foci. Ga-67 is also thought to bind to lactoferrin which is present 
in high concentrations in the inflammatory foci. Direct bacterial uptake and accumulation as 
well as Ga-67 transportation bound to the leukocytes is also another factor studied. Bacteria 
and some fungi produce low molecular weight chelates called siderophores present on their 
cell surfaces and these have a high affinity for Ga-67. The Ga-67/siderophore complex 
facilitates the transport of Ga-67 within the cell itself. This mechanism of Ga-67 uptake may 
be attributable to the accumulation of Ga-67 within an abscess in neutropenic patients. 
Ga-67 is a cyclotron produced radioisotope and emits principle gamma rays (93, 184, 296, 
394 KeV). These are suitable for imaging. The dosage of Ga-67 typically used is 185-370 MBq 
for infection imaging, however, in our personal experience even a lesser dose did produce 
adequate images worth interpretation. Around 15-25% of the injected dose is excreted via 
the kidneys by 24 hours. After 24 hours the principle route of excretion is the colon. At 48 
hours 75% of the injected dose remains in the body and is equally distributed among the 
liver, bone, bone marrow and soft tissues. The physical half-life of Ga-67 is 78 hours while 
the biological half-life of around 25 days gives ample opportunity to take delayed images 
even after days post injection. 
2.2 Gallium-67: Imaging protocols and pre-requisites 
Ga-67 imaging is usually performed 18-72 hours post injection, however, we also routinely 
image the patients at 6 hours post injection particularly if the suspected focus of infection is 
in the abdomen. This we have found to be helpful in a number of cases. Limited spot views 
or whole body imaging can be done depending upon the clinical indication and the use of a 
medium energy collimator is a standard. Patients’ preparation with laxatives and enemas 
has been considered by some but the effectiveness of such preparation seems limited. Recent 
Gadolinium exposure as in an MR contrast study or multiple blood transfusions resulting in 
excess ferric ion may alter the Ga-67 biodistribution by saturation of the protein-binding 
sites. This needs to be sorted out in history while preparing the patient for injection and 
imaging. 
2.3 Gallium-67: Clinical utilities and applications 
Ga-67 citrate has been extensively used in the past four decades in clinical practice for 
several pathological conditions particularly whenever infection or inflammation has been in 
question. Ga-67 has demonstrated high sensitivity for both acute and chronic infectious 
process as well as non-infectious inflammation. Moreover, the Ga-67 tracer activity parallels 
acute inflammation, returning to normal as the disease process resolves. 
The most common of the clinical scenarios where Ga-67 has been and is still utilized include 
fever of unknown origin (FUO), sarcoidosis, pulmonary infections like pneumocystis carnii 
pneumonia (PCP), drug-induced pulmonary toxicity as is seen with bleomycin or 
amiodarone, and in cases of malignant otitis externa. Further Ga-67 has been successfully 
utilized in spinal discitis and vertebral osteomyelitis. Mediastinal infections in 
immunocompromised patients have been detected by Ga-67. 
In patients with the clinical diagnosis of FUO, anatomical imaging is less helpful as 
functional changes occur prior to anatomical alteration at a suspected site resulting in 
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normal anatomical imaging. FUO has numerous causes and neoplasms including 
lymphoma account for up to 25% of these cases. Although PET/CT and labelled leukocytes 
are more frequently employed for FUO but Ga-67 can still be helpful with good detection 
rates where these formal are not available (Figure 1).  
 
 
Fig. 1. A 40-year-old male with FUO. Ga-67 scintigraphy shows intense tracer accumulation 
in the left side of abdomen. SPECT/CT images localize the abnormal uptake to the 
thickened gastric wall measuring over 50mm. SPECT/CT report raised the suspicion of 
lymphoma and suggested subsequent endoscopic biopsy; the report of which showed 
findings consistent with gastric lymphoma. 
Sarcoidosis is a systemic disorder that involves the lungs in up to 90% of the cases. Hilar 
lymph nodal involvement is evident in over 80% of the cases. Pulmonary accumulation of 
Ga-67 in these patients parallels active disease and there exists a good concordance between 
the Ga-67 intensity of uptake and the disease severity. Ga-67 scintigraphy has a sensitivity of 
70% for detecting pulmonary parenchymal disease and a 95% for hilar adenopathy. The 
overall sensitivity is about 90%. If these patients are further subjected to a Thallium 
scintigraphic exam, it is usually negative. A characteristic Ga-67 scintigraphic pattern seen 
in patients with sarcoidosis is termed as the “Panda sign” (due to typically increased and 
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more prominent lacrimal, parotid and nasopharyngeal activity). This can be seen in up to 
80% of patients with stage I disease. Moreover the pre-tracheal and bilateral hilar 
adenopathy gives rise to an inverted “Y” which is termed as a “Lambda sign” (Figure 2). It 
is important, however, to remember that the panda sign can be seen in cases of Mikulicz 
syndrome (uveoparotid fever), lymphoma, Sjogren’s syndrome and HIV. Some 
Pulmonologist believe that a panda sign on Ga-67 scintigraphy even without a lambda sign, 




Fig. 2. A 28-year-old male with suspicion of sarcoidosis. Ga-67 scintigraphy shows typical 
“Panda” and “Lambda” signs.  
The sensitivity of Ga-67 scintigraphy for PCP in HIV patients has been reported to be as 
high as 90-95%. The scintigraphic pattern is that of diffuse increased pulmonary uptake 
which is disproportionate to the clinical and radiological findings. However, due to a long 
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list of differentials that can give rise to a similar scintigraphic picture the specificity can be 
increased by considering the intensity and distribution of the tracer as well as the 
comparison of activity either with the liver uptake or the sternum. Diffuse heterogeneous 
pulmonary activity which is more intense than the liver has specificity for PCP between 95-
100%. 
In cases of drug-induced pulmonary toxicity (Bleomycin, Cyclophosphamide, Methotrexate, 
Nitrofurantoin, Amiodarone) radiologically the abnormalities are not evident at early stages 
of the toxicity. In such a scenario, Ga-67 provides early detection with usually moderate 
increased uptake seen in the lungs on the scan. More recently, Ga-67 scintigraphy (Figure 3) 
as well as PET/CT has been used to evaluate malignant otitis externa. These modalities are 
also used to evaluate the response to therapy in such cases. Vertebral osteomyelitis has been 
detected and evaluated by Ga-67, however, the specificity can be increased if the 
interpretation is done in conjunction with the bone scan. An accepted criterion in such a 
clinical scenario is to have Ga-67 uptake greater than uptake seen on the bone scan with 
incongruent tracer distribution. Labelled leukocytes, however, are more accurate for the 
evaluation of vertebral osteomyelitis. 
 
 
Fig. 3. A 46-year-old female with clinical diagnosis of right malignant otitis externa referred 
for Ga-67 scintigraphy. Transverse and coronal SPECT images show intense tracer uptake in 
the right auricular region. SPECT/CT images localize the abnormal uptake to right external 
auditory meatus without evidence of any underlying bony cortical breech. 
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2.4 Gallium-67: Hybrid SPECT/CT imaging 
Ga-67 scintigraphy is primarily characterized by poor spatial resolution and low specificity 
due to paucity of anatomical and morphological information. (Bar-Shalom et al., 2006) 
studied patients with multiple infectious conditions including FUO and concluded that 
SPECT/CT was found to be beneficial in determining the precise anatomical sites of 
infection in 85% of discordant studies. In particular, substantial benefits were observed in 
scans of the chest and abdomen. In our own experience the addition of SPECT/CT to Ga-67 
scintigraphy has a definite incremental value that helps resolve many difficult clinical 
scenarios (Figure 4).  
 
 
Fig. 4. A 21-year-old female with history of polycystic kidney disease referred for Ga-67 
scintigraphy to evaluate suspected infected right renal cyst. Ga-67 scintigraphy shows linear 
intense tracer accumulation in the infra-hepatic region. SPECT/CT images localize the 
abnormal uptake to an area in the upper pole of right kidney just above a hypodensity 
(renal cyst) that shows photopenia on SPECT images. Subsequent guided biopsy drained 
abscess just beneath the renal capsule.  
3. Bone scintigraphy 
3.1 Tc-99m MDP: Pharmacological and physiochemical characteristics 
Tc-99m Methylene-Diphosphonate (MDP) has been extensively used in the work up of 
osteomyelitis. The mechanism of uptake of diphosphonates has not been completely 
elucidated but the general presumption is that they are adsorbed to the mineral phase of 
bone with relatively lesser binding to the organic phase. Some also have postulated chemo-
adsorption to the hydroxyl-apatite mineral component of the osseous matrix itself. Tc-99m 
(Technetium 99m) is a generator produced radioisotope with the principle gamma photon of 
140 KeV optimal for imaging with low energy high resolution parallel-hole collimator. The 
physical half-life of Tc-99m is 6 hours making possible delayed imaging with good target to 
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background ratio. Approximately 50% of the injected dose is localized to the bone. The 
tracer uptake is dependent upon the blood flow and the rate of new bone formation. 
3.2 Tc-99m MDP: Imaging protocols and pre-requisites 
When bone scintigraphy is performed for the evaluation of osteomyelitis, the study is done 
in three phases. These include a dynamic sequence termed as the flow or perfusion phase, 
followed by immediate static image of the area of interest termed as the blood-pool phase or 
soft tissue phase. The third phase is the static delayed imaging of the area of interest usually 
acquired 2-4 hours post injection. Some also perform a fourth phase at 24 hours which is 
usually a static spot view of the region of interest. The usual adult dosage is 740-925 MBq. 
Patients are instructed to be well hydrated and void frequently after the injection. 
3.3 Tc-99m MDP: Clinical utilities and applications 
Three-phase bone scintigraphy is the radionuclide procedure of choice for diagnosing 
osteomyelitis in non-violated bone i.e. bone that is not affected by underlying conditions. It 
is highly sensitive for diagnosing osteomyelitis and can detect the process 7-14 days before 
the manifestation of radiological changes. The reported sensitivity of 90-100% and specificity 
of 70-95% for identification of osteomyelitis is in non-violated bone. In adults a negative 
bone scan essentially rules out infection. Focal hyperperfusion, focal hyperemia, and focally 
increased bony uptake on delayed images are the characteristic scintigraphic findings for 
osteomyelitis. Many times due to some underlying bone conditions the specificity of the 
bone scan for osteomyelitis is further compromised. In such situations, the additional 
images at 24 hours (4th - phase) may improve specificity. This is due to the fact that uptake in 
woven or immature bone present in osteomyelitis continues for several more hours than 
normal bone. The accuracy of 4-phase bone scan that is more specific but less sensitive than 
a 3-phase bone scan is approximately 85%. Further the specificity of bone scan can also be 
improved by addition of Ga-67 scintigraphy. The overall accuracy of bone scan/Ga-67 
scintigraphy is approximately 65-80%. 
3.4 Tc-99m MDP: Hybrid SPECT/CT imaging 
Three-phase bone scintigraphy and MRI are considered the modalities of choice for 
diagnosing osteomyelitis. Moreover, MRI can assess the associated soft tissue complications. 
MRI has its limitations as well. The replacement of marrow fat with edema and exudate 
results in a decreased signal on T1 and an increased signal on T2-weighted images. Such 
findings are not specific for osteomyelitis and can be seen with acute infarction, fracture or 
even tumour. Therefore the overall sensitivity and specificity of MRI for detection of acute 
osteomyelitis ranges from 92-100% and 89-100% respectively. CT is more sensitive to detect 
cortical destruction. On site-based analysis by (Bar-Shalom et al., 2006) scintigraphy (planar 
& SPECT) and SPECT/CT showed concordant results for diagnosis and localization of 50% 
of infection sites. SPECT/CT defined the precise anatomical localization of 44% of infectious 
sites that were erroneous or equivocal on scintigraphy in this study. In another preliminary 
report, (Horger et al., 2003) found that SPECT/CT improved the diagnostic performance of 
three-phase bone scan for osteomyelitis avoiding false-positive or equivocal results. In our 
own experience SPECT/CT has always had an incremental value to routine planar imaging 
and in many clinical situations in particular further characterizing the abnormalities to reach 
definitive imaging diagnosis (Figure 5). 
 
12 Chapters on Nuclear Medicine 
 
78
2.4 Gallium-67: Hybrid SPECT/CT imaging 
Ga-67 scintigraphy is primarily characterized by poor spatial resolution and low specificity 
due to paucity of anatomical and morphological information. (Bar-Shalom et al., 2006) 
studied patients with multiple infectious conditions including FUO and concluded that 
SPECT/CT was found to be beneficial in determining the precise anatomical sites of 
infection in 85% of discordant studies. In particular, substantial benefits were observed in 
scans of the chest and abdomen. In our own experience the addition of SPECT/CT to Ga-67 
scintigraphy has a definite incremental value that helps resolve many difficult clinical 
scenarios (Figure 4).  
 
 
Fig. 4. A 21-year-old female with history of polycystic kidney disease referred for Ga-67 
scintigraphy to evaluate suspected infected right renal cyst. Ga-67 scintigraphy shows linear 
intense tracer accumulation in the infra-hepatic region. SPECT/CT images localize the 
abnormal uptake to an area in the upper pole of right kidney just above a hypodensity 
(renal cyst) that shows photopenia on SPECT images. Subsequent guided biopsy drained 
abscess just beneath the renal capsule.  
3. Bone scintigraphy 
3.1 Tc-99m MDP: Pharmacological and physiochemical characteristics 
Tc-99m Methylene-Diphosphonate (MDP) has been extensively used in the work up of 
osteomyelitis. The mechanism of uptake of diphosphonates has not been completely 
elucidated but the general presumption is that they are adsorbed to the mineral phase of 
bone with relatively lesser binding to the organic phase. Some also have postulated chemo-
adsorption to the hydroxyl-apatite mineral component of the osseous matrix itself. Tc-99m 
(Technetium 99m) is a generator produced radioisotope with the principle gamma photon of 
140 KeV optimal for imaging with low energy high resolution parallel-hole collimator. The 
physical half-life of Tc-99m is 6 hours making possible delayed imaging with good target to 
 
Radionuclide Infection Imaging: Conventional to Hybrid 
 
79 
background ratio. Approximately 50% of the injected dose is localized to the bone. The 
tracer uptake is dependent upon the blood flow and the rate of new bone formation. 
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When bone scintigraphy is performed for the evaluation of osteomyelitis, the study is done 
in three phases. These include a dynamic sequence termed as the flow or perfusion phase, 
followed by immediate static image of the area of interest termed as the blood-pool phase or 
soft tissue phase. The third phase is the static delayed imaging of the area of interest usually 
acquired 2-4 hours post injection. Some also perform a fourth phase at 24 hours which is 
usually a static spot view of the region of interest. The usual adult dosage is 740-925 MBq. 
Patients are instructed to be well hydrated and void frequently after the injection. 
3.3 Tc-99m MDP: Clinical utilities and applications 
Three-phase bone scintigraphy is the radionuclide procedure of choice for diagnosing 
osteomyelitis in non-violated bone i.e. bone that is not affected by underlying conditions. It 
is highly sensitive for diagnosing osteomyelitis and can detect the process 7-14 days before 
the manifestation of radiological changes. The reported sensitivity of 90-100% and specificity 
of 70-95% for identification of osteomyelitis is in non-violated bone. In adults a negative 
bone scan essentially rules out infection. Focal hyperperfusion, focal hyperemia, and focally 
increased bony uptake on delayed images are the characteristic scintigraphic findings for 
osteomyelitis. Many times due to some underlying bone conditions the specificity of the 
bone scan for osteomyelitis is further compromised. In such situations, the additional 
images at 24 hours (4th - phase) may improve specificity. This is due to the fact that uptake in 
woven or immature bone present in osteomyelitis continues for several more hours than 
normal bone. The accuracy of 4-phase bone scan that is more specific but less sensitive than 
a 3-phase bone scan is approximately 85%. Further the specificity of bone scan can also be 
improved by addition of Ga-67 scintigraphy. The overall accuracy of bone scan/Ga-67 
scintigraphy is approximately 65-80%. 
3.4 Tc-99m MDP: Hybrid SPECT/CT imaging 
Three-phase bone scintigraphy and MRI are considered the modalities of choice for 
diagnosing osteomyelitis. Moreover, MRI can assess the associated soft tissue complications. 
MRI has its limitations as well. The replacement of marrow fat with edema and exudate 
results in a decreased signal on T1 and an increased signal on T2-weighted images. Such 
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definitive imaging diagnosis (Figure 5). 
 




Fig. 5. A 19-year old male referred for evaluation of pain left lower limb. Tc-99m MDP 
images show hyperaemia, increased pool activity and intense increase tracer uptake in the 
distal end of left tibia. SPECT/CT images show a well-defined low attenuation metaphyseal 
lesion with central radiolucent area surrounded by peripheral bone sclerosis clearly 
confined to within the bone itself sparing the joint cavity. Findings consistent with diagnosis 
of osteomyelitis with features typical of a Brodie’s Abscess.  
4. Radiolabelled leukocytes scintigraphy 
4.1 Radiolabelled leukocytes: Pharmacological and physiochemical characteristics 
These days radiolabelled leukocytes are the most commonly used method to detect and 
localize infection. The leukocytes can be labelled using either Indium-111 (In-111) 
oxyquinoline or Tc-99m hexamethylpropylene amine oxime (HMPAO). In-111 oxine is a 
highly lipophilic ligand which diffuses across leukocyte membranes. Once inside the cell, it 
dissociates into oxine (8-hydroxyquinoline, which diffuses out of the cell) while In-111 is 
retained within the cytoplasm as a result of binding with intracellular proteins. In-111 
labelled leukocytes localize at sites of infection through diapedesis, chemotaxis, and 
enhanced vascular permeability. In-111 has a physical half-life of 67 hours. It decays by 
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electron capture with gamma emissions of 173 and 247 KeV. In-111 labelled leukocytes are 
normally distributed to the liver, spleen, and bone marrow. Intense pulmonary activity is 
seen soon after injection, which clears rapidly, and it is probably due to leukocyte activation 
during labelling, which impedes their movement through the pulmonary vascular bed, 
prolonging their passage through the lungs. 
Tc-99m HMPAO is a lipophilic agent that readily crosses the cell membrane of leukocytes. 
Once inside the cell the compound becomes hydrophilic and remains trapped. It is 
subsequently bound to intracellular organelles, primarily the nucleus and mitochondria. 
The bond to granulocytes is more stable than to monocytes and the tag elutes from these 
cells five times more rapidly. The normal biodistribution of Tc-99m HMPAO labeled 
leukocytes is more variable. In addition to the reticuloendothelial system, activity is also 
normally present in the genitourinary tract, large bowel, blood pool, and occasionally the 
gallbladder. Physiologic bowel excretion limits the usefulness of this agent for imaging 
abdominal infections. 
4.2 Radiolabelled leukocytes: Labeling technique 
There are a number of methods for labelling leukocytes, however, the basic principles and 
technique remains uniform. Approximately 40 ml of blood is withdrawn from the patient 
into a syringe that contains anticoagulant. This syringe containing blood is then kept in an 
upright position for about 1–2 hours to promote gravity erythrocyte sedimentation, a 
process that is facilitated by the addition of hydroxyethyl starch. The process can be 
accelerated by using hypotonic lysis of the red cells instead of gravity sedimentation as well. 
After the erythrocytes have been separated, the leukocytes must be separated from platelets. 
The leukocyte-rich plasma is centrifuged, and the leukocyte "pellet" that forms at the bottom 
of the tube is removed, incubated with the radiolabel, washed, and re-injected into the 
patient. The usual dose of In-111 labelled leukocytes is 10–18.5 MBq; while the routine dose 
of Tc-99m HMPAO labelled leukocytes is 185–370 MBq. The majority of leukocytes labelled 
are neutrophils, and hence the procedure is most useful for identifying neutrophil-mediated 
inflammatory processes, such as bacterial infections. The procedure is less useful in 
conditions where the predominant cellular response is other than neutrophilic such as 
tuberculosis. 
A total white count of at least 2000/mm3 is needed to obtain satisfactory images. ABO 
compatible donor WBC's may be used in neutropenic patients (i.e. White cell count less than 
2000/mm3). Radiolabelled leukocytes should be administered within 1–2 hours of cell 
labelling. Labelled cells stored longer than 3 hours have a significant loss of cell viability. 
Temperatures higher than 70°F tend to increase cell damage and should be avoided. Cell 
labelling should be performed by trained laboratory personnel in a laminar flow hood using 
sterile procedures. Care must be taken to ensure correct identification of patients and blood 
products. All patients and laboratory procedures should have an appropriate quality control 
program. 
4.3 Radiolabelled leukocytes: Imaging protocols and pre-requisites 
In-111 labelled leukocyte is usually performed 18-24 hours post injection because early 
imaging at 4 hours usually misses out on two-thirds of the lesions detected on later images. 
However, it is critical to obtain early (1-4 hour) images when evaluating patients for 
inflammatory bowel disease or those suspected of possible ischemic bowel disease.  
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Occasionally, 48 hour delayed images may be necessary due to prolonged circulation of 
labelled cells in about 10% of cases. Limited spot views or whole body imaging can be 
acquired depending upon the clinical indication. Images should be acquired with a 
medium-energy parallel-hole collimator. Energy discrimination is accomplished by using a 
15% window centered on the 173 KeV photopeak and a 20% window centered on the 247 
KeV photopeak. Simultaneous In-111 leukocyte/Tc-99m MDP bone images can be obtained 
using a gamma camera that can acquire and discriminate the 140 KeV Tc-99m photons from 
the In-111 photons. Each In-111 leukocyte/Tc-99m bone image is acquired using a medium 
energy collimator for 50K counts in the In-111 window or for 15 minutes, 4 hours and/or 
16–30 hours post injection of In-111 leukocytes. Tc-99m Sulphur colloid imaging can also 
performed after or simultaneously with In-111 leukocyte imaging if bone marrow 
distribution is in question. 
The interval between injection of Tc-99m HMPAO labeled leukocytes and imaging varies 
with the indication; in general, imaging is usually performed 3-4 hours post injection. Some 
centers perform only 2 hours post injection images and occasionally 24 hour delayed images 
may be necessary due to prolonged circulation of labelled cells. 
4.4 Radiolabelled leukocytes: Clinical utilities and applications 
Labelled leukocytes have been used for the diagnosis of complicated osteomyelitis after 
fractures and surgery i.e. violated bone, vascular graft infections, and various soft-tissue 
insults. In-111 labelled leukocytes are probably the preferable agent for imaging suspected 
sites of infection in the abdomen, while Ga-67 is preferable for detecting pulmonary 
pathology in the setting of FUO. There are advantages as well as certain disadvantages 
associated with both In-111 and Tc-99m labelled leukocytes. Advantages of the In-111 label 
are those of virtually constant normal distribution of activity that is limited to the liver, 
spleen, and bone marrow and its more stable in-vivo characteristics. Further In-111 labelled 
leukocytes can be used in simultaneous dual-isotope acquisitions. On the contrary, the 
drawbacks of the In-111 label include a low photon flux due to less than ideal photon 
energies. When compared to the Tc-99m label, the latter has a high photon flux and 
somewhat ideal photon energies; with relatively more radioactivity injected, the ability to 
detect abnormalities within a few hours post injection is a plus for Tc-99m label. 
Disadvantages of Tc-99m labelled leukocytes include genitourinary tract activity, which 
appears shortly after injection, and colonic activity, that appears by 4 hours post injection 
thereby obscuring potential foci of infections at these sites. 
Labelled leukocytes have been studied by many to be an accurate technique for the 
diagnosis of osteomyelitis in the setting of violated bones as well as in diabetic foot 
infection. The overall sensitivity and specificity of Tc-99m HMPAO labelled leukocytes is 
88% and 91%, respectively, for osteomyelitis in previously violated bones. However, Tc99m 
HMPAO labelled leukocytes imaging is performed only after a positive finding on a three 
phase bone imaging, because the latter is highly sensitive but significantly less expensive, 
making it more appropriate as a first-line screening procedure. (Devillers et al., 2000) 
reported an overall sensitivity, specificity, and accuracy of 93%, 100%, and 96%, 
respectively, for Tc-99m HMPAO labelled leukocytes and 100%, 17%, and 53.3%, 
respectively, for Tc-99m MDP bone imaging. In our own experience combined Tc-99m 
HMPAO/Tc-99m MDP imaging proved useful in diagnosing osteomyelitis. The specificity 
of Tc-99m MDP bone scanning improved from 30% to 78% with the addition of Tc-99m 
HMPAO labelled leukocytes (Figure 6). 
 




Fig. 6. A 30-year old female with chronic left leg pain, presented with tenderness and 
swelling at left lower leg. Tc-99m MDP bone scan show increased pool activity and increase 
tracer accumulation at the distal ½ of left fibula on delayed images. Tc-99m HMPAO 
labelled leukocytes scan showed increase tracer uptake in the distal left fibula 
corresponding to the site seen on bone scan, findings consistent with scintigraphic evidence 
of osteomyelitis. 
Labelled leukocytes imaging have been used in the diagnosis of orthopaedic implant 
infection after positive findings on three phase bone scanning. False positive scans can occur 
due to dystrophic ossification, peri-prosthetic granulomas, altered distribution of red 
marrow, and damage to the polyethelene surface of the prosthesis and metallosis. 
Combined leukocyte-marrow imaging can overcome many of the problems created by 
variable marrow distribution post-operatively. (Palestro et al., 1990) reported good results 
with combined In-111 labelled leukocytes/bone marrow imaging, with 86–100% sensitivity 
and 97–100% specificity in hip and knee prosthesis infections. (Joseph et al., 2001) also noted 
the ability of added sulphur colloid scanning to eliminate the false positive results. Our own 
experience suggest Tc-99m HMPAO labelled leukocytes scan appears significantly valuable 
in detecting osteomyelitis in patients with prosthetic implants (Figure 7). 
Labelled leukocyte imaging is the procedure of choice for the evaluation of patients with 
diabetic foot. Sensitivity and specificity of In-111 labelled leukocytes for diabetic foot 
osteomyelitis is between 72%-100% and between 67%-100%, respectively. Sensitivity of Tc-
99m HMPAO labelled leukocytes has been reported to be 90% and 93% while the specificity 
has been observed to be 86% and 100% by various groups. Interestingly, the combination of 
Tc-99m HMPAO labelled leukocytes scan with Tc-99m three phase bone scan has yielded 
both high sensitivity and high specificity (92.6% and 97.6%, respectively), moreover this 
combination is of benefit in patients with Charcot osteoarthropathy. The reported sensitivity  
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Fig. 7. A 70-year old female with history of left total knee replacement three years ago, 
presented with pain and swelling in the left knee prosthesis. Tc99m MDP bone scan show 
increased pool activity and intense increase tracer accumulation around left knee prosthesis. 
Tc-99m HMPAO labelled leukocytes scan showed increase tracer localization with rinds of 
tracer uptake at the femoral component of left knee prosthesis suggesting prosthetic 
infection. 
of 92.6% and a specificity of 97.6% by (Poirier et al., 2002) for Tc-99m HMPAO/Tc-99m MDP 
bone imaging for the diagnosis of osteomyelitis in diabetic foot ulcers appear promising and 
it is believed that neuroarthropathy does not affect the performance of this scan. In our own 
institutional experience this combination for diabetic foot ulcers proved to be useful in 
diagnosing underlying osteomyelitis (Figure 8). 
 
 
Fig. 8. A 50-year old male with history of diabetic right big toe amputation done 3 years ago, 
now presented with discharge from the right foot. Tc-99m HMPAO labelled leukocytes scan 
showed features consistent with osteomyelitis at right 3rd metatarsal bone with overlying 
soft tissue infection in the right distal foot. 
Leukocyte labelled imaging is not as sensitive for infection of the spine as it is for other 
musculoskeletal infections and may be falsely negative in up to 80% of cases. The difficulty 
in interpretation may be related to the large percentage of spinal osteomyelitis which 
produces a cold, rather than a hot lesion (marrow uptake in the spine may be higher than in 
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the adjacent inflammatory site which may mask the abnormality or cause the appearance of 
a cold defect). MRI is presumably the modality of choice when evaluating patients for 
suspected vertebral osteomyelitis. 
In-111 labelled leukocytes scans are superior to Ga-67 for evaluation of suspected abscess in 
abdomen and pelvis due to the lack of a normal bowel excretory pathway. Some abscesses 
accumulate In-111 labelled leukocytes very slowly, and 48 hour delayed imaging may be 
necessary to identify these lesions. In appendicitis a focal area of increased activity in the 
right lower quadrant may be identified. Labelled leukocyte can be used to assess for disease 
activity and distribution of inflammatory bowel disease and excellent correlation is found 
between endoscopy, histology, and scintigraphic findings for disease extent and activity. 
(Annovazzi et al., 2005) reported in a meta-analysis that leukocytes labelled with In-111 
oxine or Tc-99m HMPAO should be considered as the procedures of choice in acute phases 
of disease, since endoscopic and barium studies are contraindicated. 
Labelled leukocyte imaging has been successfully utilized to detect both cardiovascular and 
central nervous system infections with limited clinical consequences. Leukocyte 
scintigraphy provides valuable information about contrast-enhancing brain lesions seen on 
radiological imaging. Positive findings indicate that the origin of the brain lesion is almost 
assuredly infectious; a negative result rules out infection with a high degree of certainty. 
However, false positive results can be seen in brain tumours, and false-negative results in 
patients receiving high-dose steroids. Labelled leukocyte imaging is the radionuclide 
procedure of choice for diagnosis of graft infection, with a sensitivity of more than 90%; 
neither duration of symptoms nor pre-treatment with antibiotics adversely affects the study. 
The specificity of labelled leukocyte imaging is more variable, ranging from 53% to 100%. 
Causes of false-positive results include peri-graft hematomas, bleeding, graft thrombosis, 
pseudoaneurysms, and graft endothelialisation, which occur within the first 1–2 weeks after 
placement. 
4.5 Radiolabelled leukocytes: Hybrid SPECT/CT imaging 
SPECT/CT has incremental value for interpretation of labelled leukocytes imaging for an 
array of clinical indications in different regions of the body, by distinguishing normal 
physiologic distribution from accumulation due to underlying infectious process. Benefit 
has been observed when characterizing foci of labelled leukocytes accumulation near the 
major vessels. The hybrid technology helps in discriminating blood-pool activity from 
infectious sites, particularly in evaluation of suspected vascular graft infection and fever of 
unknown origin. Moreover, SPECT/CT with Tc-99m HMPAO labelled leukocytes is useful 
to image bone and joint infections, providing accurate localization especially some cases 
where planar images alone are not able to distinguish soft tissue from bone and to precisely 
define the extent of infection, thus modifying clinical patient management and therapeutic 
approaches in several cases. In particular those with diabetic foot infection, it helps support 
treatment planning and avoiding more invasive procedures. (Filippi & Schillaci, 2006) more 
recently reported that SPECT/CT avoided unnecessary bone amputation in significant 
numbers of patients. 
(Filippi & Schillaci, 2006) have evaluated the usefulness of SPECT/CT for interpreting Tc-
99m HMPAO labelled leukocytes in bone and joint infection. SPECT/CT fusion correctly 
characterized and localized the site of abnormal uptakes in all patients with osteomyelitis, 
having a substantial impact on the clinical management. Moreover, those patients with a 
suspicion of infection post orthopaedic implants, SPECT/CT offered a more accurate 
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(Filippi & Schillaci, 2006) have evaluated the usefulness of SPECT/CT for interpreting Tc-
99m HMPAO labelled leukocytes in bone and joint infection. SPECT/CT fusion correctly 
characterized and localized the site of abnormal uptakes in all patients with osteomyelitis, 
having a substantial impact on the clinical management. Moreover, those patients with a 
suspicion of infection post orthopaedic implants, SPECT/CT offered a more accurate 
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anatomic localization of the site of infection than SPECT alone allowing differentiation 
between prosthesis and soft-tissue uptake. Similarly, (Bar-Shalom et al., 2006) observed that 
using In-111 labelled leukocyte SPECT/CT contributed to accurate identification of infection 
in 55% of patients suspected to have osteomyelitis and 67% of those suspected to have a 
vascular graft infection. 
5. Tc-99m labelled Anti-granulocyte antibody scintigraphy 
5.1 Tc-99m labelled Anti-granulocyte antibody: Pharmacological and physiochemical 
characteristics 
Three anti-granulocyte antibodies have been used including anti-NCA-95 immunoglobulin 
IgG, fanelosomab (a monoclonal murine M class immunoglobulin), sulesomab (a murine 
monoclonal antibody fragment anti-NCA-90 Fab) and anti-CD15. Presently most routinely 
sulesomab (Leukoscan ®) is used in clinical practice. 
Leukoscan consists of a small murine monoclonal antibody fragment, sulesomab, labelled 
with Tc-99m. The radiolabelled antibody fragment (Fab) reacts with the normal cross 
reacting antigen (NCA-90) present on the surface of virtually all neutrophils. Therefore areas 
where neutrophils have accumulated can be detected and this proves useful in determining 
the location and extent of infection and inflammation. Uptake at sites of infection is 
therefore related to migration of antibody labelled circulating granulocytes and non-specific 
non-antigen related uptake of free antibody. The use of radiolabelled monoclonal antibodies 
against surface antigens as present on granulocytes has the advantage that labelling 
procedures are easier and do not require handling of potentially contaminated blood. Since 
the leukocytes are not removed from the patient, it is considered as in-vivo labelling 
process. Mounting of an immune response and production of human anti-mouse antibodies 
(HAMA) may pose a concern; however, in our experience and available published data the 
level of adverse events and probability of HAMA response are both low. 
5.2 Tc-99m labelled Anti-granulocyte antibody: Imaging protocols and pre-requisites 
Tc-99m Sulesomab is presented as a lyophilised powder (0.31 mg per vial) to be 
reconstituted with sodium chloride. Approximately 555-925 MBq is injected intravenously. 
Imaging should be performed 1–8 hours post injection. We usually perform imaging at 10 
minutes and 2-4 hours post injection with occasional 24 hour delayed imaging in certain 
situations to have better target to background ratio for better delineation of lesions. 
5.3 Tc-99m labelled Anti-granulocyte antibody: Clinical utilities and applications 
Tc-99m Sulesomab is commonly indicated as an adjunctive diagnostic imaging of 
infection/inflammation in patients with suspected osteomyelitis, including patients with 
diabetic foot ulcers. As Tc-99m MDP bone scan has a low specificity, Tc-99m Sulesomab 
imaging as a follow-up test reduces the false-positive rate of Tc-99m MDP imaging. The 
overall sensitivity and specificity for the diagnosis of infections is 86% and 72%, respectively. 
In patients with diabetic foot ulcers, the diagnostic accuracy of Tc-99m Sulesomab compared 
with In-111 and Tc-99m HMPAO labelled leukocytes scanning was observed not to be 
significantly different (81 and 75%, respectively). However, Tc-99m Sulesomab imaging has 
a significantly higher sensitivity. In our own experience Tc-99m Sulesomab imaging has an 
incremental diagnostic value in the detection and ruling out osteomyelitis especially when 
used subsequent to Tc-99m MDP imaging (Figure 9). 
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Tc-99m fanolesomab has been used for diagnosis of acute appendicitis. It has a good overall 
accuracy with a positive predictive value (PPV) of 74-87% and a negative predictive value 
(NPV) between 95-100%. A high NPV is helpful for the patients to avoid unnecessary 




Fig. 9. A 10-year old girl, presented with tenderness and swelling at right distal femur. Tc-
99m MDP bone scan show hyperperfusion and increases tracer accumulation at the distal 
1/3rd of right femur. Tc-99m Sulesomab imaging show increased tracer uptake at distal right 
femur corresponding to the site seen on bone scan, confirming osteomyelitis. 
5.4 Tc-99m labelled Anti-granulocyte antibody: Hybrid SPECT/CT imaging 
(Horger et al., 2003) showed that SPECT/CT changed the interpretation of 
radioimmunoscintigraphy with Tc-99m labelled anti-granulocyte antibodies in 28% of 
suggestive foci evaluated in 27 patients in whom relapsing post-traumatic osteomyelitis was 
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suspected. In another recent study (Graute V et al., 2010) concluded that SPECT/CT 
substantially improves the utility of imaging with Tc-99m labelled anti-granulocyte 
antibodies for diagnosis and localization of suspected joint infections and provide 
information on the extent of the infection. We have found that SPECT/CT imaging not only 
helps anatomical localization of the infectious site but also provides lesion characterization 
and extent of involvement of the infectious process (Figure 10). 
 
 
Fig. 10. A 25-year old female referred for evaluation of osteomyelitis in the left middle 
finger. Tc-99m MDP bone scan show hyperaemia, increased pool activity and intense linear 
increased tracer uptake in the left 3rd proximal phalanx extending up to the mid of middle 
phalanx. Tc-99m Sulesomab images show increased uptake at the same site confirming 
osteomyelitis. Further correlative SPECT/CT images show evident cortical distortion with 
low attenuation changes.  
6. F-18 fluorodeoxyglucose positron emission tomography 
6.1 F-18 FDG: Pharmacological and physiochemical characteristics 
Fluorine 18 (F-18) Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) has 
been extensively used for imaging malignant processes, however, it is also now an 
established agent for imaging benign processes such as infection, inflammation and 
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granulomatous disease. Increased F-18 FDG uptake in these tissues is attributed to the 
increased glucose consumption through the hexose monophosphate shunt, which is the 
main energy source in chemotaxis and phagocytosis. The respiratory burst or the 
phagocytes activation results in increased F-18 FDG uptake. Marked F-18 FDG uptake is 
seen in neutrophils during acute phase of inflammation while during the chronic phase it is 
the macrophages and polymorphonuclear leukocytes that take up the tracer. Therefore, in 
cases of sterile inflammation it is mainly the neutrophils and macrophages that take up F-18 
FDG. The mechanism of F-18 FDG uptake in infectious and inflammatory process is the 
same as in malignancy with metabolic trapping of the F-18 FDG-6-phosphate that cannot be 
further metabolised as it is not a substrate for the glucose 6-phosphatase isomerase enzyme. 
However, as the level of glucose 6-phosphatase remains the same in inflammatory cells as 
opposed to tumour cells where they are decreased, the F-18 FDG washes out from the 
inflammatory cells in due course. Further the numbers of GLUT (glucose transporter 
receptors) are less in inflammatory cells when compared with tumour cells. 
The normal distribution of F-18 FDG includes the brain, myocardium, and the genitourinary 
system with variable uptake seen in the stomach, bowel and the bone marrow. Increase F-18 
FDG activity can be seen in the spleen in patients with infection and presumably reflects the 
increased glucose usage by spleen in the setting of an infectious process.  
6.2 F-18 FDG PET: Imaging protocols and pre-requisites 
The patients are advised to fast for several hours before imaging. This reduces the F-18 FDG 
uptake in normal tissues. Moreover, it reduces the competition for glucose transporters. The 
physical activity of the patient is limited prior to injection and this reduces the F-18 FDG 
uptake in the striated muscles. Some centers also administer benzodiazepines 30-60 minutes 
prior to injection to reduce the brown fat and muscle uptake. Patient is routinely injected 
370-550 MBq of F-18 FDG intravenously and laid to rest in a comfortable bed. Imaging is 
usually done at 60 minutes post injection, however, some centers may extend the uptake 
period to 90 minutes or may acquire images twice at different times (dual point) particularly 
in cases of granulomatous processes such as tuberculosis. Whole body imaging is preferred 
in cases where a focus of infection is to be investigated. F-18 is cyclotron produced 
radioisotope. The physical half-life of F-18 is 110 minutes. The principal gamma photons 
produced are of 511 KeV energy generated by positron emission.  
6.3 F-18 FDG PET: Clinical utilities and applications 
The indications for F-18 FDG PET for imaging infection are not different from those 
discussed previously, however, in particular investigation for the site of infection or 
ascertaining the cause in FUO, vasculitis, HIV-AIDS, infected prostheses, as well as 
osteomyelitis, diabetic foot infections, sarcoidosis and tuberculosis have been studied. 
In case of FUO, the sensitivity and specificity of F-18 FDG PET has been observed to be 84-
93% and 86-90% respectively. In most studies, it has helped in the management of about 35-
37% cases. The reported PPV is 87% and the NPV 95%. Negative F-18 FDG PET makes it 
very unlikely that a morphologic origin of the fever will be identified. Infective endocarditis 
that can be a source of FUO has also been studied with F-18 FDG PET. 
F-18 FDG accumulation has been observed in certain conditions resulting in vasculitis. 
These include giant cell arteritis, Takayasu arteritis, polymyalgia rheumatica, aortitis/peri-
aortitis, infectious vasculitis and unspecified large vessel vasculitis. Inflammation of the 
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vessel walls cannot be detected in the early phase on conventional anatomical imaging. F-18 
FDG assists in early diagnosis, assessing the extent of the disease and has also been found 
superior to MRI in depicting disease activity and treatment response. High brain uptake, 
relatively high skin background and the smaller diameter of the vessels lower the sensitivity 
of F-18 FDG PET in temporal arteritis. Giant cell arteritis in arteries greater than 4mm in 
diameter is nicely demonstrated by F-18 FDG PET. It is important to remember that 
vasculitis can be one of the causes of FUO as we have observed in some of our referred 
patients (Figure 11). Assessment for this is done by observing both non-attenuation 
corrected and attenuation corrected PET images.  
 
 
Fig. 11. A 56-year old female with FUO referred for detecting potential site(s) of infection. F-
18 FDG PET/CT scan show diffuse increased FDG uptake evident in major blood vessels 
including the carotids, brachiocephalics, aortic arch, descending thoracic aorta extending up 
to the renal level. Findings consistent with the inflammatory etiology of vasculitis. 
In patients with HIV-AIDS, there is increased likelihood of opportunistic infections as well as 
malignancy. (O’Doherty et al., 1997) reported that F-18 FDG PET has a sensitivity of 92% and 
specificity of 94% in localizing abnormalities that required treatment in these patients; 
however, they also concluded that it is not possible to clearly distinguish infectious from a 
malignant process in these patients. Toxoplasmosis is the commonest of the opportunistic  
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infections in AIDS patients. Most commonly the central nervous system is affected. F-18 
FDG has been reported to be superior and more accurate than MRI in differentiating CNS 
lymphoma from conditions such as toxoplasmosis, progressive multi-focal 
leukoencephalopathy and syphilis. Further on quantitative assessment it has been shown 
that the standardized uptake values of toxoplasmosis are significantly lower than 
lymphoma with virtually no overlap. 
F-18 FDG PET has been used extensively to evaluate painful lower limb joint prostheses. It 
has a limited significance especially when distinguishing infected joint prosthesis from 
aseptic prosthetic loosening. As inflammation is part of both the conditions, there is 
increased F-18 FDG peri-prosthetic accumulation observed in both. F-18 FDG PET is 
considered highly sensitive for evaluation of chronic osteomyelitis. Unlike bone 
scintigraphy F-18 FDG uptake normalizes in less than 2-3 months following treatment, 
thereby, reducing the false positive scans seen when osteomyelitis is suspected in 
complicated fractures. F-18 FDG PET has also been used with variable utility in diabetic foot 
infections, sarcoidosis, tuberculosis, organ transplantation and inflammatory bowel disease. 
In case of sarcoidosis the imaging findings are similar to those seen and discussed with Ga-
67 scintigraphy. Further F-18 FDG PET can detect metastatic infectious foci with high 
sensitivity even if other imaging is negative. 
6.4 F-18 FDG PET: Hybrid PET/CT imaging  
Hybrid PET/CT systems in fact gained more popularity than the SPECT/CT systems and 
PET imaging is synonymously used for PET/CT imaging. The incorporation of anatomical 
data fused with the functional PET images results in accurate localization of the 
abnormalities and moreover detailed characterization of the lesions can be ascertained. In 
our experience PET/CT imaging for infectious process has limited utility, primarily in cases 
of FUO, vasculitis, malignant otitis externa and assessment of chronic osteomyelitis. 
However, as more evidence based data surface, this modality may prove to be an important 
method in detection and management of a number of infective conditions.  
7. Brief considerations and limitations regarding anatomic imaging 
modalities 
Radiograph or plain films are almost always the initial imaging study for diagnosing and 
assessing osteomyelitis. Finding on plain films to suggest or support infectious process 
include periosteal elevation or thickening, cortical thickening, irregularity with loss of 
trabecular architecture, sclerosis, osteolysis, and new bone formation. It is however 
important to note that these changes may not be evident at least until 5-7 days in children 
and 10-14 days in adults. Plain films show lytic changes only after at least 50%-75% of the 
bone matrix is destroyed.  
Ultra-sonography is mostly utilized in evaluation and diagnosing of fluid collections, 
involvement of the periosteum, along with assessing surrounding soft tissue abnormalities. 
It may provide guidance for diagnostic or therapeutic aspirations, subsequent drainage 
and/or tissue biopsy.  
Anatomic imaging modalities including CT and MR imaging provide excellent structural 
resolution for the detection and characterization of infectious or inflammatory conditions. 
These provide a high-quality assessment of infection related structural abnormalities. 
However, the limitation is that these techniques rely solely on structural changes and, 
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therefore, differentiation between active and structural but indolent alterations following 
surgery or other interventions is difficult to differentiate and these modalities are generally 
of limited value in detecting early disease regardless of the cause. In evaluation of infectious 
process CT scans may assist in the assessment of disruption of the bony cortex and soft-
tissue involvement. Furthermore, CT may also reveal edema, intra-osseous fistula and 
cortical defects that lead to soft tissue sinus tracts. 
CT is better suited for an evaluation of cortical bone, whereas MR imaging is more useful for 
the evaluation of internal architecture of structures such as the bone marrow, muscles, 
tendons, ligaments, cartilage etc. MR imaging has high accuracy in the acute osteomyelitis 
evaluation and detection primarily delineating adjacent soft tissue infection; particularly 
when no prior alterations in osseous or soft structure are present. However, in patients who 
have undergone previous surgical intervention, MR imaging may not be able to clearly 
distinguish signal abnormality secondary to bone marrow edema or enhancement related to 
a reactive phenomenon and that related to infection. Similarly, the diagnostic accuracies of 
both CT and MR imaging to evaluate osteomyelitis generally decrease in the presence of 
metallic implants due to streak and susceptibility artefacts. 
MR imaging has a higher sensitivity and specificity than plain films and CT. Further 
findings become positive earlier in the disease process with MR than with plain films. MR 
imaging is particularly better at depicting bone marrow abnormalities with sensitivity of 
82%-100% and specificity of 75%-95%. Vertebral osteomyelitis is one condition where MR 
has a characteristic pattern of confluent vertebral body and disk involvement; the diagnostic 
accuracy in such cases amount to 90%. MR imaging findings in osteomyelitis usually are 
related to the replacement of marrow fat with water secondary to edema, exudate, 
hyperemia, and bone ischemia. Findings include the following: decreased signal intensity in 
the involved bone on T1-weighted images, increased signal intensity in the involved bone 
on T2-weighted image, and increased signal intensity in the involved bone on short-tau 
inversion recovery (STIR) images. A decreased intensity on T1-weighted images with no 
change on T2-weighted images may indicate surgical or post-traumatic scarring of bone 
marrow. The MR imaging limitations are primarily due to the reason that findings of 
osteomyelitis are nonspecific, and similar changes may occur as a result of fractures, 
tumours, and a number of various intramedullary or juxtamedullary processes that result in 
bone marrow edema. 
8. Future prospects and novel agents 
The future for infection imaging looks promising with the search for an ideal agent still on. 
There has been a progression in the development of leukocytes labelled in-vitro by F-18 
FDG. Moreover, leukocytes labelled with Copper-64 (Cu-64) are being studied. 
Radiolabelled antibiotics are also in vogue. The theoretical reasoning for radiolabelled 
antibiotics would be that such would incorporate into and metabolized by bacteria, thereby, 
making it possible to localize the site of infection. Tc-99m Ciprofloxacin has been studied, 
some results published with regards to its use in post-operative infections, however, this did 
not go into routine clinical practice due to conflicting data. Tc-99m labelled anti-microbial 
peptides are also being studied including Tc-99m labelled recombinant human beta-
defensin-3 that exerts bactericidal effects on gram positive and gram negative bacteria as 
well as some yeasts, and Tc-99m ubiquicidin whose uptake is related to number of viable 
bacteria. Most recently (Lupetti et al., 2011) in a review have mentioned radiolabelled 
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antimicrobial peptides, fluconazole and chitin targeting agents that have been studied to 
image fungal infection in mice. There is a limitation of difficulty in differentiating bacterial 
and fungal infections. However, radiolabelled fluconazole has the ability to distinguish 
Candida albicans infection from bacterial infections/sterile inflammation.  
Tc-99m ubiquicidin (Tc-99m UBI29-41), Tc-99m labelled lactoferrin (hLF1-11), Tc-99m 
fluconazole and I-123 labelled chitinase are being further studied at the moment. Tc-99m 
UBI29-41 was clinically tested in trial setting as human infection imaging agent (Akhtar et 
al., 2005) with promising results. They suggested an optimal imaging time of 30 minutes 
post injection for this agent. Another team (Salber et al., 2008) assessed and compared Tc-
99m ubiquicidin and F-18 ubiquicidin autoradiography to anti-Staphylococcus aureus 
immunofluorescence in rat muscles abscesses. However, most recently, (Assadi et al., 2011) 
assessed the diagnostic accuracy of Tc-99m UBI29-41 scintigraphy for osteomyelitis making 
a comparison to Tc-99m MDP Bone scan and MR imaging. The authors concluded that for 
fast imaging with high accuracy, Tc-99m UBI29-41 is suitable for detection of osteomyelitis. 
In this most recent study the accuracy for Tc-99m UBI29-41 for detection of infection was 
observed to be 100% as compared to 90% for Tc-99m MDP bone scan. MR imaging was done 
in more than half of these cases and showed an accuracy of 75% for detecting osteomyelitis. 
Further in another most recent preliminary study by (Nazari et al., 2011) evaluated the role 
and ability of Tc-99m UBI29-41 to assess response to antibiotic therapy in orthopedic 
infections with quantitative analysis. With these recent encouraging reports, Tc-99m UBI29-
41 seems a novel agent of the future for infection imaging. 
N-formyl products (fMLF or fMLP) labelled with Tc-99m are also being studied in rabbits 
for localization of infection. Tc-99m labelled Interleukin-8 (IL-8) seems another promising 
agent for the future as after initial animal model experiments it has been tried in humans 
with promising initial results.  
9. Conclusion 
Radionuclide imaging plays a significant role in infection detection and localization. 
Currently the selection of infection imaging agent depends upon the availability and local 
expertise especially in cases of labelling leukocytes which require time consuming labelling 
procedures. SPECT-CT provides essential anatomical localization especially in cases of 
vertebral osteomyelitis, diabetic foot, and infected prosthesis, cardiovascular, abdominal 
and pulmonary infections. Gallium scintigraphy can be replaced with FDG PET where 
available. FDG PET is a preferred procedure of choice for pyrexia of unknown origin, 
vasculitis, sarcoidosis, infected grafts and inflammatory bowel disease, moreover 
quantitative FDG PET analysis appears another promising further advance. Finally, with the 
progress in hybrid imaging the diagnostic power of conventional scintigraphy in detection 
and localization of infection has greatly augmented and the development of newer infection 
seeking agents pave the way for improved patient management in future. 
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1. Introduction 
Nuclear medicine supplies with functional perspective in the diagnosis of different 
pathologies of the musculoskeletal system. Bone scintigraphy is one of the most used 
nuclear medicine techniques in our clinical practice for location, evaluation and diagnosis of 
these pathologies because of its high sensitivity. This technique identifies functional changes 
before structural lesions have been established. For the study of musculoskeletal disorders, 
the usage of three-phase bone scintigraphy is applied more often than conventional bone 
scintigraphy. However, due to its low specificity, it has been replaced by other techniques 
such as magnetic resonance imaging (MRI) in the evaluation of localized lesions. New 
techniques in nuclear medicine which provide precision with high sensitivity are currently 
available, such as single-photon emission computed tomography (SPECT), useful in the 
evaluation of lumbar and hip pathology, or the presence of inflammation in small joints 
(hands and feet), and positron emission tomography (PET), which provides a metabolic 
imaging. Several radionuclides can be used in the scintigraphic evaluation, although the 
most commonly used for bone scintigraphy are labelled with technetium 99-m (99mTc), 
standing out diphosphonate compounds such as methylene diphosphonate (MDP). This 
radiopharmaceutical (Tc-99m-MDP) is used for studying metabolic bone diseases like 
Paget´s disease, transient osteoporosis and reflex sympathetic dystrophy. And it is also 
useful in the location of polytopic forms of avascular osteonecrosis, in the study of hidden 
painful radiologic bone lesions such as osteoid osteoma or others bone tumours, in the 
evaluation of soft-tissue lesions, and in the assessment of spread pattern of bone metastases. 
Furthermore, this radionuclide may locate bone fractures, identify the cause of pain in 
patients with chronic pain after arthroplasty, show the evolution of heterotopic ossification 
and provide information about musculoskeletal system infections (in combination with 
other radionuclides) and paediatric diseases. Other radionuclides commonly used in the 
evaluation of infectious or inflammatory processes in the musculoskeletal system are 
gallium citrate and indium 111-labelled leukocytes, since the latter increases the specificity 
of technetium radiotracer. Local treatments can be applied by radio isotopic techniques. One 
of these is radiosynoviorthesis, used in the treatment of patients with persistent 
monoarthritis in different stages (from inflammatory poliarthritis to pigmentary 
villonodular sinovitis).  
 
12 Chapters on Nuclear Medicine 
 
96
Pakos, EE.; Trikalinos, TA. Fotopoulos, AD. et al (2007). Prosthesis infection: diagnosis after 
total joint arthroplasty with antigranulocyte scintigraphy with 99mTc-labeled 
monoclonal antibodies-a meta-analysis. Radiology. Vol. 242, No. 1, (January 2007), 
pp. 101-108, ISSN 0033-8419 
Palestro, CJ.; Kim, CK. Swyer, AJ. et al (1990). Total-hip arthroplasty: periprosthetic indium-
111-labeled leukocyte activity and complementary technetium-99m-sulfur colloid 
imaging in suspected infection. Journal of Nuclear Medicine, Vol.31, No.12, 
(December 1990), pp. 1950-1955, ISSN 0161-5505 
Palestro, CJ. (1994). The current role of gallium imaging in infection. Seminars in Nuclear 
Medicine, Vol.24, No.2, (April 1994), pp. 128-141, ISSN 0001-2998 
Palestro, CJ. & Torres, MA. (1997) Radionuclide imaging in orthopedic infections. Seminars 
in Nuclear Medicine, Vol.27, No.4, (October 1997), pp. 334–345, ISSN 0001-2998 
Palestro, CJ. (2009). Radionuclide imaging of infection: in search of the grail. Journal of 
Nuclear Medicine, Vol.50, No.5, (May 2009) pp. 671-673, ISSN 0161-5505  
Petruzzi, N.; Shanthly, N. & Thakur, M. (2009). Recent trends in soft tissue infection 
imaging. Seminars in Nuclear Medicine, Vol.39, No.2, (March 2009), pp. 115-123, ISSN 
0001-2998 
Poirier, JY.; Garin, E. Derrien, C. et al (2002). Diagnosis of osteomyelitis in the diabetic foot 
with a 99mTc-HMPAO leucocyte scintigraphy combined with a 99mTc-MDP bone 
scintigraphy. Diabetes Metabolism, Vol.28, No.6, (December 2002), pp. 485–490, ISSN 
1262-3636 
Salber, D.; Gunawan, J. Langen, KJ. et al (2008). Comparison of 99mTc- and 18F- ubiquicidin 
autoradiography to anti-Staphylococcus aureus immunofluorescene in rat muscle 
abscesses. Journal of Nuclear Medicine, Vol.49, No.6, (June 2005), pp.995-999, ISSN 
0161-5505 
Santiago, CR.; Giménez, CR. & McCarthy K. (2003). Imaging of osteomyelitis and 
musculoskeletal soft tissue infections: current concepts. Rheumatic diseases clinics of 
North America, Vol.29, No.1, (February 2003), pp. 89-109, ISSN 0889-8573 
Scher, DM.; Pak, K. Lonner, JH. et al (2000). The predictive value of Indium-111 leukocyte 
scans in the diagnosis of infected total hip, knee, or resection arthroplasties. Journal 
of. Arthroplasty, Vol.15, No.3, (April 2000), pp. 295-300, ISSN 1532-8406 
Tsan, MF. (1985). Mechanism of gallium-67 accumulation in inflammatory lesions. Journal of 
Nuclear Medicine, Vol.26, No.1, (January 1985), pp. 88-92, ISSN 0161-5505 
van Eerd, JE.; Boerman, OC. & Corstens, FH. (2003). Radiolabeled chemotactic cytokines: 
New agents for scintigraphic imaging of infection and inflammation. Quarterly 
Journal of Nuclear Medicine, Vol.47, No.4, (December 2003), pp. 246-255, ISSN 1824-
4785 
Wegener, WA. & Alavi, A. (1991). Diagnostic imaging of musculoskeletal infection. 
Roentgenography; gallium, indium-labeled white blood cell, gammaglobulin, bone 
scintigraphy; and MRI. Orthopaedics Clinics of North America. Vol.22, No.3, (July 
1991), pp. 401-418, ISSN 0030-5898 
Zhuang, H. & Alavi, A. (2002). 18-fluorodeoxyglucose positron emission tomographic 
imaging in the detection and monitoring of infection and inflammation. Seminars in 
Nuclear Medicine, Vol.32, No.1, (January 2002), pp. 47-59, ISSN 0001-2998  
5 
Nuclear Medicine in Musculoskeletal Disorders: 
Clinical Approach 
Noelia Medina-Gálvez1 and Teresa Pedraz2 
1Hospital Universitario de San de Juan de Alicante, Department of Physical Medicine and 
Rehabilitation, Miguel Hernández University 
2Hospital General Universitario de Alicante, Department of Rheumatology 
Spain 
1. Introduction 
Nuclear medicine supplies with functional perspective in the diagnosis of different 
pathologies of the musculoskeletal system. Bone scintigraphy is one of the most used 
nuclear medicine techniques in our clinical practice for location, evaluation and diagnosis of 
these pathologies because of its high sensitivity. This technique identifies functional changes 
before structural lesions have been established. For the study of musculoskeletal disorders, 
the usage of three-phase bone scintigraphy is applied more often than conventional bone 
scintigraphy. However, due to its low specificity, it has been replaced by other techniques 
such as magnetic resonance imaging (MRI) in the evaluation of localized lesions. New 
techniques in nuclear medicine which provide precision with high sensitivity are currently 
available, such as single-photon emission computed tomography (SPECT), useful in the 
evaluation of lumbar and hip pathology, or the presence of inflammation in small joints 
(hands and feet), and positron emission tomography (PET), which provides a metabolic 
imaging. Several radionuclides can be used in the scintigraphic evaluation, although the 
most commonly used for bone scintigraphy are labelled with technetium 99-m (99mTc), 
standing out diphosphonate compounds such as methylene diphosphonate (MDP). This 
radiopharmaceutical (Tc-99m-MDP) is used for studying metabolic bone diseases like 
Paget´s disease, transient osteoporosis and reflex sympathetic dystrophy. And it is also 
useful in the location of polytopic forms of avascular osteonecrosis, in the study of hidden 
painful radiologic bone lesions such as osteoid osteoma or others bone tumours, in the 
evaluation of soft-tissue lesions, and in the assessment of spread pattern of bone metastases. 
Furthermore, this radionuclide may locate bone fractures, identify the cause of pain in 
patients with chronic pain after arthroplasty, show the evolution of heterotopic ossification 
and provide information about musculoskeletal system infections (in combination with 
other radionuclides) and paediatric diseases. Other radionuclides commonly used in the 
evaluation of infectious or inflammatory processes in the musculoskeletal system are 
gallium citrate and indium 111-labelled leukocytes, since the latter increases the specificity 
of technetium radiotracer. Local treatments can be applied by radio isotopic techniques. One 
of these is radiosynoviorthesis, used in the treatment of patients with persistent 
monoarthritis in different stages (from inflammatory poliarthritis to pigmentary 
villonodular sinovitis).  
 
12 Chapters on Nuclear Medicine 
 
98
The objective of this chapter is to make a simple but detailed review of the main nuclear 
medicine clinical applications in the appraisal and management of musculoskeletal problems.  
2. Normal bone scintigraphy 
Bone scan is a diagnostic technique used to assess the presence of anomalies in the 
distribution pattern of bone formation. It has high sensitivity, but specificity is frequently 
variable or limited. Three-phase bone scintigraphy is currently the most used technique 
because it allows evaluating the degree of hyperemia (flow phase), increased of articular 
permeability (blood pool phase) and the presence of alterations in bone remodeling (bone 
tissue phase). Traditional technique is based on the biological properties of bisphosphonates 
marked with 99mTc, usually MDP, when they are integrated into the bone metabolism after 
intravenous administration. Typically, 30% of the injected dose of Tc-99m-MDP remains in 
the skeleton, and most of bone uptake occurs in the first hour. The remainder is eliminated 
from the tissues and blood by the kidneys and imaging is obtained 3 – 4 hours later. In 
general, uptake of the tracer depends on local blood flow, osteoblastic activity and 
extraction efficiency. Normal scintigraphy imaging depends on technical equipment and 
employees, but it is also significantly influenced by other factors such as age and 
constitution of the patient, intake of drugs, degree of hydration, renal function and/or the 
presence of impaired circulation. Therefore a whole body study is recommended, with 
anterior and posterior screenings that allows assessing the symmetry or asymmetry in the 
distribution of the drug. However, a located study may be sufficient in some cases, since 
provides greater image quality and requires less time and is less expensive. In other 
patients, especially when a spine study is necessary or avascular osteonecrosis located in the 
hip or knee is suspected, it will require a SPECT, that is more sensitive for detecting 
abnormalities and provides, combined with tomography, three-dimensional images. 
It is necessary to have knowledge of normal variants and patterns of abnormality to 
minimize misinterpretation. Whole body bone scan shows normal variations in the uptake 
of the radiotracer, as this is higher in areas with high bone remodeling. The age of the 
patient has a fundamental role in the appearance of the scan, especially during the growth 
period and in the elderly. In children, as they have a growing skeleton, there is a diffuse 
bone uptake and a striking uptake at the growth plates of bones, especially in metaphyseal-
epiphyseal areas of long bones and cranial sutures. This decreases over the years until 
complete fusion of the epiphyses takes place. On the other hand, bone scan images are often 
of poor quality in old people. Aging may be reflected in scintigraphic images by a diffuse 
reduction of bone uptake of the radioisotope, although diffuse uptake at the dome or 
symmetrical uptake in the peripheral joints (secondary to osteoarthritis) may be present. 
Associated degenerative processes may lead to increased uptake in the involved joints. 
Obese people also get lower quality images. In addition, insufficient hydration and/or renal 
failure hamper the radiopharmaceutical removal of soft tissues and modify the end result.  
The sternum and the sacroiliacs joints are normal uptake areas in scintigraphic studies (Fig. 
1). Other areas that may appear as normal increased uptake (table 1) are forewings of the 
iliac bone, coracoid process, tip of the scapula and, sometimes, costochondral junction, 
lower portion of the cervical spine, kneecaps and some muscle attachments. Thoracic 
kyphosis and lumbar lordosis may cause the parts of the column that are farther away, 
appear as less warm. In patients with scoliosis, concave side usually appears hotter than the 
convex. There is also a physiological uptake located at renal pelvis and the bladder, since 
radiotracers are eliminated by the kidneys (Murray, 1998; Schneider, 2006).  
 




Fig. 1. Normal bone scintigraphy. 
 
Head and neck:       Skull sutures, pterion, occipital protuberance, angle of mandible, 
hyperostosis frontalis, sinuses (ethmoidal and maxillary), dental 
disease and microcalcification of thyroid cartilage 
Thorax:  Sternoclavicular joint, acromioclavicular joint, sternal foramina, 
costochondral uptake, manubrium sternum/xiphisternum, tip of 
scapulae, symmetrical muscle insertion in the posterior ribs of 
paraspinal muscles (stippled appearance) 
Abdomen and pelvis:  Kidney, bladder, bladder diverticulae, pelvic diastasis (post 
partum women) 
Long bones:   Deltoid tuberosity/deltoid insertion, trochanteric bursitis 
Table 1. Normal Variants of uptake on 99mTc-MDP Bone Scan. 
Many causes may lead to false pathologic imaging or pitfalls (Naddaf et al., 2004). Bladder 
diverticula or bladder image over pubic bones, urine leakage or urinary retention and patient 
rotation are some common examples. Artifacts on bone scintigraphy can be technical or 
patient-related (Table 2). The technical artifacts include equipment, radiopharmaceutical, and 
image processing-related problems. Equipment-related artifacts may be due to inadequate 
quality-control procedures and calibration. Faulty radiopharmaceutical preparation alters 
biodistribution and can compromise the diagnostic quality of the images. Increased tracer 
uptake in the stomach, thyroid, and salivary glands can be seen if there is free pertechnetate, in 
the radiopharmaceutical. A number of factors, for example, presence of reduced aluminum 
ions, if the radiopharmaceutical is left unused for a long time, inappropriately high pH and 
addition of dextrose solutions, may affect uptake of radioactivity in bone. 
Finally, the most common artifact on the bone scan is due to extravasation at the site of 
injection, that may occasionally cause confusion with a bone abnormality, and it is therefore 
important to document the site of injection in all patients. Further, ipsilateral lymph node(s) 
may be seen due to extravasation of radiotracer and can on occasion cause confusion,  
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Radiopharmaceutical: Free pertechnetate (stomach, thyroid, salivary glands) 
Technical:  Injection site, lymph node (radiotracer extravasations), 
injection into central venous catheter, arterial injection 
Patient:  Urine contamination, patient motion, breast prosthesis, 
metallic prosthesis (elbow, shoulder, knee and hip) 
Metallic:    Belt buckle, medallion, jewellery, pace maker 
Instrumentation:    Photomultiplier tube, cobalt peak, image contrast 
Treatment:  Postradiotherapy
Table 2. Common Artifacts in Bone Scintigraphy. 
particularly if overlying the scapula or a rib (Gnanasegaran et al., 2009). Photon-deficient 
areas commonly seen on the bone scan are due to metallic objects. Patients should be asked 
to remove metallic objects wherever possible before performing the scan.  Urinary 
contamination is a common problem, which may simulate focal lesions, especially if close to 
or overlying the bone. It is useful to remove the clothing or to wash the skin and reimage the 
patient around the region of interest to avoid any confusion. The patient should void before 
the study and rarely delayed imaging or bladder catheterization may be required. Further, 
radioactive urine in the bladder is a frequent cause of artifact in patients evaluated with 
SPECT for pelvic metastases (prostate cancer) or low-back pain. Increased radioactive urine 
in the bladder can cause streak artifacts on the reconstructed images and overlap bony 
structures. Further, intense tracer retention in the bladder is reported to cause pixel 
overload, resulting in a relatively cold area close to the region of interest of the femoral 
heads, which hinders its interpretation.  
3. Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic autoimmune systemic disease of unknown origin, 
with an overall prevalence of 1%. It mainly affects joints with symmetrical and polyarticular 
pattern and may lead up to progressive structural damage, functional disability and extra–
articular complications. It can affect many organ systems and it is also associated with a 
higher prevalence of other diseases such as infections, neoplasms and cardiovascular 
disease. It has been shown that 50% of patients with RA are disabled within 10 years of 
onset of disease and survival is reduced (Malviya et al., 2010; as cited in Solomon et al., 2003, 
Wolfe et al., 1994, 2002, 2003).  
Conventional radiology is the most wide-spread technique for the appraisal of RA, since it 
allows the evaluation of the presence or absence of erosions, joint space narrowing or 
articular osteopenia, but only when symptoms have been present for several months or 
years. The importance of early diagnosis in patients with RA, based on the possibility of 
modifying the prognosis with an early treatment, has led to the introduction of new 
techniques that identify the characteristic changes in an accurate and reliable way. MRI and 
High-Frequency Ultrasonography (US) have shown their reliability for detecting early bony, 
vascular and soft tissue changes in patients with RA and are the techniques most commonly 
used with this aim. Nuclear medicine techniques, such as imaging with nanocolloids, PET or 
three-phase bone scintigraphy may also be useful in this field. Three-phase bone 
scintigraphy is still used in clinical practice in patients with RA because it allows the 
detection of changes (hyperemia, increased permeability, altered bone metabolism) before 
the structural lesions appear, and may display the pattern of joint involvement and even 
predict the development of erosions (Colamussi et al., 2004; as cited in Mottonen et al., 
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1988). The intensity of uptake on scintigraphy is correlated to some clinical and laboratory 
indexes of disease activity (De Leonardis et al., 2008; as cited in Park et al., 1977) and the 
monitoring during treatment can evaluate the effectiveness of it (De Leonardis et al., 2008; as 
cited in Palmer et al., 1993; Elzinga et al., 2010). It is also a useful technique when an 
additional pathology (eg, osteonecrosis, stress fractures or metastatis) is suspected.  
Furthermore, in patients with nonspecific polyarthralgia, normal bone scan excludes the 
presence of active arthritis (Colamussi et al., 2004; as cited in Shearman et al., 1982). It is a 
sensitive tool but not highly specific, and may be altered in other diseases such as 
osteoarthritis. Nevertheless, planar bone scintigraphy is clearly less sensitive than SPECT in 
the evaluation of early stages of this disease or mild abnormalities. Multipinhole SPECT of 
the hands has been used to identify patients with minimal changes in bone metabolism 
(Gotthardt et al., 2010). This technique proven to equal MRI in sensitivity and also detected 
increased bone metabolism in two patients in whom MRI had negative results, 
demonstrating that multipinhole SPECT may be even more sensitive than MRI in some 
cases (Gotthardt et al., 2010; as cited in Ostendorf et al., 2010). PET may also be used for 
imaging of synovial inflammation. The most commonly used radiotracer in clinical PET 
scanning is fluorodeoxyglucose (18F-FDG), and since inflammation is a glucose-avid 
oxidative process, 18F-FDG-PET allows a quantitative measurement of the uptake of tracer 
concentration with a positive correlation with the degree of joint inflammation in patients 
with RA. Recently, it has been demonstrated its correlation with parameters of disease 
activity (swelling, tenderness, serum markers) and findings from gold standard techniques 
such as US and MRI. This quantitative assessment could be useful for evaluating the 
therapeutic effectiveness. Besides 18F-FDG, tracers such as 11C-choline may be used for 
measurement of cell proliferation and evaluation of synovitis with high accuracy (Gotthardt 
et al., 2010; as cited in Roivainen, 2003). Other techniques, including the imaging of sinovitis 
with 99mTc-nanocolloids, have shown high sensitivity and specificity in this field. Thus, 
nuclear medicine techniques, especially PET and multipinhole SPECT of small joints, may 
play a role in identifying RA at an early stage, but the usefulness of these techniques 
compared with MRI and US needs to be proven in RA imaging. Currently, US and MRI are 
the techniques of choice for serial assessments of patients with RA due to practical reasons 
and the required exposure of the patient to radiation in the nuclear medicine studies. Large 
systematic prospective studies on the efficient use of imaging modalities to assess the 
efficacy of treatment in early RA are lacking. Nevertheless, new imaging modalities are 
assuming an important role in the investigation and management of RA. Tagging important 
cellular and protein mediator may allow us improving the knowledge of RA 
pathophysiology. In recent years, the use of labelled immunoglobulins (Igs) that head for 
areas of inflammation and where they stay accumulated (aspecific polyclonal IgG-type 
antibodies labelled in most cases with Tc-99m), has been developed (Table 3).  
 
mAbs     Type   Class    Isotope Target 
Infliximab (Remicade)   Chimeric  IgG1   
Adalimumab (Humira)   Fully human  IgG1   
Rituximab (Rituxan/Mabthera)  Chimeric  IgG1  
MAX.16H5                                   Murine   IgG1  
1.2B6    Murine   IgG1   
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Radiopharmaceutical: Free pertechnetate (stomach, thyroid, salivary glands) 
Technical:  Injection site, lymph node (radiotracer extravasations), 
injection into central venous catheter, arterial injection 
Patient:  Urine contamination, patient motion, breast prosthesis, 
metallic prosthesis (elbow, shoulder, knee and hip) 
Metallic:    Belt buckle, medallion, jewellery, pace maker 
Instrumentation:    Photomultiplier tube, cobalt peak, image contrast 
Treatment:  Postradiotherapy
Table 2. Common Artifacts in Bone Scintigraphy. 
particularly if overlying the scapula or a rib (Gnanasegaran et al., 2009). Photon-deficient 
areas commonly seen on the bone scan are due to metallic objects. Patients should be asked 
to remove metallic objects wherever possible before performing the scan.  Urinary 
contamination is a common problem, which may simulate focal lesions, especially if close to 
or overlying the bone. It is useful to remove the clothing or to wash the skin and reimage the 
patient around the region of interest to avoid any confusion. The patient should void before 
the study and rarely delayed imaging or bladder catheterization may be required. Further, 
radioactive urine in the bladder is a frequent cause of artifact in patients evaluated with 
SPECT for pelvic metastases (prostate cancer) or low-back pain. Increased radioactive urine 
in the bladder can cause streak artifacts on the reconstructed images and overlap bony 
structures. Further, intense tracer retention in the bladder is reported to cause pixel 
overload, resulting in a relatively cold area close to the region of interest of the femoral 
heads, which hinders its interpretation.  
3. Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic autoimmune systemic disease of unknown origin, 
with an overall prevalence of 1%. It mainly affects joints with symmetrical and polyarticular 
pattern and may lead up to progressive structural damage, functional disability and extra–
articular complications. It can affect many organ systems and it is also associated with a 
higher prevalence of other diseases such as infections, neoplasms and cardiovascular 
disease. It has been shown that 50% of patients with RA are disabled within 10 years of 
onset of disease and survival is reduced (Malviya et al., 2010; as cited in Solomon et al., 2003, 
Wolfe et al., 1994, 2002, 2003).  
Conventional radiology is the most wide-spread technique for the appraisal of RA, since it 
allows the evaluation of the presence or absence of erosions, joint space narrowing or 
articular osteopenia, but only when symptoms have been present for several months or 
years. The importance of early diagnosis in patients with RA, based on the possibility of 
modifying the prognosis with an early treatment, has led to the introduction of new 
techniques that identify the characteristic changes in an accurate and reliable way. MRI and 
High-Frequency Ultrasonography (US) have shown their reliability for detecting early bony, 
vascular and soft tissue changes in patients with RA and are the techniques most commonly 
used with this aim. Nuclear medicine techniques, such as imaging with nanocolloids, PET or 
three-phase bone scintigraphy may also be useful in this field. Three-phase bone 
scintigraphy is still used in clinical practice in patients with RA because it allows the 
detection of changes (hyperemia, increased permeability, altered bone metabolism) before 
the structural lesions appear, and may display the pattern of joint involvement and even 
predict the development of erosions (Colamussi et al., 2004; as cited in Mottonen et al., 
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1988). The intensity of uptake on scintigraphy is correlated to some clinical and laboratory 
indexes of disease activity (De Leonardis et al., 2008; as cited in Park et al., 1977) and the 
monitoring during treatment can evaluate the effectiveness of it (De Leonardis et al., 2008; as 
cited in Palmer et al., 1993; Elzinga et al., 2010). It is also a useful technique when an 
additional pathology (eg, osteonecrosis, stress fractures or metastatis) is suspected.  
Furthermore, in patients with nonspecific polyarthralgia, normal bone scan excludes the 
presence of active arthritis (Colamussi et al., 2004; as cited in Shearman et al., 1982). It is a 
sensitive tool but not highly specific, and may be altered in other diseases such as 
osteoarthritis. Nevertheless, planar bone scintigraphy is clearly less sensitive than SPECT in 
the evaluation of early stages of this disease or mild abnormalities. Multipinhole SPECT of 
the hands has been used to identify patients with minimal changes in bone metabolism 
(Gotthardt et al., 2010). This technique proven to equal MRI in sensitivity and also detected 
increased bone metabolism in two patients in whom MRI had negative results, 
demonstrating that multipinhole SPECT may be even more sensitive than MRI in some 
cases (Gotthardt et al., 2010; as cited in Ostendorf et al., 2010). PET may also be used for 
imaging of synovial inflammation. The most commonly used radiotracer in clinical PET 
scanning is fluorodeoxyglucose (18F-FDG), and since inflammation is a glucose-avid 
oxidative process, 18F-FDG-PET allows a quantitative measurement of the uptake of tracer 
concentration with a positive correlation with the degree of joint inflammation in patients 
with RA. Recently, it has been demonstrated its correlation with parameters of disease 
activity (swelling, tenderness, serum markers) and findings from gold standard techniques 
such as US and MRI. This quantitative assessment could be useful for evaluating the 
therapeutic effectiveness. Besides 18F-FDG, tracers such as 11C-choline may be used for 
measurement of cell proliferation and evaluation of synovitis with high accuracy (Gotthardt 
et al., 2010; as cited in Roivainen, 2003). Other techniques, including the imaging of sinovitis 
with 99mTc-nanocolloids, have shown high sensitivity and specificity in this field. Thus, 
nuclear medicine techniques, especially PET and multipinhole SPECT of small joints, may 
play a role in identifying RA at an early stage, but the usefulness of these techniques 
compared with MRI and US needs to be proven in RA imaging. Currently, US and MRI are 
the techniques of choice for serial assessments of patients with RA due to practical reasons 
and the required exposure of the patient to radiation in the nuclear medicine studies. Large 
systematic prospective studies on the efficient use of imaging modalities to assess the 
efficacy of treatment in early RA are lacking. Nevertheless, new imaging modalities are 
assuming an important role in the investigation and management of RA. Tagging important 
cellular and protein mediator may allow us improving the knowledge of RA 
pathophysiology. In recent years, the use of labelled immunoglobulins (Igs) that head for 
areas of inflammation and where they stay accumulated (aspecific polyclonal IgG-type 
antibodies labelled in most cases with Tc-99m), has been developed (Table 3).  
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The immunoscintigraphy has proven to be more sensitive than clinical examination for 
identifying synovitis and have a high positive predictive value for the onset of RA in 
patients with nonspecific arthropathy, and its usefulness for monitoring and assessing 
treatment response (Colamussi et al., 2004; as cited in De Bois et al., 1995a, 1995b, 1996). It 
can also be used to detect infection, although the preferred technique in these cases is 
labelled leukocyte scintigraphy, in which two tracers are often used: 99mTc-HMPAO or 
111In-oxine (De Gersem & Jamar, 2010). Labelled leukocyte scintigraphy is also useful in 
assessing therapeutic response in RA patients and it has been correlated with other indices 
of activity in this disease (Collamussi et al., 2004; as cited in Al-Janabi et al., 1988). However, 
immunoscintigraphy seems to be more accurate than labelled leukocyte scintigraphy for the 
identification of synovitis in RA (Collamussi et al., 2004; as cited in Liberatore et al., 1992). 
Other molecules and receptors (e.g. 64Cu-labelled anti-GPI, 68Ga-labelled annexin V or 
123I-antileukoproteinase) are being identified as therapeutic targets and used to develop 
new radiopharmaceuticals which accumulate in areas of inflammation where they can be 
located and quantified. Their study and description will allow improving the understanding 
of the complex pathophysiology of RA and detecting changes in very early stages of this 
disease and will give us the possibility of a pre-therapy scintigraphic approach with 
radiolabelled monoclonal antibodies that will let us evaluate the presence of target 
molecules in the inflammatory lesion, thus helping in the selection of the most efficient 
therapy and predicting therapy response (Glaudemans et al., 2010; Malviya et al., 2010). But 
currently, these techniques are not used in clinical practice and remain like a research tool 
inside selected laboratories. Bioluminescence and fluorescence reflectance imaging are other 
approaches that allow imaging, and potentially the delivery of therapeutic agents at a 
molecular level (McQueen & Ostergaard, 2007). 
4. Sacroilitis 
Sacroiliac joint involvement is a common finding in the spondyloarthropathies (SpA) group 
and it is an important parameter included in the diagnostic criteria. Conventional radiology 
is essential in the evaluation of the sacroiliac joints, but it does not detect early abnormalities 
and, therefore, the use of other complementary techniques currently available, such as CT, 
MRI, US, and bone scintigraphy, is necessary to avoid delaying the diagnosis.  
Until only a few years ago, bone scintigraphy was the gold standard technique for early 
diagnosis of inflammatory processes at this joint. The assessment of sacroilitis by 
scintigraphy is based on the quantification of radiotracer uptake in the sacrum and sacroiliac 
joints. This technique can help to differentiate between degenerative and inflammatory 
disorders in patients with nonespecific radiological changes. Both conventional bone 
scintigraphy and SPECT mode are sensitive techniques for early detection of SpA in patients 
with low back pain and who still do not have typical radiological changes, because the 
uptake of radiopharmaceutical at sacroiliac joints is produced before structural damage 
happens. However, in the sclerotic phase of evolved SpA, scintigraphy frequently does not 
detect any abnormalities. MRI, more sensitive in detecting early changes and more specific, 
has shifted to the bone scan. In this regard, a published review (Schneider, 2006; Song et al., 
2008) realized with the aim to assess the diagnostic value of scintigraphy for detecting 
sacroilitis in patients with established and/or probable ankylosing spondylitis, has proven 
limited value of scintigraphy both in the early detection of sacroilitis and in patients with 
established ankylosing spondylitis. In patients with SpA and gastrointestinal symptoms but 
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negative endoscopic or radiological test results, abdominal scintigraphy with labelled 
leukocytes can be used to assess the abdominal involvement (Colamussi et al., 2004; as cited 
in Elkayam et al., 2002). 
5. Infection 
In the setting of infection four entities can be established: osteomyelitis, septic arthritis, soft 
tissues infections and joint replacement infection. 
5.1 Osteomyelitis 
Osteomyelitis is defined by infection localized to bone. It can occur as a result of 
hematogenous seeding, contiguous spread of infection to bone from adjacent soft tissues 
and joints, or direct inoculation of infection into the bone as a result of trauma or surgery 
(Lalani, 2011). Three-phase bone scan with 99mTc-hydroxymethylene diphosphonate or Tc-
99m-MDP has long been used as the standard method for the detection of osteomyelitis 
(Gotthard et al., 2010), and positive focally increased uptake on all three phases (Fig. 2) is 
usually seen (Love et al., 2003). 
 
 
Fig. 2. Three-phase bone scan: Focally increased uptake on all three phases in a patient with 
osteomyelitis of the right great toe. 
In contrast, in the setting of cellulitis there is increased activity only in the first two phases and 
normal or mild diffuse increased activity in the third phase (Brown et al., 1993; Horwich, 2011). 
Radiographic studies do not show any change for at least 1- 2 weeks after initial infection, 
contrary to the three-phase bone scan where imaging of the infection can be seen in the first 24 
- 48 hours of the infection (Díaz & De haro, 2005).  Bone scintigraphy has a high sensitivity 
exceeding 80% and a limited specificity reaching up to 50% (Gotthard et al., 2010, as cited in 
Hakim et al., 2006; Palestro et al., 2002). The limited specificity can be explained by uptake of 
the radiopharmaceutical at all sites of increased bone metabolism irrespective of the 
underlying cause. Other conditions such as tumors, fractures, joint neuropathy may mimic 
osteomyelitis at three-phase bone scintigraphy. To improve specificity, complementary 
imaging with gallium-67 (67Ga) citrate (for spinal infection) or indium-111-labelled autologous 
leukocytes (for the appendicular skeleton) is often performed (Love et al., 2003).  
Gallium scans utilize the affinity of gallium-67 to acute phase reactants (lactoferrin, transferrin, 
and others) to demonstrate areas of inflammation that may be related to infection (Horwich, 
2011). Intense uptake on 67Ga bone scintigraphy in two adjacent vertebrae with loss of the disc 
space is highly suggestive of spinal osteomyelitis (Palestro & Torres, 1997). This method is 
quite sensitive and more specific than three-phase bone scan (Horwich, 2011; as cited in 
Palestro, 1991; Tumeh, 1986). It is typically performed 24 hours following inyection and 
therefore should be reserved for patients who are clinically stable and do not require prompt 
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The immunoscintigraphy has proven to be more sensitive than clinical examination for 
identifying synovitis and have a high positive predictive value for the onset of RA in 
patients with nonspecific arthropathy, and its usefulness for monitoring and assessing 
treatment response (Colamussi et al., 2004; as cited in De Bois et al., 1995a, 1995b, 1996). It 
can also be used to detect infection, although the preferred technique in these cases is 
labelled leukocyte scintigraphy, in which two tracers are often used: 99mTc-HMPAO or 
111In-oxine (De Gersem & Jamar, 2010). Labelled leukocyte scintigraphy is also useful in 
assessing therapeutic response in RA patients and it has been correlated with other indices 
of activity in this disease (Collamussi et al., 2004; as cited in Al-Janabi et al., 1988). However, 
immunoscintigraphy seems to be more accurate than labelled leukocyte scintigraphy for the 
identification of synovitis in RA (Collamussi et al., 2004; as cited in Liberatore et al., 1992). 
Other molecules and receptors (e.g. 64Cu-labelled anti-GPI, 68Ga-labelled annexin V or 
123I-antileukoproteinase) are being identified as therapeutic targets and used to develop 
new radiopharmaceuticals which accumulate in areas of inflammation where they can be 
located and quantified. Their study and description will allow improving the understanding 
of the complex pathophysiology of RA and detecting changes in very early stages of this 
disease and will give us the possibility of a pre-therapy scintigraphic approach with 
radiolabelled monoclonal antibodies that will let us evaluate the presence of target 
molecules in the inflammatory lesion, thus helping in the selection of the most efficient 
therapy and predicting therapy response (Glaudemans et al., 2010; Malviya et al., 2010). But 
currently, these techniques are not used in clinical practice and remain like a research tool 
inside selected laboratories. Bioluminescence and fluorescence reflectance imaging are other 
approaches that allow imaging, and potentially the delivery of therapeutic agents at a 
molecular level (McQueen & Ostergaard, 2007). 
4. Sacroilitis 
Sacroiliac joint involvement is a common finding in the spondyloarthropathies (SpA) group 
and it is an important parameter included in the diagnostic criteria. Conventional radiology 
is essential in the evaluation of the sacroiliac joints, but it does not detect early abnormalities 
and, therefore, the use of other complementary techniques currently available, such as CT, 
MRI, US, and bone scintigraphy, is necessary to avoid delaying the diagnosis.  
Until only a few years ago, bone scintigraphy was the gold standard technique for early 
diagnosis of inflammatory processes at this joint. The assessment of sacroilitis by 
scintigraphy is based on the quantification of radiotracer uptake in the sacrum and sacroiliac 
joints. This technique can help to differentiate between degenerative and inflammatory 
disorders in patients with nonespecific radiological changes. Both conventional bone 
scintigraphy and SPECT mode are sensitive techniques for early detection of SpA in patients 
with low back pain and who still do not have typical radiological changes, because the 
uptake of radiopharmaceutical at sacroiliac joints is produced before structural damage 
happens. However, in the sclerotic phase of evolved SpA, scintigraphy frequently does not 
detect any abnormalities. MRI, more sensitive in detecting early changes and more specific, 
has shifted to the bone scan. In this regard, a published review (Schneider, 2006; Song et al., 
2008) realized with the aim to assess the diagnostic value of scintigraphy for detecting 
sacroilitis in patients with established and/or probable ankylosing spondylitis, has proven 
limited value of scintigraphy both in the early detection of sacroilitis and in patients with 
established ankylosing spondylitis. In patients with SpA and gastrointestinal symptoms but 
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negative endoscopic or radiological test results, abdominal scintigraphy with labelled 
leukocytes can be used to assess the abdominal involvement (Colamussi et al., 2004; as cited 
in Elkayam et al., 2002). 
5. Infection 
In the setting of infection four entities can be established: osteomyelitis, septic arthritis, soft 
tissues infections and joint replacement infection. 
5.1 Osteomyelitis 
Osteomyelitis is defined by infection localized to bone. It can occur as a result of 
hematogenous seeding, contiguous spread of infection to bone from adjacent soft tissues 
and joints, or direct inoculation of infection into the bone as a result of trauma or surgery 
(Lalani, 2011). Three-phase bone scan with 99mTc-hydroxymethylene diphosphonate or Tc-
99m-MDP has long been used as the standard method for the detection of osteomyelitis 
(Gotthard et al., 2010), and positive focally increased uptake on all three phases (Fig. 2) is 
usually seen (Love et al., 2003). 
 
 
Fig. 2. Three-phase bone scan: Focally increased uptake on all three phases in a patient with 
osteomyelitis of the right great toe. 
In contrast, in the setting of cellulitis there is increased activity only in the first two phases and 
normal or mild diffuse increased activity in the third phase (Brown et al., 1993; Horwich, 2011). 
Radiographic studies do not show any change for at least 1- 2 weeks after initial infection, 
contrary to the three-phase bone scan where imaging of the infection can be seen in the first 24 
- 48 hours of the infection (Díaz & De haro, 2005).  Bone scintigraphy has a high sensitivity 
exceeding 80% and a limited specificity reaching up to 50% (Gotthard et al., 2010, as cited in 
Hakim et al., 2006; Palestro et al., 2002). The limited specificity can be explained by uptake of 
the radiopharmaceutical at all sites of increased bone metabolism irrespective of the 
underlying cause. Other conditions such as tumors, fractures, joint neuropathy may mimic 
osteomyelitis at three-phase bone scintigraphy. To improve specificity, complementary 
imaging with gallium-67 (67Ga) citrate (for spinal infection) or indium-111-labelled autologous 
leukocytes (for the appendicular skeleton) is often performed (Love et al., 2003).  
Gallium scans utilize the affinity of gallium-67 to acute phase reactants (lactoferrin, transferrin, 
and others) to demonstrate areas of inflammation that may be related to infection (Horwich, 
2011). Intense uptake on 67Ga bone scintigraphy in two adjacent vertebrae with loss of the disc 
space is highly suggestive of spinal osteomyelitis (Palestro & Torres, 1997). This method is 
quite sensitive and more specific than three-phase bone scan (Horwich, 2011; as cited in 
Palestro, 1991; Tumeh, 1986). It is typically performed 24 hours following inyection and 
therefore should be reserved for patients who are clinically stable and do not require prompt 
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imaging results for urgent management decisions. Gallium not only enhances the specificity of 
the diagnosis but provides information about surrounding soft tissue infection (Palestro & 
Torres, 1997). If gallium scan is negative, it effectively excludes the diagnosis of osteomyelitis 
(Horwich, 2011; as cited in Pineda, 2006). A gallium scan can be performed concurrently with a 
technetium labelled three-phase bone scan, and the information gathered may be more useful 
than that of either examination alone (Horwich, 2011; as cited in Tumed, 1986). Both 
radionuclides can be injected at the same time and the scintigraphic images can be obtained 
three to four hours after injection, while gallium images will be obtained up to 24 hours later 
(Horwich, 2011). This combination is probably the best nuclear medicine tool for the 
evaluation of vertebral osteomyelitis (Palestro & Torres, 1997).  
Labelled leukocyte imaging is a good alternative in the evaluation of osteomyleitis, but is of 
little value in vertebral osteomyelitis because this entity often presents as a non specific 
photopenic defect (Gotthard et al., 2010; as cited in Van Der Bruggen et al., 2010). But, in the 
diabetic foot diagnosis, labelled leukocyte imaging alone is sufficient to determine the 
presence of osteomyelitis in the forefoot. In the midfoot and hindfoot it may be necessary to 
combine leukocyte scintigraphy with others radiotracers to precisely localize the infection 
(Palestro & Torres, 1997). The combined imaging approach of 99mTc-colloid bone 
marrow/labelled-leukocyte scanning enhances the sensitivity and specificity above 90%, 
avoiding the problem of physiologic uptake into bone marrow. Because in osteomyelitis 
bone marrow is replaced by the infectious process, bone marrow imaging will be negative 
whereas leukocyte scanning in the same location will be positive (Gotthardt et al., 2010, as 
cited in Palestro et al., 2006).  
In chronic osteomyelitis the specificity of Tc-99m-MDP bone scans is very low even with 
active exacerbation because positive uptake also occurs with the healing process (El-
Maghraby et al., 2006). Other false negative results are possible in areas of relative ischemia, 
since radiotracer may not be adequately delivered to the target site (Horwich, 2011). 67Ga 
combined with Tc-99m-MDP allows identification of active chronic osteomyelitis. 
Discordance between 67Ga and Tc-99m-MDP with more intense 67Ga or different 
distribution is highly specific at 80-100% (El-Maghraby et al., 2006). 18F-FDG-PET is a 
promising modality for imaging musculoskeletal infection and might play an important role 
in the evaluation of chronic osteomyelitis and spinal infection (Strobel & Stumpe, 2007).  The 
specificity for spinal infection drops only if patients underwent surgery less than 6 months 
before PET and if osteosynthetic material is present (Gotthardt et al., 2010; as cited in De 
Winter et al., 2003). However, because MRI may not be an option in patients with metallic 
implants in situ, PET currently is the most sensitive imaging modality in the evaluation of 
such patients (Gotthardt et al., 2010; as cited in De Winter et al., 2003). Furthermore, in cases 
of severe defenerative disk disease with oedema-like changes in the endplates and the 
adjacent discs, MRI can give false-positive results (Gotthardt et al., 2010; as cited in Palestro 
et al., 2006). Other tracers for diagnosing spinal osteomyelitis are also under investigation, 
including radiolabelled antibiotics and antifungical tracers (Gemmel et al., 2006). 
5.2 Septic arthritis 
Septic arthritis is the infection of the synovial tissues. It often occurs as a result of 
hematogenous seeding and less often by direct inoculation as a result of trauma or surgery 
(Díaz & De haro, 2005). Although it may occur at any age, it is most common in children 
under 3 years. Over 90% of cases are mono-articular (El-Maghraby et al., 2006). The most 
commonly involved joints are the hips and the knees (Díaz & De haro, 2005). Despite MRI  
 
Nuclear Medicine in Musculoskeletal Disorders: Clinical Approach 
 
105 
and nuclear medicine methods are used for the diagnosis or a preliminary investigation of 
infectious arthritis, the definitive diagnostic test is the identification of bacteria in the 
synovial fluid aspiration (Díaz & De haro 2005). Though, some joints are difficult to 
examine. As in the osteomyelitis, there is an increased uptake on all three phases of three-
phase bone scan (El-Maghraby et al., 2006). The hallmark of septic arthritis is symmetrical 
uptake in both sides of the joint (Díaz & De haro, 2005). However, a positive scintigraphy 
has a low specificity. The differential diagnosis is made more accurate when the 
osteoarticular scintigraphy is combined with gallium citrate or more commonly 
radiolabelled leukocyte or immunoglobulins. In the presence of septic arthritis, these agents 
demonstrate activity patterns of diffuse nature in the soft tissue in and around the joint with 
no focal abnormality in bone. However, this can be difficult to ascertain without 
demonstration of exactly where bone lies in relation to the soft tissue infection and may 
need combined imaging. Rosenthall et al have shown that a combined study does raise the 
sensitivity for the detection of septic arthritis from 54% with TC-99m-MDP alone to 84% for 
combined 67Ga/Tc-99m-MDP scanning (El-Maghraby et al., 2006; as cited in Rosenthall et 
al., 1982). Another combination is the labelled leukocytes/Tc-99m-MDP combined study, 
which is reported to be more specific than a 67Ga/Tc-99m-MDP study and produces fewer 
equivocal results (El-Maghraby et al., 2006; as cited in Tehranzadeh et al., 2001; Chengazi & 
O’Mara, 2003). For disc space infections, although the bone scan is often positive, gallium 
scintigraphy is the preferred method. Indium-111(111In)-leukocytes have been shown to be 
of limited value in the diagnosis of disc space infection; although some authors feel that the 
labelled white cell scan can be of benefit especially if the cold (photon deficient) lesions are 
considered diagnostic of disc space infection (Brown et al., 1993). 
5.3 Cellulitis 
Cellulitis is a soft tissue infection. The scan shows intense uptake in the first two phases of 
the study with diffuse extra-osseous activity, while the final image is normal after 2-4 hours. 
The presence of other processes that stimulate osteoblastic reaction, as in cases of suspected 
osteomyelitis in areas with trauma, surgery or arthritis, complicates the interpretation of the 
scintigraphic image which is completely non specific. Combined studies with different 
radiotracers such as 67Ga, 111In-leukocytes or 99mTc-HM-PAO improve the sensitivity and 
specificity, although MRI remains as gold standard technique (Díaz & De Haro, 2005). 
5.4 Painful joint replacement 
Prosthetic joint replacement is a common procedure and most patients have excellent results, 
but 20% of them develop pain during the follow-up. It may be secondary to infection, aseptic 
loosening or heterotopic bone formation (El-Maghraby et al., 2006). Differentiate betweeen 
loosening and infection is often a difficult problem, especially because clinical signs and 
symptoms, laboratory tests and radiographies are insensitive, nonspecific, or both. Cross-
sectional imaging modalities are hampered by artifacts produced by the prosthetic devices. 
Radionuclide imaging is not affected by the presence of metallic hardware and is therefore 
useful for evaluating the painful prosthesis (Love et al., 2001). Negative scintigraphic study 
rules out septic or aseptic loosening. Both conditions, however, may show increased tracer 
uptake in bone scans, but the pattern and site of uptake may help to differentiate each other. In 
aseptic loosening, focal localized uptake at the tips is seen, whereas in the infection diffuse 
intense uptake will be seen in the three phases of bone scan. The sensitivity for bone scan in 
infection is relatively high, ranging from 70% to 100% but the specificity is variable ranging 
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imaging results for urgent management decisions. Gallium not only enhances the specificity of 
the diagnosis but provides information about surrounding soft tissue infection (Palestro & 
Torres, 1997). If gallium scan is negative, it effectively excludes the diagnosis of osteomyelitis 
(Horwich, 2011; as cited in Pineda, 2006). A gallium scan can be performed concurrently with a 
technetium labelled three-phase bone scan, and the information gathered may be more useful 
than that of either examination alone (Horwich, 2011; as cited in Tumed, 1986). Both 
radionuclides can be injected at the same time and the scintigraphic images can be obtained 
three to four hours after injection, while gallium images will be obtained up to 24 hours later 
(Horwich, 2011). This combination is probably the best nuclear medicine tool for the 
evaluation of vertebral osteomyelitis (Palestro & Torres, 1997).  
Labelled leukocyte imaging is a good alternative in the evaluation of osteomyleitis, but is of 
little value in vertebral osteomyelitis because this entity often presents as a non specific 
photopenic defect (Gotthard et al., 2010; as cited in Van Der Bruggen et al., 2010). But, in the 
diabetic foot diagnosis, labelled leukocyte imaging alone is sufficient to determine the 
presence of osteomyelitis in the forefoot. In the midfoot and hindfoot it may be necessary to 
combine leukocyte scintigraphy with others radiotracers to precisely localize the infection 
(Palestro & Torres, 1997). The combined imaging approach of 99mTc-colloid bone 
marrow/labelled-leukocyte scanning enhances the sensitivity and specificity above 90%, 
avoiding the problem of physiologic uptake into bone marrow. Because in osteomyelitis 
bone marrow is replaced by the infectious process, bone marrow imaging will be negative 
whereas leukocyte scanning in the same location will be positive (Gotthardt et al., 2010, as 
cited in Palestro et al., 2006).  
In chronic osteomyelitis the specificity of Tc-99m-MDP bone scans is very low even with 
active exacerbation because positive uptake also occurs with the healing process (El-
Maghraby et al., 2006). Other false negative results are possible in areas of relative ischemia, 
since radiotracer may not be adequately delivered to the target site (Horwich, 2011). 67Ga 
combined with Tc-99m-MDP allows identification of active chronic osteomyelitis. 
Discordance between 67Ga and Tc-99m-MDP with more intense 67Ga or different 
distribution is highly specific at 80-100% (El-Maghraby et al., 2006). 18F-FDG-PET is a 
promising modality for imaging musculoskeletal infection and might play an important role 
in the evaluation of chronic osteomyelitis and spinal infection (Strobel & Stumpe, 2007).  The 
specificity for spinal infection drops only if patients underwent surgery less than 6 months 
before PET and if osteosynthetic material is present (Gotthardt et al., 2010; as cited in De 
Winter et al., 2003). However, because MRI may not be an option in patients with metallic 
implants in situ, PET currently is the most sensitive imaging modality in the evaluation of 
such patients (Gotthardt et al., 2010; as cited in De Winter et al., 2003). Furthermore, in cases 
of severe defenerative disk disease with oedema-like changes in the endplates and the 
adjacent discs, MRI can give false-positive results (Gotthardt et al., 2010; as cited in Palestro 
et al., 2006). Other tracers for diagnosing spinal osteomyelitis are also under investigation, 
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and nuclear medicine methods are used for the diagnosis or a preliminary investigation of 
infectious arthritis, the definitive diagnostic test is the identification of bacteria in the 
synovial fluid aspiration (Díaz & De haro 2005). Though, some joints are difficult to 
examine. As in the osteomyelitis, there is an increased uptake on all three phases of three-
phase bone scan (El-Maghraby et al., 2006). The hallmark of septic arthritis is symmetrical 
uptake in both sides of the joint (Díaz & De haro, 2005). However, a positive scintigraphy 
has a low specificity. The differential diagnosis is made more accurate when the 
osteoarticular scintigraphy is combined with gallium citrate or more commonly 
radiolabelled leukocyte or immunoglobulins. In the presence of septic arthritis, these agents 
demonstrate activity patterns of diffuse nature in the soft tissue in and around the joint with 
no focal abnormality in bone. However, this can be difficult to ascertain without 
demonstration of exactly where bone lies in relation to the soft tissue infection and may 
need combined imaging. Rosenthall et al have shown that a combined study does raise the 
sensitivity for the detection of septic arthritis from 54% with TC-99m-MDP alone to 84% for 
combined 67Ga/Tc-99m-MDP scanning (El-Maghraby et al., 2006; as cited in Rosenthall et 
al., 1982). Another combination is the labelled leukocytes/Tc-99m-MDP combined study, 
which is reported to be more specific than a 67Ga/Tc-99m-MDP study and produces fewer 
equivocal results (El-Maghraby et al., 2006; as cited in Tehranzadeh et al., 2001; Chengazi & 
O’Mara, 2003). For disc space infections, although the bone scan is often positive, gallium 
scintigraphy is the preferred method. Indium-111(111In)-leukocytes have been shown to be 
of limited value in the diagnosis of disc space infection; although some authors feel that the 
labelled white cell scan can be of benefit especially if the cold (photon deficient) lesions are 
considered diagnostic of disc space infection (Brown et al., 1993). 
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5.4 Painful joint replacement 
Prosthetic joint replacement is a common procedure and most patients have excellent results, 
but 20% of them develop pain during the follow-up. It may be secondary to infection, aseptic 
loosening or heterotopic bone formation (El-Maghraby et al., 2006). Differentiate betweeen 
loosening and infection is often a difficult problem, especially because clinical signs and 
symptoms, laboratory tests and radiographies are insensitive, nonspecific, or both. Cross-
sectional imaging modalities are hampered by artifacts produced by the prosthetic devices. 
Radionuclide imaging is not affected by the presence of metallic hardware and is therefore 
useful for evaluating the painful prosthesis (Love et al., 2001). Negative scintigraphic study 
rules out septic or aseptic loosening. Both conditions, however, may show increased tracer 
uptake in bone scans, but the pattern and site of uptake may help to differentiate each other. In 
aseptic loosening, focal localized uptake at the tips is seen, whereas in the infection diffuse 
intense uptake will be seen in the three phases of bone scan. The sensitivity for bone scan in 
infection is relatively high, ranging from 70% to 100% but the specificity is variable ranging 
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from 20% to 90% and the reported accuracy is around 50-70% (El-Maghraby et al., 2006; as 
cited in Rosenthall et al., 1982, Turpin & Lambert, 2001, Wilson, 2004). The combination of 
67Ga-citrate and Tc-99m-MDP bone scans has better results, with accuracy around 70-80% (El-
Maghraby et al., 2006). But lower results for this combination has also been reported because 
the uptake of both tracers can be found not only in infection, but also in the postoperative 
patient, in heterotopic bone formation, and loosening or inflammatory reaction to cement 
fixators (El-Maghraby et al., 2006; as cited in Turpin & Lambert, 2001). 
Labelled leukocyte imaging is, at least theoretically, the ideal technique for diagnosing the 
infected prosthesis because in general, white cells do not accumulate at sites of increased bone 
mineral turnover in the absence of infection (Palestro, 1998). However, labelled-leukocytes 
yield false positive results due to reactive or displaced bone marrow as a result of surgery are 
present up to more than 24 months after implantation (El-Maghraby et al., 2006; as cited in 
Oswald et al., 1990). Labelled leukocytes accumulate not only in infection but in the bone 
marrow as well. This problem has been overcome by the addition of complementary bone 
marrow imaging, which is usually performed with Tc-99m sulfur colloid. Both, labelled 
leukocytes and sulfur colloid accumulate in the bone marrow, but only labelled leukocytes 
accumulate in infection. In contrast to the results reported for labelled leukocyte imaging 
alone, the results of combined leukocyte-marrow imaging of prosthetic joints have been 
uniformly excellent, with an accuracy of 90% or greater (Love et al., 2001; as cited in Palestro 
1990, 1991) and has become the method of choice to evaluate surgical prostheses (El-Maghraby 
et al., 2006; as cited in Love et al., 2001; Turpin & Lambert, 2001). Although extremely accurate, 
leukocyte-marrow scintigraphy is hampered by significant limitations. The in vitro labelling 
process is labor intensive, is not always available, and requires direct contact with blood 
products. The need for marrow imaging adds to the complexity and cost of the study and is an 
additional inconvenience to patients, many of whom are elderly and debilitated (Love et al., 
2001). In an effort to maintain the accuracy of the study while reducing or eliminating the 
disadvantages, several methods of labelling leukocytes in vivo have been investigated, but 
their role in prosthetic joint infection has not been established.   
FDG-PET has been extensively investigated, the high-resolution tomographic images, 
availability of the agent, and rapid completion of the procedure are all desirable traits. 
Published results to date, however, are inconclusive in this setting (Love et al., 2009; as cited 
in Chacko et al., 2002; Joseph et al., 2001; Love et al., 2004; Manthey et al., 2002; Pill et al., 
2006; Reinartz et al., 2005; Stumpe et al., 2004; Zhuang et al, 2001). 
6. Avascular osteonecrosis  
Osteonecrosis, also known as aseptic necrosis, avascular necrosis, ischemic necrosis, and 
osteochondritis dissecans, is a pathological process that has been associated with numerous 
conditions and therapeutic interventions. The exact prevalence of osteonecrosis is unknown. In 
the United States, there are an estimated 10,000 to 20,000 new patients diagnosed per year, and 
osteonecrosis is the underlying diagnosis in approximately 10 percent of all total hip 
replacements. The male-to-female ratio of this disorder is 8:1, but varies with different 
comorbidities (Jones, 2011). The mechanisms by which this disorder develops are not fully 
understood. Compromise of the bone vasculature leading to the death of bone and marrow 
cells (bone marrow infarction) appear to be common to most proposed etiologies. The process 
is most often progressive, resulting in joint destruction within three to five years if left 
untreated. A variety of traumatic and nontraumatic factors contribute to the etiology of 
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osteonecrosis. Glucocorticoid use and excessive alcohol intake are reported to be associated 
with more than 90% of the cases. Osteonecrosis usually occurs in the anterolateral femoral 
head, although it may also affect the femoral condyles, humeral heads, proximal tibia, 
vertebrae, and small bones of the hand and foot. Many patients have bilateral involvement at 
the time of diagnosis, including disease of the hips, knees, and shoulders. The most common 
presenting symptom of osteonecrosis is pain and patients may have eventually limitation on 
range of motion. A limp may be present late in the course of lower extremity disease. A small 
proportion of patients are asymptomatic. In these cases the diagnosis is usually incidental. 
Asymptomatic involvement contralateral to a symptomatic site is frequently noted.  
There is no pathognomonic feature of osteonecrosis. A clinical diagnosis is appropriately 
made in a symptomatic patient when imaging findings are compatible with this disease and 
other causes of pain and bony abnormalities are either unlikely or have been excluded by 
appropriate testing. The evaluation for suspected osteonecrosis should begin with plain film 
radiography, althought it can remain normal for months after symptoms of osteonecrosis 
begin. Features of osteonecrosis on plain film radiographs, radionuclide scans (Fig. 3), and 
MRI are helpful diagnostically and provide the basis for classification and staging systems. 
Early diagnosis of osteonecrosis is crucial: the earlier the stage of the lesion at the time of 
diagnosis, the better the prognosis. Clinically, early diagnosis and treatment of osteonecrosis 
might prevent unnecessary surgery (Pape et al., 2004). Therefore, early diagnosis and 
location of osteonecrosis have prognostic value and determine the therapeutic alternatives.   
 
 
Fig. 3. Radionuclide bone scan of the pelvis in a 68-year-old man with hip pain. Bilateral 
central area of diminished uptake surrounded by a zone of increased uptake in the femoral 
head consistent with avascular necrosis. 
Currently, MRI is the technique of choice for the diagnosis of avascular osteonecrosis in the 
early stages. This technique has been proven to be a highly accurate method both for early 
diagnosis (changes can be seen early in the course of disease when other studies are negative) 
and for staging of the disease (Malizos et al., 2007). MRI is far more sensitive than plain 
radiographs or bone scanning, with an overall reported sensitivity of 91% (Jones, 2011; as cited 
in Chang et al., 1993). Nevertheless, 99mTc bone scintigraphy also plays an important role in 
the early diagnosis of avascular necrosis and whole body bone scan is useful in patients with 
suspected polytopic osteonecrosis. The characteristic distribution of the radiopharmaceutical  
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MRI are helpful diagnostically and provide the basis for classification and staging systems. 
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Fig. 3. Radionuclide bone scan of the pelvis in a 68-year-old man with hip pain. Bilateral 
central area of diminished uptake surrounded by a zone of increased uptake in the femoral 
head consistent with avascular necrosis. 
Currently, MRI is the technique of choice for the diagnosis of avascular osteonecrosis in the 
early stages. This technique has been proven to be a highly accurate method both for early 
diagnosis (changes can be seen early in the course of disease when other studies are negative) 
and for staging of the disease (Malizos et al., 2007). MRI is far more sensitive than plain 
radiographs or bone scanning, with an overall reported sensitivity of 91% (Jones, 2011; as cited 
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in the affected area (cold area surrounded by a hyperfixation rim) enables early diagnosis, 
before the appearance of anatomical changes, which only show up later with radiography 
(Jones, 2011; as cited in Feggi et al., 1987 and Maillefert et al., 1997). The presence of this tipical 
pattern may increase the diagnostic accuracy to distinguish between osteonecrosis and 
transient osteoporosis, which usually has a diffuse pattern of tracer uptake, with no cold area. 
The accuracy of scintigraphy can be improved by using SPECT in patients with suspected 
avascular necrosis of the femoral head but have concomitant changes that may show up as 
false positives, such as severe acetabular osteoarthritis (Jones, 2011; as cited in Collier et al., 
1985). It also may help us to avoid overlooking a subchondral fracture. 
6.1 Transient osteoporosis 
Transient osteoporosis of the hip, also called transient marrow edema syndrome, is 
characterized by the presence of intense radionuclide uptake in the femoral head, which may 
extend to the femoral neck, to the intertrochanteric region, or to proximal femoral diaphyseal 
region. It is also typical to find hyperactivity at the images of flow phase and blood pool 
phase. Ischemia of the femoral head, that has not caused necrosis, has been suggested as a 
possible cause of this process. The reactive hyperemic response to this ischemic phenomenon, 
with a repair process, would explain scintigraphic changes. Insufficiency fractures in this 
location can provide similar scintigraphic imaging (Schneider, 2006). 
7. Reflex sympathetic dystrophy 
Reflex sympathetic dystrophy (RSD) is a complex physiologic response of the body to an 
external stimulus resulting in pain sympathetically mediated, usually nonanatomic pattern, 
which is out of proportion to the inciting event or expected healing response (Fournier & 
Holder 1998).  It is a syndrome affecting an extremity after a minor trauma or surgery, but the 
particular mechanism remains uncertain. The diagnosis of RSD relies on clinical evaluation, 
scintigraphy or MR imaging, and routine radiographs. In the spontaneous course of this 
syndrome three phases can be distinguished: Stage I is the warm or hypertrophic phase, stage 
II is called the cold or atrophic phase and the third stage corresponds to stabilization or, in rare 
instances, to healing (Driessens et al., 1999; Ornetti & Maillefert, 2004). 
 
 
Fig. 4. Bone scanning: Diffusely increased uptake in the distal right upper extremity in reflex 
sympathetic dystrophy. 
Three-phase scintigraphy has been widely utilized in both the diagnosis and monitoring of 
treatment (Murray, 1998). Scintigraphy imaging (Fig. 4) shows increased perfusion during 
the angiographic and vascular pool phases and widespread increases in radiophosphonate 
bone uptake in the late stage (Colamussi et al., 2004). The highest diagnostic accuracy is  
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provided by the combination of three signs: Increase activity ratio in the blood pool phase 
performed at 5-15 min, diffuse uptake in the carpus o tarsus and periarticular uptake in all 
the small joints (Murray, 1998). Decreased radiotracer accumulation has also been described, 
especially in children and adolescents (Driessens et al., 1999; Love et al., 2003). Bone 
scintigraphy is of major importance for the diagnosis in order to clearly differentiate from 
other conditions which are incorrectly diagnosed and treated as RSD. If the bone scan is not 
suggestive of RSD, the clinical picture, radiological examination and vascular scan may lead 
to the correct diagnosis. This may be a pseudodystrophy, in which a hypovascularization is 
found right from the start, while in true RSD there is initially a hypervascularization. Other 
conditions which may be confused with RSD are causalgia, neurotic compulsive postures, 
hysterical conversion, malingering and even self-mutilation (Driessens et al., 1999). Bone 
scintigraphy has a high sensitivity in the initial stage of Sudeck's syndrome, but after 26 
weeks, it loses accuracy (Benning & Steinert, 1988; Lee & Weeks, 1995). 
8. Metabolic bone disorders 
8.1 Osteoporosis 
Osteoporosis is defined as a systemic skeletal disease characterized by low bone density and 
microarchitectural deterioration of bone tissue, with an increase in bone fragility and 
susceptibility to fractures. Despite an increase in bone turnover that is usually present in 
osteoporosis, the bone scan has no role in the diagnosis of uncomplicated osteoporosis, but the 
Tc-99m-MDP bone scan is most often used in established osteoporosis to diagnose fractures, 
particularly at sites that are difficult to image with plain film radiography (eg, sacrum, ribs), 
and may be particularly useful in the diagnosis and timing of vertebral fractures. It also has an 
important role in assessing suspected fractures where radiography is unhelpful, either because 
of poor sensitivity related to the anatomical site of the fracture (eg, sacrum Fig. 5) or because 
adequate views are not obtainable because of the patient’s discomfort (Fogelman & Cook, 
2003). The characteristic appearance of these fractures is discussed elsewhere in this chapter. If 
a patient complains of back pain with multiple previous vertebral fractures noted on  
 
 
Fig. 5. Posterior and anterior Tc-99m-MDP bone scan showing a typical “H-shaped” pattern 
in the sacrum, indicating a sacral insufficiency fracture. 
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radiographs, and the bone scan is normal, then this essentially excludes recent fracture as the 
cause of symptoms and other causes of pain should then be considered. 
8.2 Paget 
Paget's disease is a localized disease of bone remodeling characterized by an increased bone 
resorption mediated by osteoclasts and a compensatory increase in bone formation. The 
result is a disorganized mosaic of woven and lamellar bone at affected skeletal sites. This 
structural change produces bone that is expanded in size, less compact, more vascular and 
more susceptible to deformity and fracture than in normal bone. It can affect any bone, but 
is more common in skull, hip, pelvis, legs and back. Paget’s disease may be monostotic, but 
the majority of patients have a polyostotic disease (80-90%). Most patients are 
asymptomatic, but they can experience a variety of symptoms such as bone pain, bone 
deformity, secondary arthritic problems, excessive warmth over bone area and different 
neurological complications caused by compression of adjacent neural tissues. 
Bone scintigraphy, combined with radiology, is the technique of choice for assessing the 
location and extent of the pagetic bone lesions. It allows of evaluating the entire skeleton 
and is more sensitive than radiography in identifying metabolically active lesions (Fogelman 
& Carr, 1980): there is no radiological correspondence over 10% of scintigraphic hot spots 
(Devogelaer & De Deuxchaisnes, 2003). Symptomatic lesions are usually characterized by an 
increased uptake. Characteristically, affected bones show a striking increase in metabolic 
activity that starts at one edge of the bone and extends distally or proximally, often showing 
a “V” or “flame – shaped” leading edge. Both osteolytic and osteoblastic lesions are 
associated with and increase in radiotracer uptake on bone scan (Fig. 6). Scintigraphic 
pagetic bone features are usually characteristic, presenting as "hot spots". Whole bone may 
be affected, especially at pelvis, scapula and vertebrae. Abnormal tracer accumulation 
throughout the vertebra, affecting the body and posterior elements, is the characteristic 
finding in this localization. The skull may show a different pattern with a ring of increased 
activity only in the margins of the lesion (Fogelman & Cook, 2003). The intensity of 
radiactive tracer uptake, usually Tc-99m-MDP, depends on the metabolic activity of Paget's 
disease. In later stages, the disease may go into a period of inactivity and bone scan shows 
little or no uptake. Therefore, bone scintigraphy is complementary to the use of biochemical 
markers (e.g. serum alkaline phosphatase, urine hydroxyproline) for the assessment of bone 
turnover and may be useful in assessing therapeutic efficacy, since a good correlation 
between bone scintigraphy uptake and clinical and biochemical markers has been found 
(Cook et al., 2010). Cases of scintigraphic evidence of pagetic activity in the setting of normal 
serum alkaline phosphatase have been reported. In these cases, bone scintigraphy is the 
main technique in the evaluation of the effectiveness of the treatment. Bone scan can be 
performed 3-6 months after treatment with bisphosphonates, although scintigraphic images 
may respond in a heterogeneous way (after intravenous bisphosphonate therapy, some 
bones may become normal, most bones show some improvement, and a small proportion 
remain unchanged), and even lead to infrequent images that sometimes mimic those of bone 
metastases. In these cases, knowing the medical history of the patient is essential (Fogelman 
& Cook, 2003). The superior quantitative accuracy of PET using 18F-fluoride ion has been 
described in the evaluation of pagetic bone (Cook et al., 2002), and this method has also been 
described to measure response to bisphosphonate treatment. An increase in 18F-FDG uptake 
has also been reported in pagetic bone (Cook et al., 2010; as cited in Cook et al., 1997), 
correlating also with disease activity. Bone scintigraphy can also identify complications (Fig. 
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6) of Paget's disease like fractures (shown as a linear area of increased activity perpendicular 
to the cortex) or sarcomatous degeneration. The latter should be suspected in patients with 
persistent pain. The most common scintigraphic sign in the setting of sarcomatous 
degeneration is a cold area inside an area of increased uptake. The scan may also show 
heterogeneous and irregular uptake in the study area or adjacent soft-tissue uptake. The 
evaluation of the lesion should always be completed with x-ray and, even if doubts persist, 
with an MRI, which could allow a more precise diagnosis (Fransen et al., 1998). 
 
 
Fig. 6. A Tc-99m-MDP bone scan showing Paget’s disease affecting the left humerus, mid-
thoracic and lower lumbar spine, sacrum, right 11th rib, left pelvis, left femur and tibia, and 
the right tibia. Focal linear activity in the right tibia indicates an incremental fracture 
8.3 Hyperparathyroidism 
Most cases of primary hyperparathyroidism are asymptomatic and are unlikely to be 
associated with changes on bone scintigraphy. The diagnosis is made biochemically and the 
use of bone scintigraphy does not make sense with this goal. But bone scan may be useful to 
differentiate the causes of hypercalcemia, in particular, hyperparathyroidism vs malignancy, 
so that typical features of metabolic bone disorders may be recognized. There is increased 
skeletal turnover in hyperparathyroidism, commonly seen as part of renal osteodystrophy, 
and in the more severe cases, this will be evident scintigraphically. A bone scan may show 
several features in hyperparathyroidism, but the most important is the generalized 
increased uptake throughout the skeleton that may be identified because of increased 
contrast between bone and soft tissues. This is commonly termed the metabolic superscan to 
differentiate from superscans caused by widespread bone metastases. Other typical features 
that have been described in this context include a prominent calvarium and mandible, 
beading of the costochondral junctions, and a “tie” sternum (Fogelman & Carr, 1980). Severe 
forms of hyperparathyroidism may be associated with uptake of bone radiopharmaceuticals 
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radiographs, and the bone scan is normal, then this essentially excludes recent fracture as the 
cause of symptoms and other causes of pain should then be considered. 
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described to measure response to bisphosphonate treatment. An increase in 18F-FDG uptake 
has also been reported in pagetic bone (Cook et al., 2010; as cited in Cook et al., 1997), 
correlating also with disease activity. Bone scintigraphy can also identify complications (Fig. 
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into soft tissue, related with ectopic calcification. Focal skeletal abnormalities may represent 
associated Brown tumors, although these are relatively uncommon. 
8.4 Renal osteodystrophy 
Renal osteodystrophy is secondary to a combination of bone disorders as a consequence of 
chronic renal dysfunction, and often shows the most severe cases of metabolic bone disease. 
It may include osteoporosis, osteomalacia, adynamic bone, and secondary 
hyperparathyroidism in varying degrees. The most frequent bone scan imagings are similar 
to a superscan from other metabolic bone disorders, and uptake of diphosphonate in areas 
of ectopic calcification also may be seen. A lack of bladder activity (secondary to the renal 
failure) may help in identification and differentiating this type of scintigraphic pattern from 
others. Aluminum toxicity from hemodialysis, rarely seen now, causes a poor quality bone 
scan with reduced skeletal uptake and increased soft-tissue activity, as aluminum blocks 
mineralization and hence the uptake of tracer, resulting in a pattern applicable to all forms 
of adynamic bone disease. Quantitative measurements of bone metabolism in renal 
osteodystrophy using 18F-fluoride have been compared with bone histomorphometry and 
have shown a close relationship between the net plasma clearance of 18F-fluoride to bone 
mineral and the histomorphometric indices of bone formation. The method was able to 
differentiate low turnover from high turnover states of renal osteodystrophy (Cook et al., 
2010; as cited in Messa et al., 1993). 
8.5 Osteomalacia 
Patients with osteomalacia usually demonstrate similar features of a bone scan as described 
in hyperparathyroidism, although in the early stages of the disease it may appear normal 
(Cook et al., 2010). The reason that osteomalacia shows these features is not fully 
understood. Tracer avidity may reflect diffuse uptake in osteoid, although more likely, it is 
due to the degree of secondary hyperparathyroidism that is present. In addition, the 
presence of focal lesions may represent pseudofractures or true fractures. Pseudofractures 
are characteristically found in the ribs, the lateral border of the scapula, the pubic rami, and 
the medial femoral cortices. Although osteomalacia is usually a biochemical and/or 
histologic diagnosis, the typical bone scan features can be helpful in suggesting the 
diagnosis. The detection of pseudofracutures with this technique is more sensitive than that 
with radiography (Cook et al., 2010; as cited in Fogelman et al., 1977, 1978). 
9. Bone tumors 
For the diagnosis study of primary bone tumors prevails the importance of the 
morphological study to characterize the lesion and, in many cases, the initial plain films 
guides the diagnosis. In these cases, the usefulness of bone scintigraphy is lesser, but may be 
useful for detecting a lesion that is difficult to assess radiologically because of its location, 
and supporting the suspicion about the benignity or malignancy of the lesion. Characteristic 
patterns of uptake have been described in some primary bone tumors, but they are not 
reliable enough, given that there is an overlap in the scintigraphic characteristics of the 
benign and malignant bone lesions. The differential diagnosis of a solitary bone lesion 
usually depends more on morphologic imaging techniques, including radiographs, CT, and 
MRI, and on expert histologic analysis. In contrast, a larger role is developing for 18F-FDG-
PET/CT for staging and response assessment of several bone tumors. Three-phase bone  
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scintigraphy offers information about the vascularity of the bone lesion: Malignant tumors 
tend to be more vascularized and be uptake in all three phases of the scan, while benign 
bone tumors often do not show changes in the first two phases of the scintigraphy. Normal 
uptake, even in the third stage, is a sign for the mildness of the bone lesion. Osteoid osteoma 
is a benign bone tumor that constitutes an exception to this statement: It is highly vascular 
and provides uptake images in all three phases of the scan. In fact, a normal bone scan 
excludes its diagnosis. Aneurysmal bone cyst may show similar features. In patients with a 
benign tumor and a bone scan showing intense uptake, a fracture should be suspected. 
9.1 Benign bone tumors and tumor- like disorders 
In benign bone tumors, the uptake of radiopharmaceuticals (e.g. 99mTc) varies by type of 
tumor and may be normal, mild or severe. Bone scintigraphy is useful for the diagnosis of 
osteoid osteoma, especially when it is located at the spine, pelvis or hip, where radiological 
studies are usually not diagnosed. The typical scintigraphic finding is a round focal uptake 
lesion. CT is always necessary to confirm the diagnosis and surgical treatment. Most 
enchondromas appear like hot spots at bone scan study. This technique can locate these 
tumors in multiple enchondromatosis, but it can not differentiate between enchondroma 
and chondrosarcoma. The scintigraphic feature of the giant cell tumor is increased tracer 
uptake in all phases of this study, and the image of donut of the lesion, with a rim of uptake 
surrounding a central area of low uptake. Nevertheless, this image may also appear in other 
bone tumors. In fibrous displasia, characterized by replacement of normal bone tissue by 
abnormal fibro-osseous tissue with a high bone turnover, bone scan also display areas of 
increased uptake. In other bone lesions such as Langerhans cell histiocytosis, hemangiomas 
and aneurysmal bone cysts, the sensitivity of this technique is variable (Schneider, 2006). 
9.2 Soft tissue tumors and primary malignant bone tumors 
Musculoskeletal sarcomas represent a heterogeneous group of malignancies involving bone 
and soft tissue. Multiple myeloma is the most common primary malignancy of bone in 
adults, with an incidence of 3 per 100,000 in the USA. It may affect any bone with 
hematopoietic red marrow. Patients affected are usually over 50 years of age with the most 
common age group being between 60 and 65 years of age. Excluding myeloma and 
lymphoma, malignant primary bone tumors constitute only 0.2% of all malignancies in 
adults and approximately 5% of childhood malignancies, and, excluding mieloma in adults, 
the overwhelming majority of cases consist of osteosarcoma or Ewings’ sarcoma (Green, 
2009). Both are more common in the pediatric than the adult population. Osteosarcoma is 
the most frequent primary bone malignancy in children and second in adults following 
multiple myeloma. The Ewing’s sarcoma family of tumors is the second most frequent 
primary bone malignancy in children and young adults and it is the most lethal bone tumor. 
The most common presenting symptom for primary bone tumors is a painful swelling 
arising in the bone. The presentation may be similar to acute or chronic osteomyelitis with 
systemic symptoms of fever, malaise, weight loss, and leukocytosis. Approximatly 15% of 
patients have clinically evident metastasic disease at diagnosis. Metastatic spread is mainly 
hematogenous, and the lungs are the most common site of metastases, followed by bone and 
bone marrow. Anatomic imaging techniques including radiography, US, CT and MRI, 
currently play a dominant role in the evaluation of suspected and known sarcomas of both 
soft tissue and bone. Nuclear medicine techniques such as scintigraphy, Thallium-201, and 
67Ga imaging have all been used in the assessment of primary bone tumors. However, PET 
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into soft tissue, related with ectopic calcification. Focal skeletal abnormalities may represent 
associated Brown tumors, although these are relatively uncommon. 
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mineralization and hence the uptake of tracer, resulting in a pattern applicable to all forms 
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with radiography (Cook et al., 2010; as cited in Fogelman et al., 1977, 1978). 
9. Bone tumors 
For the diagnosis study of primary bone tumors prevails the importance of the 
morphological study to characterize the lesion and, in many cases, the initial plain films 
guides the diagnosis. In these cases, the usefulness of bone scintigraphy is lesser, but may be 
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scintigraphy offers information about the vascularity of the bone lesion: Malignant tumors 
tend to be more vascularized and be uptake in all three phases of the scan, while benign 
bone tumors often do not show changes in the first two phases of the scintigraphy. Normal 
uptake, even in the third stage, is a sign for the mildness of the bone lesion. Osteoid osteoma 
is a benign bone tumor that constitutes an exception to this statement: It is highly vascular 
and provides uptake images in all three phases of the scan. In fact, a normal bone scan 
excludes its diagnosis. Aneurysmal bone cyst may show similar features. In patients with a 
benign tumor and a bone scan showing intense uptake, a fracture should be suspected. 
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osteoid osteoma, especially when it is located at the spine, pelvis or hip, where radiological 
studies are usually not diagnosed. The typical scintigraphic finding is a round focal uptake 
lesion. CT is always necessary to confirm the diagnosis and surgical treatment. Most 
enchondromas appear like hot spots at bone scan study. This technique can locate these 
tumors in multiple enchondromatosis, but it can not differentiate between enchondroma 
and chondrosarcoma. The scintigraphic feature of the giant cell tumor is increased tracer 
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surrounding a central area of low uptake. Nevertheless, this image may also appear in other 
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and soft tissue. Multiple myeloma is the most common primary malignancy of bone in 
adults, with an incidence of 3 per 100,000 in the USA. It may affect any bone with 
hematopoietic red marrow. Patients affected are usually over 50 years of age with the most 
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67Ga imaging have all been used in the assessment of primary bone tumors. However, PET 
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is becoming the most imporant modality for assessing biologic characteristics of the tumor, 
for primary staging, and for determining response to treatment. Although imaging studies 
may be highly suggestive of the diagnosis, they cannot reliably differentiate among the 
various types of malignant bone tumors, and even among malignant and benign conditions. 
Histopathologic confirmation, therefore, is required. The sites for biopsy are critical for 
accurate histological diagnosis and staging because biopsy of a small site may not represent 
the overall character of the tumor, missing high-grade areas, and non-diagnostic biopsies 
may also occur (Howman-Giles et al., 2006).  
The diagnosis of indeterminate bone lesions is limited with 18F-FDG-PET, but in general the 
greater the level of uptake, the more likely a lesion is malignant in nature. However, it has 
been reported that some giant cell tumors and fibrous dysplasia may show uptake equivalent 
to osteosarcomas and that some other benign bone lesions may show high 18F-FDG 
accumulation (Aoki et al., 2001). Despite this, 18F-FDG-PET has a high specificity for 
excluding malignant bone tumors (Cook et al., 2010). Recently, dual time point imaging and 
calculation of a retention index for 18F-FDG have shown improved discrimination of benign 
and malignant bone lesions compared with static measures, but that some overlap was still 
present (Tian et al., 2009). Lodge et al observed difference in time-activity curves between 
benign and low-grade malignant tumors that show peak activity within the first 30 minutes 
post-injection and high-grade sarcomas, which reach peak activity 4 hours after injection. 
This quantitative approach cannot separate low-grade sarcomas from benign lesions. MRI is 
the modality of choice to define the extension of tumors to surrounding soft tissue as well as 
to estimate the local tumor infiltration into bone marrow. However, in the pediatric 
population, 18F-FDG-PET is valuable for detection of skip metastases in cases of equivocal 
MRI findings due to the physiological red blood marrow in long bones (Even-Sapir, 2007; as 
cited in Wuisman P, Enneking WF, 1990). With the new hybrid imaging, it is now possible to 
take advantage of the metabolic and morphologic information from 18F-FDG-PET/CT to 
enhance discrimination between benign and malignant bone lesions by dedicated 
interpretation of the CT characteristics (Strobel et al., 2008). 18F-FDG-PET data can also assist 
in optimizing the biopsy site of heterogeneous masses by guiding sampling to active tumor 
sites and avoiding errors due to biopsy of necrotic tumor areas (Even-Sapir, 2007; as cited in 
Pezeshk et al., 2006). In general, 18F-FDG-PET or PET/CT would appear to have a 
complementary role to conventional staging procedures (Cook et al., 2010; as cited in Kleis et 
al., 2009, Kneisl et al., 2006 and Völker et al., 2007). After a diagnosis of a malignant primary 
bone lesion is made, the use of bone scintigraphy to define the extent of tumor before surgical 
resection is controversial: good correlation between increased bone tracer uptake and true 
anatomical extent that has been reported (Cook et al., 2010; as cited in Goldmann et al., 1975, 
McKillop et al., 1981, and Papanicolou et al., 1982), has not been supported by other studies 
(Chew & Hudson, 1982). These discrepancies may be due to peritumoral reactive changes 
overestimating extent or underestimations due to inability to detect marrow and soft-tissue 
involvement. For these reasons, MRI is the most accurate noninvasive assessment of tumor 
extent. On the other hand, several studies have reported the ability of bone scintigraphy to 
predict histological response to preoperative chemotherapy in patients with primary 
malignant bone tumors. Ozcan et al have reported a study of 27 patients with osteosarcoma, 
Ewing’s sarcoma, and malignant fibrous histiocytoma, which has displayed a reduction in 
hyperemia and extension as the most notable findings on three-phase bone scintigraphy. A 
reduction in tumor blood flow of 58.7% was found in 15 responding patients compared with 
19.9% in the nonresponders. A higher accuracy in assessing response was possible using all 
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the information from three-phase scintigraphy (88%), compared with static imaging alone 
(74%) where the blood flow and blood pool images showed a reduction in vascularity and 
extension. These are consisting features with the results published in previous studies (Cook 
et al., 2010; as cited in Knop et al., 1990, and Sommer et al., 1987). The sensitivity of 18F-FDG-
PET in staging primary bone tumors appears to vary between different tumor types and 
location of metastases. Spiral CT is the modality of choice for detection of relatively small 
lung metastases. Franzius et al compared the detection lung metastases of sarcoma by CT and 
18F-FDG-PET, showing a higher sensitivity for the former modality especially in lesions <9 
mm. 18F-FDG-PET may, however, assist in differentiating nonspecific lung nodules from 
metastases detected by CT in case of larger lung lesions, within the size range of PET 
resolution. 18F-FDG-PET may also identify unexpected extra pulmonary metastases. Serial 
18F-FDG-PET assessment of primary bone tumors (predominantly osteosarcomas, Ewing’s 
sarcomas, or both) is a good non-invasive method to predict pathologic neoadjuvant 
chemotherapy response (Cook et al., 2010; Even-Sapir, 2007). Another earlier study also 
showed a correlation with pathologic response but described high 18F-FDG uptake in 
granulation and/or fibrotic tissue and in the fibrous pseudocapsule of treated tumors (Cook 
et al., 2010; as cited in Jones et al., 1996).  
Multiple myeloma hardly triggers osteoblastic reaction and therefore scintigraphy is less 
sensitive than plain radiography and CT. FDG-PET indicates active myeloma and CT shows 
bone destruction. Therefore hybrid whole-body PET/CT is an excellent method to evaluate 
myeloma. Currently whole-body and spinal MRI and PET/CT are considered the imaging 
techniques of choice for initial evaluation and follow-up of these patients. Durie et al 
assessed the role of 18F-FDG-PET in 66 patients with multiple myeloma and monoclonal 
gammopathy of undetermined significance. Their results suggested that a positive 18F-FDG-
PET reliably indicates the presence of active myeloma, whereas a negative study strongly 
supports the diagnosis of monoclonal gammopathy of undetermined significance. 18F-FDG-
PET has also been reported to identify unexpected medullar and extramedullar sites of 
myelomatous disease not appreciated on X-ray, CT, or scintigraphy (Even-Sapir, 2007). In a 
recent report on 28 patients with multiple myeloma, 18F-FDG-PET/CT and MRI of the spine 
were shown to have complementary roles. Although the former modality detected more 
lesions, all of which were located outside the field of view of MRI, the latter modality was 
found superior for diagnosing an infiltrative pattern in the spine (Nanni et al., 2006). In 
another recent report, 18F-FDG-PET was found to be valuable in detecting infection in 
patients with multiple myeloma (Even-Sapir, 2007).  
Osteosarcoma represents only 0.1% of all tumors, but it is the second most frequent 
malignant primary bone tumor after myeloma. The diagnosis of osteosarcoma is based on 
characteristic histologic features in combination with typical radiographic findings. MRI of 
the entire suspected bone is performed to define the degree of penetration of the tumor 
surrounding soft tissue as well as to estimate the local tumor infiltration into bone marrow. 
Furthermore, CT of the chest and conventional bone scan are necessary for early detection of 
metastases. MRI and scintigraphy are also used to distinguish postoperative changes from 
residual or recurrent tumor tissue after local surgical treatment. Because osteosarcoma 
metastases usually incorporate bisphosphonates, bone scanning can be used for follow-up 
examinations to detect both osseous and nonosseous metastases. High-resolution CT has 
been shown to be superior to 18F-FDG-PET for detecting lung metastases. Data on the 
benefit of 18F-FDG-PET for detecting skeletal metastases in osteosarcoma patients are still 
very sparse, but successful detection of all sites of bone involvement by 18F-FDG-PET has 
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the overall character of the tumor, missing high-grade areas, and non-diagnostic biopsies 
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to osteosarcomas and that some other benign bone lesions may show high 18F-FDG 
accumulation (Aoki et al., 2001). Despite this, 18F-FDG-PET has a high specificity for 
excluding malignant bone tumors (Cook et al., 2010). Recently, dual time point imaging and 
calculation of a retention index for 18F-FDG have shown improved discrimination of benign 
and malignant bone lesions compared with static measures, but that some overlap was still 
present (Tian et al., 2009). Lodge et al observed difference in time-activity curves between 
benign and low-grade malignant tumors that show peak activity within the first 30 minutes 
post-injection and high-grade sarcomas, which reach peak activity 4 hours after injection. 
This quantitative approach cannot separate low-grade sarcomas from benign lesions. MRI is 
the modality of choice to define the extension of tumors to surrounding soft tissue as well as 
to estimate the local tumor infiltration into bone marrow. However, in the pediatric 
population, 18F-FDG-PET is valuable for detection of skip metastases in cases of equivocal 
MRI findings due to the physiological red blood marrow in long bones (Even-Sapir, 2007; as 
cited in Wuisman P, Enneking WF, 1990). With the new hybrid imaging, it is now possible to 
take advantage of the metabolic and morphologic information from 18F-FDG-PET/CT to 
enhance discrimination between benign and malignant bone lesions by dedicated 
interpretation of the CT characteristics (Strobel et al., 2008). 18F-FDG-PET data can also assist 
in optimizing the biopsy site of heterogeneous masses by guiding sampling to active tumor 
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the information from three-phase scintigraphy (88%), compared with static imaging alone 
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extension. These are consisting features with the results published in previous studies (Cook 
et al., 2010; as cited in Knop et al., 1990, and Sommer et al., 1987). The sensitivity of 18F-FDG-
PET in staging primary bone tumors appears to vary between different tumor types and 
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metastases usually incorporate bisphosphonates, bone scanning can be used for follow-up 
examinations to detect both osseous and nonosseous metastases. High-resolution CT has 
been shown to be superior to 18F-FDG-PET for detecting lung metastases. Data on the 
benefit of 18F-FDG-PET for detecting skeletal metastases in osteosarcoma patients are still 
very sparse, but successful detection of all sites of bone involvement by 18F-FDG-PET has 
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been reported recently (Even-Sapir, 2007; as cited in Franzius et al., 2002). Nevertheless, in 
children there may be an exception for primary staging, where there may be an indication 
for 18F-FDG-PET to detect intraosseous skip metastases in cases of unequivocal MRI 
findings, although no data are yet available to support this hypothesis. PET scans will not 
obviate the need for biopsy and tissue diagnosis in soft-tissue and bone masses, but it is 
remarkably helpful to guide biopsy. Non-PET–guided biopsy might miss the most 
biologically significant region, resulting in a false low pre-therapeutic tumor grading. 18F-
FDG-PET imaging data has shown reliability for prediction of tumor response to 
preoperative, neoadjuvant chemotherapy. On the other hand, for differentiation between 
benign residual mass lesions caused by post-therapeutic tissue changes and residual tumor 
tissue or local relapse, 18F-FDG PET is considered to be highly sensitive and more accurate 
than CT or MRI (Brenner et al., 2003). A high baseline uptake of 18F-FDG in osteosarcoma 
has been reported as showing an inverse correlation with prognostic indicators and is 
associated with a poor outcome with similar results for patients with high post-treatment 
FDG activity (Cook et al., 2010; as cited in Costelloe et al., 2009; Franzius et al., 2002). 
Ewing’s sarcoma is a highly malignant primary bone tumor that is being derived from red 
bone marrow. It accounts for approximately 5% of biopsy-analyzed bone tumors and 
approximately 33% of primary bone tumors. No single morphologic or functional imaging 
method provides findings for a specific diagnosis of Ewing’s sarcoma, but the results do 
contribute to tumor staging. Because the clinical symptoms of Ewing’s sarcoma are nonspecific 
and because they frequently suggest osteomyelitis, an initial conventional radiographic 
and/or MRI examination is performed. With static bone scintigraphy, Ewing’s sarcoma is 
usually depicted as a focal area of increased radionuclide activity. Whole-body bone scans can 
provide information about the primary lesion and depict skip lesions. Also, bone scintigraphy 
can be used to localize distant metastases during tumor staging. Three-phase dynamic bone 
scintigraphy can help in the assessment of treatment effects, with a reported accuracy of 88%. 
In cases that respond to treatment, a reduction of both flow and tracer uptake can be observed. 
18F-FDG-PET may help to detect lesions that are not shown on conventional bone scans. It is 
the most sensitive modality for therapeutic follow-up, and this modality can reveal early 
changes in tumor metabolism, which is an indicator of the therapeutic effect. 
Regarding the lymphomatous disease, primary skeletal involvement occurs in 3 to 5% of 
patients with non-Hodgkin’s lymphoma, and secondary bone involvement occurs in up to 
25% of patients. Moog et al have reported 18F-FDG-PET to be more sensitive and specific 
than Tc-99m-MDP bone scintigraphy for detection of osseous involvement by lymphoma. 
Early bone involvement may present as abnormal on 18F-FDG-PET with normal CT 
appearance, since detection of malignant bone involvement on CT depends on the presence 
of a considerable amount of bone destruction.  
9.3 Metastases 
Bone metastasis is the most common malignant bone tumor. It affects two thirds of cancer 
patients, and tumors that most often lead to metastases are breast, lung and prostate 
neoplasms. Bone involvement by cancer occurs most commonly by hematogenous spread, 
although tumor may occasionally extend directly from the soft tissue to the adjacent bone. 
The vast majority of bone metastases initiate as intramedullary lesions. The normal bone 
undergoes constant remodeling, maintaining a balance between osteoclastic (resorptive) and 
osteoblastic activity. As the metastatic lesion enlarges within the marrow, the surrounding 
bone undergoes osteoclastic and osteoblastic reactive changes. Based on the balance 
 
Nuclear Medicine in Musculoskeletal Disorders: Clinical Approach 
 
117 
between the osteoclastic and osteoblastic processes, the radiographic appearance of a bone 
metastasis may be lytic, sclerotic (blastic), or mixed. The osteoblastic component of the 
metastasis represents reaction of normal bone to the metastatic process. The incidence of 
lytic, blastic, and mixed types of bone metastases is different in various tumor types. Lytic 
lesions may be seen in almost all tumor types. Bone metastases of bladder, kidney, and 
thyroid cancer and lesions of multiple myeloma are invariably lytic. Blastic lesions are 
frequently seen in prostate and breast cancer, occasionally in lung, stomach, pancreas, and 
cervix carcinomas, and infrequently in colorectal cancer (Beheshti et al., 2009; Even-Sapir, 
2005). The most frequent distribution of metastasis in the human skeleton is usually 80% in 
the axial skeleton and ribs, 10% skull and 10% in long bones. Approximately 40% of patients 
with metastases have no pain at diagnosis (Diaz & De Haro, 2005). Symptoms occur mainly 
when the lesion increases in size, causing extensive bone destruction, which may lead to 
collapse or fracture, or in the presence of accompanying complications, such as spinal cord 
compression or nerve root invasion. 
Bone scan is the primary tool for screening or monitoring bone metastases due to its high 
sensitivity, versus plain radiography (Brown, 1993), and plays an integral part in tumor 
staging and management, since early detection of skeletal metastases optimizes 
management (Even-Sapir, 2005). Scintigraphic image of metastases is one or more high 
uptake foci in 98% of the cases, and the usual pattern consists of increased radiotracer 
deposition in areas of osteoblastic reparative activity in response to tumor osteolysis. The 
presence of multiple, randomly, distributed areas of increased uptake of varying size, shape, 
and intensity is highly suggestive of bone metastases, specially at sternum, scapula and ribs. 
Although multiple foci of increased activity may be encountered in other pathologic 
conditions, it is often possible to distinguish metastatic disease from other entities by 
analyzing the pattern of distribution of the abnormalities. Traumatic injury, in contrast to 
metastatic disease, generally manifests as discrete focal abnormalities of similar intensity. 
Multifocal rib trauma has a characteristic linear distribution. In patients with osteoporosis, 
the presence of kyphosis and/or an H-shaped sacral fracture suggests the correct diagnosis. 
In older patients, osteoarthritis and degenerative changes may manifest as areas of intense 
activity on radionuclide bone images. These changes can be distinguished from metastatic 
disease by virtue of their characteristic location (eg, knees, hands, wrists). Involvement of 
both sides of the joint is common in arthritis but unusual in malignant conditions. The 
remaining 2% is mild uptake foci owing to preponderance of osteolytic activity. The 
possibility of an artifact should be ruled out in cases of well-defined cold spot. In cases of 
wide-spread metastases, the radiopharmaceutical can be almost completely captured and it 
may lead to a superscan image, where kidney or bladder silhouettes are not initially seen by 
the delay in urinary excretion of radiotracer. A superscan may also be associated with 
metabolic bone disease but, in this case, the uptake is more uniform in appearance and extends 
into the distal appendicular skeleton. Intense calvarial uptake that is disproportionate to that 
in the remainder of the skeleton is another feature of a metabolic superscan. SPECT is reported 
to detect 20 to 50% more lesions in the spine compared with planar scintigraphy, and it 
increases both the sensitivity and specificity. The new hybrid system, SPECT with multislice 
CT, improves diagnostic accuracy (Dasgeb et al., 2007). The most common radiotracer is Tc-
99m-MDP but in patients with follicular thyroid carcinoma or in cases of neuroblastoma, 
iodine-131 (131I) and 123I-Metaiodobenzylguanidine (123I-MIBG) are more sensitive. 
Increased uptake of these radiotracers reflects the osteoblastic reaction of bone to the 
destruction of bone by the tumor cells, whereas increased 18F-FDG activity at the sites of bone 
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been reported recently (Even-Sapir, 2007; as cited in Franzius et al., 2002). Nevertheless, in 
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thyroid cancer and lesions of multiple myeloma are invariably lytic. Blastic lesions are 
frequently seen in prostate and breast cancer, occasionally in lung, stomach, pancreas, and 
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conditions, it is often possible to distinguish metastatic disease from other entities by 
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metastatic disease, generally manifests as discrete focal abnormalities of similar intensity. 
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Increased uptake of these radiotracers reflects the osteoblastic reaction of bone to the 
destruction of bone by the tumor cells, whereas increased 18F-FDG activity at the sites of bone 
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lesions on PET study represents active tumor itself. Bone scintigraphy is more sensitive than 
FDG-PET for detection of blastic/sclerotic lesion, whereas FDG-PET is more sensitive for lytic 
lesions and bone marrow disease. The latter has the additional ability to assess extraskeletal 
metastatic disease. Hybrid PET/CT imaging improves the specificity of FDG-PET for skeletal 
metastases (Dasgeb et al., 2007; as cited in Even-Sapir, 2005). An additional finding from 
scanning the peripheries, particularly in patients with bronchogenic carcinoma, may be the 
observation of hypertrophic osteoarthropathy secondary to cortical periostitis, that typically 
appears as symmetrical, nonuniform, irregular cortical uptake involving the long bones, most 
often seen in the femora, tibiae and wrists, and giving rise to the “tramline sign” 
(Gnanasegaran et al., 2009; Love et al., 2003; as cited in Ernstoff  & Meehan, 2000). In patients 
with bone metastases who have received chemotherapy, reparative osteoblastic reaction that 
occurs after this treatment may lead to the appearance of bone areas with intense uptake 
during the first 3 months (flare phenomenon). As healing progresses, uptake in the lesion 
disminishes and by 6 months it should generally be possible to differentiate response from 
progression (Love et al., 2003). 
18F-FDG-PET has become a routine imaging modality for staging and monitoring the 
response to therapy in patients with lymphoma. There are accumulating data indicating that 
18F-FDG-PET may detect early marrow infiltration and may add clinically relevant 
information when performed in patients with primary or secondary lymphomatous bone 
involvement. FDG-PET can detect early marrow infiltration and therefore is more sensitive 
than planar scintigraphy or CT for assessment of early skeletal involvement in lymphoma 
(Dasgeb et al., 2007). A pattern of heterogeneous patchy marrow activity should raise the 
suspicion of marrow involvement in an 18F-FDG-PET study prior to therapy, while a 
pattern of diffuse uptake, mainly in Hodgkin’s Lynphoma, is more commonly associated 
with reactive hematopoietic changes or myeloid hyperplasia (Even-Sapir, 2007).  
Metastatic disease occasionally manifests as a solitary abnormality, usually in the spine, 
although other causes such as fractures, avascular osteonecrosis, primary bone tumors and 
infections must be previously ruled out. The location and/or characteristics of the lesion 
may guide the diagnostic suspicion but, especially if it is a solitary lesion, it must be studied 
with other imaging techniques such as CT or/and MRI (Schneider, 2006). Approximately 
50% of cases in which scintigraphy detect a solitary focal uptake in a patient with a history 
of cancer, it is a metastasis. In patients with breast cancer, the sternum is a relatively 
common site to be affected often as a solitary lesion and probably results from local spread 
from the involved internal mammary lymph nodes. If a sternal lesion is situated distant 
from the manubriosternal junction, is irregular, asymmetric, or eccentric, then malignant 
involvement should be suspected. In a retrospective study of patients with breast cancer, 
3.1% presented with an isolated sternal lesion and 76% of these were found to represent 
metastatic disease (Gnanasegaran et al., 2009; as cited in Kwai et al., 1988). Vertebral body 
fractures have a characteristic appearance on bone scintigraphy, showing a horizontal linear 
pattern of increased tracer accumulation. However, it is usually not possible to differentiate 
fractures due to benign diseases, such as osteoporosis from malignant collapse. In such 
cases, further evaluation with MRI is often the most informative. However, multiple linear 
abnormalities of varying intensity favour a benign etiology with presumed osteoporotic 
fracture occurring at different time points. Also, a follow-up bone scan after a few months 
that shows reducing activity at a vertebral fracture site, suggests a benign cause and a 
healing fracture. SPECT technique improves the localization and characterization of the 
vertebral lesions, due to its ability to delineate the body, pedicles, and spinous process: 
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Lesions that extend from the vertebral body into the posterior vertebral elements or involve 
the pedicle are more likely to represent metastases than lesions confined to the facet joints, 
anterior vertebral body, or either side of a disc (Gnanasegaran et al., 2009). 
10. Osteoarthritis 
Osteoarthritis (OA) is the most prevalent chronic joint disease and it has the greatest health 
economic impact. Conventional radiography is still the first and most commonly used 
imaging technique for evaluation of a patient with a known or suspected diagnosis of OA 
(Guermazi, 2009). MRI is an appropriate tool for describing changes in cartilage volume and 
concomitant soft-tissue alterations. But for qualitative cartilage imaging, MRI has, to date, 
not been fully validated. Bone scan allows the differentiation of inflammatory from 
degenerative joint affections and may add information on the activity of the subchondral 
bone, which may develop to a prognostic marker of OA (Zacher et al., 2007). Another 
pronostic marker of slower progression that can help us deciding the most appropriate 
management is the imaging of the joints that show up as “cold” (Colamussi et al., 2004). 
Radionuclide joint imaging is more sensitive than clinical or radiographic techniques in 
detecting early joint involvement but usually it must be supplemented by other techniques 
to establish a specific diagnosis (Hoffer & Genant, 1976). 
Usefulness of molecular imaging for early diagnosis of OA is still a challenge. Cartilage 
damage in OA is being recharacterized as having an earlier dynamic phase, where cartilage 
damage is potentially reversible, followed by an irreversible pathologic phase that 
ultimately leads to joint pain and immobility (Hu & Du, 2009). The point at which cartilage 
damage is deemed irreversible has not been defined but probably depends on the size of the 
lesion, age of the patient, underlying cause, comorbid factors, activity level, use of joint 
stabilizers, genetic predisposition, and other factors. To detect early cartilage damage, 
molecular imaging research has focused on the identification of better ways to either 
visualize extracellular matrix depletion or measure events that are associated with cartilage 
damage, such as chondrocyte death and the elaboration of matrix-degrading enzymes. In 
OA, there is general acceptance that abnormal chondrocyte apoptosis is a pivotal event in 
the eventual destruction of articular cartilage (Biswal et al., 2007). A method for the study of 
cell death in living subjets is based on an endogenous protein, annexin V, whose function is 
not clearly understood but which is thought to play a role in coagulation (Biswald et al., 
2007; as cited in Reutelinsperger & Van Heerde, 1997). This protein has an extremely strong 
affinity for the cell membrane phospholipid phosphotidylserine, which is expressed to the 
outer surface of the cell membrane during the apoptotic cascade. The use of annexin V, 
labelled with either a radioisotope or a fluorescent marker, provides an excellent 
opportunity to image programmed cell death. To date, annexin V has been labelled with 
99mTc, iodine (125I, 124I, 123I), 111In, 11C, gallium (Ga-67, Ga-68), and 18F, making it 
appropriate for either SPECT or PET imaging (Biswald et al., 2007; as cited in Blankenberg, 
1998; Glaser, 2003; Lahorte, 2004; Russell, 2002; Zijlstra, 2003). However Annexin V imaging 
has yet to be applied to the assessment of human OA. Another event associated with 
cartilage damage is the elaboration of matrix-degrading enzymes. In OA damaged cartilage 
appears to activate hibernating proteases such as matrix metalloproteinases and cathepsins. 
Using a cathepsin B–sensitive near-infrared fluorescent probe, researchers have found 
significant amounts of signal arising from an arthritic knee compared with normal knees in 
an animal model of OA (Biswald et al., 2007; as cited in Lai, 2004). 
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Lesions that extend from the vertebral body into the posterior vertebral elements or involve 
the pedicle are more likely to represent metastases than lesions confined to the facet joints, 
anterior vertebral body, or either side of a disc (Gnanasegaran et al., 2009). 
10. Osteoarthritis 
Osteoarthritis (OA) is the most prevalent chronic joint disease and it has the greatest health 
economic impact. Conventional radiography is still the first and most commonly used 
imaging technique for evaluation of a patient with a known or suspected diagnosis of OA 
(Guermazi, 2009). MRI is an appropriate tool for describing changes in cartilage volume and 
concomitant soft-tissue alterations. But for qualitative cartilage imaging, MRI has, to date, 
not been fully validated. Bone scan allows the differentiation of inflammatory from 
degenerative joint affections and may add information on the activity of the subchondral 
bone, which may develop to a prognostic marker of OA (Zacher et al., 2007). Another 
pronostic marker of slower progression that can help us deciding the most appropriate 
management is the imaging of the joints that show up as “cold” (Colamussi et al., 2004). 
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detecting early joint involvement but usually it must be supplemented by other techniques 
to establish a specific diagnosis (Hoffer & Genant, 1976). 
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damage, such as chondrocyte death and the elaboration of matrix-degrading enzymes. In 
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the eventual destruction of articular cartilage (Biswal et al., 2007). A method for the study of 
cell death in living subjets is based on an endogenous protein, annexin V, whose function is 
not clearly understood but which is thought to play a role in coagulation (Biswald et al., 
2007; as cited in Reutelinsperger & Van Heerde, 1997). This protein has an extremely strong 
affinity for the cell membrane phospholipid phosphotidylserine, which is expressed to the 
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labelled with either a radioisotope or a fluorescent marker, provides an excellent 
opportunity to image programmed cell death. To date, annexin V has been labelled with 
99mTc, iodine (125I, 124I, 123I), 111In, 11C, gallium (Ga-67, Ga-68), and 18F, making it 
appropriate for either SPECT or PET imaging (Biswald et al., 2007; as cited in Blankenberg, 
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significant amounts of signal arising from an arthritic knee compared with normal knees in 
an animal model of OA (Biswald et al., 2007; as cited in Lai, 2004). 
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11. Heterotopic ossification 
Heterotopic ossification (HO) is defined by the presence of bone in soft tissue where bone 
tissue normally does not exist, and it usually takes place around large joints (Medina et al., 
2008). Its etiology is unknown, but is frequently precipitated by trauma, spinal cord injury 
or central nervous system injury (Shebab et al., 2002). The incidence of HO varies widely 
between populations. The incidence after hip replacement ranges from 16% to 53%; among 
patients with spinal cord injury HO develops in 20-25% and in brain injury patients the 
incidence of HO ranges from 10 to 20% (Medina et al., 2008; as cited in Vanden & 
Vanderstraeten, 2005). Around 20% of the patients who have an HO will develop functional 
limitation and it will be severe in 8% to 10% (Medina et al., 2008; as cited in Buschbacher, 
1992; Subbarao, 1999). HO may closely mimic the presentation of cellulitis, osteomyelitis, or 
thrombophlebitis. HO can even be confused with some bone tumors such as osteosarcoma 
or osteochondroma. To resolve such diagnostic uncertainty and to prevent functional 
limitations, clinicians often request bone scanning and other imaging studies for patients at 
risk (Shebab et al., 2002). Radiography, MRI and CT have low sensibility in early stages of 
HO and three-phase bone scintigraphy (Fig. 7) is the most sensitive imaging modality 
during this period. It is also useful for its monitoring (Vanden & Vanderstraeten, 2005).  
 
 
Fig. 7. Bone Scanning: increased uptake around the left hip consistent with Heterotopic 
Ossification. 
First and second phases of three-phase bone scintigraphy are especially sensitive to detect 
incipient HO, which may be diagnosed 2.5 weeks after injury. Findings on the third phase 
may become positive approximately 1 week later. Radiographic studies do not show any 
change for at least 5- 8 weeks after initial injury (Shebab et al., 2002; as cited in Freed et al., 
1982; Orzel & Rudd, 1985). Activity on the delayed bone scans usually peaks in a few 
months and after that the intensity of HO activity progressively lessens and thus the uptake 
of the radiotracer on the scans, which return toward normal within 12 months. However, in 
some cases activity remains slightly elevated even though the underlying HO has become 
mature (Shebab et al., 2002; as cited in Tibone et al., 1978). During the course of HO, bone 
scans made on follow-up may show radiotracer uptake on third phase even after flow and 
blood-pool images have returned to normal. Serial bone scans have been used successfully 
to monitor the metabolic activity of HO and determine the appropriate time for surgical 
resection, if needed, and to predict postoperative recurrence (Shebab et al., 2002; as cited in 
Freed et al., 1982; Muheim et al., 1973; Rossier et al., 1973; Tanaka et al., 1977). For the 
differential diagnosis of osteomyelitis complementary imaging with gallium-67 citrate (for 
spinal infection) or indium-111-labeled autologous leukocytes (for the appendicular 
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skeleton) may be necessary, as commented in that section. Gallium-67 citrate uptake in HO 
is proportional to the uptake of 99m Tc-diphosphonates, in contrast to the relatively greater 
gallium-67 citrate uptake characteristic of osteomyelitis (Shebab et al., 2002). 
A diagnostic-treatment algorithm of heterotopic ossification has been proposed, and three-
phase bone scintigraphy has been recommended, after clinical signs and laboratory test, for 
its diagnosis in patients without HO but with high risk factor. If clinical signs and symptoms 
are present but initial radiographic studies are normal, bone scan should be repeated after 4-
6 weeks, and when scintigraphic studies have displayed the HO, it should be made every 
three months during the first year. Bone scan has also been proposed during the follow-up 
after HO removal to monitor possible recurrences (Medina et al., 2008). 
12. Fractures 
Following known injury, fractures are commonly demostrated by conventional radiography 
of most sites of trauma. In such circumstances bone scintigraphy has no major role, although 
unsuspected lesions may be identified. Acute fractures show increased perfusion on the 
radionuclide angiogram; intense, poorly marginated increased tracer accumulation 
representing relatively increased vascularity on the blood pool images; and intense poorly 
defined increased tracer accumulation on delayed images (Holder, 1993). 
12.1 Occult fractures 
Scintigraphy may be valuable in the diagnosis of occult fractures, which are true fractures 
not immediately obvious on clinical examination or plain radiography, and it is particularly 
useful to detect certain type of fractures that require urgent orthopedic treatment, such as 
femoral neck and intertrochanteric fractures, scaphoid fracture, and Lisfranc fracture. Occult 
femoral neck and intertrochanteric fractures are frequents in older females with continued 
hip pain following a fall. Shortly following the time of injury, there is an increase in 
perfusion to the fracture site which can be demonstrated during the rapid sequence flow 
study and blood pool phases of the so called three-phase bone scan. The time for first 
appearance of increased uptake on delayed 99mTc-diphosphonate images remains 
controversial, fluctuating between 24 hours and 2 weeks (Collier et al., 1993; as cited in 
Holder et al., 1990; Matin, 1979; Spitz, 1991). These problems are not encountered in the 
identification of scaphoid fracture which is readily visualized within 3 days of trauma. Bone 
scan demonstrates a focus of intense uptake usually centered in the scaphoid (Collier et al., 
1993; as cited in Patel et al., 1992; Tiel-van-Buul et al., 1992). High-resolution bone scan 
images obtained with the wrist first in a neutral position and then in ulnar deviation are 
used to localize the scintigraphic abnormality to the scaphoid. With ulnar deviation there is 
movement and rotation of the scaphoid relative to adjacent bony landmarks such as the 
radial styloid (Collier et al., 1993). Premature imaging withing 48 hours must be avoided, 
particularly as the osseous scintigraphic changes may be obscured by the diffuse uptake 
resulting from superficial hyperemia or traumatic sinovitis. Prolonged delay of this study 
may also result in increased uptake associated with disuse and thus, masking the fracture 
(Murray, 1998). Scintigraphy is therefore of considerable value in identifying this lesion 
before X-ray change appears, especially as difficulty may be encountered in radiological 
diagnosis even after 2-3 weeks (Murray, 1998). Difficulties in identifying the exact anatomic 
localization of a focus of uptake can be overcome by the technique of a combined display of 
the scan and the X-ray (Murray, 1998; as cited in Hawkes, 1991). Other occult fracture that  
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skeleton) may be necessary, as commented in that section. Gallium-67 citrate uptake in HO 
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may also result in increased uptake associated with disuse and thus, masking the fracture 
(Murray, 1998). Scintigraphy is therefore of considerable value in identifying this lesion 
before X-ray change appears, especially as difficulty may be encountered in radiological 
diagnosis even after 2-3 weeks (Murray, 1998). Difficulties in identifying the exact anatomic 
localization of a focus of uptake can be overcome by the technique of a combined display of 
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can require urgent treatment is Lisfranc fracture. This fracture presents a characteristic 
appearance on bone scan with a band of increased uptake extending across multiple 
tarsometatarsal joints, typically involving the first through fifth or the second through fifth 
tarsometatarsal joints (Collier et al., 1993; as cited in Fogelman & Collier, 1989). 
12.2 Stress fractures 
Stress fracture occurs when a bone breaks after being subjected to repeated tensile or 
compressive stresses, none of which would be large enough to cause individually the bone to 
fail, in a person who is not known to have an underlying disease that would be expected to 
cause abnormal bone fragility (De Weber, 2011).  The incidence of stress fractures is less than 1 
% in the general population. The reported incidence in athletic populations varies with the 
type of athlete. Among military recruits the incidence ranges from 1 to 31 %, among runners 13 
to 52 %, and among participants in collegiate team sports 1 to 8 % (De Weber, 2011; as cited in 
Bennel, 1997). In most instances, the individuals who suffer stress fractures have been 
engaging in vigorous activity to which they have not yet become conditioned. The failure to 
recognize the characteristic clinical and imaging findings of a stress fracture and the continued 
excessive exercise by the athlete will occasionally lead to a complete fracture (Collier et al, 
1993). Imaging is needed when high risk stress fractures are suspected or a definitive diagnosis 
is necessary. The sites at high risk complications are the pars interarticularis of the lumbar 
spine, femoral head, superior side of the femoral neck, patella, anterior cortex of the tibia, 
medial malleolus, talus, tarsal navicular, proximal fifth metatarsal, great toe sesamoids, and 
the base of the second metatarsal bone (De Weber, 2011). 
 
º 
Fig. 8. Scintigraphy: localized uptake in tibial metaphysis and both internal femoral 
condyles. 
Three-phase bone scan has traditionally been used for diagnosis of stress fractures because it 
can show evidence of stress fracture within 2 to 3 days of injury and has high sensitivity. Acute 
stress fractures appear as discrete, localized, sometimes linear areas of increased uptake on all 
three phases (angiographic, soft tissue, and delayed phases) of a Tc-99m-MDP bone scan (Fig. 
8). However, the specificity of bone scan is low. Approximately 40 % of positive findings occur 
at asymptomatic sites (De Weber, 2011; as cited in Bennell et al., 1999). Bone scan can  
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also be falsely positive with shin splints, despite shin splints are typically positive only 
during the delayed phase of the scan (De Weber, 2011; as cited in Deutsch, 1997). Areas of 
increased uptake may represent subclinical sites of bone remodeling or stress reactions. 
Increased uptake can also appear in the setting of bone tumors, osteomyelitis, or avascular 
necrosis. Although rare, there are reports of false-negative bone scans (De Weber, 2011; as 
cited in Gaeta et al., 2005; Spitz & Newberg, 2002). Because of these limitations, MRI is 
supplanting bone scan as the diagnostic tool of choice when plain radiographs are negative 
and confirmation of suspected stress fracture is needed.  
12.3 Insufficiency fractures 
Insufficiency fracture occurs when the mechanical strength of a bone is reduced to the point 
that a stress which would not fracture a healthy bone breaks the weak one (De Weber, 2011). 
Most commonly postmenopausal osteoporosis is the cause for insufficiency fractures. 
Additional conditions affecting bone turnover include osteomalacia, chronic renal failure, 
and high-dose corticosteroid therapy (Krestan et al., 2011). Insufficiency fractures occur 
most commonly in the pelvis, including the sacrum, followed by the proximal femur and the 
vertebral bodies, in particular in the lower thoracic and the lumbar spine. Other sites 
frequently affected by insufficiency fractures are the tibia, fibula, and calcaneus (Krestan & 
Hojreh, 2009; as cited in Soubrier, 2003). Radiographs are the basic modality used for 
screening of insufficiency fractures, but depending on the location of the fractures, 
sensitivity is limited. Thus, MRI and CT are both standard techniques when insufficiency 
fracture is suspected and initial radiological studies are negative. MRI is a very sensitive tool 
to visualize bone marrow abnormalities associated with insufficiency fractures and allows 
differentiation of benign versus malignant fractures. Multidetector CT depicts subtle 
fracture lines allowing direct visualization of cortical and trabecular bone (Krestan et al., 
2011). Bone scintigraphy is also highly sensitive and specific when typical pattern of 
abnormality is present. One of those typical patterns of uptake is the classical H (‘Honda’ 
sign) or butterfly-shaped appearance in sacral insufficiency fracture in the elderly 
osteoporotic patient without definite trauma history. The vertical limbs of the H lie within 
the sacral ala, parallel to the sacroiliac joints, while the transverse limb of the H extends 
across the sacral body. Other sacral variant uptake patterns occur frequently and include the 
unilateral ala, incomplete H and horizontal linear dot patterns. Iliac fractures are seen as 
linear areas of increased radionuclide uptake. Pubic and supra-acetabular fractures produce 
areas of linear or focal uptake. Concomitant findings of two or more areas of increased 
uptake in the sacrum and at another pelvic site are considered diagnostic of insufficiency 
fractures of the pelvis. If a typical pattern of abnormality is not present, the radionuclide 
bone scan is much less specific. If abnormal or incomplete patterns of uptake are observed, 
findings may be mistaken for malignancy and other etiologies. PET–CT with hybrid-
scanners has been the upcoming modality for the differentiation of benign from malignant 
fractures (Krestan et al., 2011). 
12.4 Pathologic fractures 
This type of fractures is due to a localized loss of strength secondary to an underlying 
disease process. Examples of pathologic fractures include those that occur at sites of bone 
tumors (primary or metastatic), bone cysts, and infections (De Weber, 2011). About 10% of 
patients with known bone metastases will sustain a fracture. Most patients with high-risk 
conditions for bone metastasis are followed serially with bone scan to detect occult 
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metastasis. In general, lytic lesions are considered more prone to fracture than blastic ones. 
In the spine, CT or MRI are both indicated to quantify the extent of tumor infiltration, 
including any extension into the spinal cord and are useful in distinguishing osteoporotic 
vertebral collapse from pathologic fracture.  
12.5 Non-union fractures 
In the setting of impaired fracture healing we can distinguish three complications: the 
delayed union, non-union and pseudoartrhosis. Delayed union describes the situation 
where there are distinct clinical and radiological signs of prolonged fracture healing time 
(Panagiotis, 2005). Scintigrams demonstrate intense tracer concentration at the fracture site, 
as does a fracture undergoing normal or non-union. Therefore, differentiation of a normal or 
delayed union from nonunited fracture may not be possible by scintigram alone. Clinical 
findings along with roentgenograms are usually adequate to distinguish delayed healing 
from nonhealing (Desai et al., 1980). Non-union fracture is defined as the cessation of all 
reparative processes of healing without bone union 6 to 8 months following the fracture or 
by the absence of progressive repair that has not been observed radiographically between 
the third to sixth months following a fracture (Panagiotis, 2005). Two main types of non-
union fractures are differentiated according to the viability of the ends of the fragments 
(Frölke& Patka, 2007; as cited in Weber & Cech, 1976): Avascular non-union and 
hypervascular non-union. In the first type the ends of the fragments are avascular or 
atrophic, inert and incapable of biologic reaction, and therefore bone scintigraphies indicate 
a poor blood supply at the edges of the fragments (Frölke& Patka, 2007). On delayed images 
atrophic non-union rim is seen as a photon deficient band between fracture ends (Holder, 
1993). The main problem in this type is the poor quality of the bone ends and the 
significantly diminished potential for repair (Gelalis et al., 2011). In the second type the rims 
of the fragment are hypervascular or hypertrophic and are capable of biological reaction. 
Bone scintigraphy in the latter indicates a rich blood supply in the ends of the fragments 
(Frölke& Patka, 2007). The main problem in this type is inadequate fracture stability or 
reduction. The third complication, pseudoarthrosis, is a non-union fracture which may take 
years to develop and may occur without clinical symptoms. It is characterised by the 
formation of a false joint where a fibrocartilaginous cavity is lined with synovium producing 
synovial fluid (Panagiotis, 2005; as cited in McKee, 2000). Scans using Tc-99m-MDP show 
the presence of a synovial pseudoarthrosis (Csongradi & Maloney, 1989; as cited in Esterhai 
et al., 1984). Two types can be distinguished as in the non-union fractures: atrophic and 
hypertrophic pseudoarthrosis. The first one is characterized in the scintigraphy by the 
absence of peripheral accumulation in contrast with the intense uptake surrounding a 
hypertrophic pseudoarthrosis. Those finding in the bone scan are highly suspect for 
pseudoartrhosis after 12 months. The use of SPECT with bone scanning enhances the 
sensitivity and specificity, especially in the pseudoarthrosis of the spine after a lumbar 
spinal fusion (Collier et al., 1993; Lee & Worsley, 2006). SPECT identifies a more focal area of 
intense activity within the area of increased accumulation at the fusion site (Murray, 1998). 
Some authors have used radionuclide scans to determine whether the fracture has the 
biologic ability to respond to a specific therapy such as electrical stimulation. With mature 
nonunions, radionuclide scans can identify large hypovascular areas that have no potential 
for healing. In such cases, operative intervention is needed. In a case of nonunion, the 
possibility of infection must be considered. An increase in activity at the fracture site on the 
radionuclide scan is consistent with both bony healing and infection. Infection at the 
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fracture site can also be a cause of persistent pain and contribute to the non-union 
(Csongradi & Maloney, 1989). Gallium scan is indicative of infection if 67Ga uptake exceeds 
99mTc uptake on the bone scan. The most specific tracers for infection however are 
leukocytes labelled with indium-111 or 99mTc (Schelstraete et al., 1992). 
13. Technical aspects and applications of bone scintigraphy in pediatric 
populations 
13.1 Technical aspects of bone scintigraphy in pediatric populations 
Technical considerations concerning care of the child, immobilization, dosing of 
radiopharmaceuticals, and instrumentation are of major importance in pediatric nuclear 
medicine. It is routine in many dedicated pediatric nuclear medicine departments to allow 
parents or siblings to remain in the imaging room to provide a sense of security and safety 
for the child. Similarly, the patient is allowed to hold a favorite toy or a prized possession 
and parents are instructed to bring such items with them for the test. Children are often 
most worried about the needle required for the injection. Many nuclear medicine 
departments now routinely use the application of topical anesthetic creams as part of the 
preparation for the examination (Nadel & Stilwell, 2001). Immobilization techniques to gain 
patient support in pediatric studies can vary from wrapping the patient to the use of 
sedation and general anesthesia. For neonates to age 2, it may suffice to hold the patient in 
place, deprive sleep, and feed the child while on the imaging table. Papoose techniques for 
bundling and entertainment including television, movies, music, or stories can be used to 
immobilize children older than 4 to 5 years of age. The cooperation of an older child can 
often be obtained if the procedure is carefully explained to them and their parents. Children 
between the ages of 2 and 5, or who are mentally retarded, or have severe attention deficit 
problems, are more likely to require sedation (Nadel & Stilwell, 2001). Guidelines from the 
American College of Radiology and the American Academy of Pediatrics can help in 
developing an appropriate institutional sedation protocol (Shammas, 2009; as cited in 
Gilday, 2003).  
The correct dosing for administration of radiopharmaceuticals to children is available in 
standard pediatric nuclear medicine texts and can be based on either body surface area or 
the weight of the child relative to adult dosage (Nadel & Stilwell, 2001; as cited in Miller & 
Gelfand, 1994; Treves, 1995). 99mTc- MDP is the most commonly used radiopharmaceutical 
for bone scintigraphy. Scanning is usually performed as a three-phase bone scan with 
immediate blood flow and blood pool imaging of the site of symptoms obtained after 
injection, followed by delayed imaging 1.5 to 2 hours later. It is important that the children 
are well hydrated to have optimum visualization. Other radiopharmaceuticals are also 
useful in the evaluation of musculoskeletal disease, such as 67Ga citrate or labelled 
leukocytes using indium-111 or 99mTc for musculoskeletal infection or a bone marrow scan 
using a 99mTc-sulfur colloid for bone marrow infarction, particularly in sickle cell disease 
(Shammas, 2009; as cited in Connolly et al., 2007; Gilday, 2003; Nadel & Stilwell, 2001). 18F-
FDG is the most common radiopharmaceutical used for PET or PET/CT. 18F-FDG 
accumulation occurs in inflammation and infection (Shammas, 2009; as cited in Love et al., 
2005; Zhuang & Alavi, 2002). Imaging of inflammation with 18F-FDG PET relies on the fact 
that infiltrated granulocytes and tissue macrophages use glucose as an energy source. When 
they are activated in inflammation, metabolism and thus FDG uptake increases (Shammas, 
2009; as cited in Kubota et al., 1992).  
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metastasis. In general, lytic lesions are considered more prone to fracture than blastic ones. 
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nonunions, radionuclide scans can identify large hypovascular areas that have no potential 
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using a 99mTc-sulfur colloid for bone marrow infarction, particularly in sickle cell disease 
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Proper positioning is important in pediatrics particularly in young infants, and although 
children are smaller, it does not imply that more of a child can be imaged on a single 
scintigraphic view. In fact, examinations take longer in children and infants because of the 
requirement of joint-to-joint images for detailed assessment. Although the new gamma 
camera systems often allow whole-body passes it is often necessary to supplement these 
images with magnified spot views or even pinhole imaging. Image magnification either 
with camera zoom, computer magnification, or collimation is essential when performing 
scintigraphic examinations in children. Magnification is either optical with collimation or 
electronic. Optical magnification uses either a pinhole or converging collimator, enlarges the 
image, and improves overall system resolution. Electronic magnification makes the image 
bigger without altering overall system resolution. The capability for SPECT imaging is 
essential in pediatric scintigraphy. SPECT allows for improved image contrast and hence 
improved diagnostic accuracy. It is helpful in localizing and further defining most 
musculoskeletal abnormalities to include the extremities and is essential when assessing a 
child with the clinical problem of back pain. Multiple head detector gamma camera systems 
are becoming more available in pediatric centers. The advantages of these systems include 
increased resolution and sensitivity and decreased time of examination in a child. 
Correlative imaging is essential to state of the art practice of pediatric nuclear medicine. 
Computer multimodality image fusion programs are becoming available and more 
sophisticated. They allow comparison of different isotope scintigraphic studies or serial 
studies in the same patient or comparison of scintigraphy with other imaging modalities, 
such as CT, MR imaging, and PET for better correlation of anatomy and function. New 
combined gamma camera and CT devices allowing direct anatomic and physiologic 
correlation are also being manufactured and will have further impact on the care of the 
pediatric patient. 
The normal distribution in a pediatric bone scan may differ from adults (Shammas, 2009; as 
cited in Nadel, 2007). In children there is high physeal and apophyseal uptake due to their 
rich blood supply and active enchondral ossification. Absence of uptake in nonossified 
cartilaginous structures should not be mis- taken for avascular necrosis. Regions where this 
may be of concern in younger children include the femoral capital epiphysis, patella, and 
navicular bone. Before ossification, the ischiopubic synchondrosis appears as a discontinuity 
of the inferior pubic ramus. During ossification, increased uptake in ischiopubic 
synchondroses is a common normal variant and should not be misinterpreted as a 
pathological lesion (Shammas, 2009). 
13.2 Applications of bone scintigraphy in pediatric populations 
13.2.1 Infections 
Acute osteomyelitis is a common pediatric disease that mostly affects children under 5 years 
old. It usually is the result of hematogenous spread of infection due to the rich vascular 
supply of the growing skeleton. Typically, bone scan become positive 24 to 72 hours after 
the onset of infection, while plain films do not manifest evidence of infection until 3 to 4 
weeks after. Therefore, three-phase bone scintigraphy is the most sensitive imaging 
modality for early diagnosis. The sensitivity of a three-phase bone scan has been estimated 
as 94% with a specificity of 95% (Shammas, 2009; as cited in Schauwecker, 1992). Ideally, 
scintigraphic imaging should be obtained before joint aspiration, and a delayed whole-body 
scan on skeletal phase should be obtained because osteomyelitis in childhood can be 
multifocal or present with referred pain. In addition, malignant disease such as leukemia  
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and sarcoma may mimic acute osteomyelitis (Shammas, 2009; as cited in Connolly et al., 
2007; Ma et al., 2007). All three phases of the bone scan show focally high uptake in the 
affected bone. Occasionally, the affected bone in children shows low uptake or a photopenic 
defect (cold osteomyelitis) (Shammas, 2009; as cited in Pennington, 1999). This is most likely 
due to reduced tracer delivery by increased intraosseous pressure from inflammation, 
oedema, and joint effusion (Shammas, 2009). Cellulitis may be differentiated from 
osteomyelitis because the former typically demonstrates diffuse increased activity in the soft 
tissues on the first two phases, without focal osseous abnormality on the third phase 
(Shammas, 2009; as cited in Wegener & Alavi, 1991). Although chronic recurrent multifocal 
osteomyelitis (CRMO) and acute osteomyelitis share a common histopathologic feature, 
namely chronic inflammation, they are different in important ways (Nadel & Stilwell, 2001). 
CRMO occurs most frequently in the latter half of the first decade and the first half of the 
second decade of life, and it is more common in girls, differently from acute osteomyelitis 
that occurs in children under 5 years old (Shammas, 2009). A predisposing cause is not 
found for CRMO in contrast to conventional osteomyelitis (Nadel & Stilwell, 2001). Bone 
scintigraphy is helpful in identifying the multifocal bone lesions and characteristically 
displays high uptake in both symptomatic and asymptomatic lesions (Shammas, 2009, as 
cited in Connolly, 2007). Other infection typical of children under 3 years of age is septic 
arthritis. Monoarticular involvement is the most common pattern. The more affected joints 
are the knees and the hips. As in the osteomyelitis, there is an increased uptake on all three 
phases of three-phase bone scan, but in septic arthritis there is a symmetric uptake in both 
sides of the joint (Diaz& De Haro, 2005). Transient synovitis is the most common condition 
that mimics septic arthritis. In this case, three-phase bone scan may be normal or may show 
diffuse increased activity on the first two phases. Delayed images may displa periarticular 
increased activity in the affected joint (Shammas, 2009). 
13.2.2 Legg-Calve Perthe disease 
Legg-Calve Perthes disease is an idiopathic ischemic necrosis of the femoral head that 
occurs characteristically in children between 5 to 8 years. Bone scintigraphy is more 
sensitive than radiography for early diagnosis, and comparable to MRI (Shammas, 2009; as 
cited in Ma et al., 2007). Studies performed early after the onset of clinical symptoms show 
absence of activity in the capital femoral epiphysis and it may precede radiographic changes 
(Shammas, 2009; as cited Connolly & Treves, 1998). Later scans may demonstrate increased 
activity due to revascularization and remodeling. Bone scintigraphy has also a pronostic 
value and can be used in routine management to identify patients at high risk for a poor 
outcome (Shammas, 2009; as cited in Comte et al., 2003): Persistent absence of bone uptake 
in the proximal femoral epiphysis after 5 months or metaphyseal hyperactivity is highly 
correlated with more severe disease and a poorer prognosis. The early formation of a lateral 
column of tracer uptake in the capital femoral epiphysis, even before radiography, is 
associated with a good prognosis due to early revascularization (Shammas, 2009; as cited in 
Conway, 1993 and Tsao et al., 1997). 
13.2.3 Slipped capital femoral epiphysis 
Slipped capital femoral epiphysis is characterized by a displacement of the capital femoral 
epiphysis from the femoral neck through the physeal plate with medial and posterior 
rotation of the epiphysismost commonly in the adolescence. Bone scintigraphy is useful for 
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children are smaller, it does not imply that more of a child can be imaged on a single 
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and sarcoma may mimic acute osteomyelitis (Shammas, 2009; as cited in Connolly et al., 
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defect (cold osteomyelitis) (Shammas, 2009; as cited in Pennington, 1999). This is most likely 
due to reduced tracer delivery by increased intraosseous pressure from inflammation, 
oedema, and joint effusion (Shammas, 2009). Cellulitis may be differentiated from 
osteomyelitis because the former typically demonstrates diffuse increased activity in the soft 
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that occurs in children under 5 years old (Shammas, 2009). A predisposing cause is not 
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cited in Connolly, 2007). Other infection typical of children under 3 years of age is septic 
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correlated with more severe disease and a poorer prognosis. The early formation of a lateral 
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associated with a good prognosis due to early revascularization (Shammas, 2009; as cited in 
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Slipped capital femoral epiphysis is characterized by a displacement of the capital femoral 
epiphysis from the femoral neck through the physeal plate with medial and posterior 
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assessing the vascularity of the femoral head. In the absence of avascular necrosis, the bone 
scan findings in slipped capital femoral epiphysis are nonspecific and consist of mildly 
increased activity with widening and blurring of the growth plate activity (Shammas, 2009; 
as cited in Connolly et al., 2006, 2007). 
13.2.4 Sickle cell disease 
Sickle cell disease is the most common hereditary blood disorders. It occurs almost 
exclusively among black americans and black africans, related with the presence of a 
mutated form of hemoglobin, hemoglobin S. Bone and joint problems are the most common 
manifestations. Distinguishing sickle cell crisis with possible bone marrow infartion from 
osteomyelitis is a challenge (Shammas, 2009; as cited in Connolly et al., 2007). Bone marrow 
scan with 99mTc-sulfur colloid plus conventional bone scan may be used in the evaluation 
of sickle cell disease, but it should be done within the first 7 days after the pain onset to be 
helpful in the differential diagnosis (Shammas, 2009). If the bone marrow scan is abnormal 
at the site of pain, followed by normal or decreased uptake on conventional bone scan, 
infarction is the likely diagnosis. Increased uptake in blood pool and delayed images on 
conventional bone scan is more suggestive of osteomyelitis (Shammas, 2009; as cited in 
Gilday, 2003).  
13.2.5 Reflex sympathetic dystrophy 
Reflex sympathetic dystrophy has also been described elsewhere in this chapter. The typical 
findings on three-phase bone scan are hyperemia on the first two phases with intense 
periarticular activity in the affected extremity. In children, a cold variant has been reported, 
which is characterized by decreased activity in the three phases of the scintigraphy in the 
affected limb, compared with the nonaffected limb (Shammas, 2009; as cited in Nadel, 2007). 
13.2.6 Fractures 
The occult fracture more common in children is the Toddler’s fracture, which is a spiral or 
oblique fracture that can occur from pelvis to feet but mostly involves the tibia (Shammas, 
2009). Radiographic findings are often subtle and fractures may not be apparent, for that 
reason bone scan is a valuable tool for detecting this injury. Scintigraphy shows diffuse 
increased uptake in the tibial diaphysis or the bone affected. A linear or spiral pattern of 
high uptake may be seen in some children (Shammas, 2009; as cited in Connolly et al., 2006; 
Gilday 2003). 
Among stress fractures, spondylolysis is the more important in children with back pain, 
which represent a stress fracture of the pars interarticularis of the vertebra, commonly in the 
lower lumbar spine secondary to repetitive minor trauma such as hyperextension 
(Shammas, 2009). Clinical signs and symptons and radiographies are normally used for the 
diagnosis. A bone scan or a MRI may be necessary to determine if the spondylolysis is active 
or inactive. Bone scintigraphy shows little or no abnormality on blood pool images, but it 
typically demonstrates focally high uptake in the region of the pars interarticularis on 
delayed images. SPECT imaging is more sensitive than planar studies and detects 
abnormalities in about a third of individuals with normal planar examinations and so, it is 
recommended in the evaluation of low back pain in young athletes (Shammas, 2009; as cited 
in Sty, 1993). 
Scintigraphy has also an important role to provide a quick assessment for defining and 
characterizing the extent and severity of trauma in the setting of child abuse, complementary 
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to other radiologic investigations. Its major advantage is the increased sensitivity in detecting 
evidence of soft-tissue and bone trauma (25%to 50%), and in the documentation of specific and 
characteristic sites of abuse, such as in the ribs or the diaphyses of the extremities (Nadel & 
Stilwell, 2001; as cited in Conway et al., 1993, Sty & Wells, 1994). 
13.2.7 Primary bone tumors in childhood 
Benign bone tumors are by far the most common type of tumors that grow within the 
skeleton. Nonossifying fibromas, osteochondromas and simple bone cysts are the types 
most often found in children and teenagers. Children between the ages of 6 and 12 are the 
most likely to develop benign bone tumors, although the tumors sometimes show up in 
children as young as age 2. Exostosis tumors are slightly more common in boys than girls. 
Nonossifying fibroma usually is in the actively growing sections of long bones such as the 
thighbone (femur). Exostosis (osteochondroma) contains both bone and cartilage and 
usually grows in the thighbone, the shinbone (tibia) or the bone in the upper arm (humerus). 
Unicameral (simple) bone cysts are holes in the bone that fill with fluid and tissue. They 
usually occur in the bone in the upper arm or in the upper part of the thighbone. In some 
cases, a benign bone tumor can cause problems while it grows. It can weaken the child’s 
bone and make it more likely that the bone will break. Tumors also can press on nerves and 
cause pain. In cases like these, surgery may be necessary. Malignant primary bone 
tumors make up 5% of childhood malignancies, and osteosarcoma is the most commonly 
isolated malignant bone tumor in children, followed by Ewing's sarcoma. These bone 
neoplasms usually begin during childhood and adolescence, when bones are growing 
quickly and they often are taking part in sports and other physical activities. Langerhans cell 
histiocytosis is also more common in the pediatric population. A smaller number of patients 
have other diagnosis such as malignant fibrous histiocytoma, angiosarcoma and 
chondrosarcoma, but these conditions are very rare in paediatric population. The 
use of nuclear medicine techniques in the diagnosis, staging and monitoring of the different 
bone tumors has been detailed in a previous section of this chapter. FDG-PET has become to 
be one of the best tools for the baseline evaluation and follow-up, although some benign 
bone lesions may show high 18F-FDG accumulation, equivalent to osteosarcomas. Despite 
this, 18F-FDG-PET has a high specificity for excluding malignant bone tumors (Cook et al., 
2010). FDG- PET has been shown to help determine the presence and extent of sarcomas and 
even may allow the noninvasive estimation of the histologic grade of some tumors, although 
the biopsy remains necessary. This technique allows targeted biopsies, which can reduce the 
likelihood of underestimation of tumor grade and inadequate therapy. Furthermore, 18F-
FDG-PET is useful in the pediatric population for detection of skip metastases in cases of 
equivocal MRI findings (Even-Sapir, 2007). 
14. Therapeutic alternatives with radionuclides: Radiosynoviorthesis  
In the treatment of inflammatory rheumatic diseases with chronic course, operative and 
respectively arthroscopic synovectomy on the one hand and synoviorthesis on the other 
hand come into question. Synoviorthesis by corticosteroids has a very large indication if the 
corresponding measures of precaution are heeded. Chemical synoviorthesis, mainly by 
osmium tetroxide, is applied above all in exudative inflammatory diseases, whereas 
radiosynoviorthesis with the nuclides used at present is mainly applied in proliferative 
diseases. The cytotoxic effects intrinsic to the beta radiation emission from some 
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radionuclides have been exploited by nuclear medicine and, as well as treating several 
forms of neoplasia, this method can also be used to treat a number of benign articular 
pathologies in the field of rheumatology. Carry out a ‘radiosynovectomy’ procedure is 
possible after intra-articular administration of suitable radiopharmaceuticals. The direct 
irradiation of the synovial membrane can produce a therapeutic effect on persistent 
synovitis that is resistant to traditional drug treatment. The radiopharmaceuticals that have 
been used to date for radiosynovectomy are made up of small colloidal particles labelled to 
β-emitting isotopes (yttrium-90, rhenium-186, erbium-169, samarium-153). These 
compounds release their radiation energy within a radius of a few millimetres from the 
uptake sites. These substances are phagocytized by synoviocytes localised in relation to the 
synovia and it creates a radiation source that can act locally and reduce inflammatory and 
proliferative elements (Colamussi et al., 2004; as cited in Gumpel et al., 1975). The 
availability of new radiopharmaceuticals, created by replacing the colloid vector with 
hydroxyapatite crystals, has allowed the main undesired effect of these substances 
(radiation to other organs such as drainage lymph nodes, liver, spleen and bone marrow, 
due to the passage of the radio compound from the articular cavity to the lymphatic and 
then to the blood flow systems) to be avoided (Clunie et al., 1996). In the absence of side 
effect, this technique of low cost may be useful, not only in the treatment of advanced stage 
and drug-resistant arthropathies, but also to manage pain and improve articular function in 
the first stages of rheumatoid arthritis (Colamussi et al., 2004; as cited in Uyeo et al., 1978). A 
fundamental element to the success of radiosynovectomy therapy is that treatment is started 
early in the disease’s history. This is because while radiation therapy can successfully 
control proliferation of the inflamed synovial membrane, it is not effective in joints that have 
suffered advanced osteo-cartilage damage and where the synovitic component is virtually 
non-existent (Franssen et al., 1989). Cases reported would further suggest its use in a wider 
spectrum of rheumatic disorders ranging from spondylitis to Paget’s disease and from 
hæmophiliac synovitis to pigmented villonodular synovitis. Nevertheless, despite abundant 
anecdotal evidence of its efficacy, there is a paucity of controlled trials and those that have 
been done have produced conflicting results (Dos Santos et al., 2009, 2011) and/or have 
been of insufficient sample size. Two meta-analyses have been published. The first one 
(Jones,  1993) was made in order to assess the evidence on yttrium-90 therapy for chronic 
synovitis of the knee. It found out that Yttrium was superior to placebo (OR 2.42, 95% CI 
1.02-5.73), although possible publication bias limited the interpretation of this result. 
Yttrium was not superior to triamcinolone (OR 1.89, 95% CI 0.81-10.55) or other active 
modalities (OR 1.04, 95% CI 0.72-1.52). The second one and most recent (Van der Zant et al., 
2009) has been published with the objective to perform a systemic review and meta-analysis 
on the effectiveness of radiosynoviorthesis. It has shown high success rates of 
radiosynoviorthesis, but differences in effect with glucocorticoid injection are less evident, 
although there is marked heterogeneity in study design of a small number of comparative 
studies. Therefore the efficacy of radiosynovectomy alone or in combination with steroid 
therapy must be assessed by other sufficiently powered randomised controlled studies.  
15. Conclusion  
Nuclear medicine techniques supply physiological information that is complementary to 
that provided by radiological techniques and can play a fundamental role not only for the 
examination and treatment of articular disorders but also in overall patient evaluation.  
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Though scintigraphical examination is ideal in the early stages of diseases, it also plays a 
complementary role to radiographical investigations in more advanced disease stages. An 
assessment as complete as possible which includes different complementary studies must be 
performed to achieve the best diagnostic and prognostic accuracy. In this context, 
conventional scintigraphy is still a major test in a limited number of rheumatological 
diseases such as Paget, reflex sympathetic dystrophy and osteonecrosis, and can be a useful 
complementary study in other diseases. New molecular imaging tools for the evaluation of 
musculoskeletal diseases are now available and these particular tools will advance the 
understanding and management of several chronic musculoskeletal diseases. In the next 
decade, PET/CT and SPECT/CT will be the major workhorses for molecular imaging, with 
the advantage that PET-based technologies have high sensitivity and the ability to use 
biologic molecules that can be radiolabelled.  
Despite the important role of the anatomic imaging techniques in the evaluation of primary 
bone tumors and metastases, radionuclide imaging techniques have all been used in the 
assessment of these disorders. PET and hybrid PET/CT imaging are becoming the most 
important modalities in this field.  
Β-radiation emission from some radionuclides has been exploited by nuclear medicine and 
has been used to treat benign joint pathologies, as well as treating several forms of 
neoplasia. It is of interest in the field of rheumatology, since it is as a safe procedure and, 
after intra-articular administration of suitable radiopharmaceuticals, is able to control 
proliferation of the inflamed synovial membrane in the treatment of chronic arthropathies, 
particularly in the initial stages of the disease. 
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Role of the Radionuclide Metrology  
in Nuclear Medicine 
Sahagia Maria 
Horia Hulubei National Institute for R&D in Physics and  
Nuclear Engineering, IFIN-HH, 
Romania 
1. Introduction 
Nuclear medicine practices rely on the use of radiopharmaceuticals, for diagnosis and 
therapy purposes. Their use is based on the incorporation in the human body through a 
medical procedure: intravenous injection, ingestion, or inhalation. The quality of the 
administration procedure is tightly influenced by the following determining factors: the 
administration of the right activity to the patient, such as prescribed by the medical doctor, 
and the quality of the radiopharmaceutical product. The full control of these parameters is 
obtained by using high quality measurement equipment and following well established 
procedures for the measurement and application of the radiopharmaceutical. 
The radiopharmacy units, the measurement equipment providers and the nuclear medicine 
units can fulfill these requirements only by using calibrated instrumentation and following 
validated measurement methods. The technical support is offered by the Radionuclide 
Metrology Laboratories (RML) which can assure the continuity of the metrological 
traceability chain of measurement up to the highest, primary radioactivity standards. The 
metrological traceability and its chain are defined by the document: “BIPM, JCGM 200:2008 
– International vocabulary of metrology – Basic and general concepts and associated terms (VIM)”, 
as:  
- “Metrological traceability – property of a measurement result whereby the result can be related 
to a reference through a documented unbroken chain of calibrations, each contributing to the 
measurement uncertainty” 
- “Metrological traceability chain – sequence of measurement standards and calibrations that is 
used to relate a measurement result to a reference” 
From these definitions one can deduce the role of the RMLs: to develop activity standards, 
to validate them in relation with the International System of Units (SI) and to disseminate 
them as radioactive standard sources and solutions, or calibration services to the implied 
entities. 
This chapter of the book presents the following aspects: 
- Measurement requirements in radiopharmacy, in measurement instrument calibration 
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1. Introduction 
Nuclear medicine practices rely on the use of radiopharmaceuticals, for diagnosis and 
therapy purposes. Their use is based on the incorporation in the human body through a 
medical procedure: intravenous injection, ingestion, or inhalation. The quality of the 
administration procedure is tightly influenced by the following determining factors: the 
administration of the right activity to the patient, such as prescribed by the medical doctor, 
and the quality of the radiopharmaceutical product. The full control of these parameters is 
obtained by using high quality measurement equipment and following well established 
procedures for the measurement and application of the radiopharmaceutical. 
The radiopharmacy units, the measurement equipment providers and the nuclear medicine 
units can fulfill these requirements only by using calibrated instrumentation and following 
validated measurement methods. The technical support is offered by the Radionuclide 
Metrology Laboratories (RML) which can assure the continuity of the metrological 
traceability chain of measurement up to the highest, primary radioactivity standards. The 
metrological traceability and its chain are defined by the document: “BIPM, JCGM 200:2008 
– International vocabulary of metrology – Basic and general concepts and associated terms (VIM)”, 
as:  
- “Metrological traceability – property of a measurement result whereby the result can be related 
to a reference through a documented unbroken chain of calibrations, each contributing to the 
measurement uncertainty” 
- “Metrological traceability chain – sequence of measurement standards and calibrations that is 
used to relate a measurement result to a reference” 
From these definitions one can deduce the role of the RMLs: to develop activity standards, 
to validate them in relation with the International System of Units (SI) and to disseminate 
them as radioactive standard sources and solutions, or calibration services to the implied 
entities. 
This chapter of the book presents the following aspects: 
- Measurement requirements in radiopharmacy, in measurement instrument calibration 
process, and in nuclear medicine units; 
- Role of the Radionuclide Metrology Laboratory in the practical accomplishment of 
these requirements  
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2. Radiopharmaceutical products and their characterization by 
measurements 
2.1 Types of radiopharmaceutical products 
A radipharmaceutical (RPM) product contains a radionuclide in an adequate chemical form, 
the transporter, which conducts it towards the organ or tissue of interest, when it is 
administrated to the patient “in vivo” by ingestion, inhalation or intravenous injection. In the 
case of diagnosis the radionuclide is used as a “tracer”, while in therapy it is employed due to 
the cytotoxic effect of the emitted ionizing radiations. The radiopharmaceuticals are presented 
as ingerable gelatin capsules (or solutions), injectable solutions and inhalation gases. 
2.1.1 Transporters 
Various types of transporters are used, formulated such as to assure a maximum localization 
of the radiopharmaceutical in the zone of interest while exposing the neibouring area to 
minimum detriment (Kornyei.2008, Mikolajczak. 2008). The types of transporters are 
generally similar for both of nuclear medicine procedures, diagnosis and therapy; some 
formulations are presented as follows: 
- Simple inorganic compounds such as salts, containing the radionuclide in an ionic form: 
Na99mTcO4, 131INa, 89SrCl2, Na186,188ReO4  
- Simple gas molecules: 11CO2, 15O2, 81mKr 
- Labeled organic molecules: 18F-DG; 67Ga-cytrate 
- Metal-ligand complexes: 99mTc-MDP, DTPA; 188Re-HEDP; 177Lu-EDTMP  
- Colloids, labeled micro and nano spheres: 99mTc-fytate  
- Labeled biomolecules: 
i. Monoclonal antibodies (mAb): 90Y-anti-CD20; 188Re-anti-VEGF  
ii. Meta Iodo Benzil Guanidine (MIBG)-131I 
iii. Peptide Receptor Radionuclide, somatostatin analogous: Pentetroid-DTPA-111In, 
TOC-HYNIC-99mTc. 188Re-DOTA-Lan and 188Re-Lan. 
The detailed description of these compounds is outside the scope of the chapter. 
2.1.2 Radionuclides 
In contrast with the transport molecules, the choice of the radionuclides differs for the two 
types of nuclear medicine procedures: diagnosis and therapy. 
Radionuclide diagnosis principle: The incorporated radiopharmaceutical product, localized 
at the interest zone emits gamma-rays, which cross the body and are detected by the gamma 
cameras, containing a detection system, based on the use of scintillation detectors and a 
network of photomultipliers. A bi-dimensional image, called scintigram, is obtained; if the 
computer tomography principle is applied, a 3D image appears. In principle it is necessary to 
use as much as possible of the emitted radiation for detection and to avoid the unnecessary 
irradiation of the body; the irradiation detriment is expressed in terms of committed effective 
dose per activity unit, E/A. For this reason, the choice of radionuclides is focussed on the use of 
radionuclides with short half life and emitting low energy and intensity electrons and 
abundant gamma-rays, not much absorbed inside the body, and situated in the optimal energy 
detection interval, 100 – 600 keV. Two types of diagnosis procedures are in use: 
- Single Photon Emission Tomography (SPET) is based on the use of a single detector and 
of radionuclides decaying by isomeric transition, such as 99mTc, and by electron capture, 
123I. As an exception, 131I emitting beta-gamma radiations, is still used in some special 
procedures, like the iodine uptake in thyroidal investigations. 
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- Positron Emission Tomography (PET), sometimes associated with x-ray tomography, 
PET/CT. In this case, radionuclides decaying by positron emission are used. The 
stopped, or in flight, positron annihilates with a neighbouring electron, and two 511 
keV annihilation quanta at an angle of 1800 are emitted. These quanta can be detected in 
coincidence, using two detectors situated at 1800. The procedure allows a much better 
resolution and consequently a more precise diagnosis, due to the measurement of 
coincident radiations. The positron emitters used for PET systems have short half life 
and for this reason the E/A value is low, although they emit positive electrons, absorbed 
inside the body. The most used radionuclide is 18F.  
Table 1 presents a list of radionuclides used for the production of radiopharmaceuticals, in 
terms of production mode, nuclear decay data and E/A. Referring the E/A value, it is 
strongly dependent on the type of radiopharmaceutical, diagnostic procedure and the age of 
the patient; only for a rough information, the comparative dose values due to the ingestion 
of radionuclides by the adult public (ICRP 1996c) are given, in order to emphasize the 
strong dependence of the dose on the characteristics of the nuclear decay scheme. 
The values of E/A from Table 1 are based on the Medical Internal Radiation Dose (MIRD) 
model, while at present time the calculation models use the “voxel phantom”, defined in 
international documents as ”a computational anthropomorphic phantom based on medical 
tomographic images where the anatomy is described by small three dimensional volume elements 
(voxels) specifying the density and the atomic composition of the various organs and tissues of the 
human body”. A special attention is paid to the radionuclide 99mTc, used nowadays in about 
80% of the world diagnosis procedures. Its widespread use is due to several properties:  
i. Its committed effective dose of activity unit is E/A =0.022mSv/MBq and the 
corresponding doses in the diagnostic procedures are generally within the limits (1 -2) 
mSv, due to the short half-life and to the small content of low energy electrons.  
ii. The 140.5 keV quanta are emitted with a high intensity, being situated near the 
maximum detection efficiency of the usual scintillators.  
iii. It can be extracted from a 99Mo generator (2.75 d,) a reasonable life time for transport 
and use for a period of two weeks, or can be prepared in a pharmaceutical unit and 
delivered to the neighboring hospitals in the same day.  
iv. It is carrier free and due to its position in the Mendeleev Table, the VII-b group, with 7 
valence electrons, it can be used for binding in various chemical compounds, with 
various valence states. 
Radionuclide (targeted) therapy principle. The incorporated radiopharmaceutical is 
localized in the biological formation to be destroyed by irradiation. In this case, the entire 
energy of particles must be transferred to the matter. Consequently, low range radiations, 
such as: alpha particles and electrons - beta radiation, Auger and conversion electrons, are 
useful. This is the reason for which alpha, strong beta with high energy, electron capture 
and conversion decaying radionuclides are used. Lately a special attention is given to the 
beta-gamma triangular decay scheme radionuclides, with strong beta and weak gamma – 
ray energies and intensities, due to the ability to be monitored by a gamma camera during 
the treatment procedure. The half life can be from hours up to tens of days, in order to 
assure the prescribed dose to the biological formation to be destroyed. The choice of the 
radionuclides takes into account their chemical properties, as well as their radiations range 
in the tissue, which must be comparable with the dimensions of the biological formation to 
be destroyed. Table 2 presents a list of therapeutical radionuclides, with their modes of 
production, nuclear decay parameters and the tissue range.  
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A radipharmaceutical (RPM) product contains a radionuclide in an adequate chemical form, 
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- Simple inorganic compounds such as salts, containing the radionuclide in an ionic form: 
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- Simple gas molecules: 11CO2, 15O2, 81mKr 
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The detailed description of these compounds is outside the scope of the chapter. 
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In contrast with the transport molecules, the choice of the radionuclides differs for the two 
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Radionuclide diagnosis principle: The incorporated radiopharmaceutical product, localized 
at the interest zone emits gamma-rays, which cross the body and are detected by the gamma 
cameras, containing a detection system, based on the use of scintillation detectors and a 
network of photomultipliers. A bi-dimensional image, called scintigram, is obtained; if the 
computer tomography principle is applied, a 3D image appears. In principle it is necessary to 
use as much as possible of the emitted radiation for detection and to avoid the unnecessary 
irradiation of the body; the irradiation detriment is expressed in terms of committed effective 
dose per activity unit, E/A. For this reason, the choice of radionuclides is focussed on the use of 
radionuclides with short half life and emitting low energy and intensity electrons and 
abundant gamma-rays, not much absorbed inside the body, and situated in the optimal energy 
detection interval, 100 – 600 keV. Two types of diagnosis procedures are in use: 
- Single Photon Emission Tomography (SPET) is based on the use of a single detector and 
of radionuclides decaying by isomeric transition, such as 99mTc, and by electron capture, 
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- Positron Emission Tomography (PET), sometimes associated with x-ray tomography, 
PET/CT. In this case, radionuclides decaying by positron emission are used. The 
stopped, or in flight, positron annihilates with a neighbouring electron, and two 511 
keV annihilation quanta at an angle of 1800 are emitted. These quanta can be detected in 
coincidence, using two detectors situated at 1800. The procedure allows a much better 
resolution and consequently a more precise diagnosis, due to the measurement of 
coincident radiations. The positron emitters used for PET systems have short half life 
and for this reason the E/A value is low, although they emit positive electrons, absorbed 
inside the body. The most used radionuclide is 18F.  
Table 1 presents a list of radionuclides used for the production of radiopharmaceuticals, in 
terms of production mode, nuclear decay data and E/A. Referring the E/A value, it is 
strongly dependent on the type of radiopharmaceutical, diagnostic procedure and the age of 
the patient; only for a rough information, the comparative dose values due to the ingestion 
of radionuclides by the adult public (ICRP 1996c) are given, in order to emphasize the 
strong dependence of the dose on the characteristics of the nuclear decay scheme. 
The values of E/A from Table 1 are based on the Medical Internal Radiation Dose (MIRD) 
model, while at present time the calculation models use the “voxel phantom”, defined in 
international documents as ”a computational anthropomorphic phantom based on medical 
tomographic images where the anatomy is described by small three dimensional volume elements 
(voxels) specifying the density and the atomic composition of the various organs and tissues of the 
human body”. A special attention is paid to the radionuclide 99mTc, used nowadays in about 
80% of the world diagnosis procedures. Its widespread use is due to several properties:  
i. Its committed effective dose of activity unit is E/A =0.022mSv/MBq and the 
corresponding doses in the diagnostic procedures are generally within the limits (1 -2) 
mSv, due to the short half-life and to the small content of low energy electrons.  
ii. The 140.5 keV quanta are emitted with a high intensity, being situated near the 
maximum detection efficiency of the usual scintillators.  
iii. It can be extracted from a 99Mo generator (2.75 d,) a reasonable life time for transport 
and use for a period of two weeks, or can be prepared in a pharmaceutical unit and 
delivered to the neighboring hospitals in the same day.  
iv. It is carrier free and due to its position in the Mendeleev Table, the VII-b group, with 7 
valence electrons, it can be used for binding in various chemical compounds, with 
various valence states. 
Radionuclide (targeted) therapy principle. The incorporated radiopharmaceutical is 
localized in the biological formation to be destroyed by irradiation. In this case, the entire 
energy of particles must be transferred to the matter. Consequently, low range radiations, 
such as: alpha particles and electrons - beta radiation, Auger and conversion electrons, are 
useful. This is the reason for which alpha, strong beta with high energy, electron capture 
and conversion decaying radionuclides are used. Lately a special attention is given to the 
beta-gamma triangular decay scheme radionuclides, with strong beta and weak gamma – 
ray energies and intensities, due to the ability to be monitored by a gamma camera during 
the treatment procedure. The half life can be from hours up to tens of days, in order to 
assure the prescribed dose to the biological formation to be destroyed. The choice of the 
radionuclides takes into account their chemical properties, as well as their radiations range 
in the tissue, which must be comparable with the dimensions of the biological formation to 
be destroyed. Table 2 presents a list of therapeutical radionuclides, with their modes of 
production, nuclear decay parameters and the tissue range.  
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Type Energy, keV Intensity 
% 
SPET 131I NR*:  
130Te (n,γ)131Te, β decay, 
131I, or 235U fission 







 123I Cyclotrone: 
123Te(p,n)123I 










 67Ga Cyclotrone: 
67Zn(p,n)67Ga 







 201Tl Cyclotrone: 
203Ta(d,4n)201Pb. E.C.201Tl










 99mTc NR: 
99Mo generator (2.75 d) 
98Mo(n, γ)99Mo  
or 235U fission  














 111In Cyclotrone: 
111Cd(p,n)111In 













 81Rb generator (4.25 h) 
79Br(α,2n)81Rb 











PET 18F Cyclotrone: 
18O(p,n)18F; 16O(α,pn)18F; 
20Ne(d,α)18F 











 11C Cyclotrone: 
14N(p, α)11C 







 68Ga 68Ge generator (270.83 d)
Cyclotrone: 
66Zn(α,2n)68Ge 







 64Cu NR:63Cu(n,γ)64Cu 
Cyclotrone: 
64Zn(d,2p)64Cu 








NR* = Nuclear Reactor. In the future, most of NR produced radionuclides is expected to be obtained 
from high neutron flux sources, based on the use of a proton accelerator and the emission of neutrons 
by the accelerated protons reaction with a mercury target. 99Mo can be produced also at a linear 
accelerator: 100 99Mo( , ) Moγ n  
 
Table 1. The most used radionuclides for diagnosis. Monographie BIPM-5 (Bé et al. 2004), 
ICRP1996c (1996). 
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232Th chain,  
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124Xe (n, γ) 125Xe, EC, 
125I 





22.7 - 34.5;  
33.9% 






















 90Y NR: 
89Y(n,γ)90Y;  
 or 235U fission: 
Generator:  
90Sr (28.15 y): 
2.67 d β Max 2284, 
mean 939; 100% 
12 mm/ 
 4.0 mm 
 
 
89Sr NR:  
88Sr (n,γ)89Sr or  
235U fission 
50.65 d β Max 1492,  







130Te(n, γ)131Te, β 
decay, 131I  
or 235U fission  
8.023 d β Max 
338-605, 
mean  
97-192 ; 100% 
4mm/ 
0.8 mm 
 153Sm NR:  
152Sm(n, γ) 153Sm 






 177Lu NR: 
176Lu (n, γ)177Lu 
or: 
176Yb(n, γ)177Yb,  
β decay, 177Lu 






 186Re** NR: 
185Re(n, γ)186Re 
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 153Sm NR:  
152Sm(n, γ) 153Sm 






 177Lu NR: 
176Lu (n, γ)177Lu 
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176Yb(n, γ)177Yb,  
β decay, 177Lu 






 186Re** NR: 
185Re(n, γ)186Re 


















Tissue range  
Max./Mean 
 188Re** NR: 
187Re(n, γ)188Re  
or  
186W(n, γ)187 W 











**) When a natural Rhenium target is irradiated, a mixture 186Re+188Re is obtained. It can be used in this 
composition, for the short time irradiation of the external part of large dimension tumors by 188Re and 
for the long time irradiation of their cores by 186Re. Otherwise, after a week period 188Re decays and 
almost pure 186Re is obtained. 186Re and 188Re are very important for the obtaining of therapy 
pharmaceuticals, due to their similar chemical behavior (VII b group) with 99mTc, very extensively 
studied. 
Table 2. Radionuclides used for therapy radiopharmaceuticals. 
2.2 Technical parameters of radiopharmaceuticals and control methods  
One radiopharmaceutical product is characterized by several types of parameters, whose 
determination requires a very good knowledge of the physico-nuclear parameters of the 
radionuclide and the use of adequate methods and equipment for measurements. Their 
accepted limit values and methods of determination are described in international and 
national technical regulatory documents, such as the European Pharmacopoeia (2002). It is 
considered that the radiopharmaceuticals are products with a high pharmaceutical risk. The 
parameters are determined first of all in the radiopharmacy, which must dispose of control 
laboratories in full compliance with the requirements for Good Laboratory Practice (GLP) 
and accredited according to the international standard “General Requirements for the 
Competence of Testing and Calibration Laboratories”, ISO/IEC 17025:2005. Their determined 
values are confirmed by the national control laboratories, or are internationally recognized 
by conventions. Some parameters are controlled only in radiopharmacy, while others are 
compulsory for the nuclear medicine units, mainly when supplementary operations are 
carried. A detailed description of the requirements and of their accomplishment mode, 
regarding quality assurance in radiopharmaceutical measurement is presented in the 
document Technical Report Series 454 (TRS 454), elaborated by the International Atomic 
Energy Agency (IAEA) (2006). 
Three types of radiopharmaceuticals’ parameters are generally defined and controlled: 
radiometrologic, physico-chemical and biological-microbiological parameters. 
2.2.1 Radiometrologic parameters and their determination 
(i) Activity, Bq, and derived quantity Radioactive Concentration (Massic Activity), expressed 
in Bq g-1 of solution, or Bq mL-1. These are basic parameters of a radiopharmaceutical 
product, as the precise determination of the activity administrated to the patient, in full 
compliance with the prescriptions of the medical doctor, determines his/her committed 
effective dose, mSv, in radionuclide diagnosis and absorbed dose in the organ/tissue, mGy, 
in radionuclide therapy, and assures the safety and effectiveness of the medical procedure. 
Due to this reason, the special requirements regarding the reporting of total activity of a 
radiopharmaceutical product, on a reference time, are specified by the Basic Safety Standards  
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(1996), para.II.19, such as follows: ”the calibration of sources used for medical exposure shall be 
traceable to a Standard dosimetry laboratory“ and “unsealed sources for nuclear medicine procedures 
shall be calibrated in terms of activity of the radiopharmaceutical to be administrated, the activity 
being determined and recorded at the time of administration”. The conclusion of these assertions 
is that the activity must be precisely measured and the metrological traceability up to the 
primary level must be assured. 
In radiopharmacy and nuclear medicine units, the activity is usually determined using 
Radionuclide Activity Calibrators, or Dose Calibrators. They contain a reentrant (well type) 
ionization chamber under pressure, connected to an electrometric system. The 
manufacturers perform the calibration of the equipment in terms of calibration factors, 
introduced in dial settings, established for a list of the most used medical radionuclides. The 
calibrations are performed using sets of standard solutions, provided by the radionuclide 
metrology laboratories or by commercial producers, having metrological traceability to a 
primary activity standard declared. Usually, these factors are determined for various types 
of recipients used in hospitals, such as: P6 or Schott 10-R vials, syringes, gelatin iodide 
capsules, etc. 
The pharmacopoeias impose the uncertainty limits in the measurement of activity, as: <5% 
for therapy and <10% for dignosis. The activity is measured in radiopharmacy, but it must 
be measured also in the hospital, as several operations, such as portioning, administration 
with a syringe, are carried by the involved staff. Due to the crucial importance of these 
measuremens, the radionuclide calibrator precision in the calibration and maintenance of its 
corresponding technical condition, together with the correct method of activity 
measurement in the nuclear medicine units are matters of concern at international level. The 
IAEA initiated a program aimed to improve and harmonize the quality of activity 
measurements. In November 2002 a group of consultants had a meeting in the IAEA Vienna 
headquarters, giving advice on the Methodology of Radioactivity Standardization. The 
Coordinated Research Project (CRP) codified as: E2.10.05, entitled: ”Harmonization of quality 
practices for nuclear medicine radioactivity measurements” was started in 2004. Following the 
recommendations of the first meeting, a second consultants meeting was held and 
recommended to develop a set of procedures in the form of a draft Code of Practice in 
radioactivity measurement. Among other results of the CRP deployment, the elaboration of 
the above named document TRS454: Quality Assurance for Radioactivity Measurement in 
Nuclear Medicine was very important. The document presents in detail (Table 4, page 69) the 
types of tests and acceptance criteria for radionuclide activity calibrators to be performed 
upon the initial acceptance in the unit or after repair, daily checks in the hospital, monthly 
and annually. As for accuracy of measurement, an upper limit of 5% is imposed. In this 
respect, a radionuclide metrology laboratory is the entity providing assurance of 
metrological traceability chain directly, by providing standards, by performing calibrations 
and by organizing proficiency tests among the personnel doing measurements in 
radiopharmacy, in the control authorities, at the calibrators’ producers and the nuclear 
medicine staff.The requirement of accuracy in the metrology laboratory is 2%. It can be 
primary activity standard, or a secondary one, metrologically traceable to a primary activity 
standard, disposing of a calibrated reentrant ionisation chamber, such as described by 
(Schrader, 1997).  
(ii) Specific activity, expressed in units, Bq g-1 of solid mass. It defines the activity of the 
mass unit of the chemical element or solid compound and determines the capacity of 
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labeling, mainly for biomolecules, and also the radiopharmaceutical’s toxicity for human 
body. Two situations must be taken into consideration: 
- Obtaining of the radionuclide. If the radionuclide is obtained in the nuclear reactor by 
neutron activation, generally it contains a mass of inactive carrier, which is determined 
by spectrophotometry, or by calculation from irradiation data. The accuracy of these 
calculations rely on the precision of irradiation data: neutron flux Φ, activation section 
σ, irradiation time t, but also on the target data such as mass M, isotopic composition η, 
radionuclide half life, T1/2. In the case of radionuclides obtained by irradiation at 
cyclotrone, or separated from a radionuclide generator, or when the radionuclide of 
interrest is different from the irradiated target, as for example 131I obtained by 
irradiation of 130Te, the obtained radionuclide is carrier free. 
- Obtaining of the radiopharmaceutical product. In this case, the specific activity depends 
on the labeling yield, such as the labeling of various kits with 99mTc in the hospital, 
under the use of stanous chloride as catalist. 
2.2.2 Physico-chemical parameters  
(i) Radionuclidic purity, expressed as the ratio between the activity of the base 
radionuclide and total activity. This parameter is important from two points of view:  
i. influence of impurities on accuracy of activity measurements and  
ii. their contribution in the committed effective dose of the patient, mainly when the 
impurities have values of the E/A higher than the main radionuclide. One relevant 
example is the (99Mo- 99mTc) generator, where (E/A)Mo-99 =1.2 mSv/MBq, 55 times higher 
than for 99mTc; a 2% 99Mo impurity will duplicate the committed effective dose. For this 
reason the 99Mo impurity in 99mTc elute, known as “molybdenum breakthrough”, is 
restricted at 0.1%. The precise determination of impurity level depends on the 
knowledge of the decay parameters, such as presented in the Monographie BIPM-5 
(2004): half life, type and intensity of emitted radiations for all impurities and also on 
the precision of the method used in determination. In the simple case, when the 
involved radionuclides are gamma-ray emitters, the well-known gamma-ray 
spectrometry method, based on spectrometers provided with high resolution HPGe or 
Ge(Li) detectors, multichannel analyzers (MCA) and sets of software for processing of 
data, is used (Debertin & Helmer.1988). The energetic resolution is expressed in terms 
of full width at half maximum (FWHM) and reflects the ability of the system to 
distinguish two close energy full absorption peaks. Their calibration contains two 
components:  
- The energy calibration is expressed in terms of number of energy units per MCA 
channel (generally keV/channel) allowing the identification of all radionuclides 
contained in a sample;  
- The full absorption peak efficiency calibration consists in the determination of a 
calibration curve, generally expressed in terms of efficiency versus the logarithm of 
energy, used for the measurement of individual activities; it is established for a 
determined measurement geometry (distance detector – source) and for each type of 
measured recipient. The calibrations are performed by using sets of monoenergetic 
standard sources, covering the whole 50 keV – 3000 keV energy interval. The sets of 
standard sources are provided by a RML and are certified with uncertainties of (1- 5) 
%. The spectrometry systems are also provided with dedicated software sets, 
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allowing the determination of full absorption peak areas and for performing 
corrections for: geometry, matrix and sample volume, coincidence summation for 
multigamma emitting radionuclides. The determination of purity consists from the 
following steps: identification of the main radionuclide and of the impurities in the 
sample, according to the energy calibration; measurement of the areas of all full 
absorption peaks; calculation of individual activities, using the efficiency calibration 
curve and the gamma-ray emission intensity from the radionuclide decay scheme; 
calculation of the ratios between the activity of the main radionuclide and the sum 
(main radionuclide plus radio impurities). Generally, the impurity level is controlled 
only in the radiopharmacy, but in the case of molybdenum breakthrough, it must be 
controlled also in the hospital, due to the possible deterioration of molybdenum 
retention in the alumina column along its use. On this purpose, the radionuclide 
calibrators are usually provided with a lead shield, which absorbs the 99m Tc, 140.5 
keV gamma-rays. The detection of sole 99Mo gamma-rays and use of 99Mo calibration 
factor, corrected for the absorption of its gamma-radiations in the shield, allows the 
determination of the impurity level, expressed as the ratio between 99Mo and 99mTc 
activities. The problem is more complex when pure beta or alpha-ray emitters are 
used. Some relevant examples: 
a. Determination of 90Sr content in 90Y when a 90(Sr+Y) generator is used. In this case, 
only liquid scintillation spectrometry (Grau Malonda et al. 1994) or counting is 
used (Wyngaardt. 2006).  
b. Determination of alpha and beta impurities in 99mTc, due to fission 99Mo used for 
generator production. In this case, the restrictive limits for alpha impurities are of 
the order of 10-9 and for beta emitters of the order of 10-6. This level of impurities is 
possible to be measured only after the complete decay of the 99m Tc elute by using 
the liquid scintillation counting, alpha/beta discrimination (Terlikowska et al. 
2000). 
(ii) Radiochemical purity or ratio between the activity of the main compound and sum of 
all chemical compounds. The determination is compulsory in the radiopharmacy, but it is 
advisable also in the hospital, when operations like the preparation of labeled kits is 
performed. For example, the determination of radiochemical purity of Labeled 99mTcMDP, 
expressed as the ratio: 99mTcMDP/( 99mTcMDP+Na99mTO4). This purity determination is 
important, as the tropism of the compound to the target organ/tissue is affected, resulting in 
the dangerous irradiation of other organs. The imposed limits are generally of 97-98%. The 
radiochemical purity is determined by using the radiochromatographic methods: either thin 
layer chromatography (TLC) or more sophisticated - high purity liquid chromatography 
(high pressure liquid chromatography)-HPLC. The determination consists of the measuring 
the activities of the two fractions and calculating the ratio between the activity of the main 
fraction and the sum of main and impurity fractions. The precision of measurement depends 
mainly on the linearity of the measurement instrument, which must be verified by using 
two standard sources with activity ratio of about 100, similar with the ratio of measured 
activities. The counting rates ratio must be equal with the ratio of sources activities, which 
must be certified with uncertainties <5%. 
(iii) Chemical purity, defined by the existence of some nonradioactive elements. The 
chemical impurities can be: alumina, cooper, ions types (NH4)+ or (NO3)- in 99mTc elutes 
from a generator. Their presence can produce the toxicity of the radiopharmaceutical, or can 
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deteriorate the labeling yield of the kits. They are usually determined in the radiopharmacy, 
but in some cases, the medicine units can dispose of the necessary equipment for control. 
The methods are specific to the analytical non radiation chemistry, such as 
spectrophotometry or colorimetry. 
2.2.3 Biological and microbiological parameters 
These parameters are of maximum importance mainly when the radiopharmaceutical is 
administrated as an injection, but they are beyond the scope of this chapter and will not be 
further presented. 
3. Primary standard radionuclide metrology laboratory  
From the content of section 2, one can conclude that the nuclear medicine applications of 
radionuclides raise many challenges to the nuclear physicists, from several points of view: 
- A very long list of radionuclides is used for the production of radiopharmaceuticals. 
Other new radionuclides, presenting convenient physico-nuclear and chemical 
properties, are discovered and introduced in the radiopharmaceutical use. 
- The quality requirements can only be accomplished by the very precise determination 
of the activity of radiopharmaceuticals and by a very deep knowledge of their physico-
nuclear characteristics, generally defined as the decay scheme parameters. These two 
aspects are interconnected, each one depending strongly on the other. 
The adequate solutions of these tasks are offered by the Radionuclide Metrology Laboratories, 
generally responsible national entities, which assure the continuity of the metrological 
traceability chain from the international level up to the nuclear medicine units. 
General Metrology uses the basic terms which are defined according to the International 
vocabulary of metrology – Basic and general concepts and associated terms (VIM), JCGM 200: 
2008: 
Primary reference measurement procedure, Primary reference procedure = Reference 
measurement procedure used to obtain a measurement result without relation to a measurement 
standard for a quantity of the same kind. 
Calibration = Operation that, under specified conditions, in a first step, establishes a relation 
between the quantity values with measurement uncertainties provided by measurement standards 
and corresponding indications with associated measurement uncertainties and, in a second step, uses 
this information to establish a relation for obtaining a measurement result from an indication. 
Measurement uncertainty = Non-negative parameter characterizing the dispersion of the quantity 
values being attributed to a measurand, based on the information used. 
Metrological traceability = Property of a measurement result whereby the result can be related to a 
reference through a documented unbroken chain of calibrations, each contributing to the 
measurement uncertainty. 
3.1 Activity measurement  
The national metrology laboratories dispose of two modalities to assure traceability in 
activity measurement. In many cases, they are Secondary Standard Laboratories (SSL), 
transferring the activity unit, Becquerel, from the well know and internationally recognized 
primary standard laboratories, like NIST (USA), LNHB (France), NPL (UK), PTB (Germany), 
etc. Alternatively, a national primary standard laboratory, recognized at the international 
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level, by demonstrating the equivalence of its standards to the International System (SI), can 
solve entirely this task. 
Figure 1 presents the equivalence and traceability chain to be established in activity 
measurement, from the International System (SI), assured by the International Bureau of 
Weights and Measures (Bureau International des Poids et Mesures-BIPM) through primary 
standard laboratories which disseminate the standards to the SSLs and end users, in our 
case the nuclear medicine units. In order to accomplish its duties, one primary laboratory 
has to solve the following tasks: it must set up the installations for absolute standardization 




Fig. 1. Dissemination pathways for SI values of activity (From Woods & Sahagia. 2008). 
3.1.1 Methods and installations for primary (absolute) standardization 
The distinction between the radionuclide metrology and other metrology branches consists 
of the necessity to elaborate specific standardization methods almost for each radionuclide, 
due to the variability of decay schemes, and in the impossibility to construct an immuable 
standard, due to the radioactive dizintegration.  
In radionuclide metrology, an absolute standardization is done by the following procedure: 
one detects the radiations emitted by a radioactive source and the method for establishing 
an adequate relation between the counting rate and the activity of the source is elaborated. 
A general relation is expressed as: 
 0ε ε= =radN s A sN   (1) 
Nrad is the counting rate, s-1 (impulses per second) for the detected radiation; ε is the 
detection efficiency of the system; s, denoted also as (I, p) is the intensity of detected 
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radiations and A, or (N0) is the activity of the source, Becquerel (Bq). Every standardization 
operation aims to determine as precisely as possible the quantity ε, or to find a method to 
eliminate it from relation (1) 
Two basic methods are used, NCRP58 (1978). Methods based on the detection in a well-
defined geometry (defined solid angle), the most used being the 4πsr geometry, applicable 
for radionuclides emitting a single type of radiations, and coincidence methods used for 
those emitting coincident radiations. 
3.1.1.1 Methods based on determined geometry 
Solid angle method is based on the precise calculation of the solid angle, of the absorption 
in air and in detector window, and of the radiations scattering correction. The method is 
used for the standarization of the alpha sources, in vacuum chambers, provided with Si 
barrier surface detectors; in other cases, for example beta radiations, it is not satisfactory 
precise. 
Methods based on 4πsr geometry use a detection system assuring the quasi total detection 
of the radiations emitted by the source, which are used for measurement, what means that 
the following condition is fulfilled:  
 1ε ≈   (2) 
The method of the 4π proportional counter, known as the method 4πPC, is the most known. 
It is applicable to solid sources, or to radioactive solutions gravimetrically dropped on very 
thin solid supports, from pure beta emitters with high maximum energy, generally > 150 
keV. The remaining corrections to be applied are due to: beta rays absorption in source mass 
(selfabsorption) and in its support. The method is frequently used for the standardization of 
the radioactive gases and is known as „gas fillig counter” (Stanga et al.2002). The corrections 
are due to the wall nondetection, mainly the extremity of counters. Another applied method 
is the sum peak counting, based on the use of a large NaI(Tl) well type crystal, with a thin 
window (Nedjadi et al.2007). It is used for radionuclides emitting gamma radiations with 
high energies and intensities, as for example: 124Sb, 222Rn decay chain, etc. The corrections 
are done by using Monte Carlo programs. 
Liquid scintillator methods. The method is applicable to the radioactive solutions or gases, 
which are dissolved in a liquid scintillator. The detection geometry is 4πsr. The self-
absorption and source support absorption are eliminated but other processes occur: the 
quenching and non-detection of low energy radiations. It is applicable to pure alpha 
emitters, for which ε = 1, and high energy pure beta emitters.  
3.1.1.2 Coincidence methods 
The methods are generally applicable for the radionuclides decaying with the emission of 
mixed radiations, such as: α – γ; β - γ; x, eA – γ. It is extended to the pure beta or electron 
capture radionuclides.  
Coincidence method and installation 4πPC-γ. A classical coincidence installation contains: 
a proportional counter (PC), one or two NaI(Tl) detectors and electronic modules, allowing 
the individual recording of the impulses provided by the two detection channels, and the 
coincidences recorded by a coincidence selector. The principle of the method is the 
following: the relations between the counting rates on the three channels: proportional 
counter – NPC, gamma ray counting - Nγ, coincidence – Nc , the activity N0 and the 
corresponding detection efficiencies εPC and ε γ , are:  
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 0 0 0;    ;    γ γ γε ε ε ε= = =PC PC c PCN N N N N N   (3) 
Relations (3) are equivalent with:  
 0/γ =PC cN N N N   (4) 
Relation (4) shows that the efficiencies of the two detectors are eliminated and consequently 
the activity can be determined directly from the three counting rates. Relations (3) and (4) 
were written in very simplifying assumptions, which in reality can not be reached: the 
radiouclides have a simple decay scheme - an alpha or beta decay, followed by a gamma 
transition to the daughter ground level; the detectors are fully specialized; no perturbations 
due to the installation, such as background counting rate, dead times, resolution time of the 
coincidence circuit modifies the counting rates. The coincidence relations are more complex, 
and were written by (Gandy.1961) and (Baerg.1973). For decay scheme corrections the 
coincidence method is applied associated with an efficiency extrapolation variant, and for the 
instrumental corrections various formulae were deduced by (Grigorescu.1973) and 
(Smith.1978). Many specific methods were elaborated in the primary activity standard 
laboratories, among them being the Radionuclide Metrology Laboratory from the Horia 
Hulubei National Institute for Research & Development in Physics and Nuclear Engineering 
(IFIN-HH, RML) Bucharest, the Romanian owner of the primary activity standard. A 
coincidence installation was set up in the sixties and was continuously updated in this 
laboratory. The variant of the efficiency extrapolation, allowing to accomplish the decay 
scheme corrections, was developed and applied for many types of radionuclides. The 
classical extrapolation coincidence method was applied for the beta-gamma medical 
radionuclide 131I, for which the whole traceability chain was established (Sahagia et al.2008a). 
The therapy radionuclides 153Sm, 177Lu and 186,188Re, strong beta - weak gamma-ray emitters, 
have a “triangular” decay scheme and were standardized by a special extrapolation 
procedure (Sahagia et al.2005a,2005b,2002). For the radionuclide 99mTc, decaying by isomer 
transition in competition with internal conversion, a new type of coincidence scheme was 
applied, based on the coincidence between 119.5-138 keV conversion electrons and Tc x-rays 
(Sahagia.2006). Radionuclide 125I is an electron capture gamma emitter; it was standardized 
by the x - x, γ coincidence method (Sahagia et al.2008b). The positron emitters, used for PET, 
PET/CT systems, like 68(Ge + Ga) generator, or other radionuclides decaying by electron 
capture in competition with positron emission, were standardized by the positron-
annihilation-ray coincidence, or combinations of radiations (Grigorescu et al.2004; Grigorescu 
et al.1996). In the present time, in many laboratories, the classical, analog, coincidence set up 
is replaced by the Digital Coincidence Counting (DCC) (Buckman et al.1998). At the same 
time, instead of the PC, a liquid scintillation counter (LSC), associated with a NaI(Tl) detector 
is used for coincidence measurement (Chylinski & Radoszewski.1996) 
Efficiency tracer method is an extension of the coincidence method applied for the 
standardization of pure beta decaying radionuclides. The solution to be standardized is 
mixed with a standard solution from a beta-gamma emitting radionuclide, preferable with a 
simple decay scheme, with a beta spectrum close to that of the radionuclide to standardize 
and chemically compatible with it. For the two radionuclide’s mixture, relation (3) becomes:  
 1 01 2 02 01 01 ;    ;    γ γ γε ε ε ε ε= + = =PC PC PC c PCN N N N N N N   (5) 
Index 1 refers to the tracer and 2 to the pure beta emitter. By an extrapolation procedure, a 
relation is established between the two εPC1 and εPC2 efficiencies, allowind the calculation of 
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quenching and non-detection of low energy radiations. It is applicable to pure alpha 
emitters, for which ε = 1, and high energy pure beta emitters.  
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The methods are generally applicable for the radionuclides decaying with the emission of 
mixed radiations, such as: α – γ; β - γ; x, eA – γ. It is extended to the pure beta or electron 
capture radionuclides.  
Coincidence method and installation 4πPC-γ. A classical coincidence installation contains: 
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transition in competition with internal conversion, a new type of coincidence scheme was 
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relation is established between the two εPC1 and εPC2 efficiencies, allowind the calculation of 
 
12 Chapters on Nuclear Medicine 
 
150 
activity N02 of the pure beta radionuclide.The method is applied for therapeutic pure beta 
radionuclides, like 89Sr, or other important radionuclides as 137Cs (Razdolescu et al.2002a, 
Sahagia.1981) 32P, 90Y.  
3.1.1.3 Advanced methods based on the liquid scintillation counting  
The method consists of mixing the radioactive solution with a liquid scintillator (LS). The 
energy of the radiations is transferred to the LS; it emits light photons, which produce 
photoelectrons, multiplied in a photomultiplier (PMT). Electron impulses are collected at the 
PMT anode. The detection efficiency is superior to that of proportional counters, but it 
depends strongly on the radiations energy. A calculation model, known as the „Free 
parameter principle” was developed, leaving from the idea that the sum of fenomena: 
luminous photons emission in LS, their arrival at PMT photocathode and emission of a 
photoelectron as result of interaction, is described by a Poisson distribution law. Another 
influence of LS is the quenching; it can be due to its chemistry, but the most important is the 
ionization quenching, Q(E), which is described by an empirical relation, written by 
(Birks.1964). Taking into account all these fenomena, a relation connecting the detection 
efficiency, ε, equal to the probability of producing a photoelectron, P(λ,E), with the counter 
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λ is called the free parameter and R is the number of photomultipliers in the system. In 
relation (6) it is important to adjust the free parameter such as to reflect the measurement 
conditions. On this purpose, two main models were developed. 
CIEMAT/NIST method consists of the use of a LS counter provided with two PMTs in 
coincidence, in order to diminish the influence of background; commercial counters can be 
used. The adjustment of the free parameter is achieved by using an efficiency tracer, consisting 
of a tritium standard solution. The model contains several steps: a relation is established 
between the tritium detection efficiency and a quantity equivalent of the free parameter, 
known as quenching indicator parameter (QIP) (Grau Malonda.1999), measured by using the 
Compon radiation of an external source; a theoretical relation is calculated between the 
efficiency of tritium and that of the nuclide to standardize, for different QIP values, based on 
the beta spectra characteristics. Using a determined QIP value, one calculates the nuclide 
efficiency from the theoretical efficiency relation, corresponding to that QIP. 
Triple to double coincidence ratio (TDCR) method makes use of a special counter, 
provided with three PMTs, connected in double and triple coincidences. Leaving from the 
general equation (6), the efficiencies, equal to the probabilities of registration for the logical 
sum of double, εd , and respectively triple, εt , coincidences were written by (Broda et al.2007; 
Pochwalski&Radoszewski.1979):  
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These relations are calculated theoretically, from the radionuclide spectrum, by itteration for 
a big number of values of the free parameter λ, by using computer programs, like SPEBETA; 
TDRCB-1, 2, 7; DETECSZ, etc., elaborated at LNHB-France and RC Poland. On the other 
hand, an experimental ratio between the counting rates of the two types of coincidences, 
equal to the efficiencies’ ratio, is determined. They depend on the activity N0 and 
efficiencies, as: 
 0 0;D d T tR N R Nε ε= =   (8) 
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In this manner, the efficiencies are determined, and the activity N0 is calculated from 
relations (8) 
A TDCR system was set up in IFIN-HH,RML, with the assistance of Dr. Philippe Cassette 
from LNHB. It was used for the standardization of radionuclides as 3H, 89Sr, 63Ni and was 
validated by international comparisons (Razdolescu et al.2004; 2006). Recently, a new 
counter was set up in RML, replacing the three PMTs with 6 channel photomultipliers 
(CPM) and designing a new optical chamber (Ivan et al.2010). It has the advantage of being 
compact and portable. 
3.2 Validation of the primary installations and methods; international equivalence 
3.2.1 The International System  
The International Committee for Weights and Measures (CIPM) coordinates the metrology 
branches through the Consultative Committees, as the Comité Consultatif des 
Rayonnements Ionisants – CCRI. CCRI is divided in three sections. The Section II, CCRI(II) - 
Measurement of Radionuclides, coordinates the Radionuclide Metrology. The Bureau 
International des Poids et Mesures-BIPM, Sèvres, http://www.bipm.org France, has the 
custody of the international standards. The equivalence of the primary standards is assured 
at this level by absolute methods of standardization. At the regional level, the Regional 
Metrology Organizations (MRO) are operational. In Europe there exist: EURAMET - 
European Association of National Metrology Institutes and COOMET - Euro-Asian 
Cooperation of National Metrology Institutes. The connection between BIPM and MROs is 
assured by the Joint Committee of the Regional Metrology Organizations and the BIPM - 
JCRB. At this level one assures the traceability also by using secondary (relative) 
standardization methods. The CIPM-MRA, Mutual Recognition Arrangement (1999), 
defines the recognition of the calibration and measurement certificates issued by the 
National Metrology Institutes. For example, Romania is part of CIPM-MRA. The document 
contains four annexes: Annex A - List of signatories; the Romanian signatory is the 
Romanian Bureau of Legal Metrology - National Institute of Metrology (BRML-INM); 
Annex B - Key Comparison Data Base (KCDB) per Institute; Annex C- Calibration and 
Measurement Capabilities (CMC); Annex D - Key Comparison Data Base. The condition for 
the applicability of CIPM-MRA by the signatory countries is the demonstration of the 
equivalence of the primary standards, or of the traceability for the others, such as presented  
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These relations are calculated theoretically, from the radionuclide spectrum, by itteration for 
a big number of values of the free parameter λ, by using computer programs, like SPEBETA; 
TDRCB-1, 2, 7; DETECSZ, etc., elaborated at LNHB-France and RC Poland. On the other 
hand, an experimental ratio between the counting rates of the two types of coincidences, 
equal to the efficiencies’ ratio, is determined. They depend on the activity N0 and 
efficiencies, as: 
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(CPM) and designing a new optical chamber (Ivan et al.2010). It has the advantage of being 
compact and portable. 
3.2 Validation of the primary installations and methods; international equivalence 
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The International Committee for Weights and Measures (CIPM) coordinates the metrology 
branches through the Consultative Committees, as the Comité Consultatif des 
Rayonnements Ionisants – CCRI. CCRI is divided in three sections. The Section II, CCRI(II) - 
Measurement of Radionuclides, coordinates the Radionuclide Metrology. The Bureau 
International des Poids et Mesures-BIPM, Sèvres, http://www.bipm.org France, has the 
custody of the international standards. The equivalence of the primary standards is assured 
at this level by absolute methods of standardization. At the regional level, the Regional 
Metrology Organizations (MRO) are operational. In Europe there exist: EURAMET - 
European Association of National Metrology Institutes and COOMET - Euro-Asian 
Cooperation of National Metrology Institutes. The connection between BIPM and MROs is 
assured by the Joint Committee of the Regional Metrology Organizations and the BIPM - 
JCRB. At this level one assures the traceability also by using secondary (relative) 
standardization methods. The CIPM-MRA, Mutual Recognition Arrangement (1999), 
defines the recognition of the calibration and measurement certificates issued by the 
National Metrology Institutes. For example, Romania is part of CIPM-MRA. The document 
contains four annexes: Annex A - List of signatories; the Romanian signatory is the 
Romanian Bureau of Legal Metrology - National Institute of Metrology (BRML-INM); 
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the applicability of CIPM-MRA by the signatory countries is the demonstration of the 
equivalence of the primary standards, or of the traceability for the others, such as presented  
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in figure 1. The equivalence is demonstrated only by the participation at international 
comparisons. IFIN-HH, RML, has participated at international comparisons since 1962. The 
Key Comparison Data Base (KCDB) Annex B of the CIPM – MRA, can be found at the address: 
http://kcdb.bipm.org/AppendixB/KCDB_ApB_search.asp. The participants in CIPM-MRA 
are the National Institutes of Metrology (NMIs), but for specialized metrology branches as 
the ionizing radiations, the participants can be the Designated Institutes. In Romania, 
according to the protocol concluded between BRML-INM and IFIN-HH it is established that 
IFIN-HH is designed as the owner of the primary activity (Becquerel) and derived quantities 
standard, with national and international responsibilities in the field: 
- Designed Institute as responsible for participation in the CIPM-MRA, included in Annex 
A of the CIPM-MRA, List of signatories. 
- Associated Institute to EURAMET, responsible for the Technical Committee of Ionizing 
Radiations, TC-IR 
Due to its scientific authority, IFIN-HH became also: Member of the International 
Committee for Radionuclide Metrology (ICRM) in 1980 and Member of the Consultative 
Committee Section II, CCRI(II), in 2004 
3.2.2 Validation of methods and establishment of equivalence by key comparisons  
Definition of the Key Comparisons, according to VIM: Selected comparisons taken formally 
into account for the establishment of equivalence. CCRI(II) may approve also supplementary 
comparisons, initiated by other organizations, to be used for establishment of equivalence: 
EURAMET, COOMET, IAEA, JRC-IRMM, etc. Relative methods may be used at this level, in 
order to extend the applicability of the CIPM-MRA, Annex C.  
The Comparisons are of the categories:  
- Comparisons type « CCRI(II)-K2. Radionuclide (Ex. Am-241)”. They are organized at 
worldwide scale. A single batch of radioactive solution is used for the preparation of all 
the samples which are sent to the participants, who measure and send to the BIPM the 
filled-in Reporting Form, containing the results. The reports are evaluated at BIPM and 
the Draft reports are drawn up. The Draft B is submitted to the approval of the CCRI(II) 
and published. For example, IFIN-HH, RML is registered with such comparisons in the 
KCDB with the radionuclides: 241Am, 109Cd, 139Ce, 134Cs, 137Cs, 152Eu, 55Fe, 3H, 125I (2), 
192Ir, 177Lu, 54Mn, 32P, 75Se, 89Sr, 204Tl, 65Zn.  
- Comparisons: “BIPM.RI (II)-K1.Radionuclide”. BIPM disposes of two reentrant (well type) 
ionization chambers, CENTRONIC IG11/20A, as the basis for creation of the 
International Reference System - SIR, for gamma-ray emitters (Ratel. 2007). The key 
comparison is carried out by the individual preparation and certification of an ampoule 
with standard solution by the participant laboratory, which is then sent to the BIPM 
with the Comparison filled-in Form. It is re measured at BIPM and the two results are 
compared. IFIN-HH, RML is registered with the radionuclides: 110mAg; 133Ba; 60Co (1983 
and 2007); 134Cs; 131I; 57Co; 137Cs  
- Supplementary Comparisons 
Type: “EURAMET.RI(II)-S5.Radionuclide”. These comparisons are deployed as Decay Data 
Evaluation Projects-DDEP. The first step of comparisons is similar to the CCRI(II)-K2. The 
second step consists of the measurement of the emission intensities for x and gamma-rays. 
IFIN-HH, RML is registered with: 169Yb; 65Zn; 124Sb. 
“IAEA-CCRI(II). Matrix content. Radionuclides”. These comparisons are organized within the 
frame of the International Atomic Energy Agency (IAEA) - Coordinated Research Projects 
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(CRPs) and are approved by the CCRI(II); they refer to special types of samples and relative 
methods are accepted. IFIN-HH, RML is registered as “CCRI(II)-S6.Radionuclide”, for the 
radionuclides 57Co and 131I, of interest in nuclear medicine.  
Establishment of the SI Activity Unit (Becquerel) by key comparisons. 
The Activity Unit is established individually for each radionuclide, after the evaluation of the key 
comparison result, which is expressed as the Key Comparison Reference Value – KCRV. 
Four methods are used to calculate the KCRV (Ratel.2007): arithmetic and weighted mean, 
median and weighted median. The most adequate variant is selected; in most cases, the 
arithmetic mean is preferred. The outliers are established after applying the exclusion 
criteria. The KCRV and its uncertainty are approved by the CCRI(II) and may be modified 
in time, after accumulating new results for the respective radionuclide. The “outliers” are 
not eliminated from KCDB, but their difference from KCRV must be taken into account 
when reporting the calibration uncertainties.  
When both the SIR-BIPM.RI(II)-K1.Radionuclide and the CCRI(II)-K2. Radionuclide 
comparison results are registered for the gamma-ray emitters, a link is established between 
the two types of comparisons, through the measurement in the BIPM ionization chamber of 
the ampoules sent for the K2 comparison.  
Equivalence. An equivalence matrix is calculated. Two main quantities are reported and 
compared: Difference between the individual result and KCRV, (Di) and its uncertainty (Ui), 
for a coverage interval k =2. The ratio of these quantities is the measure of degree of 
equivalence. The CCRI(II) approved “Draft B” is published in the KCDB and in Metrologia, 
Technical Supplement issues. IFIN-HH, RML, is registered in KCDB with 28 radionuclides.  
Equivalence validity. A validity interval was adopted by consensus. Consequently, in order to 
maintain the equivalence for some radionuclides, IFIN-HH repeated the comparison. It 
participated in 1983 and in 2007 at the SIR-BIPM.RI(II)-K1.Co-60 comparisons. As for 134Cs, 
the participations were: CCRI(II)-K2 in 1978 and SIR-BIPM.RI(II)-K1 in 2006 and for 137Cs, 
the participations were: CCRI(II)-K2 in 1982 and SIR-BIPM.RI(II)-K1 in 2009. 
Example: Analysis of the IFIN-HH, RML result at the medical 131I key comparison SIR-
BIPM.RI(II)-K.1.I-131, 2007 (Ratel et al.2008). KCRV = (40400 ±40) MBq; IFIN-HH value = 
(40371 ± 139) MBq; Di =0.07%; Ui=0.65% . Consequently, the IFIN-HH, RML’s result was 
taken into account in the calculation of the KCRV. 
SI Activity Unit (Becquerel) for other radionuclides. 
A matrix of radionuclides, codified by colors, according to the standardization difficulty by 
method, was established by the CIPM-CCRI(II) Key Comparison Working Group (KCWG), 
within the document Grouping Criteria Radionuclides for Supporting CMCs (Karam.2007). 
It can be used as follows. A red coded radionuclide measured by LSC, such as 3H, supports 
89Sr, 90Y, LSC measured, and green color coded. 
3.3 Implementation and recognition of the Quality Management System – Approval of 
CMC files 
An international agreement for the practical use of the results obtained by the National 
Metrology Institutes (NMI) in assurance of the traceability chain and recognition of the 
measurements and certificates was concluded through the document: “Joint statement by the 
CIPM and ILAC on the roles and responsibilities of national metrology institutes and national 
recognized accreditation bodies”. At the level of EURAMET, the implementation of the Quality 
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in figure 1. The equivalence is demonstrated only by the participation at international 
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order to extend the applicability of the CIPM-MRA, Annex C.  
The Comparisons are of the categories:  
- Comparisons type « CCRI(II)-K2. Radionuclide (Ex. Am-241)”. They are organized at 
worldwide scale. A single batch of radioactive solution is used for the preparation of all 
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and published. For example, IFIN-HH, RML is registered with such comparisons in the 
KCDB with the radionuclides: 241Am, 109Cd, 139Ce, 134Cs, 137Cs, 152Eu, 55Fe, 3H, 125I (2), 
192Ir, 177Lu, 54Mn, 32P, 75Se, 89Sr, 204Tl, 65Zn.  
- Comparisons: “BIPM.RI (II)-K1.Radionuclide”. BIPM disposes of two reentrant (well type) 
ionization chambers, CENTRONIC IG11/20A, as the basis for creation of the 
International Reference System - SIR, for gamma-ray emitters (Ratel. 2007). The key 
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(CRPs) and are approved by the CCRI(II); they refer to special types of samples and relative 
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Four methods are used to calculate the KCRV (Ratel.2007): arithmetic and weighted mean, 
median and weighted median. The most adequate variant is selected; in most cases, the 
arithmetic mean is preferred. The outliers are established after applying the exclusion 
criteria. The KCRV and its uncertainty are approved by the CCRI(II) and may be modified 
in time, after accumulating new results for the respective radionuclide. The “outliers” are 
not eliminated from KCDB, but their difference from KCRV must be taken into account 
when reporting the calibration uncertainties.  
When both the SIR-BIPM.RI(II)-K1.Radionuclide and the CCRI(II)-K2. Radionuclide 
comparison results are registered for the gamma-ray emitters, a link is established between 
the two types of comparisons, through the measurement in the BIPM ionization chamber of 
the ampoules sent for the K2 comparison.  
Equivalence. An equivalence matrix is calculated. Two main quantities are reported and 
compared: Difference between the individual result and KCRV, (Di) and its uncertainty (Ui), 
for a coverage interval k =2. The ratio of these quantities is the measure of degree of 
equivalence. The CCRI(II) approved “Draft B” is published in the KCDB and in Metrologia, 
Technical Supplement issues. IFIN-HH, RML, is registered in KCDB with 28 radionuclides.  
Equivalence validity. A validity interval was adopted by consensus. Consequently, in order to 
maintain the equivalence for some radionuclides, IFIN-HH repeated the comparison. It 
participated in 1983 and in 2007 at the SIR-BIPM.RI(II)-K1.Co-60 comparisons. As for 134Cs, 
the participations were: CCRI(II)-K2 in 1978 and SIR-BIPM.RI(II)-K1 in 2006 and for 137Cs, 
the participations were: CCRI(II)-K2 in 1982 and SIR-BIPM.RI(II)-K1 in 2009. 
Example: Analysis of the IFIN-HH, RML result at the medical 131I key comparison SIR-
BIPM.RI(II)-K.1.I-131, 2007 (Ratel et al.2008). KCRV = (40400 ±40) MBq; IFIN-HH value = 
(40371 ± 139) MBq; Di =0.07%; Ui=0.65% . Consequently, the IFIN-HH, RML’s result was 
taken into account in the calculation of the KCRV. 
SI Activity Unit (Becquerel) for other radionuclides. 
A matrix of radionuclides, codified by colors, according to the standardization difficulty by 
method, was established by the CIPM-CCRI(II) Key Comparison Working Group (KCWG), 
within the document Grouping Criteria Radionuclides for Supporting CMCs (Karam.2007). 
It can be used as follows. A red coded radionuclide measured by LSC, such as 3H, supports 
89Sr, 90Y, LSC measured, and green color coded. 
3.3 Implementation and recognition of the Quality Management System – Approval of 
CMC files 
An international agreement for the practical use of the results obtained by the National 
Metrology Institutes (NMI) in assurance of the traceability chain and recognition of the 
measurements and certificates was concluded through the document: “Joint statement by the 
CIPM and ILAC on the roles and responsibilities of national metrology institutes and national 
recognized accreditation bodies”. At the level of EURAMET, the implementation of the Quality 
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Management System (QMS) is monitored by the EURAMET, Technical Committee – 
Quality, TC-Q.  
At the level of CIPM - MRA, the statement is practically applied by the use of the Annex C 
of the CIPM-MRA, Calibration and Measurement Capability files – CMCs. The approval and 
publication of CMCs for a NMI is the result of two types of evaluation components for the 
international recognition: (i) Approval of the international equivalence for primary and of 
the traceability for secondary standards; (ii) Implementation of the QMS and recognition by 
the MRO’s, TC-Q. 
i. Approval of equivalence and traceability. The NMI, member of one MRO, draws up the 
primary or secondary CMC files. The statement is compared with the KCDB for 
primary, or in our case EURAMET for secondary standards. After the inter MROs’ peer 
review process, they are submitted for the approval of the JCRB. 
ii. Implementation and approval of the QMS. The EN/ISO/IEC 17025:2005, referential 
“General requirements for the competence of testing and calibration laboratories” is applied. A 
complete documentation and its implementation are presented at the annual meetings 
of the EURAMET, TC-Q. The technical experts monitor the documents and after the 
first approval, the QMS is annually reconfirmed. This is a prerequisite condition to 
maintain the CMCs in the published in Annex C of MRA. Example, IFIN-HH, RML 
situation. 34 CMC files, Radioactivity standards, passed the peer review process; the 
QMS was approved in 2007 and annually reviewed. All CMCs were approved by the 
JCRB in April 2008 and published in CIPM-MRA, Annex C. http://kcdb.bipm.org/ 
AppendixC/default.asp  
4. Setting up of the activity secondary standard systems 
Realisation of the activity secondary standards. 
Such as presented in figure 1 and as pointed in the references TRS 454 (2006) and 
(Zimmerman & Judge. 2007), the practical realization of the metrological traceability chain is 
possible by using the activity secondary standards. They are transfer instruments of the 
activity unit from the primary to the lower order, working standards, for the end users, 
through standard (reference) products or calibration services. They consist of installations 
for the secondary (relative) standardization; their calibration is done with sources and 
solutions absolutely standardized with the primary standards. In the case of the primary 
laboratories they use their own primary standards. In the case of the secondary standard 
laboratories (SSL), the standards leave from another primary laboratory, the traceability 
route being declared. The practical work at IFIN-HH, RML was described in (Sahagia & 
Woods.2008). 
4.1 Secondary standards for high activity radiopharmaceutical solutions 
The secondary standard for high activity solutions is a reentrant (well type) ionization 
chamber, filled with an inert gas as nitrogen or argon, at high pressure, of a special 
construction, largely described by H. Schrader in Monographie BIPM-4 (1997), or a 
commercial radionuclide calibrator. It is calibrated with standard solutions absolutely 
standardized, from the radionuclides of interest. The ionization current, registered by the 
associated electrometric circuit, is due to the radiations entering in the sensitive volume of 
the chamber and ionizing the filling gas. This chamber is mainly used for the measurement 
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of activity for gamma-ray, but also for strong beta-ray emitters, when the ionization current is 
produced by the bremsstrahlung radiations. Usually, the calibration factor is expressed in 
terms of absolute or relative efficiency, or in ionization current per activity unit, pA MBq-1. The 
calibration must be performed for several geometries of the recipients containing radioactive 
solution, or gelatin capsules in the case of iodine radioisotopes, as the calibration factor 
depends on the geometrical dimensions. For example, the IFIN-HH, RML well type ionization 
chamber is of the type CENTRONIC IG12/20A, filled with argon at a pressure of 2MPa 
(20Atm); its construction was first described in (Grigorescu et al. 2003). Recently, the old 
electrometric system was replaced with an electrometer Keithley E6517A. The validation of the 
calibration factors was done by several comparisons: (i) with the measurements performed at 
PTB-Braunschweig-Germany with PTB standard solutions; (ii) with the IFIN-HH, RML results 
obtained in international comparisons; (iii) respectively with the value of the KCRV (Sahagia et 
al. 2010). The calibration factors are determined for the radionuclides: 241Am, 57Co, 99mTc, 186Re, 
188Re, 153Sm, 177Lu, 75Se, 169Yb, 131I, 133Ba, 51Cr, 192Ir, 134Cs, 137Cs, 54Mn, 65Zn, 60Co, 152Eu and for 
three geometries: (i) Solid sources; (ii) 131I gelatin capsules; (iii) Solutions of volumes: 2 mL 
(PTB), 3.6 mL (SIR-BIPM), 5 mL (P6 used for radiopharmaceuticals). From the above list one 
may notice that the calibration is assured for the majority of medical radionuclides. The 
determined calibration factors allow the measurement and certification of the 
radiopharmaceutical solutions or capsules to be used for: (a) the calibration of the radionuclide 
calibrators, including those belonging to the radiopharmaceutical unit from IFIN-HH, (b) to be 
distributed to the interested laboratories, or (c) to be used for organization of national 
comparisons. The chamber operation is in compliance with the QMS rules, established in 
agreement with the requirements of the EN ISO/IEC 17025:2005 and TRS 454 document. The 
calibration uncertainty is in all cased less than 2.0%.  
4.2 High resolution spectrometric system 
In the field of nuclear medicine, spectrometric systems are used for the measurement of the 
radionuclide impurity level in radiopharmaceuticals (RPMs); in order to perform an 
adequate check of the requirements imposed to the RPMs, the system must have a high 
resolution, to allow the identification of the main radionuclide and impurities, and to be 
sensitive enough (to have a low background) in order to detect impurities content of the 
order of <0.1%, such as it is required for 99Mo content in 99mTc.  
IFIN-HH, RML disposes of a system containing a high resolution HPGe detector: relative 
efficiency 29%; energy interval 35 keV – 3 MeV; resolution: 0.85 keV (122 keV) and 1.74 keV 
(1.332 MeV) and a computer driven, software GAMMA VISION, V 6.01 spectrometric 
analyser. The specialized program GESPECOR (Sima & Arnold. 2002), for geometry, matrix 
and coincidence summation corrections is implemented. An efficient shield, consisting from: 
10 cm old lead; 1 mm tin; 2 mm electrolytic cooper, assures a maximum integral background 
rate on the whole energy interval of 1.4 s-1. The system is calibrated in terms of energy and 
efficiency with standard sources, in various geometries from point sources up to volume 
recipients, prepared from standard solution absolutely standardized, by the coincidence 
method. Various distances, from zero, up to 44.3 cm from the detector surface are used in 
measurements, depending on the activity interval. The calibration of the system was also 
validated by the participation at international NPL-UK or IAEA exercises for the measurement 
of various volume samples, containing mixtures of radionuclides (Luca et al. 2010). The system 
is taken as reference for the dedicated HPGe spectrometer used in the radiopharmacy unit. 
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Management System (QMS) is monitored by the EURAMET, Technical Committee – 
Quality, TC-Q.  
At the level of CIPM - MRA, the statement is practically applied by the use of the Annex C 
of the CIPM-MRA, Calibration and Measurement Capability files – CMCs. The approval and 
publication of CMCs for a NMI is the result of two types of evaluation components for the 
international recognition: (i) Approval of the international equivalence for primary and of 
the traceability for secondary standards; (ii) Implementation of the QMS and recognition by 
the MRO’s, TC-Q. 
i. Approval of equivalence and traceability. The NMI, member of one MRO, draws up the 
primary or secondary CMC files. The statement is compared with the KCDB for 
primary, or in our case EURAMET for secondary standards. After the inter MROs’ peer 
review process, they are submitted for the approval of the JCRB. 
ii. Implementation and approval of the QMS. The EN/ISO/IEC 17025:2005, referential 
“General requirements for the competence of testing and calibration laboratories” is applied. A 
complete documentation and its implementation are presented at the annual meetings 
of the EURAMET, TC-Q. The technical experts monitor the documents and after the 
first approval, the QMS is annually reconfirmed. This is a prerequisite condition to 
maintain the CMCs in the published in Annex C of MRA. Example, IFIN-HH, RML 
situation. 34 CMC files, Radioactivity standards, passed the peer review process; the 
QMS was approved in 2007 and annually reviewed. All CMCs were approved by the 
JCRB in April 2008 and published in CIPM-MRA, Annex C. http://kcdb.bipm.org/ 
AppendixC/default.asp  
4. Setting up of the activity secondary standard systems 
Realisation of the activity secondary standards. 
Such as presented in figure 1 and as pointed in the references TRS 454 (2006) and 
(Zimmerman & Judge. 2007), the practical realization of the metrological traceability chain is 
possible by using the activity secondary standards. They are transfer instruments of the 
activity unit from the primary to the lower order, working standards, for the end users, 
through standard (reference) products or calibration services. They consist of installations 
for the secondary (relative) standardization; their calibration is done with sources and 
solutions absolutely standardized with the primary standards. In the case of the primary 
laboratories they use their own primary standards. In the case of the secondary standard 
laboratories (SSL), the standards leave from another primary laboratory, the traceability 
route being declared. The practical work at IFIN-HH, RML was described in (Sahagia & 
Woods.2008). 
4.1 Secondary standards for high activity radiopharmaceutical solutions 
The secondary standard for high activity solutions is a reentrant (well type) ionization 
chamber, filled with an inert gas as nitrogen or argon, at high pressure, of a special 
construction, largely described by H. Schrader in Monographie BIPM-4 (1997), or a 
commercial radionuclide calibrator. It is calibrated with standard solutions absolutely 
standardized, from the radionuclides of interest. The ionization current, registered by the 
associated electrometric circuit, is due to the radiations entering in the sensitive volume of 
the chamber and ionizing the filling gas. This chamber is mainly used for the measurement 
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of activity for gamma-ray, but also for strong beta-ray emitters, when the ionization current is 
produced by the bremsstrahlung radiations. Usually, the calibration factor is expressed in 
terms of absolute or relative efficiency, or in ionization current per activity unit, pA MBq-1. The 
calibration must be performed for several geometries of the recipients containing radioactive 
solution, or gelatin capsules in the case of iodine radioisotopes, as the calibration factor 
depends on the geometrical dimensions. For example, the IFIN-HH, RML well type ionization 
chamber is of the type CENTRONIC IG12/20A, filled with argon at a pressure of 2MPa 
(20Atm); its construction was first described in (Grigorescu et al. 2003). Recently, the old 
electrometric system was replaced with an electrometer Keithley E6517A. The validation of the 
calibration factors was done by several comparisons: (i) with the measurements performed at 
PTB-Braunschweig-Germany with PTB standard solutions; (ii) with the IFIN-HH, RML results 
obtained in international comparisons; (iii) respectively with the value of the KCRV (Sahagia et 
al. 2010). The calibration factors are determined for the radionuclides: 241Am, 57Co, 99mTc, 186Re, 
188Re, 153Sm, 177Lu, 75Se, 169Yb, 131I, 133Ba, 51Cr, 192Ir, 134Cs, 137Cs, 54Mn, 65Zn, 60Co, 152Eu and for 
three geometries: (i) Solid sources; (ii) 131I gelatin capsules; (iii) Solutions of volumes: 2 mL 
(PTB), 3.6 mL (SIR-BIPM), 5 mL (P6 used for radiopharmaceuticals). From the above list one 
may notice that the calibration is assured for the majority of medical radionuclides. The 
determined calibration factors allow the measurement and certification of the 
radiopharmaceutical solutions or capsules to be used for: (a) the calibration of the radionuclide 
calibrators, including those belonging to the radiopharmaceutical unit from IFIN-HH, (b) to be 
distributed to the interested laboratories, or (c) to be used for organization of national 
comparisons. The chamber operation is in compliance with the QMS rules, established in 
agreement with the requirements of the EN ISO/IEC 17025:2005 and TRS 454 document. The 
calibration uncertainty is in all cased less than 2.0%.  
4.2 High resolution spectrometric system 
In the field of nuclear medicine, spectrometric systems are used for the measurement of the 
radionuclide impurity level in radiopharmaceuticals (RPMs); in order to perform an 
adequate check of the requirements imposed to the RPMs, the system must have a high 
resolution, to allow the identification of the main radionuclide and impurities, and to be 
sensitive enough (to have a low background) in order to detect impurities content of the 
order of <0.1%, such as it is required for 99Mo content in 99mTc.  
IFIN-HH, RML disposes of a system containing a high resolution HPGe detector: relative 
efficiency 29%; energy interval 35 keV – 3 MeV; resolution: 0.85 keV (122 keV) and 1.74 keV 
(1.332 MeV) and a computer driven, software GAMMA VISION, V 6.01 spectrometric 
analyser. The specialized program GESPECOR (Sima & Arnold. 2002), for geometry, matrix 
and coincidence summation corrections is implemented. An efficient shield, consisting from: 
10 cm old lead; 1 mm tin; 2 mm electrolytic cooper, assures a maximum integral background 
rate on the whole energy interval of 1.4 s-1. The system is calibrated in terms of energy and 
efficiency with standard sources, in various geometries from point sources up to volume 
recipients, prepared from standard solution absolutely standardized, by the coincidence 
method. Various distances, from zero, up to 44.3 cm from the detector surface are used in 
measurements, depending on the activity interval. The calibration of the system was also 
validated by the participation at international NPL-UK or IAEA exercises for the measurement 
of various volume samples, containing mixtures of radionuclides (Luca et al. 2010). The system 
is taken as reference for the dedicated HPGe spectrometer used in the radiopharmacy unit. 
 
12 Chapters on Nuclear Medicine 
 
156 
Another use of the IFIN-HH, RML’s spectrometric system is the precise determination of the 
emission intensity of gamma-rays for radionuclides of medical use. These parameters are of 
maximum importance for activity standardization by primary methods, as in most of 
measurements they are basic parameters in activity calculation. On the other hand, the 
efficiency and safety of the medical procedure depends directly on their precise knowledge. 
The precise value of half life is directly used in nuclear medicine units for the calculation of 
activity at the moment of administration. The calculation of patients’ doses is based on the 
values of: activity, half life, radiations  - types, energies and emission intensities. On the 
international scale, projects of the type: “EURAMET.RI(II)-S5.Radionuclide” are organized, 
for the experimental determination of emission intensities and evaluation projects 
coordinated by the Decay Data Evaluation Program (DDEP) are deployed. IFIN-HH, RML 
participates in both types of programs. For example, recently the laboratory participated at 
the exercise, organized for the new PET radionuclide 64Cu, EURAMET project 1085 (Bé et al. 
2011). RML standardized absolutely solutions from 64Cu and 68Ga by the coincidence 
method (Sahagia et al. 2011). Point solid sources from standard solution were prepared 
gravimetrically, and were used for the determination of their decay parameters: gamma-
rays emission intensities with the calibrated HPGe spectrometric system and half life by the 
use of the CENTRONIC IG12/20A ionization chamber (Luca et al.2011). 
5. The Radionuclide Metrology Laboratory support to the nuclear medicine 
A primary/secondary standard laboratory is the entity which can assure the continuity of 
the metrological traceability in the measurement and characterization of 
radiopharmaceuticals in radiopharmacy units, national control authorities and hospitals 
from the top level, SI, up to the end user, the patient, by the following standards delivery 
and calibration operations (Zimmerman et al. 2007): 
- Radioactive standards to be used in the interested entities;  
- Calibration or Metrological Check of the Radionuclide Calibrators;  
- Organization of national comparisons and proficiency tests.  
These activities need to be accomplished under the regime of national accreditation, as a 
Calibration and Testing Laboratory, according to the provisions of the standard EN 
ISO/IEC 17025:2005 “General requirements for the competence of testing and calibration 
laboratories”. For example IFIN-HH, RML obtained the accreditation for both types of 
activities, from the Romanian accreditation body, RENAR, member of the European 
Accreditation (EA), for the products and services for clients, after implementing a Quality 
Management System (QMS). The QMS consists of the documentation and practical 
realization of the documents’ provisions. The main documents, covering the Chapters 4 and 
5 of the EN ISO/IEC 17025:2005 standard, are: RML Manual-containing the basic statement 
of the QMS, an Organizational procedure and two sets of procedures: System (Management) 
procedures (MP) and Work procedures (WP) and instructions (WI). The accreditation was 
obtained in 2009, for a 4-year period; annual survey audits of RENAR representatives are 
done. In contrast with other calibration or testing laboratories, where the accreditation refers 
to some well-defined activities, in our quality of primary standard laboratory, we have first 
of all the responsibility for the quality of primary, absolute standardizations, on the top of 
traceability chain, not in direct connection with customers’ requirements. The first 
consequences are: (i) The traceability chain must be well defined and demonstrated in the 
laboratory. (ii) An internationally recognized expert must conduct the technical evaluation 
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of the laboratory. On the other hand, as a national provider of radioactive standards, the 
RML must meet quality requirements in their production.  
(i) Definition of Activities and Establishment of Traceability Chain. Clear distinction of the two 
types of activities in relation with the RENAR accreditation was defined: Calibration 
activities and Testing activities. (a) The calibration branch required a sharp definition of the 
traceability chain and activities deployed in regime of quality management. The declared 
activities under accreditation are: (I) Attestation of the installations for the absolute (direct) 
standardization, mainly used for international comparisons, in order to prove the 
international equivalence of the Romanian standards, and for the preparation of standard 
sources and solutions used for the calibration of the secondary equipment. (II) Calibration 
and metrological check of the secondary installations for the relative (indirect) 
standardization. (III) Standardization of the radioactive standard sources and solutions. (IV) 
Preparation and relative or absolute standardization of radioactive sources and solutions, 
under the quality management system. The traceability chain continues outside the 
laboratory, in connection with the users, and implies: (V) The delivery of radioactive 
sources, with Calibration Certificates, under the quality management system. (VI) The 
calibration and metrological check of activity measurement installations. (VII) The 
organization of inter laboratory comparisons (ILCs) and proficiency tests (PTs) for the 
testing and calibration laboratories. (b) The testing branch of accredited activities refers at 
the Analysis of very low activity samples by the gamma-ray spectrometry. Another special 
aspect in the application of the requirements of the 17025:2005 Standard in our case is the 
responsibility of the National Nuclear Authority (CNCAN) regarding the radioprotection of 
the workers, public and patients. In this respect IFIN-HH, RML was CNCAN designed also 
as a notified calibration and testing laboratory for the nuclear field.  
5.1 Radioactive standards for nuclear medicine  
The calibration and metrological check of the equipment for measurement of the 
radioactivity imposed the development of technics for the preparation of a large variety of 
standard sources and solutions, to be used in-house, or delivered to the external customers 
which are performing radioactivity measurement. A general WP, coded AC-PL-LMR-10, 
describes the common operations and detailed WIs present the specific operations. 
Radioactive Solutions. A large variety of radioactive solutions, physico-chemically stable, adequate 
as radioactivity standards, are prepared (Grigorescu et al.1975). Some of them, even for external 
users’ delivery, are standardized absolutely, or alternatively, by the use of the calibrated 
ionization chamber. They are certified in terms of radioactive concentration, Bq g-1, and in total 
activity, Bq, per recipient, flame or mechanically sealed in glass ampoules or P6 vials. 
Point and Large Area Alpha and Beta Sources. These sources are of immediate interest, both for 
calibration of contamination monitors (contaminometers), as well as for the effective 
measurement of the so called “Gross Alpha” and “Gross Beta” radioactive content of 
environmental, industrial and food chain samples. Their preparation and measurement of 
the particle emission rate in a 2πsr geometry are described in (Sahagia et al. 1996a). 
5.2 Calibration and metrological check of measurement equipment  
The main requirements regarding the characteristics of the equipment for the measurement 
of activity and of the physico-chemical parameters were described in section 2. In order to 
satisfy them, a radionuclide metrology laboratory is asked to perform calibrations or other 
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metrology checks over it. The radionuclide calibrators are the most used devices for the 
measurement of activity in radiopharmacy, control units and hospitals (Razdolescu et 
al.2002b). In some cases the National Metrology legislation imposes their metrological 
control, according to legal metrology norms, and in others it is required their calibration at 
defined time intervals, by a metrology laboratory, accredited for calibration. In our case, the 
legal metrological control was mandatory until 2009. Starting with 2010, the calibration-
recalibration was preferred. In this respect, IFIN-HH, RML obtained the RENAR 
accreditation for these operations within its QMS. The WP codified as AC-PL-LMR-11 is 
applied. As a general remark from our calibration experience is that the Romanian hospitals 
staff increased in time its awareness regarding the quality of activity measurement and 
more and more nuclear medicine units benefit from our laboratory’s services of calibration, 
at present time regarding the radionuclides: 99mTc and 131I. The deviations of the calibration 
factors from the reference values are generally within ±5%. The IFIN-HH radiopharmacy is 
under the permanent metrological survey of the RML. As this unit has under study new 
radiopharmaceuticals, the laboratory was asked to assess calibration factors to the 
radionuclide calibrators for the new radiouclides: 186Re, 188Re, 153Sm, 177Lu.  
The second important action is the calibration of the HPGe spectrometric system used in the 
radiopharmacy for the control of radionuclidic impurities. It is calibrated and regularly 
recalibrated in energy and efficiency by the representatives of RML, using standard 
solutions prepared in RML, under accreditation regime, and the calibration procedure WP 
code AC-PL-LMR-0100 is applied. 
Other equipment, belonging the radiopharmacy unit, are the radiochromatographs used in 
the control of the radiochemical purity; for their calibration and linearity check, a set of solid 
point standard gamma-ray emitting sources are used; for the case of 131I control, two 133Ba 
standard sources are measured. The action is also under accreditation regime and the WP 
code AC-PL-LMR-12 is applied.  
Each nuclear medicine unit, operating with open radioactive sources, is provided with 
contaminometers for the control of radioactive contamination of surfaces, devices, clothes, 
operator hands, etc., which can occur during the medical procedures. This equipment can be 
under the legal metrological control of the state as it is in Romania, or only is recalibrated at 
defined intervals. The Romanian secondary standard laboratories performing these checks 
use large area standard sources emitting beta radiations, in most cases 90(Sr+Y) sources. 
IFIN-HH, RML is the provider of these standard sources and also performs their calibration 
(Sahagia et al. 1996b). 
5.3 Organization of national comparisons and proficiency tests 
The most significant test, recognized as relevant in the evaluation of the capability of a 
laboratory performing measurements, is the participation in proficiency tests. For example, 
even when the calibration factors of the radionuclide calibrators are correct, the 
measurement in a hospital implies also the skill of the operating staff. Non experienced 
people are possible to choose wrong calibration factors’ values, to do wrong readings and 
activity calculation on the administration time. From our practical experience, one may 
conclude that the proportion of laboratories with unsatisfactory results in proficiency tests is 
higher than that of wrong calibrated equipment. This is the reason for which in some 
countries the participation in proficiency tests is mandatory, but in others like Romania, it is 
only voluntary. IFIN-HH, RML organized in the past several national comparisons mainly 
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for a scientific output, in order to understand which explanations for noncorresponding 
results are. The comparisons regarded the measurement of 131I (Sahagia et al.1996b) and the 
set 99mTc and 57Co, (Sahagia & Woods. 2008c). Within the frame of the above cited IAEA, 
CRP E2.10.05, a series of international actions were deployed, in order to harmonize the 
measurements in the participant countries, all over the world. The actions were organized in 
two steps. The first step was the participation of the national reference laboratories (primary 
or secondary) in two comparisons organized by the IAEA, recognized also as 
supplementary CCRI(II) –S6 comparisons, on 131I and 57Co (used a as mock solution for 
99mTc), intended to verify their calibration capability. The results were presented by the 
comparisons organizers in the papers (Zimmerman et al. 2008; Zimmerman & Palm. 2010). 
After the evaluation of the results, each national laboratory organized then two national 
comparisons, for the radionuclides 131I and 99mTc. IFIN-HH, RML organized the 
comparisons according to the prescriptions of the WP code AC-PL-LMR-07, written in 
accordance with the international documents: ISO Guide 43 „Proficiency testing by 
interlaboratory comparisons” Part 1: „Development and operation of proficiency testing schemes” 
and Part 2: „Selection and use of proficiency testing schemes by laboratory accreditation bodies” and 
following also the recommendations from the Protocols on the organization of national 
comparisons of radiopharmaceuticals, established within the frame of the IAEA CRP. 
E2.10.05.The analysis of the results was reported in the papers (Sahagia et al. 2009; Sahagia 
et al. 2010b). As conclusions from these tests are the proportions of hospitals measuring 
satisfactory the activities of the two radionuclides. In the case of 131I, from a total number of 
15 reported values, a number of 11 results are within the difference limit from reference value 
<5%, and 12 results within the limit <10%, a proportion of 80% from participating units, being 
in compliance with the Pharmacopoeia; for 99mTc, from 7 reported values, a number of 5 results 
are within < 5 % difference from the reference value, and 7 results within the limit < 10 %, a 
proportion of 100% from participating units. Regarding 131I comparisons, after finalizing the 
IAEA CRP. E2.10.05, an interesting paper, summarizing all 8 national laboratories 
comparisons’ organization and results was published recently (Olsovcova et al. 2010); a 
similar paper is in preparation, for presentation of the 99mTc national comparisons. 
6. Conclusions  
- Nuclear medicine benefits from a very wide range of radionuclides, to be used as 
radiopharmaceuticals for diagnosis and therapy procedures. 
- The radiopharmaceuticals are classified as high pharmaceutical risk products, and 
therefore they must be very carefully characterized in terms of the main parameters: 
metrological, physico-chemical, biological. 
- The precise measurement of activity is of crucial interest, as it determines directly the 
committed effective dose of the patient in diagnostic and organ/tissue absorbed dose in 
therapy. 
- Precise measurements of activity are also implied indirectly in the full characterization 
of the radiopharmaceuticals’ parameters. 
- The Radionuclide Metrology Laboratory can assure the metrological traceability chain 
for activity starting from the primary level, by demonstrating its international 
equivalence, or starting from the secondary one, the traceability route being necessary 
to be declared. 
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- The Radionuclide Metrology Laboratory can offer the necessary support to the nuclear 
medicine for the safe and efficient use of radiopharmaceuticals, by assuring the 
standards and the metrology services to the implied entities: radiopharmacy, control 
laboratories, equipment producers, nuclear medicine units. 
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1. Introduction 
Breast cancer is one of the most common diseases and a major public health problem in the 
world today. It is responsible for 32% of all cancers and 15% of cancer deaths in women 
(Dirisamer et al., 2010). Advances in diagnosis and treatment of breast cancer have led to 
decline in mortality. However, just about 60% of patients can now be cured by initial 
treatments, but the rest, in spite of receiving palliation with currently available therapy 
methods die. Therefore, tremendous amounts of time and efforts are dedicated to search 
toward earlier detection and more efficient treatment of this disease. Advances in molecular 
cancer biology achieved an increased understanding of the biologic factors that contribute to 
breast cancer pathogenesis and progression. This understanding has already led to both 
early diagnosis and more effective treatment. Among different imaging and therapy 
contribution modalities, nuclear medicine provides an important role to the clinical 
management of breast cancer. In this chapter, we highlight the uses, advantages, limitations 
and possible improvements of radioimmunoscintigraphy and radioimmunotherapy 
techniques as targeted molecular imaging and therapy methods, respectively.  
2. Diagnosis of breast cancer 
Breast cancer is currently the most common cancer in females and the second highest cause 
of cancer death in female population of the world. The majority of breast cancer deaths are 
due to metastasis (Costelloe et al., 2009). If breast cancer is detected prior to metastatic 
spread, it has considerably better prognosis than the cancer that has already spread. 
Therefore, the detection of cancer in an early stage is a major factor in the reduction of 
patient mortality and leading to less cancer costs and more successful treatments. The 
management of patients with a suspicious lesion includes confirming the diagnosis, 
identifying the stage of disease and choosing an appropriate treatment for each individual 
patient. Identifying the stage of a disease in any patient is a crucial step, because it 
determines the type of treatment that is appropriate for that particular person. Also, it is 
necessary to follow patients that need therapeutic procedures to assess their response to the 
treatment. There are a number of methods available for the detection of breast cancer. This 
section briefly points out some difficulties that encounter with these conventional imaging 
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1. Introduction 
Breast cancer is one of the most common diseases and a major public health problem in the 
world today. It is responsible for 32% of all cancers and 15% of cancer deaths in women 
(Dirisamer et al., 2010). Advances in diagnosis and treatment of breast cancer have led to 
decline in mortality. However, just about 60% of patients can now be cured by initial 
treatments, but the rest, in spite of receiving palliation with currently available therapy 
methods die. Therefore, tremendous amounts of time and efforts are dedicated to search 
toward earlier detection and more efficient treatment of this disease. Advances in molecular 
cancer biology achieved an increased understanding of the biologic factors that contribute to 
breast cancer pathogenesis and progression. This understanding has already led to both 
early diagnosis and more effective treatment. Among different imaging and therapy 
contribution modalities, nuclear medicine provides an important role to the clinical 
management of breast cancer. In this chapter, we highlight the uses, advantages, limitations 
and possible improvements of radioimmunoscintigraphy and radioimmunotherapy 
techniques as targeted molecular imaging and therapy methods, respectively.  
2. Diagnosis of breast cancer 
Breast cancer is currently the most common cancer in females and the second highest cause 
of cancer death in female population of the world. The majority of breast cancer deaths are 
due to metastasis (Costelloe et al., 2009). If breast cancer is detected prior to metastatic 
spread, it has considerably better prognosis than the cancer that has already spread. 
Therefore, the detection of cancer in an early stage is a major factor in the reduction of 
patient mortality and leading to less cancer costs and more successful treatments. The 
management of patients with a suspicious lesion includes confirming the diagnosis, 
identifying the stage of disease and choosing an appropriate treatment for each individual 
patient. Identifying the stage of a disease in any patient is a crucial step, because it 
determines the type of treatment that is appropriate for that particular person. Also, it is 
necessary to follow patients that need therapeutic procedures to assess their response to the 
treatment. There are a number of methods available for the detection of breast cancer. This 
section briefly points out some difficulties that encounter with these conventional imaging 
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modalities and describes application of nuclear medicine techniques and targeted molecular 
imaging in the investigation of patients with breast cancer. 
2.1 Mammography 
Mammography is a gold standard imaging method for breast cancer screening, detection 
and diagnosis in women under forty with a relatively high sensitivity in the range of 85-90% 
(Berg et al., 2004). This method is a national screening program in the United Kingdom 
(Glasspool & Evans., 2000). Although mammography is an effective imaging tool, it is not 
without limitations like many other diagnostic modalities. First, the sensitivity of 
mammography decreases dramatically in young patients due to their dense breast tissues. 
On the other hand, its ability to detect malignant lesions in young female patients decreases 
to 68% (Nystrom et al., 2002, Kopans, 1992). As a result, some patients with breast cancer are 
missed and some others without a malignant tumor undergo unnecessary biopsies due to 
incorrect mammography findings. Secondly, mammography in patients evaluated following 
breast surgery or radiotherapy, is unreliable with a false negative rate of 25-45%, because it 
cannot always differentiate benign from malignant diseases (Fass, 2008). Many efforts have 
ever been taken to establish new tests to enable us to collect more complete information by 
non-invasive methods. These efforts minimize the use of breast biopsy in women who do 
not have breast cancer. Therefore, many other imaging modalities such as ultrasonography 
(US), magnetic resonance imaging (MRI), diffuse optical tomography (DOT), computed 
tomography (CT) and measurement of tumor markers in blood serum have been initiated to 
increase the diagnostic accuracy of mammography. 
2.2 Ultrasonography 
Ultrasonography is an important adjunct to mammography for both diagnosis and 
characterization of breast cancer and is routinely used in this role (Fass, 2009). It is non-
invasive, easily available, relatively cheap and also recommended for pregnant or lactating 
women when ionizing radiation may not be recommended (Schueller et al., 2008). It has 
been found that ultrasonography, when combined with mammography, can prevent up to 
22% of unnecessary biopsies (Zonderland, 2000). Although ultrasonography can reliably 
differentiate a cystic lesion from a solid lesion, it does not provide a high specificity to 
distinguish benign from malignant lesions (Balleyguier et al., 2008; Sauer et al., 2005). 
Another disadvantage of this method as a screening tool, when applied to general 
population, is low sensitivity and specificity and furthermore it is operator-dependent 
(Liberman, 2000).  
2.3 Magnetic Resonance Imaging (MRI) 
Breast cancer was one of the first that was examined using MRI (Ross et al., 1982). This 
method is very useful for further evaluation when mammography and ultrasonography are 
indeterminate to study the presence or location of a suspect abnormality (Glasspool et al., 
2000). However, due to cost reasons, low access and high false positives, MRI is not yet 
considered as a screening exam for breast cancer except for special cases. MRI of breast 
cancer is recommended in the repeated screening of patients who have the increased risk of 
radiation induced DNA mutations (Fass, 2008). MRI is used to screen women with a family 
history of breast cancer, women with very dense breast tissues or women with silicone 
implants that can obscure pathology in mammography (Fass, 2008).  
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2.4 Diffuse Optical Tomography (DOT) 
While breast cancer is still increasing in frequency, new diagnostic procedures must be 
available to challenge existing procedures to make diagnosis of breast cancer more accurate 
and reliable. DOT is one of the most important non-invasive and non-ionizing imaging 
modalities that are available for breast cancer diagnosis. DOT can be used to locate lesions 
within breast (Frangioni, 2008; Kepshire et al., 2007; Hawrysz et al, 2000). Despite promising 
results, there are several factors that limit the wide application of DOT for the imaging of 
breast tissue in clinic. First, the maximum depth of imaging in breast tissue is less than 15 
mm. Secondly, the spatial resolution of DOT is less than one centimeter, that is not as good 
as mammography, ultrasonography or MRI. Because of these limitations, DOT is not a 
widely-accepted imaging modality for breast cancer (Kepshire et al., 2007; Hawrysz et al., 
2000). 
2.5 Computed Tomography (CT) 
X-ray computed tomography (introduced into clinical practice in 1972) was the first of 
modern slice-imaging modalities. CT scan has several advantages including (1) unlimited 
depth penetration; (2) high spatial resolution; (3) short acquisition time (minutes); (4) 
moderately cheap and (5) ability of performing anatomical imaging. CT has some 
limitations including (1) sensitivity of CT scan decreases in early stage of breast cancer, (2) 
CT scan is associated with radiation exposure and should never be done in pregnant females 
because of radiation risk to the fetus, (3) CT is not very good at identifying pathology of soft 
tissues, (4) the dye used in CT is iodine based and is often a cause of allergy and (5) CT 
probably can not be used for molecular imaging and currently is just used for anatomical 
and functional imaging (Pysz et al., 2010).  
2.6 Measurement of tumor markers in blood 
Several biochemical compounds in the serum/plasma may act as the indicators of the 
presence, risk or prognosis of cancer. In patients with history of breast cancer, elevated 
tumor marker levels may represent cases of tumor relapse. It has been shown that increasing 
levels of tumor markers is associated with disease recurrence and may indicate the need for 
further investigations. Examples of tumor markers in blood including CA 15.3, CA 27.29, 
CA125, CEA and circulating tumor cells. While breast cancer blood marker tests are 
promising, they are not absolutely conclusive. When a breast cancer blood marker test 
comes back negative, it doesn't necessarily mean that the patient is free and clear of breast 
cancer and a positive result does not always mean that the cancer is growing (Merkle et al., 
2009).  
2.7 Nuclear medicine  
As cited, each imaging method has strengths and weaknesses in terms of sensitivity, 
specificity, spatial and temporal resolution, contrast and cost. Therefore, the fundamental 
efforts for introduction and development of new methods for breast cancer diagnosis are 
requested. Nuclear medicine is defined as a branch of medicine that employs open 
radioactive sources, commonly referred to radionuclides, in diagnosis and treatment of 
diseases (Glasspool & Evans, 2000). The application of nuclear medicine techniques to study 
patients with breast cancer has recently raised its profile particularly in the investigation of 
indeterminate mammographic lesions and for overcoming limitations of MRI, US, CT and 
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modalities and describes application of nuclear medicine techniques and targeted molecular 
imaging in the investigation of patients with breast cancer. 
2.1 Mammography 
Mammography is a gold standard imaging method for breast cancer screening, detection 
and diagnosis in women under forty with a relatively high sensitivity in the range of 85-90% 
(Berg et al., 2004). This method is a national screening program in the United Kingdom 
(Glasspool & Evans., 2000). Although mammography is an effective imaging tool, it is not 
without limitations like many other diagnostic modalities. First, the sensitivity of 
mammography decreases dramatically in young patients due to their dense breast tissues. 
On the other hand, its ability to detect malignant lesions in young female patients decreases 
to 68% (Nystrom et al., 2002, Kopans, 1992). As a result, some patients with breast cancer are 
missed and some others without a malignant tumor undergo unnecessary biopsies due to 
incorrect mammography findings. Secondly, mammography in patients evaluated following 
breast surgery or radiotherapy, is unreliable with a false negative rate of 25-45%, because it 
cannot always differentiate benign from malignant diseases (Fass, 2008). Many efforts have 
ever been taken to establish new tests to enable us to collect more complete information by 
non-invasive methods. These efforts minimize the use of breast biopsy in women who do 
not have breast cancer. Therefore, many other imaging modalities such as ultrasonography 
(US), magnetic resonance imaging (MRI), diffuse optical tomography (DOT), computed 
tomography (CT) and measurement of tumor markers in blood serum have been initiated to 
increase the diagnostic accuracy of mammography. 
2.2 Ultrasonography 
Ultrasonography is an important adjunct to mammography for both diagnosis and 
characterization of breast cancer and is routinely used in this role (Fass, 2009). It is non-
invasive, easily available, relatively cheap and also recommended for pregnant or lactating 
women when ionizing radiation may not be recommended (Schueller et al., 2008). It has 
been found that ultrasonography, when combined with mammography, can prevent up to 
22% of unnecessary biopsies (Zonderland, 2000). Although ultrasonography can reliably 
differentiate a cystic lesion from a solid lesion, it does not provide a high specificity to 
distinguish benign from malignant lesions (Balleyguier et al., 2008; Sauer et al., 2005). 
Another disadvantage of this method as a screening tool, when applied to general 
population, is low sensitivity and specificity and furthermore it is operator-dependent 
(Liberman, 2000).  
2.3 Magnetic Resonance Imaging (MRI) 
Breast cancer was one of the first that was examined using MRI (Ross et al., 1982). This 
method is very useful for further evaluation when mammography and ultrasonography are 
indeterminate to study the presence or location of a suspect abnormality (Glasspool et al., 
2000). However, due to cost reasons, low access and high false positives, MRI is not yet 
considered as a screening exam for breast cancer except for special cases. MRI of breast 
cancer is recommended in the repeated screening of patients who have the increased risk of 
radiation induced DNA mutations (Fass, 2008). MRI is used to screen women with a family 
history of breast cancer, women with very dense breast tissues or women with silicone 
implants that can obscure pathology in mammography (Fass, 2008).  
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2.4 Diffuse Optical Tomography (DOT) 
While breast cancer is still increasing in frequency, new diagnostic procedures must be 
available to challenge existing procedures to make diagnosis of breast cancer more accurate 
and reliable. DOT is one of the most important non-invasive and non-ionizing imaging 
modalities that are available for breast cancer diagnosis. DOT can be used to locate lesions 
within breast (Frangioni, 2008; Kepshire et al., 2007; Hawrysz et al, 2000). Despite promising 
results, there are several factors that limit the wide application of DOT for the imaging of 
breast tissue in clinic. First, the maximum depth of imaging in breast tissue is less than 15 
mm. Secondly, the spatial resolution of DOT is less than one centimeter, that is not as good 
as mammography, ultrasonography or MRI. Because of these limitations, DOT is not a 
widely-accepted imaging modality for breast cancer (Kepshire et al., 2007; Hawrysz et al., 
2000). 
2.5 Computed Tomography (CT) 
X-ray computed tomography (introduced into clinical practice in 1972) was the first of 
modern slice-imaging modalities. CT scan has several advantages including (1) unlimited 
depth penetration; (2) high spatial resolution; (3) short acquisition time (minutes); (4) 
moderately cheap and (5) ability of performing anatomical imaging. CT has some 
limitations including (1) sensitivity of CT scan decreases in early stage of breast cancer, (2) 
CT scan is associated with radiation exposure and should never be done in pregnant females 
because of radiation risk to the fetus, (3) CT is not very good at identifying pathology of soft 
tissues, (4) the dye used in CT is iodine based and is often a cause of allergy and (5) CT 
probably can not be used for molecular imaging and currently is just used for anatomical 
and functional imaging (Pysz et al., 2010).  
2.6 Measurement of tumor markers in blood 
Several biochemical compounds in the serum/plasma may act as the indicators of the 
presence, risk or prognosis of cancer. In patients with history of breast cancer, elevated 
tumor marker levels may represent cases of tumor relapse. It has been shown that increasing 
levels of tumor markers is associated with disease recurrence and may indicate the need for 
further investigations. Examples of tumor markers in blood including CA 15.3, CA 27.29, 
CA125, CEA and circulating tumor cells. While breast cancer blood marker tests are 
promising, they are not absolutely conclusive. When a breast cancer blood marker test 
comes back negative, it doesn't necessarily mean that the patient is free and clear of breast 
cancer and a positive result does not always mean that the cancer is growing (Merkle et al., 
2009).  
2.7 Nuclear medicine  
As cited, each imaging method has strengths and weaknesses in terms of sensitivity, 
specificity, spatial and temporal resolution, contrast and cost. Therefore, the fundamental 
efforts for introduction and development of new methods for breast cancer diagnosis are 
requested. Nuclear medicine is defined as a branch of medicine that employs open 
radioactive sources, commonly referred to radionuclides, in diagnosis and treatment of 
diseases (Glasspool & Evans, 2000). The application of nuclear medicine techniques to study 
patients with breast cancer has recently raised its profile particularly in the investigation of 
indeterminate mammographic lesions and for overcoming limitations of MRI, US, CT and 
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DOT techniques (Berghammer et al., 2001). The differences in tumor biology such as blood 
flow, metabolism, concentration of specific receptors or differences in antigen expression are 
exploited in order to target radionuclides to the tumor tissue (Glasspool & Evans, 2000). The 
major advantage of nuclear medicine is that just picomolar concentrations of radiotracers are 
required to provide a measurable signal (Cook et al., 2003). 
2.7.1 Scintimammography 
Future developments in nuclear medicine are in the area of development of specialized 
imaging systems. One example of specialized gamma camera is scintimammography in 
imaging of breast and axillary nodes. Scintimammography term is given to radionuclide 
imaging of breast cancer (Schillaci et al., 2007). Scintimammography is performed after 
injection of the radiopharmaceutical into an arm vein contralateral to the suspected tumor or 
into a pedal vein and the subsequent imaging with right and left lateral, prone and supine 
views, covering both breasts and both axillae and later computer acquisition of data 
(Nguyen et al., 2009; Brem et al., 2005). Most studies evaluating the role of 
scintimammography, have compared it with mammography, ultrasound and MRI. Its 
sensitivity has ranged from 62% to 93% with specificity from 79% to 94% (Schillaci & 
Buscombe, 2004). Its sensitivity is greater for palpable lesions. Current recommendations for 
the use of scintimammography are (Fass, 2008):  
1. As a general adjunct to mammography to differentiate between benign and malignant 
breast lesions in patients with palpable masses or suspicious mammograms. 
2. In patients referred for biopsy when lesions are considered to have a low probability of 
malignancy. 
3. In patients with probably benign findings on mammography, but are recommended for 
close follow-up (e.g. repeated mammography in 3–6 months).  
4. In patients who have dense breast tissues and are considered difficult to evaluate on 
mammography. 
5. For detection of axillary lymph node metastases in patients with confirmed breast cancer. 
The main limitations of scintimamography are low sensitivity and high dose of radionuclide 
that is used for imaging. Currently, for overcoming the cited limitations, the researchers are 
studying on targeted molecular imaging methods. 
3. Treatment of breast cancer  
To understand the diagnostic needs for breast cancer, it is important to understand the 
range of approaches for breast cancer treatment. With the exception of early and late stage 
disease, almost all breast cancer therapy methods, involve a combination of locoregional 
and systemic treatments. Locoregional therapy includes surgery and radiotherapy and 
systemic therapy includes chemotherapy, hormone therapy and targeted therapy. Because 
the breast cancer, that is metastatic beyond the regional node, is rarely cured, systemic 
therapy is the primary treatment for metastatic disease with locoregional treatment reserved 
for symptom control and is used possibly in some patients with limited metastatic disease 
who may achieve prolonged remissions. 
3.1 Surgery  
Surgery is the oldest and still the most widely used treatment modality that is available 
for breast cancer patients and can be accomplished by mastectomy, removal of the entire 
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breast or by breast-conserving surgery often termed lumpectomy of cancer. If the tumor is 
detected at early stage before spreading, surgery alone might be sufficient to reach 
complete remission. When the tumor is detected after spreading with distant metastases, 
surgery is frequently used in combination with radiotherapy or chemotherapy (Keshtgar 
et al, 2010). 
3.2 Radiotherapy 
In radiotherapy, also known as radiation therapy, high-energy ionizing radiation such as x 
or γ-rays is irradiated to the tumor tissues for killing the cancer cells. Radiation can be 
delivered via external radiation from a source outside the body directing to the tumor or by 
an internal radiation source (brachytherapy) which is positioned inside the body adjacent to 
or inside the tumor. Radiation must affect only cancer cells in the treated area and not 
normal cells. To treat secondary tumors and stopping growth of any remaining tumor cells, 
radiation therapy is often used in conjunction with other treatment modalities like 
chemotherapy and surgery (Luini et al., 2007). 
3.3 Chemotherapy  
The use of cytotoxic chemotherapy, in both advanced and early stage of breast cancer, has 
made significant progress in the last decade (Hassan et al., 2010). Chemotherapy is a 
systemic breast cancer therapy and compared to surgery and radiation therapy, it has one 
advantage. It is able to eliminate cancer cells throughout the entire body. Chemotherapeutic 
agents currently approved for treatment of breast cancer are: anthracycline, alkaloids, 
topoisomerase inhibitors, alkylating agents, and antimetabolites. The important 
disadvantage of chemotherapy is side effects of drugs such as nausea, vomiting, fatigue, 
sore mouth, diarrhea, constipation and decreased blood cells count. These side effects can 
impact patient ability to tolerate treatment, maintain a healthy diet, stay active and enjoy a 
good quality of life (Hassan et al., 2010). 
3.4 Hormone therapy 
Hormone therapy, also called "endocrine-based therapy", is a systemic treatment and plays 
an important role in breast cancer therapy. It is the first type of systemic treatment directed 
at a specific target, the hormone-dependent cancer cell, and may be referred to "targeted 
therapy" (Hind et al., 2007). The purpose of hormone therapy is to add, block or remove 
hormones. There are certain hormones that can attach to breast cancer cells and affect their 
ability to multiply such as tamoxifen, fareston, arimidex and so on (Jones& Buzdar, 2004). 
Hormone therapy may be used alone or in combination with radiation therapy. It is rarely 
used simultaneously, but is often used following chemotherapy. The benefits and side 
effects of the drugs relate only to the natural effects of the hormone itself and the hormone-
cancer cell interaction. For that reason, the typical side effects seen with chemotherapy are 
not present with hormone or endocrine-based therapies (Hind et al., 2007). 
3.5 Immunotherapy 
Immunotherapy (also called biological therapy, biotherapy or biological response modifier 
therapy) of breast cancer uses patient body's natural ability (immune system) to fight the 
disease and/or to lesson treatment-related side effects (Diss et al., 1997b). The 
immunotherapy drugs are bound to specific proteins on breast cancer cells to slow or stop 
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DOT techniques (Berghammer et al., 2001). The differences in tumor biology such as blood 
flow, metabolism, concentration of specific receptors or differences in antigen expression are 
exploited in order to target radionuclides to the tumor tissue (Glasspool & Evans, 2000). The 
major advantage of nuclear medicine is that just picomolar concentrations of radiotracers are 
required to provide a measurable signal (Cook et al., 2003). 
2.7.1 Scintimammography 
Future developments in nuclear medicine are in the area of development of specialized 
imaging systems. One example of specialized gamma camera is scintimammography in 
imaging of breast and axillary nodes. Scintimammography term is given to radionuclide 
imaging of breast cancer (Schillaci et al., 2007). Scintimammography is performed after 
injection of the radiopharmaceutical into an arm vein contralateral to the suspected tumor or 
into a pedal vein and the subsequent imaging with right and left lateral, prone and supine 
views, covering both breasts and both axillae and later computer acquisition of data 
(Nguyen et al., 2009; Brem et al., 2005). Most studies evaluating the role of 
scintimammography, have compared it with mammography, ultrasound and MRI. Its 
sensitivity has ranged from 62% to 93% with specificity from 79% to 94% (Schillaci & 
Buscombe, 2004). Its sensitivity is greater for palpable lesions. Current recommendations for 
the use of scintimammography are (Fass, 2008):  
1. As a general adjunct to mammography to differentiate between benign and malignant 
breast lesions in patients with palpable masses or suspicious mammograms. 
2. In patients referred for biopsy when lesions are considered to have a low probability of 
malignancy. 
3. In patients with probably benign findings on mammography, but are recommended for 
close follow-up (e.g. repeated mammography in 3–6 months).  
4. In patients who have dense breast tissues and are considered difficult to evaluate on 
mammography. 
5. For detection of axillary lymph node metastases in patients with confirmed breast cancer. 
The main limitations of scintimamography are low sensitivity and high dose of radionuclide 
that is used for imaging. Currently, for overcoming the cited limitations, the researchers are 
studying on targeted molecular imaging methods. 
3. Treatment of breast cancer  
To understand the diagnostic needs for breast cancer, it is important to understand the 
range of approaches for breast cancer treatment. With the exception of early and late stage 
disease, almost all breast cancer therapy methods, involve a combination of locoregional 
and systemic treatments. Locoregional therapy includes surgery and radiotherapy and 
systemic therapy includes chemotherapy, hormone therapy and targeted therapy. Because 
the breast cancer, that is metastatic beyond the regional node, is rarely cured, systemic 
therapy is the primary treatment for metastatic disease with locoregional treatment reserved 
for symptom control and is used possibly in some patients with limited metastatic disease 
who may achieve prolonged remissions. 
3.1 Surgery  
Surgery is the oldest and still the most widely used treatment modality that is available 
for breast cancer patients and can be accomplished by mastectomy, removal of the entire 
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breast or by breast-conserving surgery often termed lumpectomy of cancer. If the tumor is 
detected at early stage before spreading, surgery alone might be sufficient to reach 
complete remission. When the tumor is detected after spreading with distant metastases, 
surgery is frequently used in combination with radiotherapy or chemotherapy (Keshtgar 
et al, 2010). 
3.2 Radiotherapy 
In radiotherapy, also known as radiation therapy, high-energy ionizing radiation such as x 
or γ-rays is irradiated to the tumor tissues for killing the cancer cells. Radiation can be 
delivered via external radiation from a source outside the body directing to the tumor or by 
an internal radiation source (brachytherapy) which is positioned inside the body adjacent to 
or inside the tumor. Radiation must affect only cancer cells in the treated area and not 
normal cells. To treat secondary tumors and stopping growth of any remaining tumor cells, 
radiation therapy is often used in conjunction with other treatment modalities like 
chemotherapy and surgery (Luini et al., 2007). 
3.3 Chemotherapy  
The use of cytotoxic chemotherapy, in both advanced and early stage of breast cancer, has 
made significant progress in the last decade (Hassan et al., 2010). Chemotherapy is a 
systemic breast cancer therapy and compared to surgery and radiation therapy, it has one 
advantage. It is able to eliminate cancer cells throughout the entire body. Chemotherapeutic 
agents currently approved for treatment of breast cancer are: anthracycline, alkaloids, 
topoisomerase inhibitors, alkylating agents, and antimetabolites. The important 
disadvantage of chemotherapy is side effects of drugs such as nausea, vomiting, fatigue, 
sore mouth, diarrhea, constipation and decreased blood cells count. These side effects can 
impact patient ability to tolerate treatment, maintain a healthy diet, stay active and enjoy a 
good quality of life (Hassan et al., 2010). 
3.4 Hormone therapy 
Hormone therapy, also called "endocrine-based therapy", is a systemic treatment and plays 
an important role in breast cancer therapy. It is the first type of systemic treatment directed 
at a specific target, the hormone-dependent cancer cell, and may be referred to "targeted 
therapy" (Hind et al., 2007). The purpose of hormone therapy is to add, block or remove 
hormones. There are certain hormones that can attach to breast cancer cells and affect their 
ability to multiply such as tamoxifen, fareston, arimidex and so on (Jones& Buzdar, 2004). 
Hormone therapy may be used alone or in combination with radiation therapy. It is rarely 
used simultaneously, but is often used following chemotherapy. The benefits and side 
effects of the drugs relate only to the natural effects of the hormone itself and the hormone-
cancer cell interaction. For that reason, the typical side effects seen with chemotherapy are 
not present with hormone or endocrine-based therapies (Hind et al., 2007). 
3.5 Immunotherapy 
Immunotherapy (also called biological therapy, biotherapy or biological response modifier 
therapy) of breast cancer uses patient body's natural ability (immune system) to fight the 
disease and/or to lesson treatment-related side effects (Diss et al., 1997b). The 
immunotherapy drugs are bound to specific proteins on breast cancer cells to slow or stop 
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their growth. Currently, there are at least three FDA-approved antibodies for targeting of 
breast cancers (Stipsanelli & Valsamaki, 2005; Disis et al., 1994a, 1997b): 
• Trastuzumab (Herceptin) that is bound to the extracellular domain of Her2/neu 
receptor 
• Pertuzumab that is bound to a different epitope of Her2/neu receptor 
• Bevacizumab that is bound to vascular endothelial growth factor receptors (VEGFRs). 
Immunotherapy of breast cancer may cause side effects such as fever, chill, pain, weakness, 
nausea, vomiting, diarrhea, headache, and rash. These side effects generally become less 
severe after the first treatment. In addition, immunotherapy is a very expensive method for 
patients. 
4. Targeted molecular imaging and therapy 
The researchers are trying to improve the methods that can decrease the dose of drugs and 
transfer them just to the tumor cells with high efficiency and kill the cancer cells without 
affecting healthy cells. The recent improvements in biology of tumor cells, have introduced 
new methods in diagnosis and therapy of cancer named targeted molecular imaging and 
therapy (Sawyers, 2004). The knowledge of the diversities between tumor and normal 
tissues is the key to identify novel targets for new selective diagnosis and therapeutic 
strategies (Gasparini et al., 2005). The aim of these methods is to deliver a drug for therapy 
or a contrast agent for imaging just to the tumor site or cancer cells using different 
technologies. In these methods, not only the dose of drugs is decreased, but also the damage 
to the normal tissues is decreased. On the other hand, the probability of the diagnosis and 
therapy is increased too. In addition, the targeting methods in comparison with other 
methods have fewer side effects and the patients tolerate less physical and mental hurts. 
Tumor markers are used for targeting cancer cells in molecular imaging and therapy 
methods. Tumor marker is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes or pharmacologic responses to a therapeutic 
intervention (Meel et al., 2010). 
4.1 Targeted molecular imaging  
Recent advances in molecular and cellular biology have facilitated the discovery of novel 
molecular targets on tumor cells such as key molecules involved in proliferation, 
differentiation, cell death and apoptosis, angiogenesis, invasion and metastasis or associated 
with cancer cell stemness (William et al., 2008). Molecular imaging is defined as 
visualization, characterization and measurement of biological processes at the molecular 
and cellular levels in human beings and other living systems (Pysz et al., 2010). Today, 
molecular imaging is increasingly used in clinical oncology, because molecular imaging is a 
non-invasive diagnostic method that allows for more sensitive and specific monitoring of 
key cancer-related molecular targets in vivo and is expected to play an important role in 
future cancer diagnosis. Generally, molecular targets can be applied to (Meel et al., 2010; 
Neves & Brindle, 2006):  
1. Detection: screening high-risk groups and large populations of asymptomatic 
individuals  
2. Diagnosis of cancer in individuals with signs or symptoms 
3. As a prognostic indicator 
4. Localization of tumor and metastases 
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5. Staging the extent of disease 
6. Monitor the clinical course of cancer patients 
7. Determine the effectiveness of therapy 
8. Early detection of recurrent or metastatic cancer 
A molecular imaging agent typically consists of a signaling moiety (radionuclide in nuclear 
medicine) and a functional target. Specific targeting of cancer-associated targets with 
radiolabeled targeting agents (e.g. antibodies, peptides and non-immunoglobulin proteins) 
and the use of subsequent visualization systems like gamma camera, SPECT and PET are 
examples of molecular imaging methods in nuclear medicine. 
4.2 Targeted molecular therapy 
Major advances in molecular biology, cellular biology and genomics have substantially 
improved our understanding of cancers. Now, these advances are being translated into 
therapy. The term targeted therapy ideally connotes the ability to identify a known 
therapeutic target that is important in the biology of cancer cells and use a specific agent that 
can treat the disease by modifying the expression or activity of the target in the growth and 
progression of the cancer. With this approach, only patients with a likelihood of benefit are 
treated, so the therapeutic index will hopefully be improved. Selecting a biologically active 
target is usually the first step in molecular imaging research and leads to the design of a 
molecular imaging agent. Potential targets include proteins, DNA, RNA, carbohydrates and 
lipids. Several properties of these biomolecules as imaging targets need to be considered 
that are summarized in the following (Meel et al., 2010):  
1. High specificity (i.e. binding specifically to a tumor-associated molecular target with 
minimal non-specific binding to non-target molecules).  
2. High target binding affinity (low subnanomolar binding is typically desired).  
3. Small size (enabling fast distribution to the tumor and quick clearance from the blood 
and other compartments).  
4. High structural stability for labeling with signaling agents. 
5. Available ligands that specifically target these biomolecules. 
5. Targeted molecular agents of breast cancer 
Molecular probes in nuclear medicine are the proof of principle for targeted molecular 
imaging and therapy. Molecular nuclear medicine holds the unique potential of being able 
to find, diagnose and treat diseases as well as to monitor treatment response. Several 
molecular targeting agents have been approved for clinical uses in nuclear medicine. Many 
others are under preclinical evaluation with high potential for clinical applications. The 
molecular targeting agents, that are common in nuclear medicine, are small molecules, 
oligonucleotides /PNAs, affibodys, peptides and antibodies.  
5.1 Small molecules 
Several radiolabeled small molecules have been applied for the detection and therapy of 
breast and prostate tumors and leukemia (Cornelissen & Vallis, 2010). For example, 
radiolabeled estrogens and estrogen receptor antagonists are bound to the estrogen receptor, 
a nuclear membrane receptor, which then translocate to the nucleus. 123I- tamoxifen, an 
estrogen receptor (ER) antagonist, has been used as a diagnostic tool to determine estrogen 
receptor status in patients with breast or head-and-neck cancer (Wiele et al., 2001). Other 
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their growth. Currently, there are at least three FDA-approved antibodies for targeting of 
breast cancers (Stipsanelli & Valsamaki, 2005; Disis et al., 1994a, 1997b): 
• Trastuzumab (Herceptin) that is bound to the extracellular domain of Her2/neu 
receptor 
• Pertuzumab that is bound to a different epitope of Her2/neu receptor 
• Bevacizumab that is bound to vascular endothelial growth factor receptors (VEGFRs). 
Immunotherapy of breast cancer may cause side effects such as fever, chill, pain, weakness, 
nausea, vomiting, diarrhea, headache, and rash. These side effects generally become less 
severe after the first treatment. In addition, immunotherapy is a very expensive method for 
patients. 
4. Targeted molecular imaging and therapy 
The researchers are trying to improve the methods that can decrease the dose of drugs and 
transfer them just to the tumor cells with high efficiency and kill the cancer cells without 
affecting healthy cells. The recent improvements in biology of tumor cells, have introduced 
new methods in diagnosis and therapy of cancer named targeted molecular imaging and 
therapy (Sawyers, 2004). The knowledge of the diversities between tumor and normal 
tissues is the key to identify novel targets for new selective diagnosis and therapeutic 
strategies (Gasparini et al., 2005). The aim of these methods is to deliver a drug for therapy 
or a contrast agent for imaging just to the tumor site or cancer cells using different 
technologies. In these methods, not only the dose of drugs is decreased, but also the damage 
to the normal tissues is decreased. On the other hand, the probability of the diagnosis and 
therapy is increased too. In addition, the targeting methods in comparison with other 
methods have fewer side effects and the patients tolerate less physical and mental hurts. 
Tumor markers are used for targeting cancer cells in molecular imaging and therapy 
methods. Tumor marker is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes or pharmacologic responses to a therapeutic 
intervention (Meel et al., 2010). 
4.1 Targeted molecular imaging  
Recent advances in molecular and cellular biology have facilitated the discovery of novel 
molecular targets on tumor cells such as key molecules involved in proliferation, 
differentiation, cell death and apoptosis, angiogenesis, invasion and metastasis or associated 
with cancer cell stemness (William et al., 2008). Molecular imaging is defined as 
visualization, characterization and measurement of biological processes at the molecular 
and cellular levels in human beings and other living systems (Pysz et al., 2010). Today, 
molecular imaging is increasingly used in clinical oncology, because molecular imaging is a 
non-invasive diagnostic method that allows for more sensitive and specific monitoring of 
key cancer-related molecular targets in vivo and is expected to play an important role in 
future cancer diagnosis. Generally, molecular targets can be applied to (Meel et al., 2010; 
Neves & Brindle, 2006):  
1. Detection: screening high-risk groups and large populations of asymptomatic 
individuals  
2. Diagnosis of cancer in individuals with signs or symptoms 
3. As a prognostic indicator 
4. Localization of tumor and metastases 
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5. Staging the extent of disease 
6. Monitor the clinical course of cancer patients 
7. Determine the effectiveness of therapy 
8. Early detection of recurrent or metastatic cancer 
A molecular imaging agent typically consists of a signaling moiety (radionuclide in nuclear 
medicine) and a functional target. Specific targeting of cancer-associated targets with 
radiolabeled targeting agents (e.g. antibodies, peptides and non-immunoglobulin proteins) 
and the use of subsequent visualization systems like gamma camera, SPECT and PET are 
examples of molecular imaging methods in nuclear medicine. 
4.2 Targeted molecular therapy 
Major advances in molecular biology, cellular biology and genomics have substantially 
improved our understanding of cancers. Now, these advances are being translated into 
therapy. The term targeted therapy ideally connotes the ability to identify a known 
therapeutic target that is important in the biology of cancer cells and use a specific agent that 
can treat the disease by modifying the expression or activity of the target in the growth and 
progression of the cancer. With this approach, only patients with a likelihood of benefit are 
treated, so the therapeutic index will hopefully be improved. Selecting a biologically active 
target is usually the first step in molecular imaging research and leads to the design of a 
molecular imaging agent. Potential targets include proteins, DNA, RNA, carbohydrates and 
lipids. Several properties of these biomolecules as imaging targets need to be considered 
that are summarized in the following (Meel et al., 2010):  
1. High specificity (i.e. binding specifically to a tumor-associated molecular target with 
minimal non-specific binding to non-target molecules).  
2. High target binding affinity (low subnanomolar binding is typically desired).  
3. Small size (enabling fast distribution to the tumor and quick clearance from the blood 
and other compartments).  
4. High structural stability for labeling with signaling agents. 
5. Available ligands that specifically target these biomolecules. 
5. Targeted molecular agents of breast cancer 
Molecular probes in nuclear medicine are the proof of principle for targeted molecular 
imaging and therapy. Molecular nuclear medicine holds the unique potential of being able 
to find, diagnose and treat diseases as well as to monitor treatment response. Several 
molecular targeting agents have been approved for clinical uses in nuclear medicine. Many 
others are under preclinical evaluation with high potential for clinical applications. The 
molecular targeting agents, that are common in nuclear medicine, are small molecules, 
oligonucleotides /PNAs, affibodys, peptides and antibodies.  
5.1 Small molecules 
Several radiolabeled small molecules have been applied for the detection and therapy of 
breast and prostate tumors and leukemia (Cornelissen & Vallis, 2010). For example, 
radiolabeled estrogens and estrogen receptor antagonists are bound to the estrogen receptor, 
a nuclear membrane receptor, which then translocate to the nucleus. 123I- tamoxifen, an 
estrogen receptor (ER) antagonist, has been used as a diagnostic tool to determine estrogen 
receptor status in patients with breast or head-and-neck cancer (Wiele et al., 2001). Other 
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small-molecule radiopharmaceuticals include 125I-daunorubicin, 111In-folate, 123/131I 
metaiodo- benzyl-guanidine (MIBG), 125I-iododeoxyuridine and 111In-bleomycin (Jalilian 
et al., 2006, 2007). Small molecules such as tyrosine kinase inhibitors (TKIs) are less specific 
than therapeutic monoclonal antibodies (mAbs) (Huang & Armstrong,2004) and some of 
them can inhibit multiple targets simultaneously including cell receptors or signal 
transduction pathway proteins leading to a higher risk for toxicity (Xia et al., 2005). 
5.2 Oligonucleotides/ PNAs/ MORF 
The natural ability of oligonucleotides and the oligonucleotide mimetic peptide nucleic 
acids (PNAs) and phosphorodiamidate morpholinos (MORF) to anneal with RNA and DNA 
makes them the appealing vehicles to bring radionuclides in close proximity to the 
RNA/DNA. Both 125I and 111In have been used to radiolabel oligonucleotides and have 
been applied successfully to target over-expression of certain genes involved with cancer 
(Cornelissen & Vallis, 2010).  
Aptamers are synthetically based DNA or RNA oligonucleotides that are highly stable 
structures and are considered to have low immunogenicity. They are selected for their 
ability to bind to a target of interest (Perkins & Missailidis, 2007). Hicke et al. demonstrated 
that the aptamers cleared quickly from the blood, reaching maximum tumor uptake within 
10 min, but then decreasing to approximately 2% by 3 h. However, the rapid clearance from 
the blood and tissues resulted in highly favorable tumor/blood and kidney ratios but there 
was considerable additional clearance of the 99mTc through the liver and intestines (Hicke 
et al., 2006). However, using aptamers as the radiopharmaceuticals needs further 
improvements. 
5.3 Affibody molecules 
Affibody molecules are 58 amino-acid, three-helix bundle affinity proteins and are derived 
from the β-domain of the five-domain Ig-binding region protein A from Staphylococcus 
aureus (Orlova et al., 2007). They represent highly specific binders, selected by phage display 
from a library generated by randomization of 13 amino acids in helix 1 and 2, which are 
responsible for the Fc-binding site. Recently, affibody molecules have been investigated for 
tumor targeting purposes both for targeted imaging and therapy. The first generated and 
used affibody molecule for radionuclide imaging was ZHER2 with a binding affinity of 50 nM 
to HER2 protein (Capalaet al., 2009). Affibody molecules represent a promising novel class 
of targeting molecules that can be used as relatively small, high-affinity, cancer-specific 
ligands and that are well suited for tumor molecular imaging and therapy, providing a 
possible new route for imaging of tumor-specific receptors (Orlova et al., 2006). Since these 
structures are derived from a Staphylococcal protein, the potential immunogenicity of these 
molecules may be a concern (Sharkey & Goldenberg, 2008). 
5.4 Peptides 
During the past decade, proof of the principle that peptide receptors can be used 
successfully for in vivo targeting of human cancers, has been provided (Ferro-Flores et al., 
2010). Peptides used for tumor targeting show some advantages over antibodies. Peptides 
are small and show rapid diffusion into the target tissues resulting in rapid 
pharmacokinetics (Ferro-Flores et al., 2010). Their fast blood clearance can lead to high 
tumor to background ratio shortly after administration of the radiopeptide. In addition, they 
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can tolerate harsh chemical conditions and are easy to be purified and modified. The 
common peptides that are used in molecular imaging and therapy of breast cancer are 
somatostatin, bombesin, neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) 
(Ferro-Flores et al., 2010). The important disadvantage of peptides is rapid degrading from 
blood by endogenous peptidases and proteases (Ferro-Flores et al., 2010). 
5.5 Antibodies 
Antibodies are now increasingly recognized as important biological agents for the detection 
and treatment of cancer (Sharkey & Goldenberg, 2006). In the 1970s, polyclonal antibodies 
were already essential components of medical diagnosis as well as for therapy as antitoxins 
for the prevention of tetanus and other diseases (Goldsmith & Signore, 2010). The 
development of monoclonal antibody technology by Kohler and Milstein in the 1970s 
accelerated the exploitation of the chemo-specificity of antibodies for diagnostic and 
therapeutic purposes (Goldsmith & Signore, 2010). In the last two decades several different 
monoclonal antibodies have been approved by the Food and Drug Administration (FDA) for 
therapeutic purposes and some of these have also been radiolabeled for diagnostic and 
therapeutic purposes (Xiao et al., 2008). For imaging, it is highly desirable that targeting 
agents are rapidly excreted from the body. It is also essential that the targeting agent binds 
rapidly to its target, reducing the time between injection and imaging. The application of 
monoclonal antibodies for therapy and diagnosis is limited by generation of an immune 
response known as human anti-mouse antibody (HAMA) response (Salouti et al., 2011). One 
of the most successful approaches to overcome immunogenicity is ”humanization” of rodent 
mAbs by genetic engineering (Waldmann&Morris, 2008). A simple approach to make an 
antibody to be more humanized is the replacement of the constant domains of the antibody 
with constant domains of a human antibody. The resulting chimeric antibody contains only 
the variable regions of murine origin and would therefore be expected to be less 
immunogenic in people. Many chimeric antibodies have been prepared and shown to retain 
the full antigen binding ability of the parent murine antibody as well as taking on the 
constant region effecter functions of the human antibody used (Waldmann&Morris, 2008). 
Humanization of rodent antibodies can be taken further to produce fully humanized 
antibodies in the form of reshaped, engineered human antibodies, in which much of the 
variable domain sequences are also replaced by human antibody sequence. In these 
approaches, the antigen binding loops are derived from the rodent antibody and much of the 
supporting framework is humanized (Waldmann&Morris, 2008). Targeting agents that have 
been approved for breast cancer include trastuzumab and pertuzumab directed against 
human epidermal growth factor receptor 2 (HER2) and bevacizumab, directed against 
vascular endothelial growth factor (VEGF) (Goldsmith & Signore, 2010). Several other 
targeting agents are currently under evaluation in preclinical and clinical trials (Carl & 
Roland, 2001). 
5.5.1 Antibody derivatives 
The use of mAbs has presented challenges in radionuclide imaging. Because of their large 
size (molecular weight of ~150 kDa), mAbs penetrate slowly and have long residence time 
in the blood circulation (days-weeks) due to active recycling by the neonatal Fc receptor, 
leading to limited tumor-to-normal organs ratio in biodistribution and low contrast images 
for the detection of biomarkers/tumors (Jonathan et al., 2000). Advances in protein 
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small-molecule radiopharmaceuticals include 125I-daunorubicin, 111In-folate, 123/131I 
metaiodo- benzyl-guanidine (MIBG), 125I-iododeoxyuridine and 111In-bleomycin (Jalilian 
et al., 2006, 2007). Small molecules such as tyrosine kinase inhibitors (TKIs) are less specific 
than therapeutic monoclonal antibodies (mAbs) (Huang & Armstrong,2004) and some of 
them can inhibit multiple targets simultaneously including cell receptors or signal 
transduction pathway proteins leading to a higher risk for toxicity (Xia et al., 2005). 
5.2 Oligonucleotides/ PNAs/ MORF 
The natural ability of oligonucleotides and the oligonucleotide mimetic peptide nucleic 
acids (PNAs) and phosphorodiamidate morpholinos (MORF) to anneal with RNA and DNA 
makes them the appealing vehicles to bring radionuclides in close proximity to the 
RNA/DNA. Both 125I and 111In have been used to radiolabel oligonucleotides and have 
been applied successfully to target over-expression of certain genes involved with cancer 
(Cornelissen & Vallis, 2010).  
Aptamers are synthetically based DNA or RNA oligonucleotides that are highly stable 
structures and are considered to have low immunogenicity. They are selected for their 
ability to bind to a target of interest (Perkins & Missailidis, 2007). Hicke et al. demonstrated 
that the aptamers cleared quickly from the blood, reaching maximum tumor uptake within 
10 min, but then decreasing to approximately 2% by 3 h. However, the rapid clearance from 
the blood and tissues resulted in highly favorable tumor/blood and kidney ratios but there 
was considerable additional clearance of the 99mTc through the liver and intestines (Hicke 
et al., 2006). However, using aptamers as the radiopharmaceuticals needs further 
improvements. 
5.3 Affibody molecules 
Affibody molecules are 58 amino-acid, three-helix bundle affinity proteins and are derived 
from the β-domain of the five-domain Ig-binding region protein A from Staphylococcus 
aureus (Orlova et al., 2007). They represent highly specific binders, selected by phage display 
from a library generated by randomization of 13 amino acids in helix 1 and 2, which are 
responsible for the Fc-binding site. Recently, affibody molecules have been investigated for 
tumor targeting purposes both for targeted imaging and therapy. The first generated and 
used affibody molecule for radionuclide imaging was ZHER2 with a binding affinity of 50 nM 
to HER2 protein (Capalaet al., 2009). Affibody molecules represent a promising novel class 
of targeting molecules that can be used as relatively small, high-affinity, cancer-specific 
ligands and that are well suited for tumor molecular imaging and therapy, providing a 
possible new route for imaging of tumor-specific receptors (Orlova et al., 2006). Since these 
structures are derived from a Staphylococcal protein, the potential immunogenicity of these 
molecules may be a concern (Sharkey & Goldenberg, 2008). 
5.4 Peptides 
During the past decade, proof of the principle that peptide receptors can be used 
successfully for in vivo targeting of human cancers, has been provided (Ferro-Flores et al., 
2010). Peptides used for tumor targeting show some advantages over antibodies. Peptides 
are small and show rapid diffusion into the target tissues resulting in rapid 
pharmacokinetics (Ferro-Flores et al., 2010). Their fast blood clearance can lead to high 
tumor to background ratio shortly after administration of the radiopeptide. In addition, they 
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can tolerate harsh chemical conditions and are easy to be purified and modified. The 
common peptides that are used in molecular imaging and therapy of breast cancer are 
somatostatin, bombesin, neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) 
(Ferro-Flores et al., 2010). The important disadvantage of peptides is rapid degrading from 
blood by endogenous peptidases and proteases (Ferro-Flores et al., 2010). 
5.5 Antibodies 
Antibodies are now increasingly recognized as important biological agents for the detection 
and treatment of cancer (Sharkey & Goldenberg, 2006). In the 1970s, polyclonal antibodies 
were already essential components of medical diagnosis as well as for therapy as antitoxins 
for the prevention of tetanus and other diseases (Goldsmith & Signore, 2010). The 
development of monoclonal antibody technology by Kohler and Milstein in the 1970s 
accelerated the exploitation of the chemo-specificity of antibodies for diagnostic and 
therapeutic purposes (Goldsmith & Signore, 2010). In the last two decades several different 
monoclonal antibodies have been approved by the Food and Drug Administration (FDA) for 
therapeutic purposes and some of these have also been radiolabeled for diagnostic and 
therapeutic purposes (Xiao et al., 2008). For imaging, it is highly desirable that targeting 
agents are rapidly excreted from the body. It is also essential that the targeting agent binds 
rapidly to its target, reducing the time between injection and imaging. The application of 
monoclonal antibodies for therapy and diagnosis is limited by generation of an immune 
response known as human anti-mouse antibody (HAMA) response (Salouti et al., 2011). One 
of the most successful approaches to overcome immunogenicity is ”humanization” of rodent 
mAbs by genetic engineering (Waldmann&Morris, 2008). A simple approach to make an 
antibody to be more humanized is the replacement of the constant domains of the antibody 
with constant domains of a human antibody. The resulting chimeric antibody contains only 
the variable regions of murine origin and would therefore be expected to be less 
immunogenic in people. Many chimeric antibodies have been prepared and shown to retain 
the full antigen binding ability of the parent murine antibody as well as taking on the 
constant region effecter functions of the human antibody used (Waldmann&Morris, 2008). 
Humanization of rodent antibodies can be taken further to produce fully humanized 
antibodies in the form of reshaped, engineered human antibodies, in which much of the 
variable domain sequences are also replaced by human antibody sequence. In these 
approaches, the antigen binding loops are derived from the rodent antibody and much of the 
supporting framework is humanized (Waldmann&Morris, 2008). Targeting agents that have 
been approved for breast cancer include trastuzumab and pertuzumab directed against 
human epidermal growth factor receptor 2 (HER2) and bevacizumab, directed against 
vascular endothelial growth factor (VEGF) (Goldsmith & Signore, 2010). Several other 
targeting agents are currently under evaluation in preclinical and clinical trials (Carl & 
Roland, 2001). 
5.5.1 Antibody derivatives 
The use of mAbs has presented challenges in radionuclide imaging. Because of their large 
size (molecular weight of ~150 kDa), mAbs penetrate slowly and have long residence time 
in the blood circulation (days-weeks) due to active recycling by the neonatal Fc receptor, 
leading to limited tumor-to-normal organs ratio in biodistribution and low contrast images 
for the detection of biomarkers/tumors (Jonathan et al., 2000). Advances in protein 
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engineering have led to a number of alternative constructs for imaging and therapy. These 
alternatives characterized by smaller size include: 
• Fragment antigen binding (Fab): The area around the antibody hinge is more 
susceptible to proteolysis than the tightly folded domains and thus this is the point at 
which cleavage usually takes place. Proteolysis above the disulphide bonds in the hinge 
region with, for example papain, results in Fab fragments which are monovalent for 
antigen binding (~55 kDa). 
• Divalent fragment antigen binding (F(ab´)2): If antibody proteolysis occurs below the 
hinge disulphide bonds, with enzymes such as pepsin, it results in a divalent F(ab´)2 
fragment (~110 kDa). 
• Single chain fragment (scFv): This antibody fragment consists only the variable heavy 
(VH) and the variable light (VL) chain of an antibody tethered together by a flexible 
linker, attaching the carboxyl terminus of the VL sequence to the amino terminus of the 
VH sequence (~25 kDa). 
• Nanobody: Nanobodies are small antibody fragments (15 kDa) derived from the 
naturally occurring heavy-chain-only antibodies (Friedman. et al., 2009). These 
fragments have also been referred to VHH as they consist of a variable domain (VH) of 
the heavy chain (H) of antibodies (Meel et al., 2010). 
When compared to intact IgGs, these antibody fragments have the advantages of faster 
biodistribution, rapid penetration into the tissues and improved tumor-to-normal organs 
ratio. These forms (e.g. F(ab')2, Fab or other molecular constructs) achieve maximum tumor 
accretion more quickly with improved tumor/blood ratio that make earlier visualization, 
possible (Colcher et al., 1998). The use of fragments of antibodies has also been advocated as 
a possible means to reduce the immunogenicity of rodent antibodies in human beings. 
Antibody fragments generated by proteolysis or by genetic engineering, have been tested 
both in vitro and in vivo. As monovalent binding entities, antibody fragments suffer from 
relatively low avidity binding. Hence, to increase their binding avidity, they have also been 
engineered into multivalent constructs include: 
• Diabody: ”Diabody” is one of the engineered multivalent constructs. Diabodies can be 
produced to high levels in the form of stable dimmers (Wu & Yazaki, 2000; Hudson & 
Kortt, 1999; Lawrence et al., 1998). However, the stability of such dimeric species varies 
from one antibody to another. 
• Tribody: In some cases, particularly with direct fusions of VH and VL, stable trimeric 
species are produced which have been termed ”tribody” (Todorovskaet al., 2001). Some 
tribodies show improved avidity for antigens as expected from the increased number of 
binding sites, although this is not always the case (Todorovskaet al., 2001).  
6. Target antigens 
In recent years, there has been a significant improvement in the understanding of molecular 
events and critical pathways involved in breast cancer. The studies have confirmed the 
feasibility of using radiolabeled antibodies for imaging and therapy of primary and 
metastatic breast cancer and that a diverse array of molecules can serve as targets for 
localizing antibodies (Carlos et al., 2006). Theoretically, an ideal target for radionuclide 
detection and therapy of metastatic breast cancer would be tumor-specific, generously 
expressed on all the breast cancer cells, not expressed by normal tissues and not released 
into the blood circulation (Mohammadnejad et al., 2010). For antibody screening of breast 
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cancer, it is essential that the antibody is well characterized with little cross-reactivity to 
other antigens. The antibodies show cross-reactivity with, e.g. leucocytes, potentially 
yielding false-positive images. The majority of breast cancer targeting antibody studies have 
used antibodies against MUC1, CEA, TAG-72 and L6 antigens (Carlos et al., 2006).  
6.1 CEA  
First described by Gold and Freedman in 1965, CEA was thought to be a specific marker for 
colon adenocarcinoma. However, subsequent studies demonstrated CEA expression in 
other human adenocarcinomas including the surface membrane of breast cancer cells 
(Jonathan et al., 2000). Expression of CEA has been reported in 10% to 95% of breast cancers 
(Hong et al., 2008, Denardo, 2005). Preliminary studies with 99mTc-labeled CEA antibody 
appeared to indicate a useful role for this agent in distinguishing between benign and 
malignant breast lesions in patients with indeterminate mammographic findings (Denardo, 
2005). Therapy studies specifically in breast cancer have also been performed with T84.66 
(Koppe et al., 2005). T84.66 is a well characterized murine IgG1 antibody with high 
specificity and affinity for a unique epitope of CEA molecules. A chimeric form of T84.66 
(cT84.66) has been also used in clinical studies for the scintigraphic detection of breast 
cancer and in phase I/II therapy trials and scFv-based anti-CEA constructs are under study 
(Denardo, 2005). Another mAb that has been classified in this group is NP4. NP-4 belongs to 
the murine IgG1 subclass and is specific for CEA, reacting with a class III peptide epitope of 
CEA molecules (Richman & DeNardo, 2001). 
6.2 MUC-1  
MUC-1 mucins are large, complex glycoproteins that have a polypeptide core with multiple 
oligosaccharide side chains (Mukhopadhyay et al., 2011). The mature molecule is anchored 
within the cell surface by a characteristic transmembrane domain, but most of the mucins 
are expressed extracellular. This polar distribution is lost with neoplastic transformation and 
increased heterogenous MUC-1 synthesis is a common feature of breast cancer. This 
glycoprotein is aberrantly over expressed in adenocarcinomas including 80% of breast 
cancers (Salouti et al., 2011). Targeting, using antibodies directed against the MUC-1 antigen 
has been tested in patients with breast cancer using various antibodies. BrE-3 is an IgG1 
antibody directed against the peptide epitope of the MUC-1 antigen that have been 
evaluated for RIT (Mohammadnejad et al, 2010). The studies of the application of BrE-3 
mAbs in patients with breast cancer showed minimal cross reactivity with normal breast 
tissues (Howell et al., 1995; Blank et al., 1992). Because the majority of the patients rapidly 
showed HAMA response against the murine BrE-3 mAb, a humanized version of BrE-3 
(hBrE-3) was developed (Kramer et al., 1993). Kramer and colleagues investigated the 
pharmacokinetics and biodistribution of 111In-MX-DTPA-labeled hBrE-3 in seven patients 
with metastatic breast cancer (Kramer et al., 1993). hBrE-3 was proved to have a lower 
immunogenicity compared to murine BrE-3 (only one patient developed a HAMA response) 
while tumor-targeting properties were preserved (Denardo, 2005). Monoclonal antibody 
170H.82 (m170) is a murine IgG1 prepared using a synthetic asialo GM1 terminal 
disaccharide immunogen related to the Thomsen–Friedenreich disaccharide and selected by 
reactivity with MUC-1 expressing cancer cell membranes (Jonathan et al., 2000). The results 
of experimens showed that labeled m170 was effective for imaging of primary and 
metastatic breast cancer and was able to detect lesions as small as 1 cm in size using SPECT 
with an overall clinical accuracy of 92%. In particular, mAb 170H.82 has been studied in 
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engineering have led to a number of alternative constructs for imaging and therapy. These 
alternatives characterized by smaller size include: 
• Fragment antigen binding (Fab): The area around the antibody hinge is more 
susceptible to proteolysis than the tightly folded domains and thus this is the point at 
which cleavage usually takes place. Proteolysis above the disulphide bonds in the hinge 
region with, for example papain, results in Fab fragments which are monovalent for 
antigen binding (~55 kDa). 
• Divalent fragment antigen binding (F(ab´)2): If antibody proteolysis occurs below the 
hinge disulphide bonds, with enzymes such as pepsin, it results in a divalent F(ab´)2 
fragment (~110 kDa). 
• Single chain fragment (scFv): This antibody fragment consists only the variable heavy 
(VH) and the variable light (VL) chain of an antibody tethered together by a flexible 
linker, attaching the carboxyl terminus of the VL sequence to the amino terminus of the 
VH sequence (~25 kDa). 
• Nanobody: Nanobodies are small antibody fragments (15 kDa) derived from the 
naturally occurring heavy-chain-only antibodies (Friedman. et al., 2009). These 
fragments have also been referred to VHH as they consist of a variable domain (VH) of 
the heavy chain (H) of antibodies (Meel et al., 2010). 
When compared to intact IgGs, these antibody fragments have the advantages of faster 
biodistribution, rapid penetration into the tissues and improved tumor-to-normal organs 
ratio. These forms (e.g. F(ab')2, Fab or other molecular constructs) achieve maximum tumor 
accretion more quickly with improved tumor/blood ratio that make earlier visualization, 
possible (Colcher et al., 1998). The use of fragments of antibodies has also been advocated as 
a possible means to reduce the immunogenicity of rodent antibodies in human beings. 
Antibody fragments generated by proteolysis or by genetic engineering, have been tested 
both in vitro and in vivo. As monovalent binding entities, antibody fragments suffer from 
relatively low avidity binding. Hence, to increase their binding avidity, they have also been 
engineered into multivalent constructs include: 
• Diabody: ”Diabody” is one of the engineered multivalent constructs. Diabodies can be 
produced to high levels in the form of stable dimmers (Wu & Yazaki, 2000; Hudson & 
Kortt, 1999; Lawrence et al., 1998). However, the stability of such dimeric species varies 
from one antibody to another. 
• Tribody: In some cases, particularly with direct fusions of VH and VL, stable trimeric 
species are produced which have been termed ”tribody” (Todorovskaet al., 2001). Some 
tribodies show improved avidity for antigens as expected from the increased number of 
binding sites, although this is not always the case (Todorovskaet al., 2001).  
6. Target antigens 
In recent years, there has been a significant improvement in the understanding of molecular 
events and critical pathways involved in breast cancer. The studies have confirmed the 
feasibility of using radiolabeled antibodies for imaging and therapy of primary and 
metastatic breast cancer and that a diverse array of molecules can serve as targets for 
localizing antibodies (Carlos et al., 2006). Theoretically, an ideal target for radionuclide 
detection and therapy of metastatic breast cancer would be tumor-specific, generously 
expressed on all the breast cancer cells, not expressed by normal tissues and not released 
into the blood circulation (Mohammadnejad et al., 2010). For antibody screening of breast 
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cancer, it is essential that the antibody is well characterized with little cross-reactivity to 
other antigens. The antibodies show cross-reactivity with, e.g. leucocytes, potentially 
yielding false-positive images. The majority of breast cancer targeting antibody studies have 
used antibodies against MUC1, CEA, TAG-72 and L6 antigens (Carlos et al., 2006).  
6.1 CEA  
First described by Gold and Freedman in 1965, CEA was thought to be a specific marker for 
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malignant breast lesions in patients with indeterminate mammographic findings (Denardo, 
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(Koppe et al., 2005). T84.66 is a well characterized murine IgG1 antibody with high 
specificity and affinity for a unique epitope of CEA molecules. A chimeric form of T84.66 
(cT84.66) has been also used in clinical studies for the scintigraphic detection of breast 
cancer and in phase I/II therapy trials and scFv-based anti-CEA constructs are under study 
(Denardo, 2005). Another mAb that has been classified in this group is NP4. NP-4 belongs to 
the murine IgG1 subclass and is specific for CEA, reacting with a class III peptide epitope of 
CEA molecules (Richman & DeNardo, 2001). 
6.2 MUC-1  
MUC-1 mucins are large, complex glycoproteins that have a polypeptide core with multiple 
oligosaccharide side chains (Mukhopadhyay et al., 2011). The mature molecule is anchored 
within the cell surface by a characteristic transmembrane domain, but most of the mucins 
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cancers (Salouti et al., 2011). Targeting, using antibodies directed against the MUC-1 antigen 
has been tested in patients with breast cancer using various antibodies. BrE-3 is an IgG1 
antibody directed against the peptide epitope of the MUC-1 antigen that have been 
evaluated for RIT (Mohammadnejad et al, 2010). The studies of the application of BrE-3 
mAbs in patients with breast cancer showed minimal cross reactivity with normal breast 
tissues (Howell et al., 1995; Blank et al., 1992). Because the majority of the patients rapidly 
showed HAMA response against the murine BrE-3 mAb, a humanized version of BrE-3 
(hBrE-3) was developed (Kramer et al., 1993). Kramer and colleagues investigated the 
pharmacokinetics and biodistribution of 111In-MX-DTPA-labeled hBrE-3 in seven patients 
with metastatic breast cancer (Kramer et al., 1993). hBrE-3 was proved to have a lower 
immunogenicity compared to murine BrE-3 (only one patient developed a HAMA response) 
while tumor-targeting properties were preserved (Denardo, 2005). Monoclonal antibody 
170H.82 (m170) is a murine IgG1 prepared using a synthetic asialo GM1 terminal 
disaccharide immunogen related to the Thomsen–Friedenreich disaccharide and selected by 
reactivity with MUC-1 expressing cancer cell membranes (Jonathan et al., 2000). The results 
of experimens showed that labeled m170 was effective for imaging of primary and 
metastatic breast cancer and was able to detect lesions as small as 1 cm in size using SPECT 
with an overall clinical accuracy of 92%. In particular, mAb 170H.82 has been studied in 
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breast cancer patients, with reported a sensitivity and specificity for detecting locoregional 
soft tissue disease of 90% and 93%, respectively (Denardo, 2005). Because aberrant MUC-1 
has provided effective target for breast cancer, gene-engineered antibody fragments (scFv) 
have been developed to MUC-1 antigen by phage display immunoglobulin gene libraries 
from mice immunized with MUC-1 peptide core and MCF-7 membranes. Numerous other 
monoclonal antibodies have been generated against MUC1 and have been used for breast 
cancer imaging such as HMFG-1 and HMFG-2, SM3, DF3, 12H12, BM2 (formerly called 2El 
1), BM7, EBA-1, MA5 and PR81 (Richman & Denardo, 2001; Salouti et al., 2008). Although, 
not all of these antibodies necessarily react with the same MUC1 determinant, they have all 
shown the ability to target breast cancer either in animal xenografts or in patients. Thus, 
these antibodies have been shown to be suitable antibodies for radioimmunoscintigraphy 
and radioimmunotherapy studies in this cancer type.  
6.3 TAG-72  
Immunohistochemical and immunocytochemical techniques have demonstrated preferential 
expression of TAG-72 known as tumor-associated glycoprotein in breast, gastrointestinal 
and ovarian adenocarcinomas compared to normal tissues (Denardo, 2005). Antibodies 
against the TAG-72 antigen particularly B72.3 and chB72.3 were evaluated in patients after 
careful study in human xenograft mouse models (Lorraine et al., 1998). The TAG-72 target 
antigen reactive with B72.3 pancarcinoma antibody has been used to target and image breast 
cancer (Denardo, 2005). CC49, a newer antibody to a different epitope of TAG-72, is a 
murine IgG1 monoclonal antibody that was labeled with Lutitium-177 by Milenic et al. 
(Milenic et al., 1991). He found that Lutitium-177 was an attractive alternative radionuclide 
with a lower energy beta emission and longer half life than 90Y. The images demonstrated 
the activity uptake at the site of tumor as well as in bone marrow. 
6.4 L6  
L6 cell surface antigen is a 24-kDa surface protein containing 3 hydrophobic transmembrane 
regions that are followed by a hydrophilic region (Richman & Denardo, 2001). L6 antigen is 
related to a number of cell surface proteins with similar predicted membrane topology that 
have been implicated in cell growth. L6 antigen is highly expressed in 50% of breast cancer 
specimens. Two mAb of this family, L6 mAb and the chimeric version (ChL6) have been 
studied in clinical trials (Denardo et al., 1994). 131I-Chimeric L6 antibody demonstrated 
therapeutic promise for patients with breast cancer (John et al., 2009). 
6.5 EGFR  
Epidermal growth factor receptor (EGFR) is a family of transmembrane growth factor 
receptor tyrosine kinases involved in regulation of cell proliferation and survival of 
epithelial cells (Cleator & Heller, 2007). EGFR family includes four receptors: EGFR/ErbB1, 
HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4. EGFR and HER2 are over expressed in 
approximately 40% and 25% of breast cancers, respectively and associated with aggressive 
clinical behavior and poor prognosis. Due to the important roles of EGFR and HER2 
receptors in diagnosis and therapy of breast cancer patients, both receptors are discussed in 
details (Munagalaet al., 2011). 
• EGFR receptor  
EGFR (also known as ErbB1 or HER1) is a 170 kDa transmembrane protein with an 
intracellular tyrosine-kinase domain. Many epithelial cancers including tumors of the head 
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and neck, breast, colon, lung, kidney, prostate, brain, bladder and pancreas overexpress 
EGFR. Such overexpression is associated with poor prognosis and this leads to several 
strategies to block this pathway and improve the outcome. Cetuximab is a chimeric IgG1 
monoclonal antibody that competes with an endogenous ligand to bind to the extracellular 
domain of EGFR (Harris, 2004). On the basis of these findings and those of previous studies, 
Cetuximab received FDA approval in February 2004, for using in treatment of EGFR-
positive metastatic colorectal cancer (Harris, 2004). 
• HER2/Neu receptor 
The HER2/Neu receptor is a member of the EGFR family and another important cancer-
related receptor that is over expressed in several human tumors notably on a subset of 
breast cancer cells (Ross et al., 2004). Trastuzumab (commonly referred to Herceptin) was 
the first recombinant bivalent humanized mAb targeted against extracellular domain of 
HER2 reported in 1998, has been approved by FDA and is frequently used clinically in 
“naked antibody” therapy (Rasaneh et al., 2009). Trastuzumab binds with high affinity to 
HER2 and leads to internalisation of HER2 receptor and blockage of signal transduction. 
Unlike chemotherapy, trastuzumab do not have toxic effects such as nausea, vomiting, hair 
loss and bone marrow toxicity (Munagala, 2011). Pertuzumab, a recombinant humanized 
monoclonal antibody, binds to extracellular domain II of HER2 receptor and blocks its 
ability to dimerize with other HER family receptors (HER1, HER2, HER3, HER4) (Untch, 
2010). Pertuzumab is the first in a new class of targeted agents known as HER dimerization 
inhibitors (HDIs). The drug showed promising activity with trastuzumab in the treatment of 
metastatic breast cancer in a phase II study (Baselga et al., 2007, 2010). The patients treated 
with trastuzumab have an increased risk of developing cardiac dysfunction (Widakowich et 
al., 2007). When trastuzumab was conjugated with a radioneclide, the dose of drug was 
decreased that led to decrease its cardiac toxicity (Harris, 2004). Radioactive anti-HER2/neu 
rhumAb are considered attractive agents for RIS and RIT of aggressive HER-2/neu-positive 
breast carcinomas (Munnink, 2009). 
6.6 VEGF  
Vascular-endothelial growth factor (VEGF) is a proangiogenic growth factor that regulates 
vascular proliferation and permeability and is an antiapoptotic factor for new blood vessels. 
VEGF acts via two receptors, VEGFR1 and VEGFR2, which are expressed on the vascular 
endothelium. VEGFR expression is commonly increased in response to hypoxia, oncogenes 
and cytokines and its expression is associated with poor prognosis. Bevacizumab (Avastin) 
is a humanised monoclonal antibody that inhibits angiogenic signaling. In February, 2004, 
bevacizumab received FDA approval for using in the first line treatment of metastatic 
colorectal cancer in combination with 5-fluorouracil-based chemotherapy (Munnink, 2009). 
FDA is still moving toward stripping the cancer drug bevacizumab of its indication for 
treating advanced breast cancer, but not other cancers (Munnink, 2009). 
7. Radioimmunoscintigraphy 
It is well known that mammography provides a high sensitivity at the cost of relatively low 
specificity. Therefore, breast cancer diagnosis requires an adjunctive test to mammography 
that can increase diagnostic specificity while maintaining a high positive predictive value. 
Although sestamibi imaging has been introduced as an adjunctive test to mammography, it 
fails to provide the necessary sensitivity, specificity and predictive values for nonpalpable 
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lesions, thus resulting in a relatively high false-positive rate in patient population. Several 
strategies have been developed over the past two decades for earlier and more accurate 
diagnosis of disease and to evaluate response to therapy. One of the novel approaches for 
specific detection of cancers is the use of monoclonal antibodies conjugated with 
radionuclides so-called radioimmunoscintigraphy (is also called radioimmunodetection, 
radioimmunoimaging and radioimmunodiagnosis) (Salouti, et al., 2006). In this method, a 
radio-isotope labeled antibody is administered to a patient with cancer. Once localized to the 
tumor tissue, the radioisotope (and hence the sites of malignancy) can be detected with a 
nuclear medicine imaging system like gamma camera. The summery of history for RIS has 
been shown in table 1. The efficacy of this technique depends on antigen expression on tumor 
cells compared to normal tissues. Affinity, specificity, pharmacokinethics, properties of the 
radionuclide and imaging technique have influence on the efficacy of 
radioimmunoscintigraphy. The potential clinical applications of RIS are (1) evaluation of 
patients with suspected breast cancer, (2) locoregional staging of newly discovered breast 
cancer, (3) detection of distant metastases using whole body scintigraphy and (4) evaluation of 
tumor response to therapy (Berghammer et al., 2001).  
 
1908 Paul Ehrlich is generally recognised as the inventor of the term “magic bullets”, describing the potential of an antibody to specifically target tumor cells. 
Ehrlich, 1906 
1953 
This approach was invented by Pressman and his associates who discovered that 
radioiodinated antisera could concentrate selectively in tumors when injected 




1957 Gamma camera as initially introduced in 1957 by Hal Anger was designed to detect gamma photons within an energy window between 30 and 300 keV. 
Anger et al., 
1957 
1963 
David Kuhl and Roy Edwards were the first to present tomographic images using 
the Anger camera by acquiring multiple planar images from different angles and 





Gold and Freedman discovered carcinoembryonic antigen (CEA), the first well 
defined tumor-associated antigen and as a result of this finding purified 






Discovery of the hybridoma technique by Kohler and Milstein was perhaps the 
single most important contribution to the development of 
radioimmunoscintigraphy. Using the hybridoma technique, mass production 
antibodies of predetermined specificity with high quality became possible. 
Kohler & 
Milstein, 1975 




Methodologic improvements included the combined use of optimized 
radionuclide tracers such as SPECT and antibody fragments such as Fab 
fragments to improve the quality of nuclear medicine images of metastatic cancer 
in vivo. 
Larson et al., 
1983a, b 
1986 As a further advancement of chimeric mAbs, in 1986, Jones et al.  reported the production of humanized monoclonal antibodies. 
Jones PT et 
al.1986 
1998 Trastuzumab (Herceptin) was approved by  FDA for using in patients with metastatic breast cancer. 
Cobleigh et al, 
1999 
2004 Radioactive anti-HER-2/neu rhuMAb were considered attractive agents for radioimmunodiagnosis of aggressive HER-2/neu-positive breast carcinomas. 
Olafsen et al, 
2004 
Table 1. The summery of history for radioimmunoscintigraphy. 
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7.1 Radionuclides for imaging 
The most common radionuclides in nuclear medicine are 99mTc, 123I, 67Ga and 111In. Lower 
energy γ-rays are readily absorbed in tissues and therefore less useful for external imaging. On 
the other hand, highest energy γ-rays cause to decrease the sensitivity of imaging system 
(Berghammeret al., 2001). Technetium-99m is so far the most commonly used radionuclide in 
nuclear medicine (Hamoudeh et al., 2008). This is due to the highly interesting physical 
properties of 99mTc which is advantageous for both effective imaging and patient safety 
perspectives. Its properties include short half-life (6 h), gamma energy at 140 keV with 
practically no alpha or beta emissions and latent chemical properties, facilitating thereby the 
labeling of several types of kits for versatile diagnostic applications and readily available and 
inexpensive (it is derived as a column elute from a 99Mo/99mTc generator) (Verhaar et al., 
2000). It is most often used with smaller antibody forms such as Fab, scFv, diabodies and 
nanobodies. The gamma-ray emitting radionuclides are commonly used in gamma camera 
and single photon emission tomography (SPECT). Other groups of diagnostically used 
radionuclides are ß+ emitters such as 11C, 18F, 13N and 15O (Hamoudeh et al., 2008). The 
positron emitting radionuclides are used in positron emission tomography (PET). The positive 
electron travels only a short distance through the tissues and interacts with a free or loosely 
bound negative electron. The outcome of this interaction is two photons, consisting each of 511 
keV energy and being given off in opposite directions (Boswell & Brechbiel, 2007). 
7.2 Imaging systems in nuclear medicine 
Imaging systems in nclear medicine include gamma camera, single photon emission 
computed tomography (SPECT) and positron emission tomography (PET). 
7.2.1 Gamma camera  
Gamma camera is a one-headed, variable-angle diagnostic instrument that is used to image 
gamma radiation emitting radioisotopes, a technique known as scintigraphy. Gamma 
camera consists of a scintillation crystal, optically coupled to an array of photomultiplier 
tubes which converts the γ-rays into electric signals.  
7.2.2 Single photon emission tomography 
Single photon emission computed tomography (SPECT) is a sensitive nuclear imaging 
technique that provides a 3D spatial distribution of single-photon emitting radionuclide within 
the body (Gomes et al., 2010). Multiple 2D images, also called projections, are acquired from 
multiple angles around the patient and subsequently reconstructed using the reconstruction 
imaging methods to generate cross-sectional images of the internal distribution of the injected 
molecules (Wernick, & Aarsvold,2004). Because of the isotropic emission of γ-rays, a geometric 
collimation is needed to restrict the travelling direction of the emitted γ-rays from the body, 
through the use of lead collimators. In clinical systems, collimators typically have many 
parallel holes that produce no magnification. The photons that travel in other directions than 
those specified by the aperture of collimator are absorbed and do not contribute to the image, 
which reduces the detection efficiency and sensitivity of SPECT as compared to PET (Madsen, 
2007).  SPECT have several advantages including (1) whole body imaging, (2) quantitative 
molecular imaging and (3) can be combined with CT for preparing anatomical information. 
The disadvantages of this method are radiation exposure, low spatial resoulation (0.3-1 mm, 
12-15 mm3) and long acquisition time (Pysz et al., 2010). 
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7.2.3 Positron emission tomography (PET) 
Positron emission tomography is a nuclear medicine technique that produces high 
resolution tomographic imaging through the detection of high energy photon pairs emitted 
during positron decay (Costelloeet al., 2009). This method was initially developed in 1960s, 
but has largely been used as a research tool. However, PET can provide useful information 
for clinical practice. The images generated by PET represent the metabolic activity of the 
underlying tissues and can therefore distinguish benign from malignant lesions on the basis 
of differences in metabolic activity. Similarly, it can identify recurrent diseases in areas in 
which conventional scans are difficult to interpret because of prior treatment (Costelloeet al., 
2009). PET represents the most advanced imaging technique, because it not only allows a 
three-dimensional image reconstruction, but also it can quantify the activity uptake (Fass, 
2008). It combines the highest degree of sensitivity with a resolution of currently, 5-7 mm. 
The principal applied radionuclide for PET is Fluor-18 (18F) which is known for its ideal 
half-life to manage (1.83 h). The development of radiopharmaceutical [2-18F]-2-fluoro-2-
deoxyglucose (18FDG) has been so far an important progress for PET imaging in oncology 
(Berghammer et al., 2001). 18FDG acts as a glucose analogue allowing for the visualization 
of glucose consumption, a metabolic process being massively enhanced in many 
malignancies (Einat & Moshe, 2010). PET has several advantages include (1) unlimited 
depth penetration; (2) whole body imaging possible, (4) quantitative molecular imaging and 
(5) can be combined with CT or MRI for anatomical information (Pysz et al., 2010). The 
disadvantage of PET is that it requires a conveniently located and expensive cyclotron and 
radiochemistry facilities to produce the short-half life isotopes and to incorporate these into 
suitable probe molecules (Fass, 2008).  
8. Radioimmunotherapy 
The first theory on the existence of proteins with specific binding capabilities to pathogenic 
organisms, thus acting as "magic bullet"’, was postulated at the end of the 19th century by the 
german pathologist Paul Ehrlich (Enelich, 1906). He was the first to recognise antibodies for 
their ability to differentiate between normal cells and transformed malignant cells. He 
specifically introduced immunotherapy as a potential treatment modality for targeting and 
treating tumors. After it had been recognized in 1950 that proteins could be labeled with 131I 
without significantly altering their immunological specificity (Eisen & Keston, 1950), Pressman 
and Korngold tested the tumor-targeting potential of a 131I-labeled rabbit antiserum in rats 
bearing osteosarcoma and confirmed preferential antibody uptake in the tumor xenografts 
(Pressman & Korngold, 1953). The first clinical trial investigated the therapeutic efficacy of 
radiolabeled antibodies was performed in the 1950s by Beierwaltes, who treated fourteen 
patients with metastatic melanoma with 131I-labeled rabbit antibodies and reported a 
pathologically confirmed remission in one patient (Beierwaltes, 1974). In 1965, Gold and 
Freedman discovered carcinoembryonic antigen (CEA), the first well defined tumor-associated 
antigen. The purified polyclonal anti-CEA antibodies were shown to localize to CEA 
expressing tumors in vivo (Gold & Freedman, 1965). In the late 1970s, Goldenberg and 
colleagues successfully targeted colon cancer in patients using a polyclonal goat anti-CEA 
antiserum (Goldenberg et al., 1978). Nowadays, CEA has not only become one of the most 
extensively used tumor markers in clinical oncology, but also due to its pronounced 
expression in various carcinomas, it is one of the most targeted antigens in RIT. In 1975, Köhler 
and Milstein reformed the field of radioimmunotargeting as they introduced the hybridoma  
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technology, a method that made it possible to produce large quantities of monoclonal 
antibodies with high purity and reproducibility (Kohler & Milstein, 1975). Since then, 
numerous antigen-antibody systems have been established and several of the antibodies have 
been taken to clinical trials. Radioimmunotherapy is a method of selectively delivering 
radionuclides with toxic emissions to cancer cells, while reducing the dose to normal tissues. 
Using mAbs labeled with radionuclides has two major advantages over the application of 
mAbs conjugated with either drugs or toxins. Firstly, tumor cells not expressing the target 
antigen can still be sterilized by the so-called crossfire phenomenon, i.e., radiation energy 
emitted by radionuclides bound to antibodies targeting adjacent tumor cells. Secondly, 
radionuclides are not subject to multidrug resistance. Although promising, RIT has been less 
effective for solid tumors, in part because they are less radiosensitive. However, early 
micrometatasis of breast cancer have been demonstrated to be radiosensitive (Koppe et al., 
2005). On the other hand, an advantage of RIT is that it can target small metastatic lesions that 
are undetected by conventional scanning and would otherwise remain untreated. In addition, 
RIT is able to target multiple metastases throughout the body in a single treatment. 
8.1 Radionuclides for treatment 
The selection of a radionuclide for cancer treatments depends on several parameters including:  
1. Physical parameters: The type of radiation emitted by the radionuclide, required 
energy necessary for therapy and half-life of the radionuclide are physical parameters 
that must be considered. The type of radiation and the content of its energy are 
important factors that determine what radionuclide is suitable for killing of single 
disseminated cells, small metastases or large cancer tissues. The physical half-life of the 
radionuclides should preferably be in the same order of magnitude as the biological 
half-life. A too long physical half-life increases the necessary amount of radionuclide to 
be delivered to the tumor cells to allow the reasonable amounts of decays before 
excretion. A shorter physical half-life, on the other hand, will not give enough time for 
the targeting process to take place. It seems reasonable to assume that the most suitable 
physical half-lives ranges from a few hours up to some days when targeting of 
disseminated cells is considered (Boswell & Brechbiel, 2007). 
2. Chemical parameters: The chemical parameters are as follow: achievable specific 
activity, stability of the radionuclide/antibody complex after labeling and that the 
labeling procedure must not interfere with the immunological activity of the antibody. 
3. Biological parameters: tumor type, size and location, antibody kinetics, antigen density 
and heterogeneity and antigenicity are the most important biological parameters.  
4. Other parameters: radioisotope availability and its cost. 
Three main categories of radionuclides have been investigated for their potential therapeutic 
characterisation in radioimmunotherapy including β-particle emitters, α-particle emitters 
and auger electron cascades. 
1. β-particle emitters 
So far, the vast majority of preclinical and clinical studies have been made to use β-emitting 
radionuclides such as 131I, 90Y, 186Re and 188Re. These radionuclides have a tissue range of 
about several millimeters. This can create a ‘‘cross fire’’ effect, so that antigen or receptor 
negative cells in a tumor can also be treated. High energy B-particles are not efficient for 
killing of single disseminated cells or small metastases. So, β-particle therapy is preferred for 
large tumors (Boswell & Brechbiel, 2007). 
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7.2.3 Positron emission tomography (PET) 
Positron emission tomography is a nuclear medicine technique that produces high 
resolution tomographic imaging through the detection of high energy photon pairs emitted 
during positron decay (Costelloeet al., 2009). This method was initially developed in 1960s, 
but has largely been used as a research tool. However, PET can provide useful information 
for clinical practice. The images generated by PET represent the metabolic activity of the 
underlying tissues and can therefore distinguish benign from malignant lesions on the basis 
of differences in metabolic activity. Similarly, it can identify recurrent diseases in areas in 
which conventional scans are difficult to interpret because of prior treatment (Costelloeet al., 
2009). PET represents the most advanced imaging technique, because it not only allows a 
three-dimensional image reconstruction, but also it can quantify the activity uptake (Fass, 
2008). It combines the highest degree of sensitivity with a resolution of currently, 5-7 mm. 
The principal applied radionuclide for PET is Fluor-18 (18F) which is known for its ideal 
half-life to manage (1.83 h). The development of radiopharmaceutical [2-18F]-2-fluoro-2-
deoxyglucose (18FDG) has been so far an important progress for PET imaging in oncology 
(Berghammer et al., 2001). 18FDG acts as a glucose analogue allowing for the visualization 
of glucose consumption, a metabolic process being massively enhanced in many 
malignancies (Einat & Moshe, 2010). PET has several advantages include (1) unlimited 
depth penetration; (2) whole body imaging possible, (4) quantitative molecular imaging and 
(5) can be combined with CT or MRI for anatomical information (Pysz et al., 2010). The 
disadvantage of PET is that it requires a conveniently located and expensive cyclotron and 
radiochemistry facilities to produce the short-half life isotopes and to incorporate these into 
suitable probe molecules (Fass, 2008).  
8. Radioimmunotherapy 
The first theory on the existence of proteins with specific binding capabilities to pathogenic 
organisms, thus acting as "magic bullet"’, was postulated at the end of the 19th century by the 
german pathologist Paul Ehrlich (Enelich, 1906). He was the first to recognise antibodies for 
their ability to differentiate between normal cells and transformed malignant cells. He 
specifically introduced immunotherapy as a potential treatment modality for targeting and 
treating tumors. After it had been recognized in 1950 that proteins could be labeled with 131I 
without significantly altering their immunological specificity (Eisen & Keston, 1950), Pressman 
and Korngold tested the tumor-targeting potential of a 131I-labeled rabbit antiserum in rats 
bearing osteosarcoma and confirmed preferential antibody uptake in the tumor xenografts 
(Pressman & Korngold, 1953). The first clinical trial investigated the therapeutic efficacy of 
radiolabeled antibodies was performed in the 1950s by Beierwaltes, who treated fourteen 
patients with metastatic melanoma with 131I-labeled rabbit antibodies and reported a 
pathologically confirmed remission in one patient (Beierwaltes, 1974). In 1965, Gold and 
Freedman discovered carcinoembryonic antigen (CEA), the first well defined tumor-associated 
antigen. The purified polyclonal anti-CEA antibodies were shown to localize to CEA 
expressing tumors in vivo (Gold & Freedman, 1965). In the late 1970s, Goldenberg and 
colleagues successfully targeted colon cancer in patients using a polyclonal goat anti-CEA 
antiserum (Goldenberg et al., 1978). Nowadays, CEA has not only become one of the most 
extensively used tumor markers in clinical oncology, but also due to its pronounced 
expression in various carcinomas, it is one of the most targeted antigens in RIT. In 1975, Köhler 
and Milstein reformed the field of radioimmunotargeting as they introduced the hybridoma  
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technology, a method that made it possible to produce large quantities of monoclonal 
antibodies with high purity and reproducibility (Kohler & Milstein, 1975). Since then, 
numerous antigen-antibody systems have been established and several of the antibodies have 
been taken to clinical trials. Radioimmunotherapy is a method of selectively delivering 
radionuclides with toxic emissions to cancer cells, while reducing the dose to normal tissues. 
Using mAbs labeled with radionuclides has two major advantages over the application of 
mAbs conjugated with either drugs or toxins. Firstly, tumor cells not expressing the target 
antigen can still be sterilized by the so-called crossfire phenomenon, i.e., radiation energy 
emitted by radionuclides bound to antibodies targeting adjacent tumor cells. Secondly, 
radionuclides are not subject to multidrug resistance. Although promising, RIT has been less 
effective for solid tumors, in part because they are less radiosensitive. However, early 
micrometatasis of breast cancer have been demonstrated to be radiosensitive (Koppe et al., 
2005). On the other hand, an advantage of RIT is that it can target small metastatic lesions that 
are undetected by conventional scanning and would otherwise remain untreated. In addition, 
RIT is able to target multiple metastases throughout the body in a single treatment. 
8.1 Radionuclides for treatment 
The selection of a radionuclide for cancer treatments depends on several parameters including:  
1. Physical parameters: The type of radiation emitted by the radionuclide, required 
energy necessary for therapy and half-life of the radionuclide are physical parameters 
that must be considered. The type of radiation and the content of its energy are 
important factors that determine what radionuclide is suitable for killing of single 
disseminated cells, small metastases or large cancer tissues. The physical half-life of the 
radionuclides should preferably be in the same order of magnitude as the biological 
half-life. A too long physical half-life increases the necessary amount of radionuclide to 
be delivered to the tumor cells to allow the reasonable amounts of decays before 
excretion. A shorter physical half-life, on the other hand, will not give enough time for 
the targeting process to take place. It seems reasonable to assume that the most suitable 
physical half-lives ranges from a few hours up to some days when targeting of 
disseminated cells is considered (Boswell & Brechbiel, 2007). 
2. Chemical parameters: The chemical parameters are as follow: achievable specific 
activity, stability of the radionuclide/antibody complex after labeling and that the 
labeling procedure must not interfere with the immunological activity of the antibody. 
3. Biological parameters: tumor type, size and location, antibody kinetics, antigen density 
and heterogeneity and antigenicity are the most important biological parameters.  
4. Other parameters: radioisotope availability and its cost. 
Three main categories of radionuclides have been investigated for their potential therapeutic 
characterisation in radioimmunotherapy including β-particle emitters, α-particle emitters 
and auger electron cascades. 
1. β-particle emitters 
So far, the vast majority of preclinical and clinical studies have been made to use β-emitting 
radionuclides such as 131I, 90Y, 186Re and 188Re. These radionuclides have a tissue range of 
about several millimeters. This can create a ‘‘cross fire’’ effect, so that antigen or receptor 
negative cells in a tumor can also be treated. High energy B-particles are not efficient for 
killing of single disseminated cells or small metastases. So, β-particle therapy is preferred for 
large tumors (Boswell & Brechbiel, 2007). 
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2. α-particle emitters  
Radionuclides emitting α-particles such as 225Ac (half-life 10 days), 211At (half-life 7.2 h), 
212Bi (half-life 60.55 min) and 213Bi (half-life 45.6 min) are options for treatment of small 
tumor nests or single disseminated tumor cells. Alfa particle emitting radionuclides are 
short ranged, high-energy helium nuclei with a high linear energy transfer (LET). As a 
consequence, α-emitters have a high relative biological effectiveness (RBE) which means, if 
nuclear localisation is possible, fewer radionuclides per cell are needed (Fass, 2009).  
3. Auger electron cascades 
Auger-electrons, discovered by Lise Meitner in 1922 and by Pierre Auger in 1923, are 
formed when the vacancy created in an inner shell is filled with an electron from a higher 
energy level after electron capture. Auger-electrons have high LET Like α-particles 
(Cornelissen & Vallis,  2010). Auger-electron emitters, like 125I, deposit a concentrated 
amount of energy in even shorter distances than α-emitters. This means that these 
radionuclides need to be located in the vicinity of the tumor cell nucleus to be effective. For 
this reason, antibodies labeled with auger-emitting radionuclides need to target the entire 
tumor cell population for efficient therapy (Cornelissen & Vallis,  2010). 
9. Improving the properties of antibody in radioimmunoscintigraphy and 
radioimmunotherapy 
Several investigations using different radionuclides, engineered antibodies and methods to 
increase antibody accumulation and penetration are currently being evaluated and have so 
far shown promising results. The main properties of antibodies that have been manipulated 
to optimize efficacy are size, immunogenicity, affinity and avidity. 
9.1 Size 
Size is a factor that impacts the circulation time of antibodies. IgG antibodies are large 
proteins with a molecular weight of 150 kDa which limits the diffusion of the antibodies 
from the blood into the tumor, resulting in a heterogeneous intratumoral distribution. 
Furthermore, IgG antibodies are characterized by a long circulatory half-life in plasma for 
three to four days. Due to this slow clearance from the blood, tumor-to-background ratio is 
usually low. The primary concern for using radionuclide labeled IgG is that it remains in the 
blood for an extended period of time which continually exposes the highly sensitive red 
marrow to radiation resulting in dose-limiting myelosuppression. While intact mAbs are 
primarily catabolized by the liver and spleen, mAb fragments are mainly excreted via the 
kidneys, thereby increasing uptake in the kidneys and lead to increase consequently the 
kidney absorbed radiation dose. (Koppe et al., 2005). If radiometals are used as the 
radiolabel, they will accumulate in the hepatic parenchyma. The large size of an antibody 
impacts its ability to move through a tumor mass.  The smaller forms of  antibodies such as 
F(ab')2 or Fab fragments and more recently, molecularly engineered antibody subfragments 
with more favorable pharmacokinetic properties, are removed more rapidly from the blood, 
thereby improving tumor/blood ratio. There have been reports of improved therapeutic 
responses using smaller-sized antibodies, but these smaller entities frequently are cleared 
from the blood by renal filtration and as a result many radionuclides (eg, radiometals) 
become trapped in a higher concentration in the kidneys than in the tumor. Changes in the 
molecular size/structure of the IgG can also alter the normal tissue distribution, shifting 
uptake from the liver to the kidneys (Sharkey & Goldenberg, 2009). Reducing the size of 
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antibody below the filtration threshold of kidneys (70 kDa), increases renal excretion and 
therefore decreases toxicity to this organ. Hence, being smaller molecules, antibodies are 
more suited to RIT and RIS with short circulation time, lower absolute localisation to the 
tumor and rapid excretion by the kidneys (Yazaki et al., 2001).  
9.2 Immunogenicity 
The first mAbs being investigated for RIS and RIT were murine antibodies which can 
provoke an immune response in human beings. HAMA inactivate and eliminate murine 
antibodies after repeated administration. The formation of antibody-HAMA complexes also 
leads to the allergic-like HAMA response. In this way, therapeutic benefit of murine mAbs 
is limited by their side effect profile, short serum half-life and inability to trigger human 
immune effector functions. In order to reduce the immunogenicity of antibodies, chimeric 
antibodies were designed by combining constant domains of human antibodies with 
variable regions of murine antibodies (Carlssona et al., 2003). However, chimeric mAbs 
minimize the immunogenic content, trigger the immunologic efficiency and allow a 
prolonged serum half-life in comparison with murine mAbs. As a further advancement of 
chimeric mAbs, in 1986, Jones first reported the production of humanized monoclonal 
antibodies (Jones et al., 1986). Humanized antibodies are almost completely of human origin 
with only the complementarity determining regions (CDRs) being murine. To completely 
avoid the risk of immunogenicity, further developments have led to the production of fully 
human antibodies that contain 100% human proteins. For the development of fully human 
mAbs, phage display technology and genetically engineered mice are the key techniques 
that have been widely used to link genotype and phenotype. Immunosuppressive agents 
have been investigated to reduce HAMA. Low-dose cyclosporin, as used with a highly 
immunogenic antibody, was unable to significantly reduce HAMA following murine CC49 
delivery. Thus, cyclosporin may have some efficacy in reducing immunogenicity of murine 
antibodies in patients, but does not appear to be sufficient to permit administration of 
multiple doses in all patients (Pagel, 2009). 
9.3 Affinity and avidity 
The antibody affinity is a measure of the strength of binding of an individual antibody binding 
site to a single antigenic site. This can be considered as the sum of all the non-covalent 
interactions between antibody and antigen involved in the binding reaction. However, 
antibody molecules usually have more than one binding site and many antigens contain more 
than one antigenic site and therefore multivalent binding may be possible. The strength with 
which a multivalent antibody binds to an antigen, is termed avidity. Although high affinity is 
a requirement for good tumor localization, there seems to be a point at which further increases 
in affinity do not increase uptake at the target site (Schlomet al., 1992; Colcher et al., 1988). 
Indeed, reduced tumor uptake and limitations on penetration of antibody into the tumor 
tissue can result from the increasing of antibody affinity (Dearling & Pedley, 2007). 
10. Technical limitations of radioimmunoscintigraphy and 
radioimmunotherapy 
Although this conceptually simple technique has been investigated and refined for almost 50 
years, it still has inherent limitations. In the present part, the problems of imaging and therapy 
of breast cancer by radioimmunoscintigraphy and radioimmnotherapy methods are discussed.  
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2. α-particle emitters  
Radionuclides emitting α-particles such as 225Ac (half-life 10 days), 211At (half-life 7.2 h), 
212Bi (half-life 60.55 min) and 213Bi (half-life 45.6 min) are options for treatment of small 
tumor nests or single disseminated tumor cells. Alfa particle emitting radionuclides are 
short ranged, high-energy helium nuclei with a high linear energy transfer (LET). As a 
consequence, α-emitters have a high relative biological effectiveness (RBE) which means, if 
nuclear localisation is possible, fewer radionuclides per cell are needed (Fass, 2009).  
3. Auger electron cascades 
Auger-electrons, discovered by Lise Meitner in 1922 and by Pierre Auger in 1923, are 
formed when the vacancy created in an inner shell is filled with an electron from a higher 
energy level after electron capture. Auger-electrons have high LET Like α-particles 
(Cornelissen & Vallis,  2010). Auger-electron emitters, like 125I, deposit a concentrated 
amount of energy in even shorter distances than α-emitters. This means that these 
radionuclides need to be located in the vicinity of the tumor cell nucleus to be effective. For 
this reason, antibodies labeled with auger-emitting radionuclides need to target the entire 
tumor cell population for efficient therapy (Cornelissen & Vallis,  2010). 
9. Improving the properties of antibody in radioimmunoscintigraphy and 
radioimmunotherapy 
Several investigations using different radionuclides, engineered antibodies and methods to 
increase antibody accumulation and penetration are currently being evaluated and have so 
far shown promising results. The main properties of antibodies that have been manipulated 
to optimize efficacy are size, immunogenicity, affinity and avidity. 
9.1 Size 
Size is a factor that impacts the circulation time of antibodies. IgG antibodies are large 
proteins with a molecular weight of 150 kDa which limits the diffusion of the antibodies 
from the blood into the tumor, resulting in a heterogeneous intratumoral distribution. 
Furthermore, IgG antibodies are characterized by a long circulatory half-life in plasma for 
three to four days. Due to this slow clearance from the blood, tumor-to-background ratio is 
usually low. The primary concern for using radionuclide labeled IgG is that it remains in the 
blood for an extended period of time which continually exposes the highly sensitive red 
marrow to radiation resulting in dose-limiting myelosuppression. While intact mAbs are 
primarily catabolized by the liver and spleen, mAb fragments are mainly excreted via the 
kidneys, thereby increasing uptake in the kidneys and lead to increase consequently the 
kidney absorbed radiation dose. (Koppe et al., 2005). If radiometals are used as the 
radiolabel, they will accumulate in the hepatic parenchyma. The large size of an antibody 
impacts its ability to move through a tumor mass.  The smaller forms of  antibodies such as 
F(ab')2 or Fab fragments and more recently, molecularly engineered antibody subfragments 
with more favorable pharmacokinetic properties, are removed more rapidly from the blood, 
thereby improving tumor/blood ratio. There have been reports of improved therapeutic 
responses using smaller-sized antibodies, but these smaller entities frequently are cleared 
from the blood by renal filtration and as a result many radionuclides (eg, radiometals) 
become trapped in a higher concentration in the kidneys than in the tumor. Changes in the 
molecular size/structure of the IgG can also alter the normal tissue distribution, shifting 
uptake from the liver to the kidneys (Sharkey & Goldenberg, 2009). Reducing the size of 
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antibody below the filtration threshold of kidneys (70 kDa), increases renal excretion and 
therefore decreases toxicity to this organ. Hence, being smaller molecules, antibodies are 
more suited to RIT and RIS with short circulation time, lower absolute localisation to the 
tumor and rapid excretion by the kidneys (Yazaki et al., 2001).  
9.2 Immunogenicity 
The first mAbs being investigated for RIS and RIT were murine antibodies which can 
provoke an immune response in human beings. HAMA inactivate and eliminate murine 
antibodies after repeated administration. The formation of antibody-HAMA complexes also 
leads to the allergic-like HAMA response. In this way, therapeutic benefit of murine mAbs 
is limited by their side effect profile, short serum half-life and inability to trigger human 
immune effector functions. In order to reduce the immunogenicity of antibodies, chimeric 
antibodies were designed by combining constant domains of human antibodies with 
variable regions of murine antibodies (Carlssona et al., 2003). However, chimeric mAbs 
minimize the immunogenic content, trigger the immunologic efficiency and allow a 
prolonged serum half-life in comparison with murine mAbs. As a further advancement of 
chimeric mAbs, in 1986, Jones first reported the production of humanized monoclonal 
antibodies (Jones et al., 1986). Humanized antibodies are almost completely of human origin 
with only the complementarity determining regions (CDRs) being murine. To completely 
avoid the risk of immunogenicity, further developments have led to the production of fully 
human antibodies that contain 100% human proteins. For the development of fully human 
mAbs, phage display technology and genetically engineered mice are the key techniques 
that have been widely used to link genotype and phenotype. Immunosuppressive agents 
have been investigated to reduce HAMA. Low-dose cyclosporin, as used with a highly 
immunogenic antibody, was unable to significantly reduce HAMA following murine CC49 
delivery. Thus, cyclosporin may have some efficacy in reducing immunogenicity of murine 
antibodies in patients, but does not appear to be sufficient to permit administration of 
multiple doses in all patients (Pagel, 2009). 
9.3 Affinity and avidity 
The antibody affinity is a measure of the strength of binding of an individual antibody binding 
site to a single antigenic site. This can be considered as the sum of all the non-covalent 
interactions between antibody and antigen involved in the binding reaction. However, 
antibody molecules usually have more than one binding site and many antigens contain more 
than one antigenic site and therefore multivalent binding may be possible. The strength with 
which a multivalent antibody binds to an antigen, is termed avidity. Although high affinity is 
a requirement for good tumor localization, there seems to be a point at which further increases 
in affinity do not increase uptake at the target site (Schlomet al., 1992; Colcher et al., 1988). 
Indeed, reduced tumor uptake and limitations on penetration of antibody into the tumor 
tissue can result from the increasing of antibody affinity (Dearling & Pedley, 2007). 
10. Technical limitations of radioimmunoscintigraphy and 
radioimmunotherapy 
Although this conceptually simple technique has been investigated and refined for almost 50 
years, it still has inherent limitations. In the present part, the problems of imaging and therapy 
of breast cancer by radioimmunoscintigraphy and radioimmnotherapy methods are discussed.  
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10.1 Antibody 
Monoclonal antibodies have inherent limitations for application in targeting methods of 
imaging and therapy that can be cited in followings: 
• mAbs are large molecules and so have difficulty in penetrating to large tumor masses 
especially in the early stages of the malignancies (Sergides et al., 1999). 
• mAbs are currently not entirely sensitive for malignant tissues. For example, mAb B72.3 
recognizes TAG-72 and has been used extensively for the detection of several 
malignancies including breast, lung, ovary and colorectal (Granowska et al., 1991).  
10.2 Antigen 
Tumors produce a chaotic vascular system in which blood flow is slow and can be 
interrupted or even reversed. The ratio of tissue cells to vascular support is lower than most 
normal tissues. These effects create areas of tumor hypoxia which are relatively resistant to 
radiation therapy and therefore reduce the efficacy of RIT (Sergides et al., 1999). Some 
antigens of breast cancer are epithelial surface antigens lying on the inner surfaces of cells, 
thus being exposed to the circulation only by neoplastic architectural disruption. Other 
factors influencing the suitability of antigens for tumor targeting are internalization and 
shedding into the bloodstream. Unfortunately, the majority of identified antigens in human 
tumors represent tumor-associated antigens, not only present on the tumor tissues, but also 
detectable on normal tissues (Sergides et al., 1999). 
10.3 Background radioactivity 
A high background level of radiation due to the presence of radioactivity in normal tissues 
reduces the tumor/background  ratio which reduces the success of diagnosis and therapy. 
Tumor/background ratio may be diminished by the following factors: (1) the relative long 
circulation time of nonlocalized murine immunoglobulin in human beings; (2) binding of 
radiolabeled antibodies to antigens, released by the tumor in the blood pool; (3) the presence 
of free radionuclides and the subsequent accumulation in kidneys, bladder and other 
tissues, (4) non-specific uptake antibody by binding Fc fragment of antibody to normal 
tissues; (5) phagocytosis of murine immunoglobulin especially in the liver; (6) the presence 
of immune complexes due to the reaction of labelled antibody with Fc cell surface receptors, 
if non-fragmented immunoglobulins are used and (7) unconjugation of radio-isotope from 
antibody in the patient body (Sergides et al., 1999). 
11. Improving in radioimmunoscintigraphy and radioimmunotherapy 
techniques 
A variety of methods have been developed to counter the inherent flaws in RIS and RIT 
techniques. The following section discusses the methods for overcoming these problems. 
11.1 Pre-targeting 
The pretargeting procedure was developed from the concept that the targeting antibody 
should be separated from the targeting radionuclide through the use of a bispecific antibody 
(Chang et al., 2002). An alternative approach to improve tumor:blood ratio for RIS is the use of 
pre-targeting strategies. The pre-targeting strategies have led to significant improvements in 
T/B ratio and better diagnostic imaging (Dearling & pedley, 2007). Also, pretargeting has been 
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applied successfully for radioimmunoimaging, because the pretargeted antibody is nontoxic. 
High doses can be administered to saturate antigenic sites at the tumor. Pretargeting strategies 
for RIT have been applied to achieve higher intratumor concentration of isotope than achieved 
by conventional RIT (Kraeber–Bodere et al., 2009). The simplest form of pre-targeting is to use 
a second antibody reagent to clear blood background activity, hence improving the 
signal:noise ratio and the quality of the image. Immune complexes formed by a second 
antibody are rapidly removed from the circulation by the reticuloendothelial system, 
particularly in the liver. In the alternative approach, the administration of antibody and 
radiolabel are separated. Antibody is allowed to localize to the tumor and sufficient time is 
allowed for antibody clearance from the blood and non-target tissues (Dearling & pedley, 
2007). Radioisotope is then injected separately in a form which can be readily captured by the 
tumor bound antibody. The approaches using streptavidin/biotin binding systems raised 
much interest, because the affinity of streptavidin for biotin is exceptionally high (Gruaz-
Guyon et al., 2005). In this strategy, the high affinity of the avidin:biotin system is used to 
capture radiolabeled small molecules from the blood as a two-step imaging method. 
Antibody-avidin conjugate is injected and allowed to be localized to the tumor and cleared 
from the blood (Dearling & pedley, 2007). Radioactive avidin is then injected which localizes 
the tumor by taking advantage of the high affinity and specificity of avidin for biotin (Roland 
et al., 2010, Dearling & pedley, 2007).  
11.2 Dose fractionation 
Dose fractionation has been proposed as a method to improve the therapeutic effect of 
radioimmunotherapy (Dearling & pedley, 2007, Denardo et al., 2002). Fractionated 
radioimmunotherapy may improve therapeutic outcome by decreasing heterogeneity of the 
dose delivered to the tumor and by decreasing hematologic toxicity, thereby allowing an 
increased amount of radionuclide that can be administered (Linden et al,. 2005) . A variety 
of fractionation regimens have been developed and the studies have reported both against 
and in its favour (Goel et al., 2001; Buchsbaum et al., 1995; Pedley et al., 1993; Schlom et 
al.,1990; Beaumier et al., 1991). This technique has several advantages including more 
uniform distribution of mAb and radiation dose, patient-specific radionuclide and radiation 
dose, control toxicity by titration of an individual patient, reduced toxicity, increased tumor 
radiation and efficacy and prolongation of tumor response (Violet, 2008). This technique has 
some disadvantages including lower radiation dose rate, complex strategy to implement, 
treatment interruption, increased cost and potential delay in tumor regression (Dearling & 
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Kinetic differences in specific and non-specific uptake of radioactivity provide an 
opportunity to image at a time when the T/B ratio is optimal. Background radioactivity falls 
with time due to excretion and decay of the radioisotope. Tumor radioactivity also falls with 
time, but not as fast as the background. The optimum time for RIS is dependent on the 
selected antibody and radioisotope and detection method (Sergides et al., 1999).  
11.4 Background subtraction 
If the background is labeled using a non-specific antibody, the background signal can then 
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be remembered that this technique leads to increase the total dose of radioactivity in the 
patient body that leads to undesirable side effects. 
11.5 Pre-scouting  
In the latter application, RIS is performed as a scouting procedure prior to RIT to enable the 
confirmation of tumor targeting and the estimation of radiation dose delivered to both 
tumors and normal tissues. For this purpose, the radioimmunoconjugates used for RIS and 
RIT should demonstrate a similar biodistribution and therefore radionuclides with 
comparable chemical properties have to be chosen (Dearling & pedley, 2007). When using 
131I for RIT, both 123I and 131I can be used for a RIS scouting procedure. When using 90Y 
for RIT, 111In can be used to represent this pure beta-emitter (Dearling & pedley, 2007). 
Finally, when aiming the therapeutic use of 186Re or 188Re, either these radionuclides 
themselves can be used for an imaging procedure or 99mTc (Pontus et al., 2004). 
11.6 Increasing the dose delivery  
The result of experiments indicated that increasing the dose of antibody will increase the 
amount of radioactivity in the tumor (Begent et al., 1987). On the other hand, this technique 
has side effects due to HAMA response against the dramatic rise in dose of administered 
antibody that limits the application of this technique (Dearling & pedley, 2007). 
11.7 Combined imaging systems 
The resolution of latest-generation of PET and SPECT cameras has been improved and the 
combination of these systems with an integrated CT (and also MRI) has led to a much better 
interpretation of the data (Dearling & pedley, 2007). In addition, the indirect combination of 
nuclear imaging and optical imaging systems can also serve shared purposes (Munnink et 
al, 2009). 
11.8 Second antibody 
The background counts can be reduced by removing radioactivity from the circulation. This 
can be achieved by the use of a second antibody active against the RIS antibody. In this 
technique, after the binding time of original antibody to tumor tissue, the second antibody 
administers to the patient (Sergides et al., 1999). The second antibody binds to the 
radioactive antibody that remains in the blood stream. The reticuloendothelial system 
uptakes antibody-antibody complex and leads to concentrate radioactivity in liver and 
spleen. This technique leads to increase in T/B ratio without adverse effects. The only 
disadvantage of this method is limitation in the detection of metastases at liver and spleen 
(Sergides et al., 1999).  
11.9 Improving the internalization of the radiolabeled mAb 
One significant factor that influences the absorbed radiation dose to the tumor is the fate of 
the radiolabel after internalization of the radiolabeled mAb into the tumor cells. In case of 
internalisation, the radionuclides will come closer to the critical radiation target, i.e. nuclear 
DNA. Internalization of the antibody depends on various factors including the antibody, the 
targeted antigen and the tumor cells. On the other hand, internalisation might be 
disadvantageous, if it leads to quick degradation of the targeting agent followed by diffusion 
and elimination of the radionuclide (Boswell et al., 2007). Most antibodies including those 
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that target antigens located on the surface of the tumor cells such as anti-CEA antibodies, are 
eventually catabolized. Intracellular degradation of the targeting agent can be prevented by 
e.g. dextranation (Bue et al., 2000). Radiolabeling of antibodies with 90Y or 177Lu is 
performed by linking these radionuclides to chelators (DTPA or DOTA) which are chemical 
moieties that complex free metal ions. These chelators are conjugated to the antibodies and 
subsequently to the radiolabel. After catabolization of mAbs labeled with 90Y- or 177Lu-
DTPA/-DOTA, the catabolic products are conjugated to, in most cases, lysine (e.g. 90Y- or 
177Lu-DOTA-lysine). Whereas radioiodinated tyrosine is excreted by the cell, the 90Y- or 
177Lu-DTPA/DOTA-lysine metabolites are trapped within the lysosomes, thereby increasing 
the tumor retention time of these radiolabels (Koppe et al., 2005). Cellular excretion can also 
be limited if the radionuclides are of metal type, e.g. indium or yttrium, and this is due to 
intracellular retention of metal containing catabolic products (Press et al., 1996). 
11.10 Targeting agents 
RIS may be improved by the production of superior targeting agents to deliver radioactivity 
to tumor sites. For example, instead of using intact antibodies to target tumors, fragments of 
antibodies retaining their antigenic specificity can be used (Sergides et al., 1999). Fragments 
of an antibody have several advantages including: 
1. Shorter circulating half-life and faster execration by kidney that leads to decrease 
background signals. 
2. Smaller molecular weight that leads to faster and more deeply diffuse into tumors. 
3. Reduce non-specific antibody binding by Fc receptor on cells due to the loss of the Fc 
fragment  
4. Reduce the HAMA response due to the loss of Fc fragment that is responsible for 
immune response to foreign proteins. 
Further improvements in the structure of antibodies are being explored with antibody 
engineering technology. Single-chain antigen binding fragments (sF7) consisting of variable 
heavy (VH) or variable light (VL) domains and recombinant sF7 peptides which are VH and 
VL domains connected by peptide linkers are the productions of this technology. These 
productions has high affinity for antigen (Sergides et al., 1999). 
11.11 Antibody affinity 
The strength of the antibody:antigen interaction is measured through the binding affinity 
and is quantified through the association constant (Ka) (Boswell et al., 2007). Increasing Ka 
of antibody will be leads to an increase in uptake antibody in the tumor. However, they may 
be less able to penetrate deeply due to strongly bound at the tumor surface. The studies with 
iodine radiolabeled scFvs demonstrated that a threshold affinity between 10−7 and 10−8 M 
was required to observe detectable tumor uptake in mice 24 h post injection, whereas no 
gain in tumor accumulation was observed with affinities >10−9 M. Affinities >10−9 M were 
detrimental to rapid and uniform tumor penetration due to stable binding at the first pass of 
tumor antigens forming a binding site barrier (Adams et al., 2001). 
11.12 Multivalency 
Multivalency has been reported as an advantage in radioimmunotherapy (Dearling & pedley, 
2007). Conversion of monovalent antibodies into multivalent format increases their functional 
affinity and decreases dissociation rates for cell-surface and optimizes biodistribution 
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administers to the patient (Sergides et al., 1999). The second antibody binds to the 
radioactive antibody that remains in the blood stream. The reticuloendothelial system 
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spleen. This technique leads to increase in T/B ratio without adverse effects. The only 
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that target antigens located on the surface of the tumor cells such as anti-CEA antibodies, are 
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be limited if the radionuclides are of metal type, e.g. indium or yttrium, and this is due to 
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to tumor sites. For example, instead of using intact antibodies to target tumors, fragments of 
antibodies retaining their antigenic specificity can be used (Sergides et al., 1999). Fragments 
of an antibody have several advantages including: 
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2. Smaller molecular weight that leads to faster and more deeply diffuse into tumors. 
3. Reduce non-specific antibody binding by Fc receptor on cells due to the loss of the Fc 
fragment  
4. Reduce the HAMA response due to the loss of Fc fragment that is responsible for 
immune response to foreign proteins. 
Further improvements in the structure of antibodies are being explored with antibody 
engineering technology. Single-chain antigen binding fragments (sF7) consisting of variable 
heavy (VH) or variable light (VL) domains and recombinant sF7 peptides which are VH and 
VL domains connected by peptide linkers are the productions of this technology. These 
productions has high affinity for antigen (Sergides et al., 1999). 
11.11 Antibody affinity 
The strength of the antibody:antigen interaction is measured through the binding affinity 
and is quantified through the association constant (Ka) (Boswell et al., 2007). Increasing Ka 
of antibody will be leads to an increase in uptake antibody in the tumor. However, they may 
be less able to penetrate deeply due to strongly bound at the tumor surface. The studies with 
iodine radiolabeled scFvs demonstrated that a threshold affinity between 10−7 and 10−8 M 
was required to observe detectable tumor uptake in mice 24 h post injection, whereas no 
gain in tumor accumulation was observed with affinities >10−9 M. Affinities >10−9 M were 
detrimental to rapid and uniform tumor penetration due to stable binding at the first pass of 
tumor antigens forming a binding site barrier (Adams et al., 2001). 
11.12 Multivalency 
Multivalency has been reported as an advantage in radioimmunotherapy (Dearling & pedley, 
2007). Conversion of monovalent antibodies into multivalent format increases their functional 
affinity and decreases dissociation rates for cell-surface and optimizes biodistribution 
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(Dearling & pedley, 2007). In addition, it allows the creation of bispecific antibody molecules 
that can target two different antigens simultaneously (Sergey et al., 2008). During the last 
decade, several techniques in multivalency engineering have been developed. Each of these 
strategies proposed to link monovalent domains and to produce multivalent antibody, 
obviously has some advantages in some special cases, but none of them is universal. The 
advantages of tumor targeting with multivalent antibody derivatives have been investigated 
for scFv dimers, prepared as disulfide-linked dimers of scFv (Adams et al., 1995), non-covalent 
diabodies (Kortt et al., 2001) and some other bi(multi)valent variants of recombinant antibody 
fragments (Kubetzko et al.,2006; Shahied et al., 2004; Willuda et al., 2001). In most cases, 
dimeric/divalent antibodies showed significant improvement of their pharmacokinetics and 
biodistribution over monomers (Sergey et al., 2008). 
11.13 CockTails 
One problem of RIS is the existence of diversity of epitopes on surface tumor cells that 
reduces uptake radioactivity in tumor. An alternative approach to improve the uptake of 
radioactivity by the target is using cocktails of several radiolabelled antibodies that 
recognize different epitopes or antigens on the same tumor. However, some of the 
experiments indicated positive results by using cocktails, other experiments showed that the 
mAbs of cocktails competed to bind to epitopes with each other and reduce the efficacy of 
the mixture to less than that of one antibody used alone (sergey et al., 2008).  
11.14 Increasing tumor uptake  
By increasing the level of antigen expression, diagnosis and therapy based on targeting can 
be improved. For example, hyperthermia can increase the amount of presenting antigen in a 
tumor (Wilder et al., 1993). Furthermore, several cytokines such as interferon alpha and 
interleukin-6 have been found to upregulate the expression of cell surface antigens 
including histocompatibility antigens and tumor associated antigens such as 
carcinoembryonic antigen (CEA). In both in vivo and in vitro studies an improved antibody-
uptake has been demonstrated as a result of the administration of vasoactive peptides and 
cytokines such as IL-2 or external beam radiation therapy may result in a specific increased 
vascular permeability at the tumor site and thus an increased antibody uptake (Guadagni, et 
al., 1990). Structural modification (e.g., PEGylation) and residue mutation are both useful 
strategies in reducing chemically or physically derived nontarget organ uptake of Abs, but 
these methods do not reduce the uptake due to receptor expression within nontarget organs. 
These are research areas of high interest (Boswell & Brechbiel, 2007). 
11.15 Reducing kidney uptake 
Elevated renal uptake and prolonged retention of radiolabeled antibody is a problem in the 
therapeutic application of such agents (Dearling & pedley, 2007). Because of the negative 
charge of the basement membrane of the glomeruli, positively charged catabolites of the 
radiopharmaceutical may be retained in the kidney, increasing the toxic absorbed dose to 
this radiosensitive organ (Dearling & pedley, 2007). The result of some studies 
demonstrated that lysine, histidine and arginine were effective in reducing the renal uptake 
of radiopharmaceutical and lysine was the most effective (Lin et al., 2007). In these studies it 
has been shown that renal retention can also be minimized by the administration of lysine, a 
cationic amino acid, whereas the uptake in all other organs as well as the tumor remains 
unaffected (Behr et al., 1995). 
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12. Conclusion 
In recent years, significant developments in the application of targeted imaging and therapy 
have taken place in nuclear medicine. This chapter suggests that optimization of 
radioimmunoscintigraphy and radioimmunotherapy methods is still possible and 
emphasizes that these technologies are continuing to progress and are close to become 
routine modalities in the identification of breast cancer sites and its therapy. The 
development of effective imaging and therapy of breast cancer relies to a great extent on the 
development of effective carriers and target agents that can deliver radionuclids to the 
cancer cells. These agents should be able to carry a large load of radionuclids and selectively 
deliver them to the cancer cells with high accuracy to achieve effective cancer cells death 
without inducing nonspecific toxicity. This means that the use of new targeting agents such 
as peptides and affibodies can provide promising results. Liposomes, dendrimers, micelles 
and nanoparticles present large families of carriers that can be exploited for delivery of 
radionuclids and they can be further improved to diagnose and therapy of breast cancer in 
the future. The research in the field of targeted imaging and therapy will help us to avoid 
unnecessary costs and potentially allow these new methods to be available for the majority 
of patients who need them, leading to better quality and quantity of life. 
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1. Introduction 
Dementia describes the loss of brain function that occurs with certain diseases, and which 
has the potential to affect memory, thinking, language, judgment, and behavior. Most types 
of dementia involve irreversible neurodegeneration, and Alzheimer's disease (AD) is the 
most common form. Beyond AD however, there are many other diseases that can lead to 
dementia including dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), 
Parkinson’s disease with dementia, corticobasal degeneration (CBD) and progressive 
supranuclear palsy (PSP). Dementia can also be the result of many small strokes and, in such 
cases, is called vascular dementia. 
Whilst such clinically and neuropathologically overlapping dementia diseases can be 
predicted by clinical diagnosis, definitively differentiating them from one another has 
typically been attempted using high-risk diagnostic procedures (e.g. brain biopsy, Lumbar 
puncture) or, more commonly, during a post-mortem examination. This makes it difficult to 
a) differentiate dementias and treat each appropriately before patient death; b) manage the 
diseases early, before the onset of cognitive decline; c) select appropriate patients for 
assisting in dementia-related drug development; and d) track the impact of new dementia 
therapeutics in clinical trials. Therefore, new non-invasive diagnostic methods for managing 
dementia are in high demand and, reflecting this, many radiopharmaceuticals (drugs tagged 
with a radioactive isotope) have been developed over the last 2 decades that allow non-
invasive examination of dementia pathophysiology in living human subjects using nuclear 
medicine imaging techniques. Such techniques include positron emission tomography (PET) 
and single photon emission computed tomography (SPECT) imaging, and have greatly 
enhanced diagnostic confidence across the entire dementia disease spectrum in recent years. 
This chapter reviews radiopharmaceuticals commonly employed clinically in the 
management of dementia patients, suffering from the diseases outlined above, with nuclear 
medicine modalities. The chapter is divided by disease entity, and progress in imaging the 
pathophysiology of each disease is highlighted. In addition to those radiopharmaceuticals 
with approval for human use discussed herein, there are many experimental 
radiopharmaceuticals for dementia in pre-clinical development, which have not yet been 
translated into clinical use. Comprehensive review of such pre-clinical radiopharmaceuticals 
is outside the scope of this book, and pertinent examples are highlighted only when 
necessary to indicate key concepts involved in imaging dementia patients. The interested 
reader can obtain additional information on radiopharmaceuticals currently in development 
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for dementia from many excellent and comprehensive review articles available in the 
literature (Brücke, et al., 2000; Herholz, 2003, 2011; Herholz, et al., 2007; Ishii, 2002; Jagust, 
2004; Kadir and Nordberg, 2010; Nordberg, 2004, 2008; Pavese and Brooks, 2009; Sioka, et 
al., 2010; Vitali, et al., 2008). 
2. Alzheimer’s disease 
2.1 Introduction 
Alzheimer’s disease (AD) is the most common form of dementia, affecting, for example, 5.3 
million Americans, and this number is expected to rise as the baby boom generation comes 
of age. The cause of AD is presently not entirely understood but what is clear is that it 
results from a complex neurodegenerative cascade that includes misfolding and aggregation 
of proteins such as amyloid and tau, with concomitant decline of neurotransmitter systems. 
As set forth by the National Institute of Neurological and Communicative Diseases and 
Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) and the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV-TR), a 
diagnosis of Alzheimer’s disease (AD) requires two components: (1) clinical progressive 
dementia with episodic memory impairment and (2) hallmark neuropathological changes, 
including the presence of extracellular Aβ plaques and intraneuronal neurofibrillary tangles 
(NFTs) in the cortical brain (APA, 2000; McKhann, et al., 1984). Due to the difficulty of 
confirming histopathology in vivo, however, AD can only be definitively diagnosed post-
mortem. Consequently, the prevailing criteria only allow a probabilistic diagnosis of AD 
based on clinical phenotype. Specifically, a patient must present with manifest dementia 
above a certain severity threshold, impairment of two or more cognitive domains, which 
must cause major interference with social function, and a daily regiment to receive a clinical 
diagnosis of AD (APA, 2000). After confirming the presence of dementia, a clinician must 
exclude other conditions that might account for cognitive decline (McKhann, et al., 1984). 
Since the criteria’s enumeration in 1984, new data has emerged - specifically, with regards to 
the biological basis of AD. New clinical tests, (chiefly, MRI, CT and PET), coupled with the 
Mini-Mental State Examination (MMSE) and ECG, may foment a clinician’s ability to 
differentiate between forms of dementia. 
While clinical-neuropsychological testing remains one of the best tools in a clinician’s 
armamentarium, the utility of such testing is limited in many respects. Evidence suggests 
that AD pathology (i.e. Aβ deposition in extracellular plaques and vascular walls, tau 
neurofibrillary tangles (NFTs), cerebral atrophy, synaptic reduction, and neuronal loss) may 
develop years to decades before the appearance of cognitive deterioration (Pike, et al., 2007; 
Price and Morris, 1999; Thal, et al., 2002). As dementia represents a late stage in the 
progression of this disease, early clinical diagnosis of AD is not possible with a great degree 
of accuracy. Clinical-neuropsychological testing has low sensitivity and specificity in early 
pre-dementia stages because, in part, a mere subset of individuals that is clinically 
diagnosed with mild cognitive impairment (MCI), an at-risk population, will progress to AD 
(Forsberg, et al., 2008; Petersen, et al., 2009; Pike, et al., 2007). Even within later stages, a 
clinical diagnosis of AD is only probable, not definitive. Only 70 to 90% of persons that 
match the aforementioned criteria have their diagnoses confirmed at autopsy (Jellinger, et 
al., 1990; Kukull, et al., 1990). A clinical differential diagnosis of dementia remains 
somewhat difficult, as many of the cognitive symptoms of AD overlap with those of other 
neurodegenerative disorders. 
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It is thus apparent that there is a great need to revise the way in which AD is 
conceptualized. Accurate and definitive diagnoses need to occur ante-mortem, in lieu of post-
mortem, and preferably in the early pre-dementia (prodromal) stage. Dubois et al., having 
moved beyond the NINCDS-ADRDA criteria for probable AD, introduced new standards 
for diagnosis (Dubois, et al., 2007). They include early and significant episodic memory 
impairment and at least one abnormal in vivo biomarker- particularly, medial temporal lobe 
atrophy, abnormal CSF biomarkers (increased total tau concentrations, increased phospho-
tau concentrations, low Aß1-42 concentrations, or a combination of all three), brain Aβ load, 
temporoparietal hypometabolism on [18F]FDG-PET, and/or specific binding pattern with 
particular PET ligands. Learning more about AD biomarkers, and how they fit into the 
accepted paradigm for this disease, will allow for decreased dependence on unreliable 
clinical diagnostic criteria. Non-invasive PET imaging can be particularly useful in this 
context. Probes are being developed that target specific AD biomarkers, allowing us to 
monitor AD pathophysiology in vivo. The main strategies for exploration of AD 
pathophysiology using PET imaging have been reviewed (Jagust, 2004; Nordberg, 2004, 
2008), and are outlined in the following sections. 
2.2 Imaging Alzheimer’s disease with [18F]FDG 
[18F]Fluoro-2-deoxy-D-glucose ([18F]FDG) is the most commonly used radiopharmaceutical 
for clinical PET imaging to date. Patients receive an injection of [18F]FDG, and then images 
are typically obtained 30 – 60 min later. As a radiolabeled analog of glucose, [18F]FDG is 
typically employed as a marker of cell proliferation as it preferentially accumulates in cells 
with increased glucose consumption (e.g. tumors). Therefore, [18F]FDG finds widespread 
application in oncology including diagnosis and staging of cancers, and monitoring tumor 
response to chemotherapy. However, glucose is also the main energy supply for the brain 
and, reflecting this, levels are closely coupled to neuronal function so that measurement of 
cerebral glucose metabolism can provide diagnostically relevant information about the 
neurodegenerative disorders described above. According to Herholz and colleagues 
(Herholz, et al., 2007), typical resting state cerebral metabolic rate for glucose is 40-60 µmol 
glucose/100 g/min for grey matter, and 15 µmol glucose/100 g/min for white matter, 
although this does drop off somewhat with age (Kuhl, et al., 1982). Observed regional 
differences include higher values in the striatum and parietal cortex. Other phylogenetically 
older brain structures (e.g. medial temporal cortex and cerebellum) have glucose 
metabolism rates between grey matter and white matter. 
For at least two decades, significant efforts have been made to image patients at various 
stages of Alzheimer’s disease (including high risk, asymptomatic patients; patients with 
mild cognitive impairment (MCI); and patients with fully developed Alzheimer’s disease) 
with [18F]FDG (e.g. Figure 1). In patients considered high risk for developing AD (for 
example because of family history and possession of the ApoE  ε4 allele (Reiman, et al., 1996; 
Small, et al., 1995)), impairment of regional cerebral glucose metabolism has been observed 
decades before likely onset of dementia and certainly while the patients are still 
asymptomatic (Reiman, et al., 2004). 
In 1997, Kuhl and colleagues reported the first example of using posterior cingulate glucose 
metabolism, determined from [18F]FDG PET scans, to predict progression of disease in 
patients with MCI (Minoshima, et al., 1997). The results have been echoed by a number of 
subsequent longitudinal studies, which have confirmed the high predictive power of  
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results from a complex neurodegenerative cascade that includes misfolding and aggregation 
of proteins such as amyloid and tau, with concomitant decline of neurotransmitter systems. 
As set forth by the National Institute of Neurological and Communicative Diseases and 
Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) and the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV-TR), a 
diagnosis of Alzheimer’s disease (AD) requires two components: (1) clinical progressive 
dementia with episodic memory impairment and (2) hallmark neuropathological changes, 
including the presence of extracellular Aβ plaques and intraneuronal neurofibrillary tangles 
(NFTs) in the cortical brain (APA, 2000; McKhann, et al., 1984). Due to the difficulty of 
confirming histopathology in vivo, however, AD can only be definitively diagnosed post-
mortem. Consequently, the prevailing criteria only allow a probabilistic diagnosis of AD 
based on clinical phenotype. Specifically, a patient must present with manifest dementia 
above a certain severity threshold, impairment of two or more cognitive domains, which 
must cause major interference with social function, and a daily regiment to receive a clinical 
diagnosis of AD (APA, 2000). After confirming the presence of dementia, a clinician must 
exclude other conditions that might account for cognitive decline (McKhann, et al., 1984). 
Since the criteria’s enumeration in 1984, new data has emerged - specifically, with regards to 
the biological basis of AD. New clinical tests, (chiefly, MRI, CT and PET), coupled with the 
Mini-Mental State Examination (MMSE) and ECG, may foment a clinician’s ability to 
differentiate between forms of dementia. 
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armamentarium, the utility of such testing is limited in many respects. Evidence suggests 
that AD pathology (i.e. Aβ deposition in extracellular plaques and vascular walls, tau 
neurofibrillary tangles (NFTs), cerebral atrophy, synaptic reduction, and neuronal loss) may 
develop years to decades before the appearance of cognitive deterioration (Pike, et al., 2007; 
Price and Morris, 1999; Thal, et al., 2002). As dementia represents a late stage in the 
progression of this disease, early clinical diagnosis of AD is not possible with a great degree 
of accuracy. Clinical-neuropsychological testing has low sensitivity and specificity in early 
pre-dementia stages because, in part, a mere subset of individuals that is clinically 
diagnosed with mild cognitive impairment (MCI), an at-risk population, will progress to AD 
(Forsberg, et al., 2008; Petersen, et al., 2009; Pike, et al., 2007). Even within later stages, a 
clinical diagnosis of AD is only probable, not definitive. Only 70 to 90% of persons that 
match the aforementioned criteria have their diagnoses confirmed at autopsy (Jellinger, et 
al., 1990; Kukull, et al., 1990). A clinical differential diagnosis of dementia remains 
somewhat difficult, as many of the cognitive symptoms of AD overlap with those of other 
neurodegenerative disorders. 
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It is thus apparent that there is a great need to revise the way in which AD is 
conceptualized. Accurate and definitive diagnoses need to occur ante-mortem, in lieu of post-
mortem, and preferably in the early pre-dementia (prodromal) stage. Dubois et al., having 
moved beyond the NINCDS-ADRDA criteria for probable AD, introduced new standards 
for diagnosis (Dubois, et al., 2007). They include early and significant episodic memory 
impairment and at least one abnormal in vivo biomarker- particularly, medial temporal lobe 
atrophy, abnormal CSF biomarkers (increased total tau concentrations, increased phospho-
tau concentrations, low Aß1-42 concentrations, or a combination of all three), brain Aβ load, 
temporoparietal hypometabolism on [18F]FDG-PET, and/or specific binding pattern with 
particular PET ligands. Learning more about AD biomarkers, and how they fit into the 
accepted paradigm for this disease, will allow for decreased dependence on unreliable 
clinical diagnostic criteria. Non-invasive PET imaging can be particularly useful in this 
context. Probes are being developed that target specific AD biomarkers, allowing us to 
monitor AD pathophysiology in vivo. The main strategies for exploration of AD 
pathophysiology using PET imaging have been reviewed (Jagust, 2004; Nordberg, 2004, 
2008), and are outlined in the following sections. 
2.2 Imaging Alzheimer’s disease with [18F]FDG 
[18F]Fluoro-2-deoxy-D-glucose ([18F]FDG) is the most commonly used radiopharmaceutical 
for clinical PET imaging to date. Patients receive an injection of [18F]FDG, and then images 
are typically obtained 30 – 60 min later. As a radiolabeled analog of glucose, [18F]FDG is 
typically employed as a marker of cell proliferation as it preferentially accumulates in cells 
with increased glucose consumption (e.g. tumors). Therefore, [18F]FDG finds widespread 
application in oncology including diagnosis and staging of cancers, and monitoring tumor 
response to chemotherapy. However, glucose is also the main energy supply for the brain 
and, reflecting this, levels are closely coupled to neuronal function so that measurement of 
cerebral glucose metabolism can provide diagnostically relevant information about the 
neurodegenerative disorders described above. According to Herholz and colleagues 
(Herholz, et al., 2007), typical resting state cerebral metabolic rate for glucose is 40-60 µmol 
glucose/100 g/min for grey matter, and 15 µmol glucose/100 g/min for white matter, 
although this does drop off somewhat with age (Kuhl, et al., 1982). Observed regional 
differences include higher values in the striatum and parietal cortex. Other phylogenetically 
older brain structures (e.g. medial temporal cortex and cerebellum) have glucose 
metabolism rates between grey matter and white matter. 
For at least two decades, significant efforts have been made to image patients at various 
stages of Alzheimer’s disease (including high risk, asymptomatic patients; patients with 
mild cognitive impairment (MCI); and patients with fully developed Alzheimer’s disease) 
with [18F]FDG (e.g. Figure 1). In patients considered high risk for developing AD (for 
example because of family history and possession of the ApoE  ε4 allele (Reiman, et al., 1996; 
Small, et al., 1995)), impairment of regional cerebral glucose metabolism has been observed 
decades before likely onset of dementia and certainly while the patients are still 
asymptomatic (Reiman, et al., 2004). 
In 1997, Kuhl and colleagues reported the first example of using posterior cingulate glucose 
metabolism, determined from [18F]FDG PET scans, to predict progression of disease in 
patients with MCI (Minoshima, et al., 1997). The results have been echoed by a number of 
subsequent longitudinal studies, which have confirmed the high predictive power of  
 




Fig. 1. 18F-FDG and PiB group mean images for control, naMCI, aMCI, and AD subjects 
showing better visual separation of groups using PiB. Scaling shown to right using pons and 
cerebellar normalization, respectively. Regions with activity similar to these regions of 
normalization color in 1.0 color ranges (green), whereas regions with greater uptake show 
up in yellow and red. Color scaling is slightly different for 18F-FDG and PiB groups given 
different range of cortical ratios. (Reprinted with permission from Loew VJ, Kemp BJ, Jack CR, et 
al. Comparison of 18F-FDG and PiB PET in Cognitive Impairment. J Nucl Med. 2009;50:878-886) 
[18F]FDG PET. For example, Berent and colleagues reported 70% progression of disease in 3 
years following an abnormal PET scan, but only 30% progression after a normal PET scan 
(Berent, et al., 1999). Anchisi and co-workers also showed that a normal FDG PET scan 
indicated low chance of progression of MCI into full AD within 1 year (Anchisi, et al., 2005). 
Generally speaking [18F]FDG PET has >80% sensitivity and specificity for prediction of rapid 
progression. Moreover, a recent report by Drzezga and colleagues discovered that [18F]FDG 
PET (92% sensitivity, 89% specificity) was superior to ApoE  ε4 testing (75% sensitivity, 56% 
specificity) when used to predict disease progression (A. Drzezga, et al., 2005). Other aspects 
of [18F]FDG PET scans have also proven pertinent to the assessment of MCI. For example, 
mesial temporal metabolic impairment (Heiss, et al., 1992), as well as hippocampal and 
antorhinal metabolic impairment (de Leon, et al., 2001), although the latter can be difficult to 
assess because of small size. 
As MCI progresses and develops into Alzheimer’s disease, numerous studies over the last 
two decades have shown that both cerebral blood flow and glucose metabolism are reduced 
in a number of areas of the brain. For example, impairment of glucose metabolism in the 
temporoparietal association cortices is typical in AD (on the order of 16-19% over 3 years 
(Smith, et al., 1992)), whilst no significant decline is apparent in the corresponding normal 
controls. These cortices are also prone to amyloid deposition during AD (Bartzokis, et al., 
2007). Reduced glucose metabolism may also occur in the frontal association cortex, 
although more so as AD progresses. In contrast to the other dementia diseases discussed 
herein, the rate of glucose metabolism in other areas of the brain including the visual and 
motor cortex, basal ganglia and cerebellum is unaffected (Herholz, et al., 2007). This is in 
agreement with the clinical manifestation of AD, as primary motor and sensory function 
remain intact, whilst memory, associative thinking, planning of action and other higher 
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sensory processing decline. Such clinical and imaging differences can be used as a means of 
differentiating AD from other related disorders. 
More subtle differences between FDG PET scans of normal patients and AD patients are also 
apparent if more advanced image analysis is employed. Voxel-based analysis can detect 
differences in FDG PET that are not obvious upon visual interpretation of the scan. For 
example, comparison of FDG PET scans of AD patients versus normal controls reveals 
impaired glucose metabolism in the posterior cingulate gyrus as well as the precuneus 
(Minoshima, et al., 1997). This is not immediately obvious because metabolism in these areas 
is normally above average and the decrease in AD patients can obscure it into the 
background. The large amounts of FDG PET data obtained in AD patients now allow 
advanced analytical techniques to go one step further, and automatically detect the typical 
pattern of metabolic abnormalities associated with AD. This approach has been successfully 
used to distinguish AD patients for normal controls with >80% (and frequently >90%) 
accuracy, and such data have enabled the use of FDG PET in AD therapeutic trials (Heiss, et 
al., 1994). 
2.3 Imaging amyloid-ß (Aß) plaque burden in Alzheimer’s disease 
As Aβ deposition is considered a hallmark neuropathological sign of AD and is thought to 
be one of the primary events in the pathogenesis of AD (the “amyloid cascade hypothesis”), 
Aβ PET imaging agents are at the forefront of this expanding field (Haass and Selkoe, 2007). 
In AD patients, Aβ deposits are composed of Aβ1-40 and Aβ1-42, peptides that are 40 and 42 
amino acids in length, respectively, generated from the sequential proteolytic cleavage of 
amyloid precursor protein (APP) by β- and γ-secretases (Beyreuther and Masters, 1991; 
Martins, et al., 1991). Whilst Aβ1-42 deposits have a higher propensity to oligomerize, both 
isoforms are found in fibrillar amyloid plaques (Tamaoka, et al., 1994), characteristic β-sheet-
rich structures that represent the target for Aβ PET ligands. 
The ability to image and measure Aβ load in vitro has considerable implications for the 
future study of AD. As Aβ deposition commences long before the onset of cognitive deficits, 
Aβ-targeting probes may support earlier diagnoses and interventions in the pre-dementia 
stage of this disease (Pike, et al., 2007; Price and Morris, 1999; Thal, et al., 2002). Aβ PET 
imaging additionally has some utility in accurately differentiating AD from Aβ-negative 
forms of dementia and, thus, in increasing the specificity of a clinical diagnosis. Objectively 
monitoring treatments and selecting candidates for particular drugs and clinical trials are 
other potential uses for this imaging technology (Rafii and Aisen, 2009); for example, 
patients with low cortical Aβ load, as measured by Aβ PET, are unlikely to qualify for anti-
amyloid therapies. 
Due to the large number of possible clinical applications, there has been a dramatic rise in 
the number of probes that target Aβ plaques over the last decade. The four Aβ PET imaging 
agents under active commercial development are [11C]PIB, [18F]flutemetamol, 
[18F]florbetaben, and [18F]florbetapir. Each imaging agent is currently undergoing FDA-
approved Phase III clinical trials in the US, except [18F]Florbetapir, which is awaiting FDA 
approval. Each Aβ PET imaging agent will be discussed individually in further detail below. 
2.3.1 [11C]Pittsburgh Compound B ([11C]PiB) 
The most well-characterized and studied radiopharmaceutical for Aβ pathology is 
[11C]Pittsburgh Compound B ([11C]PiB, (N-methyl-[11C])2-(4’-methylamino-phenyl)-6-OH-
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[18F]FDG PET. For example, Berent and colleagues reported 70% progression of disease in 3 
years following an abnormal PET scan, but only 30% progression after a normal PET scan 
(Berent, et al., 1999). Anchisi and co-workers also showed that a normal FDG PET scan 
indicated low chance of progression of MCI into full AD within 1 year (Anchisi, et al., 2005). 
Generally speaking [18F]FDG PET has >80% sensitivity and specificity for prediction of rapid 
progression. Moreover, a recent report by Drzezga and colleagues discovered that [18F]FDG 
PET (92% sensitivity, 89% specificity) was superior to ApoE  ε4 testing (75% sensitivity, 56% 
specificity) when used to predict disease progression (A. Drzezga, et al., 2005). Other aspects 
of [18F]FDG PET scans have also proven pertinent to the assessment of MCI. For example, 
mesial temporal metabolic impairment (Heiss, et al., 1992), as well as hippocampal and 
antorhinal metabolic impairment (de Leon, et al., 2001), although the latter can be difficult to 
assess because of small size. 
As MCI progresses and develops into Alzheimer’s disease, numerous studies over the last 
two decades have shown that both cerebral blood flow and glucose metabolism are reduced 
in a number of areas of the brain. For example, impairment of glucose metabolism in the 
temporoparietal association cortices is typical in AD (on the order of 16-19% over 3 years 
(Smith, et al., 1992)), whilst no significant decline is apparent in the corresponding normal 
controls. These cortices are also prone to amyloid deposition during AD (Bartzokis, et al., 
2007). Reduced glucose metabolism may also occur in the frontal association cortex, 
although more so as AD progresses. In contrast to the other dementia diseases discussed 
herein, the rate of glucose metabolism in other areas of the brain including the visual and 
motor cortex, basal ganglia and cerebellum is unaffected (Herholz, et al., 2007). This is in 
agreement with the clinical manifestation of AD, as primary motor and sensory function 
remain intact, whilst memory, associative thinking, planning of action and other higher 
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sensory processing decline. Such clinical and imaging differences can be used as a means of 
differentiating AD from other related disorders. 
More subtle differences between FDG PET scans of normal patients and AD patients are also 
apparent if more advanced image analysis is employed. Voxel-based analysis can detect 
differences in FDG PET that are not obvious upon visual interpretation of the scan. For 
example, comparison of FDG PET scans of AD patients versus normal controls reveals 
impaired glucose metabolism in the posterior cingulate gyrus as well as the precuneus 
(Minoshima, et al., 1997). This is not immediately obvious because metabolism in these areas 
is normally above average and the decrease in AD patients can obscure it into the 
background. The large amounts of FDG PET data obtained in AD patients now allow 
advanced analytical techniques to go one step further, and automatically detect the typical 
pattern of metabolic abnormalities associated with AD. This approach has been successfully 
used to distinguish AD patients for normal controls with >80% (and frequently >90%) 
accuracy, and such data have enabled the use of FDG PET in AD therapeutic trials (Heiss, et 
al., 1994). 
2.3 Imaging amyloid-ß (Aß) plaque burden in Alzheimer’s disease 
As Aβ deposition is considered a hallmark neuropathological sign of AD and is thought to 
be one of the primary events in the pathogenesis of AD (the “amyloid cascade hypothesis”), 
Aβ PET imaging agents are at the forefront of this expanding field (Haass and Selkoe, 2007). 
In AD patients, Aβ deposits are composed of Aβ1-40 and Aβ1-42, peptides that are 40 and 42 
amino acids in length, respectively, generated from the sequential proteolytic cleavage of 
amyloid precursor protein (APP) by β- and γ-secretases (Beyreuther and Masters, 1991; 
Martins, et al., 1991). Whilst Aβ1-42 deposits have a higher propensity to oligomerize, both 
isoforms are found in fibrillar amyloid plaques (Tamaoka, et al., 1994), characteristic β-sheet-
rich structures that represent the target for Aβ PET ligands. 
The ability to image and measure Aβ load in vitro has considerable implications for the 
future study of AD. As Aβ deposition commences long before the onset of cognitive deficits, 
Aβ-targeting probes may support earlier diagnoses and interventions in the pre-dementia 
stage of this disease (Pike, et al., 2007; Price and Morris, 1999; Thal, et al., 2002). Aβ PET 
imaging additionally has some utility in accurately differentiating AD from Aβ-negative 
forms of dementia and, thus, in increasing the specificity of a clinical diagnosis. Objectively 
monitoring treatments and selecting candidates for particular drugs and clinical trials are 
other potential uses for this imaging technology (Rafii and Aisen, 2009); for example, 
patients with low cortical Aβ load, as measured by Aβ PET, are unlikely to qualify for anti-
amyloid therapies. 
Due to the large number of possible clinical applications, there has been a dramatic rise in 
the number of probes that target Aβ plaques over the last decade. The four Aβ PET imaging 
agents under active commercial development are [11C]PIB, [18F]flutemetamol, 
[18F]florbetaben, and [18F]florbetapir. Each imaging agent is currently undergoing FDA-
approved Phase III clinical trials in the US, except [18F]Florbetapir, which is awaiting FDA 
approval. Each Aβ PET imaging agent will be discussed individually in further detail below. 
2.3.1 [11C]Pittsburgh Compound B ([11C]PiB) 
The most well-characterized and studied radiopharmaceutical for Aβ pathology is 
[11C]Pittsburgh Compound B ([11C]PiB, (N-methyl-[11C])2-(4’-methylamino-phenyl)-6-OH-
 
12 Chapters on Nuclear Medicine 
 
204 
BTA), a 6-hydroxyl-substituted benzothiazole aniline; a team led by Mathis and Klunk 
developed this 11C-labeled neutral derivative of Thioflavin-T amyloid dye at the University 
of Pittsburgh in 2002 (W. E.  Klunk, et al., 2001; Mathis, et al., 2002). Pre-clinical studies of 
[11C]PiB have demonstrated that this radiotracer has excellent brain penetration 
(approximately 7% injected dose per gram at 2 minutes post injection) and initial brain 
uptake, rapid clearance from normal brain tissue, high binding affinity to Aβ plaques 
(Ki=0.87±0.18 nM), and moderate lipophilicity (W. E.  Klunk, et al., 2001; Mathis, et al., 2002; 
Mathis, et al., 2003). As a carbon-11 labeled ligand, [11C]PiB has the advantage of delivering 
a lower radiation burden (whole-body effective dose conversion factor for a 70-kg adult= 
4.74±0.8 μSv/MBq; typical administered dose= 489±61 MBq (13±1.65 mCi); effective dose= 
2.37±0.53 mSv). Furthermore, [11C]PiB is able to reach a maximum effect size more rapidly 
than 18F-labeled radiopharmaceuticals, leading to shorter imaging times (50-70 minutes as 
the optimal time-window) (McNamee, et al., 2009; O’Keefe, et al., 2009; Scheinin, et al., 
2007). Of particular interest, in vitro autoradiography studies have confirmed that [11C]PiB 
binds to aggregated, fibrillar Aβ deposits in the cortex, striatum, and cerebral vessel walls, 
but not to amorphous, cerebellar Aβ deposits (Greenberg, et al., 2008; W. E.  Klunk, et al., 
2003; Lockhart, et al., 2007). At nanomolar concentrations, however, [11C]PiB does not bind 
to free soluble amyloid, NFTs, or Lewy bodies (Fodero-Tavoletti, et al., 2007; W. E.  Klunk, et 
al., 2003; Lockhart, et al., 2007). 
In 2004, Klunk et al. published the results from their first in human proof-of-mechanism 
study (W. E.  Klunk, et al., 2004). With 16 mild AD patients and 9 healthy controls, this 
study supported the use of [11C]PiB uptake patterns for the reliable discrimination between 
the two diagnostic groups. AD patients had a twofold increase of [11C]PiB uptake over 
healthy controls, as measured by regional and average neocortical standard uptake value 
ratios (SUVRs) with the cerebellum as the reference region, specifically in the frontal, 
temporal, parietal, and lateral temporal cortices, portions of the occipital cortex, and the 
striatum. This pattern of [11C]PiB uptake is consistent with the distribution of Aβ plaques in 
previous post-mortem studies (Thal, et al., 2002). Three AD patients, however, had [11C]PiB 
retention levels in the range typical for healthy controls. Contrastingly, all healthy controls, 
except one, showed little or no cortical [11C]PiB binding. Non-specific binding was present 
in white matter areas, but at identical levels in healthy controls and AD patients. This study 
additionally cited a significant inverse correlation between [11C]PiB uptake and cerebral 
metabolic rate, especially in the parietal cortex, but only when healthy controls and AD 
patients were pooled together. Despite this significant trend, [11C]PiB uptake levels 
provided higher discriminatory power than cerebral metabolic rate in differentiating AD 
patients from healthy controls. 
Since this groundbreaking study, the number of investigations using [11C]PiB in humans, as 
well as research applications for this radiopharmaceutical, have greatly proliferated. 
Numerous studies have been dedicated to determining the relationship between [11C]PiB 
retention and other AD biomarkers, as well as clinical features/parameters. For example, 
[11C]PiB uptake negatively correlates with CSF Aβ1-42 levels in AD patients and healthy 
controls (Fagan, et al., 2007; Forsberg, et al., 2010). Furthermore, tracer binding is directly 
proportional to CSF tau in MCI patients, but not AD patients, cerebral atrophy as measured 
by MRI in AD subjects (although NFTs correlate better), and temporoparietal 
hypometabolism as measured by [18F]FDG-PET (Forsberg, et al., 2008; W. E.  Klunk, et al., 
2004; Storandt, et al., 2009). In addition, subjects with at least one Apolipoprotein E ε4 (ApoE 
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ε4) allele, a genotype strongly associated with AD, are more likely to have a [11C]PiB-
positive scan than a negative one (A.  Drzezga, et al., 2009; Storandt, et al., 2009). 
While [11C]PiB has primarily shown utility in differentiating AD patients from healthy 
controls, this tracer has also been assessed for the differential diagnosis of dementia. 
[11C]PiB binding patterns allow for great separation between AD and Frontotemporal Lobar 
Degeneration (FTLD) patients, as those with the frontotemporal and semantic forms of the 
latter rarely have Aβ plaques post-mortem (A. Drzezga, et al., 2008; Engler, et al., 2008; 
Rabinovici, et al., 2007; Rowe, et al., 2007). Contrastingly, due to the presence of Aβ deposits 
in a large proportion of patients with Lewy body dementia (DLB) (only 15% of cases 
represent “pure” DLB with no Aβ pathology), it is harder to distinguish DLB from AD 
solely based on [11C]PiB binding alone (McKeith, et al., 1996; Rowe, et al., 2007). In 
comparison to the distribution pattern typical of AD patients, DLB cortical [11C]PiB uptake 
has been noted to be more variable and lower in a majority of cases (Rowe, et al., 2007). 
While [11C]PiB cannot distinguish AD and DLB pathology with a high degree of accuracy, 
this technology could potentially be used to identify Aβ-negative and Aβ-positive DLB 
subsets. Whether this discrimination signifies differences in therapeutic options remains 
unknown at this time. In a study by Rowe et al., the presence of Aβ deposition (high Aβ load) 
was associated with a more rapid onset of the full DLB phenotype (Rowe, et al., 2007). 
[11C]PiB studies, thus, may be able to shed new insights into DLB pathophysiology. Healthy 
controls have been additional subjects of [11C]PiB studies because 10-30% of cognitively 
normal elderly people have Aβ plaques at levels comparable to those of AD patients post-
mortem (Aizenstein, et al., 2008; Price and Morris, 1999). Concomitantly, 10-30% of healthy 
controls with normal cognition show increased cortical [11C]PiB binding (W. E.  Klunk, et al., 
2004; Mintun, et al., 2006; Morris, et al., 2009; Rowe, et al., 2007). To date, this technology 
does not allow discrimination between healthy controls with high Aβ load and AD patients. 
The meaning of these false-positive scans is unclear; while low specificity is possible, high 
[11C]PiB uptake and thus Aβ load in cognitively normal people most likely represents either 
pre-clinical AD or “benign” pathology (Mintun, et al., 2006; Morris, et al., 2009; Rowe, et al., 
2007). 
There is evidence to suggest a prodromal stage of AD does exist, in which Aβ deposition 
begins in a small subset of adults as a primary event (Jack, et al., 2009; Pike, et al., 2007; 
Rowe, et al., 2007). As these individuals reach the MCI phase, the amount of Aβ 
accumulation approximates the levels seen in AD patients (Jack, et al., 2009; Pike, et al., 
2007). Upon conversion to AD, Aβ load either plateaus or progresses slowly. Consequently, 
clinical cognitive decline (or severity of dementia) does not correlate with Aβ load, as 
measured in vivo by [11C]PiB (Jack, et al., 2009; Rowe, et al., 2007). This time course for Aβ 
accumulation is further supported by a 2-year study in which a majority of 16 AD subjects 
did not show a significant change in [11C]PiB uptake from baseline, despite decreases in 
clinical cognitive parameters and temporoparietal metabolism (as measured by [18F]FDG-
PET) (Engler, et al., 2006). The results from this study support the use of [11C]PiB as a 
potential early biomarker for AD, but not as an indicator of disease severity. Other 
measures, such as [18F]FDG-PET and tau PET imaging agents, which track later-developing 
biomarkers, correlate better with cognitive decline and thus can be used to assess 
neurodegeneration (Meyer, et al., 2011). 
To further evidence [11C]PiB’s ability to act as an early biomarker for AD, radiotracer studies 
have been performed in MCI patients. [11C]PiB distribution patterns in MCI patients are 
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provided higher discriminatory power than cerebral metabolic rate in differentiating AD 
patients from healthy controls. 
Since this groundbreaking study, the number of investigations using [11C]PiB in humans, as 
well as research applications for this radiopharmaceutical, have greatly proliferated. 
Numerous studies have been dedicated to determining the relationship between [11C]PiB 
retention and other AD biomarkers, as well as clinical features/parameters. For example, 
[11C]PiB uptake negatively correlates with CSF Aβ1-42 levels in AD patients and healthy 
controls (Fagan, et al., 2007; Forsberg, et al., 2010). Furthermore, tracer binding is directly 
proportional to CSF tau in MCI patients, but not AD patients, cerebral atrophy as measured 
by MRI in AD subjects (although NFTs correlate better), and temporoparietal 
hypometabolism as measured by [18F]FDG-PET (Forsberg, et al., 2008; W. E.  Klunk, et al., 
2004; Storandt, et al., 2009). In addition, subjects with at least one Apolipoprotein E ε4 (ApoE 
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ε4) allele, a genotype strongly associated with AD, are more likely to have a [11C]PiB-
positive scan than a negative one (A.  Drzezga, et al., 2009; Storandt, et al., 2009). 
While [11C]PiB has primarily shown utility in differentiating AD patients from healthy 
controls, this tracer has also been assessed for the differential diagnosis of dementia. 
[11C]PiB binding patterns allow for great separation between AD and Frontotemporal Lobar 
Degeneration (FTLD) patients, as those with the frontotemporal and semantic forms of the 
latter rarely have Aβ plaques post-mortem (A. Drzezga, et al., 2008; Engler, et al., 2008; 
Rabinovici, et al., 2007; Rowe, et al., 2007). Contrastingly, due to the presence of Aβ deposits 
in a large proportion of patients with Lewy body dementia (DLB) (only 15% of cases 
represent “pure” DLB with no Aβ pathology), it is harder to distinguish DLB from AD 
solely based on [11C]PiB binding alone (McKeith, et al., 1996; Rowe, et al., 2007). In 
comparison to the distribution pattern typical of AD patients, DLB cortical [11C]PiB uptake 
has been noted to be more variable and lower in a majority of cases (Rowe, et al., 2007). 
While [11C]PiB cannot distinguish AD and DLB pathology with a high degree of accuracy, 
this technology could potentially be used to identify Aβ-negative and Aβ-positive DLB 
subsets. Whether this discrimination signifies differences in therapeutic options remains 
unknown at this time. In a study by Rowe et al., the presence of Aβ deposition (high Aβ load) 
was associated with a more rapid onset of the full DLB phenotype (Rowe, et al., 2007). 
[11C]PiB studies, thus, may be able to shed new insights into DLB pathophysiology. Healthy 
controls have been additional subjects of [11C]PiB studies because 10-30% of cognitively 
normal elderly people have Aβ plaques at levels comparable to those of AD patients post-
mortem (Aizenstein, et al., 2008; Price and Morris, 1999). Concomitantly, 10-30% of healthy 
controls with normal cognition show increased cortical [11C]PiB binding (W. E.  Klunk, et al., 
2004; Mintun, et al., 2006; Morris, et al., 2009; Rowe, et al., 2007). To date, this technology 
does not allow discrimination between healthy controls with high Aβ load and AD patients. 
The meaning of these false-positive scans is unclear; while low specificity is possible, high 
[11C]PiB uptake and thus Aβ load in cognitively normal people most likely represents either 
pre-clinical AD or “benign” pathology (Mintun, et al., 2006; Morris, et al., 2009; Rowe, et al., 
2007). 
There is evidence to suggest a prodromal stage of AD does exist, in which Aβ deposition 
begins in a small subset of adults as a primary event (Jack, et al., 2009; Pike, et al., 2007; 
Rowe, et al., 2007). As these individuals reach the MCI phase, the amount of Aβ 
accumulation approximates the levels seen in AD patients (Jack, et al., 2009; Pike, et al., 
2007). Upon conversion to AD, Aβ load either plateaus or progresses slowly. Consequently, 
clinical cognitive decline (or severity of dementia) does not correlate with Aβ load, as 
measured in vivo by [11C]PiB (Jack, et al., 2009; Rowe, et al., 2007). This time course for Aβ 
accumulation is further supported by a 2-year study in which a majority of 16 AD subjects 
did not show a significant change in [11C]PiB uptake from baseline, despite decreases in 
clinical cognitive parameters and temporoparietal metabolism (as measured by [18F]FDG-
PET) (Engler, et al., 2006). The results from this study support the use of [11C]PiB as a 
potential early biomarker for AD, but not as an indicator of disease severity. Other 
measures, such as [18F]FDG-PET and tau PET imaging agents, which track later-developing 
biomarkers, correlate better with cognitive decline and thus can be used to assess 
neurodegeneration (Meyer, et al., 2011). 
To further evidence [11C]PiB’s ability to act as an early biomarker for AD, radiotracer studies 
have been performed in MCI patients. [11C]PiB distribution patterns in MCI patients are 
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dichotomous, with one subset of MCI patients showing abundant “AD-like” neocortical 
binding ([11C]PiB-positive) and the other subset showing low, non-specific binding 
([11C]PiB-negative) (Forsberg, et al., 2008; Okello, et al., 2009; Pike, et al., 2007; Rowe, et al., 
2007). As only 40-60% of MCI patients progress to AD, longitudinal studies are needed to 
determine if this bimodal distribution pattern of [11C]PiB uptake accurately predicts those 
who will convert to AD (Forsberg, et al., 2008; Kukull, et al., 1990; Okello, et al., 2009; 
Petersen, et al., 2009). In a study by Forsberg et al., 7 out of 21 tested MCI patients converted 
to AD after 8.1±6.0 months (Forsberg, et al., 2008). Interestingly, there were detectable group 
differences between the 7 MCI converters and the 14 non-converters. MCI converters were 
shown to have lower levels of CSF Aβ1-42 and MMSE test scores compared to non-converters. 
Additionally, MCI converters were more likely to be ApoE ε4 carriers (85%) than were non-
converters (57%). Most importantly, MCI converters had high [11C]PiB uptake in the frontal, 
parietal, and temporal cortices and the posterior cingulum, similar to levels in AD patients. 
Contrastingly, MCI non-converters had significantly lower cortical [11C]PiB retention, 
indistinguishable from healthy controls. These promising results demonstrate the prognostic 
value of [11C]PiB for predicting which MCI patients will progress to AD.  
[11C]PiB has now been used in a large number of subjects, consistently showing high 
sensitivity and specificity in detecting cerebral amyloid deposition in vivo with high intra- 
and inter-reader agreement (W. E. Klunk and Mathis, 2008). Due to the short physical half-
life of carbon-11 (20.4 minutes), however, [11C]PiB is limited in clinical availability. As a 
result, Aβ tracers that are radiolabeled with fluorine-18, a radioisotope with a considerably 
longer half-life (109.4 minutes) than carbon-11, have been developed. Fluorine-18 labeled Aβ 
PET tracers do not require on-site cyclotrons for their production, thus allowing for a more 
widespread distribution of this imaging technology. 
2.3.2 [18F]Flutemetamol (3’-[18F]F-PiB or [18F]GE067) 
[18F]Flutemetamol (3’-[18F]F-6-OH-BTA1) is an 18F-labeled thioflavin analog of [11C]PiB 
licensed to GE Healthcare (Koole, et al., 2009). Due to its longer physical half-life in 
comparison to its parent molecule, [18F]flutemetamol can potentially have a larger impact in 
clinical and research settings. Unlike other 18F-labeled Aβ PET radiotracers, 
[18F]flutemetamol has the advantage that there has been extensive work done on its parent 
molecule, [11C]PiB, which can easily lend itself to the validation of [18F]flutemetamol. 
Although [11C]PiB and [18F]flutemetamol exhibit similarities in structure, the two 
radiotracers have slightly different properties. Fortunately, pre-clinical studies of 
[18F]flutemetamol have demonstrated favorable brain kinetics, good penetration of intact 
blood-brain barrier (BBB), and fairly rapid washout of non-specific binding (Nelissen, et al., 
2009). [18F]Flutemetamol has showed a good safety profile and biodistribution (Koole, et al., 
2009). The average typical administered dose is 121 MBq (range=96-147 MBq; 2.59-3.98 mCi) 
(Koole, et al., 2009); It is important to note that [18F]flutemetamol delivers an effective dose 
that is 1.7 times larger than that for [11C]PiB (2.37 mSv versus 4.12 mSv) (O’Keefe, et al., 
2009); this higher radiation burden is due to the relatively greater radiation dose associated 
with fluorine-18 (whole-body effective dose conversion factor= 33.6 μSv/MBq for 
[18F]flutemetamol versus 4.74±0.8 μSv/MBq for [11C]PiB). Nevertheless, there have been no 
adverse events reported for the use of this radiotracer and, therefore, it has been deemed 
safe for use in humans (Koole, et al., 2009). 
Under the direction of Nelissen and co-workers, [18F]flutemetamol entered Phase I clinical 
trials in 2009 (Nelissen, et al., 2009). Eight AD patients and 8 healthy controls were used in 
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this proof-of-concept study. After 80 minutes post injection, most regions of the neocortex 
showed a large difference in SUVRs (with the cerebellum as the reference region) between 
AD patients and healthy controls, except in the medial temporal cortex, which is more prone 
to NFT buildup than amyloid deposition, and the occipital cortex. This spatial distribution 
of [18F]flutemetamol uptake in AD patients closely resembles that typically seen in its parent 
molecule, [11C]PiB. Interestingly however, non-specific binding in white matter was more 
pronounced, but not statistically significant, in healthy controls injected with 
[18F]flutemetamol in comparison to when using [11C]PiB (Fodero-Tavoletti, et al., 2009). 
While this study showed that [18F]flutemetamol PET imaging can be used to differentiate 
AD patients and healthy controls, 2 AD patients had particular regional SUVRs within the 
range seen in healthy controls. These results are comparable to previous [11C]PiB studies, in 
which 10-20% of clinically diagnosed AD patients did not show high cortical tracer uptake 
(W. E.  Klunk, et al., 2004). Conversely, one healthy control had cortical SUVRs in line with 
those seen in AD patients. One possible explanation is that high white matter binding led to 
increased cortical values. The proportion of [18F]flutemetamol-positive healthy controls in 
this study, however, is comparable to the 10-30% of elderly healthy controls who have 
increased [11C]PiB brain uptake at levels indistinguishable from AD patients. 
Based on the positive Phase I results, [18F]flutemetamol continued to be investigated in a 
clinical Phase II capacity (Vandenberghe, et al., 2010). Twenty-seven patients with clinically 
probable AD, 20 patients with amnestic MCI, 15 elderly healthy controls, and 10 younger 
healthy controls were used to determine the efficacy of blinded visual assessments of 
[18F]flutemetamol scans as well as to directly measure [18F]flutemetamol against its parent 
molecule [11C]PiB in terms of its discriminatory power. Researchers found that mean SUVRs 
in the frontal cortex, lateral temporal cortex, parietal cortex, anterior/posterior cingulate, 
and striatum were significantly higher in AD patients than in the elderly healthy controls. 
These results are consistent with the Phase I clinical study for [18F]flutemetamol. Based on 
blinded visual assessments of [18F]flutemetamol scans, 25 of 27 scans from AD subjects and 1 
of 15 scans from the elderly healthy controls were PET-positive, corresponding to a 
sensitivity of 93.1% and a specificity of 93.3% against the clinical standard of truth. For MCI 
patients, 9 of 20 subjects were assigned to the high tracer uptake category.  The proportion 
of [18F]flutemetamol-positive scans for MCI patients is comparable to that reported for 
[11C]PiB (Forsberg, et al., 2008). Additionally, investigators found that the test-retest 
variability ranged from 1 to 4%, which is lower than that reported for [11C]PiB.  Most 
important to the validation of this radiotracer is that both visually and quantitatively, 
[18F]flutemetamol uptake was highly concordant with that of [11C]PiB for both AD and MCI 
patients. However, non-specific binding was greater with [18F]flutemetamol. Regardless, as 
was seen in Phase I clinical studies, high white matter uptake did not lead to any 
misclassifications of the scans by the visual readers. 
Before clinical application, flutemetamol PET imaging needs to be tested against 
histopathology findings at autopsy. Thus, GE Healthcare is currently organizing and 
recruiting for an ongoing [18F]flutemetamol Phase III clinical study (Clinical Trial 
NCT01165554) that will include patients willing to undergo post-mortem studies. Results 
from this trial are pending (GEHC, Accessed 2011). 
2.3.3 [18F]Florbetaben ([18F]BAY94-9172 or [18F]AV-1/ZK) 
[18F]Florbetaben ([18F]BAY94-9172, previously [18F]AV-1/ZK, trans-4-(N-methyl-amino)-4’-
[2-[2-(2-[18F]fluoro-ethoxy)-ethoxy]-ethoxy]-stilbene) is a fluorinated polyethylene glycol  
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dichotomous, with one subset of MCI patients showing abundant “AD-like” neocortical 
binding ([11C]PiB-positive) and the other subset showing low, non-specific binding 
([11C]PiB-negative) (Forsberg, et al., 2008; Okello, et al., 2009; Pike, et al., 2007; Rowe, et al., 
2007). As only 40-60% of MCI patients progress to AD, longitudinal studies are needed to 
determine if this bimodal distribution pattern of [11C]PiB uptake accurately predicts those 
who will convert to AD (Forsberg, et al., 2008; Kukull, et al., 1990; Okello, et al., 2009; 
Petersen, et al., 2009). In a study by Forsberg et al., 7 out of 21 tested MCI patients converted 
to AD after 8.1±6.0 months (Forsberg, et al., 2008). Interestingly, there were detectable group 
differences between the 7 MCI converters and the 14 non-converters. MCI converters were 
shown to have lower levels of CSF Aβ1-42 and MMSE test scores compared to non-converters. 
Additionally, MCI converters were more likely to be ApoE ε4 carriers (85%) than were non-
converters (57%). Most importantly, MCI converters had high [11C]PiB uptake in the frontal, 
parietal, and temporal cortices and the posterior cingulum, similar to levels in AD patients. 
Contrastingly, MCI non-converters had significantly lower cortical [11C]PiB retention, 
indistinguishable from healthy controls. These promising results demonstrate the prognostic 
value of [11C]PiB for predicting which MCI patients will progress to AD.  
[11C]PiB has now been used in a large number of subjects, consistently showing high 
sensitivity and specificity in detecting cerebral amyloid deposition in vivo with high intra- 
and inter-reader agreement (W. E. Klunk and Mathis, 2008). Due to the short physical half-
life of carbon-11 (20.4 minutes), however, [11C]PiB is limited in clinical availability. As a 
result, Aβ tracers that are radiolabeled with fluorine-18, a radioisotope with a considerably 
longer half-life (109.4 minutes) than carbon-11, have been developed. Fluorine-18 labeled Aβ 
PET tracers do not require on-site cyclotrons for their production, thus allowing for a more 
widespread distribution of this imaging technology. 
2.3.2 [18F]Flutemetamol (3’-[18F]F-PiB or [18F]GE067) 
[18F]Flutemetamol (3’-[18F]F-6-OH-BTA1) is an 18F-labeled thioflavin analog of [11C]PiB 
licensed to GE Healthcare (Koole, et al., 2009). Due to its longer physical half-life in 
comparison to its parent molecule, [18F]flutemetamol can potentially have a larger impact in 
clinical and research settings. Unlike other 18F-labeled Aβ PET radiotracers, 
[18F]flutemetamol has the advantage that there has been extensive work done on its parent 
molecule, [11C]PiB, which can easily lend itself to the validation of [18F]flutemetamol. 
Although [11C]PiB and [18F]flutemetamol exhibit similarities in structure, the two 
radiotracers have slightly different properties. Fortunately, pre-clinical studies of 
[18F]flutemetamol have demonstrated favorable brain kinetics, good penetration of intact 
blood-brain barrier (BBB), and fairly rapid washout of non-specific binding (Nelissen, et al., 
2009). [18F]Flutemetamol has showed a good safety profile and biodistribution (Koole, et al., 
2009). The average typical administered dose is 121 MBq (range=96-147 MBq; 2.59-3.98 mCi) 
(Koole, et al., 2009); It is important to note that [18F]flutemetamol delivers an effective dose 
that is 1.7 times larger than that for [11C]PiB (2.37 mSv versus 4.12 mSv) (O’Keefe, et al., 
2009); this higher radiation burden is due to the relatively greater radiation dose associated 
with fluorine-18 (whole-body effective dose conversion factor= 33.6 μSv/MBq for 
[18F]flutemetamol versus 4.74±0.8 μSv/MBq for [11C]PiB). Nevertheless, there have been no 
adverse events reported for the use of this radiotracer and, therefore, it has been deemed 
safe for use in humans (Koole, et al., 2009). 
Under the direction of Nelissen and co-workers, [18F]flutemetamol entered Phase I clinical 
trials in 2009 (Nelissen, et al., 2009). Eight AD patients and 8 healthy controls were used in 
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this proof-of-concept study. After 80 minutes post injection, most regions of the neocortex 
showed a large difference in SUVRs (with the cerebellum as the reference region) between 
AD patients and healthy controls, except in the medial temporal cortex, which is more prone 
to NFT buildup than amyloid deposition, and the occipital cortex. This spatial distribution 
of [18F]flutemetamol uptake in AD patients closely resembles that typically seen in its parent 
molecule, [11C]PiB. Interestingly however, non-specific binding in white matter was more 
pronounced, but not statistically significant, in healthy controls injected with 
[18F]flutemetamol in comparison to when using [11C]PiB (Fodero-Tavoletti, et al., 2009). 
While this study showed that [18F]flutemetamol PET imaging can be used to differentiate 
AD patients and healthy controls, 2 AD patients had particular regional SUVRs within the 
range seen in healthy controls. These results are comparable to previous [11C]PiB studies, in 
which 10-20% of clinically diagnosed AD patients did not show high cortical tracer uptake 
(W. E.  Klunk, et al., 2004). Conversely, one healthy control had cortical SUVRs in line with 
those seen in AD patients. One possible explanation is that high white matter binding led to 
increased cortical values. The proportion of [18F]flutemetamol-positive healthy controls in 
this study, however, is comparable to the 10-30% of elderly healthy controls who have 
increased [11C]PiB brain uptake at levels indistinguishable from AD patients. 
Based on the positive Phase I results, [18F]flutemetamol continued to be investigated in a 
clinical Phase II capacity (Vandenberghe, et al., 2010). Twenty-seven patients with clinically 
probable AD, 20 patients with amnestic MCI, 15 elderly healthy controls, and 10 younger 
healthy controls were used to determine the efficacy of blinded visual assessments of 
[18F]flutemetamol scans as well as to directly measure [18F]flutemetamol against its parent 
molecule [11C]PiB in terms of its discriminatory power. Researchers found that mean SUVRs 
in the frontal cortex, lateral temporal cortex, parietal cortex, anterior/posterior cingulate, 
and striatum were significantly higher in AD patients than in the elderly healthy controls. 
These results are consistent with the Phase I clinical study for [18F]flutemetamol. Based on 
blinded visual assessments of [18F]flutemetamol scans, 25 of 27 scans from AD subjects and 1 
of 15 scans from the elderly healthy controls were PET-positive, corresponding to a 
sensitivity of 93.1% and a specificity of 93.3% against the clinical standard of truth. For MCI 
patients, 9 of 20 subjects were assigned to the high tracer uptake category.  The proportion 
of [18F]flutemetamol-positive scans for MCI patients is comparable to that reported for 
[11C]PiB (Forsberg, et al., 2008). Additionally, investigators found that the test-retest 
variability ranged from 1 to 4%, which is lower than that reported for [11C]PiB.  Most 
important to the validation of this radiotracer is that both visually and quantitatively, 
[18F]flutemetamol uptake was highly concordant with that of [11C]PiB for both AD and MCI 
patients. However, non-specific binding was greater with [18F]flutemetamol. Regardless, as 
was seen in Phase I clinical studies, high white matter uptake did not lead to any 
misclassifications of the scans by the visual readers. 
Before clinical application, flutemetamol PET imaging needs to be tested against 
histopathology findings at autopsy. Thus, GE Healthcare is currently organizing and 
recruiting for an ongoing [18F]flutemetamol Phase III clinical study (Clinical Trial 
NCT01165554) that will include patients willing to undergo post-mortem studies. Results 
from this trial are pending (GEHC, Accessed 2011). 
2.3.3 [18F]Florbetaben ([18F]BAY94-9172 or [18F]AV-1/ZK) 
[18F]Florbetaben ([18F]BAY94-9172, previously [18F]AV-1/ZK, trans-4-(N-methyl-amino)-4’-
[2-[2-(2-[18F]fluoro-ethoxy)-ethoxy]-ethoxy]-stilbene) is a fluorinated polyethylene glycol  
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(PEG) stilbene derivative that was developed by Zhang et al. in 2005 through Avid 
Radiopharmaceuticals under the name [18F]AV-1/ZK (Zhang, et al., 2005a). Due to their 
high binding affinities to Aβ aggregates, stilbene derivatives have been considered as 
potential Aβ-targeting probes for PET imaging (H. F.  Kung, et al., 2001; Zhang, et al., 2005a; 
Zhang, et al., 2005b). Stilbene derivatives have similar structural characteristics as 
benzothiazoles (PiB derivatives) and thus compete for the same binding site on amyloid 
plaques (Zhang, et al., 2005b). [18F]Florbetaben was chosen from a series of stilbenes for its 
appropriate lipophilicity, high binding affinity (Ki= 6.7±0.3 nM), good safety profile, high 
initial uptake and rapid washout in normal mouse brain (4 minutes post-injection), and 
being 18F-radiolabeled (Barthel, et al., 2010; H. F.  Kung, et al., 2001; Patt, et al., 2010). The 
typical administered dose for [18F]florbetaben is 350 MBq (9.5 mCi), and the effective dose is 
5.13 mSv using this dose (whole-body effective dose conversion factor= 14.67±1.39 
μSv/MBq) (O’Keefe, et al., 2009). However, [18F]florbetaben causes a much lower radiation 
burden than most other 18F-labeled probes, such as [18F]flutemetamol (Koole, et al., 2009). In 
vivo autoradiography of transgenic mouse brain and in vitro autoradiography of post-mortem 
human AD brain tissues have demonstrated specific [18F]florbetaben binding to neuritic Aβ 
plaques and to cerebral amyloid angiopathy (Zhang, et al., 2005b); [18F]florbetaben does not 
label Lewy bodies, Pick bodies, glial cytoplasmic inclusions, α-synuclein, NFTs, or other tau 
pathology to any appreciable extent (Zhang, et al., 2005b). Due to convincing pre-clinical 
data, [18F]florbetaben entered clinical trials, under the license of Bayer Schering Pharma. 
Rowe et al. performed the first-in-man proof of mechanism study in 2008, using 15 elderly 
healthy controls, 15 patients with probable AD, and 5 patients with frontotemporal lobe 
degeneration (FTLD) (Rowe, et al., 2008). AD patients showed extensive cortical 
[18F]florbetaben uptake while healthy controls and FTLD patients only demonstrated non-
specific binding in white matter, but at levels comparable to those of AD patients.  Visual 
assessment of [18F]florbetaben scans correctly differentiated AD patients from both healthy 
controls and FTLD patients in all but two cases, leading to a sensitivity and specificity of 
100% and 90%, respectively. Results for this study are comparable with previous [11C]PiB 
studies, in terms of radiotracer distribution. However, the amount of tracer uptake is 
slightly higher for [11C]PiB. At 90-120 minutes post-injection, the mean neocortical SUVR, 
with the cerebellum as the reference region, for [18F]florbetaben was 57% greater in AD 
patients than in healthy controls; but in comparison, [11C]PiB binding is, on average, 70% 
higher in AD patients than in healthy controls (Rowe, et al., 2007). Nevertheless, 
[18F]florbetaben PET imaging was shown to be highly sensitive and specific in 
discriminating between AD patients, healthy controls, and FTLD patients, at a level similar 
to [11C]PiB. 
Subsequent studies have confirmed [18F]florbetaben’s high discriminatory power, low inter- 
and intrareader variability, and clinical utility (Barthel, et al., 2010). As an optimal imaging 
agent, [18F]florbetaben reaches maximum effect size fairly quickly (90 minutes post-
injection) and maintains this contrast for up to 4 hours post-injection (Barthel, et al., 2010; 
Rowe, et al., 2007). This implies a certain flexibility of the imaging time window, which is 
advantageous in the clinical arena. [18F]Florbetaben has also been useful in better clarifying 
the relationship between Aβ load and other AD biomarkers. For example, regional 
radiotracer uptake, particularly in the lateral temporal cortex, is slightly, but significantly 
inversely proportional to MMSE and word-list memory scores when AD patients and 
healthy controls are pooled together (Barthel, et al., 2011; Rowe, et al., 2007). Moreover, there 
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is a higher frequency of ε4 allele(s) of apolipoprotein E (APOE ε4), a strong risk factor for the 
development of AD, in AD patients with [18F]florbetaben-positive scans than in those with 
[18F]florbetaben-negative scans (Barthel, et al., 2011). These results are comparable to 
findings using [11C]PiB. 
Barthel et al. reported the largest study to date, using 81 patients with probable AD and 69 
healthy controls in the primary analysis (Barthel, et al., 2011). This Phase II study confirmed 
the diagnostic accuracy and efficacy of [18F]florbetaben in a larger cohort of subjects. 
Neocortical tracer uptake was significantly higher for AD patients compared with healthy 
controls in frontal, temporal, parietal and occipital cortices, and anterior / posterior 
cingulate. On a regional level, the posterior cingulate presented the greatest separation 
between AD patients and healthy controls and, thus, allowed for the differentiation between 
the two diagnostic groups. These results are consistent with previous [11C]PiB studies that 
have shown that tracer uptake in the posterior cingulate is a good and early indicator of 
probable AD (Ziolko, et al., 2006). Visual assessment of [18F]florbetaben scans have a 
sensitivity of 80% and specificity of 91% for distinguishing AD patients from healthy 
controls. Upon statistical adjustment, due to the fact that somewhat unreliable clinical 
diagnoses (70-90% accuracy) were used as the standard of truth, the sensitivity increased to 
96% while the specificity was determined to be 97%.   
While Phase II clinical trial showed promising results, [18F]florbetaben imaging needs to be 
compared to post-mortem studies to validate this technique. As of November 30, 2009, 
[18F]florbetaben has entered Phase III FDA-approved clinical studies in the US (Bayer, 
Accessed 2011). Using approximately 232 individuals, this trial (Clinical Trial NCT01020838) 
will assess the efficacy of [18F]florbetaben PET imaging for detection of cerebral Aß against 
the golden standard of post-mortem histopathology. The trial is not expected to be completed 
until April 2014. 
2.3.4 [18F]Florbetapir ([18F]AV-45 or Amyvid) 
[18F]Florbetapir ([18F]AV-45, (E)-2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy,)-5-(4-
methylaminostyryl)pyridine, Amyvid) was recently developed by Avid 
Radiopharmaceuticals. As a fluoropegylated stilbene derivative, [18F]Florbetapir  is similar 
in structure to [18F]florbetaben, but the stilbene backbone has been replaced with a 
styrylpyridine core (Zhang, et al., 2007; Zhang, et al., 2005a). [18F]Florbetapir was chosen 
from a small number of 18F-labeled styrylpyridine analogs due to its optimum in vivo 
kinetics and high selectivity for Aβ plaques (Zhang, et al., 2007). Pre-clinical characterization 
of [18F]florbetapir demonstrated that this radiotracer has excellent binding affinity 
(Kd=3.72±0.30 nM) to Aβ aggregates, moderate lipophilicity, high initial brain uptake 
(7.33±1.54% injected dose per gram at 2 min post-injection) and rapid washout kinetics 
(1.88±0.14% injected dose per gram remaining in the brain 60 minutes post injection) in 
normal mice and primate brain (Choi, et al., 2009). Additionally, as supported by in vitro 
autoradiography of post-mortem human brain tissue sections and ex vivo autoradiography of 
transgenic mouse brain, [18F]florbetapir selectively labels fibrillar Aβ plaques, but not tau 
NFTs (Choi, et al., 2009; Choi, et al., 2011). Non-specific binding is low or non-existent. This 
spatial distribution of [18F]florbetapir uptake is similar to the pattern observed for 
[18F]florbetaben (Zhang, et al., 2005b). 
Favorably, [18F]florbetapir also exhibits fast brain kinetics comparable to that of [11C]PiB 
(McNamee, et al., 2009). The signal-to-noise ratio for this radiotracer asymptotes at 50-60 
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(PEG) stilbene derivative that was developed by Zhang et al. in 2005 through Avid 
Radiopharmaceuticals under the name [18F]AV-1/ZK (Zhang, et al., 2005a). Due to their 
high binding affinities to Aβ aggregates, stilbene derivatives have been considered as 
potential Aβ-targeting probes for PET imaging (H. F.  Kung, et al., 2001; Zhang, et al., 2005a; 
Zhang, et al., 2005b). Stilbene derivatives have similar structural characteristics as 
benzothiazoles (PiB derivatives) and thus compete for the same binding site on amyloid 
plaques (Zhang, et al., 2005b). [18F]Florbetaben was chosen from a series of stilbenes for its 
appropriate lipophilicity, high binding affinity (Ki= 6.7±0.3 nM), good safety profile, high 
initial uptake and rapid washout in normal mouse brain (4 minutes post-injection), and 
being 18F-radiolabeled (Barthel, et al., 2010; H. F.  Kung, et al., 2001; Patt, et al., 2010). The 
typical administered dose for [18F]florbetaben is 350 MBq (9.5 mCi), and the effective dose is 
5.13 mSv using this dose (whole-body effective dose conversion factor= 14.67±1.39 
μSv/MBq) (O’Keefe, et al., 2009). However, [18F]florbetaben causes a much lower radiation 
burden than most other 18F-labeled probes, such as [18F]flutemetamol (Koole, et al., 2009). In 
vivo autoradiography of transgenic mouse brain and in vitro autoradiography of post-mortem 
human AD brain tissues have demonstrated specific [18F]florbetaben binding to neuritic Aβ 
plaques and to cerebral amyloid angiopathy (Zhang, et al., 2005b); [18F]florbetaben does not 
label Lewy bodies, Pick bodies, glial cytoplasmic inclusions, α-synuclein, NFTs, or other tau 
pathology to any appreciable extent (Zhang, et al., 2005b). Due to convincing pre-clinical 
data, [18F]florbetaben entered clinical trials, under the license of Bayer Schering Pharma. 
Rowe et al. performed the first-in-man proof of mechanism study in 2008, using 15 elderly 
healthy controls, 15 patients with probable AD, and 5 patients with frontotemporal lobe 
degeneration (FTLD) (Rowe, et al., 2008). AD patients showed extensive cortical 
[18F]florbetaben uptake while healthy controls and FTLD patients only demonstrated non-
specific binding in white matter, but at levels comparable to those of AD patients.  Visual 
assessment of [18F]florbetaben scans correctly differentiated AD patients from both healthy 
controls and FTLD patients in all but two cases, leading to a sensitivity and specificity of 
100% and 90%, respectively. Results for this study are comparable with previous [11C]PiB 
studies, in terms of radiotracer distribution. However, the amount of tracer uptake is 
slightly higher for [11C]PiB. At 90-120 minutes post-injection, the mean neocortical SUVR, 
with the cerebellum as the reference region, for [18F]florbetaben was 57% greater in AD 
patients than in healthy controls; but in comparison, [11C]PiB binding is, on average, 70% 
higher in AD patients than in healthy controls (Rowe, et al., 2007). Nevertheless, 
[18F]florbetaben PET imaging was shown to be highly sensitive and specific in 
discriminating between AD patients, healthy controls, and FTLD patients, at a level similar 
to [11C]PiB. 
Subsequent studies have confirmed [18F]florbetaben’s high discriminatory power, low inter- 
and intrareader variability, and clinical utility (Barthel, et al., 2010). As an optimal imaging 
agent, [18F]florbetaben reaches maximum effect size fairly quickly (90 minutes post-
injection) and maintains this contrast for up to 4 hours post-injection (Barthel, et al., 2010; 
Rowe, et al., 2007). This implies a certain flexibility of the imaging time window, which is 
advantageous in the clinical arena. [18F]Florbetaben has also been useful in better clarifying 
the relationship between Aβ load and other AD biomarkers. For example, regional 
radiotracer uptake, particularly in the lateral temporal cortex, is slightly, but significantly 
inversely proportional to MMSE and word-list memory scores when AD patients and 
healthy controls are pooled together (Barthel, et al., 2011; Rowe, et al., 2007). Moreover, there 
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is a higher frequency of ε4 allele(s) of apolipoprotein E (APOE ε4), a strong risk factor for the 
development of AD, in AD patients with [18F]florbetaben-positive scans than in those with 
[18F]florbetaben-negative scans (Barthel, et al., 2011). These results are comparable to 
findings using [11C]PiB. 
Barthel et al. reported the largest study to date, using 81 patients with probable AD and 69 
healthy controls in the primary analysis (Barthel, et al., 2011). This Phase II study confirmed 
the diagnostic accuracy and efficacy of [18F]florbetaben in a larger cohort of subjects. 
Neocortical tracer uptake was significantly higher for AD patients compared with healthy 
controls in frontal, temporal, parietal and occipital cortices, and anterior / posterior 
cingulate. On a regional level, the posterior cingulate presented the greatest separation 
between AD patients and healthy controls and, thus, allowed for the differentiation between 
the two diagnostic groups. These results are consistent with previous [11C]PiB studies that 
have shown that tracer uptake in the posterior cingulate is a good and early indicator of 
probable AD (Ziolko, et al., 2006). Visual assessment of [18F]florbetaben scans have a 
sensitivity of 80% and specificity of 91% for distinguishing AD patients from healthy 
controls. Upon statistical adjustment, due to the fact that somewhat unreliable clinical 
diagnoses (70-90% accuracy) were used as the standard of truth, the sensitivity increased to 
96% while the specificity was determined to be 97%.   
While Phase II clinical trial showed promising results, [18F]florbetaben imaging needs to be 
compared to post-mortem studies to validate this technique. As of November 30, 2009, 
[18F]florbetaben has entered Phase III FDA-approved clinical studies in the US (Bayer, 
Accessed 2011). Using approximately 232 individuals, this trial (Clinical Trial NCT01020838) 
will assess the efficacy of [18F]florbetaben PET imaging for detection of cerebral Aß against 
the golden standard of post-mortem histopathology. The trial is not expected to be completed 
until April 2014. 
2.3.4 [18F]Florbetapir ([18F]AV-45 or Amyvid) 
[18F]Florbetapir ([18F]AV-45, (E)-2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy,)-5-(4-
methylaminostyryl)pyridine, Amyvid) was recently developed by Avid 
Radiopharmaceuticals. As a fluoropegylated stilbene derivative, [18F]Florbetapir  is similar 
in structure to [18F]florbetaben, but the stilbene backbone has been replaced with a 
styrylpyridine core (Zhang, et al., 2007; Zhang, et al., 2005a). [18F]Florbetapir was chosen 
from a small number of 18F-labeled styrylpyridine analogs due to its optimum in vivo 
kinetics and high selectivity for Aβ plaques (Zhang, et al., 2007). Pre-clinical characterization 
of [18F]florbetapir demonstrated that this radiotracer has excellent binding affinity 
(Kd=3.72±0.30 nM) to Aβ aggregates, moderate lipophilicity, high initial brain uptake 
(7.33±1.54% injected dose per gram at 2 min post-injection) and rapid washout kinetics 
(1.88±0.14% injected dose per gram remaining in the brain 60 minutes post injection) in 
normal mice and primate brain (Choi, et al., 2009). Additionally, as supported by in vitro 
autoradiography of post-mortem human brain tissue sections and ex vivo autoradiography of 
transgenic mouse brain, [18F]florbetapir selectively labels fibrillar Aβ plaques, but not tau 
NFTs (Choi, et al., 2009; Choi, et al., 2011). Non-specific binding is low or non-existent. This 
spatial distribution of [18F]florbetapir uptake is similar to the pattern observed for 
[18F]florbetaben (Zhang, et al., 2005b). 
Favorably, [18F]florbetapir also exhibits fast brain kinetics comparable to that of [11C]PiB 
(McNamee, et al., 2009). The signal-to-noise ratio for this radiotracer asymptotes at 50-60 
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minutes post injection and remains stable until at least 90 minutes post-injection (Wong, et 
al., 2010); contrastingly, both [18F]flutemetamol and [18F]florbetaben reach maximum effect 
size at 85-90 minutes post injection (Barthel, et al., 2010; Nelissen, et al., 2009). This property 
of [18F]florbetapir creates a large time-frame to obtain a 10 minute image and allows for 
shorter imaging times, if necessary. Moreover, [18F]florbetapir has a good safety profile and 
biodistribution. The typical administered dose is 382.0±14 MBq (10.3±0.38 mCi), and the 
effective dose is 6.66±0.38 mSv using an administered dose of 370 MBq (whole-body 
effective dose conversion factor = 18.0±1.01 μSv/MBq) (Lin, et al., 2010). As expected, 
[18F]florbetapir delivers a higher radiation burden than [11C]PiB, but  still within the normal 
range for 18F-labeled radiopharmaceuticals (O’Keefe, et al., 2009); and thus it remains 
suitable for clinical imaging applications. 
Clinical studies of [18F]florbetapir have consistently shown its high discriminatory power in 
being able to differentiate between AD patients, patients with amyloid positive and amyloid 
negative MCI, and healthy controls (e.g. Figure 2) (Lister-James, et al., 2011). For example, in 
a study of 15 elderly healthy controls and 11 AD patients, [18F]florbetapir uptake was 
significantly higher in AD patients than in healthy controls, especially in cortical target 
areas, such as the frontal and temporal cortices and the precuneus (Wong, et al., 2010). 
Variable tracer uptake was seen in the occipital cortex, in which Aβ deposition is thought to 
occur inconsistently. Contrastingly, healthy controls had tracer accumulation predominantly 
in white matter areas, as non-specific binding. It was noted, however, that two elderly 
healthy controls presented with increased tracer accumulation, indistinguishable from AD 
patients, and two other healthy controls had borderline levels of tracer uptake, especially in 
the precuneus. This finding is consistent with previous [11C]PiB studies, in which 10-30% of  
 
 
Fig. 2. Florbetapir F-18 PET imaging (coronal, axial, and sagittal views). Top left, healthy 
control (SUVR = 0.98; visual read score = 0); top right: patient with clinically diagnosed AD 
and interpreted as Aß+ (SUVR = 1.68; visual read score = 3); bottom left, patient with mild 
cognitive impairment and interpreted as Aß- (SUVR = 1.03; visual read score = 0); bottom 
right, patient with mild cognitive impairment and interpreted as Aß+ (SUVR = 1.61; visual 
read score = 4). (Reprinted with permission from Lister-James J, Pontecorvo MJ, Clark C, et al. 
Florbetapir F-18: A histopathologically validated beta-amyloid positron emission tomography 
imaging agent. Semin. Nucl. Med. 2011;50:300-304) 
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cognitively intact healthy subjects have increased tracer uptake (W. E.  Klunk, et al., 2004; 
Mintun, et al., 2006; Morris, et al., 2009; Rowe, et al., 2007). 
Lin and co-workers presented similar results for [18F]florbetapir in a clinical study, using 6 
healthy controls and 3 AD patients (Lin, et al., 2010). Tracer uptake was particularly high in 
the frontal, parietal, and occipital cortices of AD patients; healthy controls showed 
substantial non-specific binding in subcortical white matter. Consequently, simple semi-
quantitative measures (SUVRs with the cerebellum as the reference region) could be used to 
discriminate between AD patients and healthy controls. Of importance, one AD patient 
showed little uptake of the radiotracer, similar to the binding pattern of healthy controls. 
This negative scan may be due to a lack of tracer sensitivity, but more likely is indicative of a 
low Aβ load in this clinically diagnosed AD patient. 
In 2011, Clark et al. published the results from the first study of its kind, comparing the 
efficacy of an Aβ PET imaging agent against the golden standard of neuropathology 
confirmation at autopsy (Clark, et al., 2011b). This study included individuals near end of 
life who consented to donating their brain after death. Thirty-six subjects with clinically 
diagnosed AD were included in the autopsy cohort (but only 29 were included in the 
primary analysis) while 74 young healthy controls were in the non-autopsy cohort. All 74 
young healthy controls were found to have a [18F]florbetapir-negative scan. For the primary 
analysis autopsy cohort, visual assessment scores of [18F]florbetapir scans and average 
neocortical and regional SUVRs (cerebellum as reference region) correlated well with post-
mortem amyloid pathology (as measured by immunohistochemistry and silver stain neuritic 
plaque score).  
Interestingly, only 15 participants met pathological criteria for AD in the primary analysis 
autopsy cohort. Of these 15 participants, 14 had [18F]florbetapir PET scans visually assessed 
as positive, giving a sensitivity of 93%. Fourteen participants in the primary analysis 
autopsy cohort had histologically-confirmed low levels of Aβ aggregation at post-mortem 
and thus did not meet the criteria for AD. All 14 participants had [18F]florbetapir-negative 
scans, leading to a specificity of 100%. This study also cited good interreader agreement 
among the three nuclear medicine physicians who visually rated the [18F]florbetapir PET 
images (0.68≤κ≤0.98). While these Phase III results are very promising, Clark cautioned that 
this study does not explicitly highlight the specific clinical applications of this imaging 
agent. Currently, only a [18F]florbetapir-negative scan is considered clinically useful, as it 
can help rule out the presence of pathologically significant levels of Aβ in the brain and thus 
AD pathology. [18F]Florbetapir cannot, however, diagnose AD because cerebral amyloid 
deposition is not specific to this diagnosis. Due to encouraging results from its Phase III 
clinical study, Avid Radiopharmaceuticals (now a sub-company under Eli Lilly and 
Company) filed for FDA approval of [18F]florbetapir in late 2010 (Sullivan, 2011). In a vote of 
13-3, the Peripheral and Central Nervous System Drugs Advisory Committee did not 
recommend approval of [18F]florbetapir in January 2011, citing high inter-reader variability 
and the lack of a single clinically applicable binary reading method as outstanding issues 
(Sullivan, 2011). The advisory committee did, however, subsequently vote 16-0 in favor of 
approval if Avid were to implement reader-training programs (Sullivan, 2011). Such 
implementation is currently in progress. 
The committee’s decision was partially based on the results presented in the study by Clark 
and co-workers (Clark, et al., 2011b). Upon independently analyzing the critical individual 
reader score data, the FDA found substantial inter-reader variability among independent, 
extensively trained readers of [18F]florbetapir PET scans for individuals in the autopsy  
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minutes post injection and remains stable until at least 90 minutes post-injection (Wong, et 
al., 2010); contrastingly, both [18F]flutemetamol and [18F]florbetaben reach maximum effect 
size at 85-90 minutes post injection (Barthel, et al., 2010; Nelissen, et al., 2009). This property 
of [18F]florbetapir creates a large time-frame to obtain a 10 minute image and allows for 
shorter imaging times, if necessary. Moreover, [18F]florbetapir has a good safety profile and 
biodistribution. The typical administered dose is 382.0±14 MBq (10.3±0.38 mCi), and the 
effective dose is 6.66±0.38 mSv using an administered dose of 370 MBq (whole-body 
effective dose conversion factor = 18.0±1.01 μSv/MBq) (Lin, et al., 2010). As expected, 
[18F]florbetapir delivers a higher radiation burden than [11C]PiB, but  still within the normal 
range for 18F-labeled radiopharmaceuticals (O’Keefe, et al., 2009); and thus it remains 
suitable for clinical imaging applications. 
Clinical studies of [18F]florbetapir have consistently shown its high discriminatory power in 
being able to differentiate between AD patients, patients with amyloid positive and amyloid 
negative MCI, and healthy controls (e.g. Figure 2) (Lister-James, et al., 2011). For example, in 
a study of 15 elderly healthy controls and 11 AD patients, [18F]florbetapir uptake was 
significantly higher in AD patients than in healthy controls, especially in cortical target 
areas, such as the frontal and temporal cortices and the precuneus (Wong, et al., 2010). 
Variable tracer uptake was seen in the occipital cortex, in which Aβ deposition is thought to 
occur inconsistently. Contrastingly, healthy controls had tracer accumulation predominantly 
in white matter areas, as non-specific binding. It was noted, however, that two elderly 
healthy controls presented with increased tracer accumulation, indistinguishable from AD 
patients, and two other healthy controls had borderline levels of tracer uptake, especially in 
the precuneus. This finding is consistent with previous [11C]PiB studies, in which 10-30% of  
 
 
Fig. 2. Florbetapir F-18 PET imaging (coronal, axial, and sagittal views). Top left, healthy 
control (SUVR = 0.98; visual read score = 0); top right: patient with clinically diagnosed AD 
and interpreted as Aß+ (SUVR = 1.68; visual read score = 3); bottom left, patient with mild 
cognitive impairment and interpreted as Aß- (SUVR = 1.03; visual read score = 0); bottom 
right, patient with mild cognitive impairment and interpreted as Aß+ (SUVR = 1.61; visual 
read score = 4). (Reprinted with permission from Lister-James J, Pontecorvo MJ, Clark C, et al. 
Florbetapir F-18: A histopathologically validated beta-amyloid positron emission tomography 
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cognitively intact healthy subjects have increased tracer uptake (W. E.  Klunk, et al., 2004; 
Mintun, et al., 2006; Morris, et al., 2009; Rowe, et al., 2007). 
Lin and co-workers presented similar results for [18F]florbetapir in a clinical study, using 6 
healthy controls and 3 AD patients (Lin, et al., 2010). Tracer uptake was particularly high in 
the frontal, parietal, and occipital cortices of AD patients; healthy controls showed 
substantial non-specific binding in subcortical white matter. Consequently, simple semi-
quantitative measures (SUVRs with the cerebellum as the reference region) could be used to 
discriminate between AD patients and healthy controls. Of importance, one AD patient 
showed little uptake of the radiotracer, similar to the binding pattern of healthy controls. 
This negative scan may be due to a lack of tracer sensitivity, but more likely is indicative of a 
low Aβ load in this clinically diagnosed AD patient. 
In 2011, Clark et al. published the results from the first study of its kind, comparing the 
efficacy of an Aβ PET imaging agent against the golden standard of neuropathology 
confirmation at autopsy (Clark, et al., 2011b). This study included individuals near end of 
life who consented to donating their brain after death. Thirty-six subjects with clinically 
diagnosed AD were included in the autopsy cohort (but only 29 were included in the 
primary analysis) while 74 young healthy controls were in the non-autopsy cohort. All 74 
young healthy controls were found to have a [18F]florbetapir-negative scan. For the primary 
analysis autopsy cohort, visual assessment scores of [18F]florbetapir scans and average 
neocortical and regional SUVRs (cerebellum as reference region) correlated well with post-
mortem amyloid pathology (as measured by immunohistochemistry and silver stain neuritic 
plaque score).  
Interestingly, only 15 participants met pathological criteria for AD in the primary analysis 
autopsy cohort. Of these 15 participants, 14 had [18F]florbetapir PET scans visually assessed 
as positive, giving a sensitivity of 93%. Fourteen participants in the primary analysis 
autopsy cohort had histologically-confirmed low levels of Aβ aggregation at post-mortem 
and thus did not meet the criteria for AD. All 14 participants had [18F]florbetapir-negative 
scans, leading to a specificity of 100%. This study also cited good interreader agreement 
among the three nuclear medicine physicians who visually rated the [18F]florbetapir PET 
images (0.68≤κ≤0.98). While these Phase III results are very promising, Clark cautioned that 
this study does not explicitly highlight the specific clinical applications of this imaging 
agent. Currently, only a [18F]florbetapir-negative scan is considered clinically useful, as it 
can help rule out the presence of pathologically significant levels of Aβ in the brain and thus 
AD pathology. [18F]Florbetapir cannot, however, diagnose AD because cerebral amyloid 
deposition is not specific to this diagnosis. Due to encouraging results from its Phase III 
clinical study, Avid Radiopharmaceuticals (now a sub-company under Eli Lilly and 
Company) filed for FDA approval of [18F]florbetapir in late 2010 (Sullivan, 2011). In a vote of 
13-3, the Peripheral and Central Nervous System Drugs Advisory Committee did not 
recommend approval of [18F]florbetapir in January 2011, citing high inter-reader variability 
and the lack of a single clinically applicable binary reading method as outstanding issues 
(Sullivan, 2011). The advisory committee did, however, subsequently vote 16-0 in favor of 
approval if Avid were to implement reader-training programs (Sullivan, 2011). Such 
implementation is currently in progress. 
The committee’s decision was partially based on the results presented in the study by Clark 
and co-workers (Clark, et al., 2011b). Upon independently analyzing the critical individual 
reader score data, the FDA found substantial inter-reader variability among independent, 
extensively trained readers of [18F]florbetapir PET scans for individuals in the autopsy  
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cohort (Carome and Wolfe, 2011); in particular, sensitivities ranged from 55% to 90%, while 
specificities were between 80% and 100%. The FDA determined that the readers probably 
had different thresholds for positive and negative scans on their visual assessment scale; 
and thus, education initiatives are needed to introduce a consistent binary reading method 
(Clark, et al., 2011a). In March 2011 the FDA echoed the advisory committee’s 
recommendation in their official response on [18F]florbetapir, requesting that Avid 
Radiopharmaceuticals work to implement a reader-training program that will lead to better 
inter-reader reliability. When this issue has been adequately addressed, it is expected that 
FDA approval will be gained for [18F]florbetapir. 
2.4 Imaging tau neurofibrillary tangle burden in Alzheimer’s disease 
2.4.1 Introduction to tauopathies 
Besides amyloid-β, tau is the other hallmark protein that plays a primary role in the 
pathogenesis of Alzheimer’s disease. Tau microtubule-associated protein is essential for 
maintaining proper neuronal function, but in some individuals this protein can accumulate 
intraneuronally due to abnormal changes in the regulation of the protein. This process is 
believed to be the cause of a wide spectrum of different types of dementias known 
collectively as neurodegenerative tauopathies. In addition to Alzheimer’s disease, other 
common tauopathies in humans include Frontotemporal dementia (FTD), Pick’s disease, 
progressive Supranuclear Palsy (PSP), and Parkinson’s disease (Ludolph, et al., 2009), and, 
unfortunately, many of these diseases are currently not curable. 
As addressed above, there is currently no effective way to definitively diagnose AD (or 
other tauopathy) patients before the disease has done irreversible damage. As is the case 
with amyloid-β plaques, risky brain biopsies can be used to determine the presence of tau, 
but post-mortem examination of the brain is needed to definitively diagnose these types of 
disease. While many clinical diagnostic techniques can be used, they require patients to be 
in moderate to late stages of the disease, a time when treatment is much less effective. New 
diagnostic techniques, however, are being explored to enable earlier and more definitive 
diagnosis of AD with PET imaging. While numerous probes have targeted amyloid-β 
plaques, the most promising possibility is to develop a tau-specific PET biomarker that 
would improve diagnostic confidence, enable detection of early stages of AD, and allow 
doctors to monitor the progress of future treatments. 
Microtubules are the cytoskeletal components that allow nutrients to be transported far 
distances along the length of axons. Axoplasmic transport in neurons is an essential process, 
necessary to maintain proper neuron function. Microtubules however are somewhat 
unstable and must be stabilized by tau proteins in order to function properly. In normally 
functioning human brains, tau binds to microtubules to promote stability and 
polymerization in order to enable axoplasmic flow and preserve overall neuronal 
functioning. Six tau isoforms exist in the adult human brain, each with an alternative exon 
splicing sequence. Three of these isoforms, known as 3R-tau are made up of three carboxy-
terminal tandem repeat sequences and the other three isoforms, known as 4R-tau consist of 
four carboxy-terminal tandem repeat sequences. In adult humans the ratio of 3R-tau to 4R-
tau is approximately 1:1 (V. M. Y.  Lee, et al., 2001). The purpose of these different isoforms 
is not completely understood. It is known, however, that only the shortest form of 3R-tau is 
expressed in the fetus, while all six isoforms are expressed in adult brains. One study 
suggests that the 4R-tau isoform is more effective in promoting microtubule binding than  
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the 3R-tau isoform. The exact mechanism by which tau is regulated in the brain is also 
largely unknown; however, recent studies suggest that phosphorylation levels of tau play an 
important role in tau regulation. Increased phosphorylation of tau likely decreases the 
ability of the protein to bind to microtubules. For this reason, it is believed that protein 
kinases and phosphatases play a role in tau regulation. The malfunction of this 
phosphorylation regulation mechanism is thought to be a major cause of tauopathies. In 
normally functioning brains, tau proteins contain approximately 2-3 moles of phosphate per 
mole of tau protein (Iqbal, et al., 2005). 
In the case of AD, tau proteins are hyperphosphorylated, which causes a decrease in the 
ability of the tau to bind to microtubules, leading to microtubule dysfunction and 
neuronal death. Hyperphosphorylated tau is observed in the plaques of AD patients upon 
post-mortem examination. The mechanism by which this hyperphosphorylated tau is 
converted into a plaque is currently unknown. One theory for this process is that 
hyperphosphorylation of the tau causes it to lose binding affinity with microtubules, 
causing the aggregation of tau into insoluble intraneuronal brain deposits. In all 
neurodegenerative tauopathies, deposits and tangles of tau proteins are observed in the 
brain. In AD, tau accumulates in the brain in different structures known as neurofibrillary 
tangles (NFTs). These NFTs are composed of different structures of tau consisting of 
paired helical filaments (PHFs) and straight filaments. Tau aggregates are very insoluble 
in neurons and ultimately cause neuronal death by interfering with the essential 
axoplasmic flow of nutrients to different cell structures. As so little is known about the 
cause of Alzheimer’s disease and other tauopathies, it is important to develop a better 
method for studying tau. 
2.4.2 PET imaging of tau neurofibrillary tangle burden 
Non-invasive functional molecular imaging techniques such as PET imaging have the 
potential to become the future diagnostic standard for Alzheimer’s disease and related 
tauopathies as they would allow for earlier and more definitive diagnosis of such diseases, 
and provide an effective method for monitoring possible treatments. One such approach 
being aggressively explored is the development of tau specific radiopharmaceuticals that 
would allow for the non-invasive quantification of tau NFTs in the brain. Developing 
appropriate biomarkers for detecting tau has proven challenging as they must cross the 
blood brain barrier (BBB), bind selectively to tau, demonstrate safe biodistribution, and 
exhibit low non-specific binding. Nevertheless, several tau-targeting radiopharmaceuticals, 
radiolabeled with fluorine-18 or carbon-11, are in various stages of clinical and pre-clinical 
development. Experimental radiopharmaceuticals including BF-158, FDDNP and T808 are 




([18F]FDDNP) is a recently developed radiopharmaceutical designed to elucidate brain 
plaques and NFTs (Small, et al., 2006). Unlike [11C]PiB, [18F]FDDNP can bind to both 
amyloid-ß plaques as well as tau NFTs, and it has been used in this capacity to quantify NFT 
and plaque build-up in AD (Small, et al., 2006). Currently [18F]FDDNP is the only biomarker 
of its kind being studied in human clinical trials, and such trials demonstrated the ability of 
[18F]FDDNP PET to distinguish healthy control patients from patients with mild cognitive 
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cohort (Carome and Wolfe, 2011); in particular, sensitivities ranged from 55% to 90%, while 
specificities were between 80% and 100%. The FDA determined that the readers probably 
had different thresholds for positive and negative scans on their visual assessment scale; 
and thus, education initiatives are needed to introduce a consistent binary reading method 
(Clark, et al., 2011a). In March 2011 the FDA echoed the advisory committee’s 
recommendation in their official response on [18F]florbetapir, requesting that Avid 
Radiopharmaceuticals work to implement a reader-training program that will lead to better 
inter-reader reliability. When this issue has been adequately addressed, it is expected that 
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Microtubules are the cytoskeletal components that allow nutrients to be transported far 
distances along the length of axons. Axoplasmic transport in neurons is an essential process, 
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the 3R-tau isoform. The exact mechanism by which tau is regulated in the brain is also 
largely unknown; however, recent studies suggest that phosphorylation levels of tau play an 
important role in tau regulation. Increased phosphorylation of tau likely decreases the 
ability of the protein to bind to microtubules. For this reason, it is believed that protein 
kinases and phosphatases play a role in tau regulation. The malfunction of this 
phosphorylation regulation mechanism is thought to be a major cause of tauopathies. In 
normally functioning brains, tau proteins contain approximately 2-3 moles of phosphate per 
mole of tau protein (Iqbal, et al., 2005). 
In the case of AD, tau proteins are hyperphosphorylated, which causes a decrease in the 
ability of the tau to bind to microtubules, leading to microtubule dysfunction and 
neuronal death. Hyperphosphorylated tau is observed in the plaques of AD patients upon 
post-mortem examination. The mechanism by which this hyperphosphorylated tau is 
converted into a plaque is currently unknown. One theory for this process is that 
hyperphosphorylation of the tau causes it to lose binding affinity with microtubules, 
causing the aggregation of tau into insoluble intraneuronal brain deposits. In all 
neurodegenerative tauopathies, deposits and tangles of tau proteins are observed in the 
brain. In AD, tau accumulates in the brain in different structures known as neurofibrillary 
tangles (NFTs). These NFTs are composed of different structures of tau consisting of 
paired helical filaments (PHFs) and straight filaments. Tau aggregates are very insoluble 
in neurons and ultimately cause neuronal death by interfering with the essential 
axoplasmic flow of nutrients to different cell structures. As so little is known about the 
cause of Alzheimer’s disease and other tauopathies, it is important to develop a better 
method for studying tau. 
2.4.2 PET imaging of tau neurofibrillary tangle burden 
Non-invasive functional molecular imaging techniques such as PET imaging have the 
potential to become the future diagnostic standard for Alzheimer’s disease and related 
tauopathies as they would allow for earlier and more definitive diagnosis of such diseases, 
and provide an effective method for monitoring possible treatments. One such approach 
being aggressively explored is the development of tau specific radiopharmaceuticals that 
would allow for the non-invasive quantification of tau NFTs in the brain. Developing 
appropriate biomarkers for detecting tau has proven challenging as they must cross the 
blood brain barrier (BBB), bind selectively to tau, demonstrate safe biodistribution, and 
exhibit low non-specific binding. Nevertheless, several tau-targeting radiopharmaceuticals, 
radiolabeled with fluorine-18 or carbon-11, are in various stages of clinical and pre-clinical 
development. Experimental radiopharmaceuticals including BF-158, FDDNP and T808 are 




([18F]FDDNP) is a recently developed radiopharmaceutical designed to elucidate brain 
plaques and NFTs (Small, et al., 2006). Unlike [11C]PiB, [18F]FDDNP can bind to both 
amyloid-ß plaques as well as tau NFTs, and it has been used in this capacity to quantify NFT 
and plaque build-up in AD (Small, et al., 2006). Currently [18F]FDDNP is the only biomarker 
of its kind being studied in human clinical trials, and such trials demonstrated the ability of 
[18F]FDDNP PET to distinguish healthy control patients from patients with mild cognitive 
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impairment, and from patients with AD. Initial studies have shown that patients with AD 
have significantly more [18F]FDDNP binding in the temporal, parietal, and frontal regions of 
the brain than the corresponding healthy controls. The non-specificity of [18F]FDDNP, 
however, appears to have limited its application to date, as the study of this probe has not 
progressed past these initial clinical studies. 
2.4.2.2 Quinoline and benzamidizole PET biomarkers 
Investigations into the possibility of using radiolabeled quinoline and benzamidizole 
derivatives for PET imaging of tau NFTs have been reported recently by Okamura and 
colleagues (N.  Okamura, et al., 2005). Initial experiments, with [11C]BF-126, [11C]BF-158, and 
[11C]BF-170, demonstrated that these compounds have a high affinity for tau NFTs. 
Furthermore, these compounds appear to bind specifically to tau, without extensive non-
specific binding to amyloid plaques. Through the use of in vitro staining of AD brain slices, 
[11C]BF-158 was shown to be the most promising compound for PET imaging of tau NFTs. 
These radiopharmaceuticals only interact with tau formations in the brains of AD patients. 
This could prove beneficial for distinguishing early AD from other types of tauopathies. For 
example, these radiopharmaceuticals do not bind strongly to the tau structures present in 
the brain slices of patients with Pick’s disease and PSP. Although these 
radiopharmaceuticals have not yet been translated into human clinical trials, the promising 
pre-clinical data suggest they possess the appropriate properties to make them realistic 
radiopharmaceuticals for future testing. 
2.4.2.3 [18F]T794, [18F]T807 and [18F]T808 
Recently, Kolb and colleagues reported development of PET radiopharmaceuticals with 
high binding affinity and selectivity for tau tangles (Szardenings, et al., 2011), and three lead 
compounds were identified: [18F]T794, [18F]T807 and [18F]T808. Initial autoradiographical 
and rodent microPET studies suggest these compounds have the desired binding affinity for 
tau and good selectivity for tau over amyloid, to fill the void in clinical tau PET imaging. 
Translation into the clinic is underway, although human imaging studies with these 
compounds have also yet to be reported. 
2.5 Imaging the cholinergic system 
The abnormal aggregation of amyloid and tau proteins in AD pathophysiology is 
accompanied by concomitant decline of neurotransmitter systems, primarily the cholinergic 
system (Bierer, et al., 1995; Bohnen, et al., 2005; Contestabile, 2011; Francis, et al., 1999; Terry 
and Buccafusco, 2003). Thus, from a diagnostic perspective, there is interest in being able to 
image the cholinergic system with PET. To date, efforts have focused upon developing 
radiolabeled analogs of acetylcholine that are substrates for acetylcholinesterase. 
Acetylcholinesterase (AChE) is the enzyme responsible for the degradation of acetylcholine, 
leading to the termination of cholinergic neurotransmission. AChE deficits in post-mortem 
AD brain samples have been observed, suggesting that cholinergic decline is part of the 
complex neurodegenerative cascade that occurs in AD. Therefore, radiopharmaceuticals 
suitable for quantifying AChE in vivo have potential for tracking the progression of the 
cholinergic aspect of this cascade in AD patients. The synthetic acetylcholinesterase 
substrate, 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) (Shao, et al., 2003; Snyder, et 
al., 1998), is currently in routine clinical use as a radiopharmaceutical for the study of AChE 
function in AD patients, and results from such studies have been encouraging (K. A.  Frey, 
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et al., 1997; Iyo, et al., 1997; Koeppe, et al., 1997; Kuhl, et al., 1996). For example, statistically 
significant decreases in the cortical hydrolysis rate of [11C]PMP in AD brains, versus age-
matched controls, have been detected, and correlations identified (Bohnen, et al., 2005; Iyo, 
et al., 1997; Kilbourn, et al., 1996; Kuhl, et al., 1996). Similar results have also been obtained 
using [11C]-N-methyl-4-piperidyl-acetate ([11C]AMP) (Namba, et al., 1994). 
2.6 Measurement of neuroinflammation 
Microglial activation is the body’s natural response to brain injury and associated 
neuroinflammation. In addition, microglial activation is also thought to play a significant 
role in the immune response to AD-related neuronal degeneration and, in AD patients, 
activated microglia can be found at sites associated with the deposition of aggregated Aβ 
(Kadir and Nordberg, 2010). There is consequently significant interest in developing 
radiopharmaceuticals that allow exploration of microglial activation using PET imaging, 
and the most common are ligands that target the peripheral benzodiazepine receptor 
including [11C]PK11195 and [11C]PBR28. Cagnin and co-workers reported increased levels of 
[11C]PK11195 in the entorhinal, temporoparietal, and cingulate cortices in patients with mild 
AD (when compared to normal controls) (A. Cagnin, et al., 2001). In related work, Edison 
and colleagues imaged AD patients with both [11C]PK11195 and [11C]PiB. They found a 
negative correlation between cortical microglial activation and cognition in AD patients, but 
there was no observable correlation between [11C]PK11195 uptake and [11C]PiB binding 
(Edison, et al., 2008). 
3. Parkinsonian dementias 
3.1 Introduction 
Parkinson's disease (PD) is a progressive degenerative neurological disease, characterized 
by asymmetric onset of resting tremors, rigidity, and bradykinesia in the limbs, leading 
ultimately to unstable posture. The disease is less common in adults under 60, but not 
unheard of, and it does become more common with increasing age. Progression of 
symptoms in PD typically occurs over 10–30 years, but progression can be accelerated in 
certain individuals, especially those with the so-called Parkinson’s-plus syndrome. 
The hallmark pathology of Parkinson’s disease is loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNc), leading to striatal dopamine deficiency, and classical 
symptoms of PD are thought to develop when 80% of striatal dopamine and 50% of the SNc 
neurons are lost. In addition to dopamine loss, concomitant formation of Lewy bodies also 
occurs in PD. Lewy bodies are composed primarily of synuclein and appearance of such 
intraneuronal Lewy body inclusions occurs initially in the lower brainstem and medulla 
oblongata, followed by midbrain and nigral involvement and, eventually, limbic and 
association cortical areas. Despite this, Pavese and Brooks indicate that even with the 
prevalence of Lewy bodies, decline of the dopaminergic system is still the primary factor in 
PD. Other related Parkinsonian syndromes are known however, and dementia occurs in 
most of them. For example, Dementia with Lewy bodies (DLB) is a common 
neurodegenerative dementia that is also associated with the development of α-synuclein 
positive Lewy body neuronal inclusions in the cortex, substantia nigra and brainstem. 
Patients with DLB, suffer from progressive cognitive decline including memory loss, visual 
hallucinations, cognitive circadian fluctuations and sleep disorders. Reflecting the 
seriousness of these conditions, enormous research has been undertaken to develop 
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impairment, and from patients with AD. Initial studies have shown that patients with AD 
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et al., 1997; Iyo, et al., 1997; Koeppe, et al., 1997; Kuhl, et al., 1996). For example, statistically 
significant decreases in the cortical hydrolysis rate of [11C]PMP in AD brains, versus age-
matched controls, have been detected, and correlations identified (Bohnen, et al., 2005; Iyo, 
et al., 1997; Kilbourn, et al., 1996; Kuhl, et al., 1996). Similar results have also been obtained 
using [11C]-N-methyl-4-piperidyl-acetate ([11C]AMP) (Namba, et al., 1994). 
2.6 Measurement of neuroinflammation 
Microglial activation is the body’s natural response to brain injury and associated 
neuroinflammation. In addition, microglial activation is also thought to play a significant 
role in the immune response to AD-related neuronal degeneration and, in AD patients, 
activated microglia can be found at sites associated with the deposition of aggregated Aβ 
(Kadir and Nordberg, 2010). There is consequently significant interest in developing 
radiopharmaceuticals that allow exploration of microglial activation using PET imaging, 
and the most common are ligands that target the peripheral benzodiazepine receptor 
including [11C]PK11195 and [11C]PBR28. Cagnin and co-workers reported increased levels of 
[11C]PK11195 in the entorhinal, temporoparietal, and cingulate cortices in patients with mild 
AD (when compared to normal controls) (A. Cagnin, et al., 2001). In related work, Edison 
and colleagues imaged AD patients with both [11C]PK11195 and [11C]PiB. They found a 
negative correlation between cortical microglial activation and cognition in AD patients, but 
there was no observable correlation between [11C]PK11195 uptake and [11C]PiB binding 
(Edison, et al., 2008). 
3. Parkinsonian dementias 
3.1 Introduction 
Parkinson's disease (PD) is a progressive degenerative neurological disease, characterized 
by asymmetric onset of resting tremors, rigidity, and bradykinesia in the limbs, leading 
ultimately to unstable posture. The disease is less common in adults under 60, but not 
unheard of, and it does become more common with increasing age. Progression of 
symptoms in PD typically occurs over 10–30 years, but progression can be accelerated in 
certain individuals, especially those with the so-called Parkinson’s-plus syndrome. 
The hallmark pathology of Parkinson’s disease is loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNc), leading to striatal dopamine deficiency, and classical 
symptoms of PD are thought to develop when 80% of striatal dopamine and 50% of the SNc 
neurons are lost. In addition to dopamine loss, concomitant formation of Lewy bodies also 
occurs in PD. Lewy bodies are composed primarily of synuclein and appearance of such 
intraneuronal Lewy body inclusions occurs initially in the lower brainstem and medulla 
oblongata, followed by midbrain and nigral involvement and, eventually, limbic and 
association cortical areas. Despite this, Pavese and Brooks indicate that even with the 
prevalence of Lewy bodies, decline of the dopaminergic system is still the primary factor in 
PD. Other related Parkinsonian syndromes are known however, and dementia occurs in 
most of them. For example, Dementia with Lewy bodies (DLB) is a common 
neurodegenerative dementia that is also associated with the development of α-synuclein 
positive Lewy body neuronal inclusions in the cortex, substantia nigra and brainstem. 
Patients with DLB, suffer from progressive cognitive decline including memory loss, visual 
hallucinations, cognitive circadian fluctuations and sleep disorders. Reflecting the 
seriousness of these conditions, enormous research has been undertaken to develop 
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numerous radiopharmaceuticals (Figure 3) that can be used to differentiate these conditions 
and monitor their progression. Progress in this area to date has also been recently reviewed 
(Pavese and Brooks, 2009; Sioka, et al., 2010). 
 
 
Fig. 3. Imaging dopamine terminal function in healthy controls and early Parkinson's 
disease. (Reprinted with permission from Pavese N and Brooks DJ, Imaging 
neurodegeneration in Parkinson’s disease. Biochim. Biophys. Acta. 2009;1792:722-729) 
3.2 Measurement of striatal aromatic amino acid decarboxylase activity 
[18F]DOPA is a radiopharmaceutical used for neuroimaging and for evaluation and 
quantification of presynaptic dopaminergic integrity. For example, analyzing the uptake of 
[18F]DOPA in the striatal nuclei provides valuable information on both the density of the 
axonal terminal plexus and the activity of striatal aromatic amino acid decarboxylase 
(AADC), an enzyme that converts [18F]DOPA to [18F]dopamine (Pavese and Brooks, 2009). 
Therefore [18F]DOPA uptake in the striatum of patients with PD is dependent upon the 
number of remaining dopaminergic cells, and can be used to track progression of the 
disease. It is worth noting, however, that early degeneration can be underestimated due to 
compensatory upregulation of AADC in remaining terminals (Ribeiro, et al., 2002). 
Significant research has been undertaken to investigate the uptake of [18F]DOPA in the 
putamen region of the brain, and noticeable [18F]DOPA reductions have been shown to 
correlate with the clinical severity of rigidity and bradykinesia in PD patients (Brooks, et al., 
1990; Broussolle, et al., 1999; Vingerhoets, et al., 1997). However, there is no correlation with 
the degree of tremors, and Pavese and Brooks highlight that this lack of correlation is 
suggestive of non-nigrostriatal and/or non-dopaminergic origins of the tremors associated 
with PD (Pavese and Brooks, 2009). In patients with hemiparkinsonism (i.e. Parkinsonian 
symptoms on one half of the body only), a corresponding reduction in dorsal posterior 
putamen uptake of [18F]DOPA on the opposite side of the body has been observed (Morrish, 
et al., 1995). As the disease progresses to become bilateral, so to does the reduction of 
[18F]DOPA uptake, and losses are detected in the ventral and anterior putamen and dorsal 
caudate. In the end stages of the disease, reduced [18F]DOPA uptake in the ventral head of 
the caudate is also apparent. Such findings also correspond well to post-mortem data  
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(Fearnley and Lees, 1991; Kish, et al., 1988). Beyond these obvious areas of reduced 
[18F]DOPA uptake, if voxel analysis of the PET scans is performed, then less obvious 
reductions in [18F]DOPA uptake can also be detected across the entire brain (Kaasinen, et al., 
2001; Rakshi, et al., 1999; Whone, et al., 2003). 
3.3 Measurement of the Vesicular Monoamine Transporter (VMAT) 2 
In neurodegenerative diseases there are typically characteristic losses of particular types of 
neurons in the human brain. As outlined above, progressive losses of dopaminergic neurons 
is the hallmark of Parkinson’s disease. Reflecting this, a number of strategies have been 
developed for in vivo imaging of such neuronal losses. One such approach involves 
targeting the vesicular monoamine transporter type 2 (VMAT2) using radioligands such as 
(+)-α-[11C]dihydrotetrabenazine ([11C]DTBZ: (2R,3R,11bR)-(1,3,4,6,7,11b-hexahydro-9-
[11C]methoxy-10-methoxy)-3-(2-methylpropyl)-2-hydroxy-2H-benzo[a]quinolizine) (K. A. 
Frey, et al., 2001). The VMAT2 is not specific for any monoamine, but is a common protein 
capable of transporting dopamine, norepinephrine, serotonin and histamine (Eiden and 
Weihe, 2011). Despite this non-specificity, the utility of VMAT2 imaging in 
neurodegenerative disease is still possible due to the compartmentalization of neuronal 
types in the human brain (K. A. Frey, et al., 2001). For example, dopaminergic nerve 
terminals predominate in the basal ganglia, and so enable specificity for examining losses of 
such terminals in PD patients (Figure 3). The VMAT2 is found in presynaptic vesicles, and 
transports monoamines from the cell cytosol into the storage vesicle, from where they can be 
released into the synapse (Wimalasena, 2011). 
Lee and colleagues conducted a comparison between [11C]DTBZ, [18F]DOPA and 
[11C]methylphenidate (a radiopharmaceutical targeting the dopamine transporter (DAT)) (C. 
S. Lee, et al., 2000). Reflecting the upregulation of aromatic amino acid decarboxylase, and 
concomitant down regulation of the DAT, that occurs to increase dopamine turnover and 
reduce its reuptake in Parkinson’s disease patients, this study found that [18F]DOPA Ki was 
reduced less than the [11C]DTBZ binding potential in the PD striatum, and [11C]DTBZ 
binding was reduced when compared to [11C]methylphenidate binding. The authors suggest 
that [11C]DTBZ PET is the most reliable method for quantifying dopaminergic terminal 
density although, per Pavese and Brooks (Pavese and Brooks, 2009), this needs to be 
validated and the effect of dopaminergic drugs upon [11C]DTBZ uptake determined. 
Reflecting the drive to convert short lived carbon-11 labeled radiopharmaceuticals (t1/2 = 20 
min) into longer lived fluorine-18 labeled analogs (t1/2 = 110 min) to facilitate distribution to 
satellite PET centers that do not own a cyclotron, [18F]FP-TBZ ([18F]AV-133) has also been 
developed to image the VMAT2, and is licensed to Avid Radiopharmaceuticals (H. F. Kung, 
et al., 2008). In studies by Frey and colleagues, AV-133 PET of normal and PD patients were 
compared (K. A. Frey, et al., 2008). Findings were similar to [11C]DTBZ, and AV-133 PET 
provided excellent images of the VMAT2. All PD patients had severe reduction of AV-133 
accumulation in the striatum, most severe in the PP contralateral to worst PD symptoms. 
Similar findings were confirmed in further studies by Okamura and co-workers in 2010 (N. 
Okamura, et al., 2010), and very clear images showing the differences in AV-133 PET 
between PD patients and healthy controls were obtained (Figure 4). 
3.4 Measurement of dopamine transporter binding 
The presynaptic dopamine transporter (DAT) is found in dendrites and axons of 
dopaminergic neurons and is responsible for uptake of dopamine. Therefore, measurement  
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numerous radiopharmaceuticals (Figure 3) that can be used to differentiate these conditions 
and monitor their progression. Progress in this area to date has also been recently reviewed 
(Pavese and Brooks, 2009; Sioka, et al., 2010). 
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(Fearnley and Lees, 1991; Kish, et al., 1988). Beyond these obvious areas of reduced 
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3.4 Measurement of dopamine transporter binding 
The presynaptic dopamine transporter (DAT) is found in dendrites and axons of 
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Fig. 4. (A) Representative images of 18F-AV-133 PET BP in HC and PD patient. (B) Areas of 
reduction in BP of PD patients, compared with HCs, in SPM analysis. Color bars represent t 
values. P < 0.05, corrected for multiple comparisons. (Reprinted with permission from Okamura 
N, Villemagne VL, Drago J, et al. In vivo measurement of vesicular monoamine transporter type 2 
density in Parkinson disease with 18F-AV-133. J Nucl Med. 2010;51:223-228) 
of the DAT can be used as an indicator of the integrity of nigrostriatal projections. Reflecting 
this, a number of radiopharmaceuticals have been developed that allow for the analysis of 
DAT activity by PET and SPECT imaging (see the review by Pavese and Brooks for 
additional information (Pavese and Brooks, 2009)). These include phenyltropane derivatives 
such as 123I-ß-CIT (Brucke, et al., 1997; Seibyl, et al., 1995), 123I-FP-CIT ([123I]ioflupane; 
DaTSCAN) (Castrejón, et al., 2005; Hauser and Grosset, 2011), and [99mTc]trodat (M. P. 
Kung, et al., 1997), that lead  to distinctive images such as those shown in Figure 3. For 
example, [123I]ioflupane, a radiolabeled analog of cocaine, is approved for clinical use in 
Europe and the United States, and marketed as DaTSCAN. Nuclear medicine physicians use 
[123I]ioflupane to diagnose Parkinson’s disease (PD), and to differentiate PD from other 
related neurological disorders that present with similar clinical symptoms (e.g. dementia 
with Lewy bodies (Antonini, 2007; Castrejón, et al., 2005)). [123I]Ioflupane has a high binding 
affinity for presynaptic dopamine transporters (DAT). Thus, a SPECT scan conducted using 
[123I]ioflupane provides physicians with a quantitative measure and the spatial distribution 
of DAT in the brain. A marked reduction in DAT in the striatal region of the brain is 
indicative of PD (Figure 3), allowing physicians to diagnose or differentiate a patient’s 
neurological condition with improved diagnostic confidence when compared to diagnosing 
from clinical symptoms alone. 
A review of the two major clinical trials of [123I]ioflupane was recently published by Hauser 
and Grosset (Hauser and Grosset, 2011). The first study compared baseline scans in patients 
with early suspected Parkinsonism to the consensus clinical diagnosis established 3 years 
later (Marshall, et al., 2009). The study found 78-79% positive agreement (abnormal baseline 
scan and positive diagnosis of PD at 3 yrs, n = 71) and 97% negative agreement (normal 
baseline scan and negative for PD at 3 yrs, n = 28). The second study was a trial of 
[123I]ioflupane in patients with established diagnoses of PD or essential tremor (ET), and 
obtained similar results (Benamer, et al., 2000). This study found 92-97% positive agreement 
(abnormal baseline scan and positive diagnosis of PD at 3 yrs, n = 158) and 74-96% negative 
agreement (normal baseline scan and clinical diagnosis of ET, n = 27).  Castrejón and  
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colleagues have also demonstrated that [123I]ioflupane SPECT can distinguish between PD 
and other Parkinsonian disorders that do not have associated degeneration of the 
nigrostriatal pathway, such as ET (Castrejón, et al., 2005). Despite these positive findings, it 
is important to note that an abnormal [123I]ioflupane SPECT scan does not necessarily 
indicate a diagnosis of PD. Similarly, a normal scan is not entirely indicative of ET (Hauser 
and Grosset, 2011). In each case, multiple other conditions must be considered and 
eliminated. For example, abnormal striatal uptake of [123I]ioflupane would be expected in all 
degenerative Parkinsonian syndromes associated with a loss of nigrostriatal dopamine 
neurons including PD, progressive supranuclear palsy (PSP), multisystem atrophy (MSA), 
and corticobasal degeneration (CBD). [123I]Ioflupane SPECT cannot differentiate these 
related disorders and so, in such cases, it might be necessary to run other tests (FDG PET, 
PiB PET etc.) to further distinguish such diseases. 
3.5 Measurement of neuroinflammation in PD 
As discussed above in the context of AD, microglial activation is the body’s natural response 
to brain injury and associated neuroinflammation. Reflecting this, [11C]PK11195 and 
[11C]PBR28 have been developed to image microglial activation, and recent studies have 
explored the use of [11C]PK11195 PET in PD patients. Such studies report significant 
increases in [11C]PK11195 uptake in striatal and extrastriatal regions of PD patients when 
compared to healthy control subjects (Gerhard, et al., 2006; Ouchi, et al., 2005; Pavese and 
Brooks, 2009). These findings, which have been correlated with reduced striatal DAT 
binding (Ouchi, et al., 2005), suggest that significant microglial activation (and associated 
neuroinflammation) could contribute to dopaminergic neuron loss in PD. This represents an 
avenue of research that has yet to be extensively explored. 
3.6 Imaging of dementia with Lewy bodies 
Dementia with Lewy bodies (DLB) is a common Parkinsonian neurodegenerative dementia 
that is characterized by the development of α-synuclein positive Lewy body neuronal 
inclusions in the cortex, substantia nigra and brainstem. Patients with DLB, suffer from 
progressive cognitive decline including memory loss, visual hallucinations, cognitive 
circadian fluctuations and sleep disorders. In FDG PET of DLB patients, unique 
hypometabolism in the medial and lateral occipital lobes is observed, and is the feature that 
distinguishes DLB from AD (Ishii, 2002). DLB can also be distinguished from AD using 
[18F]DOPA PET. Dopamine deficiencies, similar to PD, have been observed in DLB patients, 
but not in AD patients (Hu, et al., 2000). 
4. Frontotemporal lobe degeneration 
4.1 Introduction 
Frontotemporal lobe degeneration (FTLD) is a cause of degenerative dementias that recent 
research suggests, in individuals younger than 65, is as common as AD. Frontotemporal 
dementia (FTD) is the most common example of such diseases, for which clinical and 
pathological criteria were proposed in 1994 by Brun and colleagues (Brun, et al., 1994). The 
disease is characterized by behavioral and personality changes that result from the 
frontotemporal involvement and include apathy, disinhibition, and often sever impairment 
of language production. In related conditions, such as semantic dementia and progressive 
non-fluent aphasia, language impairment can be the major symptom, and dementia the 
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lesser symptom. In contrast to other dementias however, there is no (or less prominent) 
memory impairment associated with FTLD. Therefore, clinical differentiation from other 
diseases such as AD is usually relatively straightforward. The main difficulty associated 
with managing FTLD is that it is not typically diagnosed in its early stages because mild 
symptoms often go unnoticed, or are difficult to verify. To address this issue, FDG PET has 
been investigated as a possibility for diagnosing and staging the FTLD-related conditions by 
identifying areas of reduced glucose metabolism that are characteristic of these conditions. 
4.2 FDG PET for imaging frontotemporal dementia 
Reduced glucose metabolism in the frontal (mostly the frontal cortex) and anterior temporal 
regions is the characteristic hallmark observed in FDG PET scans of FTD patients. Such 
impairment is not always symmetric, and thought to be related to the aphasia and semantic 
memory deficits common in such patients. This (mostly) frontal impairment allows 
distinction of FTD from AD. For example, Foster and co-workers were recently able to 
distinguish FTD from AD with 86% specificity and 97.6% sensitivity, beyond clinical 
features alone (Foster, et al., 2007). Frontal metabolic decline, however, is not limited to FTD 
and can be apparent in certain cases of AD. In such cases where there is FTD / AD overlap 
in the FDG PET scans, it is recommended to conduct additional scans exploring microglial 
activation or amyloid deposits (see Section 2). For example, microglial activation 
characteristic of FTD has been investigated (A. Cagnin, et al., 2004). Alternatively, an 
amyloid positive scan would strongly suggest AD, whilst an amyloid negative scan would 
indicate FTD (Figure 5) (Kadir and Nordberg, 2010). 
 
 
Fig. 5. High PIB retention was observed in patient with AD (A) and patient with DLB (B). In 
contrast, low PIB retention was observed in patient with PD (not demented) (C) and in patient 
with FTD (D). (Parts A and B reprinted with permission from Ahmadul K and Nordberg A, Target-
specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med. 2010;51:1418-
1430; Part C reprinted with permission from A. Johansson, et al. [11C]-PIB imaging in patients with 
Parkinson’s disease: preliminary results. Parkinsonism Relat. Disord. 2008;14:345-347; Part D courtesy 
of Professor Henry Engler, Uppsala PET Center, Academical Hospital, Uppsala, Sweden). 
Other diseases (e.g. progressive supranuclear palsy, spino-cerebellar atrophy) or lifestyle 
choices (e.g. cocaine abuse) can also lead to frontal metabolic impairment. Consequently, other 
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areas of reduced cerebral glucose metabolism should be considered when making a diagnosis 
as, despite its name, there are more widespread hemispheric defects in glucose metabolism 
that occur in FTD. For example, reduced glucose metabolism in the orbital gyrus, anterior 
cingulate gyrus, frontal cortices, anterior temporal cortices, hippocampus, subcortical 
structures, parietal region, sensorimotor cortex, and the cerebellar cortex, discussed by Ishii 
(Ishii, 2002), are consistent with the pathological features and post-mortem findings of FTD. 
5. Imaging of other dementias 
5.1 Corticobasal degeneration 
Corticobasal degeneration (CBD) is a progressive dementia in which patients have cognitive 
decline, significant dementia and unique motor symptoms such as akineto-rigid syndrome 
(Ishii, 2002). In FDG PET of CBD patients, there is a decrease in absolute glucose metabolism 
in several regions of the brain, and distinct asymmetry in glucose metabolism patterns that 
is characteristic of the condition. For example, Hirono and colleagues showed that CBD 
patients had greater glucose metabolic asymmetries in the lateral frontal, lateral temporal, 
central and lateral parietooccipital regions than did the corresponding healthy controls 
(Hirono, et al., 2001). In the same study it was reported that the most significant pathologic 
changes in CBD appear in the pre- and post-central gyri, and parietal association cortices. 
Moreover, the associated metabolic asymmetries in the pre- and post-central gyri, as well as 
the thalamus, were larger in CBD than AD allowing differentiation of these conditions using 
FDG PET. 
5.2 Progressive supranuclear palsy 
Progressive supranuclear palsy (PSP) is a condition associated with Parkinsonism and 
dementia. Pathological changes are most common in the basal ganglia and brain stem, and 
features of this neurodegenerative condition include behavioral derangement and cognitive 
decline (Ishii, 2002). In FDG PET of PSP patients, glucose metabolism is reduced in the 
lateral and medial frontal lobes, caudate nucleus and midbrain, when compared to normal 
controls (Blin, et al., 1990; Hosaka, et al., 2002). 
5.3 Vascular dementia 
When dementia results from many small strokes, it is known as vascular dementia. In 
contrast to other dementias, it is relatively straightforward to diagnose vascular dementia 
from clinical symptoms, and with MRI or CT. Typically therefore nuclear medicine imaging 
is not needed for patients with pure vascular dementia (Ishii, 2002). On occasion however, 
vascular dementia can be associated with AD pathology. In such cases, FDG PET can be 
employed to distinguish vascular dementia from the reduced glucose metabolism profile 
associated with AD (see Section 2.2). 
6. Conclusion 
In conclusion, the sophisticated array of radiopharmaceuticals that have been developed for 
imaging dementia using PET and SPECT scans is highlighted. Using such imaging 
techniques alone, or in combination with each other (and/or MRI, CT etc.), allows 
physicians to differentiate between related, and frequently clinically overlapping, disease 
entities with a high degree of diagnostic confidence. However, whilst [18F]FDG is readily 
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physicians to differentiate between related, and frequently clinically overlapping, disease 
entities with a high degree of diagnostic confidence. However, whilst [18F]FDG is readily 
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available, the more specialized radiopharmaceuticals described herein are still limited to 
sites typically possessing a cyclotron and advanced radiochemistry laboratories. In order for 
patients and physicians alike to benefit from these radiopharmaceuticals, global access has 
to be provided. The new partnerships growing between big pharma, small 
radiopharmaceutical companies, and larger companies possessing global 
radiopharmaceutical distribution networks, as well as the appearance of mobile scanner 
technology, should greatly facilitate access to nuclear medicine imaging in the next decade. 
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available, the more specialized radiopharmaceuticals described herein are still limited to 
sites typically possessing a cyclotron and advanced radiochemistry laboratories. In order for 
patients and physicians alike to benefit from these radiopharmaceuticals, global access has 
to be provided. The new partnerships growing between big pharma, small 
radiopharmaceutical companies, and larger companies possessing global 
radiopharmaceutical distribution networks, as well as the appearance of mobile scanner 
technology, should greatly facilitate access to nuclear medicine imaging in the next decade. 
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1. Introduction 
Therapy with radioiodine (I-131) has been used for patients with well-differentiated thyroid 
cancer such as papillary and follicular thyroid carcinoma to ablate normal thyroid tissue or 
to treat metastatic lesions. The improvement of survival rates and decrease of recurrence 
rates after I-131 therapy has been documented by retrospective studies (Mazzaferri & 
Jhiang, 1994; Samaan et al., 1992). Even those patients categorized as low risk also had 
significantly lower recurrence and death rates after they received I-131 (Dietlein et al., 2005). 
Diagnostic I-123 or I-131 whole body scan (DxWBS) can be performed to detect persistent 
disease before radioiodine therapy. The post-therapeutic I-131 whole body scan (RxWBS) 
can be done after administration of therapeutic dose of I-131. 
1.1 Rationale of RxWBS 
The purpose of RxWBS is for detection and localization or exclusion of functioning thyroid 
remnants, persistent or recurrent local disease or distant metastasis in patients receiving I-
131 therapy (Luster et al., 2008). There are several reports regarding the higher detection 
ability of RxWBS than DxWBS. Therefore, the disease stage also can be changed after 
RxWBS. Fatourechi et al. reported that 13% of 117 patients of thyroid papillary cancer 
demonstrated abnormal foci on RxWBS, which were not seen on DxWBS (111 MBq (3 mCi), 
I-131) (Fatourechi et al., 2000). They also reported that RxWBS changed management 
strategy in 9% of 81 patients. Souza Rosario et al. reported that RxWBS on first ablation 
changed the disease stage in 8.3% of the patients and therapeutic approach in another 15% 
among total 106 patients (Souza Rosario et al., 2004). They also reported that RxWBS 
provided clinically relevant information for 26% of patients with 1 previous ablation. In 
their report, even when excluding cases whose lesions were known before scanning, the 
therapeutic approach was influenced by RxWBS in 15.6% of the patients.  
There are also several reports regarding comparison of I-123 DxWBS and RxWBS. In the 
retrospective study by Donahue et al., they reported that RxWBS could find more lesions in 
18% of 108 patients and clinical upstaging occurred in 10% of patients compared with 
DxWBS (I-123) (Donahue et al., 2008). In a study by Alzahrani et al., they showed 209 pairs 
of 238 pairs of RxWBS and DxWBS (I-123) were concordant (87.8% concordance rate) 
(Alzahrani et al., 2001). They also revealed that there were 29 discordant pairs, 13 RxWBS 
(5.5%) demonstrated additional foci of uptake at sites that were already positive on DxWBS  
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Fig. 1. Detection of metastatic lymph nodes on RxWBS, not on DxWBS. A 53-year-old 
woman with papillary thyroid cancer who underwent total thyroidectomy with left lateral 
neck dissection. A. I-123 DxWBS reveals a focal uptake in the anterior neck, suggesting 
remnant thyroid tissues in the thyroid bed. B. On RxWBS obtained 2 days after 
administration of 6.66 GBq (180 mCi) I-131, several focal hot uptake are noted in her left 
lateral neck and right highest mediastinal area. Neck ultrasonography revealed (image not 
shown) lesions suspicious of metastatic lymph nodes.  
(I-123). Distant metastasis of thyroid cancer is not extremely rare. There have been studies 
reported the distant metastasis was found in 7-23% (Casara et al., 1991; Cooper et al., 2009; 
Mazzaferri, 1986; Samaan et al., 1985; Schlumberger et al., 1986). Iwano et al. reported that 
the concordance rates between DxWBS (I-123) and RxWBS were high for thyroid bed and 
bone metastases (89% and 86%, respectively), while they were low for lymph node and lung 
metastases on RxWBS (61% and 39%, respectively) (Iwano et al., 2009).  
There are several reasons of performing RxWBS. 
a. Metastasis is not extremely rare in thyroid cancer. 
b. Presence of distant metastasis can change treatment strategies. 
c. RxWBS has better detection performances of detecting remnant or metastatic lesions 
than DxWBS. 
d. Performing scan after therapy does not require additional radiation exposure, like other 
radiologic evaluation. 
2. Protocols of RxWBS  
2.1 Imaging protocol  
2.1.1 Gamma camera or SPECT 
The efficacy of a system for imaging I-131 is dependent on the thickness of the crystal of 
camera and the collimator (Mazzaferri, 1986). I-131 whole body scan was usually done  
 




Fig. 2. Multiple pulmonary metastases detected on RxWBS which were invisible on DxWBS. 
A 54-year-old woman who underwent total thyroidectomy for papillary thyroid cancer. A, I-
123 DxWBS shows several hot uptake in the anterior neck and upper mediastinum. B, On 
RxWBS obtained 3 days after the administration of 7.4 GBq (200 mCi) I-131, multiple 
metastatic lesions are newly detected in both the lung fields. 
using a large field of view gamma camera with a medium-energy, parallel-hole collimator, 
and the photo peak was 364 KeV with a 20% window. Continuous acquisition mode can be 
used with a scanning ratio of 9 - 13 cm/s with a 512 x 512 or 1,024 × 256 matrix. Anterior 
and posterior views of the whole body can be obtained simultaneously. Spot views of 
suspected sites of metastasis can be done additionally using a 256 × 256 matrix for a total of 
500,000 counts. Additional image such as scanning after drinking a glass of water to wash 
out physiologic uptake in the esophagus is sometimes needed (Figure 3).  
 
 
Fig. 3. Physiologic retention of I-131 in the esophagus. The physiologic I-131 retention 
(arrow) in the esophagus on RxWBS obtained after administration of 3.7 GBq (100 mCi) I-
131 (A). It disappeared after drinking a glass of water (B). 
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camera and the collimator (Mazzaferri, 1986). I-131 whole body scan was usually done  
 




Fig. 2. Multiple pulmonary metastases detected on RxWBS which were invisible on DxWBS. 
A 54-year-old woman who underwent total thyroidectomy for papillary thyroid cancer. A, I-
123 DxWBS shows several hot uptake in the anterior neck and upper mediastinum. B, On 
RxWBS obtained 3 days after the administration of 7.4 GBq (200 mCi) I-131, multiple 
metastatic lesions are newly detected in both the lung fields. 
using a large field of view gamma camera with a medium-energy, parallel-hole collimator, 
and the photo peak was 364 KeV with a 20% window. Continuous acquisition mode can be 
used with a scanning ratio of 9 - 13 cm/s with a 512 x 512 or 1,024 × 256 matrix. Anterior 
and posterior views of the whole body can be obtained simultaneously. Spot views of 
suspected sites of metastasis can be done additionally using a 256 × 256 matrix for a total of 
500,000 counts. Additional image such as scanning after drinking a glass of water to wash 
out physiologic uptake in the esophagus is sometimes needed (Figure 3).  
 
 
Fig. 3. Physiologic retention of I-131 in the esophagus. The physiologic I-131 retention 
(arrow) in the esophagus on RxWBS obtained after administration of 3.7 GBq (100 mCi) I-
131 (A). It disappeared after drinking a glass of water (B). 
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2.1.2 SPECT/CT   
Whole body imaging with SPECT/CT requires long scan time. Therefore, SPECT/CT is 
usually performed for specific site after whole body scan. The field of view (FOV) of 
SPECT/CT is usually determined by nuclear medicine physicians based on the planar image 
findings. So far, many companies have their models of SPECT/CT. This is the one of the 
usual protocol of SPECT/CT (Infinia Hawkeye 4) of our institution. First, emission SPECT 
images are acquired with counts from the 10% energy window at 364 KeV, with a matrix 
size of 128 x 128. A total image of 64 frames is acquired over 360 with an acquisition time of 
30 s/frame, angular step of 6, and zooming factor of 1. After SPECT acquisition, a CT scan 
is acquired with a low-dose, helical CT scanner. The CT parameters are 140 KeV and 5 mAs, 
and no intravenous iodinated contrast is administered. The CT data are used for attenuation 
correction. The Images are reconstructed with a conventional iterative algorithm, ordered 
subset expectation maximization (OSEM). A workstation providing multiplanar reformatted 
images are used for image display and analysis.  
2.2 Imaging timing of RxWBS 
Radioiodine is excreted slowly in hypothyroid patients, especially if they have been on a low 
iodine diet (Dietlein et al., 2005). Therefore, decreasing background activity is important for 
visualizing small metastases or remnant thyroid tissue. However, current guidelines for I-131 
therapy differ in their recommendations for the optimal time of the RxWBS ranging from 48 – 
72 hours (Becker et al., 1996; Luster et al., 2008) to 2 – 10 days (Cooper et al., 2009). Also, there 
is a lot of discrepancy in the published literature regarding the optimal timing of RxWBS 
(Cholewinski et al., 2000; Chong et al., 2010; Durante et al., 2006; Hindie et al., 2003; Hung et 
al., 2009; Khan et al., 1994; Nemec et al., 1979). So far, several studies were done for evaluating 
efficacy or accuracy of RxWBS which was done at different timing after high-dose I-131 
therapy. Khan et al. conducted scans at 2 days and 7 days post-therapy after 3.7–5.6 GBq of I-
131 administration (Khan et al., 1994). They reported a higher sensitivity for detection of 
iodine-avid tissue on RxWBS 7 days post-therapy than earlier RxWBS. Hung et al. analyzed 
RxWBS at three different time points (first scan performed 3–4 days, second scan 5–6 days, and 
third scan 10–11 days after I-131 therapy) (Hung et al., 2009). They retrospectively analyzed 
239 patients’ scans. Twenty-eight percent of lymph node metastases, 17% of lung metastases, 
and 16% of bone metastases were missed on the late images on 10-11th day. On the other 
hand, only 5% of the remnants were missed. The ratio of early washout was different between 
remnants and metastatic lesions. Chong et al. conducted RxWBS on the third and seventh days 
after I-131 therapy in 60 cases from 52 patients with lung or bone metastases of thyroid cancer 
(Chong et al., 2010). They showed that 22% of lung metastases and 33% of bone metastases 
that were not shown on the third day scan were detected on the seventh day scan (Figure 4 
and 5). Lee et al. conducted RxWBS on the third and tenth day after I-131 therapy in 81 
patients (Lee et al., 2011). They reported that the I-131 avid lesions on the early scan were more 
easily detected by visual analysis and had higher uptake ratios than those on the delayed scan. 
The optimal timing for RxWBS is still needed to be clarified.  
2.3 Medication and diet after administration of therapeutic dose of I-131  
Published guideline for I-131 therapy recommend that low-iodine diet, when possible, <50 
μg/day, starting 1-2 weeks prior to radioiodine administration is recommended (Cooper et al., 
2009; Luster et al., 2008). However, the duration of this low-iodine diet varies. Usually, regular 
diet can be started after the treatment. Information about low-iodine diet can be obtained at 
Thyroid Cancer Survivors Association website, http://www.thyca.org/rai.htm#diet.  
 




Fig. 4. Diffuse pulmonary metastases. The metastatic uptake is not seen on I-123 DxWBS (A) 
and early RxWBS (on the third day after therapy) (B). It only appears on the RxWBS which 
was performed on the seventh day after the administration of 7.4 GBq (200 mCi ) I-131 (C).  
 
 
Fig. 5. Multiple osseous metastases. The metastatic lesion in the upper thoracic vertebra 
(arrow) is only visible on the RxWBS obtained seventh day after administration of 7.4 GBq 
(200 mCi) I-131 (B). These lesion is not visible on RxWBS obtained third day after therapy 
(A) or Tc-99m HDP WBS (C).  
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Thyroid hormone replacement may be resumed on the second or third day after therapy 
(Cooper et al., 2009; Luster et al., 2008).  
3. Findings of RxWBS  
The following data are needed to be reported: the name of patient, ID, age, the date of I-131 
therapy, I-131 dose, date of RxWBS. When it is available, the serum level of thyroglobulin, 
thyroid stimulating hormone and anti-thyroglobulin antibody are to be reported. The sites 
of significant I-131 uptake are needed to be mentioned.  
3.1 False positive RxWBS 
False positive RxWBS occurs for nonthyroidal I-131 concentration, including external 
contamination by the saliva, nasal secretions and sweat containing I-131, internal 
contamination through nasopharyngeal secretion, as well as physiologic uptake in 
nonthyroidal tissue such as the choroid plexus, salivary glands, gastric mucosa, and urinary 
tract. Carliscle et al. summarized false positive findings (Carlisle et al., 2003). I-131 uptake 
can be seen in the nose, salivary glands, mouth, thyroid bed, lactating breast, liver, gall 
bladder, stomach, esophagus and sweat (Figure 6). Physiologic uptake of I-131 in the 
salivary glands, nasal mucosa, gastric mucosa, colon, mammary glands and choroid plexus 
is due to the NIS presence in these tissues (Carlisle et al., 2003; Riedel et al., 2001). Thymic 
uptake is rare, there is a report that the incidence of thymic uptake was 1-1.2% of cases 
(Davidson & McDougall, 2000) (Figure 7).  
 
 
Fig. 6. Diffuse perspiration. (A) On the RxWBS obtained on the third day after I-131 therapy 
with 3.7 GBq (100 mCi), mild perspiration is noted in both the axillae. (B) On the RxWBS 
obtained on the seventh day after I-131 therapy, diffuse perspiration is present in both the 
axillae, chest, upper arms and hands.  
 




Fig. 7. Thymic uptake. A 12-year-old girl underwent therapy with 3.7 GBq (100 mCi) I-131. 
RxWBS were obtaind on the third day (A) and seventh day (B) after therapy. Hot uptakes 
are seen in the right lower neck and upper chest. I-131 SPECT/CT (C) and F-18 FDG 
PET/CT images (D) confirmed I-131 uptake in the upper chest to be physiologic uptake in 
the thymus. 
Diffuse hepatic uptake of I-131 is rarely found due to occult hepatic metastases but more 
commonly due to the hepatic de-ionization and conjugation of I-131 which was not 
incorporated into the thyroid hormone (Carlisle et al., 2003). Chung et al. investigated 
hepatic uptake on DxWBS or RxWBS. They analyzed scans of 399 patients. They reported 
that hepatic uptake is more often when higher dose of I-131 was administered. They also 
reported that the more uptakes appeared in the residual thyroid, the more it appeared in the 
liver. However, they found that 15 patients showed diffuse hepatic uptake without uptake 
by the remnant thyroid or metastatic lesion. They followed these patients and metastatic 
lesions were found in 7 of 15 patients. So, they insisted that diffuse liver uptake indicated 
functioning thyroid remnant or metastasis (Chung et al., 1997) (Figure 8).  
There are some reports I-131 false positive uptake in other pathologic condition unrelated to 
thyroid cancer: tracheostomy site, bronchiectasis, pulmonary inflammatory disease, pleural 
effusion, salivary gland tumor, some other carcinoma such as adenocarcinoma, squamous 
carcinoma, Barrett’s esophagus, Meckel’s diverticulum (Ain & Shih, 1994; Berquist et al., 
1975; Caplan et al., 1987; Carlisle et al., 2003; Fernandez-Ulloa et al., 1976; Hoschl et al., 1988; 
Misaki et al., 1994; Mitchell et al., 2000; Muratet & Giraud, 1996), and so on. (Figure 9) 
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Fig. 8. Diffuse hepatic uptake. A 59-year-old female underwent I-131 therapy with 370 MBq 
(100 mCi) after total thyroidectomy. On the RxWBS obtained on the third day after therapy, 
mild focal uptakes in the anterior neck and right lower anterior neck are shown (A). On the 
RxWBS obtained on the seventh day after therapy, diffuse hepatic uptake appears in 
addition to the cervical uptakes (B).  
 
 
Fig. 9. I-131 accumulation in the benign pulmonary disease. A 51-year-old female 
underwent RxWBS on the third day (A) and the seventh day (B) after the administration of 
6.66 GBq I-131. Besides the hot uptake in the neck, slightly increased, focal, linear uptake 
(arrows on A and B) is shown. On SPECT/CT (C), it is on the medial segment of the right 
middle lobe. Chest CT (D) shows peribronchial cicatrical consolidation and adhesive 
atelectasis containing mild traction bronchiectatic change in this lesion.  
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3.2 Diagnostic value of RxWBS 
The visualizing functioning metastasis as well as remnant thyroid tissue is related to the 
dose of I-131. Waxman et al. reported that more lesions were detected when the activity 
administered was increased from 74 to 370 MBq (2 to 10 mCi) and when even higher yields 
at 1,110 to 3,700 MBq (30 to 100 mCi) (Waxman et al., 1981). Spies et al. reported that with 
higher therapeutic dose, RxWBS demonstrated additional findings or more accurate 
localization compared with a diagnostic dose of 185 MBq (5 mCi) in 46% of cases (Spies et 
al., 1989).  
The diagnostic accuracy of RxWBS is also related with the time interval from the date of 
administration of I-131 and that of scanning. Khan et al. and Chong et al. reported that 
earlier scanning might miss the lesions and the effectiveness of the delayed scan on the 
seventh day from the administration of I-131 (Khan S et al., 1994). Khan et al. performed 
RxWBS on the second day and seventh day post-therapy (Khan et al., 1994). They reported 
that the seventh day scan is more sensitive than third day scan. Chong et al. reported that 
22% of lung metastasis and 33% of bone metastases that were not shown on the third day 
scan, though they were detected on the seventh day scan (Chong et al., 2010) (Figure 10).  
 
 
Fig. 10. Vertebral metastasis mimicking remnant thyroid tissue. A 61-year-old female 
underwent RxWBS after administration of 7.4 GBq (200 mCi) I-131. RxWBS shows multiple 
uptakes in the abdomen and right pelvic area suggesting distant metastases. Focal uptake in 
the anterior neck was supposed to be usual remnant thyroid tissue. However, on additional 
SPECT/CT (B, C), the uptake is detected in the cervical vertebra (C5), not in the 
thyroidectomy site. SPECT/CT also reveals I-131 uptake on thelumbar vertebra (L3, D) and 
right iliac bone (E). 
 




Fig. 8. Diffuse hepatic uptake. A 59-year-old female underwent I-131 therapy with 370 MBq 
(100 mCi) after total thyroidectomy. On the RxWBS obtained on the third day after therapy, 
mild focal uptakes in the anterior neck and right lower anterior neck are shown (A). On the 
RxWBS obtained on the seventh day after therapy, diffuse hepatic uptake appears in 
addition to the cervical uptakes (B).  
 
 
Fig. 9. I-131 accumulation in the benign pulmonary disease. A 51-year-old female 
underwent RxWBS on the third day (A) and the seventh day (B) after the administration of 
6.66 GBq I-131. Besides the hot uptake in the neck, slightly increased, focal, linear uptake 
(arrows on A and B) is shown. On SPECT/CT (C), it is on the medial segment of the right 
middle lobe. Chest CT (D) shows peribronchial cicatrical consolidation and adhesive 
atelectasis containing mild traction bronchiectatic change in this lesion.  
 
Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer 
 
239 
3.2 Diagnostic value of RxWBS 
The visualizing functioning metastasis as well as remnant thyroid tissue is related to the 
dose of I-131. Waxman et al. reported that more lesions were detected when the activity 
administered was increased from 74 to 370 MBq (2 to 10 mCi) and when even higher yields 
at 1,110 to 3,700 MBq (30 to 100 mCi) (Waxman et al., 1981). Spies et al. reported that with 
higher therapeutic dose, RxWBS demonstrated additional findings or more accurate 
localization compared with a diagnostic dose of 185 MBq (5 mCi) in 46% of cases (Spies et 
al., 1989).  
The diagnostic accuracy of RxWBS is also related with the time interval from the date of 
administration of I-131 and that of scanning. Khan et al. and Chong et al. reported that 
earlier scanning might miss the lesions and the effectiveness of the delayed scan on the 
seventh day from the administration of I-131 (Khan S et al., 1994). Khan et al. performed 
RxWBS on the second day and seventh day post-therapy (Khan et al., 1994). They reported 
that the seventh day scan is more sensitive than third day scan. Chong et al. reported that 
22% of lung metastasis and 33% of bone metastases that were not shown on the third day 
scan, though they were detected on the seventh day scan (Chong et al., 2010) (Figure 10).  
 
 
Fig. 10. Vertebral metastasis mimicking remnant thyroid tissue. A 61-year-old female 
underwent RxWBS after administration of 7.4 GBq (200 mCi) I-131. RxWBS shows multiple 
uptakes in the abdomen and right pelvic area suggesting distant metastases. Focal uptake in 
the anterior neck was supposed to be usual remnant thyroid tissue. However, on additional 
SPECT/CT (B, C), the uptake is detected in the cervical vertebra (C5), not in the 
thyroidectomy site. SPECT/CT also reveals I-131 uptake on thelumbar vertebra (L3, D) and 
right iliac bone (E). 
 
12 Chapters on Nuclear Medicine 
 
240 
Hung et al. conducted different protocol, RxWBS on the third to fourth day, fifth to sixth 
day and tenth to eleventh day post-therapy (Hung et al., 2009). They reported that there is a 
trend of decreasing visualization of I-131 uptake in sequential images and that 17% of lung 
metastasis and 16% of bone metastases were missed on the tenth to eleventh day scans. Lee 
et al. conducted RxWBS on the third and tenth day post-therapy (Lee et al., 2011). They also 
reported significant reduction in visual analysis scores and uptake ratios of I-131 avid 
lesions on the delayed RxWBS. 
In addition, diagnostic accuracy of RxWBS is related to the past-history of previous I-131 
therapy. Oh et al. reported the sensitivity of RxWBS in detecting distant metastasis after first 
I-131 therapy is 75% (Oh et al., 2011). In contrast, in patients with history of multiple 
radioiodine therapy, sensitivity of RxWBS in detecting distant metastasis is only 35%. The 
sensitivity of RxWBS and SPECT/CT is reported to be similar. However, the specificity of 
RxWBS is lower than SPECT/CT (Table 1). The sensitivity of FDG PET/CT is lower than 
RxWBS in detecting distant metastasis and the specificity of FDG PET/CT is much higher 
than RxWBS or SPECT/CT.  
 
 Sens(%) Spec(%) DA(%) PPV(%) NPV(%) 
All patients (n=140)      
WBS 65 55 59 42 76 
SPECT/CT 65 95 85 86 85 
PET/CT 61 98 86 93 84 
Single therapy (n=101)      
WBS 90 56 63 35 6 
SPECT/CT 90 96 95 86 97 
PET/CT 48 100 89 100 88 
Multiple therapies (n=39)      
WBS 44 50 46 30 33 
SPECT/CT 44 86 59 85 46 
PET/CT 72 86 77 90 63 
Table 1. Diagnostic performance of WBS, SPECT/CT and PET/CT in detecting distant 
metastasis (patient-based analysis) (adapted and modified from Oh et al., 2011). 
Sens, Sensitivity; Spec, Specificity; DA, diagnostic accuracy; PPV, positive predictive value; 
NPV, negative predictive value 
Previous radioiodine scanning might be the reason of decreased sensitivity (Rawson et al., 
1951). Thyroid stunning has been reported as the temporary impairment of thyroid tissue 
after a 111 MBq (3 mCi) or greater diagnostic I-131 dose that decreases the final absorbed 
dose in ablative therapy. However, Rosario et al. reported that diagnostic scanning using a 
185 MBq (5 mCi) of I-131 dose does not interfere with uptake of the ablative dose or with 
treatment efficacy when ablation is performed within 72 hours (Rosario et al., 2005). Dam et 
al. reported that even though, stunning might occur but there was no significant difference 
in treatment success rates (Dam et al., 2004).  
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4. Other imaging modalities  
4.1 F-18 Fluorodeoxyglucose PET/CT 
Fluorodeoxyglucose (FDG) is a glucose analogue. This is taken into the cell and 
phosphorylated by the same mechanism as glucose. In thyroid cancer, “Flip-flop 
phenomenone” is reported (Feine et al., 1996; Khan N. et al., 2003). It means the 
alternating uptake pattern of I-131 and FDG by the differentiated papillary or follicular 
thyroid cancer, which thought to be related to the differentiation of tumor (Figure 11 and 
12). Bertagna et al. reported that F-18 FDG PET/CT positive results correlated with the 
serum thyroglobulin level in patients with negative I-131 whole body scan and high 
serum thyroglobulin level. They also reported that F-18 FDG PET/CT showed highest 
accuracy when the patient’s thyroglobulin level was higher than 21 ng/mL (Bertagna et 
al., 2009). In addition to that, they also revealed that the levothyroxine therapy regimen 
does not influence F-18 FDG PET/CT results. Yoshio et al. evaluated 55 cases with 
differentiated thyroid cancer with F-18 FDG PET/CT and reported that FDG-avid lesions 




Fig. 11. Flip-flop phenomenone. A 44-year-old male underwent total thyroidectomy due to 
thyroid papillary carcinoma. I-123 DxWBS (A) shows several hot uptakes in the anterior 
neck, whereas F-18 FDG PET/CT (B) is negative.   
4.2 Tc-99m methoxyisobutylisonitrile (Tc-99m MIBI) 
Tc-99m MIBI, a lipophilic cationic molecules, was originally developed as a myocardial 
perfusion imaging agent. Today Tc-99m MIBI is also used for the study of many neoplastic 
diseases. The mechanism of Tc-99m MIBI accumulation in tumor has been reported to 
depend on the size of a tumor, the blood flow and the richness of mitochondria in the tumor  
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RxWBS in detecting distant metastasis and the specificity of FDG PET/CT is much higher 
than RxWBS or SPECT/CT.  
 
 Sens(%) Spec(%) DA(%) PPV(%) NPV(%) 
All patients (n=140)      
WBS 65 55 59 42 76 
SPECT/CT 65 95 85 86 85 
PET/CT 61 98 86 93 84 
Single therapy (n=101)      
WBS 90 56 63 35 6 
SPECT/CT 90 96 95 86 97 
PET/CT 48 100 89 100 88 
Multiple therapies (n=39)      
WBS 44 50 46 30 33 
SPECT/CT 44 86 59 85 46 
PET/CT 72 86 77 90 63 
Table 1. Diagnostic performance of WBS, SPECT/CT and PET/CT in detecting distant 
metastasis (patient-based analysis) (adapted and modified from Oh et al., 2011). 
Sens, Sensitivity; Spec, Specificity; DA, diagnostic accuracy; PPV, positive predictive value; 
NPV, negative predictive value 
Previous radioiodine scanning might be the reason of decreased sensitivity (Rawson et al., 
1951). Thyroid stunning has been reported as the temporary impairment of thyroid tissue 
after a 111 MBq (3 mCi) or greater diagnostic I-131 dose that decreases the final absorbed 
dose in ablative therapy. However, Rosario et al. reported that diagnostic scanning using a 
185 MBq (5 mCi) of I-131 dose does not interfere with uptake of the ablative dose or with 
treatment efficacy when ablation is performed within 72 hours (Rosario et al., 2005). Dam et 
al. reported that even though, stunning might occur but there was no significant difference 
in treatment success rates (Dam et al., 2004).  
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4. Other imaging modalities  
4.1 F-18 Fluorodeoxyglucose PET/CT 
Fluorodeoxyglucose (FDG) is a glucose analogue. This is taken into the cell and 
phosphorylated by the same mechanism as glucose. In thyroid cancer, “Flip-flop 
phenomenone” is reported (Feine et al., 1996; Khan N. et al., 2003). It means the 
alternating uptake pattern of I-131 and FDG by the differentiated papillary or follicular 
thyroid cancer, which thought to be related to the differentiation of tumor (Figure 11 and 
12). Bertagna et al. reported that F-18 FDG PET/CT positive results correlated with the 
serum thyroglobulin level in patients with negative I-131 whole body scan and high 
serum thyroglobulin level. They also reported that F-18 FDG PET/CT showed highest 
accuracy when the patient’s thyroglobulin level was higher than 21 ng/mL (Bertagna et 
al., 2009). In addition to that, they also revealed that the levothyroxine therapy regimen 
does not influence F-18 FDG PET/CT results. Yoshio et al. evaluated 55 cases with 
differentiated thyroid cancer with F-18 FDG PET/CT and reported that FDG-avid lesions 




Fig. 11. Flip-flop phenomenone. A 44-year-old male underwent total thyroidectomy due to 
thyroid papillary carcinoma. I-123 DxWBS (A) shows several hot uptakes in the anterior 
neck, whereas F-18 FDG PET/CT (B) is negative.   
4.2 Tc-99m methoxyisobutylisonitrile (Tc-99m MIBI) 
Tc-99m MIBI, a lipophilic cationic molecules, was originally developed as a myocardial 
perfusion imaging agent. Today Tc-99m MIBI is also used for the study of many neoplastic 
diseases. The mechanism of Tc-99m MIBI accumulation in tumor has been reported to 
depend on the size of a tumor, the blood flow and the richness of mitochondria in the tumor  
 




Fig. 12. Iodine negative and F-18 FDG PET positive case. A 65-year-old female underwent I-
123 DxWBS (A) and F-18 FDG PET/CT (B,C) for elevated serum thyroglobulin level (3 to 17 
ng/ml) after left modified radical lymph node dissection two years ago. I-123 DxWBS (A) 
does not show abnormal uptake. On F-18 FDG PET/CT (B), focal uptakes were shown in the 
left lateral neck (arrow). On axial view of fusion image (C), two hypermetabolic lesions were 
seen in the left cervical level II. Biopsy revealed recurred papillary carcinoma.  
cells (Moretti et al., 2005; Piwnica-Worms et al., 1994; Saggiorato et al., 2009). MIBI 
irreversibly passes into the mitochondria using the electrical gradient generated by a high 
negative inner transmembrane mitochondrial potential of malignant cells (Chernoff et al., 
1993; Moretti et al., 2005; Piwnica-Worms et al., 1994). Also, there is a report that TSH 
simulates both F-18 FDG PET and Tc-99m MIBI uptake in poorly differentiated papillary 
thyroid cancer in vitro experiment (Kim et al., 2009). Even though Tc-99m MIBI is inferior to 
I-131 scintigraphy in detecting I-131 avid lesions (Al Saleh et al., 2007), it can be applied for 
patients with elevated serum human thyroglobulin levels but negative I-131 whole body 
scan (Wu et al., 2003). However, there are several reports that F-18 FDG PET is more 
sensitive than Tc-99m MIBI SPECT in detecting metastatic cervical lymph node in 
differentiated thyroid cancer patients with elevated serum thyroglobulin level but negative 
I-131 whole body scan (Iwata et al., 2004; Wu et al., 2003) (Figure 13).  
4.3 Tc-99m tetrofosmin 
Tetrofosmin is a lipophilic phosphine useful for myocardial perfusion imaging. Significant 
uptake of Tc-99m tetrofosmin in the thyroid, breast and lung tumors is reported. Tc-99m 
tetrofosmin is useful in detection of thyroid metastatic disease, particularly when the tumor 
is not iodine avid. In addition, it does not require withdrawal of thyroid hormone 
suppression therapy (Sharma et al., 2007). Nishiyama et al. reported that detectability of 
thyroid cancer metastases using Tc-99m tetrofosmin was 79.4% and that Tc-99m tetrofosmin 
is more sensitive than I-131 for detection of differentiated thyroid cancer metastasis, 
particulary for regional lymph node (Nishiyama et al., 2000). Unal et al. reported different 
results that the sensitivities of Tl-201, Tc-99m tetrofosmin and I-131 in diagnosing distant 
metastases were comparable (0.85, 0.85, and 0.75, respectively) (Unal et al., 1998). 
 




Fig. 13. I-131, Tc-99m MIBI and F-18 FDG images. A 62-year-old woman with metastatic 
papillary thyroid cancer to the left proximal humerus, clavicle and sternum underwent I-131 
therapy with 7.4 GBq (200 mCi). Her serum thyroglobulin level was 260 ng/mL. I-131 
RxWBS (A) shows focal hot uptakes in the left clavicle and huemrus. On Tc-99m MIBI WBS, 
irregular hot uptakes are detected in the sternal area and faint uptake in the left clavicle (B). 
F-18 FDG PET/CT (C-E) shows multiple hypermetabolic lesions in the sternum, both hilar 
lymph nodes and lungs.   
4.4 Thallium-201 
Thallium-201 (Tl-201) is a monovalemt cationic radioisotope listed in same group with 
gallium in the periodic table. The membrane permeability for Tl-201 is almost equal to that 
for potassium (Elgazzar et al., 1993). It is suggested that intracellular accumulation of 
thallous ions is due to the transmembrane electropotential gradient (Mullins & Moore, 
1960). The primary role of Tl-201 in nuclear medicine is for imaging of myocardial perfusion 
and viability (Pauwels et al., 1998). Also, Tl-201 chloride has affinity for various malignant 
tumors, although it is not specific for malignant tumor (Senga et al., 1982). Uptake of Tl-201 
in tumor seems to be determined by blood flow, grade of malignancy, viability of tumor 
cells and tumor necrosis (Pauwels et al., 1998). There are several reports regarding Tl-201 
and thyroid cancer. Shiga et al. compared FDG PET with I-131 and Tl-201 scintigraphy and 
reported that FDG uptake was concordant with I-131 in 38% and with Tl-201 uptake in 94% 
(Shiga et al., 2001). Senga et al. reported that when tumor showed a positive scan with Tl-
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201 chloride but negative results using Ga-67 citrate, it was differentiated thyroid carcinoma 
or poorly differentiated adenoma (Senga et al., 1982). Carril et al. analyzed Tl-201 and I-131 
in ablated thyroid cancer patients. They reported that the sensitivity and specificity were 
94% and 96% for Tl-201 and 29% and 100% for I-131 (Carril et al., 1997). Nakada et al. 
reported that Tl-201 uptake correlated well with the proliferating cell nuclear antigen index, 
which represents proliferative activity (Nakada et al., 1999).  
4.5 I-124 PET/CT 
I-124 is a positron emitter with a half-life of 4.18 days, produced by a cyclotron. It can be 
used to directly image thyroid cancer using PET scanner. Van Nostrand et al. compared I-
124 PET with I-131 DxWBS in detecting residual thyroid tissue and/or metastatic lesion. 
They reported that I-124 PET identified as many as 50% more foci of radioiodine uptake 
suggestive of additional residual thyroid tissue and/or metastasis (Van Nostrand et al., 
2010). They suggest that I-124 PET produced superior results because the PET scanner 
provides images with reduced background noise and enhanced spatial and contrast 
resolution compared with I-131 DxWBS. The longer half-life of I-124 is useful for dose 
monitoring over an extended time period (Surti et al., 2009). It can be also used for lesion-
specific dosimetry. I-131 mean absorbed dose distributions can be calculated from serial I-
124 PET image (Erdi et al., 1999; Larson & Robbins, 2002). 
5. Conclusion 
The I-123 DxWBS or I-131 DxWBS is sensitive and specific for treatable remnant or 
metastatic lesion. About 25% of RxWBS detect lesions missed by DxWBS. For this reason, 
following administration of a therapeutic I-131 dose, RxWBS should always be performed in 
patients with well differentiated thyroid cancer. The timing of RxWBS is currently still 
controversial. Based on several studies, the timing of post-therapeutic I-131 WBS is within 
5th to 10th day, especially more opportune around 7th day after therapy. I-131 WBS with 
SPECT/CT may be the highly tailored approach for assessing distant metastatic lesions in 
patients who received a radioiodine therapy if SPECT/CT is available. RxWBS is especially 
likely to provide the useful information when DxWBSs are negative and the serum 
thyroglobulin levels are elevated. Other imaging modalities including F-18 FDG PET/CT is 
useful in detecting remnant thyroid tissues or metastatic thyroid cancer in patient with the 
elevated serum thyroglobulin level and negative iodine images. I-124 can be also useful in 
detection of the lesion and evaluation of lesional and whole-body dosimetry in patients with 
well-differentiated thyroid cancer. 
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detection of the lesion and evaluation of lesional and whole-body dosimetry in patients with 
well-differentiated thyroid cancer. 
6. References 
Ain, K.B. & Shih, W.J. (1994). False-positive I-131 uptake at a tracheostomy site. Discernment 
with Tl-201 imaging. Clinical Nuclear Medicine, Vol. 19, No. 7, (July 1994), pp. 619-
621, ISSN 0363-9762 
Al Saleh, K.; Safwat, R.; Al-Shammeri, I.; Abdul Naseer, M.; Hooda, H. & Al-Mohannadi, S. 
(2007). Comparison of whole body scintigraphy with Tc-99m-
methoxyisobutylisonitrile and iodine-131 NA in patients with differentiated 
thyroid cancer. The Gulf Journal of Oncology, Vol. 1, No. 1, (January 2007), pp. 29-33, 
ISSN 2078-2101 
 
Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer 
 
245 
Alzahrani, A.S.; Bakheet, S.; Al Mandil, M.; Al-Hajjaj, A.; Almahfouz, A. & Al Haj, A. (2001). 
123I isotope as a diagnostic agent in the follow-up of patients with differentiated 
thyroid cancer: comparison with post 131I therapy whole body scanning. The 
Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 11, (November 2001), pp. 
5294-5300, ISSN 1945-7197 
Becker, D.; Charkes, N.D.; Dworkin, H.; Hurley, J.; McDougall, I.R.; Price, D.; Royal, H. & 
Sarkar, S. (1996). Procedure guideline for extended scintigraphy for differentiated 
thyroid cancer: 1.0. Society of Nuclear Medicine. Journal of Nuclear Medicine, Vol. 37, 
No. 7, (July 1996), pp. 1269-1271, ISSN 0161-5505 
Berquist, T.H.; Nolan, N.G.; Stephens, D.H.  & Carlson, H.C. (1975). Radioisotope 
scintigraphy in diagnosis of Barrett's esophagus. The American journal of 
roentgenology, radium therapy, and nuclear medicine, Vol. 123, No. 2, (February 1975), 
pp. 401-411, ISSN 0002-9580 
Bertagna, F.; Bosio, G.; Biasiotto, G.; Rodella, C.; Puta, E.; Gabanelli, S.; Lucchini, S.; Merli, 
G.; Savelli, G.; Giubbini, R.; Rosenbaum, J. & Alavi, A. (2009). F-18 FDG-PET/CT 
evaluation of patients with differentiated thyroid cancer with negative I-131 total 
body scan and high thyroglobulin level. Clinical Nuclear Medicine, Vol. 34, No. 11, 
(October 2009), pp. 756-761, ISSN 0363-9762 
Caplan, R.H.; Gundersen, G.A.; Abellera, R.M. & Kisken, W.A. (1987). Uptake of iodine-131 
by a Meckel's diverticulum mimicking metastatic thyroid cancer. Clinical Nuclear 
Medicine, Vol. 12, No. 9, (September 1987), pp. 760-762, ISSN 0363-9762 
Carlisle, M.R.; Lu, C. & McDougall, I.R. (2003). The interpretation of 131I scans in the 
evaluation of thyroid cancer, with an emphasis on false positive findings. Nuclear 
Medicine Communications, Vol. 24, No. 6, (June 2003), pp. 715-735, ISSN 0143-3636 
Carril, J.M.; Quirce, R.; Serrano, J.; Banzo, I.; Jimenez-Bonilla, J.F.; Tabuenca, O. & Barquin, 
R.G. (1997). Total-body scintigraphy with thallium-201 and iodine-131 in the 
follow-up of differentiated thyroid cancer. Journal of Nuclear Medicine, Vol. 38, No. 
5, (May 1997), pp. 686-692, ISSN 0161-5505 
Casara, D.; Rubello, D.; Saladini, G.; Gallo, V.; Masarotto, G. & Busnardo, B. (1991). Distant 
metastases in differentiated thyroid cancer: long-term results of radioiodine 
treatment and statistical analysis of prognostic factors in 214 patients. Tumori, Vol. 
77, No. 5, (October 1991), pp. 432-436, ISSN 0300-8916 
Chernoff, D.M.; Strichartz, G.R. & Piwnica-Worms, D. (1993). Membrane potential 
determination in large unilamellar vesicles with hexakis(2-
methoxyisobutylisonitrile)technetium(I). Biochimica et Biophysica Acta, Vol. 1147, 
No. 2, (April 1993), pp. 262-266, ISSN 0006-3002 
Cholewinski, S.P.; Yoo, K.S.; Klieger, P.S. & O'Mara, R.E. (2000). Absence of thyroid 
stunning after diagnostic whole-body scanning with 185 MBq 131I. Journal of 
Nuclear Medicine, Vol. 41, No. 7, (July 2000), pp. 1198-1202, ISSN 0161-5505 
Chong, A.; Song, H.C.; Min, J.J.; Jeong, S.Y.; Ha, J.M.; Kim, J.; Yoo, S.U.; Oh, J.R. & Bom, H.S. 
(2010). Improved Detection of Lung or Bone Metastases with an I-131 Whole Body 
Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid 
Cancer. Nuclear Medicine and Molecular Imaging, Vol. No. (October 2010), pp. 1-9, 
ISSN 1869-3474 
Chung, J.K.; Lee, Y.J.; Jeong, J.M.; Lee, D.S.; Lee, M.C.; Cho, B.Y. & Koh, C.S. (1997). Clinical 
significance of hepatic visualization on iodine-131 whole-body scan in patients with 
 
12 Chapters on Nuclear Medicine 
 
246 
thyroid carcinoma. Journal of Nuclear Medicine, Vol. 38, No. 8, (August 1997), pp. 
1191-1195, ISSN 0161-5505 
Cooper, D.S.; Doherty, G.M.; Haugen, B.R.; Kloos, R.T.; Lee, S.L.; Mandel, S.J.; Mazzaferri, 
E.L.; McIver, B.; Pacini, F.; Schlumberger, M.; Sherman, S.I.; Steward, D.L. & Tuttle, 
R.M. (2009). Revised American Thyroid Association management guidelines for 
patients with thyroid nodules and differentiated thyroid cancer. Thyroid, Vol. 19, 
No. 11, (November 2009), pp. 1167-1214, ISSN 1557-9077 
Dam, H.Q.; Kim, S.M.; Lin, H.C. & Intenzo, C.M. (2004). 131I therapeutic efficacy is not 
influenced by stunning after diagnostic whole-body scanning. Radiology, Vol. 232, 
No. 2, (August 2004), pp. 527-533, ISSN 0033-8419 
Davidson, J. & McDougall, I.R. (2000). How frequently is the thymus seen on whole-body 
iodine-131 diagnostic and post-treatment scans? European Journal of Nuclear 
Medicine, Vol. 27, No. 4, (May 2000), pp. 425-430, ISSN 0340-6997 
Dietlein, M.; Moka, D. & Schicha, H. (2005). Radioiodine therapy for thyroid cancer, In: 
Thyroid cancer, H. J. Biersack & F. Grunwald, pp. 93, Springer, ISBN 3540413901, 
New York 
Donahue, K.P.; Shah, N.P.; Lee, S.L. & Oates, M.E. (2008). Initial staging of differentiated 
thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy. 
Radiology, Vol. 246, No. 3, (March 2008), pp. 887-894, ISSN 0033-8419 
Durante, C.; Haddy, N.; Baudin, E.; Leboulleux, S.; Hartl, D.; Travagli, J.P.; Caillou, B.; 
Ricard, M.; Lumbroso, J.D.; De Vathaire, F. & Schlumberger, M. (2006). Long-term 
outcome of 444 patients with distant metastases from papillary and follicular 
thyroid carcinoma: benefits and limits of radioiodine therapy. The Journal of Clinical 
Endocrinology & Metabolism, Vol. 91, No. 8, (August 2006), pp. 2892-2899, ISSN 0021-
972X 
Elgazzar, A.H.; Fernandez-Ulloa, M. & Silberstein, E.B. (1993). 201Tl as a tumour-localizing 
agent: current status and future considerations. Nucl Med Commun, Vol. 14, No. 2, 
(February 1993), pp. 96-103, ISSN 0143-3636 (Print) 0143-3636 (Linking)   
Erdi, Y.E.; Macapinlac, H.; Larson, S.M.; Erdi, A.K.; Yeung, H.; Furhang, E.E.  & Humm, J.L. 
(1999). Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 
PET Imaging. Clin Positron Imaging, Vol. 2, No. 1, (October 2003), pp. 41-46, ISSN 
1095-0397  
Fatourechi, V.; Hay, I.D.; Mullan, B.P.; Wiseman, G.A.; Eghbali-Fatourechi, G.Z.; Thorson, 
L.M.  & Gorman, C.A. (2000). Are posttherapy radioiodine scans informative and 
do they influence subsequent therapy of patients with differentiated thyroid 
cancer? Thyroid, Vol. 10, No. 7, (August 2000), pp. 573-577, ISSN 1050-7256 
Feine, U.; Lietzenmayer, R.; Hanke, J.P.; Held, J.; Wohrle, H. & Muller-Schauenburg, W. 
(1996). Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. Journal of 
Nuclear Medicine, Vol. 37, No. 9, (September 1996), pp. 1468-1472, ISSN 0161-5505 
Fernandez-Ulloa, M.; Maxon, H.R.; Mehta, S. & Sholiton, L.J. (1976). Iodine-131 uptake by 
primary lung adenocarcinoma. Misinterpretation of 131I scan. JAMA, Vol. 236, No. 
7, (August 1976), pp. 857-858, ISSN 0098-7484 
Hindie, E.; Melliere, D.; Lange, F.; Hallaj, I.; de Labriolle-Vaylet, C.; Jeanguillaume, C.; 
Lange, J.; Perlemuter, L.  & Askienazy, S. (2003). Functioning pulmonary 
metastases of thyroid cancer: does radioiodine influence the prognosis? European 
 
Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer 
 
247 
Journal of Nuclear Medicine and Molecular Imaging, Vol. 30, No. 7, (March 2003), pp. 
974-981, ISSN 1619-7070 
Hoschl, R.; Choy, D.H. & Gandevia, B. (1988). Iodine-131 uptake in inflammatory lung 
disease: a potential pitfall in treatment of thyroid carcinoma. Journal of Nuclear 
Medicine, Vol. 29, No. 5, (May 1988), pp. 701-706, ISSN 0161-5505 
Hung, B.T.; Huang, S.H.; Huang, Y.E. & Wang, P.W. (2009). Appropriate time for post-
therapeutic I-131 whole body scan. Clinical Nuclear Medicine, Vol. 34, No. 6, (June 
2009), pp. 339-342, ISSN 1536-0229 
Iwano, S.; Kato, K.; Nihashi, T.; Ito, S.; Tachi, Y. & Naganawa, S. (2009). Comparisons of I-
123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue 
and metastases of differentiated thyroid cancer. Annals of Nuclear Medicine, Vol. 23, 
No. 9, (September 2009), pp. 777-782, ISSN 1864-6433 (Electronic) 
Iwata, M.; Kasagi, K.; Misaki, T.; Matsumoto, K.; Iida, Y.; Ishimori, T.; Nakamoto, Y.; 
Higashi, T.; Saga, T. & Konishi, J. (2004). Comparison of whole-body 18F-FDG PET, 
99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of 
metastatic thyroid cancer. European Journal of Nuclear Medicine and Molecular 
Imaging, Vol. 31, No. 4, (April 2004), pp. 491-498, ISSN 1619-7070 
Khan, N.; Oriuchi, N.; Higuchi, T.; Zhang, H. & Endo, K. (2003). PET in the follow-up of 
differentiated thyroid cancer. British Journal of Radiology, Vol. 76, No. 910, (October 
2003), pp. 690-695, ISSN 0007-1285 
Khan, S.; Waxman, A.; Nagaraj, N. & G, B. Optimization of post ablative I-131 scintigraphy: 
comparison of 2 day vs. 7 day post therapy study in patients with differentiated 
thyroid cancer (DTC), Proceedings of 41st Annual Meeting of the Society of Nuclear 
Medicine., Cedars-sinai Medical center, Los Angeles, CA, 1994 
Kim, C.H.; Yoo Ie, R.; Chung, Y.A.; Park, Y.H.; Kim, S.H.; Sohn, H.S. & Chung, S.K. (2009). 
Influence of thyroid-stimulating hormone on 18F-fluorodeoxyglucose and 99mTc-
methoxyisobutylisonitrile uptake in human poorly differentiated thyroid cancer 
cells in vitro. Annals of Nuclear Medicine, Vol. 23, No. 2, (February 2009), pp. 131-136, 
ISSN 0914-7187 
Larson, S.M. & Robbins, R. (2002). Positron emission tomography in thyroid cancer 
management. Seminars in Roentgenology, Vol. 37, No. 2, (July 2002), pp. 169-174, 
ISSN 0037-198X 
Lee, J.W.; Lee, S.M.; Koh, G.P. & Lee, D.H. (2011). The comparison of (131)I whole-body 
scans on the third and tenth day after (131)I therapy in patients with well-
differentiated thyroid cancer: preliminary report. Annals of Nuclear Medicine, Vol. 
No. (April 2011), pp. ISSN 1864-6433 
Luster, M.; Clarke, S.E.; Dietlein, M.; Lassmann, M.; Lind, P.; Oyen, W.J.; Tennvall, J. & 
Bombardieri, E. (2008). Guidelines for radioiodine therapy of differentiated thyroid 
cancer. European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, No. 10, 
(August 2008), pp. 1941-1959, ISSN 1619-7070 
Mazzaferri, E. L. (1986). In: Treatment of carcinoma of follicular epithelium, pp. 1342-1343, 
Lippincott, ISBN 0397508026 Philadelphia 
Mazzaferri, E.L. & Jhiang, S.M. (1994). Long-term impact of initial surgical and medical 
therapy on papillary and follicular thyroid cancer. American Journal of Medicine, Vol. 
97, No. 5, (November 1994), pp. 418-428, ISSN 0002-9343 
 
12 Chapters on Nuclear Medicine 
 
246 
thyroid carcinoma. Journal of Nuclear Medicine, Vol. 38, No. 8, (August 1997), pp. 
1191-1195, ISSN 0161-5505 
Cooper, D.S.; Doherty, G.M.; Haugen, B.R.; Kloos, R.T.; Lee, S.L.; Mandel, S.J.; Mazzaferri, 
E.L.; McIver, B.; Pacini, F.; Schlumberger, M.; Sherman, S.I.; Steward, D.L. & Tuttle, 
R.M. (2009). Revised American Thyroid Association management guidelines for 
patients with thyroid nodules and differentiated thyroid cancer. Thyroid, Vol. 19, 
No. 11, (November 2009), pp. 1167-1214, ISSN 1557-9077 
Dam, H.Q.; Kim, S.M.; Lin, H.C. & Intenzo, C.M. (2004). 131I therapeutic efficacy is not 
influenced by stunning after diagnostic whole-body scanning. Radiology, Vol. 232, 
No. 2, (August 2004), pp. 527-533, ISSN 0033-8419 
Davidson, J. & McDougall, I.R. (2000). How frequently is the thymus seen on whole-body 
iodine-131 diagnostic and post-treatment scans? European Journal of Nuclear 
Medicine, Vol. 27, No. 4, (May 2000), pp. 425-430, ISSN 0340-6997 
Dietlein, M.; Moka, D. & Schicha, H. (2005). Radioiodine therapy for thyroid cancer, In: 
Thyroid cancer, H. J. Biersack & F. Grunwald, pp. 93, Springer, ISBN 3540413901, 
New York 
Donahue, K.P.; Shah, N.P.; Lee, S.L. & Oates, M.E. (2008). Initial staging of differentiated 
thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy. 
Radiology, Vol. 246, No. 3, (March 2008), pp. 887-894, ISSN 0033-8419 
Durante, C.; Haddy, N.; Baudin, E.; Leboulleux, S.; Hartl, D.; Travagli, J.P.; Caillou, B.; 
Ricard, M.; Lumbroso, J.D.; De Vathaire, F. & Schlumberger, M. (2006). Long-term 
outcome of 444 patients with distant metastases from papillary and follicular 
thyroid carcinoma: benefits and limits of radioiodine therapy. The Journal of Clinical 
Endocrinology & Metabolism, Vol. 91, No. 8, (August 2006), pp. 2892-2899, ISSN 0021-
972X 
Elgazzar, A.H.; Fernandez-Ulloa, M. & Silberstein, E.B. (1993). 201Tl as a tumour-localizing 
agent: current status and future considerations. Nucl Med Commun, Vol. 14, No. 2, 
(February 1993), pp. 96-103, ISSN 0143-3636 (Print) 0143-3636 (Linking)   
Erdi, Y.E.; Macapinlac, H.; Larson, S.M.; Erdi, A.K.; Yeung, H.; Furhang, E.E.  & Humm, J.L. 
(1999). Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 
PET Imaging. Clin Positron Imaging, Vol. 2, No. 1, (October 2003), pp. 41-46, ISSN 
1095-0397  
Fatourechi, V.; Hay, I.D.; Mullan, B.P.; Wiseman, G.A.; Eghbali-Fatourechi, G.Z.; Thorson, 
L.M.  & Gorman, C.A. (2000). Are posttherapy radioiodine scans informative and 
do they influence subsequent therapy of patients with differentiated thyroid 
cancer? Thyroid, Vol. 10, No. 7, (August 2000), pp. 573-577, ISSN 1050-7256 
Feine, U.; Lietzenmayer, R.; Hanke, J.P.; Held, J.; Wohrle, H. & Muller-Schauenburg, W. 
(1996). Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. Journal of 
Nuclear Medicine, Vol. 37, No. 9, (September 1996), pp. 1468-1472, ISSN 0161-5505 
Fernandez-Ulloa, M.; Maxon, H.R.; Mehta, S. & Sholiton, L.J. (1976). Iodine-131 uptake by 
primary lung adenocarcinoma. Misinterpretation of 131I scan. JAMA, Vol. 236, No. 
7, (August 1976), pp. 857-858, ISSN 0098-7484 
Hindie, E.; Melliere, D.; Lange, F.; Hallaj, I.; de Labriolle-Vaylet, C.; Jeanguillaume, C.; 
Lange, J.; Perlemuter, L.  & Askienazy, S. (2003). Functioning pulmonary 
metastases of thyroid cancer: does radioiodine influence the prognosis? European 
 
Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer 
 
247 
Journal of Nuclear Medicine and Molecular Imaging, Vol. 30, No. 7, (March 2003), pp. 
974-981, ISSN 1619-7070 
Hoschl, R.; Choy, D.H. & Gandevia, B. (1988). Iodine-131 uptake in inflammatory lung 
disease: a potential pitfall in treatment of thyroid carcinoma. Journal of Nuclear 
Medicine, Vol. 29, No. 5, (May 1988), pp. 701-706, ISSN 0161-5505 
Hung, B.T.; Huang, S.H.; Huang, Y.E. & Wang, P.W. (2009). Appropriate time for post-
therapeutic I-131 whole body scan. Clinical Nuclear Medicine, Vol. 34, No. 6, (June 
2009), pp. 339-342, ISSN 1536-0229 
Iwano, S.; Kato, K.; Nihashi, T.; Ito, S.; Tachi, Y. & Naganawa, S. (2009). Comparisons of I-
123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue 
and metastases of differentiated thyroid cancer. Annals of Nuclear Medicine, Vol. 23, 
No. 9, (September 2009), pp. 777-782, ISSN 1864-6433 (Electronic) 
Iwata, M.; Kasagi, K.; Misaki, T.; Matsumoto, K.; Iida, Y.; Ishimori, T.; Nakamoto, Y.; 
Higashi, T.; Saga, T. & Konishi, J. (2004). Comparison of whole-body 18F-FDG PET, 
99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of 
metastatic thyroid cancer. European Journal of Nuclear Medicine and Molecular 
Imaging, Vol. 31, No. 4, (April 2004), pp. 491-498, ISSN 1619-7070 
Khan, N.; Oriuchi, N.; Higuchi, T.; Zhang, H. & Endo, K. (2003). PET in the follow-up of 
differentiated thyroid cancer. British Journal of Radiology, Vol. 76, No. 910, (October 
2003), pp. 690-695, ISSN 0007-1285 
Khan, S.; Waxman, A.; Nagaraj, N. & G, B. Optimization of post ablative I-131 scintigraphy: 
comparison of 2 day vs. 7 day post therapy study in patients with differentiated 
thyroid cancer (DTC), Proceedings of 41st Annual Meeting of the Society of Nuclear 
Medicine., Cedars-sinai Medical center, Los Angeles, CA, 1994 
Kim, C.H.; Yoo Ie, R.; Chung, Y.A.; Park, Y.H.; Kim, S.H.; Sohn, H.S. & Chung, S.K. (2009). 
Influence of thyroid-stimulating hormone on 18F-fluorodeoxyglucose and 99mTc-
methoxyisobutylisonitrile uptake in human poorly differentiated thyroid cancer 
cells in vitro. Annals of Nuclear Medicine, Vol. 23, No. 2, (February 2009), pp. 131-136, 
ISSN 0914-7187 
Larson, S.M. & Robbins, R. (2002). Positron emission tomography in thyroid cancer 
management. Seminars in Roentgenology, Vol. 37, No. 2, (July 2002), pp. 169-174, 
ISSN 0037-198X 
Lee, J.W.; Lee, S.M.; Koh, G.P. & Lee, D.H. (2011). The comparison of (131)I whole-body 
scans on the third and tenth day after (131)I therapy in patients with well-
differentiated thyroid cancer: preliminary report. Annals of Nuclear Medicine, Vol. 
No. (April 2011), pp. ISSN 1864-6433 
Luster, M.; Clarke, S.E.; Dietlein, M.; Lassmann, M.; Lind, P.; Oyen, W.J.; Tennvall, J. & 
Bombardieri, E. (2008). Guidelines for radioiodine therapy of differentiated thyroid 
cancer. European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, No. 10, 
(August 2008), pp. 1941-1959, ISSN 1619-7070 
Mazzaferri, E. L. (1986). In: Treatment of carcinoma of follicular epithelium, pp. 1342-1343, 
Lippincott, ISBN 0397508026 Philadelphia 
Mazzaferri, E.L. & Jhiang, S.M. (1994). Long-term impact of initial surgical and medical 
therapy on papillary and follicular thyroid cancer. American Journal of Medicine, Vol. 
97, No. 5, (November 1994), pp. 418-428, ISSN 0002-9343 
 
12 Chapters on Nuclear Medicine 
 
248 
Misaki, T.; Takeuchi, R.; Miyamoto, S.; Kasagi, K.; Matsui, Y. & Konishi, J. (1994). 
Radioiodine uptake by squamous-cell carcinoma of the lung. Journal of Nuclear 
Medicine, Vol. 35, No. 3, (March 1994), pp. 474-475, ISSN 0161-5505 
Mitchell, G.; Pratt, B.E.; Vini, L.; McCready, V.R. & Harmer, C.L. (2000). False positive 131I 
whole body scans in thyroid cancer. The British Journal or Radiology, Vol. 73, No. 870, 
(July 2000), pp. 627-635, ISSN 0007-1285 
Moretti, J.L.; Hauet, N.; Caglar, M.; Rebillard, O. & Burak, Z. (2005). To use MIBI or not to 
use MIBI? That is the question when assessing tumour cells. European Journal of 
Nuclear Medicine and Molecular Imaging, Vol. 32, No. 7, (July 2005), pp. 836-842, ISSN 
1619-7070  
Mullins, L.J. & Moore, R.D. (1960). The movement of thallium ions in muscle. J Gen Physiol, 
Vol. 43, No. 4, (March 1960), pp. 759-773, ISSN 0022-1295 (Print) 0022-1295 
(Linking) 
Muratet, J.P.  & Giraud, P. (1996). Thymus accumulation of I-131 after therapeutic dose for 
thyroid carcinoma. Clinical Nuclear Medicine, Vol. 21, No. 9, (September 1996), pp. 
736-737, ISSN 0363-9762 
Nakada, K.; Katoh, C.; Morita, K.; Kanegae, K.; Tsukamoto, E.; Shiga, T.; Mochizuki, T. & 
Tamaki, N. (1999). Relationship among 201T1 uptake, nuclear DNA content and 
clinical behavior in metastatic thyroid carcinoma. Journal of Nuclear Medicine, Vol. 
40, No. 6, (August 1999), pp. 963-967, ISSN 0161-5505 
Nemec, J.; Rohling, S.; Zamrazil, V. & Pohunkova, D. (1979). Comparison of the distribution 
of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid 
cancers. Journal of Nuclear Medicine, Vol. 20, No. 2, (February 1979), pp. 92-97, ISSN 
0161-5505 
Nishiyama, Y.; Yamamoto, Y.; Ono, Y.; Takahashi, K.; Nakano, S.; Satoh, K.; Ohkawa, M. & 
Tanabe, M. (2000). Comparison of 99mTc-tetrofosmin with 201Tl and 131I in the 
detection of differentiated thyroid cancer metastases. Nuclear Medince 
Communications, Vol. 21, No. 10, (October 2000), pp. 917-923, ISSN 0143-3636 
Oh, J.R.; Byun, B.H.; Hong, S.P.; Chong, A.; Kim, J.; Yoo, S.W.; Kang, S.R.; Kim, D.Y.; Song, 
H.C.; Bom, H.S. & Min, J.J. (2011). Comparison of (131)I whole-body imaging, (131)I 
SPECT/CT, and (18)F-FDG PET/CT in the detection of metastatic thyroid cancer. 
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, No. 8, (August 
2011), pp. 1459-1468, ISSN 1619-7089 
Pauwels, E.K.; McCready, V.R.; Stoot, J.H.  & van Deurzen, D.F. (1998). The mechanism of 
accumulation of tumour-localising radiopharmaceuticals. European Journal of 
Nuclear Medicine, Vol. 25, No. 3, (March 1998), pp. 277-305, ISSN 0340-6997 
Piwnica-Worms, D.P.; Kronauge, J.F.; LeFurgey, A.; Backus, M.; Hockett, D.; Ingram, P.; 
Lieberman, M.; Holman, B.L.; Jones, A.G. & Davison, A. (1994). Mitochondrial 
localization and characterization of 99mTc-SESTAMIBI in heart cells by electron 
probe X-ray microanalysis and 99Tc-NMR spectroscopy. Magnetic Resonance 
Imaging, Vol. 12, No. 4, (January 1994), pp. 641-652, ISSN 0730-725X 
Rawson, R.W.; Rall, J.E. & Peacock, W. (1951). Limitations and indications in the treatment 
of cancer of the thyroid with radioactive iodine. The Journal of Clinical Endocrinology 
& Metabolism, Vol. 11, No. 10, (October 1951), pp. 1128-1142, ISSN 0021-972X 
Riedel, C.; Dohan, O.; De la Vieja, A.; Ginter, C.S. & Carrasco, N. (2001). Journey of the 
iodide transporter NIS: from its molecular identification to its clinical role in cancer. 
 
Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer 
 
249 
Trends in Biochemical Sciences, Vol. 26, No. 8, (August 2001), pp. 490-496, ISSN 0968-
0004 
Rosario, P.W.; Barroso, A.L.; Rezende, L.L.; Padrao, E.L.; Maia, F.F.; Fagundes, T.A. & 
Purisch, S. (2005). 5 mCi pretreatment scanning does not cause stunning when the 
ablative dose is administered within 72 hours. Arquivos Brasileiros de Endocrinologia 
& Metabologia, Vol. 49, No. 3, (March 2006), pp. 420-424, ISSN 0004-2730 
Saggiorato, E.; Angusti, T.; Rosas, R.; Martinese, M.; Finessi, M.; Arecco, F.; Trevisiol, E.; 
Bergero, N.; Puligheddu, B.; Volante, M.; Podio, V.; Papotti, M. & Orlandi, F. (2009). 
99mTc-MIBI Imaging in the presurgical characterization of thyroid follicular 
neoplasms: relationship to multidrug resistance protein expression. Journal of 
Nuclear Medicine, Vol. 50, No. 11, (November 2009), pp. 1785-1793, ISSN 1535-5667 
Samaan, N.A.; Schultz, P.N.; Haynie, T.P. & Ordonez, N.G. (1985). Pulmonary metastasis of 
differentiated thyroid carcinoma: treatment results in 101 patients. The Journal of 
Clinical Endocrinology & Metabolism, Vol. 60, No. 2, (February 1985), pp. 376-380, 
ISSN 0021-972X 
Samaan, N.A.; Schultz, P.N.; Hickey, R.C.; Goepfert, H.; Haynie, T.P.; Johnston, D.A. & 
Ordonez, N.G. (1992). The results of various modalities of treatment of well 
differentiated thyroid carcinomas: a retrospective review of 1599 patients. The 
Journal of Clinical Endocrinology & Metabolism, Vol. 75, No. 3, (September 1992), pp. 
714-720, ISSN 0021-972X 
Schlumberger, M.; Tubiana, M.; De Vathaire, F.; Hill, C.; Gardet, P.; Travagli, J.P.; Fragu, P.; 
Lumbroso, J.; Caillou, B. & Parmentier, C. (1986). Long-term results of treatment of 
283 patients with lung and bone metastases from differentiated thyroid carcinoma. 
The Journal of Clinical Endocrinology & Metabolism, Vol. 63, No. 4, (October 1986), pp. 
960-967, ISSN 0021-972X 
Senga, O.; Miyakawa, M.; Shirota, H.; Makiuchi, M.; Yano, K.; Miyazawa, M. & Takizawa, 
M. (1982). Comparison of Tl-201 chloride and Ga-67 citrate scintigraphy in the 
diagnosis of thyroid tumor: concise communication. Journal of Nuclear Medicine, 
Vol. 23, No. 3, (March 1982), pp. 225-228, ISSN 0161-5505 
Sharma, R.; Chakravarty, K.L.; Tripathi, M.; Kaushik, A.; Bharti, P.; Sahoo, M.; Chopra, M.K.; 
Rawat, H.; Misra, A.; Mondal, A. & Kashyap, R. (2007). Role of 99mTc-Tetrofosmin 
delayed scintigraphy and color Doppler sonography in characterization of solitary 
thyroid nodules. Nuclear Medicine Communcations, Vol. 28, No. 11, (September 2007), 
pp. 847-851, ISSN 0143-3636 
Shiga, T.; Tsukamoto, E.; Nakada, K.; Morita, K.; Kato, T.; Mabuchi, M.; Yoshinaga, K.; 
Katoh, C.; Kuge, Y. & Tamaki, N. (2001). Comparison of (18)F-FDG, (131)I-Na, and 
(201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. Journal of Nuclear 
Medicine, Vol. 42, No. 3, (March 2001), pp. 414-419, ISSN 0161-5505 
Souza Rosario, P.W.; Barroso, A.L.; Rezende, L.L.; Padrao, E.L.; Fagundes, T.A.; Penna, G.C. 
& Purisch, S. (2004). Post I-131 therapy scanning in patients with thyroid carcinoma 
metastases: an unnecessary cost or a relevant contribution? Clinical Nuclear 
Medicine, Vol. 29, No. 12, (Novemeber 2004), pp. 795-798, ISSN 0363-9762 
Spies, W.G.; Wojtowicz, C.H.; Spies, S.M.; Shah, A.Y. & Zimmer, A.M. (1989). Value of post-
therapy whole-body I-131 imaging in the evaluation of patients with thyroid 
carcinoma having undergone high-dose I-131 therapy. Clinical Nuclear Medicine, 
Vol. 14, No. 11, (November 1989), pp. 793-800, ISSN 0363-9762 
 
12 Chapters on Nuclear Medicine 
 
248 
Misaki, T.; Takeuchi, R.; Miyamoto, S.; Kasagi, K.; Matsui, Y. & Konishi, J. (1994). 
Radioiodine uptake by squamous-cell carcinoma of the lung. Journal of Nuclear 
Medicine, Vol. 35, No. 3, (March 1994), pp. 474-475, ISSN 0161-5505 
Mitchell, G.; Pratt, B.E.; Vini, L.; McCready, V.R. & Harmer, C.L. (2000). False positive 131I 
whole body scans in thyroid cancer. The British Journal or Radiology, Vol. 73, No. 870, 
(July 2000), pp. 627-635, ISSN 0007-1285 
Moretti, J.L.; Hauet, N.; Caglar, M.; Rebillard, O. & Burak, Z. (2005). To use MIBI or not to 
use MIBI? That is the question when assessing tumour cells. European Journal of 
Nuclear Medicine and Molecular Imaging, Vol. 32, No. 7, (July 2005), pp. 836-842, ISSN 
1619-7070  
Mullins, L.J. & Moore, R.D. (1960). The movement of thallium ions in muscle. J Gen Physiol, 
Vol. 43, No. 4, (March 1960), pp. 759-773, ISSN 0022-1295 (Print) 0022-1295 
(Linking) 
Muratet, J.P.  & Giraud, P. (1996). Thymus accumulation of I-131 after therapeutic dose for 
thyroid carcinoma. Clinical Nuclear Medicine, Vol. 21, No. 9, (September 1996), pp. 
736-737, ISSN 0363-9762 
Nakada, K.; Katoh, C.; Morita, K.; Kanegae, K.; Tsukamoto, E.; Shiga, T.; Mochizuki, T. & 
Tamaki, N. (1999). Relationship among 201T1 uptake, nuclear DNA content and 
clinical behavior in metastatic thyroid carcinoma. Journal of Nuclear Medicine, Vol. 
40, No. 6, (August 1999), pp. 963-967, ISSN 0161-5505 
Nemec, J.; Rohling, S.; Zamrazil, V. & Pohunkova, D. (1979). Comparison of the distribution 
of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid 
cancers. Journal of Nuclear Medicine, Vol. 20, No. 2, (February 1979), pp. 92-97, ISSN 
0161-5505 
Nishiyama, Y.; Yamamoto, Y.; Ono, Y.; Takahashi, K.; Nakano, S.; Satoh, K.; Ohkawa, M. & 
Tanabe, M. (2000). Comparison of 99mTc-tetrofosmin with 201Tl and 131I in the 
detection of differentiated thyroid cancer metastases. Nuclear Medince 
Communications, Vol. 21, No. 10, (October 2000), pp. 917-923, ISSN 0143-3636 
Oh, J.R.; Byun, B.H.; Hong, S.P.; Chong, A.; Kim, J.; Yoo, S.W.; Kang, S.R.; Kim, D.Y.; Song, 
H.C.; Bom, H.S. & Min, J.J. (2011). Comparison of (131)I whole-body imaging, (131)I 
SPECT/CT, and (18)F-FDG PET/CT in the detection of metastatic thyroid cancer. 
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, No. 8, (August 
2011), pp. 1459-1468, ISSN 1619-7089 
Pauwels, E.K.; McCready, V.R.; Stoot, J.H.  & van Deurzen, D.F. (1998). The mechanism of 
accumulation of tumour-localising radiopharmaceuticals. European Journal of 
Nuclear Medicine, Vol. 25, No. 3, (March 1998), pp. 277-305, ISSN 0340-6997 
Piwnica-Worms, D.P.; Kronauge, J.F.; LeFurgey, A.; Backus, M.; Hockett, D.; Ingram, P.; 
Lieberman, M.; Holman, B.L.; Jones, A.G. & Davison, A. (1994). Mitochondrial 
localization and characterization of 99mTc-SESTAMIBI in heart cells by electron 
probe X-ray microanalysis and 99Tc-NMR spectroscopy. Magnetic Resonance 
Imaging, Vol. 12, No. 4, (January 1994), pp. 641-652, ISSN 0730-725X 
Rawson, R.W.; Rall, J.E. & Peacock, W. (1951). Limitations and indications in the treatment 
of cancer of the thyroid with radioactive iodine. The Journal of Clinical Endocrinology 
& Metabolism, Vol. 11, No. 10, (October 1951), pp. 1128-1142, ISSN 0021-972X 
Riedel, C.; Dohan, O.; De la Vieja, A.; Ginter, C.S. & Carrasco, N. (2001). Journey of the 
iodide transporter NIS: from its molecular identification to its clinical role in cancer. 
 
Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer 
 
249 
Trends in Biochemical Sciences, Vol. 26, No. 8, (August 2001), pp. 490-496, ISSN 0968-
0004 
Rosario, P.W.; Barroso, A.L.; Rezende, L.L.; Padrao, E.L.; Maia, F.F.; Fagundes, T.A. & 
Purisch, S. (2005). 5 mCi pretreatment scanning does not cause stunning when the 
ablative dose is administered within 72 hours. Arquivos Brasileiros de Endocrinologia 
& Metabologia, Vol. 49, No. 3, (March 2006), pp. 420-424, ISSN 0004-2730 
Saggiorato, E.; Angusti, T.; Rosas, R.; Martinese, M.; Finessi, M.; Arecco, F.; Trevisiol, E.; 
Bergero, N.; Puligheddu, B.; Volante, M.; Podio, V.; Papotti, M. & Orlandi, F. (2009). 
99mTc-MIBI Imaging in the presurgical characterization of thyroid follicular 
neoplasms: relationship to multidrug resistance protein expression. Journal of 
Nuclear Medicine, Vol. 50, No. 11, (November 2009), pp. 1785-1793, ISSN 1535-5667 
Samaan, N.A.; Schultz, P.N.; Haynie, T.P. & Ordonez, N.G. (1985). Pulmonary metastasis of 
differentiated thyroid carcinoma: treatment results in 101 patients. The Journal of 
Clinical Endocrinology & Metabolism, Vol. 60, No. 2, (February 1985), pp. 376-380, 
ISSN 0021-972X 
Samaan, N.A.; Schultz, P.N.; Hickey, R.C.; Goepfert, H.; Haynie, T.P.; Johnston, D.A. & 
Ordonez, N.G. (1992). The results of various modalities of treatment of well 
differentiated thyroid carcinomas: a retrospective review of 1599 patients. The 
Journal of Clinical Endocrinology & Metabolism, Vol. 75, No. 3, (September 1992), pp. 
714-720, ISSN 0021-972X 
Schlumberger, M.; Tubiana, M.; De Vathaire, F.; Hill, C.; Gardet, P.; Travagli, J.P.; Fragu, P.; 
Lumbroso, J.; Caillou, B. & Parmentier, C. (1986). Long-term results of treatment of 
283 patients with lung and bone metastases from differentiated thyroid carcinoma. 
The Journal of Clinical Endocrinology & Metabolism, Vol. 63, No. 4, (October 1986), pp. 
960-967, ISSN 0021-972X 
Senga, O.; Miyakawa, M.; Shirota, H.; Makiuchi, M.; Yano, K.; Miyazawa, M. & Takizawa, 
M. (1982). Comparison of Tl-201 chloride and Ga-67 citrate scintigraphy in the 
diagnosis of thyroid tumor: concise communication. Journal of Nuclear Medicine, 
Vol. 23, No. 3, (March 1982), pp. 225-228, ISSN 0161-5505 
Sharma, R.; Chakravarty, K.L.; Tripathi, M.; Kaushik, A.; Bharti, P.; Sahoo, M.; Chopra, M.K.; 
Rawat, H.; Misra, A.; Mondal, A. & Kashyap, R. (2007). Role of 99mTc-Tetrofosmin 
delayed scintigraphy and color Doppler sonography in characterization of solitary 
thyroid nodules. Nuclear Medicine Communcations, Vol. 28, No. 11, (September 2007), 
pp. 847-851, ISSN 0143-3636 
Shiga, T.; Tsukamoto, E.; Nakada, K.; Morita, K.; Kato, T.; Mabuchi, M.; Yoshinaga, K.; 
Katoh, C.; Kuge, Y. & Tamaki, N. (2001). Comparison of (18)F-FDG, (131)I-Na, and 
(201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. Journal of Nuclear 
Medicine, Vol. 42, No. 3, (March 2001), pp. 414-419, ISSN 0161-5505 
Souza Rosario, P.W.; Barroso, A.L.; Rezende, L.L.; Padrao, E.L.; Fagundes, T.A.; Penna, G.C. 
& Purisch, S. (2004). Post I-131 therapy scanning in patients with thyroid carcinoma 
metastases: an unnecessary cost or a relevant contribution? Clinical Nuclear 
Medicine, Vol. 29, No. 12, (Novemeber 2004), pp. 795-798, ISSN 0363-9762 
Spies, W.G.; Wojtowicz, C.H.; Spies, S.M.; Shah, A.Y. & Zimmer, A.M. (1989). Value of post-
therapy whole-body I-131 imaging in the evaluation of patients with thyroid 
carcinoma having undergone high-dose I-131 therapy. Clinical Nuclear Medicine, 
Vol. 14, No. 11, (November 1989), pp. 793-800, ISSN 0363-9762 
 
12 Chapters on Nuclear Medicine 
 
250 
Surti, S.; Scheuermann, R. & Karp, J.S. (2009). Correction technique for cascade gammas in I-
124 imaging on a fully-3D, Time-of-Flight PET Scanner. IEEE Trans Nucl Sci, Vol. 
56, No. 3, (August 2009), pp. 653-660, ISSN 0018-9499 
Thyroid cancer survivors' Association, Inc. (05.23.2011). Radioactive iodine (RAI), In: Thyroid 
Cancer Survivors Association website, 06.22.2011, Available from: 
<http://www.thyca.org/rai.htm#diet> 
Unal, S.; Menda, Y.; Adalet, I.; Boztepe, H.; Ozbey, N.; Alagol, F. & Cantez, S. (1998). 
Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting 
differentiated thyroid carcinoma metastases. Journal of Nuclear Medicine, Vol. 39, 
No. 11, (November 1998), pp. 1897-1902, ISSN 0161-5505 
Van Nostrand, D.; Moreau, S.; Bandaru, V.V.; Atkins, F.; Chennupati, S.; Mete, M.; Burman, 
K. & Wartofsky, L. (2010). (124)I positron emission tomography versus (131)I 
planar imaging in the identification of residual thyroid tissue and/or metastasis in 
patients who have well-differentiated thyroid cancer. Thyroid, Vol. 20, No. 8, 
(August 2010), pp. 879-883, ISSN 1050-7256 
Waxman, A.; Ramanna, L.; Chapman, N.; Chapman, D.; Brachman, M.; Tanasescu, D.; 
Berman, D.; Catz, B. & Braunstein, G. (1981). The significance of 1-131 scan dose in 
patients with thyroid cancer: determination of ablation: concise communication. 
Journal of Nuclear Medicine, Vol. 22, No. 10, (October 1981), pp. 861-865, ISSN 0161-
5505 
Wu, H.S.; Huang, W.S.; Liu, Y.C.; Yen, R.F.; Shen, Y.Y. & Kao, C.H. (2003). Comparison of 
FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph 
nodes in well-differentiated thyroid carcinoma with elevated serum HTG but 
negative I-131 whole body scan. Anticancer Research, Vol. 23, No. 5b, (December 
2003), pp. 4235-4238, ISSN 0250-7005 
Yoshio, K.; Sato, S.; Okumura, Y.; Katsui, K.; Takemoto, M.; Suzuki, E.; Katayama, N.; Kaji, 
M. & Kanazawa, S. (2011). The local efficacy of I-131 for F-18 FDG PET positive 
lesions in patients with recurrent or metastatic thyroid carcinomas. Clincal Nuclear 
Medicine, Vol. 36, No. 2, (February 2011), pp. 113-117, ISSN 0363-9762 
10 
Apoptosis Imaging in Diseased Myocardium 
Junichi Taki, Hiroshi Wakabayashi, Anri Inaki, 
Ichiro Matsunari and Seigo Kinuya 
Kanazawa University & Medical and Pharmacological Research Center Foundation, 
Japan 
1. Introduction 
In various myocardial disorders including myocardial ischemia, infarction and subsequent 
cardiac remodelling and heart failure, myocarditis, cardiomyopathy, cardiac allograft 
rejection, chemotherapy induced cardiotoxicity, both necrosis and apoptosis are considered 
to play an important role in the underling pathophysioloy. Molecular and cellular 
dysfunction has been widely investigated in cardiovascular fields using various modalities. 
Of particular, radionuclide imaging technique has advantage for quantitative assessment of 
molecular function in vivo in patients. Especially in patients with coronary artery disease, 
perfusion imaging agents such as 201Tl, 99mTc-MIBI and tetrofosmin with combination of 
stress testing and ECG-gated data acquisition have been used for the simultaneous 
assessment of the ventricular function and severity of myocardial perfusion abnormality 
including its location and size in stress and resting condition. From these data, status of 
myocardial ischemia or jeopardized myocardium, myocardial viability and reversibility of 
wall motion abnormality can be diagnosed to some extent but still insufficiently. Molecular 
imaging may play an important role for assessing the pathophysiology and its severity in 
these various cardiovascular diseases beyond perfusion imaging. This chapter focuses on 
the apoptosis imaging that is one of the most possible nuclear molecular imaging in-vivo at 
this stage, and its clinical application might permit more precise assessment of the 
pathophysiology in various myocardial abnormalities beyond perfusion imaging. 
Four decades ago, the term apoptosis has been introduced by Kerr et. al. as a special form of 
cell death different from necrosis (Kerr, et al., 1972). Necrosis is passive and unregulated 
form of cell death, characterized by irreversible loss of plasma membrane integrity with cell 
swelling and rupture after sudden severe insults which preclude adequate homeostatic 
energy-dependent cell functions, leading to release of intracellular contents and a 
subsequent inflammatory response. Apoptosis on the other hand is characterized 
morphologically by the condensation of nuclear chromatin, cytoplasmic condensation, cell 
shrinkage, followed by the nuclear and cellular fragmentation and phagocytosis of apoptotic 
bodies by neighboring cells in the absence of inflammation. Apoptosis is considered to be an 
active and highly regulated ATP dependent programmed cell daeth process and plays an 
important roles in embryonic developement and maintenace of postnatal tissues and 
contributes to both normal physiology and pathology. Dysregulation of apoptosis results in 
either too littel or too much cell death and implicated in various diseases. For instance, 
insufficient apoptosis may contribute carcinogenesis, on the otherhand, eccessive apoptosis 
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Fig. 1. Schema of two major pathway for apoptosis. 
Apoptosis can be mediated through the death receptor pathway, or by mitochondrial pathway 
that is initiated by the release of cytochrome c into the cytosol. Both pathways result in 
activation of caspase-3, the final effector enzyme of apoptosis, leading to the cleavage of 
numerous structural and regulatory cellular proteins, thereby producing the apoptotic 
phenotype characterized by cell shrinkage, chromatin condensation, nucleus fragmentation, 
and externalization of phosphatidylserin (PS) on the outside of the cell membrane. 
Apoptosis is mediated by 2 central pathway: the extrinsic (or death receptor) pathway that 
utilizes cell surface receptors (e.g. Fas) and the intrinsic (or mitochondrial) pathway that 
involves the mitochondria and cytoplasmic reticulum (Fig. 1.). The extrinsic or death 
receptor pathway relies on the binding of specific cytokines expressed by other cells, 
including Fas ligand, tumor necrosis factor alfa, or other factors that binds to specific 
cellular receptors. Ligand binding initiates the activation of caspase-8, which in turn 
activates downstream effector caspases including caspase-3, the final effector enzyme of 
apoptosis. In contrast to extrinsic pathway that transduces a specialized set of death stimuli, 
the intrinsic or mitochondrial pathway integrates a broad spectrum of extracellular and 
intracellular stresses such as ischemia, reperfusion injury, chemotherapy, oxidative stress 
etc. These stimuli converges on the mithochondria leading to the release of several factors 
into cytosol including cytochrome c, which activates the initiator caspase-9 via the 
apoptosome followed by the activation of effector caspases. The activation of down stream 
caspases leads to the cleavage of numerous structural and regulatory cellular proteins, 
thereby producing the apoptotic phenotype characterized by cell shrinkage, chromatin 
condensation, nucleus fragmentation, and externalization of phosphatidylserin (PS) on the 
outside of the cell membrane which serves as an “eat me“ signal for phagocyte. Intracellular 
components are packaged by blebbing and the cell is fragmentated into apoptotic bodies 
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and designated to be engulfed and phagocytosed by macrophages and neighbouring cells 
without causing inflammation. 
2. Radipharmaceuticals for molecular imaging of apoptosis 
After the initial description of apoptosis based on the morphological features, several useful 
biochemical and immunohistochemical detection methods were subsequently introduced 
based on the understanding of the basic mechanisms of apoptosis. As a histochemical 
technique for the detection of apoptosis, terminal deoxynucleotidyltransferase-dUTP-nick end-
labeling (TUNEL) assays has become a standard technique for in situ labeling and localization 
of DNA breaks in individual nuclei on tissue section (Gavrieli, et al.,1992). TUNEL is based on 
the specific binding of terminal deoxynucleotidyltransferase (TdT) to 3’-OH ends of 
fragmented DNA. As DNA ladder formation is quite a late feature of apoptosis, TUNEL assay 
appears to be uniquely associated with apoptotic cell death. For the in-vivo imaging initiator 
caspases and effector caspases can be distinguished and serve as potential targets inside the 
apoptotic cells. However, for molecular target for in-vivo imaging, it is favorable that the 
target exists on cell surface rather than in cytoplasm or nucleus. Accordingly, to date, most 
noninvasive imagings of apoptosis target PS on the cell membrane, which is a membrane 
aminophospholipid that is normally located on the inner leaflet of cell membrane but is 
rapidly trnaslocated to the outer leaflet of cell membrane once the cell become apoptotic. 
Annexin V, a 36-kD physiologic protein, binds with nanomolar affinity to PS in a calcium 
dependent manner, therefore, 99mTc labeled annexin V permits imaging of apoptosis in vivo in 
its early stage (Blankenberg, et al., 1998; Hofstra, et al., 2000; Kemerink, et al., 2003). 
2.1 Radiolabeled annexin V 
Annexin V (also known as annexin A5) is consisted of 319 amino acids and a 36-kD 
endogeneous human protein that is mainly distributed intracellularly with very high 
concentrations in placenta, and lower concentrations in endothelial cells, myocardium, skeletal 
muscle, kidneys, skin, red blood cells, platelets, and monocytes. Very low concentrations of 
annexin V (1-6 ng/ml) circulate in blood of healthy humans (Andree et al., 1992). Several 
advantages for the use of annexin V for apoptotic imaging have been described including very 
high affinity for PS with low nanomolar to subnanomolar dissociation constant values, ready 
production by recombinant DNA technology, and lack of toxicity of the protein. 
In healthy cells, anionic phospholipid PS and phosphatidylethanolamine (PE) confined to 
the inner leaflet of the lipid bilayer plasma membrane by an ATP dependent enzyme called 
translocase. On the other hand, ATP dependent enzyme, floppase, pumps cationic 
phospholipids such as phosphatidylcholine (PC) and sphingomyelin to the cell surface. 
Therefore, an asymmetric distribution of different phospholipids between the inner and 
outer leaflet of the plasma membrane is maintained in normal cells. However, at the 
beginning of the execution phase of apoptosis, rapid redistribution of PS and PC across the 
cell membrane is facilitated by a calcium ion-dependent deactivation of translocase and 
floppase and activation of scramblase. Then, PS exposes on the cell surface and annexin V 
become accessible to PS. This PS exposure is attractive target for imaging apoptosis, since it 
is a near universal event in apoptosis, it occurs early after the apoptotic stimulus, and it 
presents millions of binding sites per cell on the cell surface. 
Annexin V and its derivatives have been labeled with 123I, 124I, 125I, 99mTc, 18F, thereby 
providing a broad range of imaging applications in apoptosis research from autoradiography 
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and single photon imaging including SPECT, and to PET. However, most of the 
radiolabeled annexin V used in clinical trials are 99mTc labeled annexin V, because 99mTc is 
characterized by the most suitable radionuclide properties for SPECT imaging in human 
and is inexpensive and easily available. 
99mTc-BTAP-annexin V using a diamide dimercaptide N2S2 chelate for labeling (99mTc- N2S2-
annexin V) was introduced in early 1990s and examined to detect left atrial thrombi in vivo in 
swine (Stratton et al., 1995). Biodistribution and dosimetry study of 99mTc-BTAP-annexin V in 
patients revealed that the radioactivity predominates in kidney, liver and urine bladder and 
fast and extensive bowel excretion of the tracer precludes the assessment of abdominal region 
(Kemerink, et al., 2001a). N2S2 labeling method is cumbersome but radiochemical yield is low 
and had a high degree of non specific tracer excretion into bowel via excretion to bile. 
Accordingly, an improved labeling method using the bifunctional agent 
hydrazinonicotinamide (HYNIC) was introduced (Blankenberg, et al., 1998). 99mTc-labeling 
of reconstituted HYNIC-annexin V can be performed by simply reacting the conjugate with 
99mTc-pertechnetate in the presence of stannous tricine for 5-10min in room temperature and 
it provides 99mTc-HYNIC-annexin V in high radiochemical yield (usually 92-95%) without 
requiring any additional purification step. Phase I clinical trial with 99mTc-HYNIC-annexin V 
also demonstrated strongest uptake in kidney, liver and urine bladder. However, in contrast 
to 99mTc-BTAP-annexin V no bowel excretion was observed in 99mTc-HYNIC-annexin V, 
having a favorable biodistribution for imaging of the abdominal as well as thoracic area.  
As an alternative methods for radiolabeling annexin V, self chelating annexin V mutants 
had been introduced (Tait, et al., 2000, 2005). Annexin V mutants with endogeneous site for 
99mTc chelation such as V-117 and V-128 have major advantages over the HYNIC chelatior in 
terms with lower renal retention. Many other kind of 99mTc-labeled annexin V have been 
introduced, however, only 99mTc-i-annexin V (Kemerink, et al., 2001b) was tested in clinical 
trial in addition to 99mTc-BTAP-annexin V and 99mTc-HYNIC-annexin V.  
As a PET tracer, several approaches to label annexin V with 18F have been developed 
(Grierson, et al. 2004; Murakami et al., 2004).18F-annexin V has lower uptake in the liver, 
spleen, and kidneys than 99mTc-HYNIC-annexin V.  
2.2 Radiolabeled C2A 
C2A domain of synaptotagmin I also binds PS with nanomolar affinity in a calcium-
dependent manner. The C2A is labeled in the form of C2A-GST (GST: glutathione S-
transferase) fusion protein. The fusion protein can be stably labeled with 99mTc at a 
reasonably high radiochemical yield and purity through thiolation using 2-iminothiolane 
(Zhao, et al., 2006). 99mTc-C2A-GST accumulates well in the area at risk in a rat model of 
acute myocardial infarction in both in-vivo imaging and autoradiography. Recently, 18F-
C2A-GST was synthesized and significant uptake in the VX2 rabbit lung cancer with 
paclitaxel induced apoptosis was observed in small animal PET/CT (Wang, et al., 2011). 
Radiochemical purity of 18F-C2A-GST was more than 95% and stable for 4 h after 
formulation. Biodistribution in mice was favorable with major excretion from the kidneys 
and rapid clearance from blood and nonspecific organs. 
2.3 Radiolabeled caspase targeted tracer 
Caspase activation is the central role in the execution of cell death, therefore, caspases are 
the attractive targets for apoptosis imaging. Non-peptide based isatin sulfonamide analogs 
were synthesized with nanomolar potency for inhibiting caspase-3 and caspase-7 and one of 
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the analogs, WC-II-89 was labeled with 18F (Zhou et al., 2006). 18F- WC-II-89 showed a high 
uptake in the liver of chemically induced apoptosis. Although molecules that target caspase-
3 is attractive, there are limited animal data and it is not yet known how sensitive this kind 
of  agents will be for actual imaging in humans. 
2.4 Uncategorized tracer 
Recently a novel family of low molecular mass amphipatic apoptosis markers (ApoSense) 
was developed targeting the cell membrane of apoptotic cells. 18F-labeled 5-fluoropentyl-2-
methyl-malonic acid (18F-ML-10) belongs to this family of low-molecular-weight compounds 
used for the imaging of cell death in vivo. This compound responds to alterations in plasma 
membrane potential and phospholipid scrambling, which are hallmarks of apoptotic cells. 
To which cell membrane targets this probe binds is unknown. After systemic 
administration, the compound can detect apoptotic cells from the early stages of the death 
process, cross the intact plasma membrane, and accumulate in the cytoplasm. In animal 
model of cerebral infarction, selective uptake was observed in the region of ischemia at 24 hr 
after the middle cerebral artery occlusion (Reshef et al., 2008). 
3. Apoptosis imaging in acute myocardial ischemia 
It has been believed that myocardium directly start to die via necrosis shortly after the onset 
of myocardial infarction that march of necrosis spread as a wavefront from endocardium to 
epicardium. However, recent animal experiments with permanent coronary artery occlusion 
revealed that cell death process starts as apoptosis and severe ATP depletion due to 
ischemia may preclude the execution of apoptosis and lead to plasma membrane 
permeability barrier breakdown and secondary necrosis. Therefore, apoptosis imaging 
might play important role in the assessment of myocardial cell death process in acute 
myoacrdial infarction, especially in its early stage. 
3.1 Animal experiment in permanent occlusion of coronary artery 
In a rat model of permanent coronary artery ligation, Kajstura et al. investigated the 
contribution of the apoptosis and necrosis to cardiomyocyte death using TUNEL method 
and DNA laddering for apoptosis and antimyosin monoclonal antibody labeling (Kajstura, 
et a., 1996). After 2 h of the left main coronary artery ligation, TUNEL positive myocytes 
appeared in the central portion of the left ventricular free wall and peaked at 4.5 h. Myosin 
labeled cells also appeared at 2 h after ligation and significantly increased after 6 h to 2 days. 
However, at 2 h after coronary ligation, number of apoptotic cells was 2.8 x 106 and number 
of necrotic cells was 9 x 104. Therefore, early after myocardial infarction, apoptosis is the 
predominant form of cell death, and 1 to 2 days after infarction, necrosis is the dominant 
form of cell death followed by low levels of both apoptosis and necrosis at 7 days after 
infarction. If cells undergoing apoptosis are not cleared before they deplete their 
intracellular ATP stores that are necessary to maintain plasma membrane integrity, plasma 
membrane permeability barrier breakdown occurs and cells are converted from apoptosis to 
necrosis as known as secondary necrosis, results in inflammation. 
3.2 Animal experiment in acute ischemia and reperfusion 
In a mouse model of 15 and 30 min of ischemia and 90 min of reperfusion, percentage of 
cardiomyocytes staining positivity for biotinylated annexin V was far greater than the 
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and single photon imaging including SPECT, and to PET. However, most of the 
radiolabeled annexin V used in clinical trials are 99mTc labeled annexin V, because 99mTc is 
characterized by the most suitable radionuclide properties for SPECT imaging in human 
and is inexpensive and easily available. 
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to 99mTc-BTAP-annexin V no bowel excretion was observed in 99mTc-HYNIC-annexin V, 
having a favorable biodistribution for imaging of the abdominal as well as thoracic area.  
As an alternative methods for radiolabeling annexin V, self chelating annexin V mutants 
had been introduced (Tait, et al., 2000, 2005). Annexin V mutants with endogeneous site for 
99mTc chelation such as V-117 and V-128 have major advantages over the HYNIC chelatior in 
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introduced, however, only 99mTc-i-annexin V (Kemerink, et al., 2001b) was tested in clinical 
trial in addition to 99mTc-BTAP-annexin V and 99mTc-HYNIC-annexin V.  
As a PET tracer, several approaches to label annexin V with 18F have been developed 
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spleen, and kidneys than 99mTc-HYNIC-annexin V.  
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transferase) fusion protein. The fusion protein can be stably labeled with 99mTc at a 
reasonably high radiochemical yield and purity through thiolation using 2-iminothiolane 
(Zhao, et al., 2006). 99mTc-C2A-GST accumulates well in the area at risk in a rat model of 
acute myocardial infarction in both in-vivo imaging and autoradiography. Recently, 18F-
C2A-GST was synthesized and significant uptake in the VX2 rabbit lung cancer with 
paclitaxel induced apoptosis was observed in small animal PET/CT (Wang, et al., 2011). 
Radiochemical purity of 18F-C2A-GST was more than 95% and stable for 4 h after 
formulation. Biodistribution in mice was favorable with major excretion from the kidneys 
and rapid clearance from blood and nonspecific organs. 
2.3 Radiolabeled caspase targeted tracer 
Caspase activation is the central role in the execution of cell death, therefore, caspases are 
the attractive targets for apoptosis imaging. Non-peptide based isatin sulfonamide analogs 
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the analogs, WC-II-89 was labeled with 18F (Zhou et al., 2006). 18F- WC-II-89 showed a high 
uptake in the liver of chemically induced apoptosis. Although molecules that target caspase-
3 is attractive, there are limited animal data and it is not yet known how sensitive this kind 
of  agents will be for actual imaging in humans. 
2.4 Uncategorized tracer 
Recently a novel family of low molecular mass amphipatic apoptosis markers (ApoSense) 
was developed targeting the cell membrane of apoptotic cells. 18F-labeled 5-fluoropentyl-2-
methyl-malonic acid (18F-ML-10) belongs to this family of low-molecular-weight compounds 
used for the imaging of cell death in vivo. This compound responds to alterations in plasma 
membrane potential and phospholipid scrambling, which are hallmarks of apoptotic cells. 
To which cell membrane targets this probe binds is unknown. After systemic 
administration, the compound can detect apoptotic cells from the early stages of the death 
process, cross the intact plasma membrane, and accumulate in the cytoplasm. In animal 
model of cerebral infarction, selective uptake was observed in the region of ischemia at 24 hr 
after the middle cerebral artery occlusion (Reshef et al., 2008). 
3. Apoptosis imaging in acute myocardial ischemia 
It has been believed that myocardium directly start to die via necrosis shortly after the onset 
of myocardial infarction that march of necrosis spread as a wavefront from endocardium to 
epicardium. However, recent animal experiments with permanent coronary artery occlusion 
revealed that cell death process starts as apoptosis and severe ATP depletion due to 
ischemia may preclude the execution of apoptosis and lead to plasma membrane 
permeability barrier breakdown and secondary necrosis. Therefore, apoptosis imaging 
might play important role in the assessment of myocardial cell death process in acute 
myoacrdial infarction, especially in its early stage. 
3.1 Animal experiment in permanent occlusion of coronary artery 
In a rat model of permanent coronary artery ligation, Kajstura et al. investigated the 
contribution of the apoptosis and necrosis to cardiomyocyte death using TUNEL method 
and DNA laddering for apoptosis and antimyosin monoclonal antibody labeling (Kajstura, 
et a., 1996). After 2 h of the left main coronary artery ligation, TUNEL positive myocytes 
appeared in the central portion of the left ventricular free wall and peaked at 4.5 h. Myosin 
labeled cells also appeared at 2 h after ligation and significantly increased after 6 h to 2 days. 
However, at 2 h after coronary ligation, number of apoptotic cells was 2.8 x 106 and number 
of necrotic cells was 9 x 104. Therefore, early after myocardial infarction, apoptosis is the 
predominant form of cell death, and 1 to 2 days after infarction, necrosis is the dominant 
form of cell death followed by low levels of both apoptosis and necrosis at 7 days after 
infarction. If cells undergoing apoptosis are not cleared before they deplete their 
intracellular ATP stores that are necessary to maintain plasma membrane integrity, plasma 
membrane permeability barrier breakdown occurs and cells are converted from apoptosis to 
necrosis as known as secondary necrosis, results in inflammation. 
3.2 Animal experiment in acute ischemia and reperfusion 
In a mouse model of 15 and 30 min of ischemia and 90 min of reperfusion, percentage of 
cardiomyocytes staining positivity for biotinylated annexin V was far greater than the 
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percentage staining positivity for IgG, which indicates plasma cell membrane leakage 
(Dumont et al., 2000). Accordingly, at least 90 min of reperfusion, most of the annexin V 
uptake might represent PS externalization.  
We investigated the temporal and spatial change of 99mTc-annexin V accumulation in a rat 
model of 20 min coronary artery occlusion and reperfusion. 99mTc-annexin V uptake was 
imaged at 30 min, 90 min, 6 h, 24 h, 3 day, 2 weeks after reperfusion. The strongest 99mTc-
annexin V uptake was observed in the mid myocardium of the area at risk at 30 m and 90 m 
of reperfusion and the uptake expanded to subendocardial and subepicardial layer at 6 h 
after reperfusion, followed by gradual reduction of the uptake over 3 days (Fig. 2) (Taki, et 
al., 2004). On the other hand, TUNEL positivity peaked at 6 h to 1 day after reperfusion. 
These findings are in keeping with the known temporal sequence of apoptosis, in which one 
of the earliest events is externalization of phosphatidylserine, followed by DNA 
fragmentation. Using fluorescent labeled annexin V, real time monitoring of annexin V 
binding to cardiomyocytes after 30 m ischemia and reperfusion demonstrated that 
cardiomyocytes started to bind annexin V within minute and the amount of binding reached 
a maximum within 20-25 m (Dumont, et al., 2001). These finding indicate that apoptosis 
commences just after ischemia and reperfusion and PS externalization reaches plateau 
around 30 m after reperfusion. 
 
 
Fig. 2. Autoradiography of 99mTc-annexin V and 201Tl at various reperfusion time after 20 
min of coronary artery occlusion. 
At a examination time after 20 min ischemia and reperfusion, 99mTc-annexin V (80-150 MBq) 
was injected and 1 h later 201Tl (0.74 MBq) was injected just after the coronary artery 
reocclusion to verify the area at risk. Upper low demonstrated 99mTc-annexin V images and 
lower low shows 201Tl image that represents area at risk. 
The amount of annexin V binding to apoptotic cardiomyocytes after reperfusion depends on 
the severity of ischemia and reperfusion time (Taki, et al., 2007a). In a rat model of 5 min, 10 
min, 15 min ischemia and reperfusion model, degree of 99mTc-annexin V accumulation 
depend on the length of the coronary artery occlusion time and time period after 
reperfusion: significant uptake of 99mTc-annexin V accumulation was observed in 15 min 
and 10 min ischemia (uptake ratio was 4.46±3.16 and 2.02±0.47, respectively), whereas, no 
significant uptake was observed in 5 min ischemia at 30 min after reperfusion. 99mTc-annexin 
V uptake in 15 min and 10 min ischemia reduced at 90 min (uptake ratio was 3.49±1.78 and 
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1.47±0.11, respectively) and only mild uptake was observed at 6 h and 24 h after reperfusion. 
Interestingly, no morphological sign of necrosis and apoptosis was observed until 24 h after 
reperfusion in 10 min ischemia and only micro foci of cell degeneration and cell infiltration 
were observed until 24 h after reperfusion in 15 min ischemia, with mild TUNEL positivity 
which peaked at 6 hr (1.03±0.40% in 10 min ischemia and 2.84±0.94% in 15 min ischemia). 
These data indicate that 99mTc-annexin V uptake can be observed after mild ischemic insults 
those do not result in myocardial infarction. 
Several cardioprotective interventions such as ischemic preconditioning, postconditioning, 
and caspase inhibitor preparation attenuate 99mTc-annexin V uptake (Taki, et al., 2007). 
Ischemic preconditioning suppressed 99mTc-annexin V binding by 90 % of control and 
postoconditioning and caspase inhibitor attenuate the binding by around 70 %. 
Reversibility of PS externalization in brief ischemia was demonstrated (Kenis, et al., 2010). In 
murine myocardium with 5 min ischemia and 90 min and 6 h of reperfusion, fluorescent 
labeled annexin V injected before 10 min of sacrifice binds cell surface, but not at 24 h after 
reperfusion. On the other hand fluorescent-annexin V injected at the onset of reperfusion 
exclusively localized intracellularly at 90 min, 6 h, and 24h after reperfusion. No TUNEL 
positivity was observed in this 5 min ischemia and reperfusion model. These data indicate 
that in brief ischemia, PS externalizes transiently, which is amenable to targeting by annexin 
V for at least 6 h after reperfusion, and internalize after annexin V binding (reversibility of 
the apoptotic process). 
3.3 Clinical findings and potential future application 
In human pathological study by TUNEL staining and DNA electrophoresis, widespread 
apoptosis in infarcts was observed only a few hours in age before the appearance of 
coagulative necrosis (Veinot, et al. 1997). In addition, TUNEL positibity was observed 
primarily in myocytes containing contraction bands, which occur predominantly in regions 
of reperfused myocardium. These findings are consistent with animal experiment, and in 
infarcted human myocardium, apoptosis is the early and predominant form of cell death 
and its appearance is accelerated in reperfused myocardium. 
First clinical imaging with 99mTc-annexin V in 7 patients with acute myocardial infarction 
demonstrated significant uptake of 99mTc-annexin V (injected 2 h after reperfusion) in the 
area corresponding to the perfusion defect in 6 patients (Hofstra, et al., 2000). Subsequent 
study in 9 patients with acute myocardial infarction, 99mTc-annexin V uptake (injected within 
1.5 - 7 h after reperfusion) was again clearly visualized on SPECT performed at 15 h later in 
infracted areas with a matching perfusion defect confirmed by 99mTc-sestamibi SPECT 
before reperfusion. Repeat 99mTc-sestamibi SPECT at 1 – 3 week after the onset of infarction 
demonstrated that the perfusion defects were significantly smaller than the defects in acute 
phase, suggesting that the significant amount of myocardium in perfusion defect with 99mTc-
annexin V uptake in acute phase might be in reversible damage rather than irreversible 
necrosis. Imaging of the extent of apoptosis resulting from acute coronary syndromes could 
be a valuable tool to help guide revascularization strategies and therapy with anti-apoptotic 
drugs if available in near future. Other potential application of 99mTc-annexin V imaging 
would be in the detection of myocardial ischemic insults in patients with acute coronary 
syndrome without ST elevation and troponin leakage, in assessment of the effect of 
revascularization in acute coronary syndrome, in evaluation of the effect of postconditioning 
at reperfusion therapy, in detection of transient PS exetrnalization due to brief spontaneous 
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percentage staining positivity for IgG, which indicates plasma cell membrane leakage 
(Dumont et al., 2000). Accordingly, at least 90 min of reperfusion, most of the annexin V 
uptake might represent PS externalization.  
We investigated the temporal and spatial change of 99mTc-annexin V accumulation in a rat 
model of 20 min coronary artery occlusion and reperfusion. 99mTc-annexin V uptake was 
imaged at 30 min, 90 min, 6 h, 24 h, 3 day, 2 weeks after reperfusion. The strongest 99mTc-
annexin V uptake was observed in the mid myocardium of the area at risk at 30 m and 90 m 
of reperfusion and the uptake expanded to subendocardial and subepicardial layer at 6 h 
after reperfusion, followed by gradual reduction of the uptake over 3 days (Fig. 2) (Taki, et 
al., 2004). On the other hand, TUNEL positivity peaked at 6 h to 1 day after reperfusion. 
These findings are in keeping with the known temporal sequence of apoptosis, in which one 
of the earliest events is externalization of phosphatidylserine, followed by DNA 
fragmentation. Using fluorescent labeled annexin V, real time monitoring of annexin V 
binding to cardiomyocytes after 30 m ischemia and reperfusion demonstrated that 
cardiomyocytes started to bind annexin V within minute and the amount of binding reached 
a maximum within 20-25 m (Dumont, et al., 2001). These finding indicate that apoptosis 
commences just after ischemia and reperfusion and PS externalization reaches plateau 
around 30 m after reperfusion. 
 
 
Fig. 2. Autoradiography of 99mTc-annexin V and 201Tl at various reperfusion time after 20 
min of coronary artery occlusion. 
At a examination time after 20 min ischemia and reperfusion, 99mTc-annexin V (80-150 MBq) 
was injected and 1 h later 201Tl (0.74 MBq) was injected just after the coronary artery 
reocclusion to verify the area at risk. Upper low demonstrated 99mTc-annexin V images and 
lower low shows 201Tl image that represents area at risk. 
The amount of annexin V binding to apoptotic cardiomyocytes after reperfusion depends on 
the severity of ischemia and reperfusion time (Taki, et al., 2007a). In a rat model of 5 min, 10 
min, 15 min ischemia and reperfusion model, degree of 99mTc-annexin V accumulation 
depend on the length of the coronary artery occlusion time and time period after 
reperfusion: significant uptake of 99mTc-annexin V accumulation was observed in 15 min 
and 10 min ischemia (uptake ratio was 4.46±3.16 and 2.02±0.47, respectively), whereas, no 
significant uptake was observed in 5 min ischemia at 30 min after reperfusion. 99mTc-annexin 
V uptake in 15 min and 10 min ischemia reduced at 90 min (uptake ratio was 3.49±1.78 and 
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1.47±0.11, respectively) and only mild uptake was observed at 6 h and 24 h after reperfusion. 
Interestingly, no morphological sign of necrosis and apoptosis was observed until 24 h after 
reperfusion in 10 min ischemia and only micro foci of cell degeneration and cell infiltration 
were observed until 24 h after reperfusion in 15 min ischemia, with mild TUNEL positivity 
which peaked at 6 hr (1.03±0.40% in 10 min ischemia and 2.84±0.94% in 15 min ischemia). 
These data indicate that 99mTc-annexin V uptake can be observed after mild ischemic insults 
those do not result in myocardial infarction. 
Several cardioprotective interventions such as ischemic preconditioning, postconditioning, 
and caspase inhibitor preparation attenuate 99mTc-annexin V uptake (Taki, et al., 2007). 
Ischemic preconditioning suppressed 99mTc-annexin V binding by 90 % of control and 
postoconditioning and caspase inhibitor attenuate the binding by around 70 %. 
Reversibility of PS externalization in brief ischemia was demonstrated (Kenis, et al., 2010). In 
murine myocardium with 5 min ischemia and 90 min and 6 h of reperfusion, fluorescent 
labeled annexin V injected before 10 min of sacrifice binds cell surface, but not at 24 h after 
reperfusion. On the other hand fluorescent-annexin V injected at the onset of reperfusion 
exclusively localized intracellularly at 90 min, 6 h, and 24h after reperfusion. No TUNEL 
positivity was observed in this 5 min ischemia and reperfusion model. These data indicate 
that in brief ischemia, PS externalizes transiently, which is amenable to targeting by annexin 
V for at least 6 h after reperfusion, and internalize after annexin V binding (reversibility of 
the apoptotic process). 
3.3 Clinical findings and potential future application 
In human pathological study by TUNEL staining and DNA electrophoresis, widespread 
apoptosis in infarcts was observed only a few hours in age before the appearance of 
coagulative necrosis (Veinot, et al. 1997). In addition, TUNEL positibity was observed 
primarily in myocytes containing contraction bands, which occur predominantly in regions 
of reperfused myocardium. These findings are consistent with animal experiment, and in 
infarcted human myocardium, apoptosis is the early and predominant form of cell death 
and its appearance is accelerated in reperfused myocardium. 
First clinical imaging with 99mTc-annexin V in 7 patients with acute myocardial infarction 
demonstrated significant uptake of 99mTc-annexin V (injected 2 h after reperfusion) in the 
area corresponding to the perfusion defect in 6 patients (Hofstra, et al., 2000). Subsequent 
study in 9 patients with acute myocardial infarction, 99mTc-annexin V uptake (injected within 
1.5 - 7 h after reperfusion) was again clearly visualized on SPECT performed at 15 h later in 
infracted areas with a matching perfusion defect confirmed by 99mTc-sestamibi SPECT 
before reperfusion. Repeat 99mTc-sestamibi SPECT at 1 – 3 week after the onset of infarction 
demonstrated that the perfusion defects were significantly smaller than the defects in acute 
phase, suggesting that the significant amount of myocardium in perfusion defect with 99mTc-
annexin V uptake in acute phase might be in reversible damage rather than irreversible 
necrosis. Imaging of the extent of apoptosis resulting from acute coronary syndromes could 
be a valuable tool to help guide revascularization strategies and therapy with anti-apoptotic 
drugs if available in near future. Other potential application of 99mTc-annexin V imaging 
would be in the detection of myocardial ischemic insults in patients with acute coronary 
syndrome without ST elevation and troponin leakage, in assessment of the effect of 
revascularization in acute coronary syndrome, in evaluation of the effect of postconditioning 
at reperfusion therapy, in detection of transient PS exetrnalization due to brief spontaneous 
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or stress induced ischemia. However, several questions yet to be answered concerning the 
clinical application of 99mTc-annexin V imaging. In vivo imaging 1 hr after tracer injection is 
feasible in rats because blood clearance of 99mTc-annexin V was rather fast, although, the 
earliest optimal time for imaging after tracer injection should be investigate in human. In 
heart transplantation patients, it was revealed that 99mTc-annexin V SPECT imgaing was 
possible 1 h after tracer injection (Narula, et al., 2001). Speedy imaging after tracer injection 
is crucial especially in emergency situation. Are therapeutic interventions beneficial for all 
annexin-positive myocardium, or in only specific pathological status, or in only limited time 
window? How much of the shift from necrosis to apoptosis by therapeutic intervention is 
cardioprotective (Narula, et al., 2003)? Necrosis is more harmful than apoptosis, because 
cells are removed without inflammation in apoptosis but cells are removed with 
inflammation and fibrosis follows in necrosis. Is annexin V positive scan in stress induced 
ischemia related to subsequent prognosis, or indication of PCI? These potential imaging 
concepts of the assessment of myocardial injury, stress, cell death in acute ischemia should 
be validated in clinical studies. 
It has been increasingly clear that apoptosis is a major contributor to early cardiomyocyte 
cell death after acute myocardial infarction, and is involved in post myocardial infarction 
ventricular dysfunction and adverse remodeling that develop heart failure. These findings 
emphasize the need for the reliable in-vivo imaging of apoptosis that assess the ongoing 
pathology so that rational preventive therapies can be applied and to assess the consequence 
of therapies. 99mTc-annexin V imaging might be applied to assess myocardium at risk or cell 
death in acute coronary syndrome and prediction of the ventricular remodeling after 
myocardial infarction and heart failure by allowing visualization of ongoing PS 
externalization that might precede or underlie change in pathophysiology, morphology, and 
LV dysfunction. 
4. Apoptosis imaging in heart failure and cardiomyopathy 
In spite of dramatic improvement of therapies in acute coronary syndrome, post acute 
myocardial infarction mortality has reached a plateau and post infarction heart failure due 
to ventricular remodeling is on the increase. About 15 to 25 % of acute myocardial infarction 
patients develop heart failure that remains a progressive despite of continuous 
pharmacological therapy. It has been reported that myocardial apoptosis shortly after acute 
myocardial infarction might be a strong predictor of unfavorable LV remodeling and early 
post infarction symptomatic heart failure in 16 patients dying ≥10 days after myocardial 
infarction (Abbate, et al., 2003). 
In rats with anterior myocardial infarction, 28-day infusion of caspase inhibitor after 
infarction ameliorated apoptosis, preserved myocardial contractile proteins, decreased 
myocardial interstitial collagen deposite, reduced systolic dysfunction, and attenuated LV 
remodeling (Chandrashekhar, et al., 2004). If so, apoptosis imaging could be a promising 
noninvasive method to identify patients at risk of heart failure development due to LV 
remodeling and to monitor the treatment effect if some specific anti-apoptotic agents will 
reach the stage of clinical study.  
In patients with advanced heart failure, low but abnormal rate of cardiac myocyte apoptosis 
persist for months (0.08% to 0.25% in heart failure vs 0.001% to 0.002% in normal subjects), 
thereby ultimately might result in a large loss of functional cardimyocytes (Olivetti, et al.,  
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1997; Saraste, et al., 1999; Guerra, et al., 1999). In study with transgenic mice that express a 
conditionally active caspase exclusively in the myocardium, low rate of cardiomyocyte 
apoptosis as 0.023% is sufficient to cause a lethal dilated cardiomyopathy. Conversely, 
inhibition of cardiac myocyte apoptosis by caspase inhibitor in this murine model largely 
prevents the development of cardiac dilation and contractile dysfunction, indicating that 
myocyte apoptosis may be a causal mechanism of heart failure, and inhibition of this cell 
death process may constitute the basis for novel therapies (Wencker, et al., 2003). The low 
level of cell death due to apoptosis in heart failure makes detection of apoptosis with the 
current techniques very challenging.  
In recent study in 9 consecutive patients with advanced nonischemic cardiomyopathy (8 
dilated and 1 hypertrophic cardiomyopathy) and 2 relatives, 5 patients showed focal or 
global 99mTc-annexin V uptake in the left ventricular myocardium. Interestingly, these 5 
patients with  99mTc-annexin V uptake had experienced a significant worsening or a recent 
onset of heart failure, on the contrary, 4 patients without 99mTc-annexin V uptake had no 
recent evidence of worsening of heart failure. In addition, during a follow up of 1 year, 4 
patients with 99mTc-annexin V uptake showed a decline of LVEF, on the other hand, in 
patients without 99mTc-annexin V uptake, clinical status and LVEF remained stable 
(Kietselaer, et al., 2007). These data indicate that the 99mTc-annexin V imaging in advanced 
non-ischemic cardiomyopathy, may identify the patients with high risk who might benefite 
from cell death blocking therapies. 
5. Apoptosis imaging in myocarditis 
In a rat model of autoimmune myocarditis, 99mTc-annexin V (HYNIC annexin V) and 14C-
deoxyglucose (DG) uptakes were examined (Tokita, et al.,2003). Myocarditis was triggered 
by an immunization of rats by infusing porcine cardiac myosine and the rats formed 
antibodies against the myosin and developed myocarditis. In acute phase of myocarditis, 
both 99mTc-annexin V (2.8 time more than normal rats) and 14C-DG (2.7 time more than 
normal rats) uptake increased significantly, however, only 99mTc-annexin V distribution 
correlated with the TUNEL positive area, and the distribution of 14C-DG correlated with 
inflammatory cell infiltration. In subacute phase, 99mTc-annexin V uptake returned normal 
level, on the other hand, 14C-DG uptake decreased but still higher uptake reflecting 
prolonged mild inflammatory cell infiltration. In this model of immune myocarditis, there 
was a marked difference in distribution of apoptotic cell death and inflammation. The data 
indicates that 99mTc-annexin V uptake is specific in myocardial apoptotic process induced by 
inflammation and is independent of inflammatory cell infiltration. 
Another animal experiment in a rat model that develops spontaneous myocarditis 
mimicking catecholamine induced subacute myocarditis demonstrated significantly 
increased 99mTc-annexin V uptake in planar scinitgraphy. Autoradiogrpahy confirmed 
increased 99mTc-annexin V uptake. Histopatology demonstrated patchy areas of interstitial 
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myocyte necrosis with nuclear extrusion, scattered throughout the myocardium and 
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In myocarditis, apoptosis imaging might play an important role, in confirming the diagnosis 
in terms of the extent of the involvement and disease activity, selecting patients with 
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6. Apoptosis imaging in cardiotoxicity induced by chemotherapy  
The development of chemotherapy has played a significant role in the management of 
cancer patients. Of the classic cytotoxic agents, antracyclines are the still one of the most 
important agents for cancer therapy and are well known for their dose dependent acute and 
chronic cardiotoxicity, resulting in irreversible and progressive cardiac dysfunction and 
heart failure. Although new anticancer molecular targeting agents improved the prognosis 
of cancer patients, some agents may have serious cardiovascular side effect. Standard 
clinical approaches utilize the serial monitoring of the left ventricular ejection fraction to 
identify chemotherapy induced cardiotoxicity. For this purpose, radionuclide ECG gated 
blood-pool scintigraphy has been used as a gold standard technique. However, ejection 
fraction impairment is relatively late manifestation of myocardial damage. Therefore, the 
development of more sensitive methods is required to identify the cardiotoxicity before the 
onset of ventricular dysfunction.  
In a rat model of doxorubicin cardiotoxicity (cumulative dose: 7.5mg/Kg, 10mg/Kg, 
12.5mg/Kg), planar scintigraphy detected the increase of 99mTc-annexin V uptake dose 
dependently and correlated with expression of left ventricular atrial natriuretic factor 
messenger RNA (Bennink, et al., 2004). Another study with doxorubicin treated rats 
(cumulative dose: 7.5mg/Kg and 15mg/Kg) demonstrated that dose dependent increase in 
99mTc-annexin V uptake by SPECT/CT and TUNEL positivity. In contrast in this syudy, 
echocardiography detected ventricular dysfunction only at the highest doxorubicin dose 
( Gabrielson, et al., 2008). These data suggest that apoptosis imaging could serve as a more 
sensitive early marker of doxorubicin cardiotoxixity than left ventricular dysfunction, might 
providing the opportunity to modify or stop the chemotherapy before clinically overt heart 
failure. 
7. Apoptosis imaging heart transplantation 
Acute rejection remains a limiting factor of cardiac transplantation. The histopathologic 
manifestation of transplant rejection comprises perivascular and interstitial mononuclear 
inflammatory cell infiltration associated with myocyte apoptosis and necrosis. To monitor 
the acute rejection, endomyocardial biopsies are required frequently. Current guidelines 
recommend 15-20 endomyocardial biopsies in the first year after transplantation to monitor 
potential allograft rejection. However, invasive endomyocardial biopsy may be associated 
with a small risk of complications. If non-invasive imaging for the detection of transplant 
rejection is feasible, endomyocardial biopsies might be reduced.  
Study with rat model of allograft rejection demonstrated that significant 99mTc-annexin V 
uptake correlated well with the histologic grade of rejection and scattered positive TUNEL 
stainings were observed in graft-infiltrating inflammatory cells, endothelial cells, and 
myocytes. In addition, after the treatment of rejection with cyclosporine, no TUNEL 
positivity was observed and 99mTc-annexin V uptake decreased to baseline (Vriens, et al., 
1998). In 18 patients with cardiac allograft recipients, 5 had positive myocardial uptake of 
99mTc-annexin V at 1 h after the tracer injection and all these 5 patients showed at least 
moderate transplant rejection and caspase-3 staining in their biopsy specimens. On the other 
hand, 11 of 13 patients with no cardiac uptake of 99mTc-annexin V demonstrated no finding 
of rejection and other 2 patients showed only focal lymphomononuclear cell infiltration 
(Narula, et al., 2001).  In another clinical study with 10 patients with cardiac transplant, 2 
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patients with moderate acute rejection by endomyocardial biopsy showed significant 99mTc-
annexin V uptake, however, specificity was suboptimal with 4 of 8 patients without rejection 
demonstrating significant 99mTc-annexin V uptake.  
All these animal and clinical studies revealed that the apoptosis imaging has potential to 
noninvasively identify patients with transplant rejection and monitor the response to 
immune modulation therapy. 
8. Conclusions 
For the imaging apoptosis, for the time being, it appears that agents that bind to markers 
expressing cell surface of apoptotic cells, such as annexin V and its derivatives, have 
advantage in terms of the sensitivity and specificity over other tracers. Based on the research 
achievement to date including experiences with 99mTc-annexin V imaging in patients, 99mTc-
annexin V and its related tracers are considered as one of the most suitable tracers for 
clinical application at this stage, and also the positron labeled tracers such as 18F-annexin V 
are desired to apply clinical imaging. In cardiac diseases that involve cardiomyocytes, 
myocytes loss implies loss of cardiac function because cardiomyctes cannot be regenerated 
through cell division. In acute coronary syndrome, measurement of cardiac biomarkers are 
standard diagnostic tool, but they reflect the results of cardiomyocytes death. Whereas, 
apoptosis imaging such as 99mTc-annexin V can identify the cells starting or undergoing 
apoptosis, however, part of PS exposure of these cells might be reversible and some cells are 
capable of surviving. Therefore, apoptosis imaging might be beneficial for future strategy of 
the patient’s management. Other than acute coronary syndrome, including heart failure, 
myocarditis, cardiomyopathies, and transplanted rejection, apoptotic cell death has turned 
out one of the crucial players in underlying pathophysiologies. Hence, apoptosis imaging in 
patients with various cardiac diseases will enhance the understanding of the ongoing 
pathophysiology, identification of high risk patients, and lead to effective therapies to 
salvage the myocardium in risk and be helpful in monitoring the effect of therapy. 
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Nowadays, there are interests as well as active investigations devoted to the study and
application of radiolabeled molecules able to selectively target and irradiate tumoral cells
during nuclear medicine procedures. With this kind of pharmaceuticals, spatial activity
distribution with extremely non-uniform characteristics may be assessed in patients. Actually,
this feature constitutes precisely the main advantage in view of maximizing the discrimination
between affected and healthy tissue. The mentioned situation constitutes the main motivation
for the present work. In this sense, the chapter is focused on nuclear medicine dosimetry
pointing out the main features about how to implement Monte Carlo (MC) approaches to this
aim.
Nowadays, from a general point of view, therapies with radiopharmaceuticals using
beta-emitter radionuclides are growing significantly and very fast. Beta-emitters can be
emitters of β− or β+ radiation. Commonly, β+ emitters, like 18F are used for imaging
techniques, whereas β− are mainly used with therapeutic purposes, to deliver high dose rate
on tumors. Therefore, β− emitters are usually those of more interest for dosimetry.
During nuclear medicine procedures, radiopharmaceutical activity distribution may be
determined by means of different modalities. Nowadays it is mainly assessed using imaging
techniques but otherwise it is also possible to infer it [Stabin (2008)]. This information is then
incorporated in the treatment planning system in order to obtain an estimation of the dose
distribution. More specifically, patient-specific dose distribution owing to alpha, beta and/or
gamma emitters can be calculated starting from activity distribution by means of either direct
MC simulation or analytical methods.
On the other hand, patient-specific dosimetry requires anatomical information, which shall
be further considered as input for establishing mass distribution during MC computations.
Patient anatomical information can be suitably extracted from typical non-invasive imaging
techniques, like computed tomography (CT) or magnetic resonance imaging (MRI).
Many studies have been performed by means of MC applications in Nuclear Medicine up
today, both in the imaging field, and regarding dosimetry calculations [F. Botta & Valente
(2011), Zubal & Harrel (1992), H. Yoriyaz & dos Santos (2001), M. Ljungberg & Strand (2002)].
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On the other hand, patient-specific dosimetry requires anatomical information, which shall
be further considered as input for establishing mass distribution during MC computations.
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2 Will-be-set-by-IN-TECH
Numerous Monte Carlo codes have been benchmarked and used for different purposes in
radiation transport including nuclear medicine imaging and dosimetry. Some examples
are MCPT code of Williamson (1988), EGS4 code (Luxton and Jozsef, 1999), GEANT4 code
(Agostinelli, 2003) and MCNP4 code (DeMarco et al 2002b, Bohm et al 2003). The more
recently developed PENELOPE (PENetration and Energy Loss Of Positrons and Electrons;
photon simulation was introduced later) Monte Carlo code 2001 (Salvat et al 2001) uses
cross-sections from the up-to-date EPDL97 dataset, and thus takes advantage of the latest
improvements in cross-section libraries [R.D. Stewart & Strom (2001), A. Sánchez-Crespo &
Larsson (2004)].
Although several MC codes are available allowing to transport photons and electrons in
user-defined geometries, it should be mentioned that there two codes particularly useful for
voxel dosimetry applications, named EGS4 and MCNP [E.B. Bolch & Watson (1999)].
As a particular and non common approach this chapter will discuss how to implement MC
simulation in nuclear medicine by means of the PENELOPE code.
The proposed method along with the developed computation system allow to introduce
as input data different types of images -both metabolic and anatomical- commonly used
for nuclear medicine diagnostic, like CT, MRI, SPECT, gamma camera and PET. This
capability arises from the incorporation of dedicated routines for reading and interpreting
the “Digital Imaging and Communication in Medicine” (DICOM) information code, therefore
significantly simplifying input data handling processes aimed to specific-patient absorbed
dose distribution calculation. In this sense, suitable combination of metabolic and anatomical
imaging techniques provides relevant information helpful when attempting reliable and
accurate specific-patient dosimetry. When considering all together the mentioned potential
advantages of the proposed method along with the implementation of dedicated voxelization
techniques, it would be expected that it may constitute an important tool for daily treatment
planning by means of MC simulations for specific-patient dosimetry assessment.
The estimation of dose from a distributed source is an important aspect of the application
of labeled monoclonal antibodies to targeted radiotherapy. A major contribution to the dose
arises from beta particles. The source may be described mathematically by a function giving
the activity concentration at each position in the source. The dose produced at a specific
site may then be calculated as the linear superposition of contributions from each volume
element in the distribution treated as a point source. The dose produced by a point source
of isotropic unit activity is known as dose point kernel [Prestwich WV (1985)] (DPK). Due
to its significant importance and largely proved benefits and convenience for dosimetric
purposes, carefully characterization of DPK has always received significant interests and
efforts, therefore extended discussion will be presented about DPK calculation by means of
MC techniques.
In summary, it would be desirable to assess a suitable and reliable method helpful for
patient-specific treatment planning calculating full stochastic radiation transport by means
of MC methods. Therefore, once the calculation system is already developed, it should be
carried out careful and rigorous verifications of certain parameters which can point out the
reliability of the proposed method.
In this sense, considering that the main goal of this work consists on performing dosimetry
for beta-minus radiation therapy and according to the significant importance of beta DPK in
nuclear medicine dosimetry, this quantity may be taken as a suitable parameter to check the
feasibility of the proposed MC code. With the aim of simplifying, it is established from here
that DPK will be referred as beta-DPK unless it will be explicitly specified.
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2. Monte Carlo methods and nuclear medicine
2.1 Monte Carlo radiation transport simulation
Radiation transport, including absorption and scattering processes are determined by the
Boltzmann transport equation. However, it is hard to apply and to analytically solve
Boltzmann equation within non-homogeneous media or regions consisting of complex
boundaries. Actually, it is well known that Boltzmann equation can be analytically solved
only in few cases consisting on oversimplified situations, that would strongly differ from real
clinical situations. Therefore, numerical methods have been proposed for solving Boltzmann
equation in complex situations performing full radiation transport by means of stochastic
methods. The MC techniques belong to the most important group within this category.
Physically, the evolution of an electron-photon shower has an intrinsic random nature, so MC
methods provide a convenient alternative to deal with transport problems [Salvat (2009)].
On the MC method for radiation transport, the “life” of each particle is seen as a random
sequence of free paths that end with an interaction event where the particle suffers any kind
of interaction. Generally, the “interaction event” refers to any change in the particle quantum
state and it can arise from the change of its movement direction, the loss of energy or the
production of a secondary particles. The interaction type depends on the kind of actual
particle along with the medium where it is moving by random processes because of its nature.
In order to point out main characteristics about how to handle with MC codes with the aim
of performing nuclear medicine dosimetry, it has been selected to work with the PENELOPE
main code. The fundamental motivations for using PENELOPE relays on its suitability of
electron and photon transport along with the relevant characteristic of providing open source
routines (written on fortran 77 language). The general considerations described below could
be similarly implement on any general purposes MC main code.
2.2 The PENELOPE Monte Carlo code
The PENELOPE v.2008 is a MC algorithm and computer code for the simulation of
coupled electron-photon transport. The simulation algorithm is based on scattering models
that combines numerical databases with analytical cross section models for the different
interaction mechanisms and it is applicable to energies (kinetic energies in the case of electrons
and positrons) from a few hundred eV to approximated 1GeV. Photon transport is simulated
by means of the conventional detailed method. The simulation of charged particles (electron
and positron) transport is performed by means of a mixed procedure. Hard interactions, with
scattering angle θ or energy loss W greater than preselected cutoff values θc and Wc , are
simulated in detail. Soft interactions correspond to scattering angle and energy loss less than
the corresponded cutoffs θc, Wc and these interactions are considered by means of suitable
mechanisms for simulation condensation, mainly based on multiple scattering theories, like
Mollier theory. The user can select the cutoff parameters quite large looking for speeding up
the calculation considerably, but it should be preliminary carefully studied the ranges for each
parameter that may produce non-negligible alterations in the final scores. A characteristic
feature of the here presented simulation code is that the most delicate parts of the simulation
are handled internally; electrons, positrons and photons are simulated by calling the same
subroutines. Thus PENELOPE makes the practical simulation of electrons and positrons as
simple as that of photons (although simulating a charged particle may take a longer time).
One of the main advantages of the latest version of PENELOPE (PENELOPE v. 2008 package)
regards the improvements for inner shells ionizations by electron and positron impact,
which are described by using a numerical database of total cross-sections for K, L and M
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shells derived from the theory described by Bote and Salvat (2008). It was also included
photon polarization effects in Rayleigh and Compton scattering, as well as refinements
in the modeling of Rayleigh photon scattering and of inelastic collisions of electrons and
positrons. These improvement would provide significantly better description of charged
particle transport and energy deposition.
In this study, PENELOPE v. 2008 MC code has been considered for use in nuclear medicine
dosimetry assessment as well as treatment planning approach when possible. During the
last years, PENELOPE has been widely employed for different studies by physicists on the
radiation transport field [J. Asenjo & Sánchez-Reyes (2002), S.J. Ye & Naqvi (2004), J. Sempau
& Salvat (2004), Bielajew & Salvat (2001), J. Sempau & Fernández-Varea (2001)], therefore
supporting the selected choice.
2.3 Dose Point Kernel
The Dose Point Kernel can be defined considering an extremely simplified model of a
monoenergetic isotropic point source emitting electrons which move outwards within an
homogeneous medium and slow down continuously according to a stopping power function
S(E) [W.V. Prestwich & Kwok (1989)]. If the source energy is E0, therefore the distance r from
























It can be shown that Φ(r, E0) satisfies the constraint
∫ ∞
0
4πρr2Φ(r, E0)dr = 1 (5)
It is convenient to introduce a dimensionless quantity to represent distance as the fraction of





The scaled electron DPK is defined through the relation
F(x, E0) = 4πρr2RCSDAΦ(r, E0) (7)
It will be useful to introduce a new quantity satisfying
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where the track average stopping power (< S >= E0/RCSDA)has been introduced. In this
sense, it could be possible to interpret the scaled DPK as the ratio of the stopping power at a
particular point along the electron track to the average stopping power over the entire track.
It is also customary to use radial distributions of dose around isotropic point sources of
electrons or beta-emitters in an infinite water medium, so called dose DPKs, as the basis of
many calculations of dose from various distributions of beta sources.
In fact, DPKs have proved to be adequate and remarkable useful for several dosimetric
purposes in nuclear medicine. Actually, DPKs are commonly used for daily applications
and calculations when some approximations may be acceptable, like non high tissue
inhomogeneity around the emission point.
Contrary to monoenergetic sources, for the case of beta-emitting radionuclides it will be
necessary to calculate the DPK as resulting from a spectrum of electrons. The spectrum






which represents a decomposition into N groups, each of which has a branching probability





given that the spectral distribution ni(E) is normalized to unit area.




















A scaled DPK for a beta group may also be introduced. To this end a scaled distance is defined
as the fraction of the CSDA range for an electron with energy Ei . Designating the latter ri ,
then the scaled DPK for ith beta group becomes
Fi(x) = 4πρr2riΦi(r) (14)
where x = r/ri . Scaling the distance in this manner differs from the suggested by Berger, who
uses the 90% point. It has the advantage, however, of using a quantity that is more readily
available, the CSDA range.
As indicated before, calculation of the DPK requires the evaluation of the CSDA range. In
order to accomplish this task approximations have been employed. As first approach, it may
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be useful to look for databases containing relevant and required information, like Stopping
Power and Range Tables for Electrons which may be available from the National Institute of
Standards and Technology1. A good recommemdation is that database values should be
compared with the corresponding data used by the MC code (it can be assessed using the
Table subroutine in the case of the PENELOPE v. 2008 code). In he case of PENELOPE v. 2008,
it can be seen that NIST tabulated data and PENELOPE database values present negligible
differences. Therefore, CSDA ranges required for shell thickness calculations can be derived
from internal MC database or NIST tables without distinction.
On the other hand, in order to establish the corresponding dose delivering shell thicknesses
in the case of isotope emission spectra, it may be considered the approximation of treating an
isotope spectrum as monoenergetic source with an effective energy (EE f f ) associated with the
average (properly weighted according to the actual spectrum) energy of the whole emission
spectrum. Due to the fact that shell thicknesses depend upon source energy, once material
is given, it becomes clear the motivations for introducing and determining EE f f in order to
assess some effective or equivalent energy value with the aim of calculating the corresponding
shell thickness for the DPK calculations.
As a consequence of this assumption, the corresponding shell thickness for the k-isotope






where k =90Y, 131I, 89Sr, 153Sm, 177Lu, ... and EE f f is computed according to:




Where N is the number of channels of the k-isotope energy spectrum and pi and Ei are its
weight and energy respectively. It can be seen, as reported in Table 1, two examples of the
calculated EkE f f and R
k
CSDA along with the corresponding graphic sketch (Figure 1) outlining
how EE f f may be estimated. Radionuclide emission spectra were extracted from the NIST
database tables2.








Table 1. RCSDA used and EkE f f calculated for different isotopes.
2.4 Dedicated subroutines based on Monte Carlo techniques
The Monte Carlo method has been successfully applied to radiation transport problems in
clinical dosimetry. The method is particularly useful for complex problems that can not be
solved analytically and/or deterministically or when measurements are not practical.
1 http://www.nist.gov
2 Idem 1.
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(a) (b)
Fig. 1. 90Y and 177Lu spectra compared with its EE f f calculated.
The accuracy of Monte Carlo simulations strongly depends on the accuracy in the probability
density functions, and thereby the material cross-section libraries used for radiation transport
calculations.
The PENELOPE parameter Eabs determines -for each simulated material and transported
particle type- the energy threshold for particle absorption, defining the energy value below
which transport is no longer simulated and residual energy is assumed to be deposited locally.
The lowest possible Eabs value is 100eV according to manual recommendations based on the
lower energy (50eV) in PENELOPE v. 2008 database.
With the aim of performing radiation transport for dosimetric purposes, the first step may be
the design and development of a code devoted to the DPK calculations, which may basically
consist on a main program able to allow the user to set up the energy or the spectrum to be
radiated by the point source centered in a geometry defined by concentric spheres defining
shells of thickness RCSDA/40 (the corresponding RCSDA for each material is calculated for
the actual or effective energy for monoenertic sources or radionuclides, respectively). Due
to phisical properties of charged particles, it may be enough to tally DPK up to 1.5RCSDA.
Finally, the material for which the DPK needs to be investigated along with the corresponding
simulation parameters may be adjusted by the user in the input file.
The geometry file can be obtained from a dedicated user-designed program devoted to set
up the RCSDA obtained from MC or reliable databases. Once the user provides RCSDA the
program will automatically generate the corresponding file according to internal PENELOPE
requirements for simulation geometries.
Preliminary simulations are performed to achieve Eabs parameter values in order to optimize
computation process assessing suitable balances between statistical errors and the CPU
computation times. Therefore, after exhaustive examinations, absorption cutoff values of
100eV (minimum recommendable by PENELOPE developers) have been considered for
emitting sources of energies lower than 100keV (i.e. 5keV, 10keV, 20keV and 50keV) whereas
cutoff values of 1keV have been set for emitting sources with energies equal or higher than
100keV (i.e. 100keV, 200keV, 500keV, 1MeV, 2MeV and 5MeV).
As example from the preliminary simulations devoted to achieving suitable absorption energy
cutoff valued, it can be mentioned that in the case of the 100keV monoenergetic source, it was
found a maximum difference in the DPK of 0.16% when changing cutoff value from 1keV to
the minimum possible of 100eV, which may be taken as negligible. However, the situation is
significantly different when dealing with low energy emitting sources. DPK differences up to
5% may be found when changing absorption cutoff values from 1keV to 100eV in the case of
5keV monoenergetic source.
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As reported in Figure 2, it can be shown that DPK curves do not exhibit strong differences
when calculated for 100 or 1000eV considering emission energy of 100keV.
Fig. 2. Total sDPK curves for different cutoffs (100eV, 1keV and 5keV)
2.4.1 Monte Carlo DPK calculation
It is considered a punctual source (spectral or monoenergetic) centered in a water sphere
divided in many shells. Shell thicknesses are defined according to RCSDA/40 and dose
delivered within each shell is tallied using the developed MC code system, based on physics
from PENELOPE v. 2008.
In addition, dedicated subroutines have been introduced in the MC main code with the
aim of computing separately the different contributions to the total absorbed dose. Suitable
distinction may be made between primary and scattering components, considering scattering
contribution as arising from all energy depositions belonging to non primary particles.
Also, it is necessary to establish an optimal number of showers to be simulated in view of
optimizing the compromise between short CPU calculation time and accurate enough results.
In this sense, it may be useful to carry out preliminary calculations with different number
of showers to assess a suitable choice, according to Figures 3 and 4, for example. In base of
these figures it may be suggest that 107 primary showers would be an acceptable selection.
Actually, it should be usefull to add that according to this choice the CPU time is not longer
than 8 hours for a typical microprocessor on a standard PC.
Fig. 3. Convergence analysis of the 15th shell for different numbers of initial showers tallying
deposited energy along with uncertainties calculated as three standard deviations.
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Fig. 4. Convergence analysis for the 25th (a), 35th (b), 45th (c) and 55th (d) shell. Error bars
correspond to 3σ, i.e. 99.9% of confidence.
The distinction between the scattering and the primary contributions by the developed code
is assessed by “marking” or “painting” each particle on the main code distinguishing energy
deposition arising from primary or scattered particles. It should be emphasized that this
subtlety is able because of the great -actually absolute- aperture of PENELOPE as an open
source code. Technically, this aim can be accomplished by adding a special new parameter
in the particle quantum state along with the inclusion of suitable flags during particle
tracking. With this tool it becomes possible to obtain the dose delivered by each particle while
discriminating each kind of contribution.
Therefore, dose contributions calculation is on-run performed and separated files are
generated for total, primary and scattering dose delivering tallied at each shell.
2.4.2 Monte Carlo direct simulation on patient images
The first step consists on developing a code capable of reading and interpreting
patient-specific medical images in order to use them as input data for further computation
with the simulation code.
2.4.2.1 Geometry voxelization in Monte Carlo methods
According to typical medical imaging techniques, the most commonly found image storage
formats consist on space voxelization. In this sense, it would be desiderable to have at disposal
some mechanism devoted to interpret and handle voxelized information in order to perform
patient-specific dosimetry calculations. If the MC package does not provide a voxelization
toolkit, it would be useful and/or necessary that the user may implement some dedicated
voxelization technique in order to allow the use of patient-specific data from DICOM images
within the simulation. The role of the voxelization technique regards the interpretation by the
simulation code of the patient data in order to provide the corresponding inputs for simulation
geometry and mass distribution. Some MC main codes provide voxelization capability with
user distribution, but unfortunately this is not the case of PENELOPE v.2008. Therefore,
it was necessary to develop a dedicated program for patient data upload. This aim was
accomplished by considering patient geometry as a tensor whose elements correspond to a
patient image voxel and therefore its material and mass density may be inferred from CT
calibration, which provides the Hounsfield (CT) index vs. electronic density.
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Once patient geometry is already voxelized, 3D energy and dose deposition are tallied at each
voxel.
2.4.2.2 Input data files from DICOM images
DICOM is a commonly used imaging file format in almost all medical imaging fields,
particularly in nuclear medicine. For the purposes of the present work it was developed a
specific code for reading these image files and further convertion to suitable ascii files able to
be introduced as input for the developed radiation transport code.
One comfortable way for reading and interpreting DICOM images is available in the
MATLAB® environment. The implemented method consists on exploiting the useful
MATLAB package called “dicomread” that allows the user to read DICOM files as 3D
tensors. The obtained tensor is used to generate a suitable array which elements refer to the
information at each voxel in the DICOM file. This array is further uploaded as input ascii data
providing the required patient-specific radiation transport properties for MC simulations.
2.4.2.3 Metabolic & anatomical patient-specific input data
As described above, analogous treatments apply for uploading DICOM functional or
anatomical images. Patient anatomy is used to define simulation geometry and physical
properties may be inferred by means of suitable calibrations or implementing some “ad hoc”
criterion consulting expert physicians. On the other hand, functional images, like SPECT or
PET are used to provide activity spatial distribution and knowing the corresponding infused
radionuclide spectrum, it may be possible to use this information as simulation radiation
source. Combining both of these imaging techniques as simulation inputs, it would be
possible to assess reliable patient-specific dosimetry.
The DICOM functional images provide the activity information which is interpreted by the
code to establish the source distribution and its activity everywhere.
2.4.2.4 Specific-patient dose distribution calculation
Once input data are already uploaded by means of the developed subroutines aimed
to converting DICOM images into simulation geometry and radiation source, it becomes
possible to perform the corresponding MC simulation to the actual patient-specific situation.
As reported in Figure 5, the DICOM images are successfully interpreted to establish both
a N-material (four different materials in the reported example, namely: compact bone, soft
tissue, air and lung have been selected as a simplified first approximation) patient-specific
geometry. In addition, activity intensity and spatial distribution are also satisfactory
interpreted and combined with the corresponding anatomical data show a suitable definition
of the patient body as a virtual phantom for MC calculations.
2.5 Radiobiological models
Once 3D dose distribution is assessed, radiobiological considerations can be derived by
applying the adequate models with this aim.
Most calculations of the biological effect of radiation on tumors assume that the clonogenic cell
density is uniform even if account is taken of non-uniform dose distribution. Anyway, after
implementing some methodology for to identifying tumor/normal tissues on patient images
it will be necessary to introduce a model capable of assesing Tumor Control Probability (TCP)
on the tumor [Dale (1988),D.J. Brenner & Sachs (1995),M. Guerrero (2004)] and Normal Tissue
Complications Probability (NTCP) over the normal tissue and organs closed to the treatment
region [V.A. Semenenko (2008),L.A. Dawson & Haken (2002)].
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Fig. 5. CT (a), and SPECT (b) images showing both a transversal cut of the geometry and the
activity information.
Over the two past decades, the linear-quadratic (LQ) model has emerged as a convenient
tool to quantify biological effects for radiotherapy. Therefore, just for didactics purposes
ilustrating how to proceed for implementing radiobiological calculations, the LQ model will
be taken as example. From a general point of view and without interest on going deeper,
it should be mentioned that the LQ model provides a simple method to calculate the cell
survival fraction (SF), and on its consequences it is possible to see a reliable measure of the
TCP.
Assuming the Poisson statistics to survival cells and considering the control probability of the
tumor as the probability of having them death, it can be assessed the LQ model, assuming
a dose D homogeneously distributed over a homogeneous tumor, establishes that the SF is
given by the relationship
SF = e−αD−βD2 (17)
where α and β are empiric biological parameters associated to the probability of breaking
DNA helix. The α parameter represents the probability to induce a double strand break
in DNA helix with a single energy deposition, whereas the β parameter represents the
probability to have two single strand breaks with two separate energy depositions, one on
the first DNA helix, the other on the second one, which are close enough -both spatially and
temporally- to combine together producing the same effect of a double strand break, i.e. a
lethal (non reparable) damage.





where N0 refers to the initial quantity of tumoral cells and Ns to the survival tumoral cells.
Then, the TCP is given by the equation





Whereas NTCP formulation is considered by the interpretation of empirical clinical data, since
the organ behavior cannot be easily described by equations, and also the sparing of a normal
tissue is not simply linked to the number of surviving cells, but also to the maintenance of its
functionality, which depends on the organ architecture.
The Lyman-Kutcher-Burman (LKB) [V.A. Semenenko (2008), Z. Xu & Jiang (2006)] model
proposes that the NTCP may be assessed by
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be introduced as input for the developed radiation transport code.
One comfortable way for reading and interpreting DICOM images is available in the
MATLAB® environment. The implemented method consists on exploiting the useful
MATLAB package called “dicomread” that allows the user to read DICOM files as 3D
tensors. The obtained tensor is used to generate a suitable array which elements refer to the
information at each voxel in the DICOM file. This array is further uploaded as input ascii data
providing the required patient-specific radiation transport properties for MC simulations.
2.4.2.3 Metabolic & anatomical patient-specific input data
As described above, analogous treatments apply for uploading DICOM functional or
anatomical images. Patient anatomy is used to define simulation geometry and physical
properties may be inferred by means of suitable calibrations or implementing some “ad hoc”
criterion consulting expert physicians. On the other hand, functional images, like SPECT or
PET are used to provide activity spatial distribution and knowing the corresponding infused
radionuclide spectrum, it may be possible to use this information as simulation radiation
source. Combining both of these imaging techniques as simulation inputs, it would be
possible to assess reliable patient-specific dosimetry.
The DICOM functional images provide the activity information which is interpreted by the
code to establish the source distribution and its activity everywhere.
2.4.2.4 Specific-patient dose distribution calculation
Once input data are already uploaded by means of the developed subroutines aimed
to converting DICOM images into simulation geometry and radiation source, it becomes
possible to perform the corresponding MC simulation to the actual patient-specific situation.
As reported in Figure 5, the DICOM images are successfully interpreted to establish both
a N-material (four different materials in the reported example, namely: compact bone, soft
tissue, air and lung have been selected as a simplified first approximation) patient-specific
geometry. In addition, activity intensity and spatial distribution are also satisfactory
interpreted and combined with the corresponding anatomical data show a suitable definition
of the patient body as a virtual phantom for MC calculations.
2.5 Radiobiological models
Once 3D dose distribution is assessed, radiobiological considerations can be derived by
applying the adequate models with this aim.
Most calculations of the biological effect of radiation on tumors assume that the clonogenic cell
density is uniform even if account is taken of non-uniform dose distribution. Anyway, after
implementing some methodology for to identifying tumor/normal tissues on patient images
it will be necessary to introduce a model capable of assesing Tumor Control Probability (TCP)
on the tumor [Dale (1988),D.J. Brenner & Sachs (1995),M. Guerrero (2004)] and Normal Tissue
Complications Probability (NTCP) over the normal tissue and organs closed to the treatment
region [V.A. Semenenko (2008),L.A. Dawson & Haken (2002)].
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Fig. 5. CT (a), and SPECT (b) images showing both a transversal cut of the geometry and the
activity information.
Over the two past decades, the linear-quadratic (LQ) model has emerged as a convenient
tool to quantify biological effects for radiotherapy. Therefore, just for didactics purposes
ilustrating how to proceed for implementing radiobiological calculations, the LQ model will
be taken as example. From a general point of view and without interest on going deeper,
it should be mentioned that the LQ model provides a simple method to calculate the cell
survival fraction (SF), and on its consequences it is possible to see a reliable measure of the
TCP.
Assuming the Poisson statistics to survival cells and considering the control probability of the
tumor as the probability of having them death, it can be assessed the LQ model, assuming
a dose D homogeneously distributed over a homogeneous tumor, establishes that the SF is
given by the relationship
SF = e−αD−βD2 (17)
where α and β are empiric biological parameters associated to the probability of breaking
DNA helix. The α parameter represents the probability to induce a double strand break
in DNA helix with a single energy deposition, whereas the β parameter represents the
probability to have two single strand breaks with two separate energy depositions, one on
the first DNA helix, the other on the second one, which are close enough -both spatially and
temporally- to combine together producing the same effect of a double strand break, i.e. a
lethal (non reparable) damage.





where N0 refers to the initial quantity of tumoral cells and Ns to the survival tumoral cells.
Then, the TCP is given by the equation





Whereas NTCP formulation is considered by the interpretation of empirical clinical data, since
the organ behavior cannot be easily described by equations, and also the sparing of a normal
tissue is not simply linked to the number of surviving cells, but also to the maintenance of its
functionality, which depends on the organ architecture.
The Lyman-Kutcher-Burman (LKB) [V.A. Semenenko (2008), Z. Xu & Jiang (2006)] model
proposes that the NTCP may be assessed by
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when conditions are assumed as in the LQ model for the TCP calculations, m is a
dimensionless correction factor and TD50 is the dose, over all the tumor, for that NTCP is
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where κ is a dimensionless parameter approximated by 0.8154.
3. Application of patient-specific dosimetry system
According to dosimetry calculation purposes, DPKs are all what is needed to calculate dose
distributions in homogeneous media starting from activity distributions by simply means of
analytical convolution. However, it can be shown that in cases of inhomogeneous media,
these analytical methods may not provide accurate enough results for dose distribution
calculations, as expected.
Therefore, this section will present some results about the calculation of DPK both for
monoenergetic and spectral β− sources within homogeneous as well as inhomogeneous
media with the aim of pointing out the corresponding differences.
In addition, results for preliminary dose maps along with TCP and NTCP calculations for
patient-specific images will be reported, the last ones will be considered as examples of
the wide range of possibilities in radiobiology offered by the versatility of the implemented
calculation system based on 3D dose distribution.
3.1 Monoenergetic beta-emitting sources scaled DPK
Beta-minus monoenergetic sources were simulated and their sDPK were calculated for initial
primary particles energies of 5keV, 10keV, 20keV, 50keV, 100keV, 200keV, 500keV, 1MeV,
2MeV and 5MeV. The obtained results are shown in Figures 6 and 7.
As mentioned, the implemented calculation code incorporates dedicated routines devoted
to quantify the different dosimetric contributions. Figures 8 and 9 show some obtained
results for the total sDPK along with the corresponding separation between the primary and
scattering contributions for different monoenergetic sources.
In addition, it is interesting to report the relative contribution from scattering component to
the total sDPK at different distances, as shown in Figure 10.
3.2 Spectral beta-emitting sources Dose Point Kernels
With the aim of preliminary benchmarking the capability of the developed calculation code
in the framework of clinical implementation of beta-minus radiolabeled therapy, sDPK at
different energies were calculated for homogeneous media. Therefore, some of the most
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Fig. 6. sDPK calculated for all the monoenergetic beams simulated.
Fig. 7. All monoenergetic beams simulated on log-log scale normalized to maximum,
expressed in length units [cm] highlighting differences for a wide range of emission energies.
Fig. 8. sDPK for 100keV showing total, primary and scattering contributions.
commonly used radionuclides for targeted radiotherapy treatments have been studied with
the developed calculation code. The obtained results for 90Y, 131I, 89Sr, 153Sm and 177Lu are
reported in Figures 11 and 12.
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commonly used radionuclides for targeted radiotherapy treatments have been studied with
the developed calculation code. The obtained results for 90Y, 131I, 89Sr, 153Sm and 177Lu are
reported in Figures 11 and 12.
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Fig. 9. sDPK for 1MeV showing total, primary and scattering contributions.
Fig. 10. sDPK along with relative scattering contribution for 500keV monoenergetic source.
Fig. 11. Total sDPK for different β− radionuclides.
In the case of radionuclides, the different contributions to the total delivered dose have been
assessed by means of an analogue procedure to that of the monoenergetic sources.
Figures 13 and 14 report the obtained results for the contributions to total sDPK allowing to
appreciate qualitative different behaviours according to each radionuclide.
278 12 Chapters on Nuclear Medicine Dosimetry for Beta-Emitter Radionuclides by Means of Monte Carlo Simulations 15
Fig. 12. Total radionuclide DPK normalized to global maximum pointing out the differences
in penetration capabilities.
Fig. 13. Different contributions to the 90Y sDPK.
Fig. 14. Different contributions to the 177Lu sDPK.
3.3 Scaled Dose Point Kernels for non water-equivalent media
As mentioned above, it is commonly found in clinical applications the requirement of
considering different materiales for patient dosimetry. In this sense, it may be useful to
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investigate the effect on sDPK due to the consideration of irradiated media constituted of
materials typically used in clinics other than water or normal soft tissue.
In order to show the capability of the developed calculation code to perform radiation
transport in different materials, two typical clinical tissues have been selected for this
investigation. Bone (defined according to International Commission on Radiation Units and
Measurements, ICRU) and lung (International Commission on Radiological Protection, ICRP)
tissues have been considered because they represent somehow the extreme cases in typical
clinical situations. Figures 14 and 15 report he obtained sDPK calculated over bone and lung
spheres for 100keV and 500keV sources. As a consequence of the sDPK suitable dimensionless
length normalization, it has been obtained that the sDPK qualitatively preserve the same
shape disregarding of the specific considered medium.
(a)
(b)
Fig. 15. Contributions to the sDPK calculated for 100keV (a) and 500keV (b) centered at a
bone and lung spheres, respectively.
3.4 Scaled Dose Point Kernels on inhomogeneous media
In order to highlight the effects of inserting an inhomogeneity in the calculation of the sDPK
different situations have been suitably designed and investigated. Water has been selected as
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reference medium and bone or lung inhomogeneities have been introduced considering wide
ranges of inhomogeneity thickness and relative position within the irradiated sphere.
Figures 16 and 17 report the obtained results for the above described cases. It can be
appreciated that, at least a priori, it seems to be an anomalous behaviour at the interfaces
between different materials. It has been obtained that this “peculiar” situation is always
found for all the considered cases independently of inhomogeneity type, thickness or relative
position.
Fig. 16. sDPK corresponding to different relative positions of a 6-shell ( 640 · RCSDA) thick
bone inhomogeneity.
Fig. 17. sDPK corresponding to different bone inhomogeneity thicknesses.
3.5 Patient-specific dose distribution along with TCP and NTCP calculations
Once both the anatomical and metabolic images were already uploaded to the developed
calculation code it became possible to perform the corresponding patient-specific dosimetry
establishing the desidered radionuclide and corresponding activity. As example of the
proposed method in practical cases, dual SPECT-CT images have been used to carry out
the simulation. Dose distribution calculations have been performed for different beta-minus
radionuclides, as reported in Figure 18 for 131I.
Although relative dose distribution have been presented, it should be emphasized that once
the source activity is established, it becomes possible to determine the corresponding number
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Fig. 18. Relative dose distribution on virtual patient irradiated by 131I.
of primary showers and therefore obtaining straightforwardly the corresponding absolute
dose distribution. This information will be necessary for the calculation of radiobiological
quantities.
The 3D absolute dose distribution constitutes the basic required information for implementing
suitable algorithms devoted to estimate the TCP and NTCP. As mentioned previously, the
linear quadratic model has been implemented for TCP estimation. As example of how to
proceed, it has been arbitrary taken a total infused activity of 1mCi and typical values for
the LQ radiobiological parameters have been used according to the literature, namely α =
0.12Gy−1 and β = 0.0137Gy−2 given a relationship of α/β = 8.7591. Figure 19 reports the
obtained TCP distribution for the slice of interest.
Fig. 19. TCP for the slice of interest obtained for 1mCi activity delivered by 131I.
However, it is necessary to remark that in real clinical situations TCP and NTCP estimation
will require the implementation of some mechanism dedicated to the identification of
normal/tumor tissue regions in order to proceed with the assigment of the corresponding
radiobiological parameters. Actually, TCP evaluations have to be applied to tumor region,
whereas NTCP evaluations apply to normal organs, each having different radiobiological
parameter values. Once the previous step is accomplished the calculation method is
performed following the procedure described above.
Similarly, it can be proposed some model for calculating the NTCP. With the aim of
highlighting the required procedure, typical radiobiological values for the LKB model have
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been extracted from literature [G. Luxton & King (2008)], namely TD50 = 24.5 and m = 0.18.
The obtained NCTP distribution is presented in Figure 20.
Fig. 20. NTCP for the slice of interest obtained for 1mCi activity delivered by 131I.
4. General overview and final remarks
The adequacy of the developed radiation transport simulation code based on PENELOPE
v.2008 for nuclear medicine and focused on beta-emitters dosimetry has been preliminary
investigated checking the consistency of the results expected when considering electron
transport in the energy range from 5keV to 5MeV.
In this sense, dose point kernels have been calculated for several monoenergetic and spectral
sources including the most commonly used radionuclides for typical nuclear medicine
therapies.
Contrary to other works, it was considered the RCSDA range for both monoenergetic and
spectrum sources, instead of the X90 parameter used commonly on spectrum sources.
Therefore it could be not straightforward to compare the obtained results for radionuclides
with those reported by other authors. However, it does not constitute a significant drawback
because comparisons can be performed for monoenergetic emission sources, which may help
for assessing the reliability and accuracy of the proposed method.
It is interesting to comment about the obtained results for sDPK when inserting
inhomogeneities. It has been found that non negligible abrupt changes appear in sDPK curves
poducing remarkable discontinuity on the sDPK derivate. This behaviour may make difficult
or actually avoid adequate analytical calculation of sDPK, as could be the case of realistic
clinical situations. In this sense, it constitutes one of the main advantages of developing and
implementing MC methods devoted to reliable radiation transport computation.
Technical features of simulation process have been studied in detail including convergence
of representative observable mean values and standard deviations. In view of the specific
requirements for most of the calculation performed in this work, it has been found that 107
primary showers seems to be a convenient and suitable compromise between calculation time
and accurate enough results.
Regarding the investigations about the separation and characerization of the different
contributions to the total absorbed dose, it should be mentioned that the main contribution
comes from primary radiation, as expected. Although clearly non negligible, scattering
contributions are always significantly lower than the primary component to absorbed dose.
In addition, it has been shown how to obtain the different dose contributions at different
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positions and therefore obtaining that relative importance of scattering component varies
significantly according to the tally position. Furthermore, the relative balance between
primary and scattering contributions has shown to be dependent upon the physical properties
of specific considered material.
Nevertheless, in the case of monoenergetic sources it has been obtained that the relative
greater importance of the scattering contribution occur at distances larger than the RCSDA
and it could be inferred that the same may happen for radioisotopes.
It can been concluded that a characterization of primary and scattering contributions to
the total absorbed demand significant efforts. However, the importance of investigating
about this would be relevant for further radiobiological studies, because they can take
advantage from the characterization of dose components for assessing improved results
including LET-weighted dosimetry. When dealing with beta-minus emitters the relative
impact of performing LET-weighted dosimetry could be somehow negiglibe becuase of the
almost constant LET depence on electron kinetic energy within the range of clinical interest.
However, on the other hand, implementing this kind of procedures could be really important
for alpha-emitters dosimetry due to the involved high LET values and variations between
energy fluence and particle type associated to primary and scattering components.
When considering different absorbing media, like lung or bone, it has been obtained
that sDPK show qualitatively the same behaviour found for water. Therefore, it seems
possible to propose that sDPK could be satisfactory assessed by analytical methods whenever
considering homogeneous media. Furthermore, exhaustive analysis and investigations about
the precedent results, which have not been discussed in this work, may suggest that simplified
models based on linear scaling of stopping powers could provide acceptable conversion
between different biological materials. This scenario may strongly improve calculation
comfortability for analytical methods. However, it should be emphasized that MC methods
would always provide more accurate and reliable results. Actually, MC methods should
be strongly recommended when dealing with complex situations, as may be a realistic
patient-specific dose distribution calculation.
In addition, it is important to remark that this MC direct simulation on patient images can
be very useful and convenient in some selected cases, like the presence of inhomogeneities,
whereas in case of homogeneous tissue simple methods due to their less demanding
requirements (especially in terms of computation time) even providing results with accuracy
more than adequate. In addition, poor image (anatomical or metabolic) resolution may
strongly affect MC calculation, which may be taken as a possible drawback of the proposed
method.
Significant improvements regarding CPU calculation time may be assessed in some situations
appropriate for suitable approximations allowing deterministic computation, but it is out
of the scopes of this work. Otherwise when dealing with homogeneous tissues, analytical
methods will be more adequate than MC simulations, preserving MC techniques as the most
reliable and recommendable method, at least up today, for accurate dosimetry in presence of
inhomogeneities.
Summarizing, this work presented a suitable and useful description about the main features
involved in the development and implementation of Monte Carlo techniques for nuclear
medicine purposes. A general overview of nuclear medicine dosimetry and radiation
transport concepts has been presented. In addition, simplified and detailed explanations have
been provided about how to design and elaborate dedicated Monte Carlo subroutines for
nuclear medicine purposes.
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Several application examples have been added considering typical clinical situations in order
to support the exposed concepts and procedures.
As result from the proposed method, it was possible to characterize the scaled dose point
kernel, as an important parameter of common daily use in nuclear medicine practice. In
addition, the computation of sDPK has been also used for taking advantage of preliminary
assessment of reliability and accuracy of the performed dosimetric calculations with the
developed code.
The developed simulation code adapted for nuclear medicine radiation transport and dose
delivering has been successfully integrated and complemented with dedicated algorithms
devoted to patient image reading and interpreting for both anatomical and metabolic
patient-specific medical images. Therefore, as example of the potentiality of the developed
calculation system, it was shown how to estimate realistic dose distributions computed over
reliable patient-specific virtual phantoms using activity information from SPECT DICOM
images and the geometries and materials obtained from CT DICOM images. Furthermore,
dose volume histograms (DVH) as well radiobiological quantities, like TCP and NTCP can
be straightforwardly determined once 3D absorbed dose is already calculated. In base on
the obtained performance, it should be emphasized that, after further rigorous tests and
benchmarkings, the proposed calculation system would be able to provide accurate and
reliable information enough to suggest its consideration as a suitable and useful tool for
routine dosimetric calculations.
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positions and therefore obtaining that relative importance of scattering component varies
significantly according to the tally position. Furthermore, the relative balance between
primary and scattering contributions has shown to be dependent upon the physical properties
of specific considered material.
Nevertheless, in the case of monoenergetic sources it has been obtained that the relative
greater importance of the scattering contribution occur at distances larger than the RCSDA
and it could be inferred that the same may happen for radioisotopes.
It can been concluded that a characterization of primary and scattering contributions to
the total absorbed demand significant efforts. However, the importance of investigating
about this would be relevant for further radiobiological studies, because they can take
advantage from the characterization of dose components for assessing improved results
including LET-weighted dosimetry. When dealing with beta-minus emitters the relative
impact of performing LET-weighted dosimetry could be somehow negiglibe becuase of the
almost constant LET depence on electron kinetic energy within the range of clinical interest.
However, on the other hand, implementing this kind of procedures could be really important
for alpha-emitters dosimetry due to the involved high LET values and variations between
energy fluence and particle type associated to primary and scattering components.
When considering different absorbing media, like lung or bone, it has been obtained
that sDPK show qualitatively the same behaviour found for water. Therefore, it seems
possible to propose that sDPK could be satisfactory assessed by analytical methods whenever
considering homogeneous media. Furthermore, exhaustive analysis and investigations about
the precedent results, which have not been discussed in this work, may suggest that simplified
models based on linear scaling of stopping powers could provide acceptable conversion
between different biological materials. This scenario may strongly improve calculation
comfortability for analytical methods. However, it should be emphasized that MC methods
would always provide more accurate and reliable results. Actually, MC methods should
be strongly recommended when dealing with complex situations, as may be a realistic
patient-specific dose distribution calculation.
In addition, it is important to remark that this MC direct simulation on patient images can
be very useful and convenient in some selected cases, like the presence of inhomogeneities,
whereas in case of homogeneous tissue simple methods due to their less demanding
requirements (especially in terms of computation time) even providing results with accuracy
more than adequate. In addition, poor image (anatomical or metabolic) resolution may
strongly affect MC calculation, which may be taken as a possible drawback of the proposed
method.
Significant improvements regarding CPU calculation time may be assessed in some situations
appropriate for suitable approximations allowing deterministic computation, but it is out
of the scopes of this work. Otherwise when dealing with homogeneous tissues, analytical
methods will be more adequate than MC simulations, preserving MC techniques as the most
reliable and recommendable method, at least up today, for accurate dosimetry in presence of
inhomogeneities.
Summarizing, this work presented a suitable and useful description about the main features
involved in the development and implementation of Monte Carlo techniques for nuclear
medicine purposes. A general overview of nuclear medicine dosimetry and radiation
transport concepts has been presented. In addition, simplified and detailed explanations have
been provided about how to design and elaborate dedicated Monte Carlo subroutines for
nuclear medicine purposes.
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Several application examples have been added considering typical clinical situations in order
to support the exposed concepts and procedures.
As result from the proposed method, it was possible to characterize the scaled dose point
kernel, as an important parameter of common daily use in nuclear medicine practice. In
addition, the computation of sDPK has been also used for taking advantage of preliminary
assessment of reliability and accuracy of the performed dosimetric calculations with the
developed code.
The developed simulation code adapted for nuclear medicine radiation transport and dose
delivering has been successfully integrated and complemented with dedicated algorithms
devoted to patient image reading and interpreting for both anatomical and metabolic
patient-specific medical images. Therefore, as example of the potentiality of the developed
calculation system, it was shown how to estimate realistic dose distributions computed over
reliable patient-specific virtual phantoms using activity information from SPECT DICOM
images and the geometries and materials obtained from CT DICOM images. Furthermore,
dose volume histograms (DVH) as well radiobiological quantities, like TCP and NTCP can
be straightforwardly determined once 3D absorbed dose is already calculated. In base on
the obtained performance, it should be emphasized that, after further rigorous tests and
benchmarkings, the proposed calculation system would be able to provide accurate and
reliable information enough to suggest its consideration as a suitable and useful tool for
routine dosimetric calculations.
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1. Introductions 
Bone and soft tissue disease is kind of detrimental disease and the precise diagnosis and 
timely therapy is also the clinical doctors’ object of a prolonged endeavour. This chapter will 
introduce the diagnostic and therapeutic methods of bone and soft tissue diseases with 
nuclear medicine techniques.  
The singular advantages of skeletal scintigraphy are high sensitivity in detecting early 
disease and its ability to survey the entire skeleton quickly and reasonable expense. Most 
broadly, the uptake of skeletal seeking radiotracers depicts osteoblastic activity and regional 
blood flow to bone. Any medical condition that changes either of these factors in a positive 
or negative way can result in an abnormal skeletal scintigram. 
Radionuclide distribution has played an important role in understanding normal bone 
metabolism, in addition to the metabolic effects of pathologic involvement. Radionuclide 
imaging of the skeleton is being used with increasing frequency in the evaluation of 
abnormalities involving bones and joints. Several studies have demonstrated that different 
information can be obtained by radionuclide bone imaging compared with radiography and 
blood chemistry analysis. Innovations in equipment design and other advances, such as 
single-photon emission computed tomography (SPECT), positron emission tomography 
(PET), positron emission tomography/computed tomography (PET/CT), positron emission 
tomography/magnetic resonance imaging (PET/MR) and hybrid SPECT/CT have been 
incorporated into the investigation of various musculoskeletal diseases. 
The first part of this chapter introduces the mechanism of skeletal radionuclide imaging, 
which also reviews part knowledge of skeletal anatomy and physiology. The remainder of 
the chapter discusses radionuclide imaging of the bones and joints, with an emphasis on the 
applications of the imaging procedures, and the radionuclide therapy of some bone tumors. 
2. Mechanism and technique of skeletal radionuclide imaging 
Bone scintigraphy is one of the most common investigations performed in nuclear medicine 
and routinely used in the evaluation of patients with cancer for suspected bone metastases 
and in various benign musculoskeletal conditions. The uptake of radiotracers in bone is 
associated with local osteoblastic activity and regional blood flow. More 
radiopharmaceutical is delivered to hyperemic areas. Either increased blood flow or 
increased osteogenesis for many types of lesions results in higher tracer uptake than in 
unaffected or normal parts of the skeleton. 
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1. Introductions 
Bone and soft tissue disease is kind of detrimental disease and the precise diagnosis and 
timely therapy is also the clinical doctors’ object of a prolonged endeavour. This chapter will 
introduce the diagnostic and therapeutic methods of bone and soft tissue diseases with 
nuclear medicine techniques.  
The singular advantages of skeletal scintigraphy are high sensitivity in detecting early 
disease and its ability to survey the entire skeleton quickly and reasonable expense. Most 
broadly, the uptake of skeletal seeking radiotracers depicts osteoblastic activity and regional 
blood flow to bone. Any medical condition that changes either of these factors in a positive 
or negative way can result in an abnormal skeletal scintigram. 
Radionuclide distribution has played an important role in understanding normal bone 
metabolism, in addition to the metabolic effects of pathologic involvement. Radionuclide 
imaging of the skeleton is being used with increasing frequency in the evaluation of 
abnormalities involving bones and joints. Several studies have demonstrated that different 
information can be obtained by radionuclide bone imaging compared with radiography and 
blood chemistry analysis. Innovations in equipment design and other advances, such as 
single-photon emission computed tomography (SPECT), positron emission tomography 
(PET), positron emission tomography/computed tomography (PET/CT), positron emission 
tomography/magnetic resonance imaging (PET/MR) and hybrid SPECT/CT have been 
incorporated into the investigation of various musculoskeletal diseases. 
The first part of this chapter introduces the mechanism of skeletal radionuclide imaging, 
which also reviews part knowledge of skeletal anatomy and physiology. The remainder of 
the chapter discusses radionuclide imaging of the bones and joints, with an emphasis on the 
applications of the imaging procedures, and the radionuclide therapy of some bone tumors. 
2. Mechanism and technique of skeletal radionuclide imaging 
Bone scintigraphy is one of the most common investigations performed in nuclear medicine 
and routinely used in the evaluation of patients with cancer for suspected bone metastases 
and in various benign musculoskeletal conditions. The uptake of radiotracers in bone is 
associated with local osteoblastic activity and regional blood flow. More 
radiopharmaceutical is delivered to hyperemic areas. Either increased blood flow or 
increased osteogenesis for many types of lesions results in higher tracer uptake than in 
unaffected or normal parts of the skeleton. 
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The accumulation of radionuclide in bone is related to both vascularity and rate of bone turn 
over. Increased blood supply to an area of bone result in increased activity in a blood-pool 
image (obtained immediately after radiopharmaceutical administration). 
The localization of various bone imaging agents is related to exchange with ions in the bone. 
The process of exchange of an ion native to bone for a labelled, bone-seeking ion is termed 
heter-ionic exchange. Calcium phosphate is the main inorganic constituent of bone; 
however, calcium is also found in the form of carbonate and fluoride. Calcium is located in 
microcystals of hydroxyapatite. Analog elements of calcium, such as strontium-85 (85Sr), are 
believed to exchange with the calcium. Flurorine-18 (18F) exchanges with hydroxyl ion in the 
hydroxyapatite. The accumulation of labelled phosphate compounds is probably related to 
the exchange of the phosphorus groups onto the calcium of hydroxyapatite. Although these 
mechanisms are not completely understood, the principle of bone imaging is fairly basic. 
Calcium analogs or phosphate compounds have a low concentration in blood and tissues, 
and this will supply a good bone-to-soft tissue background ratio. 
Radiopharmaceuticals used for bone imaging sometimes can localize in soft tissue areas, 
demonstrating not only calcification but also infarction, inflammation, trauma, and tumor. 
The portion of any radiopharmaceutical that does not accumulate in bone and tissue or stays 
in the circulation is eliminated from the body by various routes, depending on the 
radiopharmaceutical. 85Sr can be concentrated in the gastrointestinal tract for several days. 
18F-fluoride (18F-NaF) and phosphate scans labelled with technetium-99m (99mTc) 
demonstrate activity in the kidneys and bladder, since these agents are excreted through the 
urinary tract. 
2.1 Radiopharmaceuticals 
Because of different radiopharmaceutical defining the imaging type, it is necessary to 
introduce some tracers widely used in clinical departments. Radiopharmaceuticals are 
classified into three goups; single photon emitting agents, positron emitting agents and 
therapeutic radiopharmaceuticals according to the radiation types.  
2.1.1 Single photon emitting agents 
SPECT, which is short for single photon emission computer tomography, is the most widely 
used equipment in departments of nuclear medicine. There are lots of different kinds of 
single photon emitting radionuclides, however not all of them are suitable for skeleton 
imaging. The most widely used radionuclide is technetium-99m (99mTc). 
Technetium-99m is a metastable nuclear isomer of technetium-99, symbolized as 99mTc. 
Technetium- 99m emits gamma rays which can be detected by SPECT. It is well suited to the 
role because it emits readily detectable 140 keV (excitation energy) gamma rays, and its half-
life for gamma emission is about 6 hr. The short half life of the isotope (in terms of human-
activity and metabolism) allows for scanning procedures. The following table (table 1) 
summarizes its nuclear physics characteristics. 
The agents are composed of radiation emitter and chemical or biologic molecules. The Tc-
99m-labelled skeletal radiopharmaceuticals are distributed rapidly throughout the 
extracellular fluid space. For example, 99mTc-methylene diphosphonate (99mTc-MDP) is the 
most famous tracer of skeletal imaging, 99mTc (V)-2, 3-dimercaptosuccinic acid (99mTc (V)-








Z(p) N(n) isotopic mass (u)
half-life Decay mode(s) 
Daughter 
isotope(s) excitation energy 
99mTc 
43 56 98.9062547(21) 
6.0058 hr 
IT (99.99%) 99Tc 
140.5 keV β- (.0037%) 99Ru 
Table 1. The nuclear physics characteristics of radionuclide 99mTc 
Upon intravenous injection, the uptake of 99mTc-MDP appears to be related to bone 
metabolic activity and to skeletal blood flow. 99mTc-MDP exhibits a specific affinity for areas 
of altered osteogenesis. The adsorption is believed to occur primarily to the mineral phase of 
bone, with little biding to the organic phase. The uptake is significantly higher in 
amorphous calcium phosphate than in mature crystalline hydroxyapatite, which helps 
explain the avidity of the tracer for areas of increased osteogenic activity. Localized areas of 
decreased skeletal accumulation of 99mTc-MDP may be seen in areas of reduced or absent 
regional blood flow (i.e. bone infarction) and in areas where the skeleton has been destroyed 
to the point that no bone matrix elements are present for uptake to occur. 
99mTc (V)-DSMA and 99mTc-MIBI are usually used in seeking tumors in soft tissues. Also 
there are reports on the 99mTc (V)-DSMA scintigraphy as a monitor in the response of bone 
disease to vitamin D3 therapy in renal osteodystrophy and 99mTc (V)-DSMA whole body 
scan in detection of metastases in thyroid medullary cancer.  
Gallium-67 (67Ga) is also a single photon emitting radionuclide; it is an iron analogue which 
avidly binds to iron-binding proteins. It competes for iron sites in transferring and is 
absorbed by lysosomes and endoplasmic reticulum of white blood cells. It has been used in 
the evaluation of unknown original fever, chronic inflammations, detection and localization 
of osteomyelitis and/or disk space infection, etc. The excitation energy of 67Ga is 93.3 keV 
(36%) and has a life time of 3.26 days. 67Ga scintigraphy has been used to determine the 
treatment response in soft tissue tumors, such as osteosarcoma. 
Thalium-201 (201Tl) is another single photon emitting radionuclide, it has been used in many 
different SPECT imaging protocols such as myocardial perfusion imaging, skeleton imaging, 
tumor positive imaging, parathyroid imaging combined with pertechnetate, etc. 201Tl decays 
by electron capture and gamma emitter with subsequent gamma emission of 68.9 to 80.3 
keV (94%) and has a life time of 3.04 days. 
Although the role of 201Tl scintigraphy for staging the disease of bone tumor and 
differentiation of benign from malignant lesions is limited, it has provided important 
information on the management of patients with bone tumors. 201Tl scintigraphy reflects the 
disease activity after treatment and it should be used to determine the treatment response 
and for early diagnosis of recurrence in bone soft tissue tumors. 
2.1.2 Positron emitting agents 
PET, which is short for positron emission computed tomography, is the most advanced 
equipment in the field of nuclear medicine even in the area of image science. Lots of kinds of 
positron emitting radionuclide have been used in practice, such as 18F, 11C (carbon-11), 15O 
(oxygen-15), 13N (nitrogen-13), etc. The most widely used radionuclide is fluorine-18 (18F) 
and carbon-11 (11C). The 18F radiolabelled and 11C labelled skeletal radiopharmaceuticals are 
used in PET imaging, which reflect the bone metabolism. The following table (table 2) 
summarizes their nuclear physics characteristics. 
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(oxygen-15), 13N (nitrogen-13), etc. The most widely used radionuclide is fluorine-18 (18F) 
and carbon-11 (11C). The 18F radiolabelled and 11C labelled skeletal radiopharmaceuticals are 
used in PET imaging, which reflect the bone metabolism. The following table (table 2) 
summarizes their nuclear physics characteristics. 
 




Z(p) N(n) isotopic mass (u)
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Daughter 
isotope(s) excitation energy 
Fluorine-18 
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0.6335 MeV β- 
Carbon-11 
11C 
6 5 11.011433(10) 
20.33 min β+ 11B 
0.96 MeV 
Table 2. The nuclear physics characteristics of positron radionuclide 18F, 11C 
18F-2-fluoro-2-deoxy-d-glucose (18F-FDG), 18F sodium fluoride (18F-NaF) and 11C-choline PET 
imaging is also called bone metabolic imaging. Here we will mention 18F-FDG and 18F-NaF 
imaging. 18F-FDG (2-fluoro-2-deoxy-d-glucose) is a glucose analogue with a fluorine atom 
replacing a hydroxyl group in the C-2 position of d-glucose. 18F exchanges with the 
hydroxyl (OH) ion in the hydroxyapatite. Although the mechanisms are not completely 
understood, the principal of bone imaging is fairly basic. Radiopharmaceuticals used in 
bone imaging can localize in soft tissues, demonstrating not only calcification but also 
inflammation, trauma, and tumor. 
2.1.3 Therapeutic radiopharmaceuticals 
In the area of therapeutic nuclear medicine, there are lots of applications of different kinds 
of radiopharmaceuticals. For example, sodium of 32P-phosphate is an FDA-approved 
radiopharmaceutical indicated for treatment of polycythemia vera, chronic myelocytic 
leukemia, chronic lymphocytic leukemia, and for palliation of metastatic bone pain. 
Chromic 32P-phosphate is suspension of 32P used for intracavity installation for treatment of 
peritoneal or pleural effusions caused by metastatic disease. Phosphorus-32 decays by beta- 
emission with a half life of 14.3 days. The major toxicity noted is significant marrow 
suppression in approximately one third of patients receiving this radiopharmaceutical.  
Iodine-131 (131I) is the important therapeutic radiopharmaceutical, as a capsule or a solution 
for oral administration, which decays by beta- emission with subsequent gamma emission 
of 364 keV (82%) and has a life time of 8 days. Iodine-125 (125I) delivers a higher radiation 
dose to the patient due to the half life of 60 days and 125I seeds have been used in the therapy 
of solid tumors. 
In skeleton nuclear medicine, some radionuclides are chosen as an effective way for treating 
the bone pain caused by the bone metastases. 89Sr-chloride (Metastron) has been approved 
by the FDA for relief of bone pain in cases of painful skeletal metastases. The compound 
behaves biologically like calcium and localizes in hydroxyapatite crystal by ion exchange. 
Strontium uptake occurs preferentially at sites of active osteogenesis. This allows primary 
bone tumors and areas of metastatic involvement to accumulate significantly higher 
concentration of strontium than surrounding normal bone. 89Sr decays by beta- emission 
with a half life of 50.6 days.  
Another two radiotherapeutic agents, 186Re-HEDP and 153Sm-EDTMP are also used in the 
area. 186Re decays by beta- and gamma emission with a half life of 90.6 hr and 153Sm decays 
by beta- emission and has a half life of 46.3 hr. Both of these beta-emitting radionuclides are 
complex with bone-seeking ligands, which localize by chemisorption. The duration of 







In pediatric cases the physiology and metabolism is different from adults’ and the uptake of 
radiopharmaceuticals vary greatly, for example the bone uptake in children is up to 80% 
compared with that of adults at up to 40%. The pediatric dose of radiopharmaceuticals is 
calculated based on the standard weight method (the pediatric dose=(patient weight in 
kg×standard adult dose)÷70kg) or body surface area methods. With 99mTc labelled 
radiopharmaceuticals, we suggest a 24 to 36 hr breast feeding delay, and 67Ga based 
products for a 72 hr delay. 
In pregnant women, the nuclear medicine examinations are forbidden. 
2.2 Technique of skeletal radionuclide imaging 
After the radiopharmaceuticals prepared, an emission computed tomography is needed. 
Tomography is the process of producing a section or slice in a picture of an object. The 
emission computed tomography (ECT) can produce a picture of the distribution of 
radiopharmaceuticals administered to the patient. At present the widespread used ECT are 
SPECT and PET. 
2.2.1 Technique of skeleton SPECT imaging 
By far the most popular SPECT consists of a rotating Anger camera, which equipped with a 
large field of view detector, mounted on a 360-degree rotation gantry. Multipledetector 
SPECT has increased the diagnostic sensitivity and lessened the acquisition time. In skeletal 
imaging protocols we often chose a low energy and high resolution collimator. 
2.2.2 Technique of skeleton PET imaging 
PET is one of the exciting tomographic techniques, and provides functional information of 
blood flow and metabolism. As a positron meets a free electron in the tissue, annihilation 
occurs and the two 511keV annihilation photons are detected by coupled opposing detectors 
in coincidence. PET is more sensitivity than SPECT, and differs from SPECT by “electronic 
collimation”. 
2.3 Appearance of normal skeleton scintigram 
According to the different imaging objects, the nuclear physician chose the proper protocols. 
Generally speaking, the imaging type are divided into whole body scan, local static bone 
scan, local bone tomography, dynamic bone scan (i.e. three phase imaging: blood flow 
phase, blood-pool phase, and delay scan). The whole body bone scan is the most widely 
used scintigraphy, which reflects the whole skeleton situation.  
The appearance of the normal skeletal scintigram should be clear, symmetric and uniform 
and the uptake of joints, junctions, and scapulas increased. In some older patients the image 
may have a globally poor quality. The normal image can change dramatically among 
infancy, childhood, adolescence and mature adulthood. In adults, growth center activity 
normally becomes equal to activity in adjacent bone, on the contrary more radioactivities in 
growth center than adjacent bone in childhood. Tracer uptake is greatest in the axial 
skeleton (spine and pelvis), and relatively less intense uptake in the extremities and skull. 
The kidneys are routinely visualized in normal subjects and should have less intensity than 
the adjacent lumbar spine because the urinary system is the excretion pathway of the 
radiopharmaceuticals. If the kidneys show equal or greater intensity, a renal abnormality or 
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Fig. 1. Normal skeletal scintigram shows the symmetric and uniform activity absorption in 
anterior and posterior image. 
A number of normal variants must be recognized for correct interpretation. Here we list 
some possible conditions as below.  
①Bilaterally increased radionuclide concentration may be normal.  
②The anterior aspect of the mandible may appear as a “hot spot” on lateral views of the 
skull.  
③The laryngotracheal cartilages are usually seen in adults probably related to some degree 
of calcification.  
④The thyroid gland can be visualized because of avid accumulation of unbound 
pertechnetate.  
⑤Some mild diffuse asymmetry in paired joints is commonly seen in adults especially in 
shoulders and correlates with handedness.  
⑥Some asymmetry is frequently seen in the sacroiliac joints, and this should be interpreted 
with caution in patients with scoliosis. 
3. Applications of skeletal radionuclide imaging 
 It is definite that the skeletal radionuclide imaging can present the information of blood 
flow and osteogenesis of regional area once. There are various abnormalities in skeletal 
radionuclide imaging, whatever the defects or increased uptake of radionuclide; they can 
manifest some clue of the lesions. We conclude some abnormal results as below, and 





①Asymmetric focal areas of increased or decreased activity: basically, this type of 
abnormality can happen in almost every scintigram. Focal increased activity can be 
associated with more blood flow (caused by hyperaemia, such as trauma, inflammation, etc) 
and active of osteogenesis (such as bone metastases of prostate cancer). 
②”Super scan” is another scintigraphic pattern, with good bone-to-soft tissue background 
ratio, bone uptake showing brightly, absent or faint visualization of kidney and bladder, an 
increased uptake in the axial versus appendicular skeleton (appendicular skeleton, distal 
extremities, facial bones, subtle asymmetries of the rib, skull vault, and proximal long bones, 
and no soft-tissue uptake apparent at normal intensities). In some patients with breast 
cancer or prostate cancer the entire axial skeleton becomes diffusely and rather uniformly 
involved with metastatic disease (Figure 2).  
 
 
Fig. 2. A patient diagnosed as prostate cancer, the whole body bone scan with 99mTc-MDP 
showed “super scan”: absent visualization of kidney, increased uptake in the axial versus 
appendicular skeleton and no soft-tissue uptake apparent at normal intensities. 
③Cold areas, which means diminished activity or none distribution of activity, is indicative 
of osteonecrosis, osteoporosis, osteomalacia, multiple myeloma, radiation or steroid 
therapy, end-stage cancer patients with diminished metabolism, renal cell carcinoma, 
thyroid cancer, anaplastic tumors, neuroblastoma. 
④”Donut” sign is the typical scintigram of osteonecrosis of the femoral head. The cold area 
within the femoral head is highly specific and is the earliest scintigraphic evidence of 
avascular necrosis. Over a period of weeks to months, increased uptake represents 
revascularization and repair surrounds, and eventually replaces the region of photopenia. 
The central region of photopenia with surrounding zone of increased uptake is termed as 
“donut” sign (Figure 3). 
 
12 Chapters on Nuclear Medicine 
 
292 




Fig. 1. Normal skeletal scintigram shows the symmetric and uniform activity absorption in 
anterior and posterior image. 
A number of normal variants must be recognized for correct interpretation. Here we list 
some possible conditions as below.  
①Bilaterally increased radionuclide concentration may be normal.  
②The anterior aspect of the mandible may appear as a “hot spot” on lateral views of the 
skull.  
③The laryngotracheal cartilages are usually seen in adults probably related to some degree 
of calcification.  
④The thyroid gland can be visualized because of avid accumulation of unbound 
pertechnetate.  
⑤Some mild diffuse asymmetry in paired joints is commonly seen in adults especially in 
shoulders and correlates with handedness.  
⑥Some asymmetry is frequently seen in the sacroiliac joints, and this should be interpreted 
with caution in patients with scoliosis. 
3. Applications of skeletal radionuclide imaging 
 It is definite that the skeletal radionuclide imaging can present the information of blood 
flow and osteogenesis of regional area once. There are various abnormalities in skeletal 
radionuclide imaging, whatever the defects or increased uptake of radionuclide; they can 
manifest some clue of the lesions. We conclude some abnormal results as below, and 





①Asymmetric focal areas of increased or decreased activity: basically, this type of 
abnormality can happen in almost every scintigram. Focal increased activity can be 
associated with more blood flow (caused by hyperaemia, such as trauma, inflammation, etc) 
and active of osteogenesis (such as bone metastases of prostate cancer). 
②”Super scan” is another scintigraphic pattern, with good bone-to-soft tissue background 
ratio, bone uptake showing brightly, absent or faint visualization of kidney and bladder, an 
increased uptake in the axial versus appendicular skeleton (appendicular skeleton, distal 
extremities, facial bones, subtle asymmetries of the rib, skull vault, and proximal long bones, 
and no soft-tissue uptake apparent at normal intensities). In some patients with breast 
cancer or prostate cancer the entire axial skeleton becomes diffusely and rather uniformly 
involved with metastatic disease (Figure 2).  
 
 
Fig. 2. A patient diagnosed as prostate cancer, the whole body bone scan with 99mTc-MDP 
showed “super scan”: absent visualization of kidney, increased uptake in the axial versus 
appendicular skeleton and no soft-tissue uptake apparent at normal intensities. 
③Cold areas, which means diminished activity or none distribution of activity, is indicative 
of osteonecrosis, osteoporosis, osteomalacia, multiple myeloma, radiation or steroid 
therapy, end-stage cancer patients with diminished metabolism, renal cell carcinoma, 
thyroid cancer, anaplastic tumors, neuroblastoma. 
④”Donut” sign is the typical scintigram of osteonecrosis of the femoral head. The cold area 
within the femoral head is highly specific and is the earliest scintigraphic evidence of 
avascular necrosis. Over a period of weeks to months, increased uptake represents 
revascularization and repair surrounds, and eventually replaces the region of photopenia. 
The central region of photopenia with surrounding zone of increased uptake is termed as 
“donut” sign (Figure 3). 
 




Fig. 3. The image showed “donut” sign in bilateral femoral head (worse in left side than 
right side), which is the diagnostic evidence of femoral head necrosis resulting from long-
time use of dexamethasone. 
⑤No uptake in focal areas: patients receive radiation therapy, bone infarct, avascular 
necrosis, metal prosthesis, bone infiltrated by tumor, poor venous return, edema in 
extremity may seen cold spot in focal area. 
⑥Three phase bone imaging: it is one of the types of imaging protocols, and can help the 
qualitative diagnosis of some skeletal diseases, such as increased uptake in flow, blood pool, 
and delays in osteomyelitis cases; increased uptake in flow and blood-pool with mild or no 
uptake in delays in cellutitis; increased activity in and around joints in flow, blood pool, and 
delays in arthritis; increased vascular flow, blood pool, and delays focally in primary 
malignant tumor (Figure 4); increased blood pool and delays, focally intense in benign 
primary tumor.  
 
 
Fig. 4. Three phase bone imaging showed increased activity in left distal femur in blood flow 
phase (A), blood pool phase (C), and delayed phase (D). Malignant bone tumor: blood 
supply obviously increased in blood flow phase, vascular extension can be seen. Irregular 
tracer accumulated in soft tissue, in blood pool phase. Hot spot accumulation can be found 
on bone in delayed phase. In this case the patient was diagnosed as left femur osteogenic 





3.1 Metastatic diseases 
The most common clinical application of skeletal imaging is in evaluating patients with 
extraskeletal primary malignancies for the presence of metastatic disease and staging 
metastatic disease. In many patients the presence of extent of skeletal metastasis directly 
influences treatment decisions and prognosis. Bone imaging plays an important role in 
treatment of bone pain and pathological fracture which are common management problems 
in patients with skeletal metastatic disease.  
Anterior and posterior images of the whole body scan are generally obtained. Metastases to 
bone are common in several primary malignancies, including lung, breast, and prostate 
carcinomas (Figure 5-6). Metastases to the spine are difficult to detect radiographically, since 
loss of approximately 50% of the mineral content of the bone must occur before lytic lesions 
are detected. The usual scintigraphic pattern of skeletal metastatic disease is multiple focal 
lesions throughout the skeleton, with the greatest involvement generally in the axial 
skeleton. The area of abnormal radiopharmaceutical deposition represents the edge of the 
metastatic deposit where osteoblastic repair is attempted.  
As metastatic lesions grow in the marrow space, the surrounding bone remodels through 
osteoclastic (resorptive) and osteoblastic (depositional) activity. The relative degrees of bone 
resorption and deposition elicited are highly variable among the different types of tumors 
and sometimes even different locations for the same tumor. The relationship between the 
two remodelling processes determines whether a metastatic deposit will appear as 
predominantly lytic or sclerotic or will exhibit a mixed pattern radiographically.  
 
 
Fig. 5. The image showed multiple hot spot in skull, vertebrae, ribs, pelvis, femur, etc. 
Combined with the history of prostate cancer and night bone pain, it was concluded as bone 
metastases of prostate cancer. 
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Fig. 6. The image showed multiple focal lesions in bone of patient with breast cancer.  
False negative scans have been related to several factors. If the skeleton is diffusely involved 
with metastatic disease, the focal nature of the lesions might not be apparent. Metastatic 
lesions may have no associated osteoblastic activity and thus may not be detected by bone 
scan or may be detected as a photon-deficient area.  
3.2 Primary malignant bone tumors 
Bone scanning is also used for the evaluation of primary bone neoplasm. Usually the patient 
has already had radiographs of the primary tumor, but the bone scan offers additional 
information of that area. The extent of the abnormality on the bone scan is generally not 
much different from the radiographically apparent lesion. The value of bone scanning in 
patients with primary bone malignancy lies in the detection of the disease elsewhere.  
Uptake of bone-seeking radiopharmaceuticals in primary bone tumors is avid and 
frequently striking. PET imaging with FDG is being explored for primary bone tumors. FDG 
uptake correlates with tumor metabolism. Scans can be helpful in localizing sites for biopsy 
and in assessing response to preoperative radiation and chemotherapy. 
99mTc-MIBI have been used for sarcoma imaging to determine whether tumors are low or 
high grade and to assess response to therapy. As with FDG, high-grade tumors show higher 
uptake. Successful radiation therapy or chemotherapy is associated with decreasing uptake. 
Studies of primary tumor have led to at least one important observation about skeletal tracer 
uptake. Many tumors elicit marked hyperemia. The increased blood flow is not restricted to 
the tumor itself but affects the entire watershed distribution of regional flow, most 






Fig. 7. Anterior and posterior whole body scintigram of a patient with osteosarcoma in the 
left distal femur. The degree of tracer accumulation in the lesion is striking. Note also the 
“watershed” phenomenon with increased tracer accumulation in all of the bones of the left 
lower extremity above and below the lesion. The increased blood flow induced by the 
osteosarcoma results in increased tracer delivery to the entire limb.  
Another primary malignant disease commonly involving bone is multiple myeloma (MM). 
MM is really a disease of the red marrow space, and the most frequently involved skeletal 
structures are the vertebrae, pelvis, ribs, and skull (Figure 8). On skeletal scintigram the only 
finding in MM may be osteopenia. Unless an associated fracture or a focal lesion such as a 
plasmacytoma is present, skeletal scintigrams are often normal. MRI is an excellent modality 
for evaluating the marrow space for areas of involvement.  
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Fig. 8. Multiple myeloma, showed multiple focal accumulation of radioactivity in bone. 
3.3 Benign bone tumors 
 Skeletal imaging is highly sensitive for detecting osteoid osteomas (Figure 9), which can be 
difficult to find by standard radiography, especially in the spine.  
 
 
Fig. 9. Three phase bone scan (bottom row) of a 13 years old boy with history of pain and 
swelling in the right shin. The swelling was localized to the mid shaft of right tibia. Plain x-ray 
revealed a large area of sclerosis in the mid shaft of right tibia. Bone scan showed normal 
blood flow phase, high soft tissue uptake in the blood pool phase and a double density hot 
lesion in delayed image over the mid-shaft of right tibia. Surgical excision of the tumor 





3.4 Trauma and athletic injuries 
Skeletal trauma is common and presents both an opportunity and a problem in skeletal 
scintigraphy. As we known, the first choice for suspected bone fracture is radiography, 
which shows the fracture line and type clearly. But SPECT bone imaging has its own 
advantages in some aspects. SPECT is a useful adjunct in the course of process such as stress 
fracture. Normal bone is constantly remodelling, bone resorption and deposition are 
balanced. When the skeleton is placed under stress the rate of remodelling increases, and 
that will result in change of activity in bone scintigraphy, 
The time a fracture takes to return to normal scintigraphically depends primarily on its 
location and the degree of damage to the skeleton.  
 
 
Fig. 10. Occult fracture of the left foot 4th toe, which can not be detected by radiography. 
3.5 Osteomyelitis 
In addition to being used in the evaluation of malignant disease involving the skeleton, 
radionuclide bone imaging is helpful in the assessment of several other non-malignant 
processes, such as patients with suspected osteomyelitis and diskitis. Acute hematogenous 
osteomyelitis typically begins by seeding of the infectious organism in the marrow space.  
A three-phase bone scan is performed by acquiring a rapid blood flow sequence of images 
over the interested area during agent injection. Early images (blood flow phase) are 
important in evaluating inflammatory processes. Flow images are performed 40 to 60sec and 
2 to 4 sec for each frame. Blood pool images are then immediately obtained for totally 300 to 
500 kcounts without moving the patient, and delayed images are taken as necessary. Both 
osteomyelitis and cellutitis can cause early increased radioactivity accumulation due to an 
increased vascular response to the affected area. The third phase is routine scanning at 2 to 3 
hr after injection. Sometimes there will be a forth phase that can be added 24hr delay. 
Osteomyelitis demonstrates focally increased activity in the involved bone on both the 
blood-pool and routine images (Figure 11). Since the use of bone imaging for detecting 
osteomyelitis, it has been found that several patients do not subsequently develop the 
typical radiographic changes because the early treatment prevents the development of 
radiographic abnormalities.  
 




Fig. 8. Multiple myeloma, showed multiple focal accumulation of radioactivity in bone. 
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3.4 Trauma and athletic injuries 
Skeletal trauma is common and presents both an opportunity and a problem in skeletal 
scintigraphy. As we known, the first choice for suspected bone fracture is radiography, 
which shows the fracture line and type clearly. But SPECT bone imaging has its own 
advantages in some aspects. SPECT is a useful adjunct in the course of process such as stress 
fracture. Normal bone is constantly remodelling, bone resorption and deposition are 
balanced. When the skeleton is placed under stress the rate of remodelling increases, and 
that will result in change of activity in bone scintigraphy, 
The time a fracture takes to return to normal scintigraphically depends primarily on its 
location and the degree of damage to the skeleton.  
 
 
Fig. 10. Occult fracture of the left foot 4th toe, which can not be detected by radiography. 
3.5 Osteomyelitis 
In addition to being used in the evaluation of malignant disease involving the skeleton, 
radionuclide bone imaging is helpful in the assessment of several other non-malignant 
processes, such as patients with suspected osteomyelitis and diskitis. Acute hematogenous 
osteomyelitis typically begins by seeding of the infectious organism in the marrow space.  
A three-phase bone scan is performed by acquiring a rapid blood flow sequence of images 
over the interested area during agent injection. Early images (blood flow phase) are 
important in evaluating inflammatory processes. Flow images are performed 40 to 60sec and 
2 to 4 sec for each frame. Blood pool images are then immediately obtained for totally 300 to 
500 kcounts without moving the patient, and delayed images are taken as necessary. Both 
osteomyelitis and cellutitis can cause early increased radioactivity accumulation due to an 
increased vascular response to the affected area. The third phase is routine scanning at 2 to 3 
hr after injection. Sometimes there will be a forth phase that can be added 24hr delay. 
Osteomyelitis demonstrates focally increased activity in the involved bone on both the 
blood-pool and routine images (Figure 11). Since the use of bone imaging for detecting 
osteomyelitis, it has been found that several patients do not subsequently develop the 
typical radiographic changes because the early treatment prevents the development of 
radiographic abnormalities.  
 




Fig. 11. Plantar view flow image show increased perfusion to the right proximal tibia. Blood-
pool image also demonstrate abnormal accumulation in the same area. Delayed image have 
persistent radiopharmaceutical collection consistent with osteomyelitis. Focal hyerperfusion, 
focal hyperemia, and focally increased bony activity in the proximal right tibial metaphysic 
are the classic findings of osteomyelitis.  
3.6 Metabolic bone diseases 
A number of metabolic conditions can result in marked abnormalities on bone imaging. 
Although these do not represent important clinical indications for bone imaging, they may 
be encountered incidentally in other applications, most importantly during metabolic 
skeletal survey. Hyperthyroidism, primary hyperparathyroidism, renal osteodystrophy, 
osteomalacia, and hypervitaminosis D all can result in generalized increased tracer uptake 
throughout the skeleton that has some features in common with the “supers can” seen in 
metabolic disease(Figure 12). These features are described before, such as increased  
 
 





skeleton-to-soft tissue ratio and faint or absent visualization of the kidneys. Increased skull 
activity, involvement of the long bones of the extremities, and increased periarticular uptake 
are features that distinguish scan in these conditions from the supers can of metabolic 
disease. 
3.7 Bone marrow disorders 
Non-invasive imaging techniques have been used in the past for visualization the functional 
activity of the bone marrow compartment. Imaging with radiolabelled compounds may 
allow different bone marrow disorders to be distinguished. These imaging techniques, 
almost all of which use radiolabelled tracers, such as 99mTc-nanocolloid, 99mTc-sulphur 
colloid (99mTc-SC), 111In-chloride, and radiolabelled white blood cells (99mTc-WBC), have 
been used in nuclear medicine for several decades. The results support that the 
radiolabelled agents can be alternatives to bone marrow scan. 
4. Radionuclide therapy of skeletal tumors 
Metastatic bone cancer is a common complication of malignant tumor. It is reported that 
20%-75% of cancer patients has developed bone metastases according to necropsy results. 
Malignant bone pain is still a challenging clinical problem. Pain due to bone metastases will 
greatly decrease the patient’s quality-of-life because of patient’s gradual deterioration, local 
body dysfunction, and mental and physical collapse. Recently, there are several reports on 
therapy of painful bone metastases by radiotherapy or anticancer drugs showing 
therapeutic efficacy. The studies, however, were generally heterogeneous trials involving 
stage of diagnosis, radiopharmaceuticals dosage, combination with other therapeutic 
modalities and methods of pain assessment. In addition, there are few reports on the study 
of comparison of radionuclide therapy with chemotherapy for evaluating the therapeutic 
effectiveness of the patients with painful bone metastases. 
4.1 Radionuclide internal-radiation therapy 
Radionuclide internal-radiation therapy of severe bone pain due to multiple skeletal 
metastases has recently achieved successful stage in nuclear medicine, which has been much 
considered and widespread used. In this chapter we described the principle of treatment of 
painful disseminated skeletal metastases, therapeutic approaches, evaluation of effective 
treatment according to our clinical experience in routine clinical treatment and its future 
applications.  
89Sr-chloride (Metastron) has been approved by the FDA for relief of bone pain in cases of 
painful skeletal metastases. The compound behaves biologically like calcium and localizes in 
hydroxyapatite crystal by ion exchange. Strontium uptake occurs preferentially at sites of 
active osteogenesis. This allows primary bone tumors and areas of metastatic involvement 
to accumulate significantly higher concentrations of strontium than surrounding normal 
bone. 89Sr decays by beta- emission with a half life of 50.6 days. The conventional dose of 
89Sr-chloride is 148 MBq (4mCi), and can be reinjection after three months if necessary. 
Before administration, a blood regulation test should be checked. 
Another two radiotherapeutic agents, 186Re-HEDP and 153Sm-EDTMP are also used in the 
area. 186Re decays by beta- and gamma emission with a half life of 90.6 hr and 153Sm decays 
by beta- emission and has a half life of 46.3 hr. Both of these beta-emitting radionuclides are 
complex with bone-seeking ligands, which localize by chemisorption. The duration of 
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response is 1-12 months. The main toxicity of these radiotherapeutics is mild transient bone 
marrow suppression. 
4.2 Radionuclide seed implantation 
Radionuclide seed such as 125I、103Pd、198Au implantation has been used in lots of clinical 
departments. Mostly 125I seeds (Figure 13) have been chosen as the proper one. Iodine-125 
delivers a higher radiation dose to the patient due to the half life of 60 days and 125I seeds 





Fig. 13. 125I seed is used in the therapy of solid tumor by implantation. 
5. Recent advances of skeletal radionuclide imaging and therapy 
It’s well-known that the skeletal radionuclide imaging and therapy will have a 
prospective development in novel radiopharmaceuticals of skeletal imaging (18F-NaF) 
(Figure 14) and therapy (heavy ion Carbon-11 and boron neutron capture therapy 
(BNCT)) and advanced nuclear medicine equipments such as SPECT/CT, PET/CT and 
PET/MR. In routine clinical practice, a variety of new radiopharmaceuticals have been 
introduced in recent years. There are three commercial radiopharmaceuticals of 
Samarium-153-ethylenediaminetetramethylene phosphonic acid (153Sm-EDTMP), 
Rehnium-188-(Sn)-hydroxyethylene diphosphonate (188Re-HEDP) and Strontium-89 
chloride (89SrCl2). 89SrCl2 is still the most widely used agent due to a longer physical half 
life (T½ = 50.5 days) and a pure beta-emitter playing an important role in radionuclide 
internal radiation therapy. 188Re-HEDP (T½ = 16.9 hr) obtained from 188W-188Re generator 
is cheap and convenient in clinical practice routine, with scintigraphic imaging of gamma 
rays in order to perform individual dosimetric studies, but 188W-188Re generator must be 
imported from other countries. 153Sm-EDTMP developed by our country is one of the 
radiopharmaceutical therapeutic agents and has relatively ideal physical, chemical and 
biological properties similar to 188Re except of slightly longer have-life (T½ = 40.4 hr). The 
0.103-Mev gamma ray is suitable for imaging in vivo distribution. The benefit of the 
favourable clinical experience with 153Sm-EDTMP has been reported in several 






                                a                                          b                                   c 
Fig. 14 Normal image of 18F- Fluoride PET（a: 3D projection imaging  b: coronal slice 
iamging: c: sagittal slice imaging） 
6. Conclusion 
It is important to resolve the problems on skeletal and soft tissue tumors for clinicians to 
seek for new diagnostic and therapeutic radiopharmaceuticals. Although rapid 
developments of medical science and great progress have been made recently, there are still 
some limitations. The clinical applications of radionuclide tracing technique in diagnosis 
and treatment of skeletal and soft tissue tumor is attached importance to clinical physicians 
with widely using the technique in clinical routine practice and continuing development of 
nuclear medicine.  
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